{"PMC7129257": [], "8a800a347c157dd235813daaa911545de454b4ab": [["At the beginning of the 1st century, diari..eal disease continues to be a significant cause of morbidity and mortality worldwide.", [["eal disease", "DISEASE", 44, 55], ["eal disease", "PROBLEM", 44, 55], ["morbidity", "PROBLEM", 95, 104], ["disease", "OBSERVATION", 48, 55], ["morbidity", "OBSERVATION", 95, 104]]], ["During the period of 1986 to 2000, an estimated 1.4 billion children younger than 5 years suffered an episode of acute diarrhea every year in developing countries; among these, 123.6 million required outpatient medical care, and 9 million required hospitalization.", [["diarrhea", "DISEASE", 119, 127], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["acute diarrhea", "PROBLEM", 113, 127], ["outpatient medical care", "TREATMENT", 200, 223], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["diarrhea", "OBSERVATION", 119, 127]]], ["Approximately 2 million diarrhea-associated deaths occurred in this age group annually, primarily in the most impoverished areas of the world.'", [["diarrhea", "DISEASE", 24, 32], ["deaths", "DISEASE", 44, 50], ["2 million diarrhea", "PROBLEM", 14, 32]]], ["These estimates are somewhat lower than the more than 3 million annual deaths from diarrhea reported in the prior 10 years? indicating progress in prevention and treatment of acute diarrhea.", [["deaths", "DISEASE", 71, 77], ["diarrhea", "DISEASE", 83, 91], ["diarrhea", "DISEASE", 181, 189], ["diarrhea", "PROBLEM", 83, 91], ["treatment", "TREATMENT", 162, 171], ["acute diarrhea", "PROBLEM", 175, 189], ["somewhat", "OBSERVATION_MODIFIER", 20, 28], ["lower", "OBSERVATION_MODIFIER", 29, 34], ["diarrhea", "OBSERVATION", 83, 91], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["diarrhea", "OBSERVATION", 181, 189]]], ["In the United States, approximately 400 childhood deaths per year were reported during the late 1 9 8 0\" For very low birth weight infants (<1500g), the death rate from diarrhea is 100-fold greater than for higher-birth-weight infants.", [["deaths", "DISEASE", 50, 56], ["death", "DISEASE", 153, 158], ["diarrhea", "DISEASE", 169, 177], ["infants", "ORGANISM", 227, 234], ["infants", "SPECIES", 131, 138], ["infants", "SPECIES", 227, 234], ["the death rate", "TEST", 149, 163], ["diarrhea", "PROBLEM", 169, 177]]], ["12 This chapter discusses the pathogenesis, diagnosis, treatment, and prevention of gastroenteritis based on the available knowledge about pathogens that can cause neonatal diarrhea.", [["gastroenteritis", "DISEASE", 84, 99], ["diarrhea", "DISEASE", 173, 181], ["treatment", "TREATMENT", 55, 64], ["gastroenteritis", "PROBLEM", 84, 99], ["pathogens", "PROBLEM", 139, 148], ["neonatal diarrhea", "PROBLEM", 164, 181], ["gastroenteritis", "OBSERVATION", 84, 99]]], ["Pathogens that rarely or never cause acute diarrhea in neonates are not discussed.", [["diarrhea", "DISEASE", 43, 51], ["neonates", "ORGANISM", 55, 63], ["acute diarrhea in neonates", "PROBLEM", 37, 63], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["diarrhea", "OBSERVATION", 43, 51]]], ["After an overview of host defense mechanisms and protective factors in human milk, the remainder of the chapter is devoted to specific pathogens that cause inflammatory or noninflammatory diarrhea.ENTERIC HOST DEFENSE MECHANISMSThe neonate is a host that is uniquely susceptible to enteric infections.", [["milk", "ANATOMY", 77, 81], ["diarrhea", "DISEASE", 188, 196], ["enteric infections", "DISEASE", 282, 300], ["human", "ORGANISM", 71, 76], ["milk", "ORGANISM_SUBSTANCE", 77, 81], ["protective factors", "PROTEIN", 49, 67], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["host defense mechanisms", "TREATMENT", 21, 44], ["protective factors in human milk", "TREATMENT", 49, 81], ["inflammatory or noninflammatory diarrhea", "PROBLEM", 156, 196], ["enteric infections", "PROBLEM", 282, 300], ["inflammatory", "OBSERVATION_MODIFIER", 156, 168], ["noninflammatory", "OBSERVATION_MODIFIER", 172, 187], ["HOST DEFENSE", "OBSERVATION", 205, 217], ["enteric", "ANATOMY", 282, 289], ["infections", "OBSERVATION", 290, 300]]], ["Neonates have not had the opportunity to develop local or systemic immune responses, and in the first few days of life, they have not acquired the highly important enteric flora that protects the normal adult gastrointestinal tract.I3-\" Still less is known about the barrier effect of the neonate's gastric acidity,\" intestinal mucus,Z0 or each of which provides protection against gastrointestinal tract infections in older infants, children, and adults.ENTERIC HOST DEFENSE MECHANISMSThe gastric acid barrier appears to be least effective during the first months of life.", [["adult gastrointestinal tract", "ANATOMY", 203, 231], ["gastric", "ANATOMY", 299, 306], ["intestinal mucus", "ANATOMY", 317, 333], ["gastrointestinal tract", "ANATOMY", 382, 404], ["gastric", "ANATOMY", 490, 497], ["gastrointestinal tract infections", "DISEASE", 382, 415], ["Neonates", "ORGANISM", 0, 8], ["enteric flora", "PATHOLOGICAL_FORMATION", 164, 177], ["adult", "ORGAN", 203, 208], ["gastrointestinal tract", "ORGAN", 209, 231], ["neonate", "ORGANISM_SUBDIVISION", 289, 296], ["gastric", "ORGAN", 299, 306], ["intestinal mucus", "MULTI-TISSUE_STRUCTURE", 317, 333], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 382, 404], ["infants", "ORGANISM", 425, 432], ["children", "ORGANISM", 434, 442], ["infants", "SPECIES", 425, 432], ["children", "SPECIES", 434, 442], ["the neonate's gastric acidity", "PROBLEM", 285, 314], ["intestinal mucus", "PROBLEM", 317, 333], ["gastrointestinal tract infections", "PROBLEM", 382, 415], ["ENTERIC HOST DEFENSE MECHANISMSThe gastric acid barrier", "TREATMENT", 455, 510], ["flora", "OBSERVATION", 172, 177], ["normal", "OBSERVATION", 196, 202], ["gastrointestinal tract", "ANATOMY", 209, 231], ["gastric", "ANATOMY", 299, 306], ["acidity", "OBSERVATION", 307, 314], ["intestinal mucus", "ANATOMY", 317, 333], ["gastrointestinal tract", "ANATOMY", 382, 404], ["infections", "OBSERVATION", 405, 415], ["HOST DEFENSE", "OBSERVATION", 463, 475], ["gastric", "ANATOMY", 490, 497], ["acid barrier", "OBSERVATION", 498, 510]]], ["The average gastric pH level of the newborn is high (pH 4 to 7; mean, 6).23,24 Although the pH falls to low levels by the end of the first day of life (pH 2 to 3),23 it subsequently rises again; by 7 to 10 days of life, the hydrochloric acid output of the neonatal stomach is far less than that of older infants and The buffering action of frequent milk feedings and the short gastric emptying interpose additional factors in the neonate that would be expected to permit viable ingested organisms to reach the small intestine.ENTERIC HOST DEFENSE MECHANISMSThe intestinal epithelium serves as a nutrient absorptive machine, barrier to pathogen entry, and regulator of inflammation.", [["gastric", "ANATOMY", 12, 19], ["neonatal stomach", "ANATOMY", 256, 272], ["milk", "ANATOMY", 349, 353], ["gastric", "ANATOMY", 377, 384], ["small intestine", "ANATOMY", 510, 525], ["intestinal epithelium", "ANATOMY", 561, 582], ["hydrochloric acid", "CHEMICAL", 224, 241], ["inflammation", "DISEASE", 668, 680], ["hydrochloric acid", "CHEMICAL", 224, 241], ["gastric", "ORGAN", 12, 19], ["hydrochloric acid", "SIMPLE_CHEMICAL", 224, 241], ["neonatal stomach", "ORGAN", 256, 272], ["infants", "ORGANISM", 304, 311], ["milk", "ORGANISM_SUBSTANCE", 349, 353], ["gastric", "ORGAN", 377, 384], ["neonate", "ORGANISM", 430, 437], ["small intestine", "ORGAN", 510, 525], ["intestinal epithelium", "TISSUE", 561, 582], ["infants", "SPECIES", 304, 311], ["The average gastric pH level", "TEST", 0, 28], ["pH", "TEST", 53, 55], ["mean", "TEST", 64, 68], ["the pH falls", "PROBLEM", 88, 100], ["low levels", "PROBLEM", 104, 114], ["pH", "TEST", 152, 154], ["the hydrochloric acid output", "TEST", 220, 248], ["frequent milk feedings", "TREATMENT", 340, 362], ["the short gastric emptying", "TREATMENT", 367, 393], ["a nutrient absorptive machine", "TREATMENT", 593, 622], ["inflammation", "PROBLEM", 668, 680], ["average", "OBSERVATION_MODIFIER", 4, 11], ["gastric", "ANATOMY", 12, 19], ["pH level", "OBSERVATION", 20, 28], ["newborn", "OBSERVATION_MODIFIER", 36, 43], ["high", "OBSERVATION_MODIFIER", 47, 51], ["rises", "OBSERVATION_MODIFIER", 182, 187], ["stomach", "ANATOMY", 265, 272], ["small intestine", "ANATOMY", 510, 525], ["HOST DEFENSE", "OBSERVATION", 534, 546], ["MECHANISMSThe", "ANATOMY_MODIFIER", 547, 560], ["intestinal", "ANATOMY", 561, 571], ["epithelium", "ANATOMY_MODIFIER", 572, 582], ["inflammation", "OBSERVATION", 668, 680]]], ["Intestinal epithelial cells have receptors for bacterial products and produce chemokines (e.g., interleukm [ IL]-8, monocyte chemotactic protein type 1 [ MCP-1 1, granulocyte macrophage-cell stimulating factor [ GM-CSF] ) and proinflammatory cytokines (e.g., IL-6, tumor necrosis factor-a [TNF-a], IL-1) in response to invasion by enteropathogens.\"ENTERIC HOST DEFENSE MECHANISMSThe gut epithelium orchestrates the immune response.", [["Intestinal epithelial cells", "ANATOMY", 0, 27], ["gut epithelium", "ANATOMY", 383, 397], ["necrosis", "DISEASE", 271, 279], ["Intestinal epithelial cells", "CELL", 0, 27], ["interleukm [ IL]-8", "GENE_OR_GENE_PRODUCT", 96, 114], ["monocyte chemotactic protein type 1", "GENE_OR_GENE_PRODUCT", 116, 151], ["MCP-1 1", "GENE_OR_GENE_PRODUCT", 154, 161], ["granulocyte macrophage-cell stimulating factor", "GENE_OR_GENE_PRODUCT", 163, 209], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 212, 218], ["IL-6", "GENE_OR_GENE_PRODUCT", 259, 263], ["tumor necrosis factor-a", "GENE_OR_GENE_PRODUCT", 265, 288], ["TNF-a", "GENE_OR_GENE_PRODUCT", 290, 295], ["IL-1", "GENE_OR_GENE_PRODUCT", 298, 302], ["gut epithelium", "TISSUE", 383, 397], ["Intestinal epithelial cells", "CELL_TYPE", 0, 27], ["bacterial products", "PROTEIN", 47, 65], ["chemokines", "PROTEIN", 78, 88], ["interleukm [ IL]-8", "PROTEIN", 96, 114], ["monocyte chemotactic protein type 1 [ MCP-1 1", "PROTEIN", 116, 161], ["granulocyte macrophage-cell stimulating factor", "PROTEIN", 163, 209], ["GM", "PROTEIN", 212, 214], ["CSF", "PROTEIN", 215, 218], ["proinflammatory cytokines", "PROTEIN", 226, 251], ["IL-6", "PROTEIN", 259, 263], ["tumor necrosis factor", "PROTEIN", 265, 286], ["TNF", "PROTEIN", 290, 293], ["IL", "PROTEIN", 298, 300], ["Intestinal epithelial cells", "PROBLEM", 0, 27], ["bacterial products", "TREATMENT", 47, 65], ["chemokines", "TEST", 78, 88], ["interleukm", "TEST", 96, 106], ["IL", "TEST", 109, 111], ["monocyte chemotactic protein type", "TEST", 116, 149], ["MCP", "TEST", 154, 157], ["granulocyte macrophage", "TEST", 163, 185], ["cell stimulating factor", "TEST", 186, 209], ["GM", "TEST", 212, 214], ["CSF", "TEST", 215, 218], ["proinflammatory cytokines", "TEST", 226, 251], ["e.g.", "TEST", 253, 257], ["IL", "TEST", 259, 261], ["tumor necrosis factor", "PROBLEM", 265, 286], ["TNF", "TEST", 290, 293], ["a], IL", "TREATMENT", 294, 300], ["invasion", "PROBLEM", 319, 327], ["enteropathogens", "PROBLEM", 331, 346], ["epithelial cells", "OBSERVATION", 11, 27], ["necrosis", "OBSERVATION", 271, 279], ["invasion", "OBSERVATION", 319, 327], ["enteropathogens", "OBSERVATION", 331, 346], ["HOST DEFENSE", "OBSERVATION", 356, 368], ["immune response", "OBSERVATION", 415, 430]]], ["B and T lymphocyte functions are impaired, resulting in a preferential IgM production in response to antigenic stimulation.", [["T lymphocyte", "ANATOMY", 6, 18], ["B", "CELL", 0, 1], ["T lymphocyte", "CELL", 6, 18], ["IgM", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgM", "PROTEIN", 71, 74], ["B and T lymphocyte functions", "TEST", 0, 28], ["a preferential IgM production", "PROBLEM", 56, 85], ["antigenic stimulation", "TREATMENT", 101, 122], ["preferential", "OBSERVATION_MODIFIER", 58, 70], ["IgM production", "OBSERVATION", 71, 85], ["antigenic stimulation", "OBSERVATION", 101, 122]]], ["IgG is actively transferred from mother to infant across the placenta at about 32 weeks' gestation and peaks by about 37 weeks; premature neonates, especially those born before 28 weeks' gestation, are deficient in these maternally derived serum antib' h e 2 6 -2 9PROTECTIVE FACTORS IN HUMAN MILKThe importance of breast-feeding infants for the prevention of diarrheal disease has long been e m p h a s i~e d .~ Published studies reporting the association between breastfeeding and diarrhea are extensive and suggest that infants who are breast-fed suffer fewer episodes of diarrhea than those who are not.", [["placenta", "ANATOMY", 61, 69], ["serum", "ANATOMY", 240, 245], ["breast", "ANATOMY", 315, 321], ["breast", "ANATOMY", 539, 545], ["breast-feeding", "DISEASE", 315, 329], ["diarrheal disease", "DISEASE", 360, 377], ["diarrhea", "DISEASE", 483, 491], ["diarrhea", "DISEASE", 575, 583], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["infant", "ORGANISM", 43, 49], ["placenta", "ORGAN", 61, 69], ["neonates", "ORGANISM", 138, 146], ["serum", "ORGANISM_SUBSTANCE", 240, 245], ["breast", "ORGANISM_SUBDIVISION", 315, 321], ["infants", "ORGANISM", 330, 337], ["infants", "ORGANISM", 523, 530], ["breast", "ORGANISM_SUBDIVISION", 539, 545], ["IgG", "PROTEIN", 0, 3], ["infant", "SPECIES", 43, 49], ["infants", "SPECIES", 330, 337], ["infants", "SPECIES", 523, 530], ["premature neonates", "PROBLEM", 128, 146], ["deficient", "PROBLEM", 202, 211], ["breast-feeding infants", "TREATMENT", 315, 337], ["diarrheal disease", "PROBLEM", 360, 377], ["Published studies", "TEST", 413, 430], ["diarrhea", "PROBLEM", 483, 491], ["diarrhea", "PROBLEM", 575, 583], ["placenta", "ANATOMY", 61, 69], ["breast", "ANATOMY", 315, 321], ["breast", "ANATOMY", 539, 545]]], ["This protection is greatest during a child's first 3 months of life and declines with increasing age, During the period of weaning, partial breast-feeding confers protection that is intermediate between that gained by infants who are exclusively breast-fed and that by those who are exclusively bottle-fed.PROTECTIVE FACTORS IN HUMAN MILKA striking demonstration of the protection afforded by breast-feeding of newborns has been provided by Mata and UrrutiaI3 in their studies of a population of infants born in a rural Guatemalan village.", [["breast", "ANATOMY", 140, 146], ["breast", "ANATOMY", 246, 252], ["breast", "ANATOMY", 393, 399], ["breast", "ORGANISM_SUBDIVISION", 140, 146], ["infants", "ORGANISM", 218, 225], ["breast", "ORGANISM_SUBDIVISION", 246, 252], ["breast", "ORGANISM_SUBDIVISION", 393, 399], ["newborns", "ORGANISM", 411, 419], ["infants", "ORGANISM", 496, 503], ["infants", "SPECIES", 218, 225], ["infants", "SPECIES", 496, 503], ["partial breast-feeding confers protection", "TREATMENT", 132, 173], ["the protection afforded", "TREATMENT", 366, 389], ["greatest", "OBSERVATION_MODIFIER", 19, 27], ["breast", "ANATOMY", 140, 146], ["breast", "ANATOMY", 393, 399]]], ["Despite extremely poor sanitation and the demonstration of fecal organisms in the colostrum and milk of almost one third of diarrheal disease did not occur in any newborns.", [["colostrum", "ANATOMY", 82, 91], ["milk", "ANATOMY", 96, 100], ["diarrheal disease", "DISEASE", 124, 141], ["colostrum", "ORGANISM_SUBSTANCE", 82, 91], ["milk", "ORGANISM_SUBSTANCE", 96, 100], ["fecal organisms in the colostrum", "PROBLEM", 59, 91], ["diarrheal disease", "PROBLEM", 124, 141], ["poor", "OBSERVATION_MODIFIER", 18, 22], ["sanitation", "OBSERVATION", 23, 33], ["fecal organisms", "OBSERVATION", 59, 74], ["colostrum", "ANATOMY", 82, 91], ["diarrheal disease", "OBSERVATION", 124, 141]]], ["The incidence of diarrhea rose significantly only after these infants reached 4 to 6 months old, at which time solids and other fluids were used to supplement the human milk feedings.", [["milk", "ANATOMY", 169, 173], ["diarrhea", "DISEASE", 17, 25], ["infants", "ORGANISM", 62, 69], ["human", "ORGANISM", 163, 168], ["milk", "ORGANISM_SUBDIVISION", 169, 173], ["infants", "SPECIES", 62, 69], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["diarrhea", "PROBLEM", 17, 25], ["other fluids", "TREATMENT", 122, 134], ["the human milk feedings", "TREATMENT", 159, 182], ["diarrhea", "OBSERVATION", 17, 25]]], ["At that time, Escherichia coli and gram-negative anaerobes (e.g., Bacteroides) were found to colonize the intestinal tract.I3 In contrast, urban infants of a similar ethnic background who were partly or totally artificially fed frequently acquired diarrheal disease caused by enteropathogenic E. coli (EPEC) .PROTECTIVE FACTORS IN HUMAN MILKMultiple mechanisms by which breast-feeding protects against diarrhea have been postulated.", [["intestinal tract", "ANATOMY", 106, 122], ["breast", "ANATOMY", 370, 376], ["diarrheal disease", "DISEASE", 248, 265], ["enteropathogenic E. coli", "DISEASE", 276, 300], ["diarrhea", "DISEASE", 402, 410], ["Escherichia coli", "ORGANISM", 14, 30], ["intestinal tract", "ORGAN", 106, 122], ["infants", "ORGANISM", 145, 152], ["enteropathogenic E. coli", "ORGANISM", 276, 300], ["EPEC", "CELL", 302, 306], ["breast", "ORGANISM_SUBDIVISION", 370, 376], ["Escherichia coli", "SPECIES", 14, 30], ["infants", "SPECIES", 145, 152], ["E. coli", "SPECIES", 293, 300], ["Escherichia coli", "SPECIES", 14, 30], ["E. coli", "SPECIES", 293, 300], ["EPEC", "SPECIES", 302, 306], ["Escherichia coli", "PROBLEM", 14, 30], ["gram", "TEST", 35, 39], ["negative anaerobes", "PROBLEM", 40, 58], ["Bacteroides", "PROBLEM", 66, 77], ["diarrheal disease", "PROBLEM", 248, 265], ["enteropathogenic E. coli", "PROBLEM", 276, 300], ["HUMAN MILKMultiple mechanisms", "TREATMENT", 331, 360], ["diarrhea", "PROBLEM", 402, 410], ["Escherichia coli", "OBSERVATION", 14, 30], ["negative anaerobes", "OBSERVATION", 40, 58], ["intestinal tract", "ANATOMY", 106, 122], ["diarrheal disease", "OBSERVATION", 248, 265], ["enteropathogenic", "OBSERVATION_MODIFIER", 276, 292], ["E. coli", "OBSERVATION", 293, 300], ["breast", "ANATOMY", 370, 376]]], ["Breast-feeding confers protection by active components in milk and by decreased exposure to organisms present on or in contaminated bottles, food, or water.", [["Breast", "ANATOMY", 0, 6], ["milk", "ANATOMY", 58, 62], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["Breast-feeding confers protection", "TREATMENT", 0, 33]]], ["Many protective components have been identified in human milk and generally are classified as belonging to the major categories of cells, antibody, antiinflammatory factors, and glycoconjugates and other nonantibody f a~t o r s .'~, ''The protective effect of human milk antibodies against enteropathogen-specific disease has been described for Vibrio cholerae,62 Campylobacter j e j~n i , ~~ EPEC,59 enterotoxigenic E. coli (ETEC),64965 Shigella,66'67 and Giardia lamblia68,69 and for bovine milk concentrate against ETEC,70 rota' and Shigella.", [["milk", "ANATOMY", 57, 61], ["cells", "ANATOMY", 131, 136], ["milk", "ANATOMY", 266, 270], ["milk", "ANATOMY", 493, 497], ["enteropathogen-specific disease", "DISEASE", 290, 321], ["ETEC", "CHEMICAL", 518, 522], ["human", "ORGANISM", 51, 56], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["cells", "CELL", 131, 136], ["human", "ORGANISM", 260, 265], ["milk antibodies", "ORGANISM", 266, 281], ["Vibrio cholerae", "ORGANISM", 345, 360], ["Campylobacter j e j~n i", "ORGANISM", 364, 387], ["EPEC,59 enterotoxigenic E. coli", "ORGANISM", 393, 424], ["ETEC", "ORGANISM", 426, 430], ["64965 Shigella", "ORGANISM", 432, 446], ["Giardia lamblia68,69", "ORGANISM", 457, 477], ["bovine", "ORGANISM", 486, 492], ["milk", "ORGANISM_SUBSTANCE", 493, 497], ["ETEC", "CELL", 518, 522], ["antibody", "PROTEIN", 138, 146], ["antiinflammatory factors", "PROTEIN", 148, 172], ["human milk antibodies", "PROTEIN", 260, 281], ["human", "SPECIES", 51, 56], ["milk", "SPECIES", 57, 61], ["human", "SPECIES", 260, 265], ["milk", "SPECIES", 266, 270], ["Vibrio cholerae", "SPECIES", 345, 360], ["enterotoxigenic E. coli", "SPECIES", 401, 424], ["bovine", "SPECIES", 486, 492], ["milk", "SPECIES", 493, 497], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 260, 265], ["Vibrio cholerae", "SPECIES", 345, 360], ["Campylobacter j e j~n", "SPECIES", 364, 385], ["E. coli", "SPECIES", 417, 424], ["ETEC", "SPECIES", 426, 430], ["Giardia lamblia68,69", "SPECIES", 457, 477], ["bovine", "SPECIES", 486, 492], ["antiinflammatory factors", "PROBLEM", 148, 172], ["glycoconjugates", "TEST", 178, 193], ["human milk antibodies", "TREATMENT", 260, 281], ["enteropathogen", "PROBLEM", 290, 304], ["specific disease", "PROBLEM", 305, 321], ["Vibrio cholerae", "TEST", 345, 360], ["Campylobacter j e j~n i", "TEST", 364, 387], ["enterotoxigenic E. coli", "PROBLEM", 401, 424], ["Shigella", "TEST", 438, 446], ["Giardia", "TEST", 457, 464], ["bovine milk concentrate", "TREATMENT", 486, 509], ["ETEC", "TEST", 518, 522], ["Shigella", "PROBLEM", 536, 544]]], ["72 In 1933, the nonlactose carbohydrate fraction of human milk was found to consist mainly of oligosa~ In 1960, Montreuil and Mullet74 determined that up to 2.4% of colostrum and up to 1.3% of mature milk are oligosaccharides.", [["milk", "ANATOMY", 58, 62], ["colostrum", "ANATOMY", 165, 174], ["milk", "ANATOMY", 200, 204], ["nonlactose", "CHEMICAL", 16, 26], ["carbohydrate", "CHEMICAL", 27, 39], ["nonlactose", "SIMPLE_CHEMICAL", 16, 26], ["human", "ORGANISM", 52, 57], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["colostrum", "ORGANISM_SUBSTANCE", 165, 174], ["milk", "ORGANISM_SUBSTANCE", 200, 204], ["human", "SPECIES", 52, 57], ["milk", "SPECIES", 58, 62], ["milk", "SPECIES", 200, 204], ["human", "SPECIES", 52, 57], ["the nonlactose carbohydrate fraction of human milk", "TREATMENT", 12, 62], ["colostrum", "TEST", 165, 174]]], ["Human milk contains a larger quantity of the oligosaccharides than does milk from other mammals, and its composition is singularly complex.75 The metabolic fate of the oligosaccharides is of interest.", [["milk", "ANATOMY", 6, 10], ["milk", "ANATOMY", 72, 76], ["Human", "ORGANISM", 0, 5], ["milk", "ORGANISM_SUBSTANCE", 6, 10], ["milk", "ORGANISM_SUBSTANCE", 72, 76], ["Human", "SPECIES", 0, 5], ["milk", "SPECIES", 6, 10], ["Human", "SPECIES", 0, 5], ["Human milk", "TREATMENT", 0, 10], ["a larger quantity of the oligosaccharides", "TREATMENT", 20, 61], ["larger", "OBSERVATION_MODIFIER", 22, 28], ["quantity", "OBSERVATION_MODIFIER", 29, 37], ["metabolic fate", "OBSERVATION", 146, 160]]], ["Only water, lactose, and lipids are present in greater amounts than the oligosaccharides.", [["lactose", "CHEMICAL", 12, 19], ["lactose", "CHEMICAL", 12, 19], ["water", "SIMPLE_CHEMICAL", 5, 10], ["lactose", "SIMPLE_CHEMICAL", 12, 19], ["lipids", "SIMPLE_CHEMICAL", 25, 31], ["lactose", "TREATMENT", 12, 19], ["lipids", "TREATMENT", 25, 31]]], ["Despite the fact that substantial energy must be expended by the mother to synthesize the many hundreds of different milk oligosaccharides, the infant does not use them as food.", [["milk", "ORGANISM", 117, 121], ["infant", "ORGANISM", 144, 150], ["infant", "SPECIES", 144, 150], ["different milk oligosaccharides", "TREATMENT", 107, 138], ["substantial", "OBSERVATION_MODIFIER", 22, 33], ["energy", "OBSERVATION", 34, 40]]], ["Most of the oligosaccharides pass through the gut undigested.76377 It is thought that they are present primarily to serve as receptor analogues that misdirect enteropathogen attachment factors away from gut epithelial carbohydrate receptors.", [["gut", "ANATOMY", 46, 49], ["gut epithelial", "ANATOMY", 203, 217], ["carbohydrate", "CHEMICAL", 218, 230], ["gut", "ORGANISM_SUBDIVISION", 46, 49], ["enteropathogen attachment factors", "GENE_OR_GENE_PRODUCT", 159, 192], ["gut epithelial carbohydrate receptors", "GENE_OR_GENE_PRODUCT", 203, 240], ["enteropathogen attachment factors", "PROTEIN", 159, 192], ["gut epithelial carbohydrate receptors", "PROTEIN", 203, 240], ["receptor analogues", "TREATMENT", 125, 143], ["misdirect enteropathogen attachment factors", "PROBLEM", 149, 192]]], ["Likewise, enteropathogens use the oligosaccharide portion of glycolipids and glycoproteins as targets for attachment of whole bacteria and toxins.", [["the oligosaccharide portion of glycolipids", "TREATMENT", 30, 72], ["glycoproteins", "TREATMENT", 77, 90], ["whole bacteria", "PROBLEM", 120, 134], ["toxins", "PROBLEM", 139, 145], ["enteropathogens", "OBSERVATION", 10, 25]]], ["Evidence is emerging that these glycoconjugates may have an important role in protection of the breast-fed infant from disease.", [["breast", "ANATOMY", 96, 102], ["breast", "ORGANISM_SUBDIVISION", 96, 102], ["infant", "ORGANISM", 107, 113], ["infant", "SPECIES", 107, 113], ["disease", "PROBLEM", 119, 126], ["breast", "ANATOMY", 96, 102]]], ["48 Human milk protects suckling mice from the heat-stable enterotoxin (ST) of E. coli; on the basis of its chemical stability and physical properties, the protective factor has been deduced to be a neutral fucosyloligosaccharide.", [["milk", "ANATOMY", 9, 13], ["fucosyloligosaccharide", "CHEMICAL", 206, 228], ["fucosyloligosaccharide", "CHEMICAL", 206, 228], ["Human", "ORGANISM", 3, 8], ["milk", "ORGANISM_SUBSTANCE", 9, 13], ["mice", "ORGANISM", 32, 36], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 58, 69], ["E. coli", "ORGANISM", 78, 85], ["fucosyloligosaccharide", "SIMPLE_CHEMICAL", 206, 228], ["Human", "SPECIES", 3, 8], ["milk", "SPECIES", 9, 13], ["mice", "SPECIES", 32, 36], ["E. coli", "SPECIES", 78, 85], ["mice", "SPECIES", 32, 36], ["E. coli", "SPECIES", 78, 85], ["the heat", "TEST", 42, 50], ["E. coli", "PROBLEM", 78, 85], ["a neutral fucosyloligosaccharide", "TREATMENT", 196, 228], ["E. coli", "OBSERVATION", 78, 85], ["chemical stability", "OBSERVATION", 107, 125]]], ["79~80 Experiments have shown that EPEC attachment to HEp-2 cells can be inhibited by purified oligosaccharide fractions from human milk.59 Oligosaccharides also may be relevant to protection from Norwalk virus and other caliciviruses, because these viruses attach to human ABO, Lewis, and secretor blood group antigens.80'81 Human milk contains large amounts of these carbohydrates.", [["HEp-2 cells", "ANATOMY", 53, 64], ["milk", "ANATOMY", 131, 135], ["blood", "ANATOMY", 298, 303], ["milk", "ANATOMY", 331, 335], ["carbohydrates", "CHEMICAL", 368, 381], ["EPEC", "CELL", 34, 38], ["HEp-2 cells", "CELL", 53, 64], ["human", "ORGANISM", 125, 130], ["milk", "ORGANISM_SUBSTANCE", 131, 135], ["Norwalk virus", "ORGANISM", 196, 209], ["human", "ORGANISM", 267, 272], ["ABO", "GENE_OR_GENE_PRODUCT", 273, 276], ["secretor blood group antigens", "GENE_OR_GENE_PRODUCT", 289, 318], ["Human", "ORGANISM", 325, 330], ["milk", "ORGANISM_SUBSTANCE", 331, 335], ["HEp-2 cells", "CELL_LINE", 53, 64], ["human ABO, Lewis, and secretor blood group antigens", "PROTEIN", 267, 318], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 267, 272], ["Human", "SPECIES", 325, 330], ["human", "SPECIES", 125, 130], ["Norwalk virus", "SPECIES", 196, 209], ["human", "SPECIES", 267, 272], ["EPEC attachment", "PROBLEM", 34, 49], ["HEp-2 cells", "TREATMENT", 53, 64], ["Norwalk virus", "PROBLEM", 196, 209], ["other caliciviruses", "PROBLEM", 214, 233], ["these viruses", "PROBLEM", 243, 256], ["human ABO", "TEST", 267, 276], ["secretor blood group antigens", "PROBLEM", 289, 318], ["these carbohydrates", "TREATMENT", 362, 381], ["Norwalk virus", "OBSERVATION", 196, 209], ["large", "OBSERVATION_MODIFIER", 345, 350], ["amounts", "OBSERVATION_MODIFIER", 351, 358]]], ["The ganglioside fraction in human milk has been shown to inhibit the action of heat-labile toxin (LT) and cholera toxin on ileal loops more effectively than secretory IgA.82s83 Lactadherin in human milk has been shown to bind rotavirus and to inhibit viral replication in vitro and in V~V O . ~~ A study of infants in Mexico showed that lactadherin in human milk protected infants from symptoms of rotavirus infection.72ESCHERICHIA COLIE. coli organisms promptly colonize the lower intestinal tracts of healthy infants in their first few days of life85-88 and constitute the predominant aerobic coliform fecal flora throughout life in humans and in many animals.", [["milk", "ANATOMY", 34, 38], ["ileal loops", "ANATOMY", 123, 134], ["milk", "ANATOMY", 198, 202], ["milk", "ANATOMY", 358, 362], ["lower intestinal tracts", "ANATOMY", 476, 499], ["fecal flora", "ANATOMY", 604, 615], ["cholera toxin", "CHEMICAL", 106, 119], ["Lactadherin", "CHEMICAL", 177, 188], ["lactadherin", "CHEMICAL", 337, 348], ["rotavirus infection", "DISEASE", 398, 417], ["life85-88", "CHEMICAL", 546, 555], ["ganglioside", "CHEMICAL", 4, 15], ["lactadherin", "CHEMICAL", 337, 348], ["ganglioside", "GENE_OR_GENE_PRODUCT", 4, 15], ["human", "ORGANISM", 28, 33], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["heat-labile toxin", "SIMPLE_CHEMICAL", 79, 96], ["LT", "GENE_OR_GENE_PRODUCT", 98, 100], ["cholera toxin", "SIMPLE_CHEMICAL", 106, 119], ["ileal loops", "MULTI-TISSUE_STRUCTURE", 123, 134], ["IgA.82s83", "GENE_OR_GENE_PRODUCT", 167, 176], ["Lactadherin", "GENE_OR_GENE_PRODUCT", 177, 188], ["human", "ORGANISM", 192, 197], ["milk", "ORGANISM_SUBSTANCE", 198, 202], ["rotavirus", "ORGANISM", 226, 235], ["infants", "ORGANISM", 307, 314], ["lactadherin", "SIMPLE_CHEMICAL", 337, 348], ["human", "ORGANISM", 352, 357], ["milk", "ORGANISM_SUBSTANCE", 358, 362], ["infants", "ORGANISM", 373, 380], ["rotavirus", "ORGANISM", 398, 407], ["coli", "ORGANISM", 439, 443], ["intestinal tracts", "MULTI-TISSUE_STRUCTURE", 482, 499], ["infants", "ORGANISM", 511, 518], ["fecal flora", "PATHOLOGICAL_FORMATION", 604, 615], ["humans", "ORGANISM", 635, 641], ["heat-labile toxin", "PROTEIN", 79, 96], ["LT", "PROTEIN", 98, 100], ["cholera toxin", "PROTEIN", 106, 119], ["secretory IgA.82s83 Lactadherin", "PROTEIN", 157, 188], ["V~V O", "CELL_LINE", 285, 290], ["human", "SPECIES", 28, 33], ["milk", "SPECIES", 34, 38], ["human", "SPECIES", 192, 197], ["milk", "SPECIES", 198, 202], ["infants", "SPECIES", 307, 314], ["human", "SPECIES", 352, 357], ["milk", "SPECIES", 358, 362], ["infants", "SPECIES", 373, 380], ["coli", "SPECIES", 439, 443], ["infants", "SPECIES", 511, 518], ["humans", "SPECIES", 635, 641], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 192, 197], ["rotavirus", "SPECIES", 226, 235], ["human", "SPECIES", 352, 357], ["rotavirus", "SPECIES", 398, 407], ["coli", "SPECIES", 439, 443], ["humans", "SPECIES", 635, 641], ["labile toxin", "PROBLEM", 84, 96], ["cholera toxin on ileal loops", "PROBLEM", 106, 134], ["Lactadherin in human milk", "TREATMENT", 177, 202], ["rotavirus", "PROBLEM", 226, 235], ["viral replication", "TREATMENT", 251, 268], ["A study", "TEST", 296, 303], ["lactadherin in human milk", "TREATMENT", 337, 362], ["symptoms", "PROBLEM", 386, 394], ["rotavirus infection", "PROBLEM", 398, 417], ["coli organisms", "PROBLEM", 439, 453], ["the predominant aerobic coliform fecal flora", "PROBLEM", 571, 615], ["ganglioside fraction", "OBSERVATION", 4, 24], ["ileal loops", "ANATOMY", 123, 134], ["rotavirus", "OBSERVATION_MODIFIER", 398, 407], ["infection", "OBSERVATION", 408, 417], ["lower", "ANATOMY_MODIFIER", 476, 481], ["intestinal tracts", "ANATOMY", 482, 499], ["healthy infants", "OBSERVATION", 503, 518], ["predominant", "OBSERVATION_MODIFIER", 575, 586], ["aerobic", "OBSERVATION_MODIFIER", 587, 594], ["coliform fecal flora", "OBSERVATION", 595, 615]]], ["The concept that this species might cause enteric disease was first suggested in the late 19th and early 20th centuries, when several veterinary workers described the association of diarrhea (i.e.,scours) in newborn calves with certain strains of E. C O Z' -~~In 1905, M0r0'~ observed that Bacterium (now Escherichia) coli was found more often in the small intestines of children with diarrhea than in children without diarrhea.", [["intestines", "ANATOMY", 357, 367], ["enteric disease", "DISEASE", 42, 57], ["diarrhea", "DISEASE", 182, 190], ["Bacterium", "CHEMICAL", 290, 299], ["diarrhea", "DISEASE", 385, 393], ["diarrhea", "DISEASE", 419, 427], ["calves", "ORGANISM", 216, 222], ["Bacterium", "ORGANISM", 290, 299], ["Escherichia) coli", "ORGANISM", 305, 322], ["small intestines", "ORGAN", 351, 367], ["children", "ORGANISM", 371, 379], ["children", "ORGANISM", 402, 410], ["calves", "SPECIES", 216, 222], ["Escherichia) coli", "SPECIES", 305, 322], ["children", "SPECIES", 371, 379], ["children", "SPECIES", 402, 410], ["Escherichia) coli", "SPECIES", 305, 322], ["enteric disease", "PROBLEM", 42, 57], ["diarrhea", "PROBLEM", 182, 190], ["Bacterium", "PROBLEM", 290, 299], ["Escherichia) coli", "PROBLEM", 305, 322], ["diarrhea", "PROBLEM", 385, 393], ["diarrhea", "PROBLEM", 419, 427], ["diarrhea", "OBSERVATION", 182, 190], ["small", "OBSERVATION_MODIFIER", 351, 356], ["intestines", "ANATOMY", 357, 367]]], ["The isolation of ETEC is uncommon in sporadic diarrheal illnesses in temperate climates where sanitation facilities are good and where winter viral patterns of diarrhea predominate.", [["ETEC", "DISEASE", 17, 21], ["diarrheal illnesses", "DISEASE", 46, 65], ["diarrhea", "DISEASE", 160, 168], ["ETEC", "ORGANISM", 17, 21], ["ETEC", "PROBLEM", 17, 21], ["sporadic diarrheal illnesses", "PROBLEM", 37, 65], ["diarrhea", "PROBLEM", 160, 168], ["ETEC", "OBSERVATION_MODIFIER", 17, 21], ["uncommon", "OBSERVATION_MODIFIER", 25, 33], ["sporadic", "OBSERVATION_MODIFIER", 37, 45], ["diarrheal illnesses", "OBSERVATION", 46, 65]]], ["ETEC is commonly isolated from infants and children with acute watery summer diarrhea in areas where sanitary facilities are less than optimal.35-165 However, not all strains of E. coli belonging to the 10 serogroups associated with dysentery-lke illness are pathogenic, because a large (140 MDa) invasive plasmid is also required.205 Additional biologic tests, including the guinea pig conjunctivitis (Sereny) test or a gene probe for the plasmid, are used to confirm the property of inva Although an outbreak of foodborne EIEC diarrhea has been well documented among adults who ate an imported cheese,\"' little is known about the epidemiology and transmission of this organism, especially in newborns and infants.", [["plasmid", "ANATOMY", 306, 313], ["plasmid", "ANATOMY", 440, 447], ["ETEC", "DISEASE", 0, 4], ["diarrhea", "DISEASE", 77, 85], ["dysentery-lke illness", "DISEASE", 233, 254], ["conjunctivitis", "DISEASE", 387, 401], ["EIEC diarrhea", "DISEASE", 524, 537], ["infants", "ORGANISM", 31, 38], ["children", "ORGANISM", 43, 51], ["E. coli", "ORGANISM", 178, 185], ["guinea pig", "ORGANISM", 376, 386], ["newborns", "ORGANISM", 694, 702], ["infants", "ORGANISM", 707, 714], ["infants", "SPECIES", 31, 38], ["children", "SPECIES", 43, 51], ["E. coli", "SPECIES", 178, 185], ["guinea pig conjunctivitis", "SPECIES", 376, 401], ["infants", "SPECIES", 707, 714], ["ETEC", "SPECIES", 0, 4], ["E. coli", "SPECIES", 178, 185], ["dysentery-lke", "SPECIES", 233, 246], ["guinea pig", "SPECIES", 376, 386], ["EIEC", "SPECIES", 524, 528], ["ETEC", "PROBLEM", 0, 4], ["acute watery summer diarrhea", "PROBLEM", 57, 85], ["E. coli", "PROBLEM", 178, 185], ["dysentery", "PROBLEM", 233, 242], ["illness", "PROBLEM", 247, 254], ["pathogenic", "PROBLEM", 259, 269], ["a large (140 MDa) invasive plasmid", "PROBLEM", 279, 313], ["Additional biologic tests", "TEST", 335, 360], ["the guinea pig conjunctivitis", "TREATMENT", 372, 401], ["a gene probe", "TREATMENT", 419, 431], ["the plasmid", "TREATMENT", 436, 447], ["foodborne EIEC diarrhea", "PROBLEM", 514, 537], ["this organism", "PROBLEM", 665, 678], ["coli", "OBSERVATION", 181, 185], ["dysentery", "OBSERVATION", 233, 242], ["large", "OBSERVATION_MODIFIER", 281, 286]]], ["Whether the infectious dose may be as low as it is for Shigella is unknown; however, studies of adult volunteers suggest that attack rates may be somewhat lower after ingestion of even large numbers of EIEC than would be expected with Shigella.", [["adult volunteers", "ORGANISM", 96, 112], ["Shigella", "PROBLEM", 55, 63], ["attack rates", "PROBLEM", 126, 138], ["EIEC", "PROBLEM", 202, 206], ["Shigella", "PROBLEM", 235, 243], ["infectious", "OBSERVATION", 12, 22], ["large", "OBSERVATION_MODIFIER", 185, 190], ["numbers", "OBSERVATION_MODIFIER", 191, 198]]], ["The outbreak of EIEC diarrhea resulted in a dysentery-like syndrome with an inflammatory exudate in stool and invasion and disruption of colonic mucosa.\"'", [["stool", "ANATOMY", 100, 105], ["colonic mucosa", "ANATOMY", 137, 151], ["diarrhea", "DISEASE", 21, 29], ["dysentery", "DISEASE", 44, 53], ["stool", "ORGANISM_SUBSTANCE", 100, 105], ["colonic mucosa", "MULTI-TISSUE_STRUCTURE", 137, 151], ["EIEC", "SPECIES", 16, 20], ["EIEC diarrhea", "PROBLEM", 16, 29], ["a dysentery-like syndrome", "PROBLEM", 42, 67], ["an inflammatory exudate in stool", "PROBLEM", 73, 105], ["invasion", "PROBLEM", 110, 118], ["disruption of colonic mucosa", "PROBLEM", 123, 151], ["EIEC diarrhea", "OBSERVATION", 16, 29], ["dysentery", "OBSERVATION", 44, 53], ["inflammatory", "OBSERVATION_MODIFIER", 76, 88], ["exudate", "OBSERVATION", 89, 96], ["stool", "OBSERVATION", 100, 105], ["invasion", "OBSERVATION", 110, 118], ["colonic mucosa", "ANATOMY", 137, 151]]], ["Descriptions of extensive and severe ileocolitis in infants dying with E. coli diarrhea indicate that neonatal disease also can be caused by invasive strains capable of mimicking the pathologic features of shigellosis.", [["ileocolitis", "DISEASE", 37, 48], ["E. coli diarrhea", "DISEASE", 71, 87], ["neonatal disease", "DISEASE", 102, 118], ["shigellosis", "DISEASE", 206, 217], ["ileocolitis", "CANCER", 37, 48], ["infants", "ORGANISM", 52, 59], ["E. coli", "ORGANISM", 71, 78], ["infants", "SPECIES", 52, 59], ["E. coli diarrhea", "SPECIES", 71, 87], ["E. coli", "SPECIES", 71, 78], ["extensive and severe ileocolitis", "PROBLEM", 16, 48], ["E. coli diarrhea", "PROBLEM", 71, 87], ["neonatal disease", "PROBLEM", 102, 118], ["invasive strains", "PROBLEM", 141, 157], ["shigellosis", "PROBLEM", 206, 217], ["extensive", "OBSERVATION_MODIFIER", 16, 25], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["ileocolitis", "OBSERVATION", 37, 48], ["E. coli", "OBSERVATION_MODIFIER", 71, 78], ["neonatal disease", "OBSERVATION", 102, 118], ["shigellosis", "OBSERVATION", 206, 217]]], ["206 The immunofluorescent demonstration of E. coli together with an acute inflammatory infiltrate2\" in the intestinal tissue of infants tends to support this impression, although it has been suggested that the organisms may have invaded the bowel wall in the postmortem ~e r i 0 d . l '~ There is still little direct evidence concerning the role of invasive strains of E. coli in the cause of neonatal diarrhea.175 The infrequency with which newborns manifest a dysentery-like syndrome makes it unlikely that this pathogen is responsible for a very large proportion of the diarrheal disease that occurs during the first month of life.Enteroinvasive Escherichia coliThe diagnosis should be suspected in infants who have an inflammatory diarrhea as evidenced by fecal polymorphonuclear neutrophils or even bloody dysenteric syndromes from whom no other invasive pathogens, such as Campylobacter, Shigella, Salmonella, Vibrio, or Yersinia, can be isolated.", [["intestinal tissue", "ANATOMY", 107, 124], ["bowel wall", "ANATOMY", 241, 251], ["fecal polymorphonuclear neutrophils", "ANATOMY", 760, 795], ["diarrhea", "DISEASE", 402, 410], ["dysentery", "DISEASE", 462, 471], ["diarrheal disease", "DISEASE", 573, 590], ["diarrhea", "DISEASE", 735, 743], ["E. coli", "ORGANISM", 43, 50], ["infiltrate2", "CANCER", 87, 98], ["intestinal tissue", "TISSUE", 107, 124], ["infants", "ORGANISM", 128, 135], ["bowel wall", "MULTI-TISSUE_STRUCTURE", 241, 251], ["E. coli", "ORGANISM", 369, 376], ["newborns", "ORGANISM", 442, 450], ["Escherichia coliThe", "ORGANISM", 649, 668], ["infants", "ORGANISM", 702, 709], ["fecal polymorphonuclear neutrophils", "CELL", 760, 795], ["Salmonella, Vibrio", "ORGANISM", 904, 922], ["fecal polymorphonuclear neutrophils", "CELL_TYPE", 760, 795], ["E. coli", "SPECIES", 43, 50], ["infants", "SPECIES", 128, 135], ["E. coli", "SPECIES", 369, 376], ["infants", "SPECIES", 702, 709], ["E. coli", "SPECIES", 43, 50], ["E. coli", "SPECIES", 369, 376], ["Escherichia coliThe", "SPECIES", 649, 668], ["The immunofluorescent", "TEST", 4, 25], ["E. coli", "PROBLEM", 43, 50], ["an acute inflammatory infiltrate2", "PROBLEM", 65, 98], ["the organisms", "PROBLEM", 206, 219], ["invasive strains", "PROBLEM", 349, 365], ["E. coli", "PROBLEM", 369, 376], ["neonatal diarrhea", "PROBLEM", 393, 410], ["a dysentery-like syndrome", "PROBLEM", 460, 485], ["this pathogen", "PROBLEM", 509, 522], ["the diarrheal disease", "PROBLEM", 569, 590], ["Enteroinvasive Escherichia coliThe diagnosis", "PROBLEM", 634, 678], ["an inflammatory diarrhea", "PROBLEM", 719, 743], ["fecal polymorphonuclear neutrophils", "PROBLEM", 760, 795], ["bloody dysenteric syndromes", "PROBLEM", 804, 831], ["other invasive pathogens", "PROBLEM", 845, 869], ["Campylobacter", "PROBLEM", 879, 892], ["Shigella", "PROBLEM", 894, 902], ["Salmonella", "PROBLEM", 904, 914], ["Vibrio", "PROBLEM", 916, 922], ["Yersinia", "PROBLEM", 927, 935], ["E. coli", "OBSERVATION", 43, 50], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["inflammatory", "OBSERVATION_MODIFIER", 74, 86], ["infiltrate2", "OBSERVATION", 87, 98], ["intestinal tissue", "ANATOMY", 107, 124], ["bowel", "ANATOMY", 241, 246], ["wall", "ANATOMY_MODIFIER", 247, 251], ["invasive", "OBSERVATION_MODIFIER", 349, 357], ["E. coli", "OBSERVATION", 369, 376], ["neonatal", "OBSERVATION_MODIFIER", 393, 401], ["diarrhea", "OBSERVATION", 402, 410], ["dysentery", "OBSERVATION", 462, 471], ["very", "OBSERVATION_MODIFIER", 544, 548], ["large", "OBSERVATION_MODIFIER", 549, 554], ["diarrheal disease", "OBSERVATION", 573, 590], ["Escherichia coliThe", "OBSERVATION", 649, 668], ["inflammatory", "OBSERVATION", 722, 734], ["fecal", "ANATOMY", 760, 765], ["polymorphonuclear neutrophils", "OBSERVATION", 766, 795], ["invasive", "OBSERVATION_MODIFIER", 851, 859], ["pathogens", "OBSERVATION", 860, 869], ["Yersinia", "OBSERVATION", 927, 935]]], ["In this instance, it may be appropriate to have the fecal E. coli isolated and serotyped or tested for invasiveness in the Sereny test.", [["fecal E. coli", "ORGANISM", 52, 65], ["E. coli", "SPECIES", 58, 65], ["E. coli", "SPECIES", 58, 65], ["the fecal E. coli", "PROBLEM", 48, 65], ["invasiveness", "PROBLEM", 103, 115], ["the Sereny test", "TEST", 119, 134], ["fecal", "ANATOMY", 52, 57], ["E. coli", "OBSERVATION", 58, 65]]], ["Plasmid pattern analysis and chromosomal restriction endonuclease digestion pattern analysis by pulsed-field gel electrophoresis have been used to evaluate strains involved in outbreaks.", [["chromosomal", "ANATOMY", 29, 40], ["chromosomal", "CELLULAR_COMPONENT", 29, 40], ["Plasmid pattern analysis", "TEST", 0, 24], ["chromosomal restriction endonuclease digestion pattern analysis", "PROBLEM", 29, 92], ["pulsed-field gel electrophoresis", "TEST", 96, 128], ["strains", "PROBLEM", 156, 163]]], ["208 The management and prevention of EIEC diarrhea should be similar to those for acute Shigella or other E. coli enteric infections.Enteropathogenic Escherichia colk Classic SerotypesThe serologic distinction of E. coli strains associated with epidemic and sporadic infantile diarrhea was first suggested by Goldschmidt in 1933209 and confirmed by Dulaney and Michelson in 1935.", [["diarrhea", "DISEASE", 42, 50], ["enteric infections", "DISEASE", 114, 132], ["infantile diarrhea", "DISEASE", 267, 285], ["E. coli enteric", "ORGANISM", 106, 121], ["E. coli", "ORGANISM", 213, 220], ["E. coli", "SPECIES", 106, 113], ["E. coli", "SPECIES", 213, 220], ["EIEC", "SPECIES", 37, 41], ["E. coli", "SPECIES", 106, 113], ["E. coli", "SPECIES", 213, 220], ["The management", "TREATMENT", 4, 18], ["EIEC diarrhea", "PROBLEM", 37, 50], ["acute Shigella", "PROBLEM", 82, 96], ["other E. coli enteric infections", "PROBLEM", 100, 132], ["Enteropathogenic Escherichia colk", "PROBLEM", 133, 166], ["Classic Serotypes", "PROBLEM", 167, 184], ["E. coli strains", "PROBLEM", 213, 228], ["epidemic", "PROBLEM", 245, 253], ["sporadic infantile diarrhea", "PROBLEM", 258, 285], ["EIEC diarrhea", "OBSERVATION", 37, 50], ["E. coli enteric infections", "OBSERVATION", 106, 132], ["Escherichia colk", "OBSERVATION", 150, 166], ["Serotypes", "OBSERVATION_MODIFIER", 175, 184], ["E. coli strains", "OBSERVATION", 213, 228], ["epidemic", "OBSERVATION_MODIFIER", 245, 253], ["sporadic", "OBSERVATION_MODIFIER", 258, 266], ["infantile diarrhea", "OBSERVATION", 267, 285]]], ["205 These researchers found that certain strains of E. coli associated with institutional outbreaks of diarrhea would agglutinate with antisera on slides.", [["diarrhea", "DISEASE", 103, 111], ["E. coli", "ORGANISM", 52, 59], ["E. coli", "SPECIES", 52, 59], ["E. coli", "SPECIES", 52, 59], ["E. coli", "PROBLEM", 52, 59], ["diarrhea", "PROBLEM", 103, 111], ["antisera on slides", "TREATMENT", 135, 153], ["E. coli", "OBSERVATION", 52, 59]]], ["In 1943, Bra?\" isolated a serologically homogeneous strain of E. coli (subsequently identified as serogroup 0111) from 95% of infants with summer diarrhea in England.", [["diarrhea", "DISEASE", 146, 154], ["E. coli", "ORGANISM", 62, 69], ["infants", "ORGANISM", 126, 133], ["E. coli", "SPECIES", 62, 69], ["infants", "SPECIES", 126, 133], ["E. coli", "SPECIES", 62, 69], ["E. coli", "PROBLEM", 62, 69], ["summer diarrhea", "PROBLEM", 139, 154], ["E. coli", "OBSERVATION", 62, 69]]], ["He subsequently summarized a larger experience with this organism isolated from only 4% of asymptomatic controls but from 88% of infants with diarrhea, one half of which was hospital This strain (initially called E. coli-gomez by Varela in 1946) also was associated with infantile diarrhea in A second type of E. coli (called beta by Giles in 1948 and subsequently identified as 055) was associated with an outbreak of infantile diarrhea in Aberdeen, S~o t l a n d .~' resulting in an asymptomatic infection rate of 2% to 5% among newborns cultured at random in nursery surveys.8519'~262 These results must be considered conservative and are probably an artifact of the sampling technique.", [["diarrhea", "DISEASE", 142, 150], ["infantile diarrhea", "DISEASE", 271, 289], ["infantile diarrhea", "DISEASE", 419, 437], ["infection", "DISEASE", 498, 507], ["infants", "ORGANISM", 129, 136], ["E. coli-gomez", "ORGANISM", 213, 226], ["E. coli", "ORGANISM", 310, 317], ["beta", "GENE_OR_GENE_PRODUCT", 326, 330], ["newborns", "ORGANISM", 531, 539], ["infants", "SPECIES", 129, 136], ["E. coli-gomez", "SPECIES", 213, 226], ["E. coli", "SPECIES", 310, 317], ["E. coli-gomez", "SPECIES", 213, 226], ["E. coli", "SPECIES", 310, 317], ["this organism", "PROBLEM", 52, 65], ["asymptomatic controls", "PROBLEM", 91, 112], ["diarrhea", "PROBLEM", 142, 150], ["This strain", "PROBLEM", 183, 194], ["infantile diarrhea", "PROBLEM", 271, 289], ["E. coli", "PROBLEM", 310, 317], ["infantile diarrhea", "PROBLEM", 419, 437], ["an asymptomatic infection rate", "PROBLEM", 482, 512], ["the sampling technique", "TEST", 666, 688], ["larger", "OBSERVATION_MODIFIER", 29, 35], ["diarrhea", "OBSERVATION", 142, 150], ["diarrhea", "OBSERVATION", 281, 289], ["E. coli", "OBSERVATION", 310, 317], ["asymptomatic", "OBSERVATION_MODIFIER", 485, 497], ["infection", "OBSERVATION", 498, 507], ["artifact", "OBSERVATION", 654, 662]]], ["One study using 150 0 antisera to identify as many E. coli as possible in fecal cultures showed a correlation between the coliform flora in 66% of motherinfant pairs?63 Of particular interest was the observation that the 0 groups of E. coli isolated from the infants' mucus immediately after delivery correlated with those subsequently recovered from their stools, supporting the contention that these organisms were acquired orally at the time of birth.", [["fecal cultures", "ANATOMY", 74, 88], ["mucus", "ANATOMY", 268, 273], ["stools", "ANATOMY", 357, 363], ["E. coli", "ORGANISM", 51, 58], ["fecal cultures", "CELL", 74, 88], ["E. coli", "ORGANISM", 233, 240], ["infants", "ORGANISM", 259, 266], ["mucus", "MULTI-TISSUE_STRUCTURE", 268, 273], ["E. coli", "SPECIES", 51, 58], ["E. coli", "SPECIES", 233, 240], ["infants", "SPECIES", 259, 266], ["E. coli", "SPECIES", 51, 58], ["E. coli", "SPECIES", 233, 240], ["One study", "TEST", 0, 9], ["many E. coli", "PROBLEM", 46, 58], ["fecal cultures", "TEST", 74, 88], ["the coliform flora", "TEST", 118, 136], ["E. coli", "PROBLEM", 233, 240], ["delivery", "TREATMENT", 292, 300], ["these organisms", "PROBLEM", 396, 411], ["E. coli", "OBSERVATION", 233, 240]]], ["In mothers whose stools contained the same 0 group as their offspring, the mean time from rupture of membranes to delivery was about 2 hours longer than in those whose infants did not acquire the same serogroups, suggesting that ascending colonization before birth also can play a role in determining the newborn's fecal flora.Epidemiology and TransmissionThe contours of the epidemiologic curves in nurse^'' outbreak.", [["membranes", "ANATOMY", 101, 110], ["fecal flora", "ANATOMY", 315, 326], ["rupture", "DISEASE", 90, 97], ["mothers", "ORGANISM", 3, 10], ["stools", "ORGANISM_SUBDIVISION", 17, 23], ["membranes", "CELLULAR_COMPONENT", 101, 110], ["infants", "ORGANISM", 168, 175], ["fecal flora", "ORGANISM_SUBSTANCE", 315, 326], ["infants", "SPECIES", 168, 175], ["rupture of membranes", "PROBLEM", 90, 110], ["delivery", "TREATMENT", 114, 122], ["ascending colonization", "PROBLEM", 229, 251], ["rupture", "OBSERVATION", 90, 97], ["ascending", "OBSERVATION_MODIFIER", 229, 238], ["colonization", "OBSERVATION", 239, 251]]], ["Because immunofluorescence does not depend on the viability of organisms and is not affected by antibiotics that suppress growth on culture plates, it can be used to advantage in following bacteriologic responses and relapses in patients receiving oral the rap\",\"^ The use of fluorescent antibody techniques offers many advantages in the surveillance and epidemiologic control of EPEC gastroenteritis.", [["oral", "ANATOMY", 248, 252], ["gastroenteritis", "DISEASE", 385, 400], ["patients", "ORGANISM", 229, 237], ["oral", "ORGANISM_SUBDIVISION", 248, 252], ["EPEC", "ORGANISM", 380, 384], ["patients", "SPECIES", 229, 237], ["EPEC", "SPECIES", 380, 384], ["immunofluorescence", "TEST", 8, 26], ["organisms", "PROBLEM", 63, 72], ["antibiotics", "TREATMENT", 96, 107], ["culture plates", "TEST", 132, 146], ["fluorescent antibody techniques", "TREATMENT", 276, 307], ["the surveillance", "TEST", 334, 350], ["EPEC gastroenteritis", "PROBLEM", 380, 400], ["EPEC gastroenteritis", "OBSERVATION", 380, 400]]], ["Immunofluorescent methods should supplement but not replace standard bacteriologic and serologic methods for identification of enteric pathogens.DiagnosisSpecific gene probes and PCR primers for the BFP adhesin, the intimin-encoding gene (eue) and for a cryptic plasmid locus (EAF) are a~ Detection of BFP or EAF are superior to detection of eue, because many non-EPEC, including nonpathogens, carry the eae gene.98B364 PCR and gene probe analysis can be performed directly on the stools of suspect infants.", [["plasmid", "ANATOMY", 262, 269], ["enteric pathogens", "DISEASE", 127, 144], ["BFP adhesin", "GENE_OR_GENE_PRODUCT", 199, 210], ["intimin", "GENE_OR_GENE_PRODUCT", 216, 223], ["BFP", "GENE_OR_GENE_PRODUCT", 302, 305], ["EAF", "GENE_OR_GENE_PRODUCT", 309, 312], ["non-EPEC", "CANCER", 360, 368], ["eae", "GENE_OR_GENE_PRODUCT", 404, 407], ["stools", "ORGANISM_SUBDIVISION", 481, 487], ["infants", "ORGANISM", 499, 506], ["DiagnosisSpecific gene probes", "DNA", 145, 174], ["PCR primers", "DNA", 179, 190], ["BFP adhesin", "DNA", 199, 210], ["intimin-encoding gene", "DNA", 216, 237], ["eue", "DNA", 239, 242], ["cryptic plasmid locus", "DNA", 254, 275], ["EAF", "DNA", 277, 280], ["BFP", "PROTEIN", 302, 305], ["eae gene", "DNA", 404, 412], ["infants", "SPECIES", 499, 506], ["Immunofluorescent methods", "TREATMENT", 0, 25], ["standard bacteriologic", "TEST", 60, 82], ["serologic methods", "TEST", 87, 104], ["enteric pathogens", "PROBLEM", 127, 144], ["DiagnosisSpecific gene probes", "TREATMENT", 145, 174], ["PCR primers", "TEST", 179, 190], ["the BFP adhesin", "TREATMENT", 195, 210], ["a cryptic plasmid locus", "PROBLEM", 252, 275], ["BFP", "PROBLEM", 302, 305], ["EAF", "PROBLEM", 309, 312], ["PCR", "TEST", 420, 423], ["gene probe analysis", "TEST", 428, 447], ["enteric", "ANATOMY", 127, 134], ["pathogens", "OBSERVATION", 135, 144]]], ["However, confirmation of infection by the identification of the organism in pure culture should be pursued.DiagnosisBefore widespread use of molecular methods, the HEp-2 cell adherence assay was proposed for EPEC diagnosis.\"'", [["HEp-2 cell", "ANATOMY", 164, 174], ["infection", "DISEASE", 25, 34], ["HEp-2 cell", "CELL", 164, 174], ["infection", "PROBLEM", 25, 34], ["the organism in pure culture", "TEST", 60, 88], ["molecular methods", "TREATMENT", 141, 158], ["the HEp-2 cell adherence assay", "TREATMENT", 160, 190], ["infection", "OBSERVATION", 25, 34]]], ["The presence of a focal or localized adherence (LA) pattern on the surface of HEp-2 or HeLa cells after 3-hour coincubation is a highly sensitive and specific test for detection of EPEC.", [["surface", "ANATOMY", 67, 74], ["HEp-2", "ANATOMY", 78, 83], ["HeLa cells", "ANATOMY", 87, 97], ["LA", "CHEMICAL", 48, 50], ["surface", "CELLULAR_COMPONENT", 67, 74], ["HEp-2", "CELL", 78, 83], ["HeLa cells", "CELL", 87, 97], ["EPEC", "CELL", 181, 185], ["HEp-2", "CELL_LINE", 78, 83], ["HeLa cells", "CELL_LINE", 87, 97], ["EPEC", "SPECIES", 181, 185], ["a focal or localized adherence (LA) pattern", "PROBLEM", 16, 59], ["HEp", "TEST", 78, 81], ["HeLa cells", "PROBLEM", 87, 97], ["EPEC", "PROBLEM", 181, 185], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["localized", "OBSERVATION_MODIFIER", 27, 36], ["adherence", "OBSERVATION_MODIFIER", 37, 46]]], ["365 The requirement for cell culture and expertise in reading this assay limits its utility to the research setting.", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28], ["cell culture", "TEST", 24, 36], ["this assay", "TEST", 62, 72]]], ["An ELISA for the BFP has been described but is not readily available?66 The capacity of LA + EPEC to polymerize F-actin can be detected in tissue culture cells stained with rhodamine-labeled phall~' This fluorescence-actin staining (FAS) test is cumbersome and impractical for routine clinical use.PrognosisThe mortality rate recorded previously in epidemics of EPEC gastroenteritis is impressive for its variability.", [["tissue culture cells", "ANATOMY", 139, 159], ["LA", "CHEMICAL", 88, 90], ["rhodamine", "CHEMICAL", 173, 182], ["gastroenteritis", "DISEASE", 367, 382], ["rhodamine", "CHEMICAL", 173, 182], ["BFP", "GENE_OR_GENE_PRODUCT", 17, 20], ["LA + EPEC", "GENE_OR_GENE_PRODUCT", 88, 97], ["F-actin", "GENE_OR_GENE_PRODUCT", 112, 119], ["tissue culture cells", "CELL", 139, 159], ["rhodamine", "SIMPLE_CHEMICAL", 173, 182], ["fluorescence-actin", "GENE_OR_GENE_PRODUCT", 204, 222], ["EPEC", "ORGANISM", 362, 366], ["BFP", "PROTEIN", 17, 20], ["F-actin", "PROTEIN", 112, 119], ["tissue culture cells", "CELL_LINE", 139, 159], ["EPEC", "SPECIES", 362, 366], ["An ELISA", "TEST", 0, 8], ["the BFP", "TEST", 13, 20], ["EPEC", "PROBLEM", 93, 97], ["tissue culture cells", "TEST", 139, 159], ["rhodamine", "TEST", 173, 182], ["This fluorescence", "TEST", 199, 216], ["actin staining (FAS) test", "TEST", 217, 242], ["The mortality rate", "TEST", 307, 325], ["EPEC gastroenteritis", "PROBLEM", 362, 382], ["EPEC gastroenteritis", "OBSERVATION", 362, 382]]], ["During the 1930s and 1940s, when organisms later recognized as classic enteropathogenic serotypes were infecting infants, the case-fatality ratio among neonates was about 50%.", [["infants", "ORGANISM", 113, 120], ["neonates", "ORGANISM", 152, 160], ["infants", "SPECIES", 113, 120], ["organisms", "PROBLEM", 33, 42], ["classic enteropathogenic serotypes", "PROBLEM", 63, 97]]], ["2099210 During the 1950s and 1960s, many nursery epidemics still claimed about one of every four infected infants, but several outbreaks involving the same serotypes under similar epidemiologic circumstances had fatality rates of less than 30h.23424131 In th e 1970s, reports appeared in the literature of a nursery epidemic with a 40% neonatal mortality rate285 and of an extensive outbreak in a nursery for premature infants with 4% fatalities265; another report stated that among \"243 consecutive infants admitted to the hospital for EPEC diarrheal disease, none died of diarrheal disease per se.\"368 A significant proportion of the infants who died during or shortly after an episode of gastroenteritis already were compromised by preexisting disease233,283,330 or by congenital m a l f~r m a t i o n s,~~ at the time they acquired their illness.", [["2099210", "CHEMICAL", 0, 7], ["fatalities", "DISEASE", 435, 445], ["diarrheal disease", "DISEASE", 542, 559], ["diarrheal disease", "DISEASE", 574, 591], ["gastroenteritis", "DISEASE", 691, 706], ["infants", "ORGANISM", 106, 113], ["infants", "ORGANISM", 419, 426], ["infants", "ORGANISM", 500, 507], ["infants", "ORGANISM", 636, 643], ["infants", "SPECIES", 106, 113], ["infants", "SPECIES", 419, 426], ["infants", "SPECIES", 500, 507], ["infants", "SPECIES", 636, 643], ["fatality rates", "TEST", 212, 226], ["premature infants", "PROBLEM", 409, 426], ["EPEC diarrheal disease", "PROBLEM", 537, 559], ["diarrheal disease", "PROBLEM", 574, 591], ["gastroenteritis", "PROBLEM", 691, 706], ["preexisting disease", "PROBLEM", 735, 754], ["extensive", "OBSERVATION_MODIFIER", 373, 382], ["outbreak", "OBSERVATION", 383, 391], ["diarrheal disease", "OBSERVATION", 542, 559], ["gastroenteritis", "OBSERVATION", 691, 706]]], ["These underlying pathologic conditions appear to exert a strongly unfavorable influence, probably by reducing the infant's ability to respond to the added stresses imposed by the gastrointestinal tract infection.", [["gastrointestinal tract", "ANATOMY", 179, 201], ["gastrointestinal tract infection", "DISEASE", 179, 211], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 179, 201], ["infant", "SPECIES", 114, 120], ["These underlying pathologic conditions", "PROBLEM", 0, 38], ["the gastrointestinal tract infection", "PROBLEM", 175, 211], ["pathologic", "OBSERVATION", 17, 27], ["gastrointestinal tract", "ANATOMY", 179, 201], ["infection", "OBSERVATION", 202, 211]]], ["Although prematurity is often mentioned as a factor predisposing to a fatal outcome, the overall mortality rate among premature infants with EPEC gastroenteritis has not differed significantly over the years from that recorded for termTherapyThe management of EPEC gastroenteritis should be directed primarily toward prevention or correction of problems caused by loss of fluids and electr01ytes.I~~ Most neonates have a relatively mild illness that can be treated with oral rehydration.", [["oral", "ANATOMY", 470, 474], ["prematurity", "DISEASE", 9, 20], ["EPEC gastroenteritis", "DISEASE", 141, 161], ["gastroenteritis", "DISEASE", 265, 280], ["loss of fluids", "DISEASE", 364, 378], ["infants", "ORGANISM", 128, 135], ["EPEC", "ORGANISM", 260, 264], ["electr01ytes", "GENE_OR_GENE_PRODUCT", 383, 395], ["neonates", "ORGANISM", 405, 413], ["oral", "ORGANISM_SUBDIVISION", 470, 474], ["infants", "SPECIES", 128, 135], ["EPEC", "SPECIES", 141, 145], ["EPEC", "SPECIES", 260, 264], ["prematurity", "PROBLEM", 9, 20], ["a fatal outcome", "PROBLEM", 68, 83], ["premature infants", "PROBLEM", 118, 135], ["EPEC gastroenteritis", "PROBLEM", 141, 161], ["Therapy", "TREATMENT", 235, 242], ["EPEC gastroenteritis", "PROBLEM", 260, 280], ["problems", "PROBLEM", 345, 353], ["loss of fluids", "PROBLEM", 364, 378], ["electr01ytes", "TREATMENT", 383, 395], ["a relatively mild illness", "PROBLEM", 419, 444], ["oral rehydration", "TREATMENT", 470, 486], ["prematurity", "OBSERVATION", 9, 20], ["gastroenteritis", "OBSERVATION", 146, 161], ["EPEC gastroenteritis", "OBSERVATION", 260, 280], ["mild", "OBSERVATION_MODIFIER", 432, 436], ["illness", "OBSERVATION", 437, 444]]], ["Infants who appear toxic, those with voluminous diarrhea and persistent vomiting, and those with increasing weight loss should be hospitalized for observation and treatment with parenteral fluids and careful maintenance of fluid and electrolyte balance and possibly with antimicrobial therapy.", [["fluid", "ANATOMY", 223, 228], ["diarrhea", "DISEASE", 48, 56], ["vomiting", "DISEASE", 72, 80], ["weight loss", "DISEASE", 108, 119], ["Infants", "ORGANISM", 0, 7], ["fluid", "ORGANISM_SUBSTANCE", 223, 228], ["Infants", "SPECIES", 0, 7], ["voluminous diarrhea", "PROBLEM", 37, 56], ["persistent vomiting", "PROBLEM", 61, 80], ["increasing weight loss", "PROBLEM", 97, 119], ["treatment", "TREATMENT", 163, 172], ["parenteral fluids", "TREATMENT", 178, 195], ["careful maintenance of fluid and electrolyte balance", "TREATMENT", 200, 252], ["antimicrobial therapy", "TREATMENT", 271, 292], ["toxic", "OBSERVATION_MODIFIER", 19, 24], ["persistent", "OBSERVATION_MODIFIER", 61, 71], ["vomiting", "OBSERVATION", 72, 80]]], ["Clinical studies suggest that slow nasogastric infusion of an elemental diet can be valuable in treating infants who have intractable diarrhea that is unresponsive to standard modes of therapy.", [["nasogastric", "ANATOMY", 35, 46], ["diarrhea", "DISEASE", 134, 142], ["infants", "ORGANISM", 105, 112], ["infants", "SPECIES", 105, 112], ["Clinical studies", "TEST", 0, 16], ["slow nasogastric infusion", "TREATMENT", 30, 55], ["an elemental diet", "TREATMENT", 59, 76], ["intractable diarrhea", "PROBLEM", 122, 142], ["therapy", "TREATMENT", 185, 192], ["intractable", "OBSERVATION_MODIFIER", 122, 133], ["diarrhea", "OBSERVATION", 134, 142]]], ["369 There is no evidence that the use of proprietary formulas containing kaolin or pectin is effective in reducing the number of diarrheal stools in neonates with gastroenteritis.", [["kaolin", "CHEMICAL", 73, 79], ["pectin", "CHEMICAL", 83, 89], ["diarrheal stools", "DISEASE", 129, 145], ["gastroenteritis", "DISEASE", 163, 178], ["kaolin", "CHEMICAL", 73, 79], ["kaolin", "SIMPLE_CHEMICAL", 73, 79], ["pectin", "SIMPLE_CHEMICAL", 83, 89], ["proprietary formulas", "TREATMENT", 41, 61], ["kaolin", "TREATMENT", 73, 79], ["pectin", "TREATMENT", 83, 89], ["diarrheal stools in neonates", "PROBLEM", 129, 157], ["gastroenteritis", "PROBLEM", 163, 178], ["no evidence", "UNCERTAINTY", 13, 24], ["number", "OBSERVATION_MODIFIER", 119, 125], ["diarrheal stools", "OBSERVATION", 129, 145], ["gastroenteritis", "OBSERVATION", 163, 178]]], ["Attempts to suppress the growth of enteric pathogens by feeding lactobacillus to the infant in the form of yogurt, powder, or granules have not been shown to be of value.370 A trial of cholestyramine in 15 newborns with EPEC gastroenteritis had no effect on the duration or severity of the diarrhea.265 The use of atropine-like drugs, paregoric, or loperamide to reduce intestinal motility or cramping should be avoided.", [["granules", "ANATOMY", 126, 134], ["intestinal", "ANATOMY", 370, 380], ["lactobacillus", "CHEMICAL", 64, 77], ["cholestyramine", "CHEMICAL", 185, 199], ["EPEC gastroenteritis", "DISEASE", 220, 240], ["diarrhea", "DISEASE", 290, 298], ["atropine", "CHEMICAL", 314, 322], ["paregoric", "CHEMICAL", 335, 344], ["loperamide", "CHEMICAL", 349, 359], ["cramping", "DISEASE", 393, 401], ["cholestyramine", "CHEMICAL", 185, 199], ["atropine", "CHEMICAL", 314, 322], ["loperamide", "CHEMICAL", 349, 359], ["lactobacillus", "SIMPLE_CHEMICAL", 64, 77], ["yogurt", "ORGANISM_SUBDIVISION", 107, 113], ["granules", "ORGANISM_SUBSTANCE", 126, 134], ["cholestyramine", "SIMPLE_CHEMICAL", 185, 199], ["newborns", "ORGANISM", 206, 214], ["atropine", "SIMPLE_CHEMICAL", 314, 322], ["paregoric", "SIMPLE_CHEMICAL", 335, 344], ["loperamide", "SIMPLE_CHEMICAL", 349, 359], ["intestinal", "ORGAN", 370, 380], ["infant", "SPECIES", 85, 91], ["EPEC", "SPECIES", 220, 224], ["enteric pathogens", "PROBLEM", 35, 52], ["feeding lactobacillus", "TREATMENT", 56, 77], ["powder", "TREATMENT", 115, 121], ["cholestyramine", "TREATMENT", 185, 199], ["EPEC gastroenteritis", "PROBLEM", 220, 240], ["the diarrhea", "PROBLEM", 286, 298], ["atropine", "TREATMENT", 314, 322], ["drugs", "TREATMENT", 328, 333], ["paregoric", "TREATMENT", 335, 344], ["loperamide", "TREATMENT", 349, 359], ["intestinal motility", "PROBLEM", 370, 389], ["cramping", "PROBLEM", 393, 401], ["growth", "OBSERVATION_MODIFIER", 25, 31], ["gastroenteritis", "OBSERVATION", 225, 240], ["diarrhea", "OBSERVATION", 290, 298], ["intestinal", "ANATOMY", 370, 380]]], ["Inhibition of peristalsis interferes with an efficient protective mechanism designed to rid the body of intestinal pathogens and may lead to fluid retention in the lumen of the bowel that may be sufficient to mask depletion of extracellular fluid and electrolytes.TherapyThe value of antimicrobial therapy in management of neonatal EPEC gastroenteritis, if any, is uncertain.", [["body", "ANATOMY", 96, 100], ["intestinal", "ANATOMY", 104, 114], ["fluid", "ANATOMY", 141, 146], ["lumen", "ANATOMY", 164, 169], ["bowel", "ANATOMY", 177, 182], ["extracellular fluid", "ANATOMY", 227, 246], ["EPEC gastroenteritis", "DISEASE", 332, 352], ["body", "ORGANISM_SUBDIVISION", 96, 100], ["intestinal", "ORGAN", 104, 114], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 169], ["bowel", "ORGAN", 177, 182], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 227, 240], ["fluid", "ORGANISM_SUBSTANCE", 241, 246], ["EPEC", "SPECIES", 332, 336], ["Inhibition of peristalsis", "PROBLEM", 0, 25], ["an efficient protective mechanism", "TREATMENT", 42, 75], ["intestinal pathogens", "PROBLEM", 104, 124], ["fluid retention in the lumen of the bowel", "PROBLEM", 141, 182], ["extracellular fluid and electrolytes", "TEST", 227, 263], ["Therapy", "TREATMENT", 264, 271], ["antimicrobial therapy", "TREATMENT", 284, 305], ["management", "TREATMENT", 309, 319], ["neonatal EPEC gastroenteritis", "PROBLEM", 323, 352], ["peristalsis", "OBSERVATION", 14, 25], ["intestinal", "ANATOMY", 104, 114], ["pathogens", "OBSERVATION", 115, 124], ["fluid retention", "OBSERVATION", 141, 156], ["lumen", "ANATOMY_MODIFIER", 164, 169], ["bowel", "ANATOMY", 177, 182], ["fluid", "OBSERVATION", 241, 246], ["antimicrobial therapy", "OBSERVATION", 284, 305], ["EPEC gastroenteritis", "OBSERVATION", 332, 352]]], ["There are no adequately controlled studies defining the benefits of any antibiotic in eliminating EPEC from the gastrointestinal tract, reducing the risk of cross-infection in community or nursery outbreaks, or modifymg the severity of the illness.", [["gastrointestinal tract", "ANATOMY", 112, 134], ["EPEC from the gastrointestinal tract", "DISEASE", 98, 134], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 112, 134], ["EPEC", "SPECIES", 98, 102], ["any antibiotic", "TREATMENT", 68, 82], ["cross-infection", "PROBLEM", 157, 172], ["the illness", "PROBLEM", 236, 247], ["no", "UNCERTAINTY", 10, 12], ["gastrointestinal tract", "ANATOMY", 112, 134], ["cross-infection", "OBSERVATION", 157, 172], ["illness", "OBSERVATION", 240, 247]]], ["Proponents of the use of antimicrobial agents have based their claims for efficacy on anecdotal observations or comparative studies.245 Nonetheless, several clinical investigations have provided sufficient information to guide the physician faced with the dilemma of deciding whether to treat an individual infant or an entire nursery population suffering from EPEC diarrheal disease.", [["diarrheal disease", "DISEASE", 366, 383], ["infant", "SPECIES", 307, 313], ["antimicrobial agents", "TREATMENT", 25, 45], ["anecdotal observations", "TEST", 86, 108], ["comparative studies", "TEST", 112, 131], ["EPEC diarrheal disease", "PROBLEM", 361, 383], ["EPEC", "OBSERVATION_MODIFIER", 361, 365], ["diarrheal disease", "OBSERVATION", 366, 383]]], ["It should be emphasized, however, that these guidelines must be considered tentative until rigidly controlled, double-blind studies have established the efficacy of antibiotics on a more rational and scientific basis.TherapyOral therapy with n e o m y~i n ,'~ appears to be effective in rapidly reducing the number of susceptible EPEC organisms in the stool of infected infants.", [["stool", "ANATOMY", 352, 357], ["TherapyOral", "CHEMICAL", 217, 228], ["TherapyOral", "SIMPLE_CHEMICAL", 217, 228], ["'~", "SIMPLE_CHEMICAL", 257, 259], ["EPEC", "ORGANISM", 330, 334], ["stool", "ORGANISM_SUBSTANCE", 352, 357], ["infants", "ORGANISM", 370, 377], ["infants", "SPECIES", 370, 377], ["EPEC", "SPECIES", 330, 334], ["blind studies", "TEST", 118, 131], ["antibiotics", "TREATMENT", 165, 176], ["TherapyOral therapy", "TREATMENT", 217, 236], ["susceptible EPEC organisms", "PROBLEM", 318, 344], ["stool", "OBSERVATION", 352, 357], ["infected", "OBSERVATION", 361, 369]]], ["Studies comparing the responses of infants treated orally with ne' gentamicin:65 p~l p y x i n :~~ or kanamy' with the responses of infants receiving supportive therapy alone have shown that complete eradication of EPEC occurs more rapidly in those receiving an antimicrobial agent.", [["gentamicin", "CHEMICAL", 67, 77], ["EPEC", "DISEASE", 215, 219], ["gentamicin", "CHEMICAL", 67, 77], ["infants", "ORGANISM", 35, 42], ["ne' gentamicin", "SIMPLE_CHEMICAL", 63, 77], ["infants", "ORGANISM", 132, 139], ["EPEC", "ORGANISM", 215, 219], ["infants", "SPECIES", 35, 42], ["infants", "SPECIES", 132, 139], ["EPEC", "SPECIES", 215, 219], ["Studies", "TEST", 0, 7], ["ne' gentamicin", "TREATMENT", 63, 77], ["kanamy'", "PROBLEM", 102, 109], ["supportive therapy", "TREATMENT", 150, 168], ["EPEC", "PROBLEM", 215, 219], ["an antimicrobial agent", "TREATMENT", 259, 281]]], ["In most cases, stool cultures are free of EPEC 2 to 4 days after the start of therapy.2459363 Bacteriologic failure, defined as continued isolation of organisms during or after a course of an antimicrobial agent, can be expected to occur in 15% to 30% of patients?45s265 Such relapses generally are not associated with a recurrence of ~y m p t.", [["stool cultures", "ANATOMY", 15, 29], ["2459363", "CHEMICAL", 86, 93], ["stool cultures", "CELL", 15, 29], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["EPEC", "SPECIES", 42, 46], ["stool cultures", "TEST", 15, 29], ["EPEC", "PROBLEM", 42, 46], ["therapy", "TREATMENT", 78, 85], ["Bacteriologic failure", "PROBLEM", 94, 115], ["organisms", "PROBLEM", 151, 160], ["an antimicrobial agent", "TREATMENT", 189, 211], ["failure", "OBSERVATION", 108, 115]]], ["Even afebrile, well-appearing children with Salmonella gastroenteritis have been documented to have bacteremia that persists for several days.535 Although infants with bacteremia may have spontaneous resolution without therapy:36 a sufficient number develop complications to warrant empirical antimicrobial therapy when bacteremia is suspected.", [["Salmonella gastroenteritis", "DISEASE", 44, 70], ["bacteremia", "DISEASE", 100, 110], ["bacteremia", "DISEASE", 168, 178], ["bacteremia", "DISEASE", 320, 330], ["children", "ORGANISM", 30, 38], ["infants", "ORGANISM", 155, 162], ["children", "SPECIES", 30, 38], ["Salmonella gastroenteritis", "SPECIES", 44, 70], ["infants", "SPECIES", 155, 162], ["Salmonella gastroenteritis", "SPECIES", 44, 70], ["afebrile", "PROBLEM", 5, 13], ["Salmonella gastroenteritis", "PROBLEM", 44, 70], ["bacteremia", "PROBLEM", 100, 110], ["bacteremia", "PROBLEM", 168, 178], ["therapy", "TREATMENT", 219, 226], ["empirical antimicrobial therapy", "TREATMENT", 283, 314], ["bacteremia", "PROBLEM", 320, 330], ["gastroenteritis", "OBSERVATION", 55, 70], ["bacteremia", "OBSERVATION", 100, 110], ["bacteremia", "OBSERVATION", 168, 178], ["bacteremia", "OBSERVATION", 320, 330]]], ["The frequency of complications is highest in the first month of life.", [["complications", "PROBLEM", 17, 30], ["complications", "OBSERVATION", 17, 30], ["highest", "OBSERVATION_MODIFIER", 34, 41]]], ["Meningitis is the most feared complication of bacteremic Salmonella disease.", [["Meningitis", "DISEASE", 0, 10], ["Salmonella disease", "DISEASE", 57, 75], ["Salmonella", "SPECIES", 57, 67], ["Meningitis", "PROBLEM", 0, 10], ["bacteremic Salmonella disease", "PROBLEM", 46, 75], ["most feared", "OBSERVATION_MODIFIER", 18, 29], ["bacteremic", "OBSERVATION_MODIFIER", 46, 56], ["Salmonella disease", "OBSERVATION", 57, 75]]], ["Between 50% and 75% of all cases of nontyphoidal Salmonella meningitis occur in the first 4 months of life.537 The serotypes associated with neonatal meningitis (S. typhimurium, S. heidelberg, S. enteritidis, S. saint-Paul, S. newport, and S. panama)497 are serotypes frequently associated with bacteremia.", [["meningitis", "DISEASE", 60, 70], ["neonatal meningitis", "DISEASE", 141, 160], ["bacteremia", "DISEASE", 295, 305], ["nontyphoidal Salmonella", "ORGANISM", 36, 59], ["S. typhimurium", "ORGANISM", 162, 176], ["S. heidelberg", "ORGANISM", 178, 191], ["S. enteritidis", "ORGANISM", 193, 207], ["S. saint-Paul", "ORGANISM", 209, 222], ["S. newport", "ORGANISM", 224, 234], ["S. panama", "ORGANISM", 240, 249], ["S. typhimurium", "SPECIES", 162, 176], ["S. heidelberg", "SPECIES", 178, 191], ["S. enteritidis", "SPECIES", 193, 207], ["S. saint", "SPECIES", 209, 217], ["S. newport", "SPECIES", 224, 234], ["S. panama", "SPECIES", 240, 249], ["S. typhimurium", "SPECIES", 162, 176], ["S. heidelberg", "SPECIES", 178, 191], ["S. enteritidis", "SPECIES", 193, 207], ["S. saint-Paul, S. newport", "SPECIES", 209, 234], ["S. panama", "SPECIES", 240, 249], ["nontyphoidal Salmonella meningitis", "PROBLEM", 36, 70], ["The serotypes", "PROBLEM", 111, 124], ["neonatal meningitis", "PROBLEM", 141, 160], ["S. enteritidis", "PROBLEM", 193, 207], ["serotypes", "PROBLEM", 258, 267], ["bacteremia", "PROBLEM", 295, 305], ["nontyphoidal Salmonella", "OBSERVATION", 36, 59], ["meningitis", "OBSERVATION", 60, 70], ["meningitis", "OBSERVATION", 150, 160], ["bacteremia", "OBSERVATION", 295, 305]]], ["Meningitis has a high mortality rate, in part because of the high relapse rates.", [["Meningitis", "DISEASE", 0, 10], ["Meningitis", "PROBLEM", 0, 10], ["a high mortality rate", "PROBLEM", 15, 36], ["the high relapse rates", "PROBLEM", 57, 79], ["high", "OBSERVATION_MODIFIER", 17, 21], ["high", "OBSERVATION_MODIFIER", 61, 65], ["relapse", "OBSERVATION", 66, 73]]], ["Relapse has been reported in up to 64% of ca' In some studies, more than 90% of patients with meningitis have died,539 although more typically, 30% to 60% of infants die.540~ reported, only 2 were in the first year of life.", [["Relapse", "DISEASE", 0, 7], ["meningitis", "DISEASE", 94, 104], ["patients", "ORGANISM", 80, 88], ["infants", "ORGANISM", 158, 165], ["patients", "SPECIES", 80, 88], ["infants", "SPECIES", 158, 165], ["some studies", "TEST", 49, 61], ["meningitis", "PROBLEM", 94, 104], ["meningitis", "OBSERVATION", 94, 104]]], ["In areas where typhoid fever is still endemic, systematic search for infants with enteric fever has failed to find many cases.", [["typhoid fever", "DISEASE", 15, 28], ["enteric fever", "DISEASE", 82, 95], ["infants", "ORGANISM", 69, 76], ["infants", "SPECIES", 69, 76], ["typhoid fever", "PROBLEM", 15, 28], ["enteric fever", "PROBLEM", 82, 95], ["typhoid", "OBSERVATION", 15, 22]]], ["The few infections with S. typhi documented in children in the first year of life often present as a brief nondescript \"viral syndrome\" or as p n e~r n o n i t i s ?~ Blood cultures should be obtained as a routine part of evaluation of neonates with suspected or documented Salmonella infection.", [["Blood cultures", "ANATOMY", 167, 181], ["infections", "DISEASE", 8, 18], ["S. typhi", "DISEASE", 24, 32], ["viral syndrome", "DISEASE", 120, 134], ["Salmonella infection", "DISEASE", 274, 294], ["S. typhi", "ORGANISM", 24, 32], ["children", "ORGANISM", 47, 55], ["Blood", "ORGANISM_SUBSTANCE", 167, 172], ["neonates", "ORGANISM", 236, 244], ["S. typhi", "SPECIES", 24, 32], ["children", "SPECIES", 47, 55], ["S. typhi", "SPECIES", 24, 32], ["Salmonella", "SPECIES", 274, 284], ["The few infections", "PROBLEM", 0, 18], ["S. typhi", "PROBLEM", 24, 32], ["a brief nondescript \"viral syndrome", "PROBLEM", 99, 134], ["Blood cultures", "TEST", 167, 181], ["evaluation", "TEST", 222, 232], ["neonates", "PROBLEM", 236, 244], ["Salmonella infection", "PROBLEM", 274, 294], ["few", "OBSERVATION_MODIFIER", 4, 7], ["infections", "OBSERVATION", 8, 18], ["viral syndrome", "OBSERVATION", 120, 134], ["Salmonella infection", "OBSERVATION", 274, 294]]], ["Ill neonates with Salmonella infection should have a cerebrospinal fluid examination performed.", [["cerebrospinal fluid", "ANATOMY", 53, 72], ["Salmonella infection", "DISEASE", 18, 38], ["neonates", "ORGANISM", 4, 12], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 53, 72], ["Salmonella", "SPECIES", 18, 28], ["Ill neonates", "PROBLEM", 0, 12], ["Salmonella infection", "PROBLEM", 18, 38], ["a cerebrospinal fluid examination", "TEST", 51, 84], ["Salmonella", "OBSERVATION_MODIFIER", 18, 28], ["infection", "OBSERVATION", 29, 38]]], ["Bone marrow cultures also may be indicated when enteric fever is suspected.", [["Bone marrow cultures", "ANATOMY", 0, 20], ["enteric fever", "DISEASE", 48, 61], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Bone marrow cultures", "TEST", 0, 20], ["enteric fever", "PROBLEM", 48, 61], ["fever", "OBSERVATION", 56, 61]]], ["There are no consistent abnormalities in the white blood cell count.", [["white blood cell", "ANATOMY", 45, 61], ["white blood cell", "CELL", 45, 61], ["consistent abnormalities", "PROBLEM", 13, 37], ["the white blood cell count", "TEST", 41, 67], ["no consistent", "UNCERTAINTY", 10, 23], ["abnormalities", "OBSERVATION", 24, 37], ["white blood", "ANATOMY", 45, 56], ["cell count", "OBSERVATION", 57, 67]]], ["Serologic studies are not helpful in establishing the diagnosis, although antibodies to and flagellar antigens487 develop in many infected newborns.DiagnosisIf an outbreak of salmonellosis is suspected, further characterization of the organism is imperative?64 Determination of somatic and flagellar antigens to characterize the specific serotype may be critical to investigation of an outbreak.", [["somatic", "ANATOMY", 278, 285], ["salmonellosis", "DISEASE", 175, 188], ["flagellar antigens487", "GENE_OR_GENE_PRODUCT", 92, 113], ["newborns", "ORGANISM", 139, 147], ["flagellar antigens", "GENE_OR_GENE_PRODUCT", 290, 308], ["antibodies", "PROTEIN", 74, 84], ["flagellar antigens487", "PROTEIN", 92, 113], ["flagellar antigens", "PROTEIN", 290, 308], ["salmonellosis", "SPECIES", 175, 188], ["Serologic studies", "TEST", 0, 17], ["antibodies", "TEST", 74, 84], ["flagellar antigens", "TEST", 92, 110], ["many infected newborns", "PROBLEM", 125, 147], ["salmonellosis", "PROBLEM", 175, 188], ["the organism", "PROBLEM", 231, 243], ["somatic and flagellar antigens", "PROBLEM", 278, 308], ["an outbreak", "PROBLEM", 383, 394], ["many", "OBSERVATION_MODIFIER", 125, 129], ["infected", "OBSERVATION", 130, 138], ["outbreak", "OBSERVATION_MODIFIER", 163, 171], ["salmonellosis", "OBSERVATION", 175, 188], ["outbreak", "OBSERVATION", 386, 394]]], ["When the serotype found during investigation of an outbreak is a common one (e.g., S. typhimurium), antimicrobial resistance testing475,565 and use of molecular techniques such as plasmid chara~~ can be helpful in determining whether a single-strain, common-source outbreak is in progress. and ampicillin or amoxicillin versus placebo.572 In contrast to these studies, data suggest that there may be a role for quinolone antibiotics in adults and ~h i l d r e n , but these drugs are not approved for use in neonates, and resistance has been en'~ Because these studies have few data as to the risk-benefit ratio of therapy in the neonate, it is uncertain whether they should influence treatment decisions in neonates.", [["ampicillin", "CHEMICAL", 294, 304], ["amoxicillin", "CHEMICAL", 308, 319], ["quinolone", "CHEMICAL", 411, 420], ["ampicillin", "CHEMICAL", 294, 304], ["amoxicillin", "CHEMICAL", 308, 319], ["quinolone", "CHEMICAL", 411, 420], ["S. typhimurium", "ORGANISM", 83, 97], ["ampicillin", "SIMPLE_CHEMICAL", 294, 304], ["amoxicillin", "SIMPLE_CHEMICAL", 308, 319], ["quinolone", "SIMPLE_CHEMICAL", 411, 420], ["neonates", "ORGANISM", 508, 516], ["neonates", "ORGANISM", 708, 716], ["plasmid", "DNA", 180, 187], ["S. typhimurium", "SPECIES", 83, 97], ["S. typhimurium", "SPECIES", 83, 97], ["the serotype", "PROBLEM", 5, 17], ["antimicrobial resistance testing", "TEST", 100, 132], ["molecular techniques", "TREATMENT", 151, 171], ["plasmid chara", "TREATMENT", 180, 193], ["a single-strain", "PROBLEM", 234, 249], ["ampicillin", "TREATMENT", 294, 304], ["amoxicillin", "TREATMENT", 308, 319], ["placebo", "TREATMENT", 327, 334], ["these studies", "TEST", 354, 367], ["quinolone antibiotics", "TREATMENT", 411, 432], ["l d r e n", "TREATMENT", 452, 461], ["these drugs", "TREATMENT", 468, 479], ["these studies", "TEST", 555, 568], ["therapy", "TREATMENT", 615, 622]]], ["Studies that have included a small number of neonates suggest little benefit from antimicrobial therapy.47756835773578 However, because bacteremia is common in neonates, antimicrobial therapy for infants younger than 3 months who have Salmonella gastroenteritis often is recommended,532v533v561 especially if the infant appears toxic.", [["bacteremia", "DISEASE", 136, 146], ["Salmonella gastroenteritis", "DISEASE", 235, 261], ["neonates", "ORGANISM", 45, 53], ["infants", "ORGANISM", 196, 203], ["infants", "SPECIES", 196, 203], ["infant", "SPECIES", 313, 319], ["Studies", "TEST", 0, 7], ["a small number of neonates", "PROBLEM", 27, 53], ["antimicrobial therapy", "TREATMENT", 82, 103], ["bacteremia", "PROBLEM", 136, 146], ["antimicrobial therapy", "TREATMENT", 170, 191], ["Salmonella gastroenteritis", "PROBLEM", 235, 261], ["toxic", "PROBLEM", 328, 333], ["small", "OBSERVATION_MODIFIER", 29, 34], ["little benefit", "OBSERVATION_MODIFIER", 62, 76], ["antimicrobial therapy", "OBSERVATION", 82, 103], ["bacteremia", "OBSERVATION", 136, 146], ["gastroenteritis", "OBSERVATION", 246, 261], ["toxic", "OBSERVATION_MODIFIER", 328, 333]]], ["Premature infants and those who have other significant debilitating conditions also should probably be treated.", [["infants", "ORGANISM", 10, 17], ["infants", "SPECIES", 10, 17], ["Premature infants", "PROBLEM", 0, 17], ["other significant debilitating conditions", "PROBLEM", 37, 78], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["debilitating", "OBSERVATION", 55, 67]]], ["The duration of therapy is debatable but should probably be no more than 3 to 5 days if the infant is not seriously ill and if blood cultures are sterile.", [["blood cultures", "ANATOMY", 127, 141], ["infant", "ORGANISM", 92, 98], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["therapy", "TREATMENT", 16, 23], ["blood cultures", "TEST", 127, 141]]], ["If toxicity, clinical deterioration, or documented bacteremia complicates gastroenteritis, prolonged treatment is indicated.", [["toxicity", "DISEASE", 3, 11], ["bacteremia", "DISEASE", 51, 61], ["gastroenteritis", "DISEASE", 74, 89], ["toxicity", "PROBLEM", 3, 11], ["clinical deterioration", "PROBLEM", 13, 35], ["documented bacteremia", "PROBLEM", 40, 61], ["gastroenteritis", "PROBLEM", 74, 89], ["prolonged treatment", "TREATMENT", 91, 110], ["bacteremia", "OBSERVATION", 51, 61]]], ["Even with antimicrobial therapy, some infants develop complications.", [["infants", "ORGANISM", 38, 45], ["infants", "SPECIES", 38, 45], ["antimicrobial therapy", "TREATMENT", 10, 31], ["complications", "PROBLEM", 54, 67], ["antimicrobial therapy", "OBSERVATION", 10, 31], ["complications", "OBSERVATION", 54, 67]]], ["The relatively low risk of extraintestinal dissemination must be balanced against the well-documented risk of prolonging the carrier state.", [["extraintestinal dissemination", "PROBLEM", 27, 56], ["low", "OBSERVATION_MODIFIER", 15, 18], ["extraintestinal", "OBSERVATION_MODIFIER", 27, 42], ["dissemination", "OBSERVATION", 43, 56]]], ["For infants who develop chronic diarrhea and malnutrition, hyperalimentation may be required; the role of antimicrobial agents in this setting is unclear.", [["diarrhea", "DISEASE", 32, 40], ["malnutrition", "DISEASE", 45, 57], ["hyperalimentation", "DISEASE", 59, 76], ["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["chronic diarrhea", "PROBLEM", 24, 40], ["malnutrition", "PROBLEM", 45, 57], ["hyperalimentation", "TREATMENT", 59, 76], ["antimicrobial agents", "TREATMENT", 106, 126], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["diarrhea", "OBSERVATION", 32, 40], ["malnutrition", "OBSERVATION", 45, 57]]], ["The infant with typhoid fever should be treated with an antimicrobial agent; relapses sometimes occur after therapy.TherapyColonized healthy infants discovered by stool cultures during evaluation of an outbreak ought to be isolated but probably should not receive antimicrobial therapy.", [["stool cultures", "ANATOMY", 163, 177], ["typhoid fever", "DISEASE", 16, 29], ["infant", "ORGANISM", 4, 10], ["infants", "ORGANISM", 141, 148], ["infant", "SPECIES", 4, 10], ["infants", "SPECIES", 141, 148], ["typhoid fever", "PROBLEM", 16, 29], ["an antimicrobial agent", "TREATMENT", 53, 75], ["relapses", "PROBLEM", 77, 85], ["therapy", "TREATMENT", 108, 115], ["stool cultures", "TEST", 163, 177], ["evaluation", "TEST", 185, 195], ["antimicrobial therapy", "TREATMENT", 264, 285]]], ["Such infants should be discharged from the nursery as early as possible and followed carefully as outpatients.TherapyAntimicrobial treatment of neonates who have documented extraintestinal dissemination must be prolonged.", [["TherapyAntimicrobial", "CHEMICAL", 110, 130], ["infants", "ORGANISM", 5, 12], ["TherapyAntimicrobial", "SIMPLE_CHEMICAL", 110, 130], ["neonates", "ORGANISM", 144, 152], ["infants", "SPECIES", 5, 12], ["TherapyAntimicrobial treatment of neonates", "TREATMENT", 110, 152], ["extraintestinal dissemination", "PROBLEM", 173, 202], ["extraintestinal", "ANATOMY", 173, 188], ["dissemination", "OBSERVATION", 189, 202]]], ["Bacteremia without localization is generally treated with at least a 10-day course of therapy.", [["Bacteremia", "DISEASE", 0, 10], ["Bacteremia", "PROBLEM", 0, 10], ["therapy", "TREATMENT", 86, 93]]], ["Therapy for Salmonella meningitis must be given for at least 4 weeks to lessen the risk of relapse.", [["Salmonella meningitis", "DISEASE", 12, 33], ["Salmonella", "SPECIES", 12, 22], ["Therapy", "TREATMENT", 0, 7], ["Salmonella meningitis", "PROBLEM", 12, 33], ["relapse", "PROBLEM", 91, 98], ["meningitis", "OBSERVATION", 23, 33], ["relapse", "OBSERVATION", 91, 98]]], ["About three fourths of patients who have relapses have been treated for three weeks or less?37 Similar to meningitis, treatment for osteomyelitis must be prolonged to be adequate.", [["meningitis", "DISEASE", 106, 116], ["osteomyelitis", "DISEASE", 132, 145], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["meningitis", "PROBLEM", 106, 116], ["treatment", "TREATMENT", 118, 127], ["osteomyelitis", "PROBLEM", 132, 145], ["meningitis", "OBSERVATION", 106, 116], ["osteomyelitis", "OBSERVATION", 132, 145]]], ["Although cures have been reported with 3 weeks of therapy, 4 to 6 weeks of therapy is recommended.TherapyIn vitro susceptibility data for Salmonella isolates must be interpreted with caution.", [["Salmonella", "SPECIES", 138, 148], ["therapy", "TREATMENT", 50, 57], ["therapy", "TREATMENT", 75, 82], ["vitro susceptibility data", "TEST", 108, 133], ["Salmonella isolates", "PROBLEM", 138, 157]]], ["The aminoglycosides show good in vitro activity but poor clinical efficacy, perhaps because of the low pH of the phagolysosome.", [["aminoglycosides", "CHEMICAL", 4, 19], ["aminoglycosides", "CHEMICAL", 4, 19], ["aminoglycosides", "SIMPLE_CHEMICAL", 4, 19], ["phagolysosome", "CELLULAR_COMPONENT", 113, 126], ["The aminoglycosides", "TREATMENT", 0, 19], ["the low pH of the phagolysosome", "PROBLEM", 95, 126], ["good", "OBSERVATION_MODIFIER", 25, 29], ["vitro activity", "OBSERVATION", 33, 47]]], ["Aminoglycosides have poor activity in an acid environment.", [["Aminoglycosides", "CHEMICAL", 0, 15], ["Aminoglycosides", "CHEMICAL", 0, 15], ["Aminoglycosides", "SIMPLE_CHEMICAL", 0, 15], ["Aminoglycosides", "TREATMENT", 0, 15], ["poor", "OBSERVATION_MODIFIER", 21, 25], ["activity", "OBSERVATION_MODIFIER", 26, 34], ["acid environment", "OBSERVATION", 41, 57]]], ["The stability of some drugs in this acid environment also may explain in vitro and in vivo disparities.", [["some drugs", "TREATMENT", 17, 27], ["this acid environment", "TREATMENT", 31, 52], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["some", "OBSERVATION_MODIFIER", 17, 21], ["drugs", "OBSERVATION", 22, 27]]], ["The intracellular localization and survival of Salmonella within phagocytic cells also presumably explains the relapses encountered with virtually every regimen.", [["intracellular", "ANATOMY", 4, 17], ["phagocytic cells", "ANATOMY", 65, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["phagocytic cells", "CELL", 65, 81], ["phagocytic cells", "CELL_TYPE", 65, 81], ["Salmonella", "SPECIES", 47, 57], ["The intracellular localization", "TEST", 0, 30], ["Salmonella within phagocytic cells", "PROBLEM", 47, 81], ["the relapses", "PROBLEM", 107, 119], ["virtually every regimen", "TREATMENT", 137, 160], ["phagocytic cells", "OBSERVATION", 65, 81], ["relapses", "OBSERVATION", 111, 119]]], ["Resistance to antibiotics has long been a problem with Salmonella i n f e c t i~n .~' There has been a steady increase in resistance to Salmonella in the United States over the last 20 years.581 With the emergence of typhimurium type DT 104, resistance to ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline has increased from 0.6% in 1979 and 1980 to 34% in 1996.", [["typhimurium type DT 104", "CHEMICAL", 217, 240], ["ampicillin", "CHEMICAL", 256, 266], ["chloramphenicol", "CHEMICAL", 268, 283], ["streptomycin", "CHEMICAL", 285, 297], ["sulfonamides", "CHEMICAL", 299, 311], ["tetracycline", "CHEMICAL", 317, 329], ["ampicillin", "CHEMICAL", 256, 266], ["chloramphenicol", "CHEMICAL", 268, 283], ["streptomycin", "CHEMICAL", 285, 297], ["sulfonamides", "CHEMICAL", 299, 311], ["tetracycline", "CHEMICAL", 317, 329], ["typhimurium type DT 104", "ORGANISM", 217, 240], ["ampicillin", "SIMPLE_CHEMICAL", 256, 266], ["chloramphenicol", "SIMPLE_CHEMICAL", 268, 283], ["streptomycin", "SIMPLE_CHEMICAL", 285, 297], ["sulfonamides", "SIMPLE_CHEMICAL", 299, 311], ["tetracycline", "SIMPLE_CHEMICAL", 317, 329], ["Salmonella", "SPECIES", 136, 146], ["antibiotics", "TREATMENT", 14, 25], ["typhimurium type DT", "PROBLEM", 217, 236], ["ampicillin", "TREATMENT", 256, 266], ["chloramphenicol", "TREATMENT", 268, 283], ["streptomycin", "TREATMENT", 285, 297], ["sulfonamides", "TREATMENT", 299, 311], ["tetracycline", "TREATMENT", 317, 329], ["steady", "OBSERVATION_MODIFIER", 103, 109], ["increase", "OBSERVATION_MODIFIER", 110, 118], ["resistance", "OBSERVATION_MODIFIER", 122, 132], ["Salmonella", "OBSERVATION_MODIFIER", 136, 146]]], ["582 Resistance plasmids have been selected and transmitted, partly because therapy has been given for mild illness that should not have been treated566 and partly because of use of antibiotics in animal feeds.", [["plasmids", "ANATOMY", 15, 23], ["Resistance plasmids", "TREATMENT", 4, 23], ["therapy", "TREATMENT", 75, 82], ["mild illness", "PROBLEM", 102, 114], ["antibiotics", "TREATMENT", 181, 192], ["animal feeds", "TREATMENT", 196, 208]]], ["Resistance to chloramphenicol and ampicillin has made trimethoprim-sulfamethoxazole increasingly important for the treatment of Salmonella infection in those patients who require therapy.", [["chloramphenicol", "CHEMICAL", 14, 29], ["ampicillin", "CHEMICAL", 34, 44], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 54, 83], ["Salmonella infection", "DISEASE", 128, 148], ["chloramphenicol", "CHEMICAL", 14, 29], ["ampicillin", "CHEMICAL", 34, 44], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 54, 83], ["chloramphenicol", "SIMPLE_CHEMICAL", 14, 29], ["ampicillin", "SIMPLE_CHEMICAL", 34, 44], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 54, 83], ["Salmonella", "ORGANISM", 128, 138], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["Salmonella", "SPECIES", 128, 138], ["chloramphenicol", "TREATMENT", 14, 29], ["ampicillin", "TREATMENT", 34, 44], ["trimethoprim", "TREATMENT", 54, 66], ["sulfamethoxazole", "TREATMENT", 67, 83], ["Salmonella infection", "PROBLEM", 128, 148], ["therapy", "TREATMENT", 179, 186], ["Salmonella infection", "OBSERVATION", 128, 148]]], ["However, with increasing resistance to all three of these agents in Asia?83 the Middle E~r o p e ,~~ Because the second-generation cephalosporins, such as cefuroxime, are less active in vitro than the third-generation cephalosporins and are not consistently clinically effective, they should not be Data suggest that cefoperazone may sterilize blood and cause patients with typhoid fever to become afebrile more rapidly than with chl~~ perhaps because cefoperazone is excreted into bile in high concent r a t i o n~~ The third-generation cephalosporins may have higher cure and lower relapse rates than ampicillin or chloramphenicol in children with Salmonella meningitis.", [["blood", "ANATOMY", 344, 349], ["bile", "ANATOMY", 482, 486], ["cephalosporins", "CHEMICAL", 131, 145], ["cefuroxime", "CHEMICAL", 155, 165], ["cephalosporins", "CHEMICAL", 218, 232], ["cefoperazone", "CHEMICAL", 317, 329], ["typhoid fever", "DISEASE", 374, 387], ["cefoperazone", "CHEMICAL", 452, 464], ["cephalosporins", "CHEMICAL", 538, 552], ["ampicillin", "CHEMICAL", 603, 613], ["chloramphenicol", "CHEMICAL", 617, 632], ["Salmonella meningitis", "DISEASE", 650, 671], ["cephalosporins", "CHEMICAL", 131, 145], ["cefuroxime", "CHEMICAL", 155, 165], ["cephalosporins", "CHEMICAL", 218, 232], ["cefoperazone", "CHEMICAL", 317, 329], ["cefoperazone", "CHEMICAL", 452, 464], ["cephalosporins", "CHEMICAL", 538, 552], ["ampicillin", "CHEMICAL", 603, 613], ["chloramphenicol", "CHEMICAL", 617, 632], ["cephalosporins", "SIMPLE_CHEMICAL", 131, 145], ["cefuroxime", "SIMPLE_CHEMICAL", 155, 165], ["cephalosporins", "SIMPLE_CHEMICAL", 218, 232], ["cefoperazone", "SIMPLE_CHEMICAL", 317, 329], ["blood", "ORGANISM_SUBSTANCE", 344, 349], ["patients", "ORGANISM", 360, 368], ["cefoperazone", "SIMPLE_CHEMICAL", 452, 464], ["bile", "ORGAN", 482, 486], ["cephalosporins", "SIMPLE_CHEMICAL", 538, 552], ["ampicillin", "SIMPLE_CHEMICAL", 603, 613], ["chloramphenicol", "SIMPLE_CHEMICAL", 617, 632], ["children", "ORGANISM", 636, 644], ["patients", "SPECIES", 360, 368], ["children", "SPECIES", 636, 644], ["Salmonella", "SPECIES", 650, 660], ["increasing resistance", "PROBLEM", 14, 35], ["these agents", "TREATMENT", 52, 64], ["the second-generation cephalosporins", "TREATMENT", 109, 145], ["cefuroxime", "TREATMENT", 155, 165], ["the third-generation cephalosporins", "TREATMENT", 197, 232], ["cefoperazone", "TREATMENT", 317, 329], ["typhoid fever", "PROBLEM", 374, 387], ["afebrile", "PROBLEM", 398, 406], ["cefoperazone", "TREATMENT", 452, 464], ["The third-generation cephalosporins", "TREATMENT", 517, 552], ["lower relapse rates", "PROBLEM", 578, 597], ["ampicillin", "TREATMENT", 603, 613], ["chloramphenicol", "TREATMENT", 617, 632], ["Salmonella meningitis", "PROBLEM", 650, 671], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["resistance", "OBSERVATION", 25, 35], ["Middle", "ANATOMY_MODIFIER", 80, 86], ["bile", "ANATOMY", 482, 486], ["meningitis", "OBSERVATION", 661, 671]]], ["595 The doses of ampicillin, chloramphenicol, or cefotaxime used in infants with gastroenteritis pending results of blood cultures are the same as those used in treatment of sepsis.", [["blood cultures", "ANATOMY", 116, 130], ["ampicillin", "CHEMICAL", 17, 27], ["chloramphenicol", "CHEMICAL", 29, 44], ["cefotaxime", "CHEMICAL", 49, 59], ["gastroenteritis", "DISEASE", 81, 96], ["sepsis", "DISEASE", 174, 180], ["ampicillin", "CHEMICAL", 17, 27], ["chloramphenicol", "CHEMICAL", 29, 44], ["cefotaxime", "CHEMICAL", 49, 59], ["ampicillin", "SIMPLE_CHEMICAL", 17, 27], ["chloramphenicol", "SIMPLE_CHEMICAL", 29, 44], ["cefotaxime", "SIMPLE_CHEMICAL", 49, 59], ["infants", "ORGANISM", 68, 75], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["infants", "SPECIES", 68, 75], ["ampicillin", "TREATMENT", 17, 27], ["chloramphenicol", "TREATMENT", 29, 44], ["cefotaxime", "TREATMENT", 49, 59], ["gastroenteritis", "PROBLEM", 81, 96], ["blood cultures", "TEST", 116, 130], ["sepsis", "PROBLEM", 174, 180], ["sepsis", "OBSERVATION", 174, 180]]], ["Because of the risk of gray baby syndrome, chloramphenicol should not be used in neonates unless other effective agents are not available.", [["gray baby syndrome", "DISEASE", 23, 41], ["chloramphenicol", "CHEMICAL", 43, 58], ["chloramphenicol", "CHEMICAL", 43, 58], ["chloramphenicol", "SIMPLE_CHEMICAL", 43, 58], ["neonates", "ORGANISM", 81, 89], ["gray baby syndrome", "PROBLEM", 23, 41], ["chloramphenicol", "TREATMENT", 43, 58]]], ["Trimethoprim-sulfamethoxazole, although useful in older children and adults, is not used in neonates because of the risk of kernicterus.", [["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["kernicterus", "DISEASE", 124, 135], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 0, 29], ["Trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 0, 29], ["children", "ORGANISM", 56, 64], ["neonates", "ORGANISM", 92, 100], ["children", "SPECIES", 56, 64], ["Trimethoprim", "TREATMENT", 0, 12], ["sulfamethoxazole", "TREATMENT", 13, 29], ["kernicterus", "PROBLEM", 124, 135], ["kernicterus", "OBSERVATION", 124, 135]]], ["Nosocomial infection with strains of Salmonella resistant to multiple antibiotics, including third-generation cephalosporins, has emerged as a problem in South America.", [["infection", "DISEASE", 11, 20], ["Salmonella", "CHEMICAL", 37, 47], ["cephalosporins", "CHEMICAL", 110, 124], ["cephalosporins", "CHEMICAL", 110, 124], ["Salmonella", "SPECIES", 37, 47], ["Nosocomial infection", "PROBLEM", 0, 20], ["Salmonella", "PROBLEM", 37, 47], ["multiple antibiotics", "TREATMENT", 61, 81], ["third-generation cephalosporins", "TREATMENT", 93, 124], ["infection", "OBSERVATION", 11, 20], ["Salmonella resistant", "OBSERVATION", 37, 57], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["antibiotics", "OBSERVATION", 70, 81]]], ["580 Nonantibiotic interventions are important in the control of Salmonella infections.", [["Salmonella infections", "DISEASE", 64, 85], ["Salmonella", "ORGANISM", 64, 74], ["Salmonella", "SPECIES", 64, 74], ["Nonantibiotic interventions", "TREATMENT", 4, 31], ["Salmonella infections", "PROBLEM", 64, 85], ["Salmonella infections", "OBSERVATION", 64, 85]]], ["Limited data suggest that intravenous immune globulin (IGIV) (500 mg/kg on days 1,2,3, and 8 of therapy) along with antibiotic therapy may decrease the risk of bacteremia and death in preterm infants with Salmonella ga~~PreventionEarly recognition and intervention in nursery outbreaks of Salmonella are crucial to control.", [["intravenous", "ANATOMY", 26, 37], ["immune globulin", "CHEMICAL", 38, 53], ["IGIV", "CHEMICAL", 55, 59], ["bacteremia", "DISEASE", 160, 170], ["death", "DISEASE", 175, 180], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 37], ["immune globulin", "GENE_OR_GENE_PRODUCT", 38, 53], ["IGIV", "SIMPLE_CHEMICAL", 55, 59], ["infants", "ORGANISM", 192, 199], ["infants", "SPECIES", 192, 199], ["Salmonella", "SPECIES", 289, 299], ["intravenous immune globulin (IGIV)", "TREATMENT", 26, 60], ["therapy", "TREATMENT", 96, 103], ["antibiotic therapy", "TREATMENT", 116, 134], ["bacteremia", "PROBLEM", 160, 170], ["death", "PROBLEM", 175, 180], ["Salmonella ga", "TREATMENT", 205, 218], ["intervention", "TREATMENT", 252, 264], ["Salmonella", "PROBLEM", 289, 299], ["bacteremia", "OBSERVATION", 160, 170]]], ["When a neonate develops salmonellosis, a search for other infants who have been in the same nursery should be undertaken.", [["salmonellosis", "DISEASE", 24, 37], ["neonate", "ORGANISM", 7, 14], ["infants", "ORGANISM", 58, 65], ["infants", "SPECIES", 58, 65], ["salmonellosis", "PROBLEM", 24, 37], ["salmonellosis", "OBSERVATION", 24, 37]]], ["When two or more cases are recognized, environmental cultures, cultures of all infants, cohorting and contact isolation of infected infants, rigorous enforcement of hand hygiene, early discharge of infected infants, and thorough cleaning of all possible fomites in the nursery and delivery rooms are important elements of control.", [["hand", "ANATOMY", 165, 169], ["infants", "ORGANISM", 79, 86], ["infants", "ORGANISM", 132, 139], ["hand", "ORGANISM_SUBDIVISION", 165, 169], ["infants", "ORGANISM", 207, 214], ["infants", "SPECIES", 79, 86], ["infants", "SPECIES", 132, 139], ["infants", "SPECIES", 207, 214], ["environmental cultures", "TEST", 39, 61], ["cultures", "TEST", 63, 71], ["hand hygiene", "TREATMENT", 165, 177]]], ["Cultures of nursery personnel are likely to be helpful in the unusual situation of an S. typhi outbreak in which a chronic carrier may be among the caretakers.", [["S. typhi", "ORGANISM", 86, 94], ["S. typhi", "SPECIES", 86, 94], ["S. typhi", "SPECIES", 86, 94], ["Cultures", "TEST", 0, 8], ["an S. typhi outbreak", "PROBLEM", 83, 103]]], ["Culture of health care personnel during outbreaks of salmonellosis caused by other Salmonella species is debatable, although often recommended.", [["salmonellosis", "DISEASE", 53, 66], ["salmonellosis", "SPECIES", 53, 66], ["salmonellosis", "PROBLEM", 53, 66], ["other Salmonella species", "PROBLEM", 77, 101], ["salmonellosis", "OBSERVATION", 53, 66], ["Salmonella species", "OBSERVATION", 83, 101]]], ["Data suggest that nurses infected with Salmonella rarely infect patients in the hospital setting.597 The fact that nursing personnel are sometimes found to be colonized during nursery outmay be a result rather than a cause of those epidemics.PreventionThe potential role of vaccines in control of neonatal disease is minimal.", [["neonatal disease", "DISEASE", 297, 313], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["Salmonella", "SPECIES", 39, 49], ["Salmonella", "PROBLEM", 39, 49], ["those epidemics", "PROBLEM", 226, 241], ["vaccines", "TREATMENT", 274, 282], ["neonatal disease", "PROBLEM", 297, 313], ["neonatal disease", "OBSERVATION", 297, 313], ["minimal", "OBSERVATION_MODIFIER", 317, 324]]], ["For the vast number of non-S. ryphi serotypes, there is no prospect for an immunization strategy.", [["non-S. ryphi", "ORGANISM", 23, 35], ["non-S. ryphi", "SPECIES", 23, 35], ["non-S. ryphi", "SPECIES", 23, 35], ["non-S. ryphi serotypes", "PROBLEM", 23, 45], ["an immunization strategy", "TREATMENT", 72, 96], ["ryphi serotypes", "OBSERVATION", 30, 45], ["no prospect for", "UNCERTAINTY", 56, 71]]], ["Multiple doses of the commercially available oral live attenuated vaccine (Ty2la; Vivotif, Berna), has been shown in Chilean schoolchildren to reduce typhoid fever cases by more than 70%.598,599 However, the vaccine is not recommended for persons younger than 6 years, in part because immunogenicity of Ty2la is age dependent; children younger than 24 months fail to respond with development of immunity!\"", [["oral", "ANATOMY", 45, 49], ["Ty2la", "CHEMICAL", 75, 80], ["typhoid fever", "DISEASE", 150, 163], ["oral", "ORGANISM_SUBDIVISION", 45, 49], ["schoolchildren", "ORGANISM", 125, 139], ["persons", "ORGANISM", 239, 246], ["Ty2la", "GENE_OR_GENE_PRODUCT", 303, 308], ["children", "ORGANISM", 327, 335], ["schoolchildren", "SPECIES", 125, 139], ["persons", "SPECIES", 239, 246], ["children", "SPECIES", 327, 335], ["oral live attenuated vaccine", "TREATMENT", 45, 73], ["typhoid fever cases", "PROBLEM", 150, 169]]], ["Vi capsular polysaccharide vaccine is available for children older than 2 years and is effective in a single dose.", [["Vi capsular polysaccharide", "GENE_OR_GENE_PRODUCT", 0, 26], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Vi capsular polysaccharide vaccine", "TREATMENT", 0, 34]]], ["Whether some degree of protection of infants could The virulence of shigellae has been studied extensively since their recognition as major pathogens at the beginning of the 20th century.", [["shigellae", "CHEMICAL", 68, 77], ["infants", "ORGANISM", 37, 44], ["shigellae", "CANCER", 68, 77], ["infants", "SPECIES", 37, 44], ["shigellae", "PROBLEM", 68, 77], ["shigellae", "OBSERVATION", 68, 77], ["major", "OBSERVATION_MODIFIER", 134, 139], ["pathogens", "OBSERVATION", 140, 149]]], ["The major determinants of virulence are encoded by a 120-to 140-MDa p l a~m i d .", [["virulence", "PROBLEM", 26, 35]]], ["This plasmid, which is found in all virulent shigellae, encodes the synthesis of proteins that are required for invasion of mammalian cells and for the vigorous inflammatory response that is characteristic of the d i s e a~e . older children,@' and adults.661 Although this complication of toxic megacolon is rare, it appears to be more common in neonates than in older individuals.", [["plasmid", "ANATOMY", 5, 12], ["mammalian cells", "ANATOMY", 124, 139], ["toxic megacolon", "DISEASE", 290, 305], ["shigellae", "CANCER", 45, 54], ["mammalian cells", "CELL", 124, 139], ["children", "ORGANISM", 233, 241], ["megacolon", "PATHOLOGICAL_FORMATION", 296, 305], ["neonates", "ORGANISM", 347, 355], ["mammalian cells", "CELL_TYPE", 124, 139], ["children", "SPECIES", 233, 241], ["This plasmid", "PROBLEM", 0, 12], ["all virulent shigellae", "PROBLEM", 32, 54], ["the synthesis of proteins", "PROBLEM", 64, 89], ["invasion of mammalian cells", "PROBLEM", 112, 139], ["the vigorous inflammatory response", "PROBLEM", 148, 182], ["toxic megacolon", "PROBLEM", 290, 305], ["all", "OBSERVATION_MODIFIER", 32, 35], ["virulent", "OBSERVATION_MODIFIER", 36, 44], ["shigellae", "OBSERVATION", 45, 54], ["mammalian cells", "OBSERVATION", 124, 139], ["vigorous", "OBSERVATION_MODIFIER", 152, 160], ["inflammatory", "OBSERVATION", 161, 173], ["toxic", "OBSERVATION_MODIFIER", 290, 295], ["megacolon", "OBSERVATION", 296, 305]]], ["Bronchopneumonia may complicate the course of shigellosis, but shigellae are rarely isolated from lungs or tracheal secretions.\"2 The syndrome of sudden death in the setting of extreme toxicity with hyperpyrexia and convulsions but without dehydration or sepsis (i.e., Ekiri is rare in neonates.", [["shigellae", "ANATOMY", 63, 72], ["lungs", "ANATOMY", 98, 103], ["tracheal secretions", "ANATOMY", 107, 126], ["Bronchopneumonia", "DISEASE", 0, 16], ["shigellosis", "DISEASE", 46, 57], ["sudden death", "DISEASE", 146, 158], ["toxicity", "DISEASE", 185, 193], ["hyperpyrexia", "DISEASE", 199, 211], ["convulsions", "DISEASE", 216, 227], ["dehydration", "DISEASE", 240, 251], ["sepsis", "DISEASE", 255, 261], ["shigellae", "CANCER", 63, 72], ["lungs", "ORGAN", 98, 103], ["Bronchopneumonia", "PROBLEM", 0, 16], ["shigellosis", "PROBLEM", 46, 57], ["shigellae", "PROBLEM", 63, 72], ["tracheal secretions", "PROBLEM", 107, 126], ["The syndrome", "PROBLEM", 130, 142], ["sudden death", "PROBLEM", 146, 158], ["extreme toxicity", "PROBLEM", 177, 193], ["hyperpyrexia", "PROBLEM", 199, 211], ["convulsions", "PROBLEM", 216, 227], ["dehydration", "PROBLEM", 240, 251], ["sepsis", "PROBLEM", 255, 261], ["rare in neonates", "PROBLEM", 278, 294], ["shigellosis", "OBSERVATION", 46, 57], ["lungs", "ANATOMY", 98, 103], ["tracheal", "ANATOMY", 107, 115], ["secretions", "OBSERVATION", 116, 126], ["syndrome", "OBSERVATION", 134, 142], ["sudden", "OBSERVATION_MODIFIER", 146, 152], ["death", "OBSERVATION", 153, 158], ["extreme", "OBSERVATION_MODIFIER", 177, 184], ["toxicity", "OBSERVATION", 185, 193], ["hyperpyrexia", "OBSERVATION", 199, 211], ["without", "UNCERTAINTY", 232, 239], ["sepsis", "OBSERVATION", 255, 261]]], ["In the nonbacteremic child, other extraintestinal foci of infection, including ~a g i n a~ availability of medical care, antibiotic resistance of many shigellae, the frequency of sepsis, and the higher frequency of S Examination of stool for leukocytes as an indication of colitis is useful in support of the clinical suspicion of shigellosis.", [["foci", "ANATOMY", 50, 54], ["stool", "ANATOMY", 232, 237], ["leukocytes", "ANATOMY", 242, 252], ["infection", "DISEASE", 58, 67], ["shigellae", "DISEASE", 151, 160], ["sepsis", "DISEASE", 179, 185], ["colitis", "DISEASE", 273, 280], ["shigellosis", "DISEASE", 331, 342], ["child", "ORGANISM", 21, 26], ["stool", "ORGANISM_SUBSTANCE", 232, 237], ["leukocytes", "CELL", 242, 252], ["colitis", "PATHOLOGICAL_FORMATION", 273, 280], ["leukocytes", "CELL_TYPE", 242, 252], ["child", "SPECIES", 21, 26], ["other extraintestinal foci of infection", "PROBLEM", 28, 67], ["medical care", "TREATMENT", 107, 119], ["antibiotic resistance", "TREATMENT", 121, 142], ["many shigellae", "PROBLEM", 146, 160], ["sepsis", "PROBLEM", 179, 185], ["S Examination", "TEST", 215, 228], ["leukocytes", "PROBLEM", 242, 252], ["colitis", "PROBLEM", 273, 280], ["shigellosis", "PROBLEM", 331, 342], ["extraintestinal", "OBSERVATION_MODIFIER", 34, 49], ["foci", "OBSERVATION", 50, 54], ["infection", "OBSERVATION", 58, 67], ["sepsis", "OBSERVATION", 179, 185], ["colitis", "OBSERVATION", 273, 280], ["shigellosis", "OBSERVATION", 331, 342]]], ["The white blood cell count and differential count also are used as supporting evidence for the diagnosis.Clinical ManifestationsLeukemoid reactions (white blood cells > 50,000/mm3) occur in almost 15% of children with S. dysenteriae serotype 1 but in less than 2% of children with other ~h i g e l l a e .", [["white blood cell", "ANATOMY", 4, 20], ["white blood cells", "ANATOMY", 149, 166], ["white blood cell", "CELL", 4, 20], ["white blood cells", "CELL", 149, 166], ["children", "ORGANISM", 204, 212], ["S. dysenteriae serotype 1", "ORGANISM", 218, 243], ["children", "ORGANISM", 267, 275], ["children", "SPECIES", 204, 212], ["S. dysenteriae serotype", "SPECIES", 218, 241], ["children", "SPECIES", 267, 275], ["S. dysenteriae serotype 1", "SPECIES", 218, 243], ["The white blood cell count", "TEST", 0, 26], ["differential count", "TEST", 31, 49], ["Clinical Manifestations", "PROBLEM", 105, 128], ["Leukemoid reactions", "PROBLEM", 128, 147], ["white blood cells", "TEST", 149, 166], ["S. dysenteriae serotype", "PROBLEM", 218, 241]]], ["Leukemoid reactions are more frequent in infants than in older ' Even when the total white blood cell count is not dramatically elevated, there may be a striking left shift.", [["white blood cell", "ANATOMY", 85, 101], ["infants", "ORGANISM", 41, 48], ["blood cell", "CELL", 91, 101], ["infants", "SPECIES", 41, 48], ["Leukemoid reactions", "PROBLEM", 0, 19], ["the total white blood cell count", "TEST", 75, 107], ["dramatically elevated", "PROBLEM", 115, 136], ["a striking left shift", "PROBLEM", 151, 172], ["not", "UNCERTAINTY", 111, 114], ["dramatically", "OBSERVATION_MODIFIER", 115, 127], ["elevated", "OBSERVATION", 128, 136], ["may be", "UNCERTAINTY", 144, 150], ["striking", "OBSERVATION_MODIFIER", 153, 161], ["left", "ANATOMY_MODIFIER", 162, 166], ["shift", "OBSERVATION", 167, 172]]], ["Almost 30% of children with shigellosis have greater than 25% bands on the differential cell Few reports address the white blood cell count in newborns, but those that do suggest that normal or low rather than elevated counts are more common.", [["cell", "ANATOMY", 88, 92], ["white blood cell", "ANATOMY", 117, 133], ["shigellosis", "DISEASE", 28, 39], ["children", "ORGANISM", 14, 22], ["cell", "CELL", 88, 92], ["white blood cell", "CELL", 117, 133], ["newborns", "ORGANISM", 143, 151], ["children", "SPECIES", 14, 22], ["shigellosis", "PROBLEM", 28, 39], ["the white blood cell count", "TEST", 113, 139], ["elevated counts", "PROBLEM", 210, 225], ["normal", "OBSERVATION", 184, 190]]], ["Although serum and fecal antibodies develop to lipopolysaccharides and the virulence plasmid-associated polypeptide~ serologic studies are not useful in the diagnosis of shigellosis.", [["serum", "ANATOMY", 9, 14], ["fecal", "ANATOMY", 19, 24], ["shigellosis", "DISEASE", 170, 181], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["fecal", "ORGANISM_SUBSTANCE", 19, 24], ["serum and fecal antibodies", "PROTEIN", 9, 35], ["virulence plasmid", "DNA", 75, 92], ["serum", "TEST", 9, 14], ["fecal antibodies", "TEST", 19, 35], ["lipopolysaccharides", "TEST", 47, 66], ["the virulence plasmid", "TEST", 71, 92], ["serologic studies", "TEST", 117, 134], ["shigellosis", "PROBLEM", 170, 181], ["fecal antibodies", "ANATOMY", 19, 35], ["shigellosis", "OBSERVATION", 170, 181]]], ["PCR can identify Shigella and EIEC in feces.678 Colonoscopy typically shows inflammatory changes that are most severe in the distal segments of Therapy Because dehydration is particularly common in neonatal shigellosis, attention to correction of fluid and electrolyte disturbances is always the first concern when the illness is suspected.", [["EIEC", "ANATOMY", 30, 34], ["feces", "ANATOMY", 38, 43], ["fluid", "ANATOMY", 247, 252], ["dehydration", "DISEASE", 160, 171], ["shigellosis", "DISEASE", 207, 218], ["illness", "DISEASE", 319, 326], ["EIEC", "CANCER", 30, 34], ["feces", "ORGANISM_SUBSTANCE", 38, 43], ["fluid", "ORGANISM_SUBSTANCE", 247, 252], ["PCR", "TEST", 0, 3], ["Shigella", "PROBLEM", 17, 25], ["EIEC in feces", "PROBLEM", 30, 43], ["Colonoscopy", "TEST", 48, 59], ["inflammatory changes", "PROBLEM", 76, 96], ["Therapy", "TREATMENT", 144, 151], ["dehydration", "PROBLEM", 160, 171], ["neonatal shigellosis", "PROBLEM", 198, 218], ["fluid and electrolyte disturbances", "PROBLEM", 247, 281], ["the illness", "PROBLEM", 315, 326], ["Shigella", "OBSERVATION_MODIFIER", 17, 25], ["EIEC", "OBSERVATION_MODIFIER", 30, 34], ["feces", "OBSERVATION_MODIFIER", 38, 43], ["inflammatory", "OBSERVATION", 76, 88], ["most severe", "OBSERVATION_MODIFIER", 106, 117], ["distal segments", "ANATOMY_MODIFIER", 125, 140], ["shigellosis", "OBSERVATION", 207, 218], ["fluid", "OBSERVATION", 247, 252]]], ["Although debate continues over the indications for antimicrobial therapy in the patient with shigellosis, the benefits of therapy generally appear to outweigh the risks.", [["shigellosis", "DISEASE", 93, 104], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["antimicrobial therapy", "TREATMENT", 51, 72], ["shigellosis", "PROBLEM", 93, 104], ["therapy", "TREATMENT", 122, 129], ["shigellosis", "OBSERVATION", 93, 104]]], ["The chief disadvantages of antimicrobial therapy include cost, drug toxicity, and emergence of antibiotic-resistant shigellae.", [["toxicity", "DISEASE", 68, 76], ["shigellae", "DISEASE", 116, 125], ["shigellae", "CANCER", 116, 125], ["antimicrobial therapy", "TREATMENT", 27, 48], ["cost", "TREATMENT", 57, 61], ["drug toxicity", "PROBLEM", 63, 76], ["antibiotic", "TREATMENT", 95, 105], ["resistant shigellae", "PROBLEM", 106, 125]]], ["Because of the self-limited nature of shigellosis, it has been argued that less severe illness should not be treated.", [["shigellosis", "DISEASE", 38, 49], ["shigellosis", "PROBLEM", 38, 49], ["less severe illness", "PROBLEM", 75, 94], ["shigellosis", "OBSERVATION", 38, 49], ["less", "OBSERVATION_MODIFIER", 75, 79], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["illness", "OBSERVATION", 87, 94]]], ["However, children can feel quite ill during the typical bout of shigellosis, and appropriate antimicrobial therapy shortens the duration of illness and eliminates shigellae from stool, decreasing secondary spread.", [["shigellae", "ANATOMY", 163, 172], ["stool", "ANATOMY", 178, 183], ["shigellosis", "DISEASE", 64, 75], ["illness", "DISEASE", 140, 147], ["children", "ORGANISM", 9, 17], ["shigellae", "CANCER", 163, 172], ["stool", "ORGANISM_SUBSTANCE", 178, 183], ["children", "SPECIES", 9, 17], ["shigellosis", "PROBLEM", 64, 75], ["appropriate antimicrobial therapy", "TREATMENT", 81, 114], ["illness", "PROBLEM", 140, 147], ["shigellae from stool", "PROBLEM", 163, 183], ["decreasing secondary spread", "PROBLEM", 185, 212], ["shigellosis", "OBSERVATION", 64, 75], ["decreasing", "OBSERVATION_MODIFIER", 185, 195], ["secondary spread", "OBSERVATION", 196, 212]]], ["Complications are probably decreased by antibiotics.", [["antibiotics", "TREATMENT", 40, 51], ["probably", "UNCERTAINTY", 18, 26], ["decreased", "OBSERVATION_MODIFIER", 27, 36]]], ["Given the high mortality rates of neonatal shigellosis, therapy should not be withheld.Clinical ManifestationsThe empirical choice of an antimicrobial agent is dictated by susceptibility data for strains circulating in the community at the time the patient's infection occurs.", [["shigellosis", "DISEASE", 43, 54], ["infection", "DISEASE", 259, 268], ["patient", "ORGANISM", 249, 256], ["patient", "SPECIES", 249, 256], ["neonatal shigellosis", "PROBLEM", 34, 54], ["therapy", "TREATMENT", 56, 63], ["Clinical Manifestations", "PROBLEM", 87, 110], ["an antimicrobial agent", "TREATMENT", 134, 156], ["strains", "PROBLEM", 196, 203], ["the patient's infection", "PROBLEM", 245, 268], ["neonatal", "OBSERVATION_MODIFIER", 34, 42], ["shigellosis", "OBSERVATION", 43, 54], ["infection", "OBSERVATION", 259, 268]]], ["Multiresistant shigellae complicate the choice of empirical therapy before availability of susceptibility data for the patient's isolate.", [["shigellae", "DISEASE", 15, 24], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["Multiresistant shigellae", "PROBLEM", 0, 24], ["empirical therapy", "TREATMENT", 50, 67], ["susceptibility data", "TEST", 91, 110], ["the patient's isolate", "TREATMENT", 115, 136]]], ["Plasmid-encoded resistance (R factors) for multiple antibiotics has been observed frequently in S. dysenteriae serotype 1 outbreaks682 and with other ''~ Antimicrobial resistance patterns fluctuate from year to year in a given locale.686 However, despite the guesswork involved, early preemptive therapy is indicated when an illness is strongly suggestive of shigellosis.", [["shigellosis", "DISEASE", 359, 370], ["R factors", "GENE_OR_GENE_PRODUCT", 28, 37], ["S. dysenteriae serotype 1", "ORGANISM", 96, 121], ["R factors", "PROTEIN", 28, 37], ["S. dysenteriae serotype", "SPECIES", 96, 119], ["S. dysenteriae serotype 1", "SPECIES", 96, 121], ["Plasmid", "TREATMENT", 0, 7], ["encoded resistance (R factors", "PROBLEM", 8, 37], ["multiple antibiotics", "TREATMENT", 43, 63], ["Antimicrobial resistance patterns", "PROBLEM", 154, 187], ["early preemptive therapy", "TREATMENT", 279, 303], ["an illness", "PROBLEM", 322, 332], ["shigellosis", "PROBLEM", 359, 370], ["resistance", "OBSERVATION_MODIFIER", 16, 26], ["strongly suggestive of", "UNCERTAINTY", 336, 358], ["shigellosis", "OBSERVATION", 359, 370]]], ["Cefa~ furazolidone,688 amo' kanam' and ~e f a m a n d o l e all are relatively ineffective agents.Clinical ManifestationsThe optimal duration of therapy is debatable.", [["Cefa", "CHEMICAL", 0, 4], ["furazolidone", "CHEMICAL", 6, 18], ["furazolidone", "CHEMICAL", 6, 18], ["amo' kanam", "CHEMICAL", 23, 33], ["Cefa", "SIMPLE_CHEMICAL", 0, 4], ["furazolidone", "SIMPLE_CHEMICAL", 6, 18], ["Cefa", "TREATMENT", 0, 4], ["furazolidone", "TREATMENT", 6, 18], ["Clinical Manifestations", "PROBLEM", 98, 121], ["therapy", "TREATMENT", 145, 152]]], ["Studies in children older than 2 years and in adults suggest that singledose regimens may be as effective in relieving symptoms as courses given for 5 days.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["singledose regimens", "TREATMENT", 66, 85], ["relieving symptoms", "PROBLEM", 109, 127]]], ["The single-dose regimens generally are not as effective in eliminating shigellae from the feces as are the longer courses.", [["feces", "ANATOMY", 90, 95], ["shigellae", "CANCER", 71, 80], ["feces", "ORGANISM_SUBSTANCE", 90, 95], ["The single-dose regimens", "TREATMENT", 0, 24], ["shigellae", "PROBLEM", 71, 80], ["feces", "OBSERVATION", 90, 95]]], ["A third-generation cephalosporin, such as ceftriaxone, may be the best empirical choice.", [["cephalosporin", "CHEMICAL", 19, 32], ["ceftriaxone", "CHEMICAL", 42, 53], ["cephalosporin", "CHEMICAL", 19, 32], ["ceftriaxone", "CHEMICAL", 42, 53], ["cephalosporin", "SIMPLE_CHEMICAL", 19, 32], ["ceftriaxone", "SIMPLE_CHEMICAL", 42, 53], ["A third-generation cephalosporin", "TREATMENT", 0, 32], ["ceftriaxone", "TREATMENT", 42, 53]]], ["Optimal doses for newborns with shigellosis have not been established.", [["shigellosis", "DISEASE", 32, 43], ["newborns", "ORGANISM", 18, 26], ["shigellosis", "PROBLEM", 32, 43], ["shigellosis", "OBSERVATION", 32, 43]]], ["Trimethoprim at a dose of lOmg/kg/day (maximum, 160 mg/day) and sulfamethoxazole at a dose of 50 mg/kg/day (maximum, 800 mg/day) in two divided doses for a total of 5 days are recommended for the older child if the organism is s~s c e p t i b l e .", [["Trimethoprim", "CHEMICAL", 0, 12], ["sulfamethoxazole", "CHEMICAL", 64, 80], ["Trimethoprim", "CHEMICAL", 0, 12], ["sulfamethoxazole", "CHEMICAL", 64, 80], ["Trimethoprim", "SIMPLE_CHEMICAL", 0, 12], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 64, 80], ["child", "ORGANISM", 202, 207], ["Trimethoprim", "TREATMENT", 0, 12], ["sulfamethoxazole", "TREATMENT", 64, 80], ["the organism", "TEST", 211, 223]]], ["6~ If the condition of the infant does not permit orally administration, the drug usually is divided into three doses given intravenously over 1Clinical ManifestationsAmpicillin at a dose of 100 mg/kg/day in four divided doses taken orally for 5 days may be used if the strain is susceptible.", [["orally", "ANATOMY", 50, 56], ["Ampicillin", "CHEMICAL", 167, 177], ["Ampicillin", "CHEMICAL", 167, 177], ["infant", "ORGANISM", 27, 33], ["Ampicillin", "SIMPLE_CHEMICAL", 167, 177], ["infant", "SPECIES", 27, 33], ["orally administration", "TREATMENT", 50, 71], ["1Clinical ManifestationsAmpicillin", "TREATMENT", 143, 177], ["the strain", "PROBLEM", 266, 276]]], ["676 For the rare newborn who acquires shigellosis, appropriate therapy often is delayed until susceptibility data are available.", [["shigellosis", "DISEASE", 38, 49], ["shigellosis", "PROBLEM", 38, 49], ["appropriate therapy", "TREATMENT", 51, 70], ["susceptibility data", "TEST", 94, 113], ["shigellosis", "OBSERVATION", 38, 49]]], ["This occurs because shigellosis is so rare in newborns that it is almost never the presumptive diagnosis of the child with watery or bloody diarrhea.", [["shigellosis", "DISEASE", 20, 31], ["diarrhea", "DISEASE", 140, 148], ["newborns", "ORGANISM", 46, 54], ["child", "ORGANISM", 112, 117], ["watery", "ORGANISM_SUBDIVISION", 123, 129], ["shigellosis", "PROBLEM", 20, 31], ["watery or bloody diarrhea", "PROBLEM", 123, 148], ["shigellosis", "OBSERVATION", 20, 31]]], ["Although a sulfonamide is as efficacious as ampicillin when the infecting strain is sus~ sulfonamides are avoided in neonates because of concern about the potential risk of kernicterus.", [["sulfonamide", "CHEMICAL", 11, 22], ["ampicillin", "CHEMICAL", 44, 54], ["sus~ sulfonamides", "CHEMICAL", 84, 101], ["kernicterus", "DISEASE", 173, 184], ["sulfonamide", "CHEMICAL", 11, 22], ["ampicillin", "CHEMICAL", 44, 54], ["sulfonamides", "CHEMICAL", 89, 101], ["sulfonamide", "SIMPLE_CHEMICAL", 11, 22], ["ampicillin", "SIMPLE_CHEMICAL", 44, 54], ["sus~ sulfonamides", "SIMPLE_CHEMICAL", 84, 101], ["a sulfonamide", "TREATMENT", 9, 22], ["ampicillin", "TREATMENT", 44, 54], ["the infecting strain", "PROBLEM", 60, 80], ["sulfonamides", "TREATMENT", 89, 101], ["kernicterus", "PROBLEM", 173, 184], ["kernicterus", "OBSERVATION", 173, 184]]], ["The risk of empirical ampicillin therapy is that shigellae are frequently resistant to the drug; 50% of shigellae currently circulating in the United States are ampicillin resistant.6963697 For the neonate infected with ampicillin-resistant Shigella, there are few data on which to base a recommendation.", [["ampicillin", "CHEMICAL", 22, 32], ["shigellae", "CHEMICAL", 49, 58], ["shigellae", "CHEMICAL", 104, 113], ["ampicillin", "CHEMICAL", 161, 171], ["6963697", "CHEMICAL", 182, 189], ["ampicillin", "CHEMICAL", 220, 230], ["ampicillin", "CHEMICAL", 22, 32], ["ampicillin", "CHEMICAL", 161, 171], ["ampicillin", "CHEMICAL", 220, 230], ["ampicillin", "SIMPLE_CHEMICAL", 22, 32], ["shigellae", "SIMPLE_CHEMICAL", 49, 58], ["shigellae", "CANCER", 104, 113], ["ampicillin", "SIMPLE_CHEMICAL", 161, 171], ["ampicillin", "SIMPLE_CHEMICAL", 220, 230], ["empirical ampicillin therapy", "TREATMENT", 12, 40], ["shigellae", "PROBLEM", 49, 58], ["the drug", "TREATMENT", 87, 95], ["shigellae", "TREATMENT", 104, 113], ["ampicillin", "TREATMENT", 161, 171], ["ampicillin", "TREATMENT", 220, 230], ["resistant Shigella", "PROBLEM", 231, 249]]], ["Ceftriaxone is generally active against shigellae, but in the neonate, this drug can displace bilirubin-binding sites and elicit clinically significant cholestasis.", [["shigellae", "ANATOMY", 40, 49], ["Ceftriaxone", "CHEMICAL", 0, 11], ["bilirubin", "CHEMICAL", 94, 103], ["cholestasis", "DISEASE", 152, 163], ["Ceftriaxone", "CHEMICAL", 0, 11], ["bilirubin", "CHEMICAL", 94, 103], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["shigellae", "CELL", 40, 49], ["neonate", "ORGANISM", 62, 69], ["bilirubin", "SIMPLE_CHEMICAL", 94, 103], ["Ceftriaxone", "TREATMENT", 0, 11], ["shigellae", "PROBLEM", 40, 49], ["bilirubin", "TEST", 94, 103], ["binding sites", "PROBLEM", 104, 117], ["significant cholestasis", "PROBLEM", 140, 163], ["active", "OBSERVATION_MODIFIER", 25, 31], ["significant", "OBSERVATION_MODIFIER", 140, 151], ["cholestasis", "OBSERVATION", 152, 163]]], ["Data on children and adults suggest that clinical improvement occurs with c e f t r i a x~n e .~ After infection is introduced into a nursery, rotavirus probably will spread steadily and remain endemic until the nursery is closed to new admissions or nursing practices permit interruption of the cycle.1205 Exactly how the virus is introduced and transmitted is uncertain, although limited observations and experience with other types of enteric disease in maternity units suggest several possibilities.", [["infection", "DISEASE", 103, 112], ["rotavirus", "DISEASE", 143, 152], ["enteric disease", "DISEASE", 438, 453], ["children", "ORGANISM", 8, 16], ["rotavirus", "ORGANISM", 143, 152], ["children", "SPECIES", 8, 16], ["rotavirus", "SPECIES", 143, 152], ["infection", "PROBLEM", 103, 112], ["rotavirus", "PROBLEM", 143, 152], ["nursing practices", "TREATMENT", 251, 268], ["enteric disease", "PROBLEM", 438, 453], ["infection", "OBSERVATION", 103, 112], ["virus", "OBSERVATION", 323, 328], ["enteric", "ANATOMY", 438, 445], ["disease", "OBSERVATION", 446, 453]]], ["The early appearance of virus in stools of some neonates indicates that infection probably was acquired at delivery.", [["infection", "DISEASE", 72, 81], ["stools", "ORGANISM_SUBDIVISION", 33, 39], ["neonates", "ORGANISM", 48, 56], ["virus in stools", "PROBLEM", 24, 39], ["some neonates", "PROBLEM", 43, 56], ["infection", "PROBLEM", 72, 81], ["early", "OBSERVATION_MODIFIER", 4, 9], ["virus", "OBSERVATION", 24, 29], ["infection", "OBSERVATION", 72, 81]]], ["Virus particles can be detected on the first45v11s6 or second\"98 day of life in a significant number of infected infants.", [["Virus", "ORGANISM", 0, 5], ["infants", "ORGANISM", 113, 120], ["infants", "SPECIES", 113, 120], ["Virus particles", "PROBLEM", 0, 15], ["infected", "OBSERVATION", 104, 112]]], ["By day 3 or 4, most infected infants who will shed virus, with or without signs of illness, are doing so.117431186,1198 The large numbers of virus particles e x~r e t e d \"~~ suggest a fairly large and early oral inoculum.", [["oral", "ANATOMY", 208, 212], ["illness", "DISEASE", 83, 90], ["117431186,1198", "CHEMICAL", 105, 119], ["infants", "ORGANISM", 29, 36], ["oral", "ORGANISM_SUBDIVISION", 208, 212], ["infants", "SPECIES", 29, 36], ["illness", "PROBLEM", 83, 90], ["a fairly large and early oral inoculum", "PROBLEM", 183, 221], ["large", "OBSERVATION_MODIFIER", 124, 129], ["numbers", "OBSERVATION_MODIFIER", 130, 137], ["virus particles", "OBSERVATION", 141, 156], ["fairly", "OBSERVATION_MODIFIER", 185, 191], ["large", "OBSERVATION_MODIFIER", 192, 197], ["early", "OBSERVATION_MODIFIER", 202, 207], ["oral", "ANATOMY", 208, 212], ["inoculum", "OBSERVATION", 213, 221]]], ["It is unlikely that contamination from any source other than maternal feces could provide an inoculum large enough to cause infection by the second day.EpidemiologyTransfer of particles from infant to infant on the hands of nursing and medical staff is probably the most important means of viral spread.", [["feces", "ANATOMY", 70, 75], ["infection", "DISEASE", 124, 133], ["feces", "ORGANISM_SUBDIVISION", 70, 75], ["infant", "SPECIES", 191, 197], ["infant", "SPECIES", 201, 207], ["contamination", "PROBLEM", 20, 33], ["maternal feces", "PROBLEM", 61, 75], ["an inoculum", "PROBLEM", 90, 101], ["infection", "PROBLEM", 124, 133], ["viral spread", "PROBLEM", 290, 302], ["unlikely", "UNCERTAINTY", 6, 14], ["contamination", "OBSERVATION", 20, 33], ["infection", "OBSERVATION", 124, 133], ["viral spread", "OBSERVATION", 290, 302]]], ["With 10' to 10\" viral particles usually present in 1 g of stool, the hands of personnel easily could become contaminated after infection is introduced into a nursery.", [["stool", "ANATOMY", 58, 63], ["infection", "DISEASE", 127, 136], ["stool", "ORGANISM_SUBSTANCE", 58, 63], ["viral particles", "PROBLEM", 16, 31], ["infection", "PROBLEM", 127, 136], ["stool", "OBSERVATION", 58, 63], ["infection", "OBSERVATION", 127, 136]]], ["There are numerous reports of nosocomial and daycare center rotavirus gastroenteritis outbreaks that attest179~1202-1203to the ease with which this agent spreads through a hospital or institutional setting.'Io8 Admission of a symptomatic child usually is the initiating event, although transfer of a neonate with inapparent infection from one ward to another also has been incriminated.", [["gastroenteritis", "DISEASE", 70, 85], ["infection", "DISEASE", 324, 333], ["child", "ORGANISM", 238, 243], ["neonate", "ORGANISM", 300, 307], ["nosocomial", "PROBLEM", 30, 40], ["rotavirus gastroenteritis", "PROBLEM", 60, 85], ["inapparent infection", "PROBLEM", 313, 333], ["nosocomial", "OBSERVATION", 30, 40], ["symptomatic", "OBSERVATION_MODIFIER", 226, 237], ["infection", "OBSERVATION", 324, 333]]], ["The most important factors influencing the incidence of rotavirus diarrhea in a nursery are the proximity to other newborns and the frequency of handling.1187 During a 4-month study, infants cared for by nursing staff and kept in communal nurseries experienced three epidemics of diarrhea with attack rates between 20% and 50%.", [["diarrhea", "DISEASE", 66, 74], ["diarrhea", "DISEASE", 280, 288], ["rotavirus", "ORGANISM", 56, 65], ["newborns", "ORGANISM", 115, 123], ["infants", "ORGANISM", 183, 190], ["infants", "SPECIES", 183, 190], ["rotavirus", "SPECIES", 56, 65], ["rotavirus diarrhea", "PROBLEM", 56, 74], ["diarrhea", "PROBLEM", 280, 288], ["attack rates", "TEST", 294, 306], ["rotavirus", "OBSERVATION_MODIFIER", 56, 65], ["diarrhea", "OBSERVATION", 66, 74]]], ["During the same period, only 2% of infants rooming in with their mothers became ill, even though they had frequent contact with adult relatives and siblings.179~1202-1203There is no clear evidence of airborne or droplet infection originating in the upper respiratory tract or spread by aerosolization of diarrheal fluid while diapers are changed.", [["upper respiratory tract", "ANATOMY", 249, 272], ["ill", "DISEASE", 80, 83], ["infection", "DISEASE", 220, 229], ["diarrheal", "DISEASE", 304, 313], ["infants", "ORGANISM", 35, 42], ["mothers", "ORGANISM", 65, 72], ["upper respiratory", "ORGANISM_SUBDIVISION", 249, 266], ["tract", "ORGANISM_SUBDIVISION", 267, 272], ["fluid", "ORGANISM_SUBSTANCE", 314, 319], ["infants", "SPECIES", 35, 42], ["airborne", "PROBLEM", 200, 208], ["droplet infection", "PROBLEM", 212, 229], ["the upper respiratory tract", "PROBLEM", 245, 272], ["diarrheal fluid", "PROBLEM", 304, 319], ["no clear evidence of", "UNCERTAINTY", 179, 199], ["airborne", "OBSERVATION", 200, 208], ["droplet", "OBSERVATION_MODIFIER", 212, 219], ["infection", "OBSERVATION", 220, 229], ["upper", "ANATOMY_MODIFIER", 249, 254], ["respiratory tract", "ANATOMY", 255, 272], ["spread", "OBSERVATION_MODIFIER", 276, 282], ["aerosolization", "OBSERVATION_MODIFIER", 286, 300], ["diarrheal", "OBSERVATION_MODIFIER", 304, 313], ["fluid", "OBSERVATION", 314, 319]]], ["Indirect evidence of airborne transmission includes the high infection rate in closed settings, the isolation of the virus from respiratory secretions,Izo6 and the experimental observation of transmission by aerosol droplets in mice.'207 However, the respiratory isolation achieved by placin an evidence indicates that transplacental or ascending intrauterine infection occurs.", [["respiratory secretions", "ANATOMY", 128, 150], ["respiratory", "ANATOMY", 251, 262], ["intrauterine", "ANATOMY", 347, 359], ["infection", "DISEASE", 61, 70], ["intrauterine infection", "DISEASE", 347, 369], ["Izo6", "GENE_OR_GENE_PRODUCT", 151, 155], ["mice", "ORGANISM", 228, 232], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 347, 359], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 228, 232], ["airborne transmission", "PROBLEM", 21, 42], ["the high infection rate", "PROBLEM", 52, 75], ["the virus", "PROBLEM", 113, 122], ["respiratory secretions", "PROBLEM", 128, 150], ["Izo6", "TREATMENT", 151, 155], ["aerosol droplets", "TREATMENT", 208, 224], ["the respiratory isolation", "TREATMENT", 247, 272], ["ascending intrauterine infection", "PROBLEM", 337, 369], ["evidence of", "UNCERTAINTY", 9, 20], ["airborne transmission", "OBSERVATION", 21, 42], ["high", "OBSERVATION_MODIFIER", 56, 60], ["infection", "OBSERVATION", 61, 70], ["respiratory secretions", "OBSERVATION", 128, 150], ["ascending", "OBSERVATION_MODIFIER", 337, 346], ["intrauterine", "OBSERVATION_MODIFIER", 347, 359], ["infection", "OBSERVATION", 360, 369]]], ["Transmission of virus through contaminated fomites, formula, or food is possible but has not been documented in newborns.", [["newborns", "ORGANISM", 112, 120], ["virus", "PROBLEM", 16, 21], ["virus", "OBSERVATION", 16, 21]]], ["Rotavirus particles have not been found in human milk or c o l o~t r u m .~Clinical ManifestationsExposure of a newborn to rotavirus can result in asymptomatic infection or cause mild or severe gastro-Outbreaks with high attack rates as measured by rotavirus excretion have been described but the extent of symptomatic infection Severe rotavirus infection is seldom reported during the newborn period1203 but the extent of underreporting of severe disease, especially in the less developed areas of the world, has not been evaluated.Clinical ManifestationsIt has been hypothesized that asymptomatic infections during the newborn period are the result of naturally attenuated strains circulating in this environment.", [["milk", "ANATOMY", 49, 53], ["rotavirus", "DISEASE", 123, 132], ["infection", "DISEASE", 160, 169], ["infection", "DISEASE", 319, 328], ["rotavirus infection", "DISEASE", 336, 355], ["infections", "DISEASE", 599, 609], ["Rotavirus", "ORGANISM", 0, 9], ["human", "ORGANISM", 43, 48], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["newborn", "ORGANISM", 112, 119], ["rotavirus", "ORGANISM", 123, 132], ["rotavirus", "ORGANISM", 249, 258], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["rotavirus", "SPECIES", 123, 132], ["rotavirus", "SPECIES", 249, 258], ["rotavirus", "SPECIES", 336, 345], ["Rotavirus particles", "PROBLEM", 0, 19], ["Clinical Manifestations", "PROBLEM", 75, 98], ["rotavirus", "PROBLEM", 123, 132], ["asymptomatic infection", "PROBLEM", 147, 169], ["mild or severe gastro-Outbreaks", "PROBLEM", 179, 210], ["high attack rates", "PROBLEM", 216, 233], ["rotavirus excretion", "PROBLEM", 249, 268], ["symptomatic infection", "PROBLEM", 307, 328], ["Severe rotavirus infection", "PROBLEM", 329, 355], ["severe disease", "PROBLEM", 441, 455], ["Clinical Manifestations", "PROBLEM", 533, 556], ["asymptomatic infections", "PROBLEM", 586, 609], ["naturally attenuated strains", "PROBLEM", 654, 682], ["asymptomatic", "OBSERVATION_MODIFIER", 147, 159], ["infection", "OBSERVATION", 160, 169], ["mild", "OBSERVATION_MODIFIER", 179, 183], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["gastro", "ANATOMY", 194, 200], ["symptomatic", "OBSERVATION_MODIFIER", 307, 318], ["infection", "OBSERVATION", 319, 328], ["Severe", "OBSERVATION_MODIFIER", 329, 335], ["rotavirus", "OBSERVATION_MODIFIER", 336, 345], ["infection", "OBSERVATION", 346, 355], ["severe", "OBSERVATION_MODIFIER", 441, 447], ["disease", "OBSERVATION", 448, 455], ["less", "OBSERVATION_MODIFIER", 475, 479], ["asymptomatic", "OBSERVATION_MODIFIER", 586, 598], ["infections", "OBSERVATION", 599, 609]]], ["RNA electrophoretic patterns of rotaviruses found in certain nurseries have shown uniform and it has been suggested that these strains may be attenuated.", [["rotaviruses", "ORGANISM", 32, 43], ["RNA electrophoretic patterns", "TEST", 0, 28], ["rotaviruses", "PROBLEM", 32, 43], ["these strains", "PROBLEM", 121, 134], ["rotaviruses", "OBSERVATION", 32, 43], ["may be", "UNCERTAINTY", 135, 141], ["attenuated", "OBSERVATION_MODIFIER", 142, 152]]], ["The presence of unusual antigenic types such as the P2A[6] type within nurseries also suggests \"less virulent strains.\"", [["less virulent strains", "PROBLEM", 96, 117], ["unusual", "OBSERVATION_MODIFIER", 16, 23], ["antigenic types", "OBSERVATION", 24, 39], ["less virulent", "OBSERVATION_MODIFIER", 96, 109]]], ["At least 10 rotavirus strains were documented to co-circulate in a tertiary care center during a 2-month period12\" and in a different setting the same rotavirus strains by electropherotype produced asymptomatic infection in neonates and symptomatic infection in older infants.1183 Newborns within a nursery exposed to a given rotavirus strain can develop symptomatic or asymptomatic infection.", [["rotavirus", "DISEASE", 151, 160], ["electropherotype", "CHEMICAL", 172, 188], ["infection", "DISEASE", 211, 220], ["infection", "DISEASE", 249, 258], ["infection", "DISEASE", 383, 392], ["rotavirus", "ORGANISM", 12, 21], ["rotavirus", "ORGANISM", 151, 160], ["neonates", "ORGANISM", 224, 232], ["infants", "ORGANISM", 268, 275], ["Newborns", "ORGANISM", 281, 289], ["rotavirus", "ORGANISM", 326, 335], ["infants", "SPECIES", 268, 275], ["Newborns", "SPECIES", 281, 289], ["rotavirus", "SPECIES", 12, 21], ["rotavirus", "SPECIES", 151, 160], ["rotavirus", "SPECIES", 326, 335], ["rotavirus strains", "PROBLEM", 12, 29], ["the same rotavirus strains", "PROBLEM", 142, 168], ["asymptomatic infection in neonates", "PROBLEM", 198, 232], ["symptomatic infection", "PROBLEM", 237, 258], ["rotavirus strain", "PROBLEM", 326, 342], ["asymptomatic infection", "PROBLEM", 370, 392], ["asymptomatic", "OBSERVATION_MODIFIER", 198, 210], ["infection", "OBSERVATION", 211, 220], ["symptomatic", "OBSERVATION_MODIFIER", 237, 248], ["infection", "OBSERVATION", 249, 258], ["asymptomatic", "OBSERVATION_MODIFIER", 370, 382], ["infection", "OBSERVATION", 383, 392]]], ["130~1 2 1 0~1 2 I Because newborns routinely have frequent relatively loose stools, it is possible that mild diarrhea episodes caused by rotavirus are being wrongly labeled as asymptomatic episodes.Clinical ManifestationsNo clinical feature is pathognomonic of rotaviral gastroenteritis.", [["diarrhea", "DISEASE", 109, 117], ["rotavirus", "DISEASE", 137, 146], ["rotaviral gastroenteritis", "DISEASE", 261, 286], ["newborns", "ORGANISM", 26, 34], ["stools", "ORGANISM_SUBSTANCE", 76, 82], ["rotavirus", "ORGANISM", 137, 146], ["rotavirus", "SPECIES", 137, 146], ["frequent relatively loose stools", "PROBLEM", 50, 82], ["mild diarrhea episodes", "PROBLEM", 104, 126], ["rotavirus", "PROBLEM", 137, 146], ["asymptomatic episodes", "PROBLEM", 176, 197], ["rotaviral gastroenteritis", "PROBLEM", 261, 286], ["mild", "OBSERVATION_MODIFIER", 104, 108], ["diarrhea", "OBSERVATION", 109, 117], ["rotaviral gastroenteritis", "OBSERVATION", 261, 286]]], ["Early signs of illness, such as lethargy, irritability, vomiting, and poor feeding, usually are followed in a few hours by the passage of watery yellow or green stools free of blood but sometimes containing mucus.1187,1212-1214 Diarrhea usually decreases by the second day of illness and is much infant in a closed incubator is not fully protective.118 s No enteritisel 129.", [["blood", "ANATOMY", 176, 181], ["mucus", "ANATOMY", 207, 212], ["illness", "DISEASE", 15, 22], ["lethargy", "DISEASE", 32, 40], ["irritability", "DISEASE", 42, 54], ["vomiting", "DISEASE", 56, 64], ["Diarrhea", "DISEASE", 228, 236], ["stools", "ORGANISM_SUBSTANCE", 161, 167], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["mucus", "ORGANISM_SUBSTANCE", 207, 212], ["illness", "PROBLEM", 15, 22], ["lethargy", "PROBLEM", 32, 40], ["irritability", "PROBLEM", 42, 54], ["vomiting", "PROBLEM", 56, 64], ["watery yellow or green stools free of blood", "PROBLEM", 138, 181], ["Diarrhea", "PROBLEM", 228, 236], ["enteritisel", "TEST", 358, 369], ["illness", "OBSERVATION", 15, 22], ["poor feeding", "OBSERVATION_MODIFIER", 70, 82], ["mucus", "OBSERVATION", 207, 212], ["decreases", "OBSERVATION_MODIFIER", 245, 254]]], ["Occasionally, intestinal fluid loss and poor weight gain may continue for 1 or 2 weeks, particularly in low-birth-weight infants.", [["intestinal fluid", "ANATOMY", 14, 30], ["intestinal fluid loss", "DISEASE", 14, 35], ["weight gain", "DISEASE", 45, 56], ["intestinal", "ORGAN", 14, 24], ["infants", "ORGANISM", 121, 128], ["infants", "SPECIES", 121, 128], ["intestinal fluid loss", "PROBLEM", 14, 35], ["poor weight gain", "PROBLEM", 40, 56], ["intestinal", "ANATOMY", 14, 24], ["fluid loss", "OBSERVATION", 25, 35]]], ["1175 Although reducing substances frequently are present in early fecal ~a m p l e s \"' 176~1187 this finding is not necessarily abnormal in neonates, particularly those who are breast-fed.1215 Nevertheless, infants with prolonged diarrhea should be investigated for monosaccharide or disaccharide malabsorption or intolerance to cow's milk protein orClinical ManifestationsIn a prospective 49% of newborns with gastrointestinal symptoms in a neonatal intensive care unit had rotavirus detected in their stools.", [["breast", "ANATOMY", 178, 184], ["gastrointestinal", "ANATOMY", 412, 428], ["diarrhea", "DISEASE", 231, 239], ["malabsorption", "DISEASE", 298, 311], ["gastrointestinal symptoms", "DISEASE", 412, 437], ["monosaccharide", "CHEMICAL", 267, 281], ["disaccharide", "CHEMICAL", 285, 297], ["breast", "ORGANISM_SUBDIVISION", 178, 184], ["infants", "ORGANISM", 208, 215], ["monosaccharide", "SIMPLE_CHEMICAL", 267, 281], ["disaccharide", "SIMPLE_CHEMICAL", 285, 297], ["cow", "ORGANISM", 330, 333], ["milk", "ORGANISM_SUBSTANCE", 336, 340], ["newborns", "ORGANISM", 398, 406], ["gastrointestinal", "ORGAN", 412, 428], ["rotavirus", "ORGANISM", 476, 485], ["infants", "SPECIES", 208, 215], ["cow", "SPECIES", 330, 333], ["cow", "SPECIES", 330, 333], ["rotavirus", "SPECIES", 476, 485], ["abnormal in neonates", "PROBLEM", 129, 149], ["prolonged diarrhea", "PROBLEM", 221, 239], ["monosaccharide", "PROBLEM", 267, 281], ["disaccharide malabsorption", "PROBLEM", 285, 311], ["intolerance", "PROBLEM", 315, 326], ["gastrointestinal symptoms", "PROBLEM", 412, 437], ["rotavirus", "PROBLEM", 476, 485], ["not necessarily", "UNCERTAINTY", 113, 128], ["breast", "ANATOMY", 178, 184], ["gastrointestinal", "ANATOMY", 412, 428]]], ["Frequent stooling (present in 60%), bloody mucoid stool (42%), and watery stools (24%) were risk factors for a rotavirus infection.", [["mucoid stool", "ANATOMY", 43, 55], ["bloody mucoid stool", "DISEASE", 36, 55], ["watery stools", "DISEASE", 67, 80], ["rotavirus infection", "DISEASE", 111, 130], ["rotavirus", "ORGANISM", 111, 120], ["rotavirus", "SPECIES", 111, 120], ["Frequent stooling", "PROBLEM", 0, 17], ["bloody mucoid stool", "PROBLEM", 36, 55], ["watery stools", "PROBLEM", 67, 80], ["risk factors", "PROBLEM", 92, 104], ["a rotavirus infection", "PROBLEM", 109, 130], ["stooling", "OBSERVATION", 9, 17], ["rotavirus infection", "OBSERVATION", 111, 130]]], ["Bloody mucoid stools, intestinal dilatation, and abdominal distention were significantly more common in preterm infants, but severe outcomes such as necrotizing enterocolitis and death did not differ among infected term and preterm infants.Clinical ManifestationsLongitudinal studies in newborn nurseries and investigations of outbreaks among neonates rarely describe a severe adverse outcome or death.1139,1168,1187 Because these infants are under constant observation, early detection of excessive fluid losses and the availability of immediate medical care are probably major factors in determining outcome.", [["mucoid stools", "ANATOMY", 7, 20], ["intestinal", "ANATOMY", 22, 32], ["abdominal", "ANATOMY", 49, 58], ["fluid", "ANATOMY", 500, 505], ["abdominal distention", "DISEASE", 49, 69], ["necrotizing enterocolitis", "DISEASE", 149, 174], ["death", "DISEASE", 179, 184], ["death", "DISEASE", 396, 401], ["intestinal", "ORGAN", 22, 32], ["abdominal", "ORGANISM_SUBDIVISION", 49, 58], ["infants", "ORGANISM", 112, 119], ["infants", "ORGANISM", 232, 239], ["neonates", "ORGANISM", 343, 351], ["infants", "ORGANISM", 431, 438], ["fluid", "ORGANISM_SUBSTANCE", 500, 505], ["infants", "SPECIES", 112, 119], ["infants", "SPECIES", 232, 239], ["infants", "SPECIES", 431, 438], ["Bloody mucoid stools", "PROBLEM", 0, 20], ["intestinal dilatation", "PROBLEM", 22, 43], ["abdominal distention", "PROBLEM", 49, 69], ["severe outcomes", "PROBLEM", 125, 140], ["necrotizing enterocolitis", "PROBLEM", 149, 174], ["death", "PROBLEM", 179, 184], ["Clinical Manifestations", "PROBLEM", 240, 263], ["Longitudinal studies", "TEST", 263, 283], ["a severe adverse outcome", "PROBLEM", 368, 392], ["death", "PROBLEM", 396, 401], ["excessive fluid losses", "PROBLEM", 490, 512], ["immediate medical care", "TREATMENT", 537, 559], ["mucoid", "OBSERVATION_MODIFIER", 7, 13], ["stools", "OBSERVATION", 14, 20], ["intestinal", "ANATOMY", 22, 32], ["dilatation", "OBSERVATION", 33, 43], ["abdominal", "ANATOMY", 49, 58], ["distention", "OBSERVATION", 59, 69], ["more common", "OBSERVATION_MODIFIER", 89, 100], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["necrotizing", "OBSERVATION_MODIFIER", 149, 160], ["enterocolitis", "OBSERVATION", 161, 174], ["excessive", "OBSERVATION_MODIFIER", 490, 499], ["fluid losses", "OBSERVATION", 500, 512]]], ["Rotavirus gastroenteritis causes almost 400,000 deaths of infants every year,I2I7 concentrated largely in the poorest regions of the world.", [["Rotavirus gastroenteritis", "DISEASE", 0, 25], ["deaths", "DISEASE", 48, 54], ["infants", "ORGANISM", 58, 65], ["infants", "SPECIES", 58, 65], ["Rotavirus gastroenteritis", "PROBLEM", 0, 25]]], ["It is likely that in places where hospital-based care is uncommon, rotavirus causes neonatal deaths secondary to dehydration.Clinical ManifestationsGroup A rotavirus has been associated with a wide array of diseases in infants and children; Reye syndromes, encephalitis-aseptic meningitis, sudden infant death syndrome, inflammatory bowel disease, and Kawasaki syndrome have been described but not systematically studied.", [["bowel", "ANATOMY", 333, 338], ["rotavirus", "DISEASE", 67, 76], ["deaths", "DISEASE", 93, 99], ["dehydration", "DISEASE", 113, 124], ["rotavirus", "DISEASE", 156, 165], ["Reye syndromes", "DISEASE", 241, 255], ["encephalitis", "DISEASE", 257, 269], ["meningitis", "DISEASE", 278, 288], ["sudden infant death syndrome", "DISEASE", 290, 318], ["inflammatory bowel disease", "DISEASE", 320, 346], ["Kawasaki syndrome", "DISEASE", 352, 369], ["rotavirus", "ORGANISM", 67, 76], ["infants", "ORGANISM", 219, 226], ["children", "ORGANISM", 231, 239], ["bowel", "ORGAN", 333, 338], ["infants", "SPECIES", 219, 226], ["children", "SPECIES", 231, 239], ["rotavirus", "SPECIES", 67, 76], ["rotavirus", "PROBLEM", 67, 76], ["neonatal deaths", "PROBLEM", 84, 99], ["dehydration", "PROBLEM", 113, 124], ["Clinical ManifestationsGroup A rotavirus", "PROBLEM", 125, 165], ["diseases", "PROBLEM", 207, 215], ["Reye syndromes", "PROBLEM", 241, 255], ["encephalitis", "PROBLEM", 257, 269], ["aseptic meningitis", "PROBLEM", 270, 288], ["sudden infant death syndrome", "PROBLEM", 290, 318], ["inflammatory bowel disease", "PROBLEM", 320, 346], ["Kawasaki syndrome", "PROBLEM", 352, 369], ["is likely", "UNCERTAINTY", 3, 12], ["dehydration", "OBSERVATION", 113, 124], ["diseases", "OBSERVATION", 207, 215], ["encephalitis", "OBSERVATION", 257, 269], ["aseptic", "OBSERVATION_MODIFIER", 270, 277], ["meningitis", "OBSERVATION", 278, 288], ["death syndrome", "OBSERVATION", 304, 318], ["inflammatory", "OBSERVATION_MODIFIER", 320, 332], ["bowel", "ANATOMY", 333, 338], ["disease", "OBSERVATION", 339, 346], ["Kawasaki syndrome", "OBSERVATION", 352, 369]]], ["1108 Case reports and small case series have associated neonatal rotavirus infection with necrotizing e n t e r o c~l i t i s .", [["rotavirus infection", "DISEASE", 65, 84], ["rotavirus", "ORGANISM", 65, 74], ["rotavirus", "SPECIES", 65, 74], ["small case series", "PROBLEM", 22, 39], ["neonatal rotavirus infection", "PROBLEM", 56, 84], ["small", "OBSERVATION_MODIFIER", 22, 27], ["rotavirus", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 75, 84], ["necrotizing", "OBSERVATION_MODIFIER", 90, 101]]], ["Rotavirus infection may play a role in a small proportion of cases of necrotizing enterocolitis, although it probably represents one of many potential triggering factors.", [["Rotavirus infection", "DISEASE", 0, 19], ["necrotizing enterocolitis", "DISEASE", 70, 95], ["Rotavirus", "ORGANISM", 0, 9], ["Rotavirus infection", "PROBLEM", 0, 19], ["necrotizing enterocolitis", "PROBLEM", 70, 95], ["infection", "OBSERVATION", 10, 19], ["necrotizing", "OBSERVATION_MODIFIER", 70, 81], ["enterocolitis", "OBSERVATION", 82, 95], ["probably represents", "UNCERTAINTY", 109, 128]]], ["A significant association between neonatal rotavirus infection and bradycardia-apnea episodes was detected in one prospective study.1220 The possible association between natural rotavirus infection and i n t u s s u~c e p t i o n~ gained support after the association was made between the human-simian reassortant vaccine and intussusception in infants older than 2 months (attributable risk = 1: 10,000).", [["rotavirus infection", "DISEASE", 43, 62], ["bradycardia", "DISEASE", 67, 78], ["apnea", "DISEASE", 79, 84], ["rotavirus infection", "DISEASE", 178, 197], ["intussusception", "DISEASE", 326, 341], ["rotavirus", "ORGANISM", 43, 52], ["rotavirus", "ORGANISM", 178, 187], ["human", "ORGANISM", 289, 294], ["simian", "ORGANISM", 295, 301], ["infants", "ORGANISM", 345, 352], ["human", "SPECIES", 289, 294], ["infants", "SPECIES", 345, 352], ["rotavirus", "SPECIES", 43, 52], ["human", "SPECIES", 289, 294], ["neonatal rotavirus infection", "PROBLEM", 34, 62], ["bradycardia", "PROBLEM", 67, 78], ["apnea episodes", "PROBLEM", 79, 93], ["one prospective study", "TEST", 110, 131], ["natural rotavirus infection", "PROBLEM", 170, 197], ["the human-simian reassortant vaccine", "TREATMENT", 285, 321], ["intussusception", "PROBLEM", 326, 341], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["rotavirus", "OBSERVATION_MODIFIER", 43, 52], ["infection", "OBSERVATION", 53, 62], ["rotavirus", "OBSERVATION_MODIFIER", 178, 187], ["infection", "OBSERVATION", 188, 197]]], ["1224 Intussusception is extremely uncommon in the newborn; it is highly unlikely that rotavirus triggers this disease in neonates.DiagnosisThere are many methods used for detection of rotavirus in stool specimens, including electron microscopy, immune electron microscopy, ELISA, latex agglutination, gel electrophoresis, culture of the virus, and reverse transcriptasepolymerase chain reaction.", [["stool specimens", "ANATOMY", 197, 212], ["Intussusception", "DISEASE", 5, 20], ["rotavirus", "DISEASE", 86, 95], ["rotavirus", "ORGANISM", 86, 95], ["neonates", "ORGANISM", 121, 129], ["rotavirus", "ORGANISM", 184, 193], ["rotavirus", "SPECIES", 86, 95], ["rotavirus", "SPECIES", 184, 193], ["rotavirus", "PROBLEM", 86, 95], ["this disease in neonates", "PROBLEM", 105, 129], ["rotavirus in stool specimens", "PROBLEM", 184, 212], ["electron microscopy", "TEST", 224, 243], ["immune electron microscopy", "TEST", 245, 271], ["ELISA", "TEST", 273, 278], ["latex agglutination", "TEST", 280, 299], ["gel electrophoresis", "TEST", 301, 320], ["culture", "TEST", 322, 329], ["the virus", "PROBLEM", 333, 342], ["reverse transcriptasepolymerase chain reaction", "PROBLEM", 348, 394], ["Intussusception", "OBSERVATION", 5, 20], ["highly unlikely", "UNCERTAINTY", 65, 80], ["rotavirus", "OBSERVATION", 86, 95]]], ["ELISA and latex agglutination currently are the most widely used diagnostic techniques for detection of rotavirus in clinical samples.", [["samples", "ANATOMY", 126, 133], ["rotavirus", "DISEASE", 104, 113], ["rotavirus", "ORGANISM", 104, 113], ["rotavirus", "SPECIES", 104, 113], ["ELISA", "TEST", 0, 5], ["latex agglutination", "TEST", 10, 29], ["rotavirus in clinical samples", "PROBLEM", 104, 133], ["latex agglutination", "OBSERVATION", 10, 29]]], ["In general, latex agglutination assays are more rapid than ELISAs but are less sensitive.", [["latex agglutination assays", "TEST", 12, 38]]], ["The sensitivity and specificity of the commercially available ELISAs surpass 90%.", [["The sensitivity", "TEST", 0, 15], ["ELISAs surpass", "TEST", 62, 76]]], ["Checking of the ELISA by another method such as gel electrophoresis or PCR amplification may be desirable if there is concern about false-positive results.DiagnosisFecal material for detection of rotavirus infection should be obtained during the acute phase of illness.", [["rotavirus infection", "DISEASE", 196, 215], ["rotavirus", "ORGANISM", 196, 205], ["rotavirus", "SPECIES", 196, 205], ["the ELISA", "TEST", 12, 21], ["gel electrophoresis", "TREATMENT", 48, 67], ["PCR amplification", "TREATMENT", 71, 88], ["DiagnosisFecal material", "PROBLEM", 155, 178], ["rotavirus infection", "PROBLEM", 196, 215], ["illness", "PROBLEM", 261, 268], ["rotavirus", "OBSERVATION", 196, 205]]], ["Whole-stool samples are preferred, although suspensions of rectal swab specimens have been adequate for detection of rotavirus byDiagnosisRotavirus are relatively resistant to environmental temperatures, even tropical temperatures, 1232 although 4\u00b0C is desirable for short-term storage and -70\u00b0C for prolonged storage.'Io8 Excretion of viral particles may precede signs of illness by several days' 190; maximal excretion by older infants and children usually occurs 3 to 4 days after onset of symptoms.1233 Neonates can shed virus for 1 to 2 weeks after onset of symptoms.Therapy and PreventionThe primary goal of therapy is restoration and maintenance of fluid and electrolyte balance.", [["samples", "ANATOMY", 12, 19], ["rectal swab specimens", "ANATOMY", 59, 80], ["fluid", "ANATOMY", 656, 661], ["byDiagnosisRotavirus", "DISEASE", 127, 147], ["illness", "DISEASE", 373, 380], ["stool samples", "ORGANISM_SUBSTANCE", 6, 19], ["rectal swab specimens", "CANCER", 59, 80], ["rotavirus byDiagnosisRotavirus", "ORGANISM", 117, 147], ["Io8", "GENE_OR_GENE_PRODUCT", 319, 322], ["children", "ORGANISM", 442, 450], ["Neonates", "ORGANISM", 507, 515], ["fluid", "ORGANISM_SUBSTANCE", 656, 661], ["electrolyte", "SIMPLE_CHEMICAL", 666, 677], ["infants", "SPECIES", 430, 437], ["children", "SPECIES", 442, 450], ["rotavirus byDiagnosisRotavirus", "SPECIES", 117, 147], ["Whole-stool samples", "TEST", 0, 19], ["rectal swab specimens", "TEST", 59, 80], ["rotavirus byDiagnosisRotavirus", "PROBLEM", 117, 147], ["tropical temperatures", "TEST", 209, 230], ["short-term storage", "PROBLEM", 267, 285], ["prolonged storage", "PROBLEM", 300, 317], ["viral particles", "PROBLEM", 336, 351], ["illness", "PROBLEM", 373, 380], ["symptoms", "PROBLEM", 493, 501], ["symptoms", "PROBLEM", 563, 571], ["Therapy", "TREATMENT", 572, 579], ["Prevention", "TREATMENT", 584, 594], ["therapy", "TREATMENT", 614, 621], ["restoration", "TREATMENT", 625, 636], ["fluid and electrolyte balance", "TEST", 656, 685], ["rectal", "ANATOMY", 59, 65], ["viral particles", "OBSERVATION", 336, 351]]], ["Despite the documented defect in carbohydrate digestion with rotavirus diarrhea, rehydration often can be accomplished with glucoseelectrolyte or sucrose-electrolyte solutions given orally .199,1234-1236 Intravenous fluids may be needed in neonates who are severely dehydrated, who have ileus, or who refuse to feed.", [["rotavirus diarrhea", "DISEASE", 61, 79], ["glucoseelectrolyte", "CHEMICAL", 124, 142], ["sucrose", "CHEMICAL", 146, 153], [".199,1234-1236", "CHEMICAL", 189, 203], ["ileus", "DISEASE", 287, 292], ["carbohydrate", "CHEMICAL", 33, 45], ["glucoseelectrolyte", "CHEMICAL", 124, 142], ["sucrose", "CHEMICAL", 146, 153], ["glucoseelectrolyte", "SIMPLE_CHEMICAL", 124, 142], ["sucrose", "SIMPLE_CHEMICAL", 146, 153], ["neonates", "ORGANISM", 240, 248], ["rotavirus", "SPECIES", 61, 70], ["the documented defect in carbohydrate digestion", "PROBLEM", 8, 55], ["rotavirus diarrhea", "PROBLEM", 61, 79], ["rehydration", "TREATMENT", 81, 92], ["glucoseelectrolyte", "TREATMENT", 124, 142], ["sucrose-electrolyte solutions", "TREATMENT", 146, 175], ["Intravenous fluids", "TREATMENT", 204, 222], ["severely dehydrated", "PROBLEM", 257, 276], ["ileus", "PROBLEM", 287, 292], ["defect", "OBSERVATION", 23, 29], ["carbohydrate digestion", "OBSERVATION", 33, 55], ["ileus", "OBSERVATION", 287, 292]]], ["Persistent or recurrent diarrhea after introduction of milkbased formulas or human milk warrants investigation for secondary carbohydrate or milk protein i n t~l e r a n c e . '' although not convincingly shown1242; the widespread clinical use of these measures seems remote.", [["milk", "ANATOMY", 83, 87], ["diarrhea", "DISEASE", 24, 32], ["carbohydrate", "CHEMICAL", 125, 137], ["human", "ORGANISM", 77, 82], ["milk", "ORGANISM_SUBSTANCE", 83, 87], ["milk", "ORGANISM_SUBSTANCE", 141, 145], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["Persistent or recurrent diarrhea", "PROBLEM", 0, 32], ["introduction of milkbased formulas", "TREATMENT", 39, 73], ["human milk", "TREATMENT", 77, 87], ["secondary carbohydrate", "PROBLEM", 115, 137], ["these measures", "TREATMENT", 247, 261], ["recurrent", "OBSERVATION_MODIFIER", 14, 23], ["diarrhea", "OBSERVATION", 24, 32]]], ["One study suggests that use of lactobacillus during the diarrheal episode may decrease the duration of rotavirus-associated hospital stays, especially when used early in the course of the disease, although more studies are needed before recommending widespread use.", [["lactobacillus", "CHEMICAL", 31, 44], ["diarrheal", "DISEASE", 56, 65], ["lactobacillus", "ORGANISM", 31, 44], ["rotavirus", "ORGANISM", 103, 112], ["rotavirus", "SPECIES", 103, 112], ["One study", "TEST", 0, 9], ["lactobacillus", "TREATMENT", 31, 44], ["the diarrheal episode", "PROBLEM", 52, 73], ["rotavirus", "PROBLEM", 103, 112], ["the disease", "PROBLEM", 184, 195], ["disease", "OBSERVATION", 188, 195]]], ["1241 Hand hygiene before and after contact with each infant remains the single most important means of preventing the spread of infection.", [["1241", "CHEMICAL", 0, 4], ["infection", "DISEASE", 128, 137], ["infant", "SPECIES", 53, 59], ["infection", "PROBLEM", 128, 137], ["hygiene", "OBSERVATION", 10, 17], ["infection", "OBSERVATION", 128, 137]]], ["Because rotavirus is often excreted several days before illness is recognized, isolation of an infant with diarrhea may be too late to prevent cross-infection unless all nursing personnel and medical staff have adhered to this fundamental precaution.", [["rotavirus", "DISEASE", 8, 17], ["diarrhea", "DISEASE", 107, 115], ["rotavirus", "ORGANISM", 8, 17], ["infant", "SPECIES", 95, 101], ["rotavirus", "SPECIES", 8, 17], ["rotavirus", "PROBLEM", 8, 17], ["illness", "PROBLEM", 56, 63], ["diarrhea", "PROBLEM", 107, 115], ["cross-infection", "PROBLEM", 143, 158], ["this fundamental precaution", "TREATMENT", 222, 249]]], ["Infants who develop gastroenteritis should be moved out of the nursery area if adequate facilities are available and the infant's condition permits transfer.", [["gastroenteritis", "DISEASE", 20, 35], ["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7], ["gastroenteritis", "PROBLEM", 20, 35], ["gastroenteritis", "OBSERVATION", 20, 35]]], ["The use of an incubator is of value in reducing transmission of disease only by serving as a reminder that proper hand-hygiene and glove techniques are required, but is of little value as a physical barrier to the spread of Encouraging rooming-in of infants with their mothers has been shown to be helpful in preventing or containing nursery epidemics.'243 Temporary closure of the nursery may be required for clinically significant outbreaks that cannot be controlled with other measures.1128VaccinesDevelopment of rotavirus vaccines began in the early 1980s.", [["hand", "ANATOMY", 114, 118], ["infants", "ORGANISM", 250, 257], ["rotavirus", "ORGANISM", 516, 525], ["infants", "SPECIES", 250, 257], ["rotavirus", "SPECIES", 516, 525], ["an incubator", "TREATMENT", 11, 23], ["disease", "PROBLEM", 64, 71], ["glove techniques", "TREATMENT", 131, 147], ["Temporary closure of the nursery", "TREATMENT", 357, 389], ["clinically significant outbreaks", "PROBLEM", 410, 442], ["rotavirus vaccines", "TREATMENT", 516, 534], ["disease", "OBSERVATION", 64, 71], ["rotavirus vaccines", "OBSERVATION", 516, 534]]], ["Candidate vaccines included bovine and rhesus monkey ELISA.", [["bovine", "ORGANISM", 28, 34], ["rhesus", "ORGANISM", 39, 45], ["monkey", "ORGANISM", 46, 52], ["bovine", "SPECIES", 28, 34], ["rhesus monkey", "SPECIES", 39, 52], ["bovine", "SPECIES", 28, 34], ["rhesus monkey", "SPECIES", 39, 52], ["Candidate vaccines", "TREATMENT", 0, 18], ["bovine", "TREATMENT", 28, 34]]], ["1230, 1231 attenuated strains, human attenuated strains, and bovinehuman and rhesus-human reassortant strains.\"\"", [["human", "ORGANISM", 31, 36], ["rhesus", "ORGANISM", 77, 83], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 31, 36], ["rhesus-", "SPECIES", 77, 84], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 31, 36], ["attenuated strains", "PROBLEM", 11, 29], ["human attenuated strains", "PROBLEM", 31, 55], ["bovinehuman", "TREATMENT", 61, 72]]], ["In August 1998, the first licensed rotavirus vaccine, Rotashield, an oral formulation of a simian-human quadrivalent reassortant vaccine, was recommended for use in children when they were 2, 4, and 6 months old.", [["oral", "ANATOMY", 69, 73], ["Rotashield", "CHEMICAL", 54, 64], ["rotavirus", "ORGANISM", 35, 44], ["Rotashield", "SIMPLE_CHEMICAL", 54, 64], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["simian", "ORGANISM", 91, 97], ["human", "ORGANISM", 98, 103], ["children", "ORGANISM", 165, 173], ["simian-", "SPECIES", 91, 98], ["human", "SPECIES", 98, 103], ["quadrivalent reassortant vaccine", "SPECIES", 104, 136], ["children", "SPECIES", 165, 173], ["rotavirus", "SPECIES", 35, 44], ["simian-human quadrivalent reassortant", "SPECIES", 91, 128], ["rotavirus vaccine", "TREATMENT", 35, 52], ["Rotashield", "TREATMENT", 54, 64], ["an oral formulation", "TREATMENT", 66, 85], ["a simian-human quadrivalent reassortant vaccine", "TREATMENT", 89, 136]]], ["After approximately 500,000 children were vaccinated with more than 1 million doses, a significantly increased risk of intussusception was observed among vaccinated children, with an overall odds ratio of 1.8.Iz4 Use of this vaccine was terminated.", [["intussusception", "DISEASE", 119, 134], ["children", "ORGANISM", 28, 36], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 28, 36], ["children", "SPECIES", 165, 173], ["intussusception", "PROBLEM", 119, 134], ["an overall odds ratio", "TEST", 180, 201], ["this vaccine", "TREATMENT", 220, 232], ["intussusception", "OBSERVATION", 119, 134]]], ["Two new vaccine candidates are undergoing phase I11 clinical trials: a \"pentavalent\" bovine-human reassortant vaccine including G types Gl-G4 and P type PlA[8] and a monovalent human attenuated PlA[ 8]G1 vaccine.", [["bovine", "ORGANISM", 85, 91], ["human", "ORGANISM", 92, 97], ["Gl-G4", "SIMPLE_CHEMICAL", 136, 141], ["human", "ORGANISM", 177, 182], ["bovine", "SPECIES", 85, 91], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 177, 182], ["Two new vaccine candidates", "TREATMENT", 0, 26], ["a \"pentavalent\" bovine-human reassortant vaccine", "TREATMENT", 69, 117], ["a monovalent human attenuated PlA", "TREATMENT", 164, 197], ["G1 vaccine", "TREATMENT", 201, 211]]], ["The epidemiology of rotavirus infection will change significantly if one or both candidates become widely available in the future.", [["rotavirus infection", "DISEASE", 20, 39], ["rotavirus", "ORGANISM", 20, 29], ["rotavirus", "SPECIES", 20, 29], ["rotavirus infection", "PROBLEM", 20, 39], ["rotavirus", "OBSERVATION_MODIFIER", 20, 29], ["infection", "OBSERVATION", 30, 39]]], ["The impact on neonatal infection will depend on the effect of herd immunity in decreasing circulation of rotavirus strains.DIFFERENTIAL DIAGNOSISStools from breast-fed neonates are typically watery and yellow, green, or brown.", [["breast", "ANATOMY", 157, 163], ["neonatal infection", "DISEASE", 14, 32], ["herd", "ORGANISM_SUBDIVISION", 62, 66], ["rotavirus", "ORGANISM", 105, 114], ["breast", "ORGANISM_SUBDIVISION", 157, 163], ["neonates", "ORGANISM", 168, 176], ["watery", "ORGANISM_SUBDIVISION", 191, 197], ["rotavirus", "SPECIES", 105, 114], ["neonatal infection", "PROBLEM", 14, 32], ["herd immunity", "TREATMENT", 62, 75], ["rotavirus strains", "PROBLEM", 105, 122], ["watery", "PROBLEM", 191, 197], ["yellow", "PROBLEM", 202, 208], ["infection", "OBSERVATION", 23, 32], ["breast", "ANATOMY", 157, 163], ["watery", "OBSERVATION_MODIFIER", 191, 197]]], ["The frequency of stooling can vary from one every other day to eight evacuations per day.", [["stooling", "OBSERVATION", 17, 25]]], ["In an active, healthy infant who is feeding well, has no vomiting, and has a soft abdomen, these varied patterns of stooling are not a cause for concern.", [["soft abdomen", "ANATOMY", 77, 89], ["vomiting", "DISEASE", 57, 65], ["stooling", "DISEASE", 116, 124], ["infant", "ORGANISM", 22, 28], ["abdomen", "ORGAN", 82, 89], ["infant", "SPECIES", 22, 28], ["vomiting", "PROBLEM", 57, 65], ["a soft abdomen", "PROBLEM", 75, 89], ["active", "OBSERVATION_MODIFIER", 6, 12], ["soft", "ANATOMY_MODIFIER", 77, 81], ["abdomen", "ANATOMY", 82, 89], ["stooling", "OBSERVATION", 116, 124]]], ["Physicians need to consider the child's previous frequency and consistency of stools and establish a diagnosis of acute diarrhea on an individual basis.", [["diarrhea", "DISEASE", 120, 128], ["stools", "ORGANISM_SUBSTANCE", 78, 84], ["stools", "PROBLEM", 78, 84], ["acute diarrhea", "PROBLEM", 114, 128], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["diarrhea", "OBSERVATION", 120, 128]]], ["Close follow-up of weight increase in infants with nonformed stools can help confirm the clinical impression.", [["infants", "ORGANISM", 38, 45], ["infants", "SPECIES", 38, 45], ["weight increase in infants with nonformed stools", "PROBLEM", 19, 67]]], ["A normal weight gain should direct medical action away from stool exams or treatment.DIFFERENTIAL DIAGNOSISDiarrhea during the neonatal period is a clinical manifestation of a wide variety of disorders (Table 20-6).", [["stool", "ANATOMY", 60, 65], ["weight gain", "DISEASE", 9, 20], ["stool", "ORGANISM_SUBSTANCE", 60, 65], ["stool exams", "TEST", 60, 71], ["treatment", "TREATMENT", 75, 84], ["a wide variety of disorders", "PROBLEM", 174, 201], ["normal", "OBSERVATION", 2, 8]]], ["The most common initiating factor is a primary infection of the gastrointestinal tract that is mild to moderate in severity, Chapter 20 self-limited, and responsive to supportive measures.", [["gastrointestinal tract", "ANATOMY", 64, 86], ["primary infection of the gastrointestinal tract", "DISEASE", 39, 86], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 64, 86], ["a primary infection of the gastrointestinal tract", "PROBLEM", 37, 86], ["mild to moderate in severity", "PROBLEM", 95, 123], ["supportive measures", "TREATMENT", 168, 187], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["primary", "OBSERVATION_MODIFIER", 39, 46], ["infection", "OBSERVATION", 47, 56], ["gastrointestinal tract", "ANATOMY", 64, 86], ["mild", "OBSERVATION_MODIFIER", 95, 99], ["moderate", "OBSERVATION_MODIFIER", 103, 111], ["severity", "OBSERVATION_MODIFIER", 115, 123]]], ["Acute diarrhea can also be an initial manifestation of a systemic infection, including bacterial and viral neonatal sepsis.", [["diarrhea", "DISEASE", 6, 14], ["infection", "DISEASE", 66, 75], ["sepsis", "DISEASE", 116, 122], ["Acute diarrhea", "PROBLEM", 0, 14], ["a systemic infection", "PROBLEM", 55, 75], ["bacterial and viral neonatal sepsis", "PROBLEM", 87, 122], ["diarrhea", "OBSERVATION", 6, 14], ["systemic", "OBSERVATION_MODIFIER", 57, 65], ["infection", "OBSERVATION", 66, 75], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["viral", "OBSERVATION_MODIFIER", 101, 106], ["neonatal", "OBSERVATION_MODIFIER", 107, 115], ["sepsis", "OBSERVATION", 116, 122]]], ["Infants with moderate to severe diarrhea require close monitoring until the etiologic diagnosis and the clinical evolution are clarified.", [["diarrhea", "DISEASE", 32, 40], ["Infants", "SPECIES", 0, 7], ["moderate to severe diarrhea", "PROBLEM", 13, 40], ["close monitoring", "TEST", 49, 65], ["moderate", "OBSERVATION_MODIFIER", 13, 21], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["diarrhea", "OBSERVATION", 32, 40]]], ["There are noninfectious diseases leading to chronic intractable diarrhea that may result in severe nutritional disturbances or even death unless the specific underlying condition is identified and treated appropriately.", [["noninfectious diseases", "DISEASE", 10, 32], ["diarrhea", "DISEASE", 64, 72], ["nutritional disturbances", "DISEASE", 99, 123], ["death", "DISEASE", 132, 137], ["noninfectious diseases", "PROBLEM", 10, 32], ["chronic intractable diarrhea", "PROBLEM", 44, 72], ["severe nutritional disturbances", "PROBLEM", 92, 123], ["even death", "PROBLEM", 127, 137], ["the specific underlying condition", "PROBLEM", 145, 178], ["noninfectious", "OBSERVATION", 10, 23], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["intractable", "OBSERVATION_MODIFIER", 52, 63], ["diarrhea", "OBSERVATION", 64, 72], ["severe", "OBSERVATION_MODIFIER", 92, 98]]], ["The differential diagnosis of a diarrheal illness requires a careful clinical examination to determine whether the child has a localized or a systemic process.", [["diarrheal illness", "DISEASE", 32, 49], ["child", "ORGANISM", 115, 120], ["a diarrheal illness", "PROBLEM", 30, 49], ["a careful clinical examination", "TEST", 59, 89], ["a systemic process", "PROBLEM", 140, 158], ["diarrheal illness", "OBSERVATION", 32, 49], ["systemic", "OBSERVATION", 142, 150]]], ["Lethargy, abnormalities in body temperature, hypothermia or hyperthermia, decreased feeding, abdominal distention, vomiting, pallor, respiratory distress, apnea, cyanosis, hernodynamic instability, hypotension, hepatomegaly or splenomegaly, coagulation or bleeding disorders, petechiae, and exanthemas should lead to an intense laboratory investigation directed at systemic viral or bacterial infection.", [["body", "ANATOMY", 27, 31], ["abdominal", "ANATOMY", 93, 102], ["respiratory", "ANATOMY", 133, 144], ["petechiae", "ANATOMY", 276, 285], ["Lethargy", "DISEASE", 0, 8], ["hypothermia", "DISEASE", 45, 56], ["hyperthermia", "DISEASE", 60, 72], ["abdominal distention", "DISEASE", 93, 113], ["vomiting", "DISEASE", 115, 123], ["pallor", "DISEASE", 125, 131], ["respiratory distress", "DISEASE", 133, 153], ["apnea", "DISEASE", 155, 160], ["cyanosis", "DISEASE", 162, 170], ["hernodynamic instability", "DISEASE", 172, 196], ["hypotension", "DISEASE", 198, 209], ["hepatomegaly", "DISEASE", 211, 223], ["splenomegaly", "DISEASE", 227, 239], ["coagulation", "DISEASE", 241, 252], ["bleeding disorders", "DISEASE", 256, 274], ["petechiae", "DISEASE", 276, 285], ["exanthemas", "DISEASE", 291, 301], ["systemic viral or bacterial infection", "DISEASE", 365, 402], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["abdominal", "ORGANISM_SUBDIVISION", 93, 102], ["petechiae", "PATHOLOGICAL_FORMATION", 276, 285], ["Lethargy", "PROBLEM", 0, 8], ["abnormalities in body temperature", "PROBLEM", 10, 43], ["hypothermia", "PROBLEM", 45, 56], ["hyperthermia", "PROBLEM", 60, 72], ["decreased feeding", "PROBLEM", 74, 91], ["abdominal distention", "PROBLEM", 93, 113], ["vomiting", "PROBLEM", 115, 123], ["pallor", "PROBLEM", 125, 131], ["respiratory distress", "PROBLEM", 133, 153], ["apnea", "PROBLEM", 155, 160], ["cyanosis", "PROBLEM", 162, 170], ["hernodynamic instability", "PROBLEM", 172, 196], ["hypotension", "PROBLEM", 198, 209], ["hepatomegaly", "PROBLEM", 211, 223], ["splenomegaly", "PROBLEM", 227, 239], ["coagulation", "PROBLEM", 241, 252], ["bleeding disorders", "PROBLEM", 256, 274], ["petechiae", "PROBLEM", 276, 285], ["exanthemas", "PROBLEM", 291, 301], ["an intense laboratory investigation", "TEST", 317, 352], ["bacterial infection", "PROBLEM", 383, 402], ["hypothermia", "OBSERVATION", 45, 56], ["hyperthermia", "OBSERVATION", 60, 72], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["abdominal", "ANATOMY", 93, 102], ["distention", "OBSERVATION", 103, 113], ["respiratory distress", "OBSERVATION", 133, 153], ["cyanosis", "OBSERVATION", 162, 170], ["hypotension", "OBSERVATION", 198, 209], ["hepatomegaly", "OBSERVATION", 211, 223], ["splenomegaly", "OBSERVATION", 227, 239], ["petechiae", "OBSERVATION", 276, 285], ["bacterial", "OBSERVATION_MODIFIER", 383, 392], ["infection", "OBSERVATION", 393, 402]]], ["If the process is deemed a localized intestinal infection, initial evaluation can be focused on differentiating an inflammatory-invasive pathogen from those that cause a noninflammatory process.", [["intestinal", "ANATOMY", 37, 47], ["intestinal infection", "DISEASE", 37, 57], ["intestinal", "ORGAN", 37, 47], ["a localized intestinal infection", "PROBLEM", 25, 57], ["initial evaluation", "TEST", 59, 77], ["an inflammatory-invasive pathogen", "PROBLEM", 112, 145], ["a noninflammatory process", "PROBLEM", 168, 193], ["localized", "OBSERVATION_MODIFIER", 27, 36], ["intestinal", "ANATOMY", 37, 47], ["infection", "OBSERVATION", 48, 57], ["inflammatory", "OBSERVATION_MODIFIER", 115, 127], ["invasive", "OBSERVATION_MODIFIER", 128, 136], ["noninflammatory", "OBSERVATION", 170, 185]]], ["For this, stool examination for fecal leukocytes, red blood cells, and lactoferrin can be a helpful indicator of the former.DIFFERENTIAL DIAGNOSISInflammatory diarrhea can be caused by Shigella, Salmonella, Carnpylobacter, V parahaemolyticus, k: enterocolitica, EIEC, EAEC, C. difjcile, necrotizing enterocolitis, antibioticassociated colitis, and allergic colitis (i.e., milk or soy intolerance).", [["stool", "ANATOMY", 10, 15], ["fecal leukocytes", "ANATOMY", 32, 48], ["red blood cells", "ANATOMY", 50, 65], ["milk", "ANATOMY", 372, 376], ["diarrhea", "DISEASE", 159, 167], ["C. difjcile", "DISEASE", 274, 285], ["necrotizing enterocolitis", "DISEASE", 287, 312], ["antibioticassociated colitis", "DISEASE", 314, 342], ["allergic colitis", "DISEASE", 348, 364], ["soy intolerance", "DISEASE", 380, 395], ["stool", "ORGANISM_SUBSTANCE", 10, 15], ["fecal leukocytes", "CELL", 32, 48], ["red blood cells", "CELL", 50, 65], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 71, 82], ["Carnpylobacter, V parahaemolyticus", "ORGANISM", 207, 241], ["k: enterocolitica", "ORGANISM", 243, 260], ["EIEC", "CELL", 262, 266], ["C. difjcile", "ORGANISM", 274, 285], ["milk", "ORGANISM_SUBDIVISION", 372, 376], ["soy", "ORGANISM_SUBDIVISION", 380, 383], ["fecal leukocytes", "CELL_TYPE", 32, 48], ["red blood cells", "CELL_TYPE", 50, 65], ["lactoferrin", "PROTEIN", 71, 82], ["V parahaemolyticus", "SPECIES", 223, 241], ["enterocolitica", "SPECIES", 246, 260], ["C. difjcile", "SPECIES", 274, 285], ["milk", "SPECIES", 372, 376], ["V parahaemolyticus", "SPECIES", 223, 241], ["C. difjcile", "SPECIES", 274, 285], ["this, stool examination", "TEST", 4, 27], ["fecal leukocytes", "TEST", 32, 48], ["red blood cells", "TEST", 50, 65], ["lactoferrin", "TREATMENT", 71, 82], ["DIFFERENTIAL DIAGNOSISInflammatory diarrhea", "PROBLEM", 124, 167], ["Shigella", "PROBLEM", 185, 193], ["Salmonella", "PROBLEM", 195, 205], ["Carnpylobacter", "PROBLEM", 207, 221], ["enterocolitica", "PROBLEM", 246, 260], ["EIEC", "PROBLEM", 262, 266], ["EAEC", "PROBLEM", 268, 272], ["C. difjcile", "PROBLEM", 274, 285], ["necrotizing enterocolitis", "PROBLEM", 287, 312], ["antibioticassociated colitis", "PROBLEM", 314, 342], ["allergic colitis", "PROBLEM", 348, 364], ["soy intolerance", "PROBLEM", 380, 395], ["fecal leukocytes", "ANATOMY", 32, 48], ["Shigella", "OBSERVATION", 185, 193], ["necrotizing", "OBSERVATION_MODIFIER", 287, 298], ["enterocolitis", "OBSERVATION", 299, 312], ["antibioticassociated colitis", "OBSERVATION", 314, 342], ["allergic colitis", "OBSERVATION", 348, 364]]], ["Noninflammatory causes of diarrhea include ETEC, EPEC, rotaviruses, enteric adenoviruses, calicivirus, astrovirus, G. larnblia and Cryptosporidium.", [["diarrhea", "DISEASE", 26, 34], ["ETEC", "DISEASE", 43, 47], ["enteric adenoviruses", "DISEASE", 68, 88], ["calicivirus, astrovirus", "DISEASE", 90, 113], ["EPEC", "GENE_OR_GENE_PRODUCT", 49, 53], ["enteric adenoviruses", "ORGANISM", 68, 88], ["calicivirus", "ORGANISM", 90, 101], ["astrovirus", "ORGANISM", 103, 113], ["G. larnblia", "ORGANISM", 115, 126], ["Cryptosporidium", "ORGANISM", 131, 146], ["calicivirus", "SPECIES", 90, 101], ["G. larnblia", "SPECIES", 115, 126], ["G. larnblia", "SPECIES", 115, 126], ["Noninflammatory causes", "PROBLEM", 0, 22], ["diarrhea", "PROBLEM", 26, 34], ["ETEC", "PROBLEM", 43, 47], ["EPEC", "PROBLEM", 49, 53], ["rotaviruses", "PROBLEM", 55, 66], ["enteric adenoviruses", "PROBLEM", 68, 88], ["calicivirus", "PROBLEM", 90, 101], ["astrovirus", "PROBLEM", 103, 113], ["Cryptosporidium", "PROBLEM", 131, 146], ["diarrhea", "OBSERVATION", 26, 34], ["rotaviruses", "OBSERVATION", 55, 66], ["enteric adenoviruses", "ANATOMY", 68, 88], ["Cryptosporidium", "OBSERVATION", 131, 146]]], ["Although supportive fluid therapy is mandatory for all types of diarrhea, the brief examination for fecal leukocytes and red blood cells can direct the diagnostic and therapeutic approach.", [["fluid", "ANATOMY", 20, 25], ["fecal leukocytes", "ANATOMY", 100, 116], ["red blood cells", "ANATOMY", 121, 136], ["diarrhea", "DISEASE", 64, 72], ["fecal leukocytes", "CELL", 100, 116], ["red blood cells", "CELL", 121, 136], ["fecal leukocytes", "CELL_TYPE", 100, 116], ["red blood cells", "CELL_TYPE", 121, 136], ["supportive fluid therapy", "TREATMENT", 9, 33], ["diarrhea", "PROBLEM", 64, 72], ["the brief examination", "TEST", 74, 95], ["fecal leukocytes", "TEST", 100, 116], ["red blood cells", "TEST", 121, 136], ["therapeutic approach", "TREATMENT", 167, 187], ["supportive", "OBSERVATION_MODIFIER", 9, 19], ["fluid therapy", "OBSERVATION", 20, 33], ["diarrhea", "OBSERVATION", 64, 72]]], ["Pathogens such as Shigella, Salmonella, and EHEC can cause watery or bloody diarrhea, depending on the specific host-pathogen interaction and the pathogenic mechanisms involved.", [["EHEC", "CHEMICAL", 44, 48], ["watery", "DISEASE", 59, 65], ["diarrhea", "DISEASE", 76, 84], ["Shigella, Salmonella", "ORGANISM", 18, 38], ["EHEC", "ORGANISM", 44, 48], ["watery", "ORGANISM_SUBDIVISION", 59, 65], ["EHEC", "SPECIES", 44, 48], ["Pathogens", "PROBLEM", 0, 9], ["Shigella", "PROBLEM", 18, 26], ["Salmonella", "PROBLEM", 28, 38], ["EHEC", "PROBLEM", 44, 48], ["watery or bloody diarrhea", "PROBLEM", 59, 84]]], ["Some of the noninfectious diseases responsible for neonatal diarrhea are listed in Table 20", [["noninfectious diseases", "DISEASE", 12, 34], ["diarrhea", "DISEASE", 60, 68], ["the noninfectious diseases", "PROBLEM", 8, 34], ["neonatal diarrhea", "PROBLEM", 51, 68], ["noninfectious", "OBSERVATION", 12, 25]]]], "74a81638dc54bc8e0fee501f23723bda2761195b": [["INTRODUCTIONAdenosine diphosphate (ADP)-ribosylation is a covalent modification in which the ADP-ribose (ADPr) group from nicotinamide adenine dinucleotide (NAD + ) is transferred to diverse target molecules: proteins, nucleic acids and small molecules such as phosphate or acetate (1) .", [["INTRODUCTIONAdenosine diphosphate", "CHEMICAL", 0, 33], ["ADP", "CHEMICAL", 35, 38], ["ADP", "CHEMICAL", 93, 96], ["ribose", "CHEMICAL", 97, 103], ["ADPr", "CHEMICAL", 105, 109], ["nicotinamide adenine dinucleotide", "CHEMICAL", 122, 155], ["NAD", "CHEMICAL", 157, 160], ["nucleic acids", "CHEMICAL", 219, 232], ["phosphate or acetate", "CHEMICAL", 261, 281], ["INTRODUCTIONAdenosine diphosphate", "CHEMICAL", 0, 33], ["ADP", "CHEMICAL", 35, 38], ["ADP", "CHEMICAL", 93, 96], ["ribose", "CHEMICAL", 97, 103], ["ADPr", "CHEMICAL", 105, 109], ["nicotinamide adenine dinucleotide", "CHEMICAL", 122, 155], ["NAD + )", "CHEMICAL", 157, 164], ["phosphate", "CHEMICAL", 261, 270], ["acetate", "CHEMICAL", 274, 281], ["INTRODUCTIONAdenosine diphosphate", "GENE_OR_GENE_PRODUCT", 0, 33], ["ADP", "SIMPLE_CHEMICAL", 35, 38], ["ADP-ribose", "SIMPLE_CHEMICAL", 93, 103], ["ADPr", "SIMPLE_CHEMICAL", 105, 109], ["nicotinamide adenine dinucleotide", "SIMPLE_CHEMICAL", 122, 155], ["NAD +", "SIMPLE_CHEMICAL", 157, 162], ["nucleic acids", "SIMPLE_CHEMICAL", 219, 232], ["phosphate", "SIMPLE_CHEMICAL", 261, 270], ["acetate", "SIMPLE_CHEMICAL", 274, 281], ["target molecules", "PROTEIN", 191, 207], ["INTRODUCTIONAdenosine diphosphate (ADP)", "TREATMENT", 0, 39], ["ribosylation", "TREATMENT", 40, 52], ["a covalent modification", "TREATMENT", 56, 79], ["the ADP-ribose (ADPr)", "TREATMENT", 89, 110], ["nicotinamide adenine dinucleotide (NAD + )", "TREATMENT", 122, 164], ["nucleic acids", "TEST", 219, 232], ["small molecules", "PROBLEM", 237, 252], ["phosphate or acetate", "TREATMENT", 261, 281]]], ["This modification changes physical and chemical properties or localization of target molecules and regulates many important cellular processes in both prokaryotes and eukaryotes (2) .", [["cellular", "ANATOMY", 124, 132], ["cellular", "CELL", 124, 132], ["target molecules", "PROTEIN", 78, 94], ["target molecules", "PROBLEM", 78, 94]]], ["ADP-ribosylation was first described as a mechanism of pathogenicity used by pathogenic bacterial exotoxins that irreversibly modify crucial host cell proteins (3) .", [["cell", "ANATOMY", 146, 150], ["ADP", "CHEMICAL", 0, 3], ["ADP", "CHEMICAL", 0, 3], ["ADP", "SIMPLE_CHEMICAL", 0, 3], ["host cell", "CELL", 141, 150], ["host cell proteins", "PROTEIN", 141, 159], ["ADP-ribosylation", "TREATMENT", 0, 16], ["pathogenicity", "PROBLEM", 55, 68], ["pathogenic bacterial exotoxins", "PROBLEM", 77, 107], ["host cell proteins", "OBSERVATION", 141, 159]]], ["Two divergent bacterial toxins, diphtheria and cholera toxin are founders of two major ADP-ribosyl transferase (ART) groups (4, 5) .", [["diphtheria", "DISEASE", 32, 42], ["cholera toxin", "CHEMICAL", 47, 60], ["ADP", "CHEMICAL", 87, 90], ["ribosyl", "CHEMICAL", 91, 98], ["ADP", "CHEMICAL", 87, 90], ["ribosyl", "CHEMICAL", 91, 98], ["diphtheria", "GENE_OR_GENE_PRODUCT", 32, 42], ["cholera toxin", "SIMPLE_CHEMICAL", 47, 60], ["ADP-ribosyl transferase", "GENE_OR_GENE_PRODUCT", 87, 110], ["major ADP-ribosyl transferase", "PROTEIN", 81, 110], ["Two divergent bacterial toxins", "TEST", 0, 30], ["diphtheria", "PROBLEM", 32, 42], ["cholera toxin", "PROBLEM", 47, 60], ["divergent", "OBSERVATION_MODIFIER", 4, 13], ["bacterial toxins", "OBSERVATION", 14, 30]]], ["Poly(ADP-ribose) polymerases (PARPs), the best studied and largest ART subgroup, belong to diphtheria toxin-like ADP-ribosyl transferases.", [["Poly(ADP-ribose", "CHEMICAL", 0, 15], ["ADP", "CHEMICAL", 113, 116], ["Poly(ADP-ribose)", "CHEMICAL", 0, 16], ["ADP", "CHEMICAL", 113, 116], ["ribosyl", "CHEMICAL", 117, 124], ["Poly(ADP-ribose) polymerases", "GENE_OR_GENE_PRODUCT", 0, 28], ["PARPs", "GENE_OR_GENE_PRODUCT", 30, 35], ["diphtheria toxin-like ADP-ribosyl transferases", "GENE_OR_GENE_PRODUCT", 91, 137], ["Poly(ADP-ribose) polymerases", "PROTEIN", 0, 28], ["PARPs", "PROTEIN", 30, 35], ["diphtheria toxin-like ADP-ribosyl transferases", "PROTEIN", 91, 137], ["Poly(ADP-ribose) polymerases (PARPs", "TREATMENT", 0, 35], ["diphtheria toxin", "TEST", 91, 107], ["ADP", "TEST", 113, 116]]], ["PARPs are present in all eukaryotes (except yeast) and sporadically in bacteria; they regulate important cellular processes such as DNA damage repair, transcription, protein degradation, cell-cycle progression, host-virus interaction, cell division, ageing, cell death and bacterial metabolism (6) (7) (8) (9) .", [["cellular", "ANATOMY", 105, 113], ["cell", "ANATOMY", 187, 191], ["cell", "ANATOMY", 235, 239], ["cell", "ANATOMY", 258, 262], ["death", "DISEASE", 263, 268], ["PARPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 105, 113], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["cell", "CELL", 187, 191], ["cell", "CELL", 235, 239], ["cell", "CELL", 258, 262], ["PARPs", "PROTEIN", 0, 5], ["yeast", "SPECIES", 44, 49], ["yeast", "SPECIES", 44, 49], ["PARPs", "PROBLEM", 0, 5], ["yeast", "PROBLEM", 44, 49], ["sporadically in bacteria", "PROBLEM", 55, 79], ["DNA damage repair", "TREATMENT", 132, 149], ["transcription", "TREATMENT", 151, 164], ["protein degradation", "PROBLEM", 166, 185], ["cell-cycle progression", "PROBLEM", 187, 209], ["host-virus interaction", "PROBLEM", 211, 233], ["cell death", "PROBLEM", 258, 268], ["bacterial metabolism", "PROBLEM", 273, 293], ["all eukaryotes", "OBSERVATION_MODIFIER", 21, 35], ["bacteria", "OBSERVATION", 71, 79], ["cellular processes", "OBSERVATION", 105, 123], ["cell death", "OBSERVATION", 258, 268], ["bacterial metabolism", "OBSERVATION", 273, 293]]], ["The human genome encodes for seventeen PARPs with different domain architecture and functions (2) . tRNA 2phosphotransferase 1 (TRPT1/Tpt1/KptA) is sometimes referred to as the eighteenth PARP family member (4) .", [["human", "ORGANISM", 4, 9], ["PARPs", "GENE_OR_GENE_PRODUCT", 39, 44], ["tRNA 2phosphotransferase 1", "GENE_OR_GENE_PRODUCT", 100, 126], ["TRPT1", "GENE_OR_GENE_PRODUCT", 128, 133], ["Tpt1", "GENE_OR_GENE_PRODUCT", 134, 138], ["KptA", "GENE_OR_GENE_PRODUCT", 139, 143], ["PARP", "GENE_OR_GENE_PRODUCT", 188, 192], ["human genome", "DNA", 4, 16], ["PARPs", "PROTEIN", 39, 44], ["tRNA 2phosphotransferase 1", "PROTEIN", 100, 126], ["TRPT1", "PROTEIN", 128, 133], ["Tpt1", "PROTEIN", 134, 138], ["KptA", "PROTEIN", 139, 143], ["eighteenth PARP family member", "PROTEIN", 177, 206], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["seventeen PARPs", "PROBLEM", 29, 44], ["tRNA 2phosphotransferase", "TEST", 100, 124], ["TRPT1", "TEST", 128, 133], ["Tpt1", "TEST", 134, 138]]], ["Several PARP family members (PARP1, PARP2 and tankyrases) synthesize long chains of poly-ADPr, while the other PARP family members transfer a single ADPr group on targets (such as PARP3 and PARP16) (7) .INTRODUCTIONADP-ribosylation is a dynamic chemical modification that is regulated both at the level of addition and the removal of ADPr groups.", [["poly-ADPr", "CHEMICAL", 84, 93], ["poly-ADPr", "CHEMICAL", 84, 93], ["ADPr", "CHEMICAL", 334, 338], ["PARP", "GENE_OR_GENE_PRODUCT", 8, 12], ["PARP1", "GENE_OR_GENE_PRODUCT", 29, 34], ["PARP2", "GENE_OR_GENE_PRODUCT", 36, 41], ["tankyrases", "GENE_OR_GENE_PRODUCT", 46, 56], ["poly-ADPr", "SIMPLE_CHEMICAL", 84, 93], ["PARP", "GENE_OR_GENE_PRODUCT", 111, 115], ["ADPr", "GENE_OR_GENE_PRODUCT", 149, 153], ["PARP3", "GENE_OR_GENE_PRODUCT", 180, 185], ["PARP16", "GENE_OR_GENE_PRODUCT", 190, 196], ["ADPr", "GENE_OR_GENE_PRODUCT", 334, 338], ["PARP family members", "PROTEIN", 8, 27], ["PARP1", "PROTEIN", 29, 34], ["PARP2", "PROTEIN", 36, 41], ["tankyrases", "PROTEIN", 46, 56], ["ADPr", "PROTEIN", 89, 93], ["PARP family members", "PROTEIN", 111, 130], ["ADPr group", "PROTEIN", 149, 159], ["PARP3", "PROTEIN", 180, 185], ["PARP16", "PROTEIN", 190, 196], ["PARP1, PARP2 and tankyrases)", "TREATMENT", 29, 57], ["a single ADPr group", "TREATMENT", 140, 159], ["ribosylation", "TREATMENT", 219, 231], ["a dynamic chemical modification", "TREATMENT", 235, 266], ["the removal of ADPr groups", "TREATMENT", 319, 345], ["ADPr groups", "OBSERVATION", 334, 345]]], ["PARPs have been shown to target mostly Glu/Asp or Ser residues (8) (9) (10) (11) (12) .", [["Glu", "CHEMICAL", 39, 42], ["Glu", "CHEMICAL", 39, 42], ["Asp", "CHEMICAL", 43, 46], ["Ser", "CHEMICAL", 50, 53], ["PARPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["Asp", "AMINO_ACID", 43, 46], ["Ser residues", "AMINO_ACID", 50, 62], ["PARPs", "PROTEIN", 0, 5], ["PARPs", "PROBLEM", 0, 5], ["Glu/Asp", "TEST", 39, 46], ["Ser residues", "TEST", 50, 62]]], ["Poly-ADP-ribosylation can be removed by the action of two divergent enzymes, poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosylhydrolase 3 (ARH3) (13, 14) .", [["Poly-ADP", "CHEMICAL", 0, 8], ["poly(ADP-ribose", "CHEMICAL", 77, 92], ["ADP", "CHEMICAL", 120, 123], ["Poly-ADP", "CHEMICAL", 0, 8], ["poly(ADP-ribose)", "CHEMICAL", 77, 93], ["ADP", "CHEMICAL", 120, 123], ["Poly-ADP-ribosylation", "GENE_OR_GENE_PRODUCT", 0, 21], ["poly(ADP-ribose) glycohydrolase", "GENE_OR_GENE_PRODUCT", 77, 108], ["PARG", "GENE_OR_GENE_PRODUCT", 110, 114], ["ADP-ribosylhydrolase 3", "GENE_OR_GENE_PRODUCT", 120, 142], ["ARH3", "GENE_OR_GENE_PRODUCT", 144, 148], ["divergent enzymes", "PROTEIN", 58, 75], ["poly(ADP-ribose) glycohydrolase", "PROTEIN", 77, 108], ["PARG", "PROTEIN", 110, 114], ["ADP-ribosylhydrolase 3", "PROTEIN", 120, 142], ["ARH3", "PROTEIN", 144, 148], ["Poly-ADP-ribosylation", "TREATMENT", 0, 21], ["two divergent enzymes", "TEST", 54, 75], ["poly(ADP-ribose) glycohydrolase (PARG)", "TREATMENT", 77, 115], ["ADP-ribosylhydrolase", "TREATMENT", 120, 140]]], ["PARG is unable to remove the last ADPr group attached to target proteins (13) while ARH3 is the only hydrolase that can completely remove both poly-and mono-ADPr signal from serine residue (15) , a modification catalysed by PARP1/HPF1 and PARP2/HPF1 complexes (11, 16) .", [["ADPr", "CHEMICAL", 34, 38], ["poly-and mono-ADPr", "CHEMICAL", 143, 161], ["serine", "CHEMICAL", 174, 180], ["PARG", "GENE_OR_GENE_PRODUCT", 0, 4], ["ARH3", "GENE_OR_GENE_PRODUCT", 84, 88], ["mono-ADPr", "SIMPLE_CHEMICAL", 152, 161], ["serine residue (15)", "AMINO_ACID", 174, 193], ["PARP1", "GENE_OR_GENE_PRODUCT", 224, 229], ["HPF1", "GENE_OR_GENE_PRODUCT", 230, 234], ["PARP2", "GENE_OR_GENE_PRODUCT", 239, 244], ["HPF1", "GENE_OR_GENE_PRODUCT", 245, 249], ["PARG", "PROTEIN", 0, 4], ["ADPr group", "PROTEIN", 34, 44], ["target proteins", "PROTEIN", 57, 72], ["ARH3", "PROTEIN", 84, 88], ["hydrolase", "PROTEIN", 101, 110], ["ADPr", "PROTEIN", 157, 161], ["PARP1", "PROTEIN", 224, 229], ["HPF1", "PROTEIN", 230, 234], ["PARP2", "PROTEIN", 239, 244], ["HPF1 complexes", "PROTEIN", 245, 259], ["the last ADPr group", "TREATMENT", 25, 44], ["mono-ADPr signal from serine residue", "PROBLEM", 152, 188], ["PARP1/HPF1", "TEST", 224, 234], ["PARP2/HPF1 complexes", "TEST", 239, 259]]], ["Terminal ADPr linked to Glu/Asp is removed by macrodomain containing enzymes namely terminal ADPr glycohydrolase 1 (TARG1/OARD1), MACROD1 and MACROD2 (17) (18) (19) (20) .", [["Glu", "CHEMICAL", 24, 27], ["Glu", "CHEMICAL", 24, 27], ["Asp", "CHEMICAL", 28, 31], ["ADPr", "GENE_OR_GENE_PRODUCT", 9, 13], ["Glu", "AMINO_ACID", 24, 27], ["Asp", "AMINO_ACID", 28, 31], ["ADPr glycohydrolase 1", "GENE_OR_GENE_PRODUCT", 93, 114], ["TARG1", "GENE_OR_GENE_PRODUCT", 116, 121], ["OARD1", "GENE_OR_GENE_PRODUCT", 122, 127], ["macrodomain containing enzymes", "PROTEIN", 46, 76], ["terminal ADPr glycohydrolase 1", "PROTEIN", 84, 114], ["TARG1", "PROTEIN", 116, 121], ["OARD1", "PROTEIN", 122, 127], ["MACROD1", "PROTEIN", 130, 137], ["Terminal ADPr", "PROBLEM", 0, 13], ["Glu/Asp", "TEST", 24, 31], ["enzymes", "TEST", 69, 76], ["terminal ADPr glycohydrolase", "TEST", 84, 112], ["MACROD1", "TEST", 130, 137], ["MACROD2", "TEST", 142, 149]]], ["Enzymes with phosphodiesterase activity, NUDT16 (nucleoside diphosphate-linked moiety X-type motif 16) and ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1), can cleave py-rophosphate from both poly-and mono-ADPr modified targets leaving phosphoribose tags on the proteins (21, 22) .INTRODUCTIONAlthough ADP-ribosylation has historically been considered to mostly target proteins, there has been increasing evidence that DNA can also be a target for ADP-ribosylation.", [["nucleoside diphosphate", "CHEMICAL", 49, 71], ["py-rophosphate", "CHEMICAL", 178, 192], ["phosphoribose", "CHEMICAL", 247, 260], ["ADP", "CHEMICAL", 313, 316], ["ADP", "CHEMICAL", 459, 462], ["nucleoside diphosphate", "CHEMICAL", 49, 71], ["ectonucleotide", "CHEMICAL", 114, 128], ["py-rophosphate", "CHEMICAL", 178, 192], ["poly-and mono-ADPr", "CHEMICAL", 203, 221], ["phosphoribose", "CHEMICAL", 247, 260], ["ADP", "CHEMICAL", 313, 316], ["ADP", "CHEMICAL", 459, 462], ["NUDT16", "SIMPLE_CHEMICAL", 41, 47], ["nucleoside diphosphate", "SIMPLE_CHEMICAL", 49, 71], ["ENPP1", "GENE_OR_GENE_PRODUCT", 107, 112], ["ectonucleotide pyrophosphatase/phosphodiesterase 1", "GENE_OR_GENE_PRODUCT", 114, 164], ["py-rophosphate", "SIMPLE_CHEMICAL", 178, 192], ["mono-ADPr", "SIMPLE_CHEMICAL", 212, 221], ["phosphoribose", "SIMPLE_CHEMICAL", 247, 260], ["ADP", "SIMPLE_CHEMICAL", 313, 316], ["DNA", "CELLULAR_COMPONENT", 430, 433], ["ADP", "SIMPLE_CHEMICAL", 459, 462], ["nucleoside diphosphate-linked moiety X-type motif 16", "PROTEIN", 49, 101], ["ENPP1", "PROTEIN", 107, 112], ["ectonucleotide pyrophosphatase", "PROTEIN", 114, 144], ["phosphodiesterase 1", "PROTEIN", 145, 164], ["Enzymes", "TEST", 0, 7], ["phosphodiesterase activity", "TEST", 13, 39], ["NUDT16", "TEST", 41, 47], ["nucleoside diphosphate", "TREATMENT", 49, 71], ["moiety X-type motif", "TREATMENT", 79, 98], ["ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase", "TREATMENT", 107, 162], ["ADPr", "TREATMENT", 217, 221], ["the proteins", "TEST", 269, 281], ["ADP-ribosylation", "TREATMENT", 313, 329], ["DNA", "PROBLEM", 430, 433], ["ADP-ribosylation", "TREATMENT", 459, 475]]], ["The first enzymes reported to ADP-ribosylate DNA were pierisins, toxins expressed by cabbage butterfly and related species.", [["ADP", "CHEMICAL", 30, 33], ["ADP", "CHEMICAL", 30, 33], ["ADP", "SIMPLE_CHEMICAL", 30, 33], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["pierisins", "SIMPLE_CHEMICAL", 54, 63], ["cabbage butterfly", "ORGANISM", 85, 102], ["ADP-ribosylate DNA", "DNA", 30, 48], ["cabbage", "SPECIES", 85, 92], ["cabbage", "SPECIES", 85, 92], ["The first enzymes", "TEST", 0, 17], ["ADP", "TEST", 30, 33], ["ribosylate DNA", "PROBLEM", 34, 48], ["toxins", "PROBLEM", 65, 71], ["related species", "PROBLEM", 107, 122]]], ["Piersins irreversibly ADP-ribosylate DNA on guanines (23, 24) .", [["ADP", "CHEMICAL", 22, 25], ["guanines", "CHEMICAL", 44, 52], ["Piersins", "CHEMICAL", 0, 8], ["ADP", "CHEMICAL", 22, 25], ["guanines", "CHEMICAL", 44, 52], ["Piersins", "SIMPLE_CHEMICAL", 0, 8], ["ADP", "SIMPLE_CHEMICAL", 22, 25], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["guanines", "SIMPLE_CHEMICAL", 44, 52], ["Piersins irreversibly ADP-ribosylate DNA on guanines", "PROBLEM", 0, 52], ["ribosylate DNA", "OBSERVATION_MODIFIER", 26, 40]]], ["More recently, it was discovered that the bacterial toxin-antitoxin system DarT-DarG mediates reversible DNA ADP-ribosylation on thymidine residues in single-stranded DNA (in a sequence specific manner) (25) .", [["ADP", "CHEMICAL", 109, 112], ["thymidine", "CHEMICAL", 129, 138], ["ADP", "CHEMICAL", 109, 112], ["thymidine", "CHEMICAL", 129, 138], ["DarT", "GENE_OR_GENE_PRODUCT", 75, 79], ["DarG", "GENE_OR_GENE_PRODUCT", 80, 84], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["ADP", "SIMPLE_CHEMICAL", 109, 112], ["thymidine", "SIMPLE_CHEMICAL", 129, 138], ["DNA", "CELLULAR_COMPONENT", 167, 170], ["bacterial toxin-antitoxin system", "PROTEIN", 42, 74], ["DarT", "PROTEIN", 75, 79], ["DarG", "PROTEIN", 80, 84], ["single-stranded DNA", "DNA", 151, 170], ["the bacterial toxin", "TEST", 38, 57], ["antitoxin system", "TEST", 58, 74], ["reversible DNA ADP", "PROBLEM", 94, 112], ["thymidine residues", "TREATMENT", 129, 147], ["single-stranded DNA", "TREATMENT", 151, 170], ["stranded DNA", "OBSERVATION_MODIFIER", 158, 170]]], ["Furthermore, it was shown that DNA repair PARPs (PARP1, PARP2 and PARP3) can modify DNA on phosphates at DNA breaks (26) (27) (28) (29) .", [["phosphates", "CHEMICAL", 91, 101], ["phosphates", "CHEMICAL", 91, 101], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["PARPs", "GENE_OR_GENE_PRODUCT", 42, 47], ["PARP1", "GENE_OR_GENE_PRODUCT", 49, 54], ["PARP2", "GENE_OR_GENE_PRODUCT", 56, 61], ["PARP3", "GENE_OR_GENE_PRODUCT", 66, 71], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["phosphates", "SIMPLE_CHEMICAL", 91, 101], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["PARPs", "PROTEIN", 42, 47], ["PARP1", "PROTEIN", 49, 54], ["PARP2", "PROTEIN", 56, 61], ["PARP3", "PROTEIN", 66, 71], ["DNA repair PARPs", "TREATMENT", 31, 47], ["PARP1", "TEST", 49, 54], ["PARP2", "TEST", 56, 61], ["PARP3", "TEST", 66, 71], ["phosphates", "TEST", 91, 101], ["DNA breaks", "TEST", 105, 115]]], ["The ADPr groups on phosphates at DNA breaks are efficiently removed by several cellular hydrolases, most notably by PARG, MACROD1/2, TARG1 and ARH3 (26, 27, 30) .INTRODUCTIONThe pool of cellular substrates for ADP-ribosylation has continued to expand and it was recently shown that a PARP-like proteins TRPT1/Tpt1/KptA from bacteria and fungi can ADP-ribosylate RNA and DNA ends (31) .INTRODUCTIONIn this paper, we reveal that ADP-ribosylation of RNA at the terminal phosphate is more widespread than initially thought.", [["cellular", "ANATOMY", 79, 87], ["cellular", "ANATOMY", 186, 194], ["phosphates", "CHEMICAL", 19, 29], ["ADP", "CHEMICAL", 210, 213], ["ADP", "CHEMICAL", 347, 350], ["ADP", "CHEMICAL", 427, 430], ["phosphate", "CHEMICAL", 467, 476], ["ADPr", "CHEMICAL", 4, 8], ["phosphates", "CHEMICAL", 19, 29], ["ADP", "CHEMICAL", 210, 213], ["ADP", "CHEMICAL", 347, 350], ["ADP", "CHEMICAL", 427, 430], ["phosphate", "CHEMICAL", 467, 476], ["ADPr", "SIMPLE_CHEMICAL", 4, 8], ["phosphates", "SIMPLE_CHEMICAL", 19, 29], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["cellular", "CELL", 79, 87], ["PARG", "GENE_OR_GENE_PRODUCT", 116, 120], ["MACROD1/2", "GENE_OR_GENE_PRODUCT", 122, 131], ["TARG1", "GENE_OR_GENE_PRODUCT", 133, 138], ["ARH3", "GENE_OR_GENE_PRODUCT", 143, 147], ["cellular", "CELL", 186, 194], ["ADP", "SIMPLE_CHEMICAL", 210, 213], ["PARP", "GENE_OR_GENE_PRODUCT", 284, 288], ["TRPT1", "GENE_OR_GENE_PRODUCT", 303, 308], ["Tpt1", "GENE_OR_GENE_PRODUCT", 309, 313], ["KptA", "GENE_OR_GENE_PRODUCT", 314, 318], ["ADP", "SIMPLE_CHEMICAL", 347, 350], ["DNA", "CELLULAR_COMPONENT", 370, 373], ["ADP", "SIMPLE_CHEMICAL", 427, 430], ["cellular hydrolases", "PROTEIN", 79, 98], ["PARG", "PROTEIN", 116, 120], ["MACROD1", "PROTEIN", 122, 129], ["TARG1", "PROTEIN", 133, 138], ["ARH3", "PROTEIN", 143, 147], ["PARP-like proteins", "PROTEIN", 284, 302], ["TRPT1", "PROTEIN", 303, 308], ["Tpt1", "PROTEIN", 309, 313], ["KptA", "PROTEIN", 314, 318], ["ADP-ribosylate RNA", "RNA", 347, 365], ["The ADPr groups", "TREATMENT", 0, 15], ["phosphates at DNA breaks", "TREATMENT", 19, 43], ["several cellular hydrolases", "PROBLEM", 71, 98], ["PARG", "TEST", 116, 120], ["MACROD1", "TEST", 122, 129], ["TARG1", "TEST", 133, 138], ["ARH3", "TEST", 143, 147], ["ADP-ribosylation", "PROBLEM", 210, 226], ["a PARP", "TEST", 282, 288], ["proteins TRPT1", "TEST", 294, 308], ["Tpt1", "TEST", 309, 313], ["KptA", "PROBLEM", 314, 318], ["bacteria", "PROBLEM", 324, 332], ["fungi", "PROBLEM", 337, 342], ["ADP", "TEST", 347, 350], ["ADP-ribosylation of RNA", "PROBLEM", 427, 450], ["the terminal phosphate", "TEST", 454, 476], ["cellular hydrolases", "OBSERVATION", 79, 98], ["cellular substrates", "OBSERVATION", 186, 205], ["more widespread", "OBSERVATION_MODIFIER", 480, 495]]], ["We demonstrate that homologues of TRPT1 in higher organisms as well as human PARP10, PARP11 and PARP15 can ADP-ribosylate phosphorylated ends of RNA.", [["ADP", "CHEMICAL", 107, 110], ["ADP", "CHEMICAL", 107, 110], ["TRPT1", "GENE_OR_GENE_PRODUCT", 34, 39], ["human", "ORGANISM", 71, 76], ["PARP10", "GENE_OR_GENE_PRODUCT", 77, 83], ["PARP11", "GENE_OR_GENE_PRODUCT", 85, 91], ["PARP15", "GENE_OR_GENE_PRODUCT", 96, 102], ["ADP", "SIMPLE_CHEMICAL", 107, 110], ["TRPT1", "PROTEIN", 34, 39], ["human PARP10", "PROTEIN", 71, 83], ["PARP11", "PROTEIN", 85, 91], ["PARP15", "PROTEIN", 96, 102], ["RNA", "RNA", 145, 148], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["TRPT1 in higher organisms", "PROBLEM", 34, 59], ["human PARP10", "TREATMENT", 71, 83], ["PARP11", "TREATMENT", 85, 91], ["PARP15", "TREATMENT", 96, 102], ["ADP", "TEST", 107, 110]]], ["We also show that RNA ADP-ribosylation is a reversible process that can be accomplished by several human hydrolases as well as by some viral and bacterial macrodomains.", [["ADP", "CHEMICAL", 22, 25], ["ADP", "CHEMICAL", 22, 25], ["ADP", "SIMPLE_CHEMICAL", 22, 25], ["human", "ORGANISM", 99, 104], ["human hydrolases", "PROTEIN", 99, 115], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["RNA ADP-ribosylation", "PROBLEM", 18, 38], ["a reversible process", "PROBLEM", 42, 62], ["several human hydrolases", "PROBLEM", 91, 115], ["some viral and bacterial macrodomains", "PROBLEM", 130, 167], ["reversible", "OBSERVATION_MODIFIER", 44, 54], ["process", "OBSERVATION", 55, 62], ["viral", "OBSERVATION", 135, 140], ["bacterial macrodomains", "OBSERVATION", 145, 167]]], ["Thus, this study provides the first evidence of reversible ADP-ribosylation of RNA.Plasmid and protein purificationPlasmids expressing full length (FL) PARP3 was cloned into pDEST17 vector with His tag. cDNA encoding the human PARP4 catalytic and BRCT domains (1-572aa) were obtained using gBlock gene fragments and cloned into a pET-His-SUMO-TEV using ligation independent cloning.", [["ADP", "CHEMICAL", 59, 62], ["ADP", "CHEMICAL", 59, 62], ["His", "CHEMICAL", 194, 197], ["ADP", "SIMPLE_CHEMICAL", 59, 62], ["FL", "GENE_OR_GENE_PRODUCT", 148, 150], ["PARP3", "GENE_OR_GENE_PRODUCT", 152, 157], ["pDEST17", "GENE_OR_GENE_PRODUCT", 174, 181], ["human", "ORGANISM", 221, 226], ["PARP4", "GENE_OR_GENE_PRODUCT", 227, 232], ["BRCT", "GENE_OR_GENE_PRODUCT", 247, 251], ["pET-His-SUMO-TEV", "GENE_OR_GENE_PRODUCT", 330, 346], ["full length (FL) PARP3", "DNA", 135, 157], ["pDEST17 vector", "DNA", 174, 188], ["His tag", "DNA", 194, 201], ["cDNA", "DNA", 203, 207], ["human PARP4 catalytic and BRCT domains", "PROTEIN", 221, 259], ["gBlock gene fragments", "DNA", 290, 311], ["pET-His-SUMO", "DNA", 330, 342], ["TEV", "PROTEIN", 343, 346], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["this study", "TEST", 6, 16], ["reversible ADP-ribosylation of RNA", "PROBLEM", 48, 82], ["Plasmid and protein purification", "TREATMENT", 83, 115], ["the human PARP4 catalytic", "TREATMENT", 217, 242], ["BRCT domains", "PROBLEM", 247, 259], ["gBlock gene fragments", "TREATMENT", 290, 311], ["ligation independent cloning", "TREATMENT", 353, 381], ["reversible", "OBSERVATION_MODIFIER", 48, 58], ["ADP", "OBSERVATION", 59, 62], ["ribosylation of RNA", "OBSERVATION", 63, 82], ["protein purification", "OBSERVATION", 95, 115]]], ["PARP5bcat (Tankyrase2 catalytic domain) was cloned into pET-His6 vector.", [["PARP5bcat", "GENE_OR_GENE_PRODUCT", 0, 9], ["Tankyrase2", "GENE_OR_GENE_PRODUCT", 11, 21], ["pET-His6", "GENE_OR_GENE_PRODUCT", 56, 64], ["PARP5bcat", "PROTEIN", 0, 9], ["Tankyrase2 catalytic domain", "PROTEIN", 11, 38], ["pET-His6 vector", "DNA", 56, 71], ["PARP5bcat (Tankyrase2 catalytic domain", "TREATMENT", 0, 38]]], ["PARP10 catalytic domain (818-1025aa) WT and G888W mutant genes were cloned into pGEX-4T1 vector with GST tag.", [["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["G888W", "GENE_OR_GENE_PRODUCT", 44, 49], ["GST tag", "GENE_OR_GENE_PRODUCT", 101, 108], ["PARP10 catalytic domain (818-1025aa) WT and G888W mutant genes", "DNA", 0, 62], ["pGEX-4T1 vector", "DNA", 80, 95], ["GST tag", "DNA", 101, 108], ["WT", "TEST", 37, 39], ["mutant genes", "PROBLEM", 50, 62], ["GST tag", "PROBLEM", 101, 108]]], ["PARP10 FL and PARP16 FL genes were cloned into pET-His6-SUMO-TEV vector.", [["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["FL", "GENE_OR_GENE_PRODUCT", 7, 9], ["PARP16 FL", "GENE_OR_GENE_PRODUCT", 14, 23], ["pET-His6", "GENE_OR_GENE_PRODUCT", 47, 55], ["SUMO", "GENE_OR_GENE_PRODUCT", 56, 60], ["PARP10 FL and PARP16 FL genes", "DNA", 0, 29], ["pET-His6-SUMO-TEV vector", "DNA", 47, 71], ["pET", "TEST", 47, 50]]], ["PARP11 catalytic domain (128-338aa) was cloned in pET28a vector.", [["PARP11", "GENE_OR_GENE_PRODUCT", 0, 6], ["pET28a", "GENE_OR_GENE_PRODUCT", 50, 56], ["PARP11 catalytic domain", "PROTEIN", 0, 23], ["128-338aa", "PROTEIN", 25, 34], ["pET28a vector", "DNA", 50, 63]]], ["The catalytic domain of human PARP12 (489-684aa) was PCR-amplified from the cDNA library using primers with non-complementary restriction enzyme sites located at the 5 (EcoRI) and 3 (XhoI) ends.", [["human", "ORGANISM", 24, 29], ["PARP12", "GENE_OR_GENE_PRODUCT", 30, 36], ["EcoRI", "GENE_OR_GENE_PRODUCT", 169, 174], ["XhoI", "GENE_OR_GENE_PRODUCT", 183, 187], ["catalytic domain", "PROTEIN", 4, 20], ["human PARP12", "PROTEIN", 24, 36], ["cDNA library", "DNA", 76, 88], ["non-complementary restriction enzyme sites", "DNA", 108, 150], ["5 (EcoRI) and 3 (XhoI) ends", "DNA", 166, 193], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["human PARP12", "TEST", 24, 36], ["PCR", "TEST", 53, 56], ["the cDNA library using primers", "TREATMENT", 72, 102], ["non-complementary restriction enzyme sites", "PROBLEM", 108, 150]]], ["The amplified product was cloned into pET-28b+ (Novagen).", [["Novagen", "GENE_OR_GENE_PRODUCT", 48, 55], ["pET", "PROTEIN", 38, 41], ["Novagen", "PROTEIN", 48, 55], ["pET", "TEST", 38, 41]]], ["PARP13 catalytic domain (716-902aa) was PCR amplified and cloned into pET28a vector using BamHI and XhoI cloning sites.", [["PARP13", "GENE_OR_GENE_PRODUCT", 0, 6], ["pET28a", "GENE_OR_GENE_PRODUCT", 70, 76], ["BamHI", "GENE_OR_GENE_PRODUCT", 90, 95], ["XhoI", "GENE_OR_GENE_PRODUCT", 100, 104], ["PARP13 catalytic domain", "PROTEIN", 0, 23], ["pET28a vector", "DNA", 70, 83], ["BamHI and XhoI cloning sites", "DNA", 90, 118], ["PCR", "TEST", 40, 43], ["BamHI and XhoI cloning sites", "TREATMENT", 90, 118]]], ["PARP14 wwe and catalytic domain (1459-1801aa) and PARP15 catalytic domain (481-678aa) were cloned into pNic-Bsa4-6xHis vector.", [["PARP14", "GENE_OR_GENE_PRODUCT", 0, 6], ["pNic", "GENE_OR_GENE_PRODUCT", 103, 107], ["PARP14", "PROTEIN", 0, 6], ["catalytic domain", "PROTEIN", 15, 31], ["1459-1801aa", "PROTEIN", 33, 44], ["PARP15 catalytic domain", "PROTEIN", 50, 73], ["pNic", "PROTEIN", 103, 107], ["Bsa4", "PROTEIN", 108, 112], ["6xHis vector", "DNA", 113, 125], ["PARP15 catalytic domain", "TREATMENT", 50, 73]]], ["TRPT1 gene (Uniprot Q86TN4) was codon optimized and synthesized with His tag from Invitrogen GeneArt Gene synthesis and then further cloned into pET28a vector using NcoI and XhoI restriction enzyme cloning.", [["His", "CHEMICAL", 69, 72], ["TRPT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["pET28a", "GENE_OR_GENE_PRODUCT", 145, 151], ["NcoI", "GENE_OR_GENE_PRODUCT", 165, 169], ["XhoI", "GENE_OR_GENE_PRODUCT", 174, 178], ["TRPT1 gene", "DNA", 0, 10], ["Uniprot Q86TN4", "DNA", 12, 26], ["His tag", "DNA", 69, 76], ["pET28a vector", "DNA", 145, 158], ["TRPT1 gene (Uniprot Q86TN4", "TREATMENT", 0, 26], ["His tag from Invitrogen GeneArt Gene synthesis", "TREATMENT", 69, 115], ["NcoI", "TREATMENT", 165, 169], ["XhoI restriction enzyme cloning", "TREATMENT", 174, 205]]], ["Point mutants of TRPT1 were prepared by using Agilent Quick Change Lighting Site Directed Mutagenesis kit.", [["TRPT1", "GENE_OR_GENE_PRODUCT", 17, 22], ["TRPT1", "PROTEIN", 17, 22], ["Point mutants of TRPT1", "PROBLEM", 0, 22], ["Agilent Quick Change Lighting", "TREATMENT", 46, 75]]], ["Streptomyces coelicolor KptA homologue (SCO3953) was cloned from S. coelicolor genomic DNA into pET15b.Plasmid and protein purificationPARP3 FL was purified as mentioned earlier (27) .", [["SCO3953", "CHEMICAL", 40, 47], ["Streptomyces coelicolor", "ORGANISM", 0, 23], ["KptA", "GENE_OR_GENE_PRODUCT", 24, 28], ["SCO3953", "ORGANISM", 40, 47], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["pET15b", "GENE_OR_GENE_PRODUCT", 96, 102], ["Plasmid", "CELLULAR_COMPONENT", 103, 110], ["protein purificationPARP3 FL", "GENE_OR_GENE_PRODUCT", 115, 143], ["Streptomyces coelicolor KptA homologue", "DNA", 0, 38], ["S. coelicolor genomic DNA", "DNA", 65, 90], ["pET15b", "DNA", 96, 102], ["protein purificationPARP3 FL", "PROTEIN", 115, 143], ["Streptomyces coelicolor", "SPECIES", 0, 23], ["S. coelicolor", "SPECIES", 65, 78], ["Streptomyces coelicolor", "SPECIES", 0, 23], ["S. coelicolor", "SPECIES", 65, 78], ["Streptomyces coelicolor", "TREATMENT", 0, 23], ["Plasmid and protein purificationPARP3 FL", "TEST", 103, 143], ["purificationPARP3 FL", "OBSERVATION", 123, 143]]], ["PARP4, Tankyrase2 cat (32), PARP12 cat and PARP16 FL plasmids were transformed into Escherichia coli BL21 (DE3) competent cells (Millipore) and grown on LB agar plates with Kanamycin (50 mg/ml) and Chloramphenicol (34 mg/ml) overnight at 37 \u2022 C. A swath of cells were inoculated into a 50 ml starter culture of LB media with Kanamycin and Chloramphenicol at 225 rpm, 37 \u2022 C overnight.", [["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 257, 262], ["Kanamycin", "CHEMICAL", 173, 182], ["Chloramphenicol", "CHEMICAL", 198, 213], ["Kanamycin", "CHEMICAL", 325, 334], ["Chloramphenicol", "CHEMICAL", 339, 354], ["Kanamycin", "CHEMICAL", 173, 182], ["Chloramphenicol", "CHEMICAL", 198, 213], ["Kanamycin", "CHEMICAL", 325, 334], ["Chloramphenicol", "CHEMICAL", 339, 354], ["PARP4", "GENE_OR_GENE_PRODUCT", 0, 5], ["Tankyrase2 cat (32)", "GENE_OR_GENE_PRODUCT", 7, 26], ["PARP12 cat", "GENE_OR_GENE_PRODUCT", 28, 38], ["PARP16", "GENE_OR_GENE_PRODUCT", 43, 49], ["Escherichia coli", "ORGANISM", 84, 100], ["BL21", "ORGANISM", 101, 105], ["DE3", "GENE_OR_GENE_PRODUCT", 107, 110], ["cells", "CELL", 122, 127], ["Kanamycin", "SIMPLE_CHEMICAL", 173, 182], ["Chloramphenicol", "SIMPLE_CHEMICAL", 198, 213], ["cells", "CELL", 257, 262], ["Kanamycin", "SIMPLE_CHEMICAL", 325, 334], ["Chloramphenicol", "SIMPLE_CHEMICAL", 339, 354], ["PARP4", "DNA", 0, 5], ["Tankyrase2 cat (32), PARP12 cat and PARP16 FL plasmids", "DNA", 7, 61], ["Escherichia coli BL21 (DE3) competent cells", "CELL_LINE", 84, 127], ["Escherichia coli BL21", "SPECIES", 84, 105], ["Escherichia coli BL21", "SPECIES", 84, 105], ["DE3", "SPECIES", 107, 110], ["PARP4", "TEST", 0, 5], ["PARP12 cat", "TREATMENT", 28, 38], ["PARP16 FL plasmids", "TREATMENT", 43, 61], ["Escherichia coli BL21", "TREATMENT", 84, 105], ["LB agar plates", "TREATMENT", 153, 167], ["Kanamycin", "TREATMENT", 173, 182], ["Chloramphenicol", "TREATMENT", 198, 213], ["LB media", "TREATMENT", 311, 319], ["Kanamycin", "TREATMENT", 325, 334], ["Chloramphenicol", "TREATMENT", 339, 354], ["Escherichia coli BL21", "OBSERVATION", 84, 105]]], ["For each protein of interest 1 L of terrific broth (TB) media (12 g Bacto Tryptone, 24 g yeast extract, 0.4% glycerol, 17 mM KH 2 PO 4 , 72 mM K 2 HPO 4 , 1% glucose, 50 g/ml Kanamycin, 34 g/ml Chloramphenicol) was inoculated with the starter culture and grown to 0.8-1.0 OD 600 at 37 \u2022 C, 225 rpm.", [["extract", "ANATOMY", 95, 102], ["Tryptone", "CHEMICAL", 74, 82], ["glycerol", "CHEMICAL", 109, 117], ["K", "CHEMICAL", 143, 144], ["glucose", "CHEMICAL", 158, 165], ["Kanamycin", "CHEMICAL", 175, 184], ["Chloramphenicol", "CHEMICAL", 194, 209], ["glycerol", "CHEMICAL", 109, 117], ["glucose", "CHEMICAL", 158, 165], ["Kanamycin", "CHEMICAL", 175, 184], ["Chloramphenicol", "CHEMICAL", 194, 209], ["glycerol", "SIMPLE_CHEMICAL", 109, 117], ["glucose", "SIMPLE_CHEMICAL", 158, 165], ["Kanamycin", "SIMPLE_CHEMICAL", 175, 184], ["Chloramphenicol", "SIMPLE_CHEMICAL", 194, 209], ["yeast", "SPECIES", 89, 94], ["yeast", "SPECIES", 89, 94], ["terrific broth (TB) media", "TREATMENT", 36, 61], ["Bacto Tryptone", "TREATMENT", 68, 82], ["glycerol", "TREATMENT", 109, 117], ["K", "TEST", 143, 144], ["HPO", "TEST", 147, 150], ["glucose", "TEST", 158, 165], ["Kanamycin", "TREATMENT", 175, 184], ["Chloramphenicol", "TREATMENT", 194, 209], ["the starter culture", "TEST", 231, 250]]], ["IPTG (Sigma-Aldrich) was added to 0.4 mM to induce protein expression for 18-24 h at 16 \u2022 C, 225 rpm.", [["IPTG", "CHEMICAL", 0, 4], ["Sigma-Aldrich", "CHEMICAL", 6, 19], ["IPTG", "CHEMICAL", 0, 4], ["IPTG", "SIMPLE_CHEMICAL", 0, 4], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 6, 19], ["IPTG (Sigma-Aldrich)", "TREATMENT", 0, 20], ["protein expression", "TEST", 51, 69]]], ["Cells were harvested by centrifugation, resuspended in lysis buffer (20 mM HEPES, pH 7.5, 1 mM \u2424-mercaptoethanol, 1 mM benzamidine, 0.2% NP-40, 0.2% Tween-20, 500 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 8.3 mg/l DNAse I (Roche)) and lysed by sonication at 0 \u2022 C (Branson sonifier 450).", [["Cells", "ANATOMY", 0, 5], ["\u2424-mercaptoethanol", "CHEMICAL", 95, 112], ["NP-40", "CHEMICAL", 137, 142], ["Tween-20", "CHEMICAL", 149, 157], ["NaCl", "CHEMICAL", 166, 170], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 177, 206], ["PMSF", "CHEMICAL", 208, 212], ["HEPES", "CHEMICAL", 75, 80], ["\u2424-mercaptoethanol", "CHEMICAL", 95, 112], ["benzamidine", "CHEMICAL", 119, 130], ["Tween-20", "CHEMICAL", 149, 157], ["NaCl", "CHEMICAL", 166, 170], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 177, 206], ["PMSF", "CHEMICAL", 208, 212], ["Cells", "CELL", 0, 5], ["\u2424-mercaptoethanol", "SIMPLE_CHEMICAL", 95, 112], ["benzamidine", "SIMPLE_CHEMICAL", 119, 130], ["NP-40", "SIMPLE_CHEMICAL", 137, 142], ["Tween-20", "SIMPLE_CHEMICAL", 149, 157], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 177, 206], ["PMSF", "SIMPLE_CHEMICAL", 208, 212], ["lysis buffer", "TREATMENT", 55, 67], ["HEPES", "TEST", 75, 80], ["pH", "TEST", 82, 84], ["mercaptoethanol", "TEST", 97, 112], ["1 mM benzamidine", "TREATMENT", 114, 130], ["NP", "TEST", 137, 139], ["NaCl", "TREATMENT", 166, 170], ["1 mM phenylmethylsulfonyl fluoride", "TREATMENT", 172, 206]]], ["Lysates were incubated with pre-washed Ni-NTA agarose resin (50% slurry, Qiagen) with end-over-end rotation at 4 \u2022 C for 1 h.", [["Lysates", "ANATOMY", 0, 7], ["Ni-NTA", "CHEMICAL", 39, 45], ["Ni-NTA", "CHEMICAL", 39, 45], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Ni-NTA", "SIMPLE_CHEMICAL", 39, 45], ["Lysates", "TEST", 0, 7], ["pre-washed Ni-NTA agarose resin", "TREATMENT", 28, 59]]], ["Following extensive washing with buffer B1+20 (20 mM HEPES, pH 7.5, 1 mM \u2424-Me, 1 mM PMSF, 1 mM benzamidine, 500 mM NaCl, 20 mM imidazole) protein was eluted in four fractions of B1 containing 100-400 mM imidazole.", [["NaCl", "CHEMICAL", 115, 119], ["imidazole", "CHEMICAL", 127, 136], ["imidazole", "CHEMICAL", 203, 212], ["HEPES", "CHEMICAL", 53, 58], ["PMSF", "CHEMICAL", 84, 88], ["benzamidine", "CHEMICAL", 95, 106], ["NaCl", "CHEMICAL", 115, 119], ["imidazole", "CHEMICAL", 127, 136], ["imidazole", "CHEMICAL", 203, 212], ["PMSF", "SIMPLE_CHEMICAL", 84, 88], ["benzamidine", "SIMPLE_CHEMICAL", 95, 106], ["imidazole", "SIMPLE_CHEMICAL", 203, 212], ["buffer B1", "TEST", 33, 42], ["HEPES", "TEST", 53, 58], ["pH", "TEST", 60, 62], ["Me", "TEST", 75, 77], ["PMSF", "TEST", 84, 88], ["1 mM benzamidine", "TREATMENT", 90, 106], ["500 mM NaCl", "TREATMENT", 108, 119], ["20 mM imidazole) protein", "TREATMENT", 121, 145]]], ["Fractions containing protein were collected and dialysed against 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 1 mM \u2424-Me, 0.4 M NaCl at 4 \u2022 C.Plasmid and protein purificationPARP10 catalytic domain (WT and G888W mutant) were purified as mentioned earlier (22) .", [["Tris-HCl", "CHEMICAL", 71, 79], ["Me", "CHEMICAL", 109, 111], ["NaCl", "CHEMICAL", 119, 123], ["Tris-HCl", "CHEMICAL", 71, 79], ["EDTA", "CHEMICAL", 96, 100], ["Me", "CHEMICAL", 109, 111], ["NaCl", "CHEMICAL", 119, 123], ["Tris-HCl", "SIMPLE_CHEMICAL", 71, 79], ["EDTA", "SIMPLE_CHEMICAL", 96, 100], ["\u2424-Me", "SIMPLE_CHEMICAL", 107, 111], ["protein purificationPARP10 catalytic domain", "PROTEIN", 145, 188], ["WT", "PROTEIN", 190, 192], ["G888W mutant", "PROTEIN", 197, 209], ["protein", "TEST", 21, 28], ["Tris", "TEST", 71, 75], ["pH", "TEST", 81, 83], ["EDTA", "TEST", 96, 100], ["0.4 M NaCl", "TREATMENT", 113, 123], ["WT", "TEST", 190, 192]]], ["In short, GSTtagged PARP10 was transformed into Rosetta DE3 competent cells and grown in LB media supplemented with Ampicillin and Chloramphenicol.", [["cells", "ANATOMY", 70, 75], ["Ampicillin", "CHEMICAL", 116, 126], ["Chloramphenicol", "CHEMICAL", 131, 146], ["Ampicillin", "CHEMICAL", 116, 126], ["Chloramphenicol", "CHEMICAL", 131, 146], ["PARP10", "GENE_OR_GENE_PRODUCT", 20, 26], ["DE3", "GENE_OR_GENE_PRODUCT", 56, 59], ["cells", "CELL", 70, 75], ["Ampicillin", "SIMPLE_CHEMICAL", 116, 126], ["Chloramphenicol", "SIMPLE_CHEMICAL", 131, 146], ["GSTtagged PARP10", "PROTEIN", 10, 26], ["Rosetta DE3 competent cells", "CELL_LINE", 48, 75], ["Rosetta DE3", "SPECIES", 48, 59], ["Ampicillin", "TREATMENT", 116, 126], ["Chloramphenicol", "TREATMENT", 131, 146]]], ["Cultures were induced with 0.5 mM IPTG at 0.8-1.0 OD 600 and grown overnight at 16 \u2022 C. Following centrifugation, PARP10 cat bacterial cell pellet was resuspended in PBS buffer supplemented with BugBuster protein extraction reagent, Benzonase, 10% glycerol, 1 mM DTT and Complete Protease inhibitor cocktail and allowed to lyse by incubation at 4 \u2022 C for 1 h.", [["cell", "ANATOMY", 135, 139], ["IPTG", "CHEMICAL", 34, 38], ["Benzonase", "CHEMICAL", 233, 242], ["glycerol", "CHEMICAL", 248, 256], ["IPTG", "CHEMICAL", 34, 38], ["Benzonase", "CHEMICAL", 233, 242], ["glycerol", "CHEMICAL", 248, 256], ["DTT", "CHEMICAL", 263, 266], ["cat", "ORGANISM", 121, 124], ["bacterial cell", "CELL", 125, 139], ["BugBuster", "SIMPLE_CHEMICAL", 195, 204], ["Benzonase", "SIMPLE_CHEMICAL", 233, 242], ["glycerol", "SIMPLE_CHEMICAL", 248, 256], ["DTT", "SIMPLE_CHEMICAL", 263, 266], ["Cultures", "TEST", 0, 8], ["0.5 mM IPTG", "TREATMENT", 27, 38], ["centrifugation", "TEST", 98, 112], ["PARP10 cat bacterial cell pellet", "TREATMENT", 114, 146], ["BugBuster protein extraction reagent", "TREATMENT", 195, 231], ["Benzonase", "TREATMENT", 233, 242], ["glycerol", "TREATMENT", 248, 256], ["1 mM DTT", "TREATMENT", 258, 266], ["Complete Protease inhibitor cocktail", "TREATMENT", 271, 307], ["bacterial cell pellet", "OBSERVATION", 125, 146]]], ["Lysate was further centrifuged and cleared lysate was applied to glutathione sepharose beads for 1 h at 4 \u2022 C. GST-tagged PARP10 was eluted using lysis buffer supplemented with 20 mM reduced glutathione.", [["lysate", "ANATOMY", 43, 49], ["glutathione", "CHEMICAL", 65, 76], ["glutathione", "CHEMICAL", 191, 202], ["glutathione", "CHEMICAL", 65, 76], ["reduced glutathione", "CHEMICAL", 183, 202], ["Lysate", "ORGANISM_SUBSTANCE", 0, 6], ["glutathione", "SIMPLE_CHEMICAL", 65, 76], ["GST", "GENE_OR_GENE_PRODUCT", 111, 114], ["PARP10", "GENE_OR_GENE_PRODUCT", 122, 128], ["glutathione", "SIMPLE_CHEMICAL", 191, 202], ["GST", "PROTEIN", 111, 114], ["tagged PARP10", "PROTEIN", 115, 128], ["Lysate", "TREATMENT", 0, 6], ["glutathione sepharose beads", "TREATMENT", 65, 92], ["lysis buffer", "TREATMENT", 146, 158], ["20 mM reduced glutathione", "TREATMENT", 177, 202]]], ["Eluted protein was further dialysed against 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and 1 mM DTT.", [["Tris-HCl", "CHEMICAL", 50, 58], ["NaCl", "CHEMICAL", 74, 78], ["glycerol", "CHEMICAL", 84, 92], ["Tris-HCl", "CHEMICAL", 50, 58], ["NaCl", "CHEMICAL", 74, 78], ["glycerol", "CHEMICAL", 84, 92], ["DTT", "CHEMICAL", 102, 105], ["Tris-HCl", "SIMPLE_CHEMICAL", 50, 58], ["glycerol", "SIMPLE_CHEMICAL", 84, 92], ["DTT", "SIMPLE_CHEMICAL", 102, 105], ["Eluted protein", "TEST", 0, 14], ["Tris", "TEST", 50, 54], ["HCl pH", "TEST", 55, 61], ["NaCl", "TEST", 74, 78], ["10% glycerol", "TREATMENT", 80, 92]]], ["PARP10 cat WT and G888W mutant were further purified on Superdex 200 column.Plasmid and protein purificationPARP10 FL was transformed into Rosetta DE3 competent cells and grown in 6 l 2\u00d7 YT media supplemented with Kanamycin.", [["cells", "ANATOMY", 161, 166], ["FL", "CHEMICAL", 115, 117], ["Kanamycin", "CHEMICAL", 214, 223], ["Kanamycin", "CHEMICAL", 214, 223], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["G888W", "GENE_OR_GENE_PRODUCT", 18, 23], ["Plasmid", "CELLULAR_COMPONENT", 76, 83], ["DE3", "GENE_OR_GENE_PRODUCT", 147, 150], ["cells", "CELL", 161, 166], ["Kanamycin", "SIMPLE_CHEMICAL", 214, 223], ["PARP10", "PROTEIN", 0, 6], ["G888W mutant", "PROTEIN", 18, 30], ["protein purificationPARP10 FL", "PROTEIN", 88, 117], ["Rosetta DE3 competent cells", "CELL_LINE", 139, 166], ["Rosetta DE3", "SPECIES", 139, 150], ["PARP10 cat WT", "TEST", 0, 13], ["Plasmid and protein purificationPARP10 FL", "TREATMENT", 76, 117], ["YT media", "TREATMENT", 187, 195], ["Kanamycin", "TREATMENT", 214, 223]]], ["Cultures were induced with 0.5 mM IPTG at 0.6-0.8 OD 600 and grown overnight at 18 \u2022 C. Bacterial pellet was resuspended in lysis buffer (20 mM HEPES pH 8, 500 mM NaCl, 10 mM imidazole and 0.5 mM TCEP).", [["pellet", "ANATOMY", 98, 104], ["IPTG", "CHEMICAL", 34, 38], ["NaCl", "CHEMICAL", 163, 167], ["imidazole", "CHEMICAL", 175, 184], ["IPTG", "CHEMICAL", 34, 38], ["NaCl", "CHEMICAL", 163, 167], ["imidazole", "CHEMICAL", 175, 184], ["TCEP", "CHEMICAL", 196, 200], ["imidazole", "SIMPLE_CHEMICAL", 175, 184], ["Cultures", "TEST", 0, 8], ["0.5 mM IPTG", "TREATMENT", 27, 38], ["Bacterial pellet", "PROBLEM", 88, 104], ["lysis buffer", "TREATMENT", 124, 136], ["HEPES pH", "TEST", 144, 152], ["NaCl", "TEST", 163, 167], ["10 mM imidazole", "TREATMENT", 169, 184], ["Bacterial pellet", "OBSERVATION", 88, 104]]], ["PARP10 FL was purified via three-step purification process involving Nickel column purification, heparin column and gel filtration column.", [["Nickel", "CHEMICAL", 69, 75], ["heparin", "CHEMICAL", 97, 104], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["Nickel", "SIMPLE_CHEMICAL", 69, 75], ["heparin", "SIMPLE_CHEMICAL", 97, 104], ["PARP10 FL", "PROTEIN", 0, 9], ["PARP10 FL", "TEST", 0, 9], ["three-step purification process", "TREATMENT", 27, 58], ["Nickel column purification", "TREATMENT", 69, 95], ["heparin column", "TREATMENT", 97, 111], ["gel filtration column", "TREATMENT", 116, 137], ["Nickel column", "OBSERVATION", 69, 82], ["heparin column", "OBSERVATION", 97, 111], ["filtration column", "OBSERVATION", 120, 137]]], ["Cells were lysed by addition of BugBuster, protease inhibitor cocktail, benzonase and lysozyme and allowed to lyse for 1 h at 4 \u2022 C. Cleared lysate was incubated with pre-washed Ni-NTA agarose resin (50% slurry, Qiagen) with end-over-end rotation at 4 \u2022 C for 1 h.", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 141, 147], ["benzonase", "CHEMICAL", 72, 81], ["Ni-NTA", "CHEMICAL", 178, 184], ["Ni-NTA", "CHEMICAL", 178, 184], ["Cells", "CELL", 0, 5], ["BugBuster", "SIMPLE_CHEMICAL", 32, 41], ["benzonase", "SIMPLE_CHEMICAL", 72, 81], ["lysozyme", "GENE_OR_GENE_PRODUCT", 86, 94], ["Ni-NTA", "SIMPLE_CHEMICAL", 178, 184], ["lysozyme", "PROTEIN", 86, 94], ["BugBuster", "TREATMENT", 32, 41], ["protease inhibitor cocktail", "TREATMENT", 43, 70], ["benzonase", "TREATMENT", 72, 81], ["lysozyme", "TREATMENT", 86, 94], ["pre-washed Ni-NTA agarose resin", "TREATMENT", 167, 198], ["end-over-end rotation", "TREATMENT", 225, 246]]], ["Beads were then further washed with high salt buffer (20 mM HEPES pH 8, 1 M NaCl, 10 mM imidazole and 0.5 mM TCEP) followed by gradient elution over 10 mM-1 M imidazole.", [["NaCl", "CHEMICAL", 76, 80], ["imidazole", "CHEMICAL", 88, 97], ["imidazole", "CHEMICAL", 159, 168], ["NaCl", "CHEMICAL", 76, 80], ["imidazole", "CHEMICAL", 88, 97], ["TCEP", "CHEMICAL", 109, 113], ["imidazole", "CHEMICAL", 159, 168], ["Beads", "CELL", 0, 5], ["imidazole", "SIMPLE_CHEMICAL", 88, 97], ["M imidazole", "SIMPLE_CHEMICAL", 157, 168], ["high salt buffer", "TREATMENT", 36, 52], ["mM HEPES pH", "TREATMENT", 57, 68], ["1 M NaCl", "TREATMENT", 72, 80], ["imidazole", "TREATMENT", 88, 97], ["0.5 mM TCEP", "TREATMENT", 102, 113], ["gradient elution", "TREATMENT", 127, 143]]], ["Eluted protein was assessed by SDS-PAGE gel and further dialysed against 25 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA and 0.1 mM TCEP.", [["NaCl", "CHEMICAL", 99, 103], ["NaCl", "CHEMICAL", 99, 103], ["EDTA", "CHEMICAL", 110, 114], ["TCEP", "CHEMICAL", 126, 130], ["EDTA", "SIMPLE_CHEMICAL", 110, 114], ["Eluted protein", "TEST", 0, 14], ["Tris pH", "TEST", 79, 86], ["NaCl", "TEST", 99, 103], ["EDTA", "TEST", 110, 114]]], ["Dialysed protein sample was further diluted using no salt buffer (25 mM Tris pH 7.5, 1 mM EDTA and 0.1 mM TCEP) to get the salt concentration to 30 mM NaCl and was applied onto Heparin column to remove any nucleic acid contamination.", [["sample", "ANATOMY", 17, 23], ["NaCl", "CHEMICAL", 151, 155], ["nucleic acid", "CHEMICAL", 206, 218], ["EDTA", "CHEMICAL", 90, 94], ["TCEP", "CHEMICAL", 106, 110], ["NaCl", "CHEMICAL", 151, 155], ["EDTA", "SIMPLE_CHEMICAL", 90, 94], ["salt", "SIMPLE_CHEMICAL", 123, 127], ["Heparin", "SIMPLE_CHEMICAL", 177, 184], ["nucleic acid", "SIMPLE_CHEMICAL", 206, 218], ["Dialysed protein sample", "TREATMENT", 0, 23], ["salt buffer", "TREATMENT", 53, 64], ["Tris pH", "TEST", 72, 79], ["1 mM EDTA", "TREATMENT", 85, 94], ["the salt concentration", "TREATMENT", 119, 141], ["NaCl", "TREATMENT", 151, 155], ["Heparin column", "TREATMENT", 177, 191], ["any nucleic acid contamination", "PROBLEM", 202, 232]]], ["Small fraction of protein bound onto Heparin column while most ran out as flow through in the condition tested.", [["Small fraction of protein bound", "PROBLEM", 0, 31], ["Heparin column", "TREATMENT", 37, 51], ["fraction", "OBSERVATION", 6, 14], ["protein bound", "OBSERVATION", 18, 31], ["Heparin column", "OBSERVATION", 37, 51], ["flow", "OBSERVATION", 74, 78]]], ["The Heparin column bound protein was eluted with gradient of 30 mM-1 M NaCl concentration.", [["NaCl", "CHEMICAL", 71, 75], ["NaCl", "CHEMICAL", 71, 75], ["Heparin", "SIMPLE_CHEMICAL", 4, 11], ["Heparin column bound protein", "PROTEIN", 4, 32], ["The Heparin column bound protein", "TREATMENT", 0, 32], ["gradient", "TEST", 49, 57]]], ["At this stage, the purity of eluted protein was tested by SDS-PAGE gel.", [["eluted protein", "PROTEIN", 29, 43], ["eluted protein", "PROBLEM", 29, 43]]], ["Protein fractions were concentrated and further subjected to size exclusion chromatography using Superdex 200 column.Plasmid and protein purificationPARP13 cat (716-902aa) and PARP14 wwe and cat (1459-1801aa) plasmids were transformed in Rosetta DE3 competent cells and grown in 2\u00d7 YT media supplemented with Kanamycin.", [["plasmids", "ANATOMY", 209, 217], ["cells", "ANATOMY", 260, 265], ["Kanamycin", "CHEMICAL", 309, 318], ["Kanamycin", "CHEMICAL", 309, 318], ["protein purificationPARP13 cat (716-902aa)", "GENE_OR_GENE_PRODUCT", 129, 171], ["PARP14", "GENE_OR_GENE_PRODUCT", 176, 182], ["cells", "CELL", 260, 265], ["Kanamycin", "SIMPLE_CHEMICAL", 309, 318], ["protein purificationPARP13 cat (716-902aa) and PARP14 wwe and cat (1459-1801aa) plasmids", "DNA", 129, 217], ["Rosetta DE3 competent cells", "CELL_LINE", 238, 265], ["Rosetta DE3", "SPECIES", 238, 249], ["Protein fractions", "TEST", 0, 17], ["Plasmid", "TREATMENT", 117, 124], ["PARP14", "TEST", 176, 182], ["cat", "TEST", 191, 194], ["aa) plasmids", "TREATMENT", 205, 217], ["YT media", "TREATMENT", 282, 290], ["Kanamycin", "TREATMENT", 309, 318], ["size", "OBSERVATION_MODIFIER", 61, 65]]], ["Induction was carried out at 0.6-0.8 OD 600 using 0.5 mM IPTG and cells were allowed to grow overnight at 18 \u2022 C. Bacterial pellet was lysed in lysis buffer (20 mM HEPES pH 8, 500 mM NaCl, 10 mM imidazole and 0.5 mM TCEP) supplemented with BugBuster, protease inhibitor cocktail, benzonase and lysozyme.", [["cells", "ANATOMY", 66, 71], ["pellet", "ANATOMY", 124, 130], ["IPTG", "CHEMICAL", 57, 61], ["NaCl", "CHEMICAL", 183, 187], ["imidazole", "CHEMICAL", 195, 204], ["BugBuster", "CHEMICAL", 240, 249], ["benzonase", "CHEMICAL", 280, 289], ["IPTG", "CHEMICAL", 57, 61], ["NaCl", "CHEMICAL", 183, 187], ["imidazole", "CHEMICAL", 195, 204], ["TCEP", "CHEMICAL", 216, 220], ["cells", "CELL", 66, 71], ["imidazole", "SIMPLE_CHEMICAL", 195, 204], ["BugBuster", "SIMPLE_CHEMICAL", 240, 249], ["benzonase", "SIMPLE_CHEMICAL", 280, 289], ["lysozyme", "GENE_OR_GENE_PRODUCT", 294, 302], ["lysozyme", "PROTEIN", 294, 302], ["0.5 mM IPTG", "TREATMENT", 50, 61], ["Bacterial pellet", "PROBLEM", 114, 130], ["lysis buffer", "TREATMENT", 144, 156], ["HEPES pH", "TEST", 164, 172], ["NaCl", "TEST", 183, 187], ["10 mM imidazole", "TREATMENT", 189, 204], ["0.5 mM TCEP", "TREATMENT", 209, 220], ["BugBuster", "TREATMENT", 240, 249], ["protease inhibitor cocktail", "TREATMENT", 251, 278], ["benzonase", "TREATMENT", 280, 289], ["lysozyme", "TREATMENT", 294, 302]]], ["Cleared lysate was then bound to pre-washed Ni-NTA agarose resin followed by washes with lysis buffer.", [["lysate", "ANATOMY", 8, 14], ["Ni-NTA", "CHEMICAL", 44, 50], ["Ni-NTA", "CHEMICAL", 44, 50], ["lysate", "ORGANISM_SUBSTANCE", 8, 14], ["Ni-NTA agarose resin", "SIMPLE_CHEMICAL", 44, 64], ["Ni-NTA agarose resin", "TREATMENT", 44, 64], ["lysis buffer", "TREATMENT", 89, 101]]], ["Proteins were eluted using elution buffer (20 mM HEPES pH 8, 500 mM NaCl and 0.5 mM TCEP) with an incremental gradient of 10-500 mM imidazole.", [["NaCl", "CHEMICAL", 68, 72], ["imidazole", "CHEMICAL", 132, 141], ["NaCl", "CHEMICAL", 68, 72], ["TCEP", "CHEMICAL", 84, 88], ["imidazole", "CHEMICAL", 132, 141], ["imidazole", "SIMPLE_CHEMICAL", 132, 141], ["Proteins", "TEST", 0, 8], ["elution buffer", "TREATMENT", 27, 41], ["20 mM HEPES pH", "TREATMENT", 43, 57], ["NaCl", "TEST", 68, 72], ["an incremental gradient", "TEST", 95, 118]]], ["Proteins purity was assessed by SDS-PAGE gel.", [["Proteins purity", "TEST", 0, 15]]], ["PARP13 protein was dialysed overnight against 25 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA and 0.1 mM TCEP buffer.", [["NaCl", "CHEMICAL", 72, 76], ["NaCl", "CHEMICAL", 72, 76], ["EDTA", "CHEMICAL", 83, 87], ["TCEP", "CHEMICAL", 99, 103], ["PARP13", "GENE_OR_GENE_PRODUCT", 0, 6], ["EDTA", "SIMPLE_CHEMICAL", 83, 87], ["PARP13 protein", "PROTEIN", 0, 14], ["protein", "TEST", 7, 14], ["Tris pH", "TEST", 52, 59], ["NaCl", "TEST", 72, 76], ["EDTA", "TEST", 83, 87], ["0.1 mM TCEP buffer", "TREATMENT", 92, 110]]], ["PARP14 protein was dialysed overnight against 20 mM HEPES pH 7.5, 300 mM NaCl and 0.5 mM TCEP and further subjected to Superdex 75 column for size exclusion chromatography.", [["NaCl", "CHEMICAL", 73, 77], ["NaCl", "CHEMICAL", 73, 77], ["TCEP", "CHEMICAL", 89, 93], ["PARP14", "GENE_OR_GENE_PRODUCT", 0, 6], ["PARP14 protein", "PROTEIN", 0, 14], ["protein", "TEST", 7, 14], ["pH", "TEST", 58, 60], ["NaCl", "TEST", 73, 77], ["size exclusion chromatography", "TEST", 142, 171]]], ["The catalytic domain of PARP15 (481-678aa) was purified as mentioned earlier (33) .", [["PARP15", "GENE_OR_GENE_PRODUCT", 24, 30], ["catalytic domain", "PROTEIN", 4, 20], ["PARP15", "PROTEIN", 24, 30], ["PARP15", "TEST", 24, 30]]], ["TRPT1 was purified as described earlier (34) , in short TRPT1 plasmid was transformed into Rosetta DE3 competent cells and grown in LB media supplemented with Kanamycin.", [["plasmid", "ANATOMY", 62, 69], ["cells", "ANATOMY", 113, 118], ["Kanamycin", "CHEMICAL", 159, 168], ["Kanamycin", "CHEMICAL", 159, 168], ["TRPT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TRPT1", "GENE_OR_GENE_PRODUCT", 56, 61], ["DE3", "GENE_OR_GENE_PRODUCT", 99, 102], ["cells", "CELL", 113, 118], ["Kanamycin", "SIMPLE_CHEMICAL", 159, 168], ["TRPT1", "PROTEIN", 0, 5], ["TRPT1 plasmid", "DNA", 56, 69], ["Rosetta DE3 competent cells", "CELL_LINE", 91, 118], ["Rosetta DE3", "SPECIES", 91, 102], ["TRPT1", "TEST", 0, 5], ["short TRPT1 plasmid", "PROBLEM", 50, 69], ["Kanamycin", "TREATMENT", 159, 168]]], ["Cultures were induced with 0.2-0.5 mM IPTG at 0.8 OD 600 and grown overnight at 16 \u2022 C. Following centrifugation, TRPT1 bacterial pellet (WT or mutants) was resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and 10 mM imidazole) supplemented with BugBuster, Benzonase, 0.5 mM TCEP and Complete protease inhibitor cocktail and lysed by mixing for 1 h at 4 \u2022 C. Lysate was centrifuged at 17 000 rpm for 50 min and the cleared lysate was incubated with prewashed nickel NTA agarose beads for 1 h at 4 \u2022 C. His-tagged TRPT1 protein was eluted using elution buffer (50 mM Tris-HCl pH 8, 0.1 M NaCl, 10% glycerol) with an incremental gradient of 10-500 mM imidazole.", [["lysate", "ANATOMY", 451, 457], ["IPTG", "CHEMICAL", 38, 42], ["Tris-HCl", "CHEMICAL", 192, 200], ["NaCl", "CHEMICAL", 216, 220], ["glycerol", "CHEMICAL", 226, 234], ["imidazole", "CHEMICAL", 245, 254], ["BugBuster", "CHEMICAL", 274, 283], ["Benzonase", "CHEMICAL", 285, 294], ["nickel", "CHEMICAL", 487, 493], ["Tris-HCl", "CHEMICAL", 594, 602], ["NaCl", "CHEMICAL", 615, 619], ["glycerol", "CHEMICAL", 625, 633], ["imidazole", "CHEMICAL", 677, 686], ["IPTG", "CHEMICAL", 38, 42], ["Tris-HCl", "CHEMICAL", 192, 200], ["NaCl", "CHEMICAL", 216, 220], ["glycerol", "CHEMICAL", 226, 234], ["imidazole", "CHEMICAL", 245, 254], ["BugBuster", "CHEMICAL", 274, 283], ["Benzonase", "CHEMICAL", 285, 294], ["TCEP", "CHEMICAL", 303, 307], ["nickel NTA", "CHEMICAL", 487, 497], ["Tris-HCl", "CHEMICAL", 594, 602], ["NaCl", "CHEMICAL", 615, 619], ["glycerol", "CHEMICAL", 625, 633], ["imidazole", "CHEMICAL", 677, 686], ["TRPT1", "GENE_OR_GENE_PRODUCT", 114, 119], ["glycerol", "SIMPLE_CHEMICAL", 226, 234], ["imidazole", "SIMPLE_CHEMICAL", 245, 254], ["BugBuster", "SIMPLE_CHEMICAL", 274, 283], ["Benzonase", "SIMPLE_CHEMICAL", 285, 294], ["TCEP", "SIMPLE_CHEMICAL", 303, 307], ["Lysate", "ORGANISM_SUBSTANCE", 387, 393], ["TRPT1", "GENE_OR_GENE_PRODUCT", 541, 546], ["glycerol", "SIMPLE_CHEMICAL", 625, 633], ["imidazole", "SIMPLE_CHEMICAL", 677, 686], ["TRPT1 protein", "PROTEIN", 541, 554], ["Cultures", "TEST", 0, 8], ["centrifugation", "TEST", 98, 112], ["TRPT1 bacterial pellet", "TEST", 114, 136], ["lysis buffer", "TREATMENT", 172, 184], ["Tris", "TEST", 192, 196], ["pH", "TEST", 201, 203], ["NaCl", "TEST", 216, 220], ["glycerol", "TREATMENT", 226, 234], ["BugBuster", "TREATMENT", 274, 283], ["Benzonase", "TREATMENT", 285, 294], ["0.5 mM TCEP", "TREATMENT", 296, 307], ["Complete protease inhibitor cocktail", "TREATMENT", 312, 348], ["the cleared lysate", "TREATMENT", 439, 457], ["prewashed nickel NTA agarose beads", "TREATMENT", 477, 511], ["His-tagged TRPT1 protein", "TREATMENT", 530, 554], ["elution buffer", "TREATMENT", 572, 586], ["Tris", "TEST", 594, 598], ["NaCl", "TREATMENT", 615, 619], ["an incremental gradient", "TEST", 640, 663]]], ["Eluted TRPT1 protein was dialysed overnight against column buffer (50 mM Tris-HCl pH 8, 50 mM NaCl, 2 mM DTT and 10% glycerol).", [["Tris-HCl", "CHEMICAL", 73, 81], ["NaCl", "CHEMICAL", 94, 98], ["glycerol", "CHEMICAL", 117, 125], ["Tris-HCl", "CHEMICAL", 73, 81], ["NaCl", "CHEMICAL", 94, 98], ["DTT", "CHEMICAL", 105, 108], ["glycerol", "CHEMICAL", 117, 125], ["TRPT1", "GENE_OR_GENE_PRODUCT", 7, 12], ["glycerol", "SIMPLE_CHEMICAL", 117, 125], ["TRPT1 protein", "PROTEIN", 7, 20], ["Eluted TRPT1 protein", "TREATMENT", 0, 20], ["column buffer", "TREATMENT", 52, 65], ["Tris", "TEST", 73, 77], ["pH", "TEST", 82, 84], ["NaCl", "TEST", 94, 98], ["DTT", "TEST", 105, 108], ["10% glycerol", "TREATMENT", 113, 125]]], ["TRPT1Plasmid and protein purificationWT protein was further purified by size exclusion chromatography using Superdex 75 column.Plasmid and protein purificationStreptomyces coelicolor KptA homologue (SCO3953) gene was expressed in Escherichia coli BL21(DE3) cells and were grown for 3 h at 30 \u2022 C with 0.8 mM IPTG added at 0.8 OD 600 .", [["DE3) cells", "ANATOMY", 252, 262], ["IPTG", "CHEMICAL", 308, 312], ["IPTG", "CHEMICAL", 308, 312], ["TRPT1Plasmid", "GENE_OR_GENE_PRODUCT", 0, 12], ["protein purificationStreptomyces coelicolor KptA homologue", "GENE_OR_GENE_PRODUCT", 139, 197], ["SCO3953", "GENE_OR_GENE_PRODUCT", 199, 206], ["Escherichia coli", "ORGANISM", 230, 246], ["BL21", "ORGANISM", 247, 251], ["DE3) cells", "CELL", 252, 262], ["TRPT1Plasmid", "PROTEIN", 0, 12], ["protein purificationWT protein", "PROTEIN", 17, 47], ["Streptomyces coelicolor KptA homologue (SCO3953) gene", "DNA", 159, 212], ["Escherichia coli BL21(DE3) cells", "CELL_LINE", 230, 262], ["Streptomyces coelicolor", "SPECIES", 159, 182], ["Escherichia coli BL21", "SPECIES", 230, 251], ["Streptomyces coelicolor", "SPECIES", 159, 182], ["Escherichia coli BL21", "SPECIES", 230, 251], ["DE3", "SPECIES", 252, 255], ["TRPT1Plasmid", "TREATMENT", 0, 12], ["protein purificationWT protein", "TEST", 17, 47], ["Plasmid and protein purificationStreptomyces coelicolor", "TREATMENT", 127, 182], ["Escherichia coli BL21(DE3) cells", "TEST", 230, 262], ["0.8 mM IPTG", "TREATMENT", 301, 312], ["Escherichia coli", "OBSERVATION", 230, 246]]], ["Recombinant protein was purified using TALON affinity resin according to standard procedure.", [["TALON", "SIMPLE_CHEMICAL", 39, 44], ["Recombinant protein", "PROBLEM", 0, 19], ["TALON affinity resin", "TREATMENT", 39, 59], ["standard procedure", "TREATMENT", 73, 91]]], ["Streptomyces coelicolor MacroD homologue (SCO6450) was obtained as described earlier (30) .Plasmid and protein purificationProteins listed below were gifts from other members of the lab.", [["Streptomyces coelicolor", "ORGANISM", 0, 23], ["MacroD", "GENE_OR_GENE_PRODUCT", 24, 30], ["Streptomyces coelicolor MacroD homologue", "PROTEIN", 0, 40], ["Streptomyces coelicolor", "SPECIES", 0, 23], ["Streptomyces coelicolor", "SPECIES", 0, 23], ["Streptomyces coelicolor MacroD homologue", "TREATMENT", 0, 40], ["Plasmid and protein purification", "TREATMENT", 91, 123], ["protein purification", "OBSERVATION", 103, 123]]], ["Mycobacterium tuberculosis (Mtb) DarG-macro was cloned with 155 N-terminal amino acids as described earlier (25) .", [["Mycobacterium tuberculosis", "DISEASE", 0, 26], ["N-terminal amino acids", "CHEMICAL", 64, 86], ["N", "CHEMICAL", 64, 65], ["amino acids", "CHEMICAL", 75, 86], ["Mycobacterium tuberculosis", "ORGANISM", 0, 26], ["Mtb", "GENE_OR_GENE_PRODUCT", 28, 31], ["DarG", "GENE_OR_GENE_PRODUCT", 33, 37], ["amino acids", "AMINO_ACID", 75, 86], ["DarG", "PROTEIN", 33, 37], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Mycobacterium tuberculosis", "PROBLEM", 0, 26], ["155 N-terminal amino acids", "TREATMENT", 60, 86]]], ["Catalytic domains of PARP11 (128-338aa) (35), MACROD1 (30, 36) , MACROD2 (19) , TARG1 (17), PARG (37), NUDT16 (21) and ARH 1-3 (15) were purified as described earlier.", [["PARP11", "GENE_OR_GENE_PRODUCT", 21, 27], ["TARG1 (17)", "GENE_OR_GENE_PRODUCT", 80, 90], ["PARG (37)", "GENE_OR_GENE_PRODUCT", 92, 101], ["NUDT16 (21)", "GENE_OR_GENE_PRODUCT", 103, 114], ["ARH 1-3", "GENE_OR_GENE_PRODUCT", 119, 126], ["PARP11", "PROTEIN", 21, 27], ["TARG1", "PROTEIN", 80, 85], ["PARG", "PROTEIN", 92, 96], ["NUDT16", "PROTEIN", 103, 109], ["ARH 1", "PROTEIN", 119, 124], ["Catalytic domains", "TEST", 0, 17], ["PARP11", "TEST", 21, 27], ["aa", "TEST", 36, 38], ["MACROD1", "TEST", 46, 53], ["MACROD2", "TEST", 65, 72], ["TARG1", "TEST", 80, 85], ["PARG", "TEST", 92, 96], ["NUDT16", "TEST", 103, 109], ["ARH", "TEST", 119, 122]]], ["Viral macrodomain-containing hydrolases from VEEV (38) and SARS Coronavirus (39) were prepared as described earlier.OligonucleotideSingle stranded (ss) RNA and DNA oligos used in this study were commercially ordered from Sigma-Aldrich and Invitrogen, respectively, and are listed in Table 1 .", [["VEEV", "ORGANISM", 45, 49], ["SARS Coronavirus", "ORGANISM", 59, 75], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 221, 234], ["Invitrogen", "ORGANISM", 239, 249], ["Viral macrodomain-containing hydrolases", "PROTEIN", 0, 39], ["VEEV", "SPECIES", 45, 49], ["Viral macrodomain", "TEST", 0, 17], ["VEEV", "TEST", 45, 49], ["SARS Coronavirus", "TEST", 59, 75], ["OligonucleotideSingle stranded (ss) RNA", "TREATMENT", 116, 155], ["DNA oligos", "TREATMENT", 160, 170], ["this study", "TEST", 179, 189]]], ["Oligonucleotides were diluted to 100 M stock solution in 20 mM HEPES-KOH (pH 7.6) and 50 mM KCl buffer.", [["HEPES-KOH", "CHEMICAL", 63, 72], ["KCl", "CHEMICAL", 92, 95], ["HEPES", "CHEMICAL", 63, 68], ["KOH", "CHEMICAL", 69, 72], ["KCl", "CHEMICAL", 92, 95], ["HEPES-KOH", "SIMPLE_CHEMICAL", 63, 72], ["Oligonucleotides", "TREATMENT", 0, 16], ["HEPES", "TEST", 63, 68], ["KOH", "TEST", 69, 72], ["pH", "TEST", 74, 76], ["50 mM KCl buffer", "TREATMENT", 86, 102]]], ["Double stranded (ds) DNA was prepared by annealing complementary strands of DNA (ssDNA oligo with RexT) at 95 \u2022 C for 5 min and then allowed to gradually cool down to room temperature.Oligonucleotide10 pmol noP ssRNA (with or without Cyanine3 tag at 3 end) was radioactively labelled at 5 end using T4 polynucleotide kinase 3 phosphatase minus (NEB) in presence of \u2425 32 P ATP (Perkin Elmer) and heated at 37 \u2022 C for 30 min followed by heat inactivation at 65 \u2022 C for 20 min.", [["oligo", "CHEMICAL", 87, 92], ["ATP", "CHEMICAL", 372, 375], ["Perkin Elmer", "CHEMICAL", 377, 389], ["Cyanine3", "CHEMICAL", 234, 242], ["ATP", "CHEMICAL", 372, 375], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["T4 polynucleotide kinase 3", "GENE_OR_GENE_PRODUCT", 299, 325], ["ATP", "SIMPLE_CHEMICAL", 372, 375], ["Double stranded (ds) DNA", "DNA", 0, 24], ["Cyanine3 tag", "DNA", 234, 246], ["T4 polynucleotide kinase 3 phosphatase minus", "PROTEIN", 299, 343], ["NEB", "PROTEIN", 345, 348], ["Double stranded (ds) DNA", "TREATMENT", 0, 24], ["DNA (ssDNA oligo", "TREATMENT", 76, 92], ["RexT", "TREATMENT", 98, 102], ["Oligonucleotide10 pmol noP ssRNA", "PROBLEM", 184, 216], ["Cyanine3 tag", "TREATMENT", 234, 246], ["T4 polynucleotide kinase", "TEST", 299, 323], ["stranded", "OBSERVATION", 7, 15]]], ["Radiolabelled oligo was further desalted on G25 column to remove any unincorporated ATP.", [["oligo", "CHEMICAL", 14, 19], ["ATP", "CHEMICAL", 84, 87], ["ATP", "CHEMICAL", 84, 87], ["oligo", "SIMPLE_CHEMICAL", 14, 19], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["Radiolabelled oligo", "PROBLEM", 0, 19], ["G25 column", "TREATMENT", 44, 54], ["any unincorporated ATP", "TREATMENT", 65, 87]]], ["This radiolabelled oligo was used as size marker as indicated in figures.ADP-ribosylation assayADP-ribosylation assays with RNA were performed as described previously for DNA ADP-ribosylation (27) .", [["oligo", "CHEMICAL", 19, 24], ["ADP", "CHEMICAL", 73, 76], ["ADP", "CHEMICAL", 175, 178], ["ADP", "CHEMICAL", 73, 76], ["ADP", "CHEMICAL", 175, 178], ["ADP", "SIMPLE_CHEMICAL", 73, 76], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["This radiolabelled oligo", "TREATMENT", 0, 24], ["size marker", "TREATMENT", 37, 48], ["ADP", "TEST", 73, 76], ["ribosylation assayADP", "TREATMENT", 77, 98], ["ribosylation assays", "TEST", 99, 118], ["DNA ADP-ribosylation", "TREATMENT", 171, 191]]], ["All buffers were made in DNase/RNase free water and filter sterilized prior to use.", [["DNase", "GENE_OR_GENE_PRODUCT", 25, 30], ["RNase", "GENE_OR_GENE_PRODUCT", 31, 36], ["DNase", "PROTEIN", 25, 30], ["RNase", "PROTEIN", 31, 36], ["All buffers", "TREATMENT", 0, 11], ["DNase/RNase free water", "TREATMENT", 25, 47], ["filter", "TREATMENT", 52, 58]]], ["In short, 10 l reaction mix was prepared in buffer containing 20 mM HEPES-KOH (pH 7.6), 50 mM KCl, 5 mM MgCl 2 and 1 mM DTT.", [["HEPES-KOH", "CHEMICAL", 68, 77], ["KCl", "CHEMICAL", 94, 97], ["MgCl", "CHEMICAL", 104, 108], ["HEPES", "CHEMICAL", 68, 73], ["KOH", "CHEMICAL", 74, 77], ["KCl", "CHEMICAL", 94, 97], ["MgCl", "CHEMICAL", 104, 108], ["DTT", "CHEMICAL", 120, 123], ["HEPES-KOH", "SIMPLE_CHEMICAL", 68, 77], ["DTT", "SIMPLE_CHEMICAL", 120, 123], ["10 l reaction mix", "TREATMENT", 10, 27], ["pH", "TEST", 79, 81], ["50 mM KCl", "TREATMENT", 88, 97], ["5 mM MgCl", "TREATMENT", 99, 108]]], ["RNA substrate (10 M) was added along with 2 M protein, 50 M NAD + (Trevigen) and 50 kBq 32 P labelled NAD + (PerkinElmer) per reaction.", [["NAD", "CHEMICAL", 60, 63], ["NAD", "CHEMICAL", 102, 105], ["NAD", "CHEMICAL", 60, 63], ["Trevigen", "CHEMICAL", 67, 75], ["NAD +", "CHEMICAL", 102, 107], ["NAD +", "SIMPLE_CHEMICAL", 60, 65], ["Trevigen", "SIMPLE_CHEMICAL", 67, 75], ["NAD +", "SIMPLE_CHEMICAL", 102, 107], ["RNA substrate", "TREATMENT", 0, 13], ["NAD", "PROBLEM", 102, 105]]], ["Protein and NAD + concentrations were used as mentioned above unless stated otherwise.", [["NAD", "CHEMICAL", 12, 15], ["NAD +", "CHEMICAL", 12, 17], ["NAD +", "SIMPLE_CHEMICAL", 12, 17], ["Protein", "TEST", 0, 7], ["NAD", "PROBLEM", 12, 15], ["concentrations", "PROBLEM", 18, 32]]], ["Reactions were incubated at 37 \u2022 C for 30 min and stopped by addition of 50 ng/l Proteinase K and 0.15% SDS and heating the reaction at 50 \u2022 C for 30 min, unless stated otherwise.", [["K", "CHEMICAL", 92, 93], ["SDS", "CHEMICAL", 104, 107], ["Proteinase K", "SIMPLE_CHEMICAL", 81, 93], ["l Proteinase K", "TREATMENT", 79, 93]]], ["Reactions that were treated with Benzonase or calf intestinal phosphatase (CIP) were heated at 37 \u2022 C for 30 min.", [["Benzonase", "CHEMICAL", 33, 42], ["Benzonase", "CHEMICAL", 33, 42], ["Benzonase", "SIMPLE_CHEMICAL", 33, 42], ["calf intestinal phosphatase", "GENE_OR_GENE_PRODUCT", 46, 73], ["calf intestinal phosphatase", "PROTEIN", 46, 73], ["CIP", "PROTEIN", 75, 78], ["calf", "SPECIES", 46, 50], ["Benzonase", "TREATMENT", 33, 42], ["calf intestinal phosphatase", "TREATMENT", 46, 73], ["intestinal phosphatase", "ANATOMY", 51, 73]]], ["Samples were further heated at 95 \u2022 C for 3 min with 2\u00d7 TBE urea sample buffer (8 M urea, 20 M EDTA pH 8.0, 2 M Tris pH 7.5 and bromophenol blue).", [["Samples", "ANATOMY", 0, 7], ["TBE urea", "CHEMICAL", 56, 64], ["urea", "CHEMICAL", 84, 88], ["Tris pH 7.5 and bromophenol blue", "CHEMICAL", 112, 144], ["urea", "CHEMICAL", 60, 64], ["urea", "CHEMICAL", 84, 88], ["EDTA", "CHEMICAL", 95, 99], ["bromophenol blue", "CHEMICAL", 128, 144], ["bromophenol blue", "SIMPLE_CHEMICAL", 128, 144], ["TBE", "SPECIES", 56, 59], ["Samples", "TEST", 0, 7], ["TBE urea sample", "TEST", 56, 71], ["buffer", "TEST", 72, 78], ["urea", "TEST", 84, 88], ["EDTA", "TEST", 95, 99], ["pH", "TEST", 100, 102], ["M Tris pH", "TEST", 110, 119], ["bromophenol blue", "TEST", 128, 144]]], ["The samples were loaded on a prerun denaturing urea PAGE gel made of 20% (w/v) polyacrylamide, 8 M urea and 1\u00d7 TBE.", [["samples", "ANATOMY", 4, 11], ["urea", "CHEMICAL", 47, 51], ["M urea", "CHEMICAL", 97, 103], ["urea", "CHEMICAL", 47, 51], ["polyacrylamide", "CHEMICAL", 79, 93], ["urea", "CHEMICAL", 99, 103], ["urea", "SIMPLE_CHEMICAL", 47, 51], ["urea", "SIMPLE_CHEMICAL", 99, 103], ["TBE", "SPECIES", 111, 114], ["The samples", "TEST", 0, 11], ["a prerun denaturing urea PAGE gel", "TREATMENT", 27, 60], ["polyacrylamide", "TREATMENT", 79, 93]]], ["The gel was run at 7 W/gel in 0.5\u00d7 TBE buffer.", [["The gel", "TREATMENT", 0, 7], ["TBE buffer", "TREATMENT", 35, 45]]], ["The gel was dried under vacuum and visualized by autoradiography.", [["The gel", "TREATMENT", 0, 7], ["vacuum", "TREATMENT", 24, 30], ["vacuum", "OBSERVATION", 24, 30]]], ["Non-radioactive RNA ADP-ribosylation assay was performed using Cyanine3 labelled RNA essentially similar to radioactive assay with exception of using 1 M labelled RNA oligo and 500 M NAD + .", [["ADP", "CHEMICAL", 20, 23], ["NAD", "CHEMICAL", 183, 186], ["ADP", "CHEMICAL", 20, 23], ["Cyanine3", "CHEMICAL", 63, 71], ["NAD +", "CHEMICAL", 183, 188], ["ADP", "SIMPLE_CHEMICAL", 20, 23], ["Cyanine3", "SIMPLE_CHEMICAL", 63, 71], ["NAD +", "SIMPLE_CHEMICAL", 183, 188], ["Non-radioactive RNA ADP-ribosylation assay", "TEST", 0, 42], ["radioactive assay", "TEST", 108, 125]]], ["The gel was visualized using Molecular Imager PharosFX systems using laser excitation for Cyanine3 fluorophore at 532 nM wavelength.", [["Cyanine3", "CHEMICAL", 90, 98], ["Cyanine3", "CHEMICAL", 90, 98], ["Cyanine3 fluorophore", "SIMPLE_CHEMICAL", 90, 110], ["The gel", "TREATMENT", 0, 7], ["Molecular Imager PharosFX systems", "TREATMENT", 29, 62], ["laser excitation", "TREATMENT", 69, 85], ["Cyanine3 fluorophore", "TREATMENT", 90, 110]]], ["All ADP-ribosylation assays were individually repeated three times.ADP-ribosylation assayTo study the effect of time kinetics on PARP10 cat and TRPT1 mediated RNA ADP-ribosylation, reaction samples were prepared as mentioned earlier.", [["samples", "ANATOMY", 190, 197], ["ADP", "CHEMICAL", 4, 7], ["ADP", "CHEMICAL", 67, 70], ["ADP", "CHEMICAL", 163, 166], ["ADP", "CHEMICAL", 4, 7], ["ADP", "CHEMICAL", 67, 70], ["ADP", "CHEMICAL", 163, 166], ["ADP", "SIMPLE_CHEMICAL", 4, 7], ["ADP", "SIMPLE_CHEMICAL", 67, 70], ["PARP10", "GENE_OR_GENE_PRODUCT", 129, 135], ["cat", "ORGANISM", 136, 139], ["TRPT1", "GENE_OR_GENE_PRODUCT", 144, 149], ["ADP", "SIMPLE_CHEMICAL", 163, 166], ["PARP10", "PROTEIN", 129, 135], ["TRPT1", "PROTEIN", 144, 149], ["All ADP-ribosylation assays", "TEST", 0, 27], ["ADP", "TEST", 67, 70], ["ribosylation assay", "TEST", 71, 89], ["time kinetics", "TEST", 112, 125], ["PARP10 cat", "TREATMENT", 129, 139], ["TRPT1 mediated RNA ADP", "TREATMENT", 144, 166], ["reaction samples", "TEST", 181, 197]]], ["Aliquots were taken out at different time points (3, 10 and 30 min).", [["Aliquots", "ANATOMY", 0, 8], ["Aliquots", "TREATMENT", 0, 8]]], ["The 0 min time was done by placing the reaction on ice.", [["ice", "TREATMENT", 51, 54]]], ["Reactions were stopped by addition of 2\u00d7 TBE urea sample buffer.ADP-ribosylation assayTo study the effect of NAD + concentration dependence of PARP10 cat and TRPT1 the assay was performed as described earlier with different concentrations (0-1500 M) of NAD + in reaction.", [["TBE urea", "CHEMICAL", 41, 49], ["ADP", "CHEMICAL", 64, 67], ["NAD", "CHEMICAL", 109, 112], ["NAD", "CHEMICAL", 253, 256], ["urea", "CHEMICAL", 45, 49], ["ADP", "CHEMICAL", 64, 67], ["NAD +", "CHEMICAL", 109, 114], ["NAD +", "CHEMICAL", 253, 258], ["ADP", "SIMPLE_CHEMICAL", 64, 67], ["NAD +", "SIMPLE_CHEMICAL", 109, 114], ["cat", "ORGANISM", 150, 153], ["TRPT1", "GENE_OR_GENE_PRODUCT", 158, 163], ["NAD +", "SIMPLE_CHEMICAL", 253, 258], ["PARP10 cat", "PROTEIN", 143, 153], ["TRPT1", "PROTEIN", 158, 163], ["TBE", "SPECIES", 41, 44], ["TBE urea sample buffer", "TREATMENT", 41, 63], ["ADP", "TEST", 64, 67], ["ribosylation assay", "TEST", 68, 86], ["NAD", "PROBLEM", 109, 112], ["PARP10 cat", "TEST", 143, 153], ["TRPT1 the assay", "TEST", 158, 173], ["NAD", "PROBLEM", 253, 256], ["reaction", "PROBLEM", 262, 270]]], ["NAD + concentration dependence study was performed in non-radioactive setup using Cya-nine3 labelled RNA.ADP-ribosylation assayRNA ADP-ribosylation reaction studying the effect of adenosine mono-phosphate (AMP) or 5phosphoadenosine 3 phosphate (PAP) on PARP10 mediated RNA modification was performed by supplementing the reaction with 0, 50 or 250 M concentration of AMP or PAP.ADP-ribosylhydrolase assayPARP10 catalysed RNA ADP-ribosylation reactions were stopped by addition of PARP inhibitor, 3-aminobenzamine (3ABA) before treating with hydrolases.", [["NAD", "CHEMICAL", 0, 3], ["ADP", "CHEMICAL", 105, 108], ["ADP", "CHEMICAL", 131, 134], ["adenosine mono-phosphate", "CHEMICAL", 180, 204], ["AMP", "CHEMICAL", 206, 209], ["5phosphoadenosine 3 phosphate", "CHEMICAL", 214, 243], ["PAP", "CHEMICAL", 245, 248], ["AMP", "CHEMICAL", 367, 370], ["ADP", "CHEMICAL", 378, 381], ["ADP", "CHEMICAL", 425, 428], ["3-aminobenzamine", "CHEMICAL", 496, 512], ["3ABA", "CHEMICAL", 514, 518], ["NAD", "CHEMICAL", 0, 3], ["Cya-nine3", "CHEMICAL", 82, 91], ["ADP", "CHEMICAL", 105, 108], ["ADP", "CHEMICAL", 131, 134], ["adenosine mono-phosphate", "CHEMICAL", 180, 204], ["AMP", "CHEMICAL", 206, 209], ["5phosphoadenosine 3 phosphate", "CHEMICAL", 214, 243], ["PAP", "CHEMICAL", 245, 248], ["AMP", "CHEMICAL", 367, 370], ["PAP", "CHEMICAL", 374, 377], ["ADP", "CHEMICAL", 378, 381], ["ADP", "CHEMICAL", 425, 428], ["3-aminobenzamine", "CHEMICAL", 496, 512], ["3ABA", "CHEMICAL", 514, 518], ["NAD +", "SIMPLE_CHEMICAL", 0, 5], ["Cya-nine3", "SIMPLE_CHEMICAL", 82, 91], ["ADP", "SIMPLE_CHEMICAL", 105, 108], ["ADP", "SIMPLE_CHEMICAL", 131, 134], ["adenosine mono-phosphate", "SIMPLE_CHEMICAL", 180, 204], ["AMP", "SIMPLE_CHEMICAL", 206, 209], ["5phosphoadenosine 3 phosphate", "SIMPLE_CHEMICAL", 214, 243], ["PAP", "SIMPLE_CHEMICAL", 245, 248], ["PARP10", "GENE_OR_GENE_PRODUCT", 253, 259], ["AMP", "SIMPLE_CHEMICAL", 367, 370], ["PAP", "GENE_OR_GENE_PRODUCT", 374, 377], ["ADP-ribosylhydrolase", "GENE_OR_GENE_PRODUCT", 378, 398], ["assayPARP10", "SIMPLE_CHEMICAL", 399, 410], ["ADP", "SIMPLE_CHEMICAL", 425, 428], ["PARP", "GENE_OR_GENE_PRODUCT", 480, 484], ["3-aminobenzamine", "SIMPLE_CHEMICAL", 496, 512], ["3ABA", "SIMPLE_CHEMICAL", 514, 518], ["Cya-nine3 labelled RNA", "RNA", 82, 104], ["PARP10", "PROTEIN", 253, 259], ["PAP", "PROTEIN", 374, 377], ["PARP", "PROTEIN", 480, 484], ["NAD", "PROBLEM", 0, 3], ["concentration dependence study", "TEST", 6, 36], ["Cya-nine3 labelled RNA", "TREATMENT", 82, 104], ["ADP", "TEST", 105, 108], ["ribosylation assayRNA ADP-ribosylation reaction", "TREATMENT", 109, 156], ["adenosine mono-phosphate (AMP)", "TREATMENT", 180, 210], ["5phosphoadenosine 3 phosphate (PAP)", "TREATMENT", 214, 249], ["PARP10 mediated RNA modification", "TREATMENT", 253, 285], ["AMP or PAP", "TREATMENT", 367, 377], ["ADP", "TEST", 378, 381], ["ribosylhydrolase assayPARP10", "TREATMENT", 382, 410], ["RNA ADP-ribosylation reactions", "TREATMENT", 421, 451], ["PARP inhibitor", "TREATMENT", 480, 494], ["aminobenzamine", "TREATMENT", 498, 512], ["hydrolases", "TREATMENT", 541, 551], ["concentration dependence", "OBSERVATION_MODIFIER", 6, 30]]], ["2 M hydrolase enzymes were added per reaction and heated at 30 \u2022 C for 30 min.", [["M hydrolase", "GENE_OR_GENE_PRODUCT", 2, 13], ["M hydrolase enzymes", "PROTEIN", 2, 21], ["M hydrolase enzymes", "TEST", 2, 21]]], ["Reactions containing NUDT16 were supplemented with 15 mM MgCl 2 (21) .PARP10 can ADP-ribosylate phosphorylated RNA endsIn recent years there has been increasing evidence of DNA as a new target for reversible ADP-ribosylation.", [["NUDT16", "CHEMICAL", 21, 27], ["MgCl 2", "CHEMICAL", 57, 63], ["ADP", "CHEMICAL", 81, 84], ["ADP", "CHEMICAL", 208, 211], ["NUDT16", "CHEMICAL", 21, 27], ["MgCl 2", "CHEMICAL", 57, 63], ["ADP", "CHEMICAL", 81, 84], ["ADP", "CHEMICAL", 208, 211], ["NUDT16", "SIMPLE_CHEMICAL", 21, 27], ["PARP10", "GENE_OR_GENE_PRODUCT", 70, 76], ["ADP-ribosylate", "GENE_OR_GENE_PRODUCT", 81, 95], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["ADP", "SIMPLE_CHEMICAL", 208, 211], ["PARP10", "PROTEIN", 70, 76], ["ADP-ribosylate phosphorylated RNA ends", "RNA", 81, 119], ["15 mM MgCl", "TREATMENT", 51, 61], ["ADP-ribosylate phosphorylated RNA ends", "TREATMENT", 81, 119], ["DNA", "PROBLEM", 173, 176], ["reversible ADP-ribosylation", "PROBLEM", 197, 224], ["increasing", "OBSERVATION_MODIFIER", 150, 160], ["evidence of", "UNCERTAINTY", 161, 172], ["DNA", "OBSERVATION", 173, 176]]], ["We wanted to investigate whether RNA could also be similarly ADPribosylated by any known ARTs.", [["ARTs", "GENE_OR_GENE_PRODUCT", 89, 93], ["ARTs", "PROTEIN", 89, 93]]], ["We decided to initially test PARP3 as it was recently demonstrated that this protein has robust ART activity on DNA (27) (28) (29) .", [["PARP3", "GENE_OR_GENE_PRODUCT", 29, 34], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["PARP3", "PROTEIN", 29, 34], ["test PARP3", "TEST", 24, 34], ["this protein", "PROBLEM", 72, 84], ["DNA", "TEST", 112, 115]]], ["In addition, we focused on another member of the PARP family, PARP10, which contains a RNA-recognition motif (RRM domain) (40) .", [["PARP", "GENE_OR_GENE_PRODUCT", 49, 53], ["PARP10", "GENE_OR_GENE_PRODUCT", 62, 68], ["PARP family", "PROTEIN", 49, 60], ["PARP10", "PROTEIN", 62, 68], ["RNA-recognition motif", "PROTEIN", 87, 108], ["RRM domain", "PROTEIN", 110, 120]]], ["Purified PARP3 and PARP10 (catalytic domain) were first tested with a 21 nucleotide single-stranded RNA (ss-RNA) oligo with or without a phosphate group at the 5 end in the presence of 32 P labelled NAD + as an ADPr donor.", [["nucleotide", "CHEMICAL", 73, 83], ["phosphate", "CHEMICAL", 137, 146], ["NAD", "CHEMICAL", 199, 202], ["nucleotide", "CHEMICAL", 73, 83], ["phosphate", "CHEMICAL", 137, 146], ["NAD +", "CHEMICAL", 199, 204], ["ADPr", "CHEMICAL", 211, 215], ["PARP3", "GENE_OR_GENE_PRODUCT", 9, 14], ["PARP10", "GENE_OR_GENE_PRODUCT", 19, 25], ["phosphate", "SIMPLE_CHEMICAL", 137, 146], ["NAD +", "SIMPLE_CHEMICAL", 199, 204], ["ADPr", "SIMPLE_CHEMICAL", 211, 215], ["PARP3", "PROTEIN", 9, 14], ["PARP10", "PROTEIN", 19, 25], ["catalytic domain", "PROTEIN", 27, 43], ["21 nucleotide single-stranded RNA", "RNA", 70, 103], ["Purified PARP3", "TEST", 0, 14], ["PARP10 (catalytic domain", "TEST", 19, 43], ["oligo", "PROBLEM", 113, 118], ["a phosphate group", "TREATMENT", 135, 152], ["NAD", "PROBLEM", 199, 202], ["an ADPr donor", "TREATMENT", 208, 221], ["ADPr donor", "OBSERVATION", 211, 221]]], ["Double-stranded DNA was used as a positive control (Figure 1A , lane 1) for ADP-ribosylation on DNA by PARP3 (27) .", [["ADP", "CHEMICAL", 76, 79], ["ADP", "CHEMICAL", 76, 79], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["ADP", "SIMPLE_CHEMICAL", 76, 79], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["Double-stranded DNA", "DNA", 0, 19], ["Double-stranded DNA", "TREATMENT", 0, 19], ["a positive control", "TREATMENT", 32, 50], ["ADP-ribosylation", "TREATMENT", 76, 92]]], ["Strikingly, PARP10 substantially modified the 5 phosphorylated ssRNA oligo ( Figure 1A, lane 7) reducing its mobility compared to the phosphorylated oligo labelled on its 5 phosphate using 32 P labelled gamma-ATP ( Figure 1A , lane 2).", [["5 phosphate", "CHEMICAL", 171, 182], ["gamma-ATP", "CHEMICAL", 203, 212], ["phosphate", "CHEMICAL", 173, 182], ["gamma-ATP", "CHEMICAL", 203, 212], ["PARP10", "GENE_OR_GENE_PRODUCT", 12, 18], ["5 phosphate", "SIMPLE_CHEMICAL", 171, 182], ["gamma-ATP", "SIMPLE_CHEMICAL", 203, 212], ["PARP10", "PROTEIN", 12, 18], ["32 P labelled gamma", "PROTEIN", 189, 208], ["the 5 phosphorylated ssRNA oligo", "TREATMENT", 42, 74], ["its mobility", "PROBLEM", 105, 117], ["the phosphorylated oligo", "TEST", 130, 154], ["its 5 phosphate", "TREATMENT", 167, 182]]], ["PARP10 was not able to ADP-ribosylate ss-RNA without a 5 phosphate group ( Figure 1A , lane 7 compared to lane 9), suggesting that RNA ADP-ribosylation by PARP10 occurs on the 5 phosphate.", [["ADP", "CHEMICAL", 23, 26], ["5 phosphate", "CHEMICAL", 55, 66], ["ADP", "CHEMICAL", 135, 138], ["PARP10", "CHEMICAL", 155, 161], ["5 phosphate", "CHEMICAL", 176, 187], ["ADP", "CHEMICAL", 23, 26], ["phosphate", "CHEMICAL", 57, 66], ["ADP", "CHEMICAL", 135, 138], ["phosphate", "CHEMICAL", 178, 187], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["ADP", "SIMPLE_CHEMICAL", 23, 26], ["ADP", "SIMPLE_CHEMICAL", 135, 138], ["PARP10", "GENE_OR_GENE_PRODUCT", 155, 161], ["PARP10", "PROTEIN", 0, 6], ["ADP-ribosylate ss-RNA", "RNA", 23, 44], ["PARP10", "PROTEIN", 155, 161], ["PARP10", "TEST", 0, 6], ["ADP", "TEST", 23, 26], ["RNA ADP", "TEST", 131, 138], ["the 5 phosphate", "TREATMENT", 172, 187]]], ["Importantly, PARP3 could only ADP-ribosylate DNA ends and did not have any activity on RNA oligos, while PARP10 specifically modified phosphorylated ssRNA oligo in the conditions tested ( Figure 1A and B).", [["ADP", "CHEMICAL", 30, 33], ["oligo", "CHEMICAL", 155, 160], ["ADP", "CHEMICAL", 30, 33], ["PARP3", "GENE_OR_GENE_PRODUCT", 13, 18], ["ADP", "SIMPLE_CHEMICAL", 30, 33], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["PARP10", "GENE_OR_GENE_PRODUCT", 105, 111], ["PARP3", "PROTEIN", 13, 18], ["RNA oligos", "RNA", 87, 97], ["PARP10", "PROTEIN", 105, 111], ["ADP-ribosylate DNA ends", "TREATMENT", 30, 53], ["RNA oligos", "TREATMENT", 87, 97], ["modified phosphorylated ssRNA oligo", "TREATMENT", 125, 160]]], ["We further demonstrate RNA ADPribosylation activity of PARP10 is time and NAD + concentration dependent (Supplementary Figure S1A and B) but independent of MgCl 2 presence ( Supplementary Figure S1C, lanes 1 and 2) .", [["NAD", "CHEMICAL", 74, 77], ["NAD +", "CHEMICAL", 74, 79], ["MgCl 2", "CHEMICAL", 156, 162], ["PARP10", "GENE_OR_GENE_PRODUCT", 55, 61], ["NAD +", "SIMPLE_CHEMICAL", 74, 79], ["MgCl 2", "GENE_OR_GENE_PRODUCT", 156, 162], ["PARP10", "PROTEIN", 55, 61], ["MgCl 2", "PROTEIN", 156, 162], ["NAD", "PROBLEM", 74, 77], ["concentration dependent", "PROBLEM", 80, 103], ["RNA ADPribosylation activity", "OBSERVATION", 23, 51]]], ["To further ascertain the specificity of ADP-ribosylation by PARP10 on DNA and/or RNA ends we tested both single-stranded oligos with or without a phosphorylated moiety at either 5 or 3 end.", [["ADP", "CHEMICAL", 40, 43], ["ADP", "CHEMICAL", 40, 43], ["ADP", "SIMPLE_CHEMICAL", 40, 43], ["PARP10", "GENE_OR_GENE_PRODUCT", 60, 66], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["PARP10", "PROTEIN", 60, 66], ["ADP", "TEST", 40, 43], ["ribosylation", "TREATMENT", 44, 56], ["DNA", "TREATMENT", 70, 73], ["RNA ends", "TREATMENT", 81, 89], ["a phosphorylated moiety", "TREATMENT", 144, 167]]], ["PARP10 modified ssRNA oligos phosphorylated at either end but did not show activity on ssDNA oligo irrespective of the terminal phosphorylation state ( Figure 1C, lanes 5 and 6) .", [["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["PARP10", "PROTEIN", 0, 6], ["modified ssRNA oligos phosphorylated", "TREATMENT", 7, 43]]], ["The reaction product catalysed by PARP10 in presence of phosphorylated ssRNA was stable against Proteinase K treatment ( Figure 1D, lanes 3 and 6) but not against treatment with Benzonase ( Figure 1D, lanes 4 and 7) confirming that the modification was on nucleic acid and not on protein.", [["PARP10", "CHEMICAL", 34, 40], ["Proteinase K", "CHEMICAL", 96, 108], ["Benzonase", "CHEMICAL", 178, 187], ["nucleic acid", "CHEMICAL", 256, 268], ["Benzonase", "CHEMICAL", 178, 187], ["PARP10", "SIMPLE_CHEMICAL", 34, 40], ["Proteinase K", "SIMPLE_CHEMICAL", 96, 108], ["Benzonase", "SIMPLE_CHEMICAL", 178, 187], ["nucleic acid", "SIMPLE_CHEMICAL", 256, 268], ["PARP10", "PROTEIN", 34, 40], ["phosphorylated ssRNA", "TREATMENT", 56, 76], ["Proteinase K treatment", "TREATMENT", 96, 118], ["Figure 1D, lanes", "TREATMENT", 121, 137], ["Benzonase ( Figure 1D, lanes", "TREATMENT", 178, 206], ["nucleic acid", "TREATMENT", 256, 268], ["phosphorylated ssRNA", "OBSERVATION", 56, 76]]], ["Next we wanted to assess the specificity of PARP10 for modification of the phosphate groups on RNA.", [["phosphate", "CHEMICAL", 75, 84], ["phosphate", "CHEMICAL", 75, 84], ["PARP10", "GENE_OR_GENE_PRODUCT", 44, 50], ["phosphate", "SIMPLE_CHEMICAL", 75, 84], ["PARP10", "PROTEIN", 44, 50], ["PARP10", "TREATMENT", 44, 50], ["modification of the phosphate groups on RNA", "TREATMENT", 55, 98]]], ["For this, we analysed RNA ADP-ribosylation catalysed by PARP10 catalytic domain in the excess presence of adenosine mono-phosphate (AMP) or 5 -phosphoadenosine 3 phosphate (PAP) as potential competitors and we observed no significant change in RNA modification in presence of nucleotide analogue in excess (Supplementary Figure S1D) .", [["ADP", "CHEMICAL", 26, 29], ["adenosine", "CHEMICAL", 106, 115], ["AMP", "CHEMICAL", 132, 135], ["5 -phosphoadenosine 3 phosphate", "CHEMICAL", 140, 171], ["nucleotide", "CHEMICAL", 276, 286], ["ADP", "CHEMICAL", 26, 29], ["adenosine mono-phosphate", "CHEMICAL", 106, 130], ["AMP", "CHEMICAL", 132, 135], ["5 -phosphoadenosine 3 phosphate", "CHEMICAL", 140, 171], ["PAP", "CHEMICAL", 173, 176], ["nucleotide", "CHEMICAL", 276, 286], ["ADP", "SIMPLE_CHEMICAL", 26, 29], ["PARP10", "GENE_OR_GENE_PRODUCT", 56, 62], ["adenosine mono-phosphate", "SIMPLE_CHEMICAL", 106, 130], ["AMP", "SIMPLE_CHEMICAL", 132, 135], ["5 -phosphoadenosine 3 phosphate", "SIMPLE_CHEMICAL", 140, 171], ["PAP", "GENE_OR_GENE_PRODUCT", 173, 176], ["PARP10 catalytic domain", "PROTEIN", 56, 79], ["RNA ADP-ribosylation", "TREATMENT", 22, 42], ["adenosine mono-phosphate (AMP)", "TREATMENT", 106, 136], ["5 -phosphoadenosine 3 phosphate (PAP", "TREATMENT", 140, 176], ["significant change in RNA modification", "PROBLEM", 222, 260], ["nucleotide analogue in excess", "PROBLEM", 276, 305], ["significant", "OBSERVATION_MODIFIER", 222, 233], ["change", "OBSERVATION", 234, 240], ["RNA modification", "OBSERVATION", 244, 260]]], ["To further demonstrate that ADP-ribosylation of RNA by PARP10 occurs on terminal phosphates we designed 5 and 3 phosphorylated ssRNAs with the Cyanine3 (Cy3) label at the opposite end to the phosphorylation for more sensitive detection.", [["ADP", "CHEMICAL", 28, 31], ["ADP", "CHEMICAL", 28, 31], ["phosphates", "CHEMICAL", 81, 91], ["Cyanine3", "CHEMICAL", 143, 151], ["ADP", "SIMPLE_CHEMICAL", 28, 31], ["PARP10", "GENE_OR_GENE_PRODUCT", 55, 61], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 127, 133], ["Cyanine3", "SIMPLE_CHEMICAL", 143, 151], ["PARP10", "PROTEIN", 55, 61], ["Cyanine3 (Cy3) label", "PROTEIN", 143, 163], ["ADP-ribosylation of RNA", "PROBLEM", 28, 51], ["terminal phosphates", "TREATMENT", 72, 91], ["the Cyanine3 (Cy3)", "TREATMENT", 139, 157]]], ["We also produced non-phosphorylated versions of these oligos as additional controls.", [["these oligos", "TREATMENT", 48, 60]]], ["The phosphorylated oligos 5P ssRNA 3Cy3 and 3P ssRNA 5Cy3 treated with PARP10 produced a slower migrating ADPribosylated product ( Figure 1E and F, lane 2) .", [["PARP10", "CHEMICAL", 71, 77], ["PARP10", "SIMPLE_CHEMICAL", 71, 77], ["phosphorylated oligos 5P ssRNA 3Cy3 and 3P ssRNA 5Cy3", "DNA", 4, 57], ["PARP10", "PROTEIN", 71, 77], ["ADPribosylated product", "PROTEIN", 106, 128], ["The phosphorylated oligos", "TREATMENT", 0, 25], ["ssRNA 3Cy3", "TREATMENT", 29, 39], ["3P ssRNA 5Cy3", "TREATMENT", 44, 57], ["PARP10", "TREATMENT", 71, 77]]], ["When the reaction was further treated with calf intestinal phosphatase (CIP, phosphatase), the slower migrating ADP-ribosylated band remains intact while the lower unmodified band shifts upwards due to the removal of a charged phosphate group by CIP phosphatase treatment ( Figure 1E and F, lane 3) and now migrates the same as non-phosphorylated oligo control ( Figure 1E and F, lane 5) .", [["ADP", "CHEMICAL", 112, 115], ["phosphate", "CHEMICAL", 227, 236], ["CIP", "CHEMICAL", 246, 249], ["ADP", "CHEMICAL", 112, 115], ["phosphate", "CHEMICAL", 227, 236], ["intestinal", "ORGAN", 48, 58], ["CIP", "SIMPLE_CHEMICAL", 72, 75], ["ADP", "SIMPLE_CHEMICAL", 112, 115], ["phosphate", "SIMPLE_CHEMICAL", 227, 236], ["CIP phosphatase", "GENE_OR_GENE_PRODUCT", 246, 261], ["calf intestinal phosphatase", "PROTEIN", 43, 70], ["CIP", "PROTEIN", 72, 75], ["phosphatase", "PROTEIN", 77, 88], ["CIP phosphatase", "PROTEIN", 246, 261], ["calf", "SPECIES", 43, 47], ["calf intestinal phosphatase", "TEST", 43, 70], ["phosphatase", "TEST", 77, 88], ["the slower migrating ADP", "PROBLEM", 91, 115], ["ribosylated band", "TREATMENT", 116, 132], ["the lower unmodified band shifts", "PROBLEM", 154, 186], ["the removal", "TREATMENT", 202, 213], ["a charged phosphate group", "TREATMENT", 217, 242], ["CIP phosphatase treatment", "TREATMENT", 246, 271], ["non-phosphorylated oligo control", "TREATMENT", 328, 360], ["intestinal phosphatase", "ANATOMY", 48, 70], ["intact", "OBSERVATION", 141, 147]]], ["When the phosphorylated oligos 5P ssRNA 3Cy3 and 3P ssRNA 5Cy3 (Figure 1E and F, lane 1) are treated directly with CIP in absence of PARP10, dephosphorylation of oligo is observed which is confirmed by similar migrating pattern as the nonphosphorylated oligo ( Figure 1E and F, lanes 4 and 5).", [["F, lane 1", "GENE_OR_GENE_PRODUCT", 78, 87], ["CIP", "SIMPLE_CHEMICAL", 115, 118], ["PARP10", "GENE_OR_GENE_PRODUCT", 133, 139], ["phosphorylated oligos 5P ssRNA 3Cy3 and 3P ssRNA 5Cy3", "DNA", 9, 62], ["lane 1", "DNA", 81, 87], ["PARP10", "PROTEIN", 133, 139], ["the phosphorylated oligos", "TREATMENT", 5, 30], ["ssRNA", "TEST", 34, 39], ["3P ssRNA", "TREATMENT", 49, 57], ["Figure 1E and F, lane", "TREATMENT", 64, 85], ["CIP", "TREATMENT", 115, 118], ["dephosphorylation of oligo", "PROBLEM", 141, 167]]], ["PARP10 modified 5 phosphorylated end more efficiently than 3 phosphorylated RNA end.", [["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["PARP10 modified 5 phosphorylated end", "PROTEIN", 0, 36], ["3 phosphorylated RNA end", "RNA", 59, 83], ["PARP10 modified 5 phosphorylated end", "TREATMENT", 0, 36]]], ["These results show that ADP-ribosylation of RNA by PARP10 occurs on the phosphate group thereby protecting the phosphate group from the dephosphorylation activity of CIP.", [["ADP", "CHEMICAL", 24, 27], ["PARP10", "CHEMICAL", 51, 57], ["phosphate", "CHEMICAL", 72, 81], ["phosphate", "CHEMICAL", 111, 120], ["ADP", "CHEMICAL", 24, 27], ["phosphate", "CHEMICAL", 72, 81], ["phosphate", "CHEMICAL", 111, 120], ["ADP", "SIMPLE_CHEMICAL", 24, 27], ["PARP10", "GENE_OR_GENE_PRODUCT", 51, 57], ["phosphate", "SIMPLE_CHEMICAL", 72, 81], ["phosphate", "SIMPLE_CHEMICAL", 111, 120], ["CIP", "SIMPLE_CHEMICAL", 166, 169], ["PARP10", "PROTEIN", 51, 57], ["ADP-ribosylation of RNA", "PROBLEM", 24, 47], ["the phosphate group", "TREATMENT", 68, 87], ["the phosphate group", "TREATMENT", 107, 126], ["the dephosphorylation activity of CIP", "TREATMENT", 132, 169], ["dephosphorylation activity", "OBSERVATION", 136, 162]]], ["Since the catalytic domain of PARP10 lacks two-thirds of the protein including the RRM we wanted to assess the activity of the FL PARP10 on RNA substrate.", [["PARP10", "GENE_OR_GENE_PRODUCT", 30, 36], ["FL PARP10", "GENE_OR_GENE_PRODUCT", 127, 136], ["catalytic domain", "PROTEIN", 10, 26], ["PARP10", "PROTEIN", 30, 36], ["RRM", "PROTEIN", 83, 86], ["FL PARP10", "PROTEIN", 127, 136], ["RNA substrate", "TREATMENT", 140, 153], ["RRM", "OBSERVATION", 83, 86]]], ["We expressed and purified full length PARP10 and tested it for RNA modification activity.", [["PARP10", "GENE_OR_GENE_PRODUCT", 38, 44], ["PARP10", "PROTEIN", 38, 44], ["full length PARP10", "TREATMENT", 26, 44], ["RNA modification activity", "TREATMENT", 63, 88]]], ["We observed PARP10 full length can also ADP-ribosylate phosphorylated RNA ends ( Figure 1G, lane 2) , however, in comparison to WT PARP10 catalytic domain the activity was much weaker ( Figure 1G, lane 4) .", [["ADP", "CHEMICAL", 40, 43], ["ADP", "CHEMICAL", 40, 43], ["PARP10", "GENE_OR_GENE_PRODUCT", 12, 18], ["ADP", "SIMPLE_CHEMICAL", 40, 43], ["PARP10", "GENE_OR_GENE_PRODUCT", 131, 137], ["PARP10", "PROTEIN", 12, 18], ["WT PARP10 catalytic domain", "PROTEIN", 128, 154], ["ADP", "TEST", 40, 43]]], ["A possible explanation for this finding may be that the isolated FL PARP10 exists in an autoinhibited state, due to the inhibitory function of another domain within the protein.", [["FL", "CHEMICAL", 65, 67], ["FL", "GENE_OR_GENE_PRODUCT", 65, 67], ["PARP10", "GENE_OR_GENE_PRODUCT", 68, 74], ["FL PARP10", "PROTEIN", 65, 74], ["the isolated FL PARP10", "PROBLEM", 52, 74], ["an autoinhibited state", "PROBLEM", 85, 107], ["possible explanation for", "UNCERTAINTY", 2, 26]]], ["Such autoinhibitory property has been already well characterized for PARP1 (41) .", [["PARP1", "GENE_OR_GENE_PRODUCT", 69, 74], ["PARP1", "PROTEIN", 69, 74], ["PARP1", "TEST", 69, 74]]], ["We observed no RNA modification by previously characterized catalytic mutant of PARP10 G888W ( Figure 1G, lane 3) .ADP-ribosylation of RNA ends by PARP10 is a reversible processADP-ribosylation of proteins and DNA is reversible.", [["PARP10", "GENE_OR_GENE_PRODUCT", 80, 86], ["PARP10", "GENE_OR_GENE_PRODUCT", 147, 153], ["DNA", "CELLULAR_COMPONENT", 210, 213], ["catalytic mutant", "PROTEIN", 60, 76], ["PARP10 G888W", "PROTEIN", 80, 92], ["Figure 1G, lane 3", "PROTEIN", 95, 112], ["RNA ends", "RNA", 135, 143], ["PARP10", "PROTEIN", 147, 153], ["processADP", "PROTEIN", 170, 180], ["RNA modification", "PROBLEM", 15, 31], ["Figure 1G, lane", "TREATMENT", 95, 110], ["ribosylation of RNA ends", "TREATMENT", 119, 143], ["a reversible processADP", "PROBLEM", 157, 180], ["ribosylation of proteins", "PROBLEM", 181, 205], ["DNA", "PROBLEM", 210, 213], ["no", "UNCERTAINTY", 12, 14], ["RNA modification", "OBSERVATION", 15, 31], ["reversible", "OBSERVATION_MODIFIER", 159, 169], ["reversible", "OBSERVATION_MODIFIER", 217, 227]]], ["We wanted to investigate whether RNA ADP-ribosylation by PARP10 is also a reversible process.", [["ADP", "CHEMICAL", 37, 40], ["ADP", "CHEMICAL", 37, 40], ["ADP", "SIMPLE_CHEMICAL", 37, 40], ["PARP10", "GENE_OR_GENE_PRODUCT", 57, 63], ["PARP10", "PROTEIN", 57, 63], ["RNA ADP", "TEST", 33, 40], ["a reversible process", "PROBLEM", 72, 92], ["reversible", "OBSERVATION_MODIFIER", 74, 84], ["process", "OBSERVATION", 85, 92]]], ["Since PARP10 can ADP-ribosylate both 5 and 3 phosphorylated ends of RNA, we tested both of these modified oligos as substrates for well characterized human ADP-ribosylhydrolases: PARG, TARG1, MACROD1, MACROD2 and ARH1-3.", [["ADP", "CHEMICAL", 17, 20], ["ADP", "CHEMICAL", 156, 159], ["ADP", "CHEMICAL", 17, 20], ["ADP", "CHEMICAL", 156, 159], ["PARP10", "GENE_OR_GENE_PRODUCT", 6, 12], ["ADP-ribosylate", "GENE_OR_GENE_PRODUCT", 17, 31], ["human", "ORGANISM", 150, 155], ["ADP-ribosylhydrolases", "GENE_OR_GENE_PRODUCT", 156, 177], ["PARG", "GENE_OR_GENE_PRODUCT", 179, 183], ["TARG1", "GENE_OR_GENE_PRODUCT", 185, 190], ["MACROD1", "GENE_OR_GENE_PRODUCT", 192, 199], ["MACROD2", "GENE_OR_GENE_PRODUCT", 201, 208], ["ARH1-3", "GENE_OR_GENE_PRODUCT", 213, 219], ["PARP10", "PROTEIN", 6, 12], ["5 and 3 phosphorylated ends", "DNA", 37, 64], ["human ADP-ribosylhydrolases", "PROTEIN", 150, 177], ["PARG", "PROTEIN", 179, 183], ["TARG1", "PROTEIN", 185, 190], ["MACROD1", "PROTEIN", 192, 199], ["MACROD2", "PROTEIN", 201, 208], ["ARH1-3", "PROTEIN", 213, 219], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["PARP10", "TEST", 6, 12], ["ADP", "TEST", 17, 20], ["PARG", "PROBLEM", 179, 183], ["MACROD2", "TEST", 201, 208], ["ARH1", "TEST", 213, 217]]], ["We also tested human NUDT16 which is known to cleave the pyrophosphate bond in ADP-ribosylated proteins to generate phospho-ribose modified proteins (21).", [["NUDT16", "CHEMICAL", 21, 27], ["pyrophosphate", "CHEMICAL", 57, 70], ["ADP", "CHEMICAL", 79, 82], ["phospho-ribose", "CHEMICAL", 116, 130], ["pyrophosphate", "CHEMICAL", 57, 70], ["ADP", "CHEMICAL", 79, 82], ["phospho-ribose", "CHEMICAL", 116, 130], ["human", "ORGANISM", 15, 20], ["NUDT16", "GENE_OR_GENE_PRODUCT", 21, 27], ["pyrophosphate", "SIMPLE_CHEMICAL", 57, 70], ["ADP", "SIMPLE_CHEMICAL", 79, 82], ["phospho-ribose", "SIMPLE_CHEMICAL", 116, 130], ["human NUDT16", "PROTEIN", 15, 27], ["ADP-ribosylated proteins", "PROTEIN", 79, 103], ["phospho-ribose modified proteins", "PROTEIN", 116, 148], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["ADP", "TEST", 79, 82], ["ribosylated proteins", "TREATMENT", 83, 103], ["phospho-ribose modified proteins", "TREATMENT", 116, 148]]], ["All above mentioned hydrolases, except for ARH1 and ARH2, were able to remove ADP-ribosylation from either 5 or 3 phosphates at the end of RNA substrates (Figure 2A and B) .", [["ADP", "CHEMICAL", 78, 81], ["ADP", "CHEMICAL", 78, 81], ["phosphates", "CHEMICAL", 114, 124], ["ARH1", "GENE_OR_GENE_PRODUCT", 43, 47], ["ARH2", "GENE_OR_GENE_PRODUCT", 52, 56], ["ADP", "SIMPLE_CHEMICAL", 78, 81], ["hydrolases", "PROTEIN", 20, 30], ["ARH1", "PROTEIN", 43, 47], ["ARH2", "PROTEIN", 52, 56], ["hydrolases", "TEST", 20, 30], ["ARH1", "PROBLEM", 43, 47], ["ARH2", "PROBLEM", 52, 56], ["ADP-ribosylation", "TREATMENT", 78, 94], ["RNA substrates", "TEST", 139, 153]]], ["Importantly, catalytically inactive mutants of MACROD1 (G270E) and ARH3 (D77A) (27, 30) did not remove ADPr from phosphorylated-ssRNA (Fig-ure 2C) , demonstrating that the enzymatic activity of these ADP-ribosylhydrolases is required for efficient removal of ADP-ribose from RNA phosphorylated ends.", [["ADPr", "CHEMICAL", 103, 107], ["ADP", "CHEMICAL", 200, 203], ["ADP", "CHEMICAL", 259, 262], ["ADPr", "CHEMICAL", 103, 107], ["ADP", "CHEMICAL", 200, 203], ["ADP", "CHEMICAL", 259, 262], ["ribose", "CHEMICAL", 263, 269], ["MACROD1", "GENE_OR_GENE_PRODUCT", 47, 54], ["ARH3", "GENE_OR_GENE_PRODUCT", 67, 71], ["ADPr", "GENE_OR_GENE_PRODUCT", 103, 107], ["Fig-ure 2C", "GENE_OR_GENE_PRODUCT", 135, 145], ["ADP-ribosylhydrolases", "GENE_OR_GENE_PRODUCT", 200, 221], ["ADP-ribose", "SIMPLE_CHEMICAL", 259, 269], ["catalytically inactive mutants", "PROTEIN", 13, 43], ["MACROD1", "PROTEIN", 47, 54], ["G270E", "PROTEIN", 56, 61], ["ADPr", "PROTEIN", 103, 107], ["MACROD1", "TEST", 47, 54], ["ARH3", "TEST", 67, 71], ["ADPr", "TEST", 103, 107], ["phosphorylated", "TEST", 113, 127], ["ssRNA", "TEST", 128, 133], ["Fig", "TEST", 135, 138], ["these ADP", "TEST", 194, 203], ["ribosylhydrolases", "TREATMENT", 204, 221], ["efficient removal of ADP", "TREATMENT", 238, 262], ["ribose from RNA phosphorylated ends", "TREATMENT", 263, 298]]], ["Together, these results demonstrate that ADP-ribosylation of phosphorylated-RNA oligos catalysed by PARP10 is a reversible process.ADP-ribosylation of RNA ends by PARP10 is a reversible processPrevious studies have shown PARP10 to be an interferon induced gene that inhibits replication of Venezuelan equine encephalitis virus (VEEV) and other alphaviruses (42) , yet the physiological substrates for PARP10 antiviral activity remain unknown.", [["ADP", "CHEMICAL", 41, 44], ["PARP10", "CHEMICAL", 100, 106], ["ADP", "CHEMICAL", 131, 134], ["Venezuelan equine encephalitis", "DISEASE", 290, 320], ["ADP", "CHEMICAL", 41, 44], ["ADP", "CHEMICAL", 131, 134], ["ADP", "SIMPLE_CHEMICAL", 41, 44], ["PARP10", "GENE_OR_GENE_PRODUCT", 100, 106], ["ADP", "SIMPLE_CHEMICAL", 131, 134], ["PARP10", "GENE_OR_GENE_PRODUCT", 163, 169], ["PARP10", "GENE_OR_GENE_PRODUCT", 221, 227], ["Venezuelan equine encephalitis virus", "ORGANISM", 290, 326], ["VEEV", "ORGANISM", 328, 332], ["PARP10", "GENE_OR_GENE_PRODUCT", 401, 407], ["PARP10", "PROTEIN", 100, 106], ["RNA ends", "RNA", 151, 159], ["PARP10", "PROTEIN", 163, 169], ["PARP10", "PROTEIN", 221, 227], ["interferon", "PROTEIN", 237, 247], ["PARP10", "PROTEIN", 401, 407], ["Venezuelan equine encephalitis virus", "SPECIES", 290, 326], ["Venezuelan equine encephalitis virus", "SPECIES", 290, 326], ["VEEV", "SPECIES", 328, 332], ["ADP", "TEST", 41, 44], ["phosphorylated-RNA oligos", "TREATMENT", 61, 86], ["a reversible process", "PROBLEM", 110, 130], ["ribosylation of RNA ends", "TREATMENT", 135, 159], ["a reversible process", "PROBLEM", 173, 193], ["Previous studies", "TEST", 193, 209], ["PARP10", "PROBLEM", 221, 227], ["an interferon induced gene", "PROBLEM", 234, 260], ["Venezuelan equine encephalitis virus", "PROBLEM", 290, 326], ["other alphaviruses", "PROBLEM", 338, 356], ["the physiological substrates", "TREATMENT", 368, 396], ["PARP10 antiviral activity", "TREATMENT", 401, 426], ["reversible", "OBSERVATION_MODIFIER", 112, 122], ["process", "OBSERVATION", 123, 130], ["reversible", "OBSERVATION_MODIFIER", 175, 185], ["process", "OBSERVATION", 186, 193], ["interferon", "OBSERVATION", 237, 247]]], ["Thus, we tested viral macrodomain-containing hydrolases from VEEV and severe acute respiratory syndrome coronavirus (SARS CoV) for their ADP-ribosylhydrolase activity on RNA substrates.", [["acute respiratory syndrome coronavirus", "DISEASE", 77, 115], ["SARS", "DISEASE", 117, 121], ["ADP", "CHEMICAL", 137, 140], ["ADP", "CHEMICAL", 137, 140], ["VEEV", "ORGANISM", 61, 65], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 70, 115], ["SARS CoV", "ORGANISM", 117, 125], ["ADP", "SIMPLE_CHEMICAL", 137, 140], ["viral macrodomain-containing hydrolases", "PROTEIN", 16, 55], ["VEEV", "SPECIES", 61, 65], ["severe acute respiratory syndrome coronavirus", "SPECIES", 70, 115], ["SARS CoV", "SPECIES", 117, 125], ["viral macrodomain", "PROBLEM", 16, 33], ["hydrolases", "PROBLEM", 45, 55], ["VEEV", "PROBLEM", 61, 65], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 70, 115], ["their ADP", "TEST", 131, 140], ["RNA substrates", "TREATMENT", 170, 184], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory syndrome coronavirus", "OBSERVATION", 83, 115]]], ["These viral hydrolases are known to support the ability of viruses to replicate in host cells (38, 39, (43) (44) (45) , but their physiological substrates have yet to be identified.", [["cells", "ANATOMY", 88, 93], ["host cells", "CELL", 83, 93], ["viral hydrolases", "PROTEIN", 6, 22], ["host cells", "CELL_TYPE", 83, 93], ["These viral hydrolases", "PROBLEM", 0, 22], ["viruses", "PROBLEM", 59, 66], ["viruses", "OBSERVATION", 59, 66]]], ["Strikingly, 5 and 3 phosphorylated ssRNA ADP-ribosylated by PARP10 could be efficiently reversed by the addition of viral macrodomain proteins ( Figure 2D ).", [["ADP", "CHEMICAL", 41, 44], ["PARP10", "CHEMICAL", 60, 66], ["ADP", "CHEMICAL", 41, 44], ["3", "GENE_OR_GENE_PRODUCT", 18, 19], ["ADP", "SIMPLE_CHEMICAL", 41, 44], ["PARP10", "SIMPLE_CHEMICAL", 60, 66], ["PARP10", "PROTEIN", 60, 66], ["viral macrodomain proteins", "PROTEIN", 116, 142], ["Figure 2D", "PROTEIN", 145, 154], ["3 phosphorylated ssRNA ADP", "TREATMENT", 18, 44], ["viral macrodomain proteins", "TREATMENT", 116, 142]]], ["The ability of viral macrodomains to remove ADPr from PARP10-modified phosphorylated-ssRNA could indicate a potential biological role for PARP10 in antiviral response acting on viral RNAs and the role of viral macrodomains in suppressing this function.", [["ADPr", "GENE_OR_GENE_PRODUCT", 44, 48], ["PARP10", "GENE_OR_GENE_PRODUCT", 54, 60], ["PARP10", "GENE_OR_GENE_PRODUCT", 138, 144], ["ADPr", "PROTEIN", 44, 48], ["PARP10", "PROTEIN", 54, 60], ["PARP10", "PROTEIN", 138, 144], ["viral RNAs", "RNA", 177, 187], ["viral macrodomains", "TREATMENT", 15, 33], ["ADPr", "TREATMENT", 44, 48], ["PARP10", "TREATMENT", 54, 60], ["ssRNA", "TREATMENT", 85, 90], ["PARP10", "TREATMENT", 138, 144], ["antiviral response", "TREATMENT", 148, 166], ["viral RNAs", "TREATMENT", 177, 187], ["viral macrodomains", "TREATMENT", 204, 222]]], ["Viral macrodomains could also reverse ADPribosylation of both double stranded and single stranded DNA similar to single stranded RNA modification ( Figure 2E ).NAD + dependent phosphotransferase TRPT1 reversibly caps RNA endsNext we decided to check several other human PARPs for their ability to modify RNA.", [["NAD", "CHEMICAL", 160, 163], ["NAD +", "CHEMICAL", 160, 165], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["NAD + dependent phosphotransferase TRPT1", "GENE_OR_GENE_PRODUCT", 160, 200], ["human", "ORGANISM", 264, 269], ["PARPs", "GENE_OR_GENE_PRODUCT", 270, 275], ["double stranded and single stranded DNA", "DNA", 62, 101], ["NAD + dependent phosphotransferase", "PROTEIN", 160, 194], ["TRPT1", "PROTEIN", 195, 200], ["caps RNA ends", "RNA", 212, 225], ["human PARPs", "PROTEIN", 264, 275], ["human", "SPECIES", 264, 269], ["human", "SPECIES", 264, 269], ["Viral macrodomains", "PROBLEM", 0, 18], ["single stranded DNA", "TREATMENT", 82, 101], ["single stranded RNA modification", "TREATMENT", 113, 145], ["NAD", "PROBLEM", 160, 163], ["dependent phosphotransferase", "PROBLEM", 166, 194], ["several other human PARPs", "TREATMENT", 250, 275], ["both", "OBSERVATION_MODIFIER", 57, 61], ["double", "OBSERVATION_MODIFIER", 62, 68], ["stranded", "OBSERVATION", 69, 77], ["stranded RNA modification", "OBSERVATION", 120, 145], ["+ dependent", "OBSERVATION_MODIFIER", 164, 175], ["caps RNA", "OBSERVATION", 212, 220]]], ["We tested full length PARP3 and PARP16 (46) ; catalytic domains of PARP4, Tankyrase2 (47), PARP10, PARP11, PARP12, PARP13, PARP14 and PARP15 and a highly diverged PARP-like protein sometimes annotated as 18th human PARP-TRPT1 (4,48) for RNA ADP-ribosylation activity.NAD + dependent phosphotransferase TRPT1 reversibly caps RNA endsWe observed that, in addition to PARP10, PARP11, PARP15 and human TRPT1 were also able to ADPribosylate 5 phosphorylated ssRNA ( Figure 3A , lanes 5, 6, 10 and 12).", [["ADP", "CHEMICAL", 241, 244], ["NAD", "CHEMICAL", 267, 270], ["ADP", "CHEMICAL", 241, 244], ["NAD +", "CHEMICAL", 267, 272], ["ADPribosylate", "CHEMICAL", 422, 435], ["PARP3", "GENE_OR_GENE_PRODUCT", 22, 27], ["PARP16 (46)", "GENE_OR_GENE_PRODUCT", 32, 43], ["PARP4", "GENE_OR_GENE_PRODUCT", 67, 72], ["Tankyrase2 (47)", "GENE_OR_GENE_PRODUCT", 74, 89], ["PARP10", "GENE_OR_GENE_PRODUCT", 91, 97], ["PARP11", "GENE_OR_GENE_PRODUCT", 99, 105], ["PARP12", "GENE_OR_GENE_PRODUCT", 107, 113], ["PARP13", "GENE_OR_GENE_PRODUCT", 115, 121], ["PARP14", "GENE_OR_GENE_PRODUCT", 123, 129], ["PARP15", "GENE_OR_GENE_PRODUCT", 134, 140], ["PARP", "GENE_OR_GENE_PRODUCT", 163, 167], ["human", "ORGANISM", 209, 214], ["PARP-TRPT1 (4,48)", "GENE_OR_GENE_PRODUCT", 215, 232], ["ADP", "SIMPLE_CHEMICAL", 241, 244], ["NAD + dependent phosphotransferase TRPT1", "GENE_OR_GENE_PRODUCT", 267, 307], ["PARP10", "GENE_OR_GENE_PRODUCT", 365, 371], ["PARP11", "GENE_OR_GENE_PRODUCT", 373, 379], ["PARP15", "GENE_OR_GENE_PRODUCT", 381, 387], ["human", "ORGANISM", 392, 397], ["TRPT1", "GENE_OR_GENE_PRODUCT", 398, 403], ["PARP3", "PROTEIN", 22, 27], ["PARP16 (46)", "PROTEIN", 32, 43], ["catalytic domains", "PROTEIN", 46, 63], ["PARP4", "PROTEIN", 67, 72], ["Tankyrase2 (47)", "PROTEIN", 74, 89], ["PARP10", "PROTEIN", 91, 97], ["PARP11", "PROTEIN", 99, 105], ["PARP12", "PROTEIN", 107, 113], ["PARP13", "PROTEIN", 115, 121], ["PARP14", "PROTEIN", 123, 129], ["PARP15", "PROTEIN", 134, 140], ["PARP-like protein", "PROTEIN", 163, 180], ["18th human PARP", "PROTEIN", 204, 219], ["TRPT1", "PROTEIN", 220, 225], ["NAD + dependent phosphotransferase", "PROTEIN", 267, 301], ["TRPT1", "PROTEIN", 302, 307], ["PARP10", "PROTEIN", 365, 371], ["PARP11", "PROTEIN", 373, 379], ["PARP15", "PROTEIN", 381, 387], ["human TRPT1", "PROTEIN", 392, 403], ["ADPribosylate 5 phosphorylated ssRNA", "PROTEIN", 422, 458], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 392, 397], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 392, 397], ["PARP16", "TEST", 32, 38], ["PARP4", "TEST", 67, 72], ["Tankyrase2", "TEST", 74, 84], ["PARP10", "TEST", 91, 97], ["PARP11", "TEST", 99, 105], ["PARP12", "TREATMENT", 107, 113], ["PARP13", "TREATMENT", 115, 121], ["PARP14", "TREATMENT", 123, 129], ["PARP15", "TREATMENT", 134, 140], ["human PARP", "TEST", 209, 219], ["TRPT1", "TEST", 220, 225], ["RNA ADP", "TEST", 237, 244], ["ribosylation activity", "PROBLEM", 245, 266], ["NAD", "PROBLEM", 267, 270], ["dependent phosphotransferase", "PROBLEM", 273, 301], ["PARP10", "TREATMENT", 365, 371], ["PARP11", "TREATMENT", 373, 379], ["PARP15", "TREATMENT", 381, 387], ["human TRPT1", "TREATMENT", 392, 403], ["ribosylation activity", "OBSERVATION", 245, 266], ["+ dependent", "OBSERVATION_MODIFIER", 271, 282], ["phosphotransferase TRPT1", "OBSERVATION", 283, 307], ["reversibly", "OBSERVATION_MODIFIER", 308, 318], ["caps RNA", "OBSERVATION", 319, 327]]], ["However, in the conditions tested, the other PARPs were unable to ADP-ribosylate 5 phosphorylated ssRNA ( Figure 3A ).", [["ADP", "CHEMICAL", 66, 69], ["ADP", "CHEMICAL", 66, 69], ["PARPs", "GENE_OR_GENE_PRODUCT", 45, 50], ["ADP-ribosylate 5", "GENE_OR_GENE_PRODUCT", 66, 82], ["PARPs", "PROTEIN", 45, 50], ["ADP-ribosylate 5 phosphorylated ssRNA", "PROTEIN", 66, 103], ["the other PARPs", "PROBLEM", 35, 50], ["ADP", "TEST", 66, 69], ["ribosylate", "TREATMENT", 70, 80]]], ["We focused on the ADP-ribosylation activity of TRPT1.", [["ADP", "CHEMICAL", 18, 21], ["ADP", "CHEMICAL", 18, 21], ["ADP", "SIMPLE_CHEMICAL", 18, 21], ["TRPT1", "GENE_OR_GENE_PRODUCT", 47, 52], ["TRPT1", "PROTEIN", 47, 52], ["the ADP", "TEST", 14, 21], ["TRPT1", "PROBLEM", 47, 52], ["ribosylation activity", "OBSERVATION", 22, 43]]], ["We wanted to test whether the ADPribosylation by TRPT1 was phosphate dependent and had specificity towards DNA and/or RNA.", [["phosphate", "CHEMICAL", 59, 68], ["phosphate", "CHEMICAL", 59, 68], ["TRPT1", "GENE_OR_GENE_PRODUCT", 49, 54], ["phosphate", "SIMPLE_CHEMICAL", 59, 68], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["TRPT1", "PROTEIN", 49, 54], ["the ADPribosylation", "TEST", 26, 45], ["phosphate dependent", "PROBLEM", 59, 78], ["DNA", "PROBLEM", 107, 110], ["RNA", "PROBLEM", 118, 121]]], ["For this, we tested ssDNA and ssRNA oligo with a phosphate group at either 5 or 3 end or without phosphate group (noP).", [["phosphate", "CHEMICAL", 49, 58], ["phosphate", "CHEMICAL", 97, 106], ["phosphate", "CHEMICAL", 49, 58], ["phosphate", "CHEMICAL", 97, 106], ["ssDNA", "CELLULAR_COMPONENT", 20, 25], ["phosphate", "SIMPLE_CHEMICAL", 49, 58], ["phosphate", "SIMPLE_CHEMICAL", 97, 106], ["noP", "SIMPLE_CHEMICAL", 114, 117], ["ssRNA oligo", "TREATMENT", 30, 41], ["a phosphate group", "TREATMENT", 47, 64]]], ["We observed TRPT1 can ADP-ribosylate both DNA and RNA but only in the presence of 5 phosphorylated end ( Figure 3B ).", [["ADP", "CHEMICAL", 22, 25], ["ADP", "CHEMICAL", 22, 25], ["TRPT1", "GENE_OR_GENE_PRODUCT", 12, 17], ["ADP", "SIMPLE_CHEMICAL", 22, 25], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["TRPT1", "PROTEIN", 12, 17], ["5 phosphorylated end", "PROTEIN", 82, 102], ["TRPT1", "TEST", 12, 17], ["ADP", "TEST", 22, 25]]], ["We observe TRPT1 based RNA modification is time and NAD + concentration dependent ( Supplementary Figure S2A and B) however independent of MgCl 2 (Supplementary Figure S1C, lanes 3 and 4) .", [["NAD", "CHEMICAL", 52, 55], ["NAD +", "CHEMICAL", 52, 57], ["MgCl 2", "CHEMICAL", 139, 145], ["TRPT1", "GENE_OR_GENE_PRODUCT", 11, 16], ["NAD +", "SIMPLE_CHEMICAL", 52, 57], ["MgCl 2", "GENE_OR_GENE_PRODUCT", 139, 145], ["TRPT1", "PROTEIN", 11, 16], ["TRPT1 based RNA modification", "TREATMENT", 11, 39], ["NAD", "PROBLEM", 52, 55], ["concentration dependent", "PROBLEM", 58, 81], ["RNA modification", "OBSERVATION", 23, 39]]], ["Conserved amino acid residues Arg-His-Arg-Arg are essential for 2 phosphotransferase function of yeast Tpt1 (34, 49) .", [["amino acid", "CHEMICAL", 10, 20], ["Arg-His-Arg-Arg", "CHEMICAL", 30, 45], ["amino acid", "CHEMICAL", 10, 20], ["Arg-His-Arg-Arg", "CHEMICAL", 30, 45], ["amino acid", "AMINO_ACID", 10, 20], ["Arg", "AMINO_ACID", 30, 33], ["Arg-Arg", "AMINO_ACID", 38, 45], ["2 phosphotransferase", "GENE_OR_GENE_PRODUCT", 64, 84], ["yeast Tpt1", "PROTEIN", 97, 107], ["yeast", "SPECIES", 97, 102], ["yeast", "SPECIES", 97, 102], ["Conserved amino acid residues", "TEST", 0, 29], ["Arg", "TEST", 30, 33], ["yeast Tpt1", "TEST", 97, 107], ["amino acid", "OBSERVATION", 10, 20]]], ["Based on sequence alignment we mutated the corresponding residues in human TRPT1 into single alanine based point mutations (R40A, H41A, R86A and R150A).", [["alanine", "CHEMICAL", 93, 100], ["alanine", "CHEMICAL", 93, 100], ["human", "ORGANISM", 69, 74], ["TRPT1", "GENE_OR_GENE_PRODUCT", 75, 80], ["alanine", "AMINO_ACID", 93, 100], ["human TRPT1", "PROTEIN", 69, 80], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["sequence alignment", "TEST", 9, 27], ["R40A", "TEST", 124, 128], ["H41A", "TEST", 130, 134]]], ["These point mutants were un- able to ADP-ribosylate 5 phosphorylated end of RNA ( Figure 3C ).", [["ADP", "CHEMICAL", 37, 40], ["ADP", "CHEMICAL", 37, 40], ["ADP", "SIMPLE_CHEMICAL", 37, 40], ["ADP-ribosylate 5 phosphorylated end", "PROTEIN", 37, 72], ["RNA", "RNA", 76, 79], ["ADP", "TEST", 37, 40], ["ribosylate", "TREATMENT", 41, 51]]], ["This suggests ADP-ribosylation at 5 end of RNA is also mediated via the same active site as originally studied for NAD-dependent 2 RNA phosphotransferase activity of yeast Tpt1.", [["ADP", "CHEMICAL", 14, 17], ["NAD", "CHEMICAL", 115, 118], ["ADP", "CHEMICAL", 14, 17], ["NAD", "CHEMICAL", 115, 118], ["ADP", "SIMPLE_CHEMICAL", 14, 17], ["NAD-dependent 2", "GENE_OR_GENE_PRODUCT", 115, 130], ["Tpt1", "GENE_OR_GENE_PRODUCT", 172, 176], ["NAD-dependent 2 RNA phosphotransferase", "PROTEIN", 115, 153], ["yeast Tpt1", "PROTEIN", 166, 176], ["yeast", "SPECIES", 166, 171], ["yeast", "SPECIES", 166, 171], ["ADP", "TEST", 14, 17], ["ribosylation", "PROBLEM", 18, 30], ["NAD", "PROBLEM", 115, 118], ["yeast Tpt1", "PROBLEM", 166, 176], ["yeast Tpt1", "OBSERVATION", 166, 176]]], ["To further establish that the ADPribosylation signal observed in the presence of TRPT1 was an RNA dependent modification, we further treated the reaction with Proteinase K or Benzonase.", [["Proteinase K", "CHEMICAL", 159, 171], ["Benzonase", "CHEMICAL", 175, 184], ["Benzonase", "CHEMICAL", 175, 184], ["TRPT1", "GENE_OR_GENE_PRODUCT", 81, 86], ["Proteinase K", "SIMPLE_CHEMICAL", 159, 171], ["Benzonase", "SIMPLE_CHEMICAL", 175, 184], ["TRPT1", "PROTEIN", 81, 86], ["the ADPribosylation signal", "TEST", 26, 52], ["TRPT1", "PROBLEM", 81, 86], ["an RNA dependent modification", "PROBLEM", 91, 120], ["the reaction", "PROBLEM", 141, 153], ["Proteinase K", "TREATMENT", 159, 171], ["Benzonase", "TREATMENT", 175, 184], ["RNA dependent", "OBSERVATION_MODIFIER", 94, 107]]], ["The band observed in presence of TRPT1 and 5 P ssRNA was resistant towards Proteinase K treatment but not Benzonase, which validates the band to be nucleic acid related ADP-ribosylation (Figure 3D) .", [["K", "CHEMICAL", 86, 87], ["Benzonase", "CHEMICAL", 106, 115], ["nucleic acid", "CHEMICAL", 148, 160], ["ADP", "CHEMICAL", 169, 172], ["Benzonase", "CHEMICAL", 106, 115], ["ADP", "CHEMICAL", 169, 172], ["TRPT1", "GENE_OR_GENE_PRODUCT", 33, 38], ["Proteinase K", "SIMPLE_CHEMICAL", 75, 87], ["Benzonase", "SIMPLE_CHEMICAL", 106, 115], ["ADP", "SIMPLE_CHEMICAL", 169, 172], ["TRPT1 and 5 P ssRNA", "DNA", 33, 52], ["TRPT1 and 5 P ssRNA", "TREATMENT", 33, 52], ["Proteinase K treatment", "TREATMENT", 75, 97], ["Benzonase", "TREATMENT", 106, 115], ["the band", "PROBLEM", 133, 141], ["nucleic acid related ADP", "PROBLEM", 148, 172], ["ribosylation (Figure 3D)", "TREATMENT", 173, 197]]], ["We treated 5P ssRNA Cyanine3 tagged oligo (5P ssRNA 3Cy3) with TRPT1, which generated 50% of the ADP-ribosylated product of slower mobility in our conditions ( Figure 3E, lanes 1 and 2) .", [["ADP", "CHEMICAL", 97, 100], ["ADP", "CHEMICAL", 97, 100], ["TRPT1", "GENE_OR_GENE_PRODUCT", 63, 68], ["ADP", "SIMPLE_CHEMICAL", 97, 100], ["5P ssRNA Cyanine3 tagged oligo (5P ssRNA 3Cy3", "DNA", 11, 56], ["TRPT1", "PROTEIN", 63, 68], ["5P ssRNA Cyanine3 tagged oligo (5P ssRNA 3Cy3", "TREATMENT", 11, 56], ["TRPT1", "TREATMENT", 63, 68], ["the ADP", "TREATMENT", 93, 100], ["slower mobility", "OBSERVATION", 124, 139]]], ["Treatment of unmodified 5 P oligo with CIP led to a band that migrated slower, simi-lar to the non-phosphorylated oligo ( Figure 3E , lane 1 versus lanes 4 and 5).", [["oligo", "CHEMICAL", 28, 33], ["CIP", "CHEMICAL", 39, 42], ["CIP", "SIMPLE_CHEMICAL", 39, 42], ["Treatment of unmodified 5 P oligo with CIP", "TREATMENT", 0, 42], ["a band", "PROBLEM", 50, 56]]], ["CIP treatment of TRPT1 catalysed RNA substrate leaves the upward shifted ADP-ribosylated RNA oligo intact but the lower unmodified RNA oligo migrates similar to non-phosphorylated oligo ( Figure 3E, lanes 3 and 5) .", [["CIP", "CHEMICAL", 0, 3], ["TRPT1", "CHEMICAL", 17, 22], ["ADP", "CHEMICAL", 73, 76], ["ADP", "CHEMICAL", 73, 76], ["CIP", "SIMPLE_CHEMICAL", 0, 3], ["TRPT1", "GENE_OR_GENE_PRODUCT", 17, 22], ["ADP", "SIMPLE_CHEMICAL", 73, 76], ["TRPT1", "PROTEIN", 17, 22], ["ADP-ribosylated RNA oligo", "RNA", 73, 98], ["CIP treatment", "TREATMENT", 0, 13], ["TRPT1 catalysed", "TREATMENT", 17, 32], ["ADP", "TEST", 73, 76], ["ribosylated RNA oligo", "TREATMENT", 77, 98], ["the lower unmodified RNA oligo", "PROBLEM", 110, 140], ["lower", "ANATOMY_MODIFIER", 114, 119]]], ["These results confirm ADP-ribosylation mediated by TRPT1 is on the RNA oligo and the modification occurs on the phosphate group at the 5 end which protects RNA against further dephosphorylation by CIP.", [["ADP", "CHEMICAL", 22, 25], ["oligo", "CHEMICAL", 71, 76], ["phosphate", "CHEMICAL", 112, 121], ["ADP", "CHEMICAL", 22, 25], ["phosphate", "CHEMICAL", 112, 121], ["ADP", "SIMPLE_CHEMICAL", 22, 25], ["TRPT1", "GENE_OR_GENE_PRODUCT", 51, 56], ["phosphate", "SIMPLE_CHEMICAL", 112, 121], ["CIP", "SIMPLE_CHEMICAL", 197, 200], ["TRPT1", "PROTEIN", 51, 56], ["ADP", "TEST", 22, 25], ["ribosylation", "PROBLEM", 26, 38], ["the RNA oligo", "TREATMENT", 63, 76], ["the phosphate group", "TREATMENT", 108, 127], ["further dephosphorylation", "TREATMENT", 168, 193]]], ["We also tested smaller 7mer and 12mer RNA oligos and established that TRPT1 activity is not affected by the length of RNA oligo ( Figure 3F ).", [["TRPT1", "GENE_OR_GENE_PRODUCT", 70, 75], ["7mer and 12mer RNA oligos", "RNA", 23, 48], ["TRPT1", "PROTEIN", 70, 75], ["12mer RNA oligos", "TREATMENT", 32, 48], ["smaller", "OBSERVATION_MODIFIER", 15, 22], ["RNA oligos", "OBSERVATION", 38, 48]]], ["Similar to PARP10 mediated RNA ADP-ribosylation, we wanted to test if the TRPT1 catalysed RNA modification could be reversed by known human ADPribosylhydrolases.", [["ADP", "CHEMICAL", 31, 34], ["ADP", "CHEMICAL", 31, 34], ["PARP10", "GENE_OR_GENE_PRODUCT", 11, 17], ["ADP", "SIMPLE_CHEMICAL", 31, 34], ["TRPT1", "GENE_OR_GENE_PRODUCT", 74, 79], ["human", "ORGANISM", 134, 139], ["ADPribosylhydrolases", "GENE_OR_GENE_PRODUCT", 140, 160], ["PARP10", "PROTEIN", 11, 17], ["TRPT1", "PROTEIN", 74, 79], ["human ADPribosylhydrolases", "PROTEIN", 134, 160], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["PARP10 mediated RNA ADP-ribosylation", "TREATMENT", 11, 47], ["the TRPT1 catalysed RNA modification", "TREATMENT", 70, 106], ["known human ADPribosylhydrolases", "PROBLEM", 128, 160]]], ["We observe the removal of ADPr signal by PARG, TARG1, MACROD1, MACROD2, ARH3 and NUDT16 ( Figure 3G ).", [["ADPr", "GENE_OR_GENE_PRODUCT", 26, 30], ["PARG", "GENE_OR_GENE_PRODUCT", 41, 45], ["TARG1", "GENE_OR_GENE_PRODUCT", 47, 52], ["MACROD1", "GENE_OR_GENE_PRODUCT", 54, 61], ["MACROD2", "GENE_OR_GENE_PRODUCT", 63, 70], ["ARH3", "GENE_OR_GENE_PRODUCT", 72, 76], ["NUDT16", "GENE_OR_GENE_PRODUCT", 81, 87], ["ADPr", "PROTEIN", 26, 30], ["PARG", "PROTEIN", 41, 45], ["TARG1", "PROTEIN", 47, 52], ["MACROD1", "PROTEIN", 54, 61], ["MACROD2", "PROTEIN", 63, 70], ["ARH3", "PROTEIN", 72, 76], ["NUDT16", "PROTEIN", 81, 87], ["Figure 3G", "PROTEIN", 90, 99], ["ADPr signal", "TEST", 26, 37], ["MACROD1", "TEST", 54, 61]]], ["ARH1 and ARH2 were unable to reverse the RNA modification.", [["ARH1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ARH2", "GENE_OR_GENE_PRODUCT", 9, 13], ["ARH1", "PROTEIN", 0, 4], ["ARH2", "PROTEIN", 9, 13], ["ARH1", "TEST", 0, 4], ["ARH2", "PROBLEM", 9, 13]]], ["Catalytically inactive mutants of MACROD1 (G270E) and ARH3 (D77A) were inactive compared against the wild-type hydrolase as seen earlier for PARP10 ( Figure 3H ).", [["MACROD1", "GENE_OR_GENE_PRODUCT", 34, 41], ["ARH3", "GENE_OR_GENE_PRODUCT", 54, 58], ["PARP10", "SIMPLE_CHEMICAL", 141, 147], ["MACROD1", "PROTEIN", 34, 41], ["G270E", "PROTEIN", 43, 48], ["ARH3", "PROTEIN", 54, 58], ["D77A", "PROTEIN", 60, 64], ["wild-type hydrolase", "PROTEIN", 101, 120], ["PARP10", "PROTEIN", 141, 147], ["MACROD1", "TEST", 34, 41], ["ARH3", "TEST", 54, 58]]], ["TRPT1 mediated DNA modification can also be reversed by the above tested human hydrolases (Supplementary Figure S2C) .", [["TRPT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["human", "ORGANISM", 73, 78], ["TRPT1", "PROTEIN", 0, 5], ["human hydrolases", "PROTEIN", 73, 89], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["TRPT1 mediated DNA modification", "TREATMENT", 0, 31], ["DNA modification", "OBSERVATION", 15, 31]]], ["We also tested hy-drolase function on the ADP-ribosylated 5P ssRNA 3Cy3 oligo.", [["ADP", "CHEMICAL", 42, 45], ["ADP", "CHEMICAL", 42, 45], ["hy-drolase", "GENE_OR_GENE_PRODUCT", 15, 25], ["ADP", "SIMPLE_CHEMICAL", 42, 45], ["hy-drolase", "PROTEIN", 15, 25], ["the ADP", "TEST", 38, 45], ["ssRNA 3Cy3 oligo", "TREATMENT", 61, 77]]], ["The phosphorylated oligo when treated with TRPT1 produces a slow migrating band and a faster migrating unmodified RNA band ( Figure 3I , lane 2).", [["oligo", "CHEMICAL", 19, 24], ["TRPT1", "CHEMICAL", 43, 48], ["TRPT1", "SIMPLE_CHEMICAL", 43, 48], ["TRPT1", "PROTEIN", 43, 48], ["The phosphorylated oligo", "TREATMENT", 0, 24], ["TRPT1", "TREATMENT", 43, 48], ["a slow migrating band", "PROBLEM", 58, 79], ["RNA band", "OBSERVATION", 114, 122]]], ["Further treatment with hydrolases: PARG, MACROD1 and MACROD2 reverses the modification observed by the loss of the slow migrating ADP-ribosylated band ( Figure 3I , lane [3] [4] [5] .", [["MACROD2", "CHEMICAL", 53, 60], ["ADP", "CHEMICAL", 130, 133], ["ADP", "CHEMICAL", 130, 133], ["PARG", "GENE_OR_GENE_PRODUCT", 35, 39], ["MACROD1", "GENE_OR_GENE_PRODUCT", 41, 48], ["MACROD2", "SIMPLE_CHEMICAL", 53, 60], ["ADP", "SIMPLE_CHEMICAL", 130, 133], ["PARG", "PROTEIN", 35, 39], ["MACROD1", "PROTEIN", 41, 48], ["MACROD2", "PROTEIN", 53, 60], ["Further treatment with hydrolases", "TREATMENT", 0, 33], ["PARG", "TREATMENT", 35, 39], ["MACROD1", "TREATMENT", 41, 48], ["MACROD2", "TREATMENT", 53, 60], ["the modification", "TREATMENT", 70, 86], ["the slow migrating ADP-ribosylated band ( Figure 3I , lane", "TREATMENT", 111, 169]]], ["However, the reversal of modification by the hydrolases does not change the migration pattern of the lower unmodified band ( Figure 3I , lane [3] [4] [5] , that still matches the migration pattern of phosphorylated ssRNA (as seen in Figure 3I , lane 1 versus [3] [4] [5] .", [["phosphorylated ssRNA", "PROTEIN", 200, 220], ["the hydrolases", "PROBLEM", 41, 55], ["phosphorylated ssRNA", "PROBLEM", 200, 220], ["migration", "OBSERVATION_MODIFIER", 76, 85], ["lower", "ANATOMY_MODIFIER", 101, 106], ["phosphorylated ssRNA", "OBSERVATION", 200, 220]]], ["This confirms the hydrolase mediated hydrolytic cleavage of ADPr group does not affect the phosphate group on which the modification is covalently attached.ADP-ribosylation activity of TRPT1 is conserved in different speciesTRPT1 homologues are distributed across eukaryal, archaeal and bacterial domains of life.", [["ADPr", "CHEMICAL", 60, 64], ["phosphate", "CHEMICAL", 91, 100], ["ADP", "CHEMICAL", 156, 159], ["ADPr", "CHEMICAL", 60, 64], ["phosphate", "CHEMICAL", 91, 100], ["ADP", "CHEMICAL", 156, 159], ["ADPr", "SIMPLE_CHEMICAL", 60, 64], ["phosphate", "SIMPLE_CHEMICAL", 91, 100], ["ADP", "SIMPLE_CHEMICAL", 156, 159], ["TRPT1", "GENE_OR_GENE_PRODUCT", 185, 190], ["speciesTRPT1", "GENE_OR_GENE_PRODUCT", 217, 229], ["TRPT1", "PROTEIN", 185, 190], ["speciesTRPT1 homologues", "PROTEIN", 217, 240], ["the hydrolase mediated hydrolytic cleavage of ADPr group", "TREATMENT", 14, 70], ["the phosphate group", "TREATMENT", 87, 106], ["ADP", "TEST", 156, 159], ["ribosylation activity of TRPT1", "TREATMENT", 160, 190], ["ribosylation activity", "OBSERVATION", 160, 181], ["bacterial domains", "OBSERVATION", 287, 304]]], ["In E. coli bacteria, these proteins are usually referred to as KptA.", [["E. coli", "ORGANISM", 3, 10], ["KptA", "GENE_OR_GENE_PRODUCT", 63, 67], ["KptA", "PROTEIN", 63, 67], ["E. coli", "SPECIES", 3, 10], ["E. coli", "SPECIES", 3, 10], ["E. coli bacteria", "PROBLEM", 3, 19], ["coli bacteria", "OBSERVATION", 6, 19]]], ["We wanted to test if RNA ADP-ribosylation by KptA homologs is conserved across different species.", [["ADP", "CHEMICAL", 25, 28], ["ADP", "CHEMICAL", 25, 28], ["ADP", "SIMPLE_CHEMICAL", 25, 28], ["KptA", "GENE_OR_GENE_PRODUCT", 45, 49], ["KptA homologs", "PROTEIN", 45, 58], ["RNA ADP", "TEST", 21, 28], ["ribosylation", "TREATMENT", 29, 41]]], ["In addition to TRPT1, we also tested KptA homolog from S. coelicolor (Sco KptA/ SCO3953) with different RNA substrates.", [["TRPT1", "GENE_OR_GENE_PRODUCT", 15, 20], ["KptA homolog", "GENE_OR_GENE_PRODUCT", 37, 49], ["S. coelicolor", "ORGANISM", 55, 68], ["TRPT1", "PROTEIN", 15, 20], ["KptA homolog", "DNA", 37, 49], ["S. coelicolor", "SPECIES", 55, 68], ["S. coelicolor (Sco KptA/ SCO3953", "SPECIES", 55, 87], ["TRPT1", "TREATMENT", 15, 20], ["different RNA substrates", "PROBLEM", 94, 118]]], ["As with earlier for TRPT1 experiment, we observe that Sco KptA could also exclusively ADP-ribosylate RNA at 5 phosphorylated end ( Figure 4A , lanes 2 and 5).", [["ADP", "CHEMICAL", 86, 89], ["ADP", "CHEMICAL", 86, 89], ["Sco KptA", "GENE_OR_GENE_PRODUCT", 54, 62], ["ADP", "SIMPLE_CHEMICAL", 86, 89], ["TRPT1", "PROTEIN", 20, 25], ["Sco KptA", "PROTEIN", 54, 62], ["ADP-ribosylate RNA", "RNA", 86, 104], ["ADP", "TEST", 86, 89]]], ["Since S. coelicolor also possesses a MacroD-like protein SCO6450 similar to human MACROD1 and MACROD2 we were interested to investigate if this macrodomain could function as potential hydrolase to remove ADP-ribosylation mediated by Sco KptA.", [["ADP", "CHEMICAL", 204, 207], ["ADP", "CHEMICAL", 204, 207], ["S. coelicolor", "ORGANISM", 6, 19], ["MacroD", "GENE_OR_GENE_PRODUCT", 37, 43], ["SCO6450", "GENE_OR_GENE_PRODUCT", 57, 64], ["human", "ORGANISM", 76, 81], ["MACROD1", "GENE_OR_GENE_PRODUCT", 82, 89], ["MACROD2", "GENE_OR_GENE_PRODUCT", 94, 101], ["ADP", "SIMPLE_CHEMICAL", 204, 207], ["Sco KptA", "SIMPLE_CHEMICAL", 233, 241], ["MacroD-like protein", "PROTEIN", 37, 56], ["SCO6450", "PROTEIN", 57, 64], ["human MACROD1", "PROTEIN", 76, 89], ["MACROD2", "PROTEIN", 94, 101], ["hydrolase", "PROTEIN", 184, 193], ["Sco KptA", "PROTEIN", 233, 241], ["S. coelicolor", "SPECIES", 6, 19], ["human", "SPECIES", 76, 81], ["S. coelicolor", "SPECIES", 6, 19], ["human", "SPECIES", 76, 81], ["a MacroD", "TEST", 35, 43], ["ADP-ribosylation", "TREATMENT", 204, 220]]], ["Using MACROD1 as a positive control for removal of ADP-ribosylation mediated by both Sco KptA and TRPT1 we tested SCO6450 and another known bacterial macrodomain fold containing hydrolase DarG (25) .", [["ADP", "CHEMICAL", 51, 54], ["ADP", "CHEMICAL", 51, 54], ["MACROD1", "GENE_OR_GENE_PRODUCT", 6, 13], ["ADP", "SIMPLE_CHEMICAL", 51, 54], ["Sco KptA", "GENE_OR_GENE_PRODUCT", 85, 93], ["TRPT1", "GENE_OR_GENE_PRODUCT", 98, 103], ["SCO6450", "GENE_OR_GENE_PRODUCT", 114, 121], ["MACROD1", "PROTEIN", 6, 13], ["Sco KptA", "PROTEIN", 85, 93], ["TRPT1", "PROTEIN", 98, 103], ["SCO6450", "PROTEIN", 114, 121], ["bacterial macrodomain fold", "PROTEIN", 140, 166], ["hydrolase DarG (25)", "PROTEIN", 178, 197], ["MACROD1", "TREATMENT", 6, 13], ["a positive control", "TREATMENT", 17, 35], ["removal", "TREATMENT", 40, 47], ["ADP-ribosylation", "TREATMENT", 51, 67], ["TRPT1", "TEST", 98, 103], ["another known bacterial macrodomain fold", "PROBLEM", 126, 166], ["bacterial macrodomain", "OBSERVATION", 140, 161]]], ["We observed that SCO6450 was proficient at reversing RNA ADP-ribosylation mediated by both Sco KptA and TRPT1, however, DarG was inactive against KptA mediated modification ( Figure 4B and C).DISCUSSIONADP-ribosylation is an important chemical modification which helps cells to adapt and survive while maintaining their genomic integrity when faced with challenging environmental conditions.", [["cells", "ANATOMY", 269, 274], ["SCO6450", "CHEMICAL", 17, 24], ["ADP", "CHEMICAL", 57, 60], ["DarG", "CHEMICAL", 120, 124], ["SCO6450", "CHEMICAL", 17, 24], ["ADP", "CHEMICAL", 57, 60], ["SCO6450", "SIMPLE_CHEMICAL", 17, 24], ["ADP", "SIMPLE_CHEMICAL", 57, 60], ["Sco KptA", "GENE_OR_GENE_PRODUCT", 91, 99], ["TRPT1", "GENE_OR_GENE_PRODUCT", 104, 109], ["DarG", "GENE_OR_GENE_PRODUCT", 120, 124], ["KptA", "SIMPLE_CHEMICAL", 146, 150], ["cells", "CELL", 269, 274], ["Sco KptA", "PROTEIN", 91, 99], ["TRPT1", "PROTEIN", 104, 109], ["DarG", "PROTEIN", 120, 124], ["KptA", "PROTEIN", 146, 150], ["SCO6450", "TEST", 17, 24], ["ribosylation", "TREATMENT", 61, 73], ["TRPT1", "TREATMENT", 104, 109], ["ribosylation", "TREATMENT", 206, 218], ["an important chemical modification", "TREATMENT", 222, 256]]], ["Classic macromolecular targets of ADP-ribosylation have been proteins, however, there have been several studies in the past few years that have demonstrated DNA as an important target for ADP-ribosylation (25) (26) (27) (28) (29) .", [["ADP", "CHEMICAL", 34, 37], ["ADP", "CHEMICAL", 188, 191], ["ADP", "CHEMICAL", 34, 37], ["ADP", "CHEMICAL", 188, 191], ["ADP", "SIMPLE_CHEMICAL", 34, 37], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["ADP-ribosylation (25) (26) (27)", "SIMPLE_CHEMICAL", 188, 219], ["ADP-ribosylation", "PROBLEM", 34, 50], ["several studies", "TEST", 96, 111], ["DNA", "PROBLEM", 157, 160], ["ADP-ribosylation", "TREATMENT", 188, 204], ["macromolecular targets", "OBSERVATION", 8, 30]]], ["Here, we set out to uncover if any member of the ADP-ribosyltransferase family could also ADP-ribosylate RNA.", [["ADP", "CHEMICAL", 49, 52], ["ADP", "CHEMICAL", 90, 93], ["ADP", "CHEMICAL", 49, 52], ["ADP", "CHEMICAL", 90, 93], ["ADP-ribosyltransferase", "GENE_OR_GENE_PRODUCT", 49, 71], ["ADP", "SIMPLE_CHEMICAL", 90, 93], ["ADP-ribosyltransferase family", "PROTEIN", 49, 78], ["ADP-ribosylate RNA", "RNA", 90, 108]]], ["We demonstrate, for the first time, that ADPribosylation of RNA can be catalysed by a few members of PARP family--PARP10, PARP11, PARP15 and a PARPlike protein -TRPT1 previously characterized as an NAD + dependent phosphotransferase (50, 51) .", [["NAD", "CHEMICAL", 198, 201], ["NAD +", "CHEMICAL", 198, 203], ["PARP", "GENE_OR_GENE_PRODUCT", 101, 105], ["PARP10", "GENE_OR_GENE_PRODUCT", 114, 120], ["PARP11", "GENE_OR_GENE_PRODUCT", 122, 128], ["PARP15", "GENE_OR_GENE_PRODUCT", 130, 136], ["TRPT1", "GENE_OR_GENE_PRODUCT", 161, 166], ["NAD + dependent phosphotransferase", "GENE_OR_GENE_PRODUCT", 198, 232], ["PARP family", "PROTEIN", 101, 112], ["PARP10", "PROTEIN", 114, 120], ["PARP11", "PROTEIN", 122, 128], ["PARP15", "PROTEIN", 130, 136], ["PARPlike protein", "PROTEIN", 143, 159], ["TRPT1", "PROTEIN", 161, 166], ["NAD + dependent phosphotransferase", "PROTEIN", 198, 232], ["PARP10", "TEST", 114, 120], ["PARP11", "TEST", 122, 128], ["PARP15", "TEST", 130, 136], ["a PARPlike protein", "TEST", 141, 159], ["an NAD + dependent phosphotransferase", "PROBLEM", 195, 232]]], ["PARP10 was one of the first intracellular mono(ADPribosyl)ating ARTs identified (52) .", [["intracellular", "ANATOMY", 28, 41], ["ADPribosyl", "CHEMICAL", 47, 57], ["ADPribosyl", "CHEMICAL", 47, 57], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 41], ["ADPribosyl", "SIMPLE_CHEMICAL", 47, 57], ["PARP10", "PROTEIN", 0, 6], ["PARP10", "TEST", 0, 6]]], ["In addition to the catalytic domain, PARP10 also contains a RNA recognition motif (RRM), two functional ubiquitin interaction motifs (UIM), a sequence that promotes nuclear targeting as well as nuclear export and a motif that mediates interaction with PCNA (PIP) (40, (52) (53) (54) (55) .", [["nuclear", "ANATOMY", 165, 172], ["nuclear", "ANATOMY", 194, 201], ["PARP10", "GENE_OR_GENE_PRODUCT", 37, 43], ["nuclear", "CELLULAR_COMPONENT", 165, 172], ["nuclear", "CELLULAR_COMPONENT", 194, 201], ["PCNA", "GENE_OR_GENE_PRODUCT", 252, 256], ["PIP", "GENE_OR_GENE_PRODUCT", 258, 261], ["catalytic domain", "PROTEIN", 19, 35], ["PARP10", "PROTEIN", 37, 43], ["RNA recognition motif", "PROTEIN", 60, 81], ["RRM", "PROTEIN", 83, 86], ["ubiquitin interaction motifs", "PROTEIN", 104, 132], ["UIM", "PROTEIN", 134, 137], ["PCNA", "PROTEIN", 252, 256], ["PIP", "PROTEIN", 258, 261], ["PARP10", "TREATMENT", 37, 43], ["a sequence", "TEST", 140, 150], ["PCNA (PIP", "TEST", 252, 261]]], ["While several protein targets of PARP10 have been suggested (35) , the physiological role of PARP10 is unclear.", [["PARP10", "GENE_OR_GENE_PRODUCT", 33, 39], ["PARP10", "GENE_OR_GENE_PRODUCT", 93, 99], ["PARP10", "PROTEIN", 33, 39], ["PARP10", "PROTEIN", 93, 99], ["PARP10", "TEST", 33, 39], ["PARP10", "TREATMENT", 93, 99]]], ["Our study sheds further light on the potential biological function of PARP10 through modification of RNA.", [["PARP10", "GENE_OR_GENE_PRODUCT", 70, 76], ["PARP10", "PROTEIN", 70, 76], ["RNA", "RNA", 101, 104], ["Our study", "TEST", 0, 9], ["PARP10", "TREATMENT", 70, 76], ["modification of RNA", "TREATMENT", 85, 104]]], ["Our results show PARP10 can ADP-ribosylate phosphorylated RNA ends with a modest preference for 5 over 3 ends.", [["ADP", "CHEMICAL", 28, 31], ["ADP", "CHEMICAL", 28, 31], ["PARP10", "GENE_OR_GENE_PRODUCT", 17, 23], ["ADP", "SIMPLE_CHEMICAL", 28, 31], ["PARP10", "PROTEIN", 17, 23], ["ADP-ribosylate phosphorylated RNA ends", "RNA", 28, 66], ["PARP10", "TEST", 17, 23], ["ADP", "TEST", 28, 31], ["ribosylate phosphorylated RNA ends", "TREATMENT", 32, 66], ["modest", "OBSERVATION_MODIFIER", 74, 80]]], ["PARP10 mediated RNA ADP-ribosylation is resistant to phosphatase treatment which would indicate a novel RNA capping mechanism possibly protecting the RNA against the nuclease attack.", [["ADP", "CHEMICAL", 20, 23], ["ADP", "CHEMICAL", 20, 23], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["ADP", "SIMPLE_CHEMICAL", 20, 23], ["PARP10", "PROTEIN", 0, 6], ["phosphatase", "PROTEIN", 53, 64], ["PARP10 mediated RNA ADP", "TREATMENT", 0, 23], ["ribosylation", "PROBLEM", 24, 36], ["phosphatase treatment", "TREATMENT", 53, 74], ["a novel RNA capping mechanism", "PROBLEM", 96, 125], ["the nuclease attack", "PROBLEM", 162, 181]]], ["While the biological relevance for this RNA based modification is currently unknown we postulate a potential role in the innate immune response.", [["this RNA based modification", "PROBLEM", 35, 62]]], ["PARP10 has previously been shown to be induced by interferon and can inhibit viral replication (42, 43, 56) .", [["PARP10", "CHEMICAL", 0, 6], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["interferon", "GENE_OR_GENE_PRODUCT", 50, 60], ["PARP10", "PROTEIN", 0, 6], ["interferon", "PROTEIN", 50, 60]]], ["PARP10 can also inhibit the activation of NF-B which is activated during infection (55) .", [["PARP10", "CHEMICAL", 0, 6], ["infection", "DISEASE", 73, 82], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["NF-B", "GENE_OR_GENE_PRODUCT", 42, 46], ["PARP10", "PROTEIN", 0, 6], ["NF-B", "PROTEIN", 42, 46], ["infection", "PROBLEM", 73, 82], ["infection", "OBSERVATION", 73, 82]]], ["ADP-ribosylation of RNA by PARP10 could act as a signal/marker to initiate an appropriate immune response.", [["ADP", "CHEMICAL", 0, 3], ["ADP", "CHEMICAL", 0, 3], ["ADP", "SIMPLE_CHEMICAL", 0, 3], ["PARP10", "GENE_OR_GENE_PRODUCT", 27, 33], ["PARP10", "PROTEIN", 27, 33], ["ADP-ribosylation of RNA", "TREATMENT", 0, 23]]], ["PARP10 has an inhibitory effect on alphavirus replication and on protein biosynthesis (42, 56) .", [["PARP10", "CHEMICAL", 0, 6], ["PARP10", "GENE_OR_GENE_PRODUCT", 0, 6], ["alphavirus", "ORGANISM", 35, 45], ["PARP10", "PROTEIN", 0, 6], ["an inhibitory effect", "PROBLEM", 11, 31], ["alphavirus replication", "TREATMENT", 35, 57], ["protein biosynthesis", "TEST", 65, 85], ["inhibitory effect", "OBSERVATION", 14, 31], ["alphavirus replication", "OBSERVATION", 35, 57]]], ["These inhibitory effects could potentially be mediated via RNA ADP-ribosylation, where the ADPr moiety acts as a RNA cap thereby preventing RNA translation or triggering signal transduction.", [["ADP", "CHEMICAL", 63, 66], ["ADP", "CHEMICAL", 63, 66], ["ADPr", "CHEMICAL", 91, 95], ["ADP", "SIMPLE_CHEMICAL", 63, 66], ["ADPr", "GENE_OR_GENE_PRODUCT", 91, 95], ["ADPr moiety", "PROTEIN", 91, 102], ["RNA cap", "RNA", 113, 120], ["RNA ADP-ribosylation", "TREATMENT", 59, 79], ["the ADPr moiety acts", "TREATMENT", 87, 107], ["a RNA cap", "TREATMENT", 111, 120], ["RNA translation", "TREATMENT", 140, 155]]], ["The presence of RRM domain in PARP10 could have a role in differentiating foreign RNA of invading pathogens from host RNA to work in tandem with the catalytic domain to ADP-ribosylate RNA and to further initiate the immune response.", [["ADP", "CHEMICAL", 169, 172], ["ADP", "CHEMICAL", 169, 172], ["PARP10", "GENE_OR_GENE_PRODUCT", 30, 36], ["ADP", "SIMPLE_CHEMICAL", 169, 172], ["RRM domain", "PROTEIN", 16, 26], ["PARP10", "PROTEIN", 30, 36], ["foreign RNA", "RNA", 74, 85], ["catalytic domain", "PROTEIN", 149, 165], ["ADP-ribosylate RNA", "RNA", 169, 187], ["RRM domain in PARP10", "PROBLEM", 16, 36], ["invading pathogens", "PROBLEM", 89, 107], ["host RNA", "PROBLEM", 113, 121], ["the catalytic domain", "TREATMENT", 145, 165], ["ADP-ribosylate RNA", "TREATMENT", 169, 187], ["RRM domain", "OBSERVATION", 16, 26], ["foreign RNA", "OBSERVATION", 74, 85]]], ["Similar function has been observed for the apoptotic role of PARP10 whereby the RRM domain contributed to pro-apoptotic activity together with the catalytic domain (57) .", [["PARP10", "GENE_OR_GENE_PRODUCT", 61, 67], ["PARP10", "PROTEIN", 61, 67], ["RRM domain", "PROTEIN", 80, 90], ["catalytic domain", "PROTEIN", 147, 163], ["PARP10", "TREATMENT", 61, 67], ["the RRM domain", "PROBLEM", 76, 90], ["pro-apoptotic activity", "PROBLEM", 106, 128], ["the catalytic domain", "TEST", 143, 163], ["RRM", "OBSERVATION", 80, 83], ["pro-apoptotic activity", "OBSERVATION", 106, 128]]], ["While RNA ADP-ribosylation could provide an interesting link towards explaining the anti-viral role of PARP10, equally this activity could function in initiating or inhibiting translation thus effecting a cascade of signal transduction.DISCUSSIONSeveral human ADP-ribosyl hydrolases PARG, TARG1, MACROD1/2 and ARH3 can reverse RNA ADPribosylation mediated by PARP10.", [["ADP", "CHEMICAL", 10, 13], ["ADP", "CHEMICAL", 260, 263], ["ADP", "CHEMICAL", 10, 13], ["ADP", "CHEMICAL", 260, 263], ["ribosyl", "CHEMICAL", 264, 271], ["ADP", "SIMPLE_CHEMICAL", 10, 13], ["PARP10", "GENE_OR_GENE_PRODUCT", 103, 109], ["human", "ORGANISM", 254, 259], ["ADP-ribosyl hydrolases PARG", "GENE_OR_GENE_PRODUCT", 260, 287], ["TARG1", "GENE_OR_GENE_PRODUCT", 289, 294], ["MACROD1/2", "GENE_OR_GENE_PRODUCT", 296, 305], ["ARH3", "GENE_OR_GENE_PRODUCT", 310, 314], ["PARP10", "GENE_OR_GENE_PRODUCT", 359, 365], ["PARP10", "PROTEIN", 103, 109], ["DISCUSSIONSeveral human ADP-ribosyl hydrolases", "PROTEIN", 236, 282], ["PARG", "PROTEIN", 283, 287], ["TARG1", "PROTEIN", 289, 294], ["MACROD1/2", "PROTEIN", 296, 305], ["ARH3", "PROTEIN", 310, 314], ["PARP10", "PROTEIN", 359, 365], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 254, 259], ["ribosylation", "PROBLEM", 14, 26], ["PARP10", "TREATMENT", 103, 109], ["a cascade of signal transduction", "TREATMENT", 203, 235], ["human ADP-ribosyl hydrolases PARG", "TREATMENT", 254, 287], ["MACROD1/2", "TREATMENT", 296, 305], ["ARH3", "TREATMENT", 310, 314]]], ["Localization of these hydrolases to nucleus, cytoplasm and mitochondria (17, 30, 58, 59) suggests that RNA ADP-ribosylation is utilized in different cellular compartments.", [["nucleus", "ANATOMY", 36, 43], ["cytoplasm", "ANATOMY", 45, 54], ["mitochondria", "ANATOMY", 59, 71], ["cellular compartments", "ANATOMY", 149, 170], ["ADP", "CHEMICAL", 107, 110], ["ADP", "CHEMICAL", 107, 110], ["nucleus", "CELLULAR_COMPONENT", 36, 43], ["cytoplasm", "ORGANISM_SUBSTANCE", 45, 54], ["mitochondria", "CELLULAR_COMPONENT", 59, 71], ["ADP", "SIMPLE_CHEMICAL", 107, 110], ["cellular", "CELL", 149, 157], ["these hydrolases", "TEST", 16, 32], ["mitochondria", "TEST", 59, 71], ["RNA ADP-ribosylation", "PROBLEM", 103, 123], ["nucleus", "ANATOMY_MODIFIER", 36, 43], ["cytoplasm", "OBSERVATION_MODIFIER", 45, 54], ["cellular compartments", "OBSERVATION", 149, 170]]], ["Interestingly, in addition to human hydrolases we also observe that VEEV and SARS viral macrodomain-containing hydrolases can remove RNA ADP-ribosylation mediated by PARP10.", [["ADP", "CHEMICAL", 137, 140], ["ADP", "CHEMICAL", 137, 140], ["human", "ORGANISM", 30, 35], ["VEEV", "ORGANISM", 68, 72], ["SARS viral", "ORGANISM", 77, 87], ["macrodomain-containing hydrolases", "GENE_OR_GENE_PRODUCT", 88, 121], ["ADP", "SIMPLE_CHEMICAL", 137, 140], ["PARP10", "GENE_OR_GENE_PRODUCT", 166, 172], ["human hydrolases", "PROTEIN", 30, 46], ["VEEV and SARS viral macrodomain-containing hydrolases", "PROTEIN", 68, 121], ["PARP10", "PROTEIN", 166, 172], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["VEEV", "SPECIES", 68, 72], ["human hydrolases", "TREATMENT", 30, 46], ["VEEV", "PROBLEM", 68, 72], ["SARS viral macrodomain", "TREATMENT", 77, 99], ["hydrolases", "TREATMENT", 111, 121], ["RNA ADP-ribosylation", "TREATMENT", 133, 153]]], ["This ability of viral macrodomains could indicate a mechanism of pathogenesis by counteracting antiviral activity of PARPs.", [["PARPs", "GENE_OR_GENE_PRODUCT", 117, 122], ["PARPs", "PROTEIN", 117, 122], ["viral macrodomains", "PROBLEM", 16, 34], ["pathogenesis", "PROBLEM", 65, 77], ["PARPs", "PROBLEM", 117, 122], ["viral macrodomains", "OBSERVATION", 16, 34], ["antiviral activity", "OBSERVATION", 95, 113]]], ["This could make viral macrodomains good candidates as a potential drug target to combat pathogenesis.DISCUSSIONIn addition to PARP10, PARP11 and PARP15 we also show ADP-ribosylation of RNA catalysed by TRPT1, an ancestral relative of PARP superfamily which is sometimes referred to as the 18 th member of PARP family.", [["ADP", "CHEMICAL", 165, 168], ["ADP", "CHEMICAL", 165, 168], ["PARP10", "GENE_OR_GENE_PRODUCT", 126, 132], ["PARP11", "GENE_OR_GENE_PRODUCT", 134, 140], ["PARP15", "GENE_OR_GENE_PRODUCT", 145, 151], ["ADP", "SIMPLE_CHEMICAL", 165, 168], ["TRPT1", "GENE_OR_GENE_PRODUCT", 202, 207], ["PARP", "GENE_OR_GENE_PRODUCT", 234, 238], ["PARP", "GENE_OR_GENE_PRODUCT", 305, 309], ["PARP10", "PROTEIN", 126, 132], ["PARP11", "PROTEIN", 134, 140], ["PARP15", "PROTEIN", 145, 151], ["TRPT1", "PROTEIN", 202, 207], ["PARP superfamily", "PROTEIN", 234, 250], ["18 th member", "PROTEIN", 289, 301], ["PARP family", "PROTEIN", 305, 316], ["viral macrodomains", "TREATMENT", 16, 34], ["pathogenesis", "PROBLEM", 88, 100], ["PARP10", "TREATMENT", 126, 132], ["PARP11", "TREATMENT", 134, 140], ["PARP15", "TREATMENT", 145, 151], ["ADP", "TEST", 165, 168], ["ribosylation of RNA", "PROBLEM", 169, 188]]], ["This gene is highly conserved in eukaryotic, archaeal and bacterial domains of life.", [["archaeal and bacterial domains of life", "TREATMENT", 45, 83]]], ["While the human gene is known as TRPT1, the yeast and bacterial version of TRPT1 are referred to as Tpt1 and KptA, respectively.", [["human", "ORGANISM", 10, 15], ["TRPT1", "GENE_OR_GENE_PRODUCT", 33, 38], ["yeast", "CELLULAR_COMPONENT", 44, 49], ["TRPT1", "GENE_OR_GENE_PRODUCT", 75, 80], ["Tpt1", "GENE_OR_GENE_PRODUCT", 100, 104], ["KptA", "GENE_OR_GENE_PRODUCT", 109, 113], ["human gene", "DNA", 10, 20], ["TRPT1", "PROTEIN", 33, 38], ["TRPT1", "PROTEIN", 75, 80], ["Tpt1", "PROTEIN", 100, 104], ["KptA", "PROTEIN", 109, 113], ["human", "SPECIES", 10, 15], ["yeast", "SPECIES", 44, 49], ["human", "SPECIES", 10, 15], ["yeast", "SPECIES", 44, 49], ["TRPT1", "PROBLEM", 33, 38], ["the yeast", "PROBLEM", 40, 49], ["bacterial version of TRPT1", "PROBLEM", 54, 80], ["bacterial version", "OBSERVATION", 54, 71]]], ["The yeast homologue has been characterized for its role in tRNA splicing acting as a NAD + dependent 2 -phosphotransferase (50, 60) .", [["NAD", "CHEMICAL", 85, 88], ["NAD +", "CHEMICAL", 85, 90], ["NAD + dependent 2 -phosphotransferase", "GENE_OR_GENE_PRODUCT", 85, 122], ["NAD + dependent 2 -phosphotransferase", "PROTEIN", 85, 122], ["yeast", "SPECIES", 4, 9], ["yeast", "SPECIES", 4, 9], ["The yeast homologue", "PROBLEM", 0, 19], ["tRNA splicing", "TREATMENT", 59, 72], ["a NAD", "TEST", 83, 88], ["yeast homologue", "OBSERVATION", 4, 19]]], ["The enzymatic role of 2 -phosphate removal by Tpt1 occurs in a two chemical steps process -first, the 2 -phosphate reacts with NAD + to release nicotinamide and form 2 -phospho-ADP-ribose RNA intermediate and second step involves generation of ADP-ribose 1 -2 cyclic phosphate and leav- ing behind the RNA with hydroxyl group at 2 end.", [["2 -phosphate", "CHEMICAL", 22, 34], ["Tpt1", "CHEMICAL", 46, 50], ["2 -phosphate", "CHEMICAL", 102, 114], ["NAD", "CHEMICAL", 127, 130], ["nicotinamide", "CHEMICAL", 144, 156], ["2 -phospho-ADP-ribose", "CHEMICAL", 166, 187], ["ADP-ribose 1 -2 cyclic phosphate", "CHEMICAL", 244, 276], ["hydroxyl", "CHEMICAL", 311, 319], ["2 -phosphate", "CHEMICAL", 22, 34], ["2 -phosphate", "CHEMICAL", 102, 114], ["NAD +", "CHEMICAL", 127, 132], ["nicotinamide", "CHEMICAL", 144, 156], ["2 -phospho-ADP-ribose", "CHEMICAL", 166, 187], ["ADP", "CHEMICAL", 244, 247], ["ribose", "CHEMICAL", 248, 254], ["cyclic phosphate", "CHEMICAL", 260, 276], ["hydroxyl", "CHEMICAL", 311, 319], ["2 -phosphate", "SIMPLE_CHEMICAL", 22, 34], ["Tpt1", "SIMPLE_CHEMICAL", 46, 50], ["2 -phosphate", "SIMPLE_CHEMICAL", 102, 114], ["NAD +", "SIMPLE_CHEMICAL", 127, 132], ["nicotinamide", "SIMPLE_CHEMICAL", 144, 156], ["2 -phospho-ADP-ribose", "SIMPLE_CHEMICAL", 166, 187], ["ADP-ribose 1 -2 cyclic phosphate", "SIMPLE_CHEMICAL", 244, 276], ["leav- ing", "SIMPLE_CHEMICAL", 281, 290], ["hydroxyl", "SIMPLE_CHEMICAL", 311, 319], ["Tpt1", "PROTEIN", 46, 50], ["2 -phosphate removal", "TREATMENT", 22, 42], ["Tpt1", "TREATMENT", 46, 50], ["NAD", "PROBLEM", 127, 130], ["nicotinamide", "TREATMENT", 144, 156], ["phospho", "TEST", 169, 176], ["ADP-ribose RNA", "TREATMENT", 177, 191], ["ADP", "TEST", 244, 247], ["ribose", "TREATMENT", 248, 254], ["2 cyclic phosphate", "TREATMENT", 258, 276], ["leav", "TREATMENT", 281, 285], ["hydroxyl group", "TREATMENT", 311, 325]]], ["While 2 -phosphotransferase activity is conserved across all diverse homologues of TRPT1 (31) there is no evidence of intron containing tRNA (that would need TRPT1 activity for splicing) and/or pathway which would generate RNA with 2 -phosphate in most of the organisms except in plants and fungal species (31, 61) .", [["2 -phosphate", "CHEMICAL", 232, 244], ["2 -phosphate", "CHEMICAL", 232, 244], ["2 -phosphotransferase", "GENE_OR_GENE_PRODUCT", 6, 27], ["TRPT1", "GENE_OR_GENE_PRODUCT", 83, 88], ["TRPT1", "GENE_OR_GENE_PRODUCT", 158, 163], ["2 -phosphate", "SIMPLE_CHEMICAL", 232, 244], ["TRPT1", "DNA", 83, 88], ["intron", "DNA", 118, 124], ["TRPT1", "PROTEIN", 158, 163], ["TRPT1", "TEST", 83, 88], ["intron containing tRNA", "PROBLEM", 118, 140], ["TRPT1 activity", "TREATMENT", 158, 172], ["phosphate", "TREATMENT", 235, 244], ["fungal species", "TEST", 291, 305], ["no evidence of", "UNCERTAINTY", 103, 117], ["fungal species", "OBSERVATION", 291, 305]]], ["Furthermore, TRPT1 knockout cells from mouse exhibit levels of tRNA splicing comparable to the wild type cells (61) .", [["TRPT1 knockout cells", "ANATOMY", 13, 33], ["wild type cells", "ANATOMY", 95, 110], ["TRPT1", "GENE_OR_GENE_PRODUCT", 13, 18], ["mouse", "ORGANISM", 39, 44], ["cells", "CELL", 105, 110], ["TRPT1 knockout cells", "CELL_LINE", 13, 33], ["wild type cells", "CELL_TYPE", 95, 110], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["TRPT1 knockout cells", "PROBLEM", 13, 33], ["levels of tRNA splicing", "PROBLEM", 53, 76], ["knockout cells", "OBSERVATION", 19, 33], ["tRNA splicing", "OBSERVATION", 63, 76]]], ["Although some bacteria possess introns in their tRNAs, they are self-splicing introns with very limited distribution to several representatives of proteobacteria and cyanobacteria (62) .", [["introns", "DNA", 31, 38], ["self-splicing introns", "DNA", 64, 85], ["some bacteria possess introns in their tRNAs", "PROBLEM", 9, 53], ["self-splicing introns", "PROBLEM", 64, 85], ["proteobacteria", "PROBLEM", 147, 161], ["cyanobacteria", "PROBLEM", 166, 179], ["bacteria possess introns", "OBSERVATION", 14, 38], ["splicing introns", "OBSERVATION", 69, 85]]], ["Therefore, the functional role of these widely conserved TRPT1 genes in other species remains elusive.", [["TRPT1", "GENE_OR_GENE_PRODUCT", 57, 62], ["TRPT1 genes", "DNA", 57, 68], ["TRPT1 genes in other species", "PROBLEM", 57, 85]]], ["A recent study has demonstrated that several archaeal species such as Aeropyrum pernix, Pyrococcus horikoshii and Archaeoglobus fulgidus and bacterial Clostridium thermocellum possess Tpt1 protein that can ADP-ribosylate RNA at 5 -phosphorylated ends (31) .DISCUSSIONIn our study, we show that TRPT1 from a higher eukaryote (human) and from a bacterium (Streptomyces species) can also ADP-ribosylate 5 -phosphorylated RNA--revealing that RNA ADP-ribosylation activity is widespread among Trpt1 proteins.", [["ADP", "CHEMICAL", 206, 209], ["ADP", "CHEMICAL", 385, 388], ["ADP", "CHEMICAL", 442, 445], ["ADP", "CHEMICAL", 206, 209], ["ADP", "CHEMICAL", 385, 388], ["ADP", "CHEMICAL", 442, 445], ["Aeropyrum pernix", "ORGANISM", 70, 86], ["Pyrococcus horikoshii", "ORGANISM", 88, 109], ["Archaeoglobus fulgidus", "ORGANISM", 114, 136], ["bacterial Clostridium thermocellum", "ORGANISM", 141, 175], ["Tpt1", "GENE_OR_GENE_PRODUCT", 184, 188], ["ADP", "SIMPLE_CHEMICAL", 206, 209], ["TRPT1", "GENE_OR_GENE_PRODUCT", 294, 299], ["human", "ORGANISM", 325, 330], ["Streptomyces species", "ORGANISM", 354, 374], ["ADP", "SIMPLE_CHEMICAL", 385, 388], ["ADP", "SIMPLE_CHEMICAL", 442, 445], ["Trpt1", "GENE_OR_GENE_PRODUCT", 488, 493], ["Tpt1 protein", "PROTEIN", 184, 196], ["ADP-ribosylate RNA", "RNA", 206, 224], ["TRPT1", "PROTEIN", 294, 299], ["ADP-ribosylate 5 -phosphorylated RNA", "RNA", 385, 421], ["Trpt1 proteins", "PROTEIN", 488, 502], ["Aeropyrum pernix", "SPECIES", 70, 86], ["Pyrococcus horikoshii", "SPECIES", 88, 109], ["Archaeoglobus fulgidus", "SPECIES", 114, 136], ["Clostridium thermocellum", "SPECIES", 151, 175], ["human", "SPECIES", 325, 330], ["Aeropyrum pernix", "SPECIES", 70, 86], ["Pyrococcus horikoshii", "SPECIES", 88, 109], ["Archaeoglobus fulgidus", "SPECIES", 114, 136], ["Clostridium thermocellum", "SPECIES", 151, 175], ["human", "SPECIES", 325, 330], ["A recent study", "TEST", 0, 14], ["several archaeal species", "PROBLEM", 37, 61], ["Aeropyrum pernix", "TREATMENT", 70, 86], ["Pyrococcus horikoshii", "PROBLEM", 88, 109], ["Archaeoglobus fulgidus", "PROBLEM", 114, 136], ["bacterial Clostridium thermocellum", "PROBLEM", 141, 175], ["Tpt1 protein", "TREATMENT", 184, 196], ["ADP", "TEST", 206, 209], ["our study", "TEST", 270, 279], ["TRPT1", "TEST", 294, 299], ["a bacterium (Streptomyces species", "PROBLEM", 341, 374], ["ADP", "TEST", 385, 388], ["phosphorylated RNA", "TEST", 403, 421], ["RNA ADP", "TEST", 438, 445], ["ribosylation activity", "PROBLEM", 446, 467], ["several", "OBSERVATION_MODIFIER", 37, 44], ["archaeal species", "OBSERVATION", 45, 61], ["Pyrococcus horikoshii", "OBSERVATION", 88, 109], ["Archaeoglobus fulgidus", "OBSERVATION", 114, 136], ["bacterial Clostridium", "OBSERVATION", 141, 162], ["ribosylation activity", "OBSERVATION", 446, 467]]], ["To summarize, our results identify RNA as a novel target of reversible ADP-ribosylation that can be catalysed by both PARP and TRPT1 classes of ARTs in vitro.", [["ADP", "CHEMICAL", 71, 74], ["ADP", "CHEMICAL", 71, 74], ["ADP", "SIMPLE_CHEMICAL", 71, 74], ["PARP", "GENE_OR_GENE_PRODUCT", 118, 122], ["TRPT1", "GENE_OR_GENE_PRODUCT", 127, 132], ["ARTs", "GENE_OR_GENE_PRODUCT", 144, 148], ["PARP", "PROTEIN", 118, 122], ["TRPT1", "PROTEIN", 127, 132], ["ARTs", "PROTEIN", 144, 148], ["reversible ADP-ribosylation", "PROBLEM", 60, 87]]], ["This modification of RNA occurs on phosphorylated terminal ends of RNA; it can be made by PARP10 and TRPT1 ARTs and reversed by several known ADP-ribosylhydrolases.", [["ADP", "CHEMICAL", 142, 145], ["ADP", "CHEMICAL", 142, 145], ["PARP10", "GENE_OR_GENE_PRODUCT", 90, 96], ["TRPT1", "GENE_OR_GENE_PRODUCT", 101, 106], ["ADP-ribosylhydrolases", "GENE_OR_GENE_PRODUCT", 142, 163], ["RNA", "RNA", 21, 24], ["PARP10", "PROTEIN", 90, 96], ["TRPT1 ARTs", "PROTEIN", 101, 111], ["ADP-ribosylhydrolases", "PROTEIN", 142, 163], ["This modification of RNA", "PROBLEM", 0, 24], ["phosphorylated terminal ends of RNA", "TREATMENT", 35, 70], ["several known ADP-ribosylhydrolases", "PROBLEM", 128, 163], ["RNA", "OBSERVATION", 21, 24], ["terminal", "OBSERVATION_MODIFIER", 50, 58]]], ["Efficient in vitro activities on RNA substrates by these enzymes suggest that RNA ADP-ribosylation reactions could be relevant in vivo.", [["ADP", "CHEMICAL", 82, 85], ["ADP", "CHEMICAL", 82, 85], ["ADP", "SIMPLE_CHEMICAL", 82, 85], ["enzymes", "PROTEIN", 57, 64], ["RNA substrates", "TREATMENT", 33, 47], ["these enzymes", "TEST", 51, 64], ["RNA ADP", "PROBLEM", 78, 85], ["ribosylation reactions", "PROBLEM", 86, 108]]], ["We hypothesize that TRPT1/PARP10 could potentially mediate ADP-ribosylation signalling on RNA substrates as an on/off switch thereby controlling the functional state of RNA, protecting RNA ends or act as a platform for recruiting other proteins.", [["ADP", "CHEMICAL", 59, 62], ["ADP", "CHEMICAL", 59, 62], ["TRPT1", "GENE_OR_GENE_PRODUCT", 20, 25], ["PARP10", "GENE_OR_GENE_PRODUCT", 26, 32], ["ADP-ribosylation", "GENE_OR_GENE_PRODUCT", 59, 75], ["TRPT1", "PROTEIN", 20, 25], ["PARP10", "PROTEIN", 26, 32], ["RNA", "RNA", 169, 172], ["RNA ends", "RNA", 185, 193], ["TRPT1/PARP10", "TREATMENT", 20, 32], ["ribosylation signalling", "PROBLEM", 63, 86], ["RNA substrates", "TREATMENT", 90, 104], ["recruiting other proteins", "PROBLEM", 219, 244]]], ["In addition we also demonstrate other PARPs--PARP11 and PARP15 to ADP-ribosylate phosphorylated RNA ends, however further characterization is required to reveal the functional role of these proteins.", [["ADP", "CHEMICAL", 66, 69], ["ADP", "CHEMICAL", 66, 69], ["PARPs", "GENE_OR_GENE_PRODUCT", 38, 43], ["PARP11", "GENE_OR_GENE_PRODUCT", 45, 51], ["PARP15", "GENE_OR_GENE_PRODUCT", 56, 62], ["ADP-ribosylate", "GENE_OR_GENE_PRODUCT", 66, 80], ["PARPs", "PROTEIN", 38, 43], ["PARP11", "PROTEIN", 45, 51], ["PARP15", "PROTEIN", 56, 62], ["ADP-ribosylate phosphorylated RNA ends", "RNA", 66, 104], ["PARPs", "TEST", 38, 43], ["PARP11", "TREATMENT", 45, 51], ["PARP15", "TREATMENT", 56, 62], ["ADP", "TEST", 66, 69], ["further characterization", "TEST", 114, 138], ["these proteins", "PROBLEM", 184, 198], ["PARPs", "OBSERVATION", 38, 43]]]], "a42902eecd48b57da041dc9ee17b1d1b6e140fee": [["INTRODUCTIONCoronavirus disease 2019 , caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in December 2019 and quickly spread all over the globe.", [["INTRODUCTIONCoronavirus disease", "DISEASE", 0, 31], ["infection", "DISEASE", 49, 58], ["acute respiratory syndrome coronavirus", "DISEASE", 71, 109], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 64, 111], ["SARS-CoV-2", "ORGANISM", 113, 123], ["severe acute respiratory syndrome coronavirus", "SPECIES", 64, 109], ["SARS-CoV-2", "SPECIES", 113, 123], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 0, 31], ["infection", "PROBLEM", 49, 58], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 64, 109], ["SARS-CoV", "TEST", 113, 121], ["infection", "OBSERVATION", 49, 58], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory syndrome", "OBSERVATION", 77, 97], ["globe", "ANATOMY", 192, 197]]], ["The clinical features are fever, dyspnoea, dry cough, fatigue and diarrhoea (Wan et.", [["fever", "DISEASE", 26, 31], ["dyspnoea", "DISEASE", 33, 41], ["dry cough", "DISEASE", 43, 52], ["fatigue", "DISEASE", 54, 61], ["diarrhoea", "DISEASE", 66, 75], ["fever", "PROBLEM", 26, 31], ["dyspnoea", "PROBLEM", 33, 41], ["dry cough", "PROBLEM", 43, 52], ["fatigue", "PROBLEM", 54, 61], ["diarrhoea", "PROBLEM", 66, 75], ["fever", "OBSERVATION", 26, 31], ["dry", "OBSERVATION_MODIFIER", 43, 46], ["cough", "OBSERVATION", 47, 52]]], ["Pharyngodynia, nasal congestion, rhinorrhoea and anosmia have also been reported (Chen et al. 2020 , Hopkins et al. 2020 , Mason 2020 , Gattinoni et al. 2020 .", [["nasal", "ANATOMY", 15, 20], ["Pharyngodynia", "DISEASE", 0, 13], ["nasal congestion", "DISEASE", 15, 31], ["rhinorrhoea", "DISEASE", 33, 44], ["anosmia", "DISEASE", 49, 56], ["nasal", "ORGANISM_SUBDIVISION", 15, 20], ["Pharyngodynia", "PROBLEM", 0, 13], ["nasal congestion", "PROBLEM", 15, 31], ["rhinorrhoea", "PROBLEM", 33, 44], ["anosmia", "PROBLEM", 49, 56], ["nasal", "ANATOMY", 15, 20], ["congestion", "OBSERVATION", 21, 31], ["rhinorrhoea", "OBSERVATION", 33, 44]]], ["Interstitial pneumonia is very common and a high percentage of patients (9-11%) develop severe acute respiratory distress syndrome (ARDS) and require intensive care (Lovato and de Filippis 2020 , Remuzzi and Remuzzi 2020 , Yuan et al. 2020 .", [["Interstitial", "ANATOMY", 0, 12], ["respiratory", "ANATOMY", 101, 112], ["Interstitial pneumonia", "DISEASE", 0, 22], ["acute respiratory distress syndrome", "DISEASE", 95, 130], ["ARDS", "DISEASE", 132, 136], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Interstitial pneumonia", "PROBLEM", 0, 22], ["severe acute respiratory distress syndrome", "PROBLEM", 88, 130], ["ARDS", "PROBLEM", 132, 136], ["intensive care", "TREATMENT", 150, 164], ["Lovato", "TREATMENT", 166, 172], ["Remuzzi", "TREATMENT", 196, 203], ["Remuzzi", "TREATMENT", 208, 215], ["pneumonia", "OBSERVATION", 13, 22], ["high", "OBSERVATION_MODIFIER", 44, 48], ["percentage", "OBSERVATION_MODIFIER", 49, 59], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory distress syndrome", "OBSERVATION", 101, 130]]], ["Current therapeutic strategy involves agents counteracting viral invasion and replication, and inhibitors of cytokine-sustained inflammatory reactions.", [["cytokine", "PROTEIN", 109, 117], ["Current therapeutic strategy", "TREATMENT", 0, 28], ["agents", "TREATMENT", 38, 44], ["viral invasion", "TREATMENT", 59, 73], ["replication", "TREATMENT", 78, 89], ["inhibitors", "TREATMENT", 95, 105], ["cytokine", "TREATMENT", 109, 117], ["sustained inflammatory reactions", "PROBLEM", 118, 150], ["inflammatory", "OBSERVATION_MODIFIER", 128, 140]]], ["No specific antiviral therapy has yet been identified (Capecchi et al. 2020 , Conticini et al. 2020 .INTRODUCTIONUltrasound imaging of the lung (LUS) is a promising technique in many acute and chronic parenchymal conditions that determine interstitial syndrome.", [["lung", "ANATOMY", 139, 143], ["LUS", "ANATOMY", 145, 148], ["parenchymal", "ANATOMY", 201, 212], ["interstitial", "ANATOMY", 239, 251], ["interstitial syndrome", "DISEASE", 239, 260], ["lung", "ORGAN", 139, 143], ["LUS", "MULTI-TISSUE_STRUCTURE", 145, 148], ["specific antiviral therapy", "TREATMENT", 3, 29], ["imaging", "TEST", 124, 131], ["many acute and chronic parenchymal conditions", "PROBLEM", 178, 223], ["interstitial syndrome", "PROBLEM", 239, 260], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["antiviral therapy", "OBSERVATION", 12, 29], ["lung", "ANATOMY", 139, 143], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["chronic", "OBSERVATION_MODIFIER", 193, 200], ["parenchymal", "ANATOMY_MODIFIER", 201, 212], ["conditions", "OBSERVATION", 213, 223], ["interstitial syndrome", "OBSERVATION", 239, 260]]], ["These include cardiogenic and noncardiogenic pulmonary oedema, ARDS, interstitial pulmonary fibrosis and a variety of conditions determining lung consolidations, such as pneumonia and lung cancer (Mojoli et al. 2019 ).", [["pulmonary", "ANATOMY", 45, 54], ["interstitial pulmonary", "ANATOMY", 69, 91], ["lung", "ANATOMY", 141, 145], ["lung cancer", "ANATOMY", 184, 195], ["cardiogenic", "DISEASE", 14, 25], ["pulmonary oedema", "DISEASE", 45, 61], ["ARDS", "DISEASE", 63, 67], ["interstitial pulmonary fibrosis", "DISEASE", 69, 100], ["lung consolidations", "DISEASE", 141, 160], ["pneumonia", "DISEASE", 170, 179], ["lung cancer", "DISEASE", 184, 195], ["pulmonary", "ORGAN", 45, 54], ["pulmonary", "ORGAN", 82, 91], ["lung", "ORGAN", 141, 145], ["lung cancer", "CANCER", 184, 195], ["cardiogenic", "PROBLEM", 14, 25], ["noncardiogenic pulmonary oedema", "PROBLEM", 30, 61], ["ARDS", "PROBLEM", 63, 67], ["interstitial pulmonary fibrosis", "PROBLEM", 69, 100], ["lung consolidations", "PROBLEM", 141, 160], ["pneumonia", "PROBLEM", 170, 179], ["lung cancer", "PROBLEM", 184, 195], ["cardiogenic", "OBSERVATION", 14, 25], ["noncardiogenic", "OBSERVATION_MODIFIER", 30, 44], ["pulmonary", "ANATOMY", 45, 54], ["oedema", "OBSERVATION", 55, 61], ["ARDS", "OBSERVATION", 63, 67], ["interstitial", "ANATOMY_MODIFIER", 69, 81], ["pulmonary", "ANATOMY", 82, 91], ["fibrosis", "OBSERVATION", 92, 100], ["variety", "OBSERVATION_MODIFIER", 107, 114], ["lung", "ANATOMY", 141, 145], ["consolidations", "OBSERVATION", 146, 160], ["pneumonia", "OBSERVATION", 170, 179], ["lung", "ANATOMY", 184, 188], ["cancer", "OBSERVATION", 189, 195]]], ["In COVID-19 patients, it demonstrated clinical utility due to the typical sonographic characteristics of affected lungs by providing indications for clinical decisions and the management of associated respiratory failure and lung injury (Smith et al. 2020) .INTRODUCTIONThe aim of the present study was to evaluate the possibilities of a portable pocket-sized ultrasound scanner in the evaluation of lung involvement in patients with COVID-19 pneumonia.5We conducted 34 LUS evaluations on patients admitted to the COVID Unit of Siena University Hospital with symptoms compatible with COVID-19, a positive SARS-CoV-2 nasalpharyngeal swab and radiological evidence of interstitial pneumonia.5The patients were divided into three severity categories based on respiratory impairment: Mild PaO2/FiO2 > 300 in room air or oxygen flow; Moderate PaO2/FiO2 between 150 and 300 in room air or oxygen-therapy, CPAP, NIV or HFNC; Severe PaO2/FiO2 < 150 on oxygen-therapy, CPAP, NIV, HFNC or mechanical ventilation.", [["lungs", "ANATOMY", 114, 119], ["respiratory", "ANATOMY", 201, 212], ["lung", "ANATOMY", 225, 229], ["lung", "ANATOMY", 400, 404], ["interstitial", "ANATOMY", 666, 678], ["respiratory", "ANATOMY", 756, 767], ["respiratory failure", "DISEASE", 201, 220], ["lung injury", "DISEASE", 225, 236], ["pneumonia", "DISEASE", 443, 452], ["interstitial pneumonia", "DISEASE", 666, 688], ["respiratory impairment", "DISEASE", 756, 778], ["oxygen", "CHEMICAL", 816, 822], ["oxygen", "CHEMICAL", 883, 889], ["oxygen", "CHEMICAL", 944, 950], ["oxygen", "CHEMICAL", 816, 822], ["oxygen", "CHEMICAL", 883, 889], ["oxygen", "CHEMICAL", 944, 950], ["CPAP", "CHEMICAL", 960, 964], ["NIV", "CHEMICAL", 966, 969], ["patients", "ORGANISM", 12, 20], ["lungs", "ORGAN", 114, 119], ["lung", "ORGAN", 225, 229], ["lung", "ORGAN", 400, 404], ["patients", "ORGANISM", 420, 428], ["patients", "ORGANISM", 489, 497], ["patients", "ORGANISM", 694, 702], ["oxygen", "SIMPLE_CHEMICAL", 816, 822], ["oxygen", "SIMPLE_CHEMICAL", 883, 889], ["oxygen", "SIMPLE_CHEMICAL", 944, 950], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 420, 428], ["patients", "SPECIES", 489, 497], ["patients", "SPECIES", 694, 702], ["affected lungs", "PROBLEM", 105, 119], ["the management", "TREATMENT", 172, 186], ["associated respiratory failure", "PROBLEM", 190, 220], ["lung injury", "PROBLEM", 225, 236], ["the present study", "TEST", 281, 298], ["a portable pocket-sized ultrasound scanner", "TEST", 336, 378], ["the evaluation", "TEST", 382, 396], ["lung involvement", "PROBLEM", 400, 416], ["COVID", "TEST", 434, 439], ["pneumonia", "PROBLEM", 443, 452], ["LUS evaluations", "TEST", 470, 485], ["symptoms", "PROBLEM", 559, 567], ["COVID", "TEST", 584, 589], ["a positive SARS", "PROBLEM", 594, 609], ["CoV", "TEST", 610, 613], ["nasalpharyngeal swab", "TEST", 616, 636], ["interstitial pneumonia", "PROBLEM", 666, 688], ["respiratory impairment", "PROBLEM", 756, 778], ["Mild PaO2", "PROBLEM", 780, 789], ["FiO2", "TEST", 790, 794], ["oxygen flow", "TEST", 816, 827], ["Moderate PaO2", "TEST", 829, 842], ["FiO2", "TEST", 843, 847], ["oxygen", "TREATMENT", 883, 889], ["therapy", "TREATMENT", 890, 897], ["CPAP", "TREATMENT", 899, 903], ["NIV", "TREATMENT", 905, 908], ["HFNC", "TREATMENT", 912, 916], ["Severe PaO2", "TEST", 918, 929], ["FiO2", "TREATMENT", 930, 934], ["oxygen", "TREATMENT", 944, 950], ["therapy", "TREATMENT", 951, 958], ["CPAP", "TREATMENT", 960, 964], ["NIV", "TREATMENT", 966, 969], ["HFNC", "TREATMENT", 971, 975], ["mechanical ventilation", "TREATMENT", 979, 1001], ["lungs", "ANATOMY", 114, 119], ["respiratory", "ANATOMY", 201, 212], ["failure", "OBSERVATION", 213, 220], ["lung", "ANATOMY", 225, 229], ["injury", "OBSERVATION", 230, 236], ["lung", "ANATOMY", 400, 404], ["involvement", "OBSERVATION", 405, 416], ["pneumonia", "OBSERVATION", 443, 452], ["evidence of", "UNCERTAINTY", 654, 665], ["interstitial", "ANATOMY_MODIFIER", 666, 678], ["pneumonia", "OBSERVATION", 679, 688], ["Mild", "OBSERVATION_MODIFIER", 780, 784], ["oxygen flow", "OBSERVATION", 816, 827], ["Moderate", "OBSERVATION_MODIFIER", 829, 837], ["mechanical ventilation", "OBSERVATION", 979, 1001]]], ["Up to six regions of the chest were identified: anterosuperior (A); anteroinferior (B); lateralsuperior (C); lateralinferior (D); posterosuperior (E); posteroinferior (F).", [["chest", "ANATOMY", 25, 30], ["anteroinferior", "ANATOMY", 68, 82], ["chest", "ORGAN", 25, 30], ["anterosuperior (A); anteroinferior (B); lateralsuperior (C); lateralinferior (D); posterosuperior (E); posteroinferior (F)", "PROBLEM", 48, 170], ["chest", "ANATOMY", 25, 30]]], ["One of four different aeration patterns was recorded according to a specific scoring system: A = 0 points (normal aeration, presence of lung sliding with A lines or less than two isolated B lines), B1 = 1 point (moderate loss of lung aeration, multiple well-defined B lines), B2 = 2 points (severe loss of lung aeration, multiple coalescent B lines), C = 3 points (lung consolidation and tissue-like pattern).5Pleural effusion and pneumothorax were also recorded.", [["lung", "ANATOMY", 136, 140], ["B lines", "ANATOMY", 188, 195], ["lung", "ANATOMY", 229, 233], ["B lines", "ANATOMY", 266, 273], ["lung", "ANATOMY", 306, 310], ["B lines", "ANATOMY", 341, 348], ["lung", "ANATOMY", 365, 369], ["tissue", "ANATOMY", 388, 394], ["Pleural", "ANATOMY", 410, 417], ["loss of lung aeration", "DISEASE", 298, 319], ["Pleural effusion", "DISEASE", 410, 426], ["pneumothorax", "DISEASE", 431, 443], ["lung", "ORGAN", 136, 140], ["B lines", "CELL", 188, 195], ["lung", "ORGAN", 229, 233], ["B lines", "CELL", 266, 273], ["lung", "ORGAN", 306, 310], ["lung", "ORGAN", 365, 369], ["tissue", "TISSUE", 388, 394], ["Pleural", "ORGANISM_SUBSTANCE", 410, 417], ["B lines", "CELL_LINE", 266, 273], ["A lines", "TREATMENT", 154, 161], ["two isolated B lines", "TREATMENT", 175, 195], ["B1", "TEST", 198, 200], ["moderate loss of lung aeration", "PROBLEM", 212, 242], ["B2", "TEST", 276, 278], ["severe loss of lung aeration", "PROBLEM", 291, 319], ["multiple coalescent B lines", "TREATMENT", 321, 348], ["C = 3 points (lung consolidation and tissue", "PROBLEM", 351, 394], ["Pleural effusion", "PROBLEM", 410, 426], ["pneumothorax", "PROBLEM", 431, 443], ["different", "OBSERVATION_MODIFIER", 12, 21], ["aeration", "OBSERVATION", 22, 30], ["aeration", "OBSERVATION_MODIFIER", 114, 122], ["lung", "ANATOMY", 136, 140], ["sliding", "OBSERVATION_MODIFIER", 141, 148], ["moderate", "OBSERVATION_MODIFIER", 212, 220], ["loss", "OBSERVATION_MODIFIER", 221, 225], ["lung", "ANATOMY", 229, 233], ["aeration", "OBSERVATION_MODIFIER", 234, 242], ["multiple", "OBSERVATION_MODIFIER", 244, 252], ["severe", "OBSERVATION_MODIFIER", 291, 297], ["loss", "OBSERVATION_MODIFIER", 298, 302], ["lung", "ANATOMY", 306, 310], ["aeration", "OBSERVATION_MODIFIER", 311, 319], ["multiple", "OBSERVATION_MODIFIER", 321, 329], ["coalescent", "OBSERVATION_MODIFIER", 330, 340], ["B lines", "OBSERVATION", 341, 348], ["lung", "ANATOMY", 365, 369], ["consolidation", "OBSERVATION", 370, 383], ["tissue", "OBSERVATION_MODIFIER", 388, 394], ["effusion", "OBSERVATION", 418, 426], ["pneumothorax", "OBSERVATION", 431, 443]]], ["A score of 0 was normal and 36 was the worst.", [["A score", "TEST", 0, 7]]], ["Due to clinical conditions, the upper posterior region (E) could not explored in some patients, so the mean of the regions explored was calculated for the purposes of statistical analysis (total sum (0 to 36) divided by number of regions explored (5 or 6 on each side).", [["upper", "ORGANISM_SUBDIVISION", 32, 37], ["posterior region", "MULTI-TISSUE_STRUCTURE", 38, 54], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["statistical analysis", "TEST", 167, 187], ["upper", "ANATOMY_MODIFIER", 32, 37], ["posterior", "ANATOMY_MODIFIER", 38, 47]]], ["Our step-by-step approach 6 to LUS in COVID-19 patients was comparable to the CLUE protocol (Manivel V) .", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["LUS in COVID", "TEST", 31, 43]]], ["Imaging were obtained by two different operators, both experts in lung ultrasound.", [["lung", "ANATOMY", 66, 70], ["lung", "ORGAN", 66, 70], ["Imaging", "TEST", 0, 7], ["lung ultrasound", "TEST", 66, 81], ["lung", "ANATOMY", 66, 70]]], ["The research was approved by the local ethics committee (OSS_REOS n\u00b0 12908) and informed consent was obtained from each participant.Statistical analysisStudent's t-test was used to compare pairs of groups and ANOVA to compare three or more groups, followed by Holm-Sidak's multiple comparisons test, when the former were significant.Statistical analysisNormal distribution of data was checked using D'Agostino-Pearson test (command sktest of Stata).Statistical analysisThe presence and possible sources of systematic bias between the two instruments was investigated in the complete dataset of the individual readings at 12 thoracic location in each patient.", [["thoracic", "ANATOMY", 624, 632], ["thoracic", "ORGAN", 624, 632], ["patient", "ORGANISM", 650, 657], ["participant", "SPECIES", 120, 131], ["patient", "SPECIES", 650, 657], ["Statistical analysisStudent's t-test", "TEST", 132, 168], ["Pearson test", "TEST", 410, 422], ["Statistical analysis", "TEST", 449, 469], ["systematic bias", "PROBLEM", 506, 521], ["systematic bias", "OBSERVATION", 506, 521], ["thoracic", "ANATOMY", 624, 632]]], ["We used multilevel mixed-effects linear regression models with the difference in score on the same thoracic location (Butterfly-GE) as the outcome variable, changes in vertical level of the thoracic location (high vs. low), side (right vs. left), horizontal level (anterior, lateral, posterior) and severity as fixed effect variables, and the patient as a random effect variable.Statistical analysisThe primary outcome of the study was the assessment of the bias and of Limits of Agreement (LoA) between the total patient score obtained with the two instruments, computed with the Bland Altman method (Balnd and Altman 1986).", [["thoracic", "ANATOMY", 99, 107], ["thoracic", "ANATOMY", 190, 198], ["left", "ANATOMY", 240, 244], ["anterior", "ANATOMY", 265, 273], ["thoracic", "ORGAN", 99, 107], ["thoracic", "ORGAN", 190, 198], ["anterior", "MULTI-TISSUE_STRUCTURE", 265, 273], ["patient", "ORGANISM", 343, 350], ["patient", "ORGANISM", 514, 521], ["patient", "SPECIES", 343, 350], ["patient", "SPECIES", 514, 521], ["multilevel mixed-effects linear regression models", "TREATMENT", 8, 57], ["high vs. low), side (right vs. left), horizontal level (anterior, lateral, posterior) and severity as fixed effect variables", "PROBLEM", 209, 333], ["Statistical analysis", "TEST", 379, 399], ["the study", "TEST", 422, 431], ["the assessment", "TEST", 436, 450], ["multilevel", "OBSERVATION_MODIFIER", 8, 18], ["mixed", "OBSERVATION_MODIFIER", 19, 24], ["thoracic", "ANATOMY", 99, 107], ["vertical", "OBSERVATION_MODIFIER", 168, 176], ["thoracic", "ANATOMY", 190, 198], ["high", "OBSERVATION_MODIFIER", 209, 213], ["right", "ANATOMY_MODIFIER", 230, 235], ["left", "ANATOMY_MODIFIER", 240, 244], ["anterior", "ANATOMY_MODIFIER", 265, 273], ["lateral", "ANATOMY_MODIFIER", 275, 282], ["posterior", "ANATOMY_MODIFIER", 284, 293], ["severity", "OBSERVATION_MODIFIER", 299, 307], ["fixed effect", "OBSERVATION", 311, 323]]], ["A secondary outcome was the assessment of the concordance between the two instruments.", [["the assessment", "TEST", 24, 38]]], ["As no single measure of concordance is generallyRESULTSThe 34 paired LUS scans on 18 COVID-19 patients (14 male and 4 female; age at presentation 77.6 \u00b1 10.0 years) produced the following results.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["paired LUS scans", "TEST", 62, 78]]], ["No difference in age was found between severity groups; 16/34 scans were performed on severe, 11 on moderate and 7 on mild patients.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["scans", "TEST", 62, 67], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["No difference in days since onset of symptoms was observed between groups (23.29 \u00b1 10.07, 22.91 \u00b1 8.91, 28.56 \u00b1 11.13 days, respectively, p=0.38).RESULTSWhen assessed on the full dataset of 437 paired readings in 34 LUS, no significant differences were found between LUS scores obtained with the high-end and the portable pocket-sized ultrasound, with a mean difference in score of -0.018\u00b1 0.018 points (NS).", [["symptoms", "PROBLEM", 37, 45], ["LUS", "TEST", 216, 219], ["LUS scores", "TEST", 267, 277], ["the portable pocket-sized ultrasound", "TEST", 309, 345], ["score", "TEST", 373, 378], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["The score difference did not change significantly according to lung side (0.027 \u00b10.032 points), vertical level (-0.041\u00b10.033 points), clinical severity (0.013.\u00b10.022 points per each level).", [["lung", "ANATOMY", 63, 67], ["lung", "ORGAN", 63, 67], ["vertical level", "TEST", 96, 110], ["clinical severity", "PROBLEM", 134, 151], ["lung", "ANATOMY", 63, 67]]], ["A significant difference, however, was found between the two instruments according the horizontal location of the site, with the difference between the two instruments resulting slightly but significantly greater on the posterior compared to the anterior side of the thorax (0.082 \u00b10.021 points, p <0.01).RESULTSTotal average scores obtained with the two instruments were normally distributed, as was their difference.", [["anterior", "ANATOMY", 246, 254], ["thorax", "ANATOMY", 267, 273], ["thorax", "ORGAN", 267, 273], ["p", "TEST", 296, 297], ["RESULTSTotal average scores", "TEST", 305, 332], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION_MODIFIER", 14, 24], ["horizontal", "OBSERVATION_MODIFIER", 87, 97], ["site", "OBSERVATION_MODIFIER", 114, 118], ["two", "OBSERVATION_MODIFIER", 152, 155], ["instruments", "OBSERVATION", 156, 167], ["slightly", "OBSERVATION_MODIFIER", 178, 186], ["significantly", "OBSERVATION_MODIFIER", 191, 204], ["greater", "OBSERVATION_MODIFIER", 205, 212], ["posterior", "ANATOMY_MODIFIER", 220, 229], ["anterior", "ANATOMY_MODIFIER", 246, 254], ["thorax", "ANATOMY", 267, 273], ["distributed", "OBSERVATION_MODIFIER", 381, 392]]], ["Average patient scores correlated with clinical severity (p<0.001, Figure 1) 8 All the computed parameters showed an excellent degree of concordance between the two instruments ( Table 1)DISCUSSIONLung ultrasound imaging is a non-invasive technique that provides useful indications for clinical decisions concerning COVID-19 patients (Smith et al. 2020 , Wang et al. 2017 .", [["patient", "ORGANISM", 8, 15], ["patients", "ORGANISM", 325, 333], ["patient", "SPECIES", 8, 15], ["patients", "SPECIES", 325, 333], ["clinical severity", "TEST", 39, 56], ["All the computed parameters", "TEST", 79, 106], ["ultrasound imaging", "TEST", 202, 220], ["a non-invasive technique", "TEST", 224, 248], ["excellent", "OBSERVATION_MODIFIER", 117, 126]]], ["Here we evaluated the possibilities of a portable pocket-sized ultrasound scanner in COVID-19 patients with pneumonia.DISCUSSIONWe included a cohort of COVID-19 patients who were hospitalized with respiratory failure of different severity.", [["respiratory", "ANATOMY", 197, 208], ["pneumonia", "DISEASE", 108, 117], ["respiratory failure", "DISEASE", 197, 216], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 161, 169], ["a portable pocket-sized ultrasound scanner", "TEST", 39, 81], ["pneumonia", "PROBLEM", 108, 117], ["respiratory failure", "PROBLEM", 197, 216], ["different severity", "PROBLEM", 220, 238], ["pneumonia", "OBSERVATION", 108, 117], ["respiratory", "ANATOMY", 197, 208], ["failure", "OBSERVATION", 209, 216], ["different severity", "OBSERVATION_MODIFIER", 220, 238]]], ["All were scanned with a standard high-end ultrasound scanner and a portable pocket-sized ultrasound scanner.DISCUSSIONThe results of the portable scanner were practically identical to those of the high-end scanner in the assessment of lung interstitial syndrome according the BLUE protocol (Lichtenstein 2015):DISCUSSIONBland-Altman bias was found to be close to zero, with very narrow Limits of Agreement and all the other parameters of concordance were in the range of substantial or excellent agreement.DISCUSSIONFurthermore, no systematic bias was observed according to disease severity or anatomical site of 9 analysis, except for a statistically significant but practically negligible difference in the posterior side of the thorax, possibly a spurious finding.DISCUSSIONDue to its easy handling and dynamic nature, LUS is increasingly used in clinical settings, especially in critical care (Mojoli et al. 2019) .", [["lung interstitial", "ANATOMY", 235, 252], ["thorax", "ANATOMY", 731, 737], ["lung interstitial syndrome", "DISEASE", 235, 261], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 235, 252], ["thorax", "ORGAN", 731, 737], ["LUS", "MULTI-TISSUE_STRUCTURE", 822, 825], ["a portable pocket-sized ultrasound scanner", "TEST", 65, 107], ["the portable scanner", "TEST", 133, 153], ["the assessment", "TEST", 217, 231], ["lung interstitial syndrome", "PROBLEM", 235, 261], ["systematic bias", "PROBLEM", 532, 547], ["anatomical site of 9 analysis", "TEST", 594, 623], ["a spurious finding", "PROBLEM", 748, 766], ["LUS", "TEST", 822, 825], ["lung", "ANATOMY", 235, 239], ["interstitial syndrome", "OBSERVATION", 240, 261], ["significant", "OBSERVATION_MODIFIER", 652, 663], ["practically", "OBSERVATION_MODIFIER", 668, 679], ["negligible", "OBSERVATION_MODIFIER", 680, 690], ["difference", "OBSERVATION", 691, 701], ["posterior", "ANATOMY_MODIFIER", 709, 718], ["thorax", "ANATOMY", 731, 737], ["possibly", "UNCERTAINTY", 739, 747], ["spurious", "OBSERVATION", 750, 758]]], ["In SARS-CoV-2 infection, it is invaluable in clinical management, showing higher accuracy than chest radiography (Smith et al. 2019 ) and good correlation with CT imaging and pneumonia severity (Nouvenne et al. 2020 , Zieleskiewicz et al. 2020 ).", [["chest", "ANATOMY", 95, 100], ["SARS-CoV-2 infection", "DISEASE", 3, 23], ["pneumonia", "DISEASE", 175, 184], ["SARS-CoV-2", "ORGANISM", 3, 13], ["SARS-CoV-2", "SPECIES", 3, 13], ["SARS", "PROBLEM", 3, 7], ["CoV-2 infection", "PROBLEM", 8, 23], ["chest radiography", "TEST", 95, 112], ["CT imaging", "TEST", 160, 170], ["pneumonia severity", "PROBLEM", 175, 193], ["SARS", "OBSERVATION", 3, 7], ["CoV", "OBSERVATION_MODIFIER", 8, 11], ["infection", "OBSERVATION", 14, 23], ["chest", "ANATOMY", 95, 100], ["pneumonia", "OBSERVATION", 175, 184]]], ["In experimental models of ARDS, it was found to detect lung lesions before the onset of hypoxemia (Soldati et al. 2020) .", [["lung lesions", "ANATOMY", 55, 67], ["ARDS", "DISEASE", 26, 30], ["lung lesions", "DISEASE", 55, 67], ["hypoxemia", "DISEASE", 88, 97], ["lung lesions", "CANCER", 55, 67], ["ARDS", "PROBLEM", 26, 30], ["lung lesions", "PROBLEM", 55, 67], ["hypoxemia", "PROBLEM", 88, 97], ["ARDS", "OBSERVATION", 26, 30], ["lung", "ANATOMY", 55, 59], ["lesions", "OBSERVATION", 60, 67], ["hypoxemia", "OBSERVATION", 88, 97]]], ["Point-of-care ultrasound has great possibilities in many branches of medicine, especially emergency and critical care where it can be invaluable in the safe management of COVID-19, since it allows concomitant clinical examination and lung imaging at the bedside by the same doctor (Smith et al. 2019 , Buonsenso et al. 2020 ).", [["lung", "ANATOMY", 234, 238], ["lung", "ORGAN", 234, 238], ["ultrasound", "TEST", 14, 24], ["COVID", "TEST", 171, 176], ["concomitant clinical examination", "TEST", 197, 229], ["lung imaging", "TEST", 234, 246], ["branches", "OBSERVATION_MODIFIER", 57, 65], ["lung", "ANATOMY", 234, 238]]], ["An observational study, namedCORonavirus (COVID-19) Diagnostic Lung UltraSound Study (COR-DLUS) (ClinicalTrials.govIdentifier: NCT04351802), is currently ongoing.", [["Lung", "ANATOMY", 63, 67], ["An observational study", "TEST", 0, 22], ["namedCORonavirus", "TEST", 24, 40], ["COVID", "TEST", 42, 47], ["Diagnostic Lung UltraSound Study", "TEST", 52, 84], ["Lung", "ANATOMY", 63, 67]]], ["The study is designed to assess whether focused lung ultrasound examination can improve the diagnosis of COVID-19 lung disease and/or make an alternative diagnosis at a patient's initial hospital presentation.CORonavirus (COVID-19) Diagnostic Lung UltraSound Study (COR-DLUS) (ClinicalTrials.govIn our study we also found a statistically significant correlation between portable scanner findings and disease severity, confirming previous reports of 68.8%, 77.8%, 100.0% sensitivity, 85.7%, 76.2%, 92.9% specificity and 76.7%, 76.7%, 93.3% diagnostic accuracy in detecting mild, moderate and severe lung lesions, respectively (Lu et al. 2020) .CORonavirus (COVID-19) Diagnostic Lung UltraSound Study (COR-DLUS) (ClinicalTrials.govThe main limit of our study were its retrospective nature, preventing the analysis of the effect of the order of measurements with the two instruments and the effect of different observers (both can be considered to have been random, but there was no systematic protocol), and the limited number of patients undergoing imaging, however a considerable number of lung scans were analysed and clearly demonstrated, for the first time, that the performances of the portable and highend scanners were interchangeable.", [["lung", "ANATOMY", 48, 52], ["lung", "ANATOMY", 114, 118], ["Lung", "ANATOMY", 243, 247], ["lung lesions", "ANATOMY", 598, 610], ["Lung", "ANATOMY", 677, 681], ["lung", "ANATOMY", 1090, 1094], ["lung disease", "DISEASE", 114, 126], ["lung lesions", "DISEASE", 598, 610], ["lung", "ORGAN", 48, 52], ["lung", "ORGAN", 114, 118], ["patient", "ORGANISM", 169, 176], ["Lung", "ORGAN", 243, 247], ["lung lesions", "CANCER", 598, 610], ["patients", "ORGANISM", 1028, 1036], ["lung", "ORGAN", 1090, 1094], ["patient", "SPECIES", 169, 176], ["patients", "SPECIES", 1028, 1036], ["The study", "TEST", 0, 9], ["focused lung ultrasound examination", "TEST", 40, 75], ["COVID-19 lung disease", "PROBLEM", 105, 126], ["CORonavirus (COVID", "TEST", 209, 227], ["Diagnostic Lung UltraSound Study", "TEST", 232, 264], ["our study", "TEST", 298, 307], ["portable scanner findings", "TEST", 370, 395], ["disease severity", "TEST", 400, 416], ["sensitivity", "TEST", 470, 481], ["specificity", "TEST", 503, 514], ["diagnostic accuracy", "TEST", 539, 558], ["mild, moderate and severe lung lesions", "PROBLEM", 572, 610], ["CORonavirus (COVID", "TEST", 643, 661], ["Diagnostic Lung UltraSound Study", "TEST", 666, 698], ["our study", "TEST", 747, 756], ["the analysis", "TEST", 799, 811], ["the two instruments", "TREATMENT", 860, 879], ["systematic protocol", "TEST", 980, 999], ["imaging", "TEST", 1048, 1055], ["lung scans", "TEST", 1090, 1100], ["the portable and highend scanners", "TEST", 1186, 1219], ["lung", "ANATOMY", 48, 52], ["lung", "ANATOMY", 114, 118], ["disease", "OBSERVATION", 119, 126], ["Lung", "ANATOMY", 243, 247], ["mild", "OBSERVATION_MODIFIER", 572, 576], ["moderate", "OBSERVATION_MODIFIER", 578, 586], ["severe", "OBSERVATION_MODIFIER", 591, 597], ["lung", "ANATOMY", 598, 602], ["lesions", "OBSERVATION", 603, 610], ["Lung", "ANATOMY", 677, 681], ["main", "OBSERVATION_MODIFIER", 733, 737], ["lung", "ANATOMY", 1090, 1094]]], ["The use of portable ultrasound devices has increased in recent years, creating a flourishing market.", [["portable ultrasound devices", "TEST", 11, 38], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["flourishing market", "OBSERVATION", 81, 99]]], ["A big advantage of portable devices is time saving at the bedside and in prehospital situations; limits are battery runtime, narrow field of vision, and low penetration (Stock et al. 2020 , ESR 2019 .", [["portable devices", "TREATMENT", 19, 35], ["ESR", "TEST", 190, 193], ["low penetration", "OBSERVATION_MODIFIER", 153, 168]]], ["In COVID-19 patients, these devices could be of help for triage purpose as well by providing instant and objective information of the severity of the disease and may avoid further imaging in mild patients, however findings are not specific and may not correlate to clinical outcome and qualified operators are necessary; combination with clinical and physiological data is strongly recommended.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 196, 204], ["these devices", "TREATMENT", 22, 35], ["triage purpose", "TEST", 57, 71], ["the disease", "PROBLEM", 146, 157], ["further imaging", "TEST", 172, 187], ["clinical and physiological data", "TEST", 338, 369], ["disease", "OBSERVATION", 150, 157]]], ["Their utility has been argued by several authors (Gibson et al. 2020 , Qian et al. 2020 , but this is the first study providing a demonstration of their use in daily clinical practice in COVID-19 patients.CORonavirus (COVID-19) Diagnostic Lung UltraSound Study (COR-DLUS) (ClinicalTrials.govIn conclusion, our study confirms the possibilities of portable ultrasound imaging of the lung in COVID-19 patients.", [["Lung", "ANATOMY", 239, 243], ["lung", "ANATOMY", 381, 385], ["patients", "ORGANISM", 196, 204], ["Lung", "ORGAN", 239, 243], ["lung", "ORGAN", 381, 385], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 398, 406], ["CORonavirus (COVID", "TEST", 205, 223], ["Diagnostic Lung UltraSound Study", "TEST", 228, 260], ["our study", "TEST", 306, 315], ["portable ultrasound imaging", "TEST", 346, 373], ["Lung", "ANATOMY", 239, 243], ["lung", "ANATOMY", 381, 385]]], ["Portable pocket-sized ultrasound scanners are cheap, easy to handle and equivalent to standard scanners for non-invasive assessment of severity and dynamic observation of lung lesions in COVID-19 patients with pneumonia.", [["lung lesions", "ANATOMY", 171, 183], ["lung lesions", "DISEASE", 171, 183], ["pneumonia", "DISEASE", 210, 219], ["lung lesions", "CANCER", 171, 183], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["Portable pocket-sized ultrasound scanners", "TEST", 0, 41], ["non-invasive assessment", "TEST", 108, 131], ["severity", "TEST", 135, 143], ["dynamic observation", "TEST", 148, 167], ["lung lesions", "PROBLEM", 171, 183], ["pneumonia", "PROBLEM", 210, 219], ["sized", "OBSERVATION_MODIFIER", 16, 21], ["lung", "ANATOMY", 171, 175], ["lesions", "OBSERVATION", 176, 183], ["pneumonia", "OBSERVATION", 210, 219]]], ["These ultrasound scanners can play a decisive role when healthcare resources are scarce, during pandemics and in emergency situations, such as the present COVID-19 outbreak.", [["These ultrasound scanners", "TEST", 0, 25]]]], "d5722738d8a265e7e0f4792c3baedc6759e58d64": [["In general, it gives rise to a dynamic process which evolves in time with its early stages being reasonably well approximated by considering the patient zero as the root (apex) of a tree whose branches encode the interactions through which the disease can propagate.", [["root", "ANATOMY", 165, 169], ["patient", "ORGANISM", 145, 152], ["root", "TISSUE", 165, 169], ["patient", "SPECIES", 145, 152], ["a dynamic process", "PROBLEM", 29, 46], ["the disease", "PROBLEM", 240, 251], ["root", "ANATOMY", 165, 169], ["apex", "ANATOMY_MODIFIER", 171, 175], ["tree", "ANATOMY_MODIFIER", 182, 186], ["branches", "OBSERVATION_MODIFIER", 193, 201]]], ["In such epidemiological and percolation problems it is commonly assumed that each individual has an equal probability to transmit the disease to any of its contacts.", [["percolation problems", "PROBLEM", 28, 48], ["the disease", "PROBLEM", 130, 141], ["percolation problems", "OBSERVATION", 28, 48]]], ["However, this is an over-simplification of the actual situation as the same person can have several classes of interactions.", [["person", "SPECIES", 76, 82]]], ["Namely, it is conceivable that it is more likely that an infected individual will transmit the disease to someone with which it maintains a close familiar relation than to someone which it sporadically meets.", [["the disease", "PROBLEM", 91, 102], ["more likely", "UNCERTAINTY", 37, 48], ["infected", "OBSERVATION", 57, 65]]], ["In this setting we shall encode these different probabilities of transmitting the disease by distinct trees T 1 , . . . , T n all with the same root which is the patient zero.", [["root", "ANATOMY", 144, 148], ["root", "ORGAN", 144, 148], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["the disease", "PROBLEM", 78, 89], ["distinct", "OBSERVATION_MODIFIER", 93, 101], ["trees", "OBSERVATION", 102, 107], ["root", "OBSERVATION_MODIFIER", 144, 148]]], ["To each tree T i we associated a probability T i of transmitting the disease along an interaction modeled by the corresponding tree.", [["the disease", "PROBLEM", 65, 76], ["disease", "OBSERVATION", 69, 76], ["tree", "ANATOMY_MODIFIER", 127, 131]]], ["In the case when the T i are all the same for each vertex (individual) it is known that the basic reproduction number R 0 controls the possibility of almost surely avoiding an epidemic, see [Br, Ha, Ja, KA, Sc] and [Ca] which phrases these results in terms of the percolation interpretation.", [["Ca", "CHEMICAL", 216, 218], ["[Br, Ha, Ja, KA, Sc] and [Ca]", "CHEMICAL", 190, 219], ["T i", "GENE_OR_GENE_PRODUCT", 21, 24], ["[Ca]", "SIMPLE_CHEMICAL", 215, 219], ["the percolation interpretation", "TEST", 260, 290]]]], "044808367554fe47db084d9636259432cf00879d": [["(Continued from previous page)Conclusions: ME better related to underlying lung pathology and patient outcome than MP.", [["lung", "ANATOMY", 75, 79], ["MP", "DISEASE", 115, 117], ["lung", "ORGAN", 75, 79], ["patient", "ORGANISM", 94, 101], ["MP", "GENE_OR_GENE_PRODUCT", 115, 117], ["patient", "SPECIES", 94, 101], ["underlying lung pathology", "PROBLEM", 64, 89], ["lung", "ANATOMY", 75, 79], ["pathology", "OBSERVATION", 80, 89]]], ["The delivery of generated energy to the lung was not dependent on ETT size during PC ventilation.", [["lung", "ANATOMY", 40, 44], ["lung", "ORGAN", 40, 44], ["PC ventilation", "TREATMENT", 82, 96], ["lung", "ANATOMY", 40, 44], ["size", "OBSERVATION_MODIFIER", 70, 74], ["PC ventilation", "OBSERVATION", 82, 96]]], ["Further studies are needed to identify injurious MErs thresholds in ventilated children.(Continued from previous page)Keywords: Mechanical power, Energy per breath, Mechanical ventilation, Pediatric, Ventilator-induced lung injury (VILI)BackgroundMechanical ventilation (MV) as life-saving intervention is ubiquitous in pediatric intensive care units (PICU) but may simultaneously lead to ventilator-induced lung injury (VILI) [1] .", [["lung", "ANATOMY", 219, 223], ["lung", "ANATOMY", 408, 412], ["Ventilator-induced lung injury", "DISEASE", 200, 230], ["ventilator-induced lung injury", "DISEASE", 389, 419], ["VILI", "DISEASE", 421, 425], ["children", "ORGANISM", 79, 87], ["lung", "ORGAN", 219, 223], ["lung", "ORGAN", 408, 412], ["children", "SPECIES", 79, 87], ["MV", "SPECIES", 271, 273], ["Further studies", "TEST", 0, 15], ["injurious MErs thresholds", "PROBLEM", 39, 64], ["Mechanical power", "TREATMENT", 128, 144], ["Mechanical ventilation", "TREATMENT", 165, 187], ["Ventilator", "TREATMENT", 200, 210], ["lung injury", "PROBLEM", 219, 230], ["Mechanical ventilation (MV)", "TREATMENT", 247, 274], ["ventilator", "TREATMENT", 389, 399], ["lung injury", "PROBLEM", 408, 419], ["Mechanical ventilation", "OBSERVATION", 165, 187], ["lung", "ANATOMY", 219, 223], ["injury", "OBSERVATION", 224, 230], ["Mechanical ventilation", "OBSERVATION", 247, 269], ["lung", "ANATOMY", 408, 412], ["injury", "OBSERVATION", 413, 419]]], ["Experimental and clinical studies have identified factors contributing to VILI to include volutrauma (i.e., delivery of large tidal volumes (Vt) as a surrogate for lung strain), lung stress, and atelectrauma (i.e., the repetitive opening and closure of alveoli) albeit that their exact role in the pediatric setting is not well understood [1, 2] .BackgroundMechanical power (MPrs) has been proposed as a measure and potential driver of VILI [3] .", [["lung", "ANATOMY", 164, 168], ["lung", "ANATOMY", 178, 182], ["alveoli", "ANATOMY", 253, 260], ["VILI", "DISEASE", 74, 78], ["volutrauma", "DISEASE", 90, 100], ["atelectrauma", "DISEASE", 195, 207], ["lung", "ORGAN", 164, 168], ["lung", "ORGAN", 178, 182], ["alveoli", "MULTI-TISSUE_STRUCTURE", 253, 260], ["clinical studies", "TEST", 17, 33], ["VILI", "PROBLEM", 74, 78], ["volutrauma", "PROBLEM", 90, 100], ["large tidal volumes", "PROBLEM", 120, 139], ["lung strain", "PROBLEM", 164, 175], ["lung stress", "PROBLEM", 178, 189], ["atelectrauma", "PROBLEM", 195, 207], ["closure of alveoli", "TREATMENT", 242, 260], ["large", "OBSERVATION_MODIFIER", 120, 125], ["tidal volumes", "OBSERVATION", 126, 139], ["lung", "ANATOMY", 164, 168], ["lung", "ANATOMY", 178, 182], ["stress", "OBSERVATION", 183, 189], ["alveoli", "ANATOMY", 253, 260]]], ["MPrs is the energy per breathing cycle multiplied by ventilation frequency [4] .", [["MPrs", "SIMPLE_CHEMICAL", 0, 4]]], ["It can be calculated during volumecontrolled (VC) ventilation using the respiratory rate (RR), peak inspiratory pressure (PIP), plateau pressure (Pplat), and positive end-expiratory pressure (PEEP) [5] .", [["volumecontrolled (VC) ventilation", "TREATMENT", 28, 61], ["the respiratory rate", "TEST", 68, 88], ["RR", "TEST", 90, 92], ["peak inspiratory pressure", "TEST", 95, 120], ["PIP", "TEST", 122, 125], ["plateau pressure (Pplat)", "TREATMENT", 128, 152], ["positive end-expiratory pressure (PEEP", "TREATMENT", 158, 196]]], ["Although MPrs has been associated with mortality in ARDS patients, it is not well-established if MPrs should be normalized to lung volume or predicted bodyweight and how much power is delivered to the lung [3, [6] [7] [8] .BackgroundIt has not been studied how the conceptual framework of power translates to mechanically ventilated children.", [["lung", "ANATOMY", 126, 130], ["lung", "ANATOMY", 201, 205], ["MPrs", "CHEMICAL", 9, 13], ["ARDS", "DISEASE", 52, 56], ["MPrs", "GENE_OR_GENE_PRODUCT", 9, 13], ["patients", "ORGANISM", 57, 65], ["MPrs", "SIMPLE_CHEMICAL", 97, 101], ["lung", "ORGAN", 126, 130], ["lung", "ORGAN", 201, 205], ["children", "ORGANISM", 333, 341], ["MPrs", "PROTEIN", 9, 13], ["patients", "SPECIES", 57, 65], ["children", "SPECIES", 333, 341], ["ARDS", "PROBLEM", 52, 56], ["MPrs", "TEST", 97, 101], ["lung volume", "TEST", 126, 137], ["ARDS", "OBSERVATION", 52, 56], ["lung", "ANATOMY", 126, 130], ["volume", "OBSERVATION", 131, 137], ["lung", "ANATOMY", 201, 205]]], ["Obviously, two key components of MPrs (i.e., Vt and RR) are age-dependent (i.e., the older the child, the larger the Vt and the lower the RR), making those injurious thresholds for MPrs not uniform across the entire pediatric spectrum.", [["MPrs", "GENE_OR_GENE_PRODUCT", 33, 37], ["MPrs", "TEST", 33, 37], ["Vt", "TEST", 45, 47], ["RR", "TEST", 52, 54], ["MPrs", "TEST", 181, 185], ["larger", "OBSERVATION_MODIFIER", 106, 112], ["Vt", "OBSERVATION", 117, 119], ["lower", "ANATOMY_MODIFIER", 128, 133]]], ["Furthermore, pediatric critical care practitioners predominantly use a pressure-controlled (PC) mode of ventilation whereas the concept MPrs is based on VC ventilation although Becher et al. have proposed an approach to measure MPrs during PC ventilation using peak inspiratory pressure (PIP) instead of Pplat [9] [10] [11] .", [["Pplat [9] [10] [11]", "CHEMICAL", 304, 323], ["MPrs", "SIMPLE_CHEMICAL", 228, 232], ["a pressure-controlled (PC) mode of ventilation", "TREATMENT", 69, 115], ["VC ventilation", "TREATMENT", 153, 167], ["PC ventilation", "TREATMENT", 240, 254], ["peak inspiratory pressure (PIP", "TREATMENT", 261, 291]]], ["It needs to be studied if these modifications can be used to study mechanical power in children.", [["children", "ORGANISM", 87, 95], ["children", "SPECIES", 87, 95]]], ["Aside from these methodological aspects, infants and young children are generally ventilated with small endotracheal tube (ETT) sizes with high gas flow and high ventilation rate, all contributing to resistance (Rrs) [12] .", [["infants", "ORGANISM", 41, 48], ["children", "ORGANISM", 59, 67], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 104, 121], ["infants", "SPECIES", 41, 48], ["children", "SPECIES", 59, 67], ["small endotracheal tube", "TREATMENT", 98, 121], ["high gas flow", "TREATMENT", 139, 152], ["high ventilation rate", "TREATMENT", 157, 178], ["small", "OBSERVATION_MODIFIER", 98, 103], ["endotracheal tube", "OBSERVATION", 104, 121], ["high", "OBSERVATION_MODIFIER", 139, 143], ["gas flow", "OBSERVATION", 144, 152], ["high ventilation", "OBSERVATION", 157, 173]]], ["Added to that, especially young children often suffer from disease conditions characterized by increased airway resistance such as viral bronchiolitis or pneumonia [13] .", [["airway", "ANATOMY", 105, 111], ["bronchiolitis", "DISEASE", 137, 150], ["pneumonia", "DISEASE", 154, 163], ["children", "ORGANISM", 32, 40], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["children", "SPECIES", 32, 40], ["disease conditions", "PROBLEM", 59, 77], ["increased airway resistance", "PROBLEM", 95, 122], ["viral bronchiolitis", "PROBLEM", 131, 150], ["pneumonia", "PROBLEM", 154, 163], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["airway resistance", "OBSERVATION", 105, 122], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["bronchiolitis", "OBSERVATION", 137, 150], ["pneumonia", "OBSERVATION", 154, 163]]], ["It is thus unclear how much of the power is delivered to the lungs and how much is dissipated in the native airways.BackgroundWe therefore sought to explore how MPrs and energy with Vt normalized to bodyweight (thereby eliminating age dependency) correlated with underlying lung pathology and patient outcome.", [["lungs", "ANATOMY", 61, 66], ["airways", "ANATOMY", 108, 115], ["lung", "ANATOMY", 274, 278], ["lungs", "ORGAN", 61, 66], ["airways", "MULTI-TISSUE_STRUCTURE", 108, 115], ["MPrs", "SIMPLE_CHEMICAL", 161, 165], ["lung", "ORGAN", 274, 278], ["patient", "ORGANISM", 293, 300], ["patient", "SPECIES", 293, 300], ["Vt", "PROBLEM", 182, 184], ["underlying lung pathology", "PROBLEM", 263, 288], ["lungs", "ANATOMY", 61, 66], ["native", "ANATOMY_MODIFIER", 101, 107], ["airways", "ANATOMY", 108, 115], ["lung", "ANATOMY", 274, 278], ["pathology", "OBSERVATION", 279, 288]]], ["In addition, we wanted to study if ETT size impacted energy delivery to the lung.MethodsWe analyzed routinely collected demographic, physiological, and laboratory data from deeply sedated and/or paralyzed children < 18 years with and without lung injury on weekdays at 8 am during the first 3 days of MV.", [["lung", "ANATOMY", 76, 80], ["lung", "ANATOMY", 242, 246], ["lung injury", "DISEASE", 242, 253], ["lung", "ORGAN", 76, 80], ["children", "ORGANISM", 205, 213], ["lung", "ORGAN", 242, 246], ["children", "SPECIES", 205, 213], ["MV", "SPECIES", 301, 303], ["laboratory data", "TEST", 152, 167], ["lung injury", "PROBLEM", 242, 253], ["lung", "ANATOMY", 76, 80], ["without", "UNCERTAINTY", 234, 241], ["lung", "ANATOMY", 242, 246], ["injury", "OBSERVATION", 247, 253]]], ["Data from patients with obstructive airway disease, documented chronic lung disease, neuromuscular disorders, premature birth with age corrected for postconceptional age less than 40 weeks, severe traumatic brain injury (i.e., Glasgow Coma Scale < 8), chronic lung disease (i.e., tracheostomy ventilation), and severe pulmonary hypertension, managed with high-frequency oscillation ventilation or with an ETT leakage > 18% were excluded.", [["airway", "ANATOMY", 36, 42], ["lung", "ANATOMY", 71, 75], ["neuromuscular", "ANATOMY", 85, 98], ["brain", "ANATOMY", 207, 212], ["lung", "ANATOMY", 260, 264], ["pulmonary", "ANATOMY", 318, 327], ["obstructive airway disease", "DISEASE", 24, 50], ["chronic lung disease", "DISEASE", 63, 83], ["neuromuscular disorders", "DISEASE", 85, 108], ["premature birth", "DISEASE", 110, 125], ["traumatic brain injury", "DISEASE", 197, 219], ["Coma", "DISEASE", 235, 239], ["chronic lung disease", "DISEASE", 252, 272], ["pulmonary hypertension", "DISEASE", 318, 340], ["patients", "ORGANISM", 10, 18], ["airway", "MULTI-TISSUE_STRUCTURE", 36, 42], ["lung", "ORGAN", 71, 75], ["brain", "ORGAN", 207, 212], ["lung", "ORGAN", 260, 264], ["pulmonary", "ORGAN", 318, 327], ["patients", "SPECIES", 10, 18], ["obstructive airway disease", "PROBLEM", 24, 50], ["chronic lung disease", "PROBLEM", 63, 83], ["neuromuscular disorders", "PROBLEM", 85, 108], ["premature birth", "PROBLEM", 110, 125], ["severe traumatic brain injury", "PROBLEM", 190, 219], ["Glasgow Coma Scale", "TEST", 227, 245], ["chronic lung disease", "PROBLEM", 252, 272], ["tracheostomy ventilation", "TREATMENT", 280, 304], ["severe pulmonary hypertension", "PROBLEM", 311, 340], ["high-frequency oscillation ventilation", "TREATMENT", 355, 393], ["an ETT leakage", "TEST", 402, 416], ["obstructive airway disease", "OBSERVATION", 24, 50], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["lung", "ANATOMY", 71, 75], ["disease", "OBSERVATION", 76, 83], ["neuromuscular", "ANATOMY", 85, 98], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["traumatic", "OBSERVATION_MODIFIER", 197, 206], ["brain", "ANATOMY", 207, 212], ["injury", "OBSERVATION", 213, 219], ["chronic", "OBSERVATION_MODIFIER", 252, 259], ["lung", "ANATOMY", 260, 264], ["disease", "OBSERVATION", 265, 272], ["tracheostomy ventilation", "OBSERVATION", 280, 304], ["severe", "OBSERVATION_MODIFIER", 311, 317], ["pulmonary", "ANATOMY", 318, 327], ["hypertension", "OBSERVATION", 328, 340]]], ["The severity of the disease was assessed by the 24-h Pediatric Risk of Mortality II (PRISM II) [14] .", [["the disease", "PROBLEM", 16, 27], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["disease", "OBSERVATION", 20, 27]]], ["Patients were stratified according to underlying respiratory system mechanics subgroups proposed by the Pediatric Mechanical Ventilation Consensus Conference (PEMV ECC) definition and pediatric acute lung injury consensus conference (PALICC) definition for PARDS [13, 15] .", [["lung", "ANATOMY", 200, 204], ["acute lung injury", "DISEASE", 194, 211], ["PARDS", "DISEASE", 257, 262], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 200, 204], ["Patients", "SPECIES", 0, 8], ["pediatric acute lung injury", "PROBLEM", 184, 211], ["respiratory system", "ANATOMY", 49, 67], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["lung", "ANATOMY", 200, 204], ["injury", "OBSERVATION", 205, 211]]], ["The Institutional Review Board approved the study and waived the need for informed consent.", [["the study", "TEST", 40, 49]]], ["A bench study was performed to study how the ETT affected energy transmission to the lung (see Additional file 1).MethodsPatients were ventilated in a PC ventilation mode, limiting inspiratory pressures < 28-32 cmH 2 O and expiratory Vt (Vt-exp) 5-7 mL/kg actual bodyweight (as there was no obesity in the patient cohort).", [["lung", "ANATOMY", 85, 89], ["obesity", "DISEASE", 291, 298], ["lung", "ORGAN", 85, 89], ["patient", "ORGANISM", 306, 313], ["patient", "SPECIES", 306, 313], ["A bench study", "TEST", 0, 13], ["MethodsPatients", "TREATMENT", 114, 129], ["a PC ventilation mode", "TREATMENT", 149, 170], ["inspiratory pressures", "TEST", 181, 202], ["expiratory Vt", "TEST", 223, 236], ["Vt", "TEST", 238, 240], ["obesity", "PROBLEM", 291, 298], ["lung", "ANATOMY", 85, 89], ["inspiratory pressures", "OBSERVATION", 181, 202], ["no", "UNCERTAINTY", 288, 290], ["obesity", "OBSERVATION", 291, 298]]], ["Vt-exp was measured near the Y-piece in children < 10 kg (VarFlex\u2122, Vyaire, Mettawa, Ill, USA).", [["Vt-exp", "GENE_OR_GENE_PRODUCT", 0, 6], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["Vt", "TEST", 0, 2], ["exp", "PROBLEM", 3, 6]]], ["Mandatory breath rate setting was guided by the underlying pathology and age; the flow-time scalar is carefully monitored to identify appropriate inspiratory time setting and to avoid the development of intrinsic PEEP.", [["intrinsic PEEP", "TREATMENT", 203, 217], ["intrinsic PEEP", "OBSERVATION", 203, 217]]], ["The I to E ratio is not fixed.", [["The I to E ratio", "TEST", 0, 16], ["not", "UNCERTAINTY", 20, 23], ["fixed", "OBSERVATION", 24, 29]]], ["Initial PEEP was 4-6 cm H 2 O and further titrated at the discretion of the attending physician, targeting SpO 2 88-92% for patients with lung injury.", [["lung", "ANATOMY", 138, 142], ["lung injury", "DISEASE", 138, 149], ["patients", "ORGANISM", 124, 132], ["lung", "ORGAN", 138, 142], ["patients", "SPECIES", 124, 132], ["Initial PEEP", "TREATMENT", 0, 12], ["SpO", "TEST", 107, 110], ["lung injury", "PROBLEM", 138, 149], ["lung", "ANATOMY", 138, 142], ["injury", "OBSERVATION", 143, 149]]], ["Unless dictated otherwise, the target pH was > 7.20.MethodsDemographic, physiological, and laboratory data were manually extracted from the patient's medical record.", [["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["the target pH", "TEST", 27, 40], ["laboratory data", "TEST", 91, 106]]], ["Ventilator settings and parameters were read from the ventilator.", [["Ventilator settings", "TREATMENT", 0, 19], ["the ventilator", "TREATMENT", 50, 64]]], ["Plateau pressure (Pplat) and quasi-static compliance (Crs) were measured at end-inspiration by a manual inspiratory hold maneuver of 3 s.", [["Plateau pressure", "TEST", 0, 16], ["a manual inspiratory hold maneuver", "TREATMENT", 95, 129], ["pressure", "OBSERVATION_MODIFIER", 8, 16]]], ["Metrics for oxygenation included the oxygenation index [OI] ([mean airway pressure \u00d7 FiO 2 \u00d7 100]/PaO 2 ) and if the SpO 2 was < 98% the oxygen saturation index [OSI] [mean airway pressure \u00d7 FiO 2 \u00d7 100]/SpO 2 ).", [["airway", "ANATOMY", 67, 73], ["airway", "ANATOMY", 173, 179], ["OI", "DISEASE", 56, 58], ["oxygen", "CHEMICAL", 137, 143], ["SpO 2", "CHEMICAL", 117, 122], ["oxygen", "CHEMICAL", 137, 143], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 137, 143], ["airway", "MULTI-TISSUE_STRUCTURE", 173, 179], ["the oxygenation index", "TEST", 33, 54], ["OI", "PROBLEM", 56, 58], ["mean airway pressure", "TEST", 62, 82], ["FiO", "TEST", 85, 88], ["the SpO", "TEST", 113, 120], ["the oxygen saturation index", "TEST", 133, 160], ["OSI", "TEST", 162, 165], ["mean airway pressure", "TEST", 168, 188], ["FiO", "TEST", 191, 194]]], ["We calculated ventilatorfree days (VFD) through day 28, defined as the number of days within 28 days that a subject is alive and free of MV [16] .", [["MV", "SPECIES", 137, 139]]], ["Patients were assigned 0 VFD if they remained intubated or died prior to day 28 without remaining extubated for more than 24 h.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["intubated", "TREATMENT", 46, 55]]], ["MPrs was calculated as previously described [5] .", [["MPrs", "GENE_OR_GENE_PRODUCT", 0, 4], ["MPrs", "PROTEIN", 0, 4], ["MPrs", "TEST", 0, 4]]], ["The mechanical energy of the respiratory (MErs) was calculated byStatistical analysisThe normality of data was assessed using the Kolmogorov-Smirnov test.", [["the Kolmogorov-Smirnov test", "TEST", 126, 153], ["mechanical energy", "OBSERVATION", 4, 21], ["respiratory", "ANATOMY", 29, 40]]], ["Continuous data are presented as median and 25-75 interquartile range (IQR) and analyzed using the Mann-Whitney U test (for comparing two groups) or Kruskal-Wallis test; Spearman correlation coefficient (r s ) was calculated to analyze correlations.", [["the Mann-Whitney U test", "TEST", 95, 118], ["Kruskal-Wallis test", "TEST", 149, 168]]], ["The \u03c7 2 test with Yates continuity correction was used to analyze categorical data.", [["The \u03c7 2 test", "TEST", 0, 12], ["Yates continuity correction", "TREATMENT", 18, 45]]], ["The primary outcome measure was the duration of mechanical ventilation (MV).", [["MV", "SPECIES", 72, 74], ["mechanical ventilation", "TREATMENT", 48, 70]]], ["Competing risk regression analysis (Fine and Gray model) was used to identify independent contributors to the duration of MV with death as a competing risk [17] .", [["death", "DISEASE", 130, 135], ["MV", "SPECIES", 122, 124], ["death", "PROBLEM", 130, 135]]], ["All statistical analyses were performed using software IBM SPSS, v24.0 (IBM Corp., Chicago, III, USA) with P < 0.05 considered statistically significant.Correlation MPrs and MErs with underlying lung pathology and patient outcomeData of 312 patients with a median age of 7.8 (1.7-44.2) months was analyzed (Table 1 ).", [["lung", "ANATOMY", 195, 199], ["lung", "ORGAN", 195, 199], ["patient", "ORGANISM", 214, 221], ["patients", "ORGANISM", 241, 249], ["patient", "SPECIES", 214, 221], ["patients", "SPECIES", 241, 249], ["All statistical analyses", "TEST", 0, 24], ["software IBM SPSS", "TEST", 46, 63], ["v", "TEST", 65, 66], ["P", "TEST", 107, 108], ["Correlation MPrs", "TEST", 153, 169], ["underlying lung pathology", "TEST", 184, 209], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["lung", "ANATOMY", 195, 199], ["pathology", "OBSERVATION", 200, 209]]], ["Of these, 186 patients (61.5%) were younger than 12 months of age.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Primary admission diagnosis was respiratory failure in 102 (32.7%) and cardiac (including post-cardiac surgery) in 81 (26.0%) patients.", [["respiratory", "ANATOMY", 32, 43], ["cardiac", "ANATOMY", 71, 78], ["cardiac", "ANATOMY", 95, 102], ["respiratory failure", "DISEASE", 32, 51], ["cardiac", "ORGAN", 71, 78], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["respiratory failure", "PROBLEM", 32, 51], ["cardiac surgery", "TREATMENT", 95, 110], ["respiratory failure", "OBSERVATION", 32, 51], ["cardiac", "ANATOMY", 71, 78], ["cardiac", "ANATOMY", 95, 102], ["surgery", "OBSERVATION", 103, 110]]], ["Sixty-nine (22.1%) patients met PEMVECC criteria for restrictive and 78 (25.0%) for mixed lung disease, and 7.7% of patients met PALICC criteria for PARDS.", [["lung", "ANATOMY", 90, 94], ["lung disease", "DISEASE", 90, 102], ["PARDS", "DISEASE", 149, 154], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 90, 94], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 116, 124], ["restrictive", "TEST", 53, 64], ["mixed lung disease", "PROBLEM", 84, 102], ["PARDS", "PROBLEM", 149, 154], ["lung", "ANATOMY", 90, 94], ["disease", "OBSERVATION", 95, 102]]], ["The duration of MV was 93 (44-163) hours.", [["MV", "SPECIES", 16, 18], ["MV", "TEST", 16, 18]]], ["Thirteen (4.2%) patients died.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Patients were ventilated for a median of 17.3 h (11.6-21.2) before the first measurement on day 1 was made.Correlation MPrs and MErs with underlying lung pathology and patient outcomeData on MPrs was available on the first day of MV for all patients, on day 2 for 169 (53.9%), and on day 3 for 96 (30.0%) patients.", [["lung", "ANATOMY", 149, 153], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 149, 153], ["patient", "ORGANISM", 168, 175], ["patients", "ORGANISM", 241, 249], ["patients", "ORGANISM", 305, 313], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 168, 175], ["patients", "SPECIES", 241, 249], ["patients", "SPECIES", 305, 313], ["MV", "SPECIES", 230, 232], ["Correlation MPrs", "TEST", 107, 123], ["underlying lung pathology", "PROBLEM", 138, 163], ["MPrs", "TEST", 191, 195], ["lung", "ANATOMY", 149, 153], ["pathology", "OBSERVATION", 154, 163]]], ["We found a direct relationship between age and MPrs (r s 0.814, p < 0.001).", [["MPrs", "TEST", 47, 51], ["r s", "TEST", 53, 56]]], ["Vt-exp (r s 0.112, p < 0.01), weight (r s 0.837, p < 0.001), and RR (r s \u2212 0.459, p < 0.001) were also significantly correlated with MPrs.", [["Vt-exp", "GENE_OR_GENE_PRODUCT", 0, 6], ["MPrs", "PROTEIN", 133, 137], ["Vt", "TEST", 0, 2], ["exp (r s", "TEST", 3, 11], ["p", "TEST", 19, 20], ["weight", "TEST", 30, 36], ["r s", "TEST", 38, 41], ["p", "TEST", 49, 50], ["RR", "TEST", 65, 67]]], ["There was also a significant correlation between MPrs and oxygen saturation index (OSI) (r s 0.189, p < 0.001) but not with oxygenation index (OI) or PaO 2 / FiO 2 ratio.", [["oxygen", "CHEMICAL", 58, 64], ["oxygen", "CHEMICAL", 58, 64], ["PaO 2", "CHEMICAL", 150, 155], ["FiO 2", "CHEMICAL", 158, 163], ["MPrs", "SIMPLE_CHEMICAL", 49, 53], ["oxygen", "SIMPLE_CHEMICAL", 58, 64], ["PaO 2", "GENE_OR_GENE_PRODUCT", 150, 155], ["FiO 2", "GENE_OR_GENE_PRODUCT", 158, 163], ["MPrs", "TEST", 49, 53], ["oxygen saturation index", "TEST", 58, 81], ["OSI", "TEST", 83, 86], ["r s", "TEST", 89, 92], ["oxygenation index", "TEST", 124, 141], ["OI", "TEST", 143, 145], ["PaO", "TEST", 150, 153], ["FiO 2 ratio", "TEST", 158, 169], ["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["PEEP was significantly correlated with MPrs (r s 0.311, p < 0.001).Correlation MPrs and MErs with underlying lung pathology and patient outcomeThe distribution of MPrs on day 1 was significantly different (p < 0.001) across the cohort after stratification by PEMVECC criteria (Fig. 1) .", [["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["patient", "ORGANISM", 128, 135], ["MPrs", "PROTEIN", 163, 167], ["patient", "SPECIES", 128, 135], ["PEEP", "TREATMENT", 0, 4], ["MPrs", "TEST", 39, 43], ["Correlation MPrs", "TEST", 67, 83], ["underlying lung pathology", "TEST", 98, 123], ["lung", "ANATOMY", 109, 113], ["pathology", "OBSERVATION", 114, 123], ["distribution", "OBSERVATION_MODIFIER", 147, 159]]], ["Linear regression analysis showed that age in months (\u03b2 \u2212 0.012 [95%CI \u2212 0.018 \u2212 \u2212 0.007, p < 0.001), RR (\u03b2 0.047 [95%CI 0.034-0.060, p < 0.001), and total Vt (i.e., not normalized to bodyweight) (\u03b2 10.028 [95%CI 0.024-0.031, p < 0.001) were independently associated with MPrs.Correlation MPrs and MErs with underlying lung pathology and patient outcomeNext, we analyzed the mechanical energy per breath (MErs) [expressed as mJ/kg] after normalizing Vt to actual bodyweight.", [["lung", "ANATOMY", 319, 323], ["lung", "ORGAN", 319, 323], ["patient", "ORGANISM", 338, 345], ["patient", "SPECIES", 338, 345], ["Linear regression analysis", "TEST", 0, 26], ["CI", "TEST", 68, 70], ["p", "TEST", 90, 91], ["RR", "TEST", 102, 104], ["CI", "TEST", 118, 120], ["p", "TEST", 134, 135], ["total Vt", "TEST", 150, 158], ["bodyweight", "TEST", 184, 194], ["CI", "TEST", 210, 212], ["Correlation MPrs", "TEST", 277, 293], ["underlying lung pathology", "TEST", 308, 333], ["lung", "ANATOMY", 319, 323], ["pathology", "OBSERVATION", 324, 333]]], ["For the whole cohort, MErs was 10.2 (8.2-12.2) mJ/kg.", [["MErs", "TEST", 22, 26]]], ["MErs was not significantly correlated with age in months.", [["MErs", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["There was a significant correlation between MErs and OI (rs 0.412, p < 0.001), OSI (rs 0.438, p < 0.001), and PaO 2 /FiO 2 ratio (rs \u2212 0.263, p < 0.001).", [["OI", "DISEASE", 53, 55], ["PaO 2", "GENE_OR_GENE_PRODUCT", 110, 115], ["FiO 2", "GENE_OR_GENE_PRODUCT", 117, 122], ["OI", "TEST", 53, 55], ["rs", "TEST", 57, 59], ["OSI", "TEST", 79, 82], ["rs", "TEST", 84, 86], ["p", "TEST", 94, 95], ["PaO", "TEST", 110, 113], ["FiO", "TEST", 117, 120], ["rs", "TEST", 130, 132], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The distribution of MErs was significantly different (p < 0.001) across the cohort after stratification by PEMVECC criteria (Fig. 1b) .", [["MErs", "GENE_OR_GENE_PRODUCT", 20, 24], ["MErs", "PROBLEM", 20, 24], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["MErs", "OBSERVATION", 20, 24], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["different", "OBSERVATION_MODIFIER", 43, 52]]], ["MErs was 9.7 mJ/kg (8.0-12.3) in patients with normal lung mechanics, 10.7 mJ/kg (8.6-12.5) in patients with the restrictive disease, and 10.6 mJ/kg (8.6-12.5) in patients with mixed disease although this difference did not reach statistical significance.", [["lung", "ANATOMY", 54, 58], ["restrictive disease", "DISEASE", 113, 132], ["patients", "ORGANISM", 33, 41], ["lung", "ORGAN", 54, 58], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 163, 171], ["the restrictive disease", "PROBLEM", 109, 132], ["mixed disease", "PROBLEM", 177, 190], ["lung", "ANATOMY", 54, 58], ["mechanics", "ANATOMY_MODIFIER", 59, 68], ["restrictive", "OBSERVATION_MODIFIER", 113, 124], ["disease", "OBSERVATION", 125, 132], ["mixed", "OBSERVATION_MODIFIER", 177, 182], ["disease", "OBSERVATION", 183, 190]]], ["MErs but not MPrs was significantly higher in non-survivors (11.7 [8.9-15.", [["MPrs", "TEST", 13, 17], ["non-survivors", "TEST", 46, 59]]], ["Univariate analysis showed that for the entire cohort only MErs was significantly correlated with VFD (r s \u2212 0.243, p < 0.001).", [["Univariate analysis", "TEST", 0, 19], ["VFD (r s", "TEST", 98, 106]]], ["After stratification by age, we found a significant correlation between MPrs, MErs, and VFD in two age categories (0-12 months and 1-5 years) but not in children > 5 years.", [["MPrs", "GENE_OR_GENE_PRODUCT", 72, 76], ["children", "ORGANISM", 153, 161], ["MPrs", "PROTEIN", 72, 76], ["MErs", "PROTEIN", 78, 82], ["children", "SPECIES", 153, 161], ["significant", "OBSERVATION_MODIFIER", 40, 51]]], ["Competing risk regression analysis adjusting for PRISM III 24 h score, age (in months), and PEMVECC stratification showed that MPrs on day 1 or day 2 of MV was not independently associated with VFD, whereas MErs on day 1 or day 2 was (p < 0.001).Bench model testingThe median mechanical energy measured in the lung was significantly higher with VC (4.8 [2.7-8.2] than with PC ventilation (2.3 [1.2-3.4] mJ/kg, p < 0.001).", [["lung", "ANATOMY", 310, 314], ["VFD", "DISEASE", 194, 197], ["lung", "ORGAN", 310, 314], ["MV", "SPECIES", 153, 155], ["PEMVECC stratification", "TEST", 92, 114], ["VFD", "PROBLEM", 194, 197], ["Bench model testing", "TEST", 246, 265], ["The median mechanical energy", "TEST", 265, 293], ["VC", "TEST", 345, 347], ["PC ventilation", "TEST", 373, 387], ["lung", "ANATOMY", 310, 314], ["significantly", "OBSERVATION_MODIFIER", 319, 332], ["higher", "OBSERVATION_MODIFIER", 333, 339]]], ["We also found that the mechanical energy lost due to resistive properties of the respiratory system was significantly higher with VC (7.4 [4.7-12.4 ] than with PC (3.8 [1.6-7.2] mJ/kg, p < 0.001).", [["the mechanical energy", "PROBLEM", 19, 40], ["the respiratory system", "TEST", 77, 99], ["VC", "TEST", 130, 132], ["PC", "TEST", 160, 162], ["mechanical energy", "OBSERVATION", 23, 40], ["resistive", "OBSERVATION", 53, 62], ["respiratory system", "ANATOMY", 81, 99]]], ["ETT size was significantly correlated with mechanical energy in the lung (r s \u2212 0.055, p < 0.01) and mechanical energy lost due to resistive properties of the respiratory system (r s \u2212 0.050, p < 0.01).", [["lung", "ANATOMY", 68, 72], ["respiratory system", "ANATOMY", 159, 177], ["lung", "ORGAN", 68, 72], ["mechanical energy", "PROBLEM", 101, 118], ["size", "OBSERVATION_MODIFIER", 4, 8], ["significantly", "OBSERVATION_MODIFIER", 13, 26], ["mechanical energy", "OBSERVATION", 43, 60], ["lung", "ANATOMY", 68, 72], ["resistive", "OBSERVATION", 131, 140], ["respiratory system", "ANATOMY", 159, 177]]], ["Multivariate analysis showed that for VC but not PC, ETT size (p < 0.001) was independently associated with the percentage of MEventilator delivered to the lung, irrespective of compliance or resistance settings ( Table 2 ).DiscussionThis is the first pediatric study investigating energy transmission during mechanical ventilation.", [["lung", "ANATOMY", 156, 160], ["PC", "CANCER", 49, 51], ["lung", "ORGAN", 156, 160], ["Multivariate analysis", "TEST", 0, 21], ["VC", "TEST", 38, 40], ["PC", "TEST", 49, 51], ["ETT size", "TEST", 53, 61], ["resistance settings", "TREATMENT", 192, 211], ["mechanical ventilation", "TREATMENT", 309, 331], ["size", "OBSERVATION_MODIFIER", 57, 61], ["lung", "ANATOMY", 156, 160], ["mechanical ventilation", "OBSERVATION", 309, 331]]], ["We found that mechanical energy per breath correlated with underlying lung pathology and patient outcome.", [["lung", "ANATOMY", 70, 74], ["lung", "ORGAN", 70, 74], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["mechanical energy", "PROBLEM", 14, 31], ["underlying lung pathology", "PROBLEM", 59, 84], ["mechanical energy", "OBSERVATION", 14, 31], ["lung", "ANATOMY", 70, 74], ["pathology", "OBSERVATION", 75, 84]]], ["Bench testing showed that during PC ventilation, ETT size itself did not affect energy delivery to the lung.", [["lung", "ANATOMY", 103, 107], ["lung", "ORGAN", 103, 107], ["Bench testing", "TEST", 0, 13], ["PC ventilation", "TREATMENT", 33, 47], ["size", "OBSERVATION_MODIFIER", 53, 57], ["lung", "ANATOMY", 103, 107]]], ["Our data provide support to further exploring the conceptual framework of energy transmission during MV in the pediatric setting.DiscussionRecurrent delivery of tidal energy inflicts VILI when stress and strain exceed the limits of tissue tolerance.", [["tissue", "ANATOMY", 232, 238], ["tissue", "TISSUE", 232, 238], ["MV", "SPECIES", 101, 103], ["support", "TREATMENT", 17, 24], ["stress and strain", "PROBLEM", 193, 210]]], ["Experimental work linked mechanical power > 12 J/min to the development of VILI [18] [19] [20] [21] and adverse outcome in clinical studies in adults [7, 8, 22] .", [["VILI [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 75, 99], ["Experimental work linked mechanical power", "PROBLEM", 0, 41], ["VILI", "TEST", 75, 79], ["clinical studies", "TEST", 123, 139]]], ["To date, there are no pediatric studies that have examined such relationship.", [["pediatric studies", "TEST", 22, 39]]], ["Although it is not clear which component Table 1 Characteristics of the study population of N = 312 mechanically ventilated children.", [["children", "ORGANISM", 124, 132], ["children", "SPECIES", 124, 132], ["the study", "TEST", 68, 77], ["not", "UNCERTAINTY", 15, 18], ["clear", "OBSERVATION", 19, 24]]], ["Data are presented as median (25-75 interquartile range) or percentage (%) of total.", [["percentage", "TEST", 60, 70]]], ["Ventilator-free days (VFD) through day 28 were defined as the number of days within 28 days that a patient was alive and free of mechanical ventilation [16] .", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["mechanical ventilation", "TREATMENT", 129, 151], ["mechanical ventilation", "OBSERVATION", 129, 151]]], ["Patients were assigned 0 VFD if they remained intubated or died prior to day 28 without remaining extubated for more than 24 h. *Denotes p < 0.005 (Kruskal Wallis test).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["intubated", "TREATMENT", 46, 55], ["Kruskal Wallis test", "TEST", 148, 167]]], ["PRISM Pediatric Risk of Mortality; OI oxygenation index Patient stratification by Pediatric Mechanical Ventilation Consensus Conference category Normal respiratory system mechanics Restrictive respiratory system mechanics (i.e., reduced compliance) of mechanical power contributes the strongest to lung damage, none of these components have been extensively studied in mechanically ventilated children and the relationship between mechanical ventilation and VILI in children remains unclear [2] .", [["lung", "ANATOMY", 298, 302], ["lung damage", "DISEASE", 298, 309], ["VILI", "DISEASE", 458, 462], ["lung", "ORGAN", 298, 302], ["children", "ORGANISM", 393, 401], ["children", "ORGANISM", 466, 474], ["children", "SPECIES", 393, 401], ["children", "SPECIES", 466, 474], ["Mortality", "PROBLEM", 24, 33], ["OI oxygenation index", "PROBLEM", 35, 55], ["Pediatric Mechanical Ventilation", "TREATMENT", 82, 114], ["mechanical power", "PROBLEM", 252, 268], ["lung damage", "PROBLEM", 298, 309], ["mechanical ventilation", "TREATMENT", 431, 453], ["lung", "ANATOMY", 298, 302], ["damage", "OBSERVATION", 303, 309]]], ["In fact, high Vt has been linked with better outcome in observational studies of children with acute lung injury, making it impossible to identify a specific Vt threshold to be associated with adverse outcomes [23] [24] [25] .", [["lung", "ANATOMY", 101, 105], ["acute lung injury", "DISEASE", 95, 112], ["children", "ORGANISM", 81, 89], ["lung", "ORGAN", 101, 105], ["children", "SPECIES", 81, 89], ["observational studies", "TEST", 56, 77], ["acute lung injury", "PROBLEM", 95, 112], ["a specific Vt threshold", "PROBLEM", 147, 170], ["adverse outcomes", "PROBLEM", 193, 209], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["lung", "ANATOMY", 101, 105], ["injury", "OBSERVATION", 106, 112]]], ["Driving pressure has not been studied in children so far except for two observational studies reporting an association between a surrogate driving pressure (i.e., pressure gradient calculated by subtracting PEEP from the PIP measured under dynamic flow conditions) [26, 27] .DiscussionOur study shows indicates that assessing the mechanical energy per breath seems appropriate when studying the effects of energy transmission on patient outcome instead of using the proposed formula for MPrs.", [["children", "ORGANISM", 41, 49], ["patient", "ORGANISM", 429, 436], ["children", "SPECIES", 41, 49], ["patient", "SPECIES", 429, 436], ["two observational studies", "TEST", 68, 93], ["pressure gradient", "TEST", 163, 180], ["subtracting PEEP", "TREATMENT", 195, 211], ["the PIP", "TREATMENT", 217, 224], ["DiscussionOur study", "TEST", 275, 294]]], ["Not only did we find values for MPrs far below previously published injurious thresholds in adults, we also found that there was no correlation with underlying pathology based on the PEMVECC criteria [5, 18] .", [["MPrs", "GENE_OR_GENE_PRODUCT", 32, 36], ["MPrs", "PROTEIN", 32, 36], ["underlying pathology", "PROBLEM", 149, 169]]], ["In fact, we found the highest values for MPrs among patients with no lung pathology which may be perceived as counterintuitive.", [["lung", "ANATOMY", 69, 73], ["patients", "ORGANISM", 52, 60], ["lung", "ORGAN", 69, 73], ["patients", "SPECIES", 52, 60], ["lung pathology", "PROBLEM", 69, 83], ["no", "UNCERTAINTY", 66, 68], ["lung", "ANATOMY", 69, 73], ["pathology", "OBSERVATION", 74, 83]]], ["A high tidal strain is a prerequisite for poor tissue damage, underscoring the injurious role of high Vt [18, 20] .", [["tissue", "ANATOMY", 47, 53], ["tissue", "TISSUE", 47, 53], ["A high tidal strain", "PROBLEM", 0, 19], ["poor tissue damage", "PROBLEM", 42, 60], ["high", "OBSERVATION_MODIFIER", 2, 6], ["tidal strain", "OBSERVATION", 7, 19], ["poor tissue", "OBSERVATION_MODIFIER", 42, 53], ["damage", "OBSERVATION", 54, 60]]], ["We propose that our observations may largely be caused by the age-dependency of Vt and RR.", [["Vt", "PROBLEM", 80, 82], ["RR", "TEST", 87, 89]]], ["From a developmental perspective, the older the child becomes, the larger the Vt gets and the lower the RR is, indicating that higher values of MPrs are automatically found in older children and thus making comparisons across the entire pediatric spectrum impossible.", [["child", "ORGANISM", 48, 53], ["MPrs", "GENE_OR_GENE_PRODUCT", 144, 148], ["children", "ORGANISM", 182, 190], ["MPrs", "PROTEIN", 144, 148], ["children", "SPECIES", 182, 190], ["larger", "OBSERVATION_MODIFIER", 67, 73]]], ["Furthermore, it could be surmised that this is also due to differences in lung size.", [["lung", "ANATOMY", 74, 78], ["lung", "ORGAN", 74, 78], ["differences in lung size", "PROBLEM", 59, 83], ["lung", "ANATOMY", 74, 78], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["When normalized to height instead of bodyweight, younger children have a relatively larger lung surface area than adults [2] .", [["lung surface area", "ANATOMY", 91, 108], ["children", "ORGANISM", 57, 65], ["lung", "ORGAN", 91, 95], ["children", "SPECIES", 57, 65], ["larger", "OBSERVATION_MODIFIER", 84, 90], ["lung", "ANATOMY", 91, 95], ["surface", "OBSERVATION_MODIFIER", 96, 103]]], ["However, the actual delivered Vt in relation to the amount of inflatable lung volume will then be lower when still normalized to bodyweight leading to a lower lung strain compared with adults [28] .", [["lung", "ANATOMY", 73, 77], ["lung", "ANATOMY", 159, 163], ["lung", "ORGAN", 73, 77], ["lung", "ORGAN", 159, 163], ["inflatable lung volume", "PROBLEM", 62, 84], ["a lower lung strain", "PROBLEM", 151, 170], ["amount", "OBSERVATION_MODIFIER", 52, 58], ["inflatable", "OBSERVATION", 62, 72], ["lung", "ANATOMY", 73, 77], ["volume", "OBSERVATION", 78, 84], ["lower", "ANATOMY_MODIFIER", 153, 158], ["lung", "ANATOMY", 159, 163], ["strain", "OBSERVATION", 164, 170]]], ["Aside from this, PC is the predominant ventilatory mode in pediatrics.", [["PC", "CANCER", 17, 19], ["predominant", "OBSERVATION_MODIFIER", 27, 38], ["ventilatory mode", "OBSERVATION", 39, 55]]], ["Raw is not constant in PC because of the decelerative flow pattern; thus, (Ppeak -Pplat)/Flow cannot function as a proxy for Raw and Vt/Tinsp not for flow [29] .", [["PC", "CANCER", 23, 25], ["Raw", "PROTEIN", 125, 128], ["Vt", "PROTEIN", 133, 135], ["Tinsp", "PROTEIN", 136, 141], ["the decelerative flow pattern", "PROBLEM", 37, 66], ["Ppeak", "TEST", 75, 80], ["Vt", "TEST", 133, 135], ["not", "UNCERTAINTY", 7, 10], ["constant", "OBSERVATION_MODIFIER", 11, 19], ["flow", "OBSERVATION", 54, 58]]], ["We overcame this applying an inspiratory hold to generate Pplat and found that the energy transmitted to the lung remained lower during PC than during VC ventilation.", [["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["Pplat", "PROTEIN", 58, 63], ["VC ventilation", "TREATMENT", 151, 165], ["lung", "ANATOMY", 109, 113], ["lower", "OBSERVATION", 123, 128]]], ["One obvious explanation would be the significantly lower delivered Vt during PC when setting an inspiratory pressure.", [["PC", "TREATMENT", 77, 79], ["an inspiratory pressure", "TEST", 93, 116], ["inspiratory pressure", "OBSERVATION", 96, 116]]], ["Interestingly, multivariate testing showed that ETT size was not independently associated with the percentage of energy that was transmitted to the lung during PC ventilation, further supporting the use of mechanical energy rather than mechanical power in the pediatric setting where PC ventilation is very common.", [["lung", "ANATOMY", 148, 152], ["lung", "ORGAN", 148, 152], ["PC", "MULTI-TISSUE_STRUCTURE", 284, 286], ["multivariate testing", "TEST", 15, 35], ["PC ventilation", "TREATMENT", 160, 174], ["mechanical energy", "TREATMENT", 206, 223], ["mechanical power", "TREATMENT", 236, 252], ["PC ventilation", "TREATMENT", 284, 298], ["size", "OBSERVATION_MODIFIER", 52, 56], ["lung", "ANATOMY", 148, 152], ["PC ventilation", "OBSERVATION", 160, 174]]], ["Nonetheless, although mechanical energy per breath showed an observed a better relationship with lung pathology based on the PEMVECC criteria, injurious thresholds obviously need to be identified in future studies.DiscussionOur study has several limitations.", [["lung", "ANATOMY", 97, 101], ["lung", "ORGAN", 97, 101], ["mechanical energy per breath", "PROBLEM", 22, 50], ["lung pathology", "PROBLEM", 97, 111], ["injurious thresholds", "PROBLEM", 143, 163], ["future studies", "TEST", 199, 213], ["DiscussionOur study", "TEST", 214, 233], ["lung", "ANATOMY", 97, 101], ["pathology", "OBSERVATION", 102, 111]]], ["First, our clinical study was designed a single-center study that may limit the generalizability of our findings, although our unit is comparable to most large units globally.", [["our clinical study", "TEST", 7, 25], ["center study", "TEST", 48, 60]]], ["In addition, the clinical relevance of mechanical has only been studied in ARDS, but our cohort included only a small group of PARDS patients.", [["ARDS", "DISEASE", 75, 79], ["PARDS", "DISEASE", 127, 132], ["PARDS", "CANCER", 127, 132], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["ARDS", "PROBLEM", 75, 79]]], ["Second, although lung-protective ventilation is guided by a unit-specific clinical algorithm guiding pressure and Vt setting, setting the level of PEEP was not dictated by the ARDS Network grid.", [["lung", "ANATOMY", 17, 21], ["ARDS", "DISEASE", 176, 180], ["lung", "ORGAN", 17, 21], ["lung-protective ventilation", "TREATMENT", 17, 44], ["Vt setting", "TREATMENT", 114, 124], ["PEEP", "TREATMENT", 147, 151], ["lung", "ANATOMY", 17, 21], ["protective ventilation", "OBSERVATION", 22, 44]]], ["Recently, it has been shown that not adhering to the grid was associated with increased mortality, although these findings need to be universally confirmed [30] .", [["increased mortality", "PROBLEM", 78, 97], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["mortality", "OBSERVATION", 88, 97]]], ["Third, although we showed that MErs on day 1 or day 2 was independently associated with total ventilation time after adjusting for age, disease severity, and PEMVECC lung pathology type, this does not mean that there is a causative relationship between MErs and patient outcome since other confounders may not have been picked up.", [["lung", "ANATOMY", 166, 170], ["MErs", "SIMPLE_CHEMICAL", 31, 35], ["lung", "ORGAN", 166, 170], ["patient", "ORGANISM", 262, 269], ["MErs", "PROTEIN", 31, 35], ["patient", "SPECIES", 262, 269], ["total ventilation time", "TREATMENT", 88, 110], ["disease severity", "PROBLEM", 136, 152], ["PEMVECC lung pathology type", "PROBLEM", 158, 185], ["lung", "ANATOMY", 166, 170], ["pathology", "OBSERVATION", 171, 180]]], ["For example, our unit has a low threshold for using HFOV as an alternative mode of ventilation which may impact total ventilation time [31, 32] .", [["HFOV", "TREATMENT", 52, 56], ["an alternative mode of ventilation", "TREATMENT", 60, 94], ["total ventilation", "TREATMENT", 112, 129], ["low threshold", "OBSERVATION_MODIFIER", 28, 41]]], ["Also, there was no use of extubation readiness testing, thereby affecting total ventilation time [33] .", [["extubation readiness testing", "TEST", 26, 54]]], ["Importantly, it remains to be studied if mechanical energy may be interpreted as aConclusionsCompared with mechanical power, mechanical energy per breath correlates better with underlying lung pathology and patient outcome in mechanically ventilated children.", [["lung", "ANATOMY", 188, 192], ["lung", "ORGAN", 188, 192], ["patient", "ORGANISM", 207, 214], ["children", "ORGANISM", 250, 258], ["patient", "SPECIES", 207, 214], ["children", "SPECIES", 250, 258], ["mechanical energy", "PROBLEM", 41, 58], ["underlying lung pathology", "PROBLEM", 177, 202], ["lung", "ANATOMY", 188, 192], ["pathology", "OBSERVATION", 193, 202]]], ["Delivery of the generated energy was not dependent on endotracheal tube size during pressurecontrolled ventilation.", [["endotracheal tube", "ANATOMY", 54, 71], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 54, 71], ["endotracheal tube size", "TREATMENT", 54, 76], ["pressurecontrolled ventilation", "TREATMENT", 84, 114], ["endotracheal tube", "OBSERVATION", 54, 71], ["size", "OBSERVATION_MODIFIER", 72, 76], ["pressurecontrolled ventilation", "OBSERVATION", 84, 114]]], ["Future studies are needed to identify injurious thresholds of mechanical energy.Supplementary informationSupplementary information accompanies this paper at https://doi.org/10.", [["Future studies", "TEST", 0, 14], ["mechanical energy", "PROBLEM", 62, 79], ["mechanical energy", "OBSERVATION", 62, 79]]], ["Electronic Supplemental Material To Energy transmission in mechanically ventilated children: a translational study.Supplementary informationMethodology of the bench test.", [["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91], ["a translational study", "TEST", 93, 114], ["the bench test", "TEST", 155, 169], ["Supplemental Material", "OBSERVATION", 11, 32]]]], "bb929d739da4f939f66796029de4b93917c92e1a": [["Voor specifieke therapie wordt verwezen naar hoofdstuk 25 Antimicrobi\u00eble therapie waaraan wij ook hebben bijgedragen.Infecties bij gestoorde afweerDe gastheerweerstand tegen infecties kan door veel ziekteprocessen maar ook therapeutische interventies ernstig verstoord raken.Infecties bij gestoorde afweerDe eerste verdedigingslinie wordt gevormd door intacte huid en slijmvliezen.", [["Infecties", "TEST", 117, 126], ["Infecties", "PROBLEM", 275, 284]]], ["Deze verdedigingslinie kan door aantasting van de integriteit (bijv. een infuus, wonden of katheterisaties), aantasting van de kwaliteit, zoals secretie (talg, zweet, mucus of minder maagzuur door bijv. protonpompremmers!) of aantasting van de beweging (trilhaarfunctie, blaasontledigingsstoornis) bijdragen aan het ontstaan van infecties.Infecties bij gestoorde afweerStoornissen in de gastheerweerstand kunnen aangeboren (primair) zijn of verworven (secundair).Infecties bij gestoorde afweerDe gastheerweerstand kan primair worden ingedeeld in humoraal en cellulair en secundair in specifiek en niet-specifiek.", [["blaasontledigingsstoornis", "ORGANISM", 271, 296], ["Infecties", "PROBLEM", 463, 472]]], ["De cellulaire afweer wordt ook verdeeld in niet-specifiek (fagocyterende cellen, NK-cellen) en specifiek (T-lymfocyten en macrofagen).Infecties bij gestoorde afweerDe volgende omstandigheden kunnen een indicatie zijn voor een immuundefici\u00ebntie.Infecties bij gestoorde afweerInfectieuze aanwijzingen voor immuundefici\u00ebntie: -recidiverend karakter; -ongewoon of onverwacht ernstig beloop; -onverwacht langdurig herstel; -onverwachte complicaties; -bijzondere of opportunistische verwekkers.", [["NK", "ANATOMY", 81, 83], ["NK-cellen", "CELL", 81, 90], ["T-lymfocyten en macrofagen", "CELL", 106, 132], ["T-lymfocyten en macrofagen", "SPECIES", 106, 132], ["Infectieuze aanwijzingen voor immuundefici\u00ebntie: -recidiverend karakter", "SPECIES", 274, 345], ["T-lymfocyten en macrofagen", "TREATMENT", 106, 132], ["Infecties", "PROBLEM", 134, 143], ["Infecties", "PROBLEM", 244, 253]]], ["Niet-infectieuze aanwijzingen voor immuundefici\u00ebntie: -slechte wondgenezing; -onverklaarde bronchi\u00ebctasie\u00ebn; -chronische diarree of tekenen van malabsorptie; -'failure to thrive' bij jonge kinderen.Infecties bij gestoorde afweerDiagnostiek Naast een zorgvuldige anamnese, familieanamnese en lichamelijk onderzoek, worden als eerste stap in het bloedonderzoek de volgende bepalingen geadviseerd: -Hb, leukocytenaantal met differentiatie en trombocytengetal; -nier-en leverfunctie; -albumine, glucose; -urinesediment op eiwit; -(indien mogelijk) immuunglobulinen IgA, IgM en IgG met eventueel subklassen van IgG; -(indien mogelijk) complement screening; -eventueel CD4.Niet-specifiek: het complementsysteemEen defici\u00ebntie van het complementsysteem kan verworven zijn en aangeboren.", [["albumine", "CHEMICAL", 481, 489], ["glucose", "CHEMICAL", 491, 498], ["glucose", "CHEMICAL", 491, 498], ["albumine", "SIMPLE_CHEMICAL", 481, 489], ["glucose", "SIMPLE_CHEMICAL", 491, 498], ["IgA", "GENE_OR_GENE_PRODUCT", 561, 564], ["IgA", "PROTEIN", 561, 564], ["IgM", "PROTEIN", 566, 569], ["IgG", "PROTEIN", 573, 576], ["IgG", "PROTEIN", 606, 609], ["eventueel CD4", "PROTEIN", 653, 666], ["Niet-infectieuze aanwijzingen voor immuundefici\u00ebntie: -slechte wondgenezing; -onverklaarde bronchi\u00ebctasie\u00ebn; -chronische diarree", "SPECIES", 0, 128], ["failure to thrive", "PROBLEM", 160, 177], ["Infecties", "PROBLEM", 198, 207], ["leukocytenaantal", "TEST", 400, 416], ["nier", "TEST", 458, 462], ["albumine", "TEST", 481, 489], ["glucose", "TEST", 491, 498], ["-urinesediment", "TEST", 500, 514], ["IgA", "TEST", 561, 564], ["IgM en IgG", "TEST", 566, 576], ["van IgG", "TEST", 602, 609], ["complement screening", "TEST", 630, 650], ["Hb", "ANATOMY", 396, 398]]], ["Verworven oorzaken van een defici\u00ebntie van het complementsysteem kunnen ondervoeding en diabetes mellitus zijn.", [["diabetes mellitus zijn", "DISEASE", 88, 110], ["Verworven oorzaken van een defici\u00ebntie van het complementsysteem kunnen ondervoeding en diabetes mellitus zijn", "SPECIES", 0, 110], ["en diabetes mellitus zijn", "PROBLEM", 85, 110]]], ["C3) zijn recidiverende infecties door gekapselde bacteri\u00ebn (bijv. pneumokokken) een belangrijk aspect.", [["een belangrijk", "OBSERVATION", 80, 94]]], ["Defici\u00ebnties van de late factoren van het complementsysteem (C6-C8) kunnen aanleiding geven tot chronische en recidiverende infecties ten gevolge van meningokokken en gonokokken.TherapieBehandeling bestaat voor sommige defici\u00ebnties uit het toedienen van het tekort aan complement, of antibioticaprofylaxe en vaccinatie tegen voornoemde verwekkers.Specifiek: immuunglobulinenVoorbeelden van aangeboren hypo-of agammaglobulinemie (tekort aan immunoglobulinen) zijn X-gebonden agammaglobulinemie (XLA) en common variable immunodeficiency (CVID).Specifiek: immuunglobulinenCVID is de meest voorkomende humorale immuundefici\u00ebntie en heeft een geschatte incidentie van 1/10.000-50.000 in de gehele populatie.", [["XLA", "DISEASE", 494, 497], ["common variable immunodeficiency", "DISEASE", 502, 534], ["CVID", "DISEASE", 536, 540], ["zijn X-gebonden agammaglobulinemie", "SIMPLE_CHEMICAL", 458, 492], ["antibioticaprofylaxe", "TREATMENT", 284, 304], ["immuunglobulinenVoorbeelden van aangeboren hypo-of agammaglobulinemie", "TREATMENT", 358, 427], ["tekort aan immunoglobulinen)", "TREATMENT", 429, 457], ["zijn X-gebonden agammaglobulinemie (XLA)", "TREATMENT", 458, 498], ["variable immunodeficiency (CVID)", "PROBLEM", 509, 541], ["C8", "ANATOMY", 64, 66], ["immunodeficiency", "OBSERVATION", 518, 534]]], ["Criteria voor het stellen van de diagnose CVID zijn een verlaagde IgG, IgA en mogelijk IgM, ziektebeeld ontstaan na de leeftijd van 2 jaar en een gestoorde vaccinatierespons op o.a. een polysacharidenvaccin.", [["CVID", "DISEASE", 42, 46], ["CVID", "TEST", 42, 46], ["zijn", "TEST", 47, 51], ["een verlaagde", "TEST", 52, 65], ["IgG", "TEST", 66, 69], ["IgA", "TEST", 71, 74], ["IgM", "TEST", 87, 90], ["een polysacharidenvaccin", "TREATMENT", 182, 206]]], ["De geschatte overleving 20 jaar na diagnose is 65%.", [["na", "CHEMICAL", 32, 34]]], ["XLA) komen in het eerste levensjaar tot uiting, maar CVID kan ook pas tussen het 20ste en 40e levensjaar tot expressie komen met recidiverende bovenste en onderste luchtweginfecties als belangrijkste uiting.Specifiek: immuunglobulinenVerworven hypogammaglobulinemie kan worden veroorzaakt door het gebruik van bepaalde medicatie (immunomodulerende medicatie als rituximab of bepaalde anti-epileptica).", [["XLA", "DISEASE", 0, 3], ["CVID", "DISEASE", 53, 57], ["rituximab", "CHEMICAL", 362, 371], ["immunomodulerende medicatie als rituximab of bepaalde anti-epileptica", "TREATMENT", 330, 399]]], ["Andere oorzaken van secundaire hypogammaglobulinemie zijn aanmaakstoornissen van immunoglobulinen (leveraandoeningen, chronisch lymfatische leukemie of de ziekte van Kahler), of een verhoogd verlies van immuunglobulinen ten gevolge van bijvoorbeeld het nefrotisch syndroom of proteinlosing-enteropathie.Specifiek: immuunglobulinenDe belangrijkste verwekkers van (met name luchtweg)infecties bij deze afweerstoornis zijn de gekapselde bacteri\u00ebn (pneumokokken, Haemophilus influenzae en meningokokken).", [["proteinlosing-enteropathie", "DISEASE", 276, 302], ["Haemophilus influenzae", "ORGANISM", 459, 481], ["Haemophilus influenzae", "SPECIES", 459, 481], ["Haemophilus influenzae en meningokokken", "SPECIES", 459, 498], ["van immunoglobulinen (leveraandoeningen", "TREATMENT", 77, 116], ["enteropathie", "PROBLEM", 290, 302], ["Haemophilus influenzae en meningokokken", "TREATMENT", 459, 498]]], ["Deze pathogenen veroorzaken bij pati\u00ebnten zonder gestoorde afweer ook infecties, maar bij een humorale afweerstoornis is er sprake van recidiverende infecties met deze verwekkers of onverwacht ernstig beloop van de infectie.Specifiek: immuunglobulinenHardnekkige darminfecties veroorzaakt door Campylobacter jejuni en Giardia lamblia kunnen ook een aanwijzing zijn voor een gestoorde humorale afweer.", [["Campylobacter jejuni", "SPECIES", 294, 314], ["Giardia lamblia", "SPECIES", 318, 333], ["Giardia lamblia kunnen ook een aanwijzing zijn voor een gestoorde humorale", "SPECIES", 318, 392], ["infecties", "PROBLEM", 70, 79], ["Specifiek", "TEST", 224, 233], ["immuunglobulinen", "TEST", 235, 251], ["Campylobacter jejuni", "PROBLEM", 294, 314]]], ["Giardiasis kan malabsorptie veroorzaken, zich uitend in gewichtverlies en buikklachten.TherapieDe behandeling van hypo-of agammaglobulinemie bestaat uit het toedienen van immuunglobulinen.", [["Giardiasis kan malabsorptie veroorzaken", "TREATMENT", 0, 39]]], ["Zelden treden de volgende ernstige verschijnselen op: hypotensie, anafylactische shock, aseptische meningitis, hemolytische anemie, nefrotoxiciteit, trombo-embolische complicaties, TIA's, CVA's of eczemato\u00efde huidafwijkingen.Niet-specifiek: fagocyterende cellenOnder de fagocyten vallen de monocyten, neutrofiele en eosinofiele granulocyten.", [["anafylactische shock", "DISEASE", 66, 86], ["aseptische meningitis", "DISEASE", 88, 109], ["TIA", "DISEASE", 181, 184], ["CVA", "DISEASE", 188, 191], ["eczemato\u00efde huidafwijkingen", "ORGANISM", 197, 224], ["hypotensie", "PROBLEM", 54, 64], ["anafylactische shock", "PROBLEM", 66, 86], ["aseptische meningitis", "PROBLEM", 88, 109], ["hemolytische anemie", "PROBLEM", 111, 130], ["nefrotoxiciteit", "PROBLEM", 132, 147], ["trombo", "PROBLEM", 149, 155], ["embolische complicaties", "PROBLEM", 156, 179], ["TIA's", "PROBLEM", 181, 186], ["CVA", "PROBLEM", 188, 191], ["eczemato\u00efde huidafwijkingen", "TREATMENT", 197, 224], ["neutrofiele en eosinofiele granulocyten", "TREATMENT", 301, 340], ["meningitis", "OBSERVATION", 99, 109]]], ["Een stoornis in de fagocytenfunctie kan gepaard gaan met infecties van huid en subcutane weefsels.", [["Een stoornis", "ORGANISM", 0, 12]]], ["Verder kunnen bij een kwantitatief tekort van neutrofiele granulocyten ernstige infecties optreden op diverse plaatsen in het lichaam.Niet-specifiek: fagocyterende cellenBelangrijke verwekkers van infecties zijn: grampositieve kokken (Staphylococcus aureus), H. influenza, Candida sp, en Aspergillus spp.Niet-specifiek: fagocyterende cellenEen voorbeeld van een aangeboren afwijking in fagocytose is chronische granulomateuze ziekte (CGD).", [["Staphylococcus aureus", "DISEASE", 235, 256], ["H. influenza", "DISEASE", 259, 271], ["CGD", "DISEASE", 434, 437], ["grampositieve kokken (", "ORGANISM", 213, 235], ["Staphylococcus aureus", "ORGANISM", 235, 256], ["H. influenza", "ORGANISM", 259, 271], ["Candida sp", "ORGANISM", 273, 283], ["Aspergillus spp", "ORGANISM", 288, 303], ["Staphylococcus aureus", "SPECIES", 235, 256], ["H. influenza", "SPECIES", 259, 271], ["Aspergillus spp", "SPECIES", 288, 303], ["Staphylococcus aureus", "SPECIES", 235, 256], ["H. influenza", "SPECIES", 259, 271], ["Staphylococcus aureus", "PROBLEM", 235, 256], ["H. influenza", "PROBLEM", 259, 271], ["Candida sp", "PROBLEM", 273, 283]]], ["Hierbij is het doden van pathogeen gestoord.Niet-specifiek: fagocyterende cellenDe meest voorkomende oorzaak van een stoornis is neutropenie (< 500 granulocyten) door cytostatische behandeling.Oorzaken van verworven neutropenieDeze kunnen worden onderverdeeld in: -verminderde aanmaak van neutrofiele granulocyten ( bijv. medicamenteus (cytostatica), tekort aan bouwstoffen (vitamine B 12 -en foliumzuurdefici\u00ebntie) of beenmergaandoeningen als leukemie en myelofibrose; -verhoogde afbraak van neutrofiele granulocyten (bijv. auto-immuunziekte); -verhoogd verbruik van neutrofiele granulocyten door bijvoorbeeld hypersplenisme.Oorzaken van verworven neutropenieSpecifiek: T-lymfocyten en macrofagen Defecten van de specifieke cellulaire afweer kunnen het gevolg zijn van stoornissen van de T-lymfocyten en van de macrofagen.Oorzaken van verworven neutropenieBij de volgende infecties en verwekkers moet gedacht worden aan een afwijking van de cellulaire immuniteit: herpessimplexvirus, varicellazostervirus, cytomegalovirus, Listeria monocytogenes, Salmonella sp, mycobacteri\u00ebn, Nocardia sp, Candida spp, Cryptococcus neoformans, Pneumocystis carinii, Toxoplasma gondii.Oorzaken van verworven neutropenieVoorbeelden van een verworven stoornis van de cellulaire immuniteit zijn maligne lymfoproliferatieve aandoeningen, SLE, chronische nierinsuffici\u00ebntie, alcoholisme en levercirrose, ondervoeding, virale infecties als hiv, EBV, CMV en gebruik van bepaalde immuunsuppressiva (prednison, ciclosporine, methotrexaat) .", [["vitamine B 12 -en foliumzuurdefici\u00ebntie", "CHEMICAL", 375, 414], ["Nocardia sp", "DISEASE", 1078, 1089], ["Candida spp", "DISEASE", 1091, 1102], ["Cryptococcus neoformans", "DISEASE", 1104, 1127], ["Pneumocystis carinii", "DISEASE", 1129, 1149], ["Toxoplasma gondii", "DISEASE", 1151, 1168], ["SLE", "DISEASE", 1318, 1321], ["prednison", "CHEMICAL", 1475, 1484], ["ciclosporine", "CHEMICAL", 1486, 1498], ["beenmergaandoeningen", "ORGANISM", 419, 439], ["myelofibrose", "SIMPLE_CHEMICAL", 456, 468], ["neutrofiele granulocyten", "ORGANISM", 493, 517], ["cytomegalovirus", "ORGANISM", 1007, 1022], ["Listeria monocytogenes", "ORGANISM", 1024, 1046], ["Salmonella sp", "ORGANISM", 1048, 1061], ["mycobacteri\u00ebn", "ORGANISM", 1063, 1076], ["Nocardia sp", "ORGANISM", 1078, 1089], ["Candida spp", "ORGANISM", 1091, 1102], ["Cryptococcus neoformans", "ORGANISM", 1104, 1127], ["Pneumocystis carinii", "ORGANISM", 1129, 1149], ["Toxoplasma gondii", "ORGANISM", 1151, 1168], ["EBV", "ORGANISM", 1423, 1426], ["CMV", "ORGANISM", 1428, 1431], ["prednison", "SIMPLE_CHEMICAL", 1475, 1484], ["ciclosporine", "SIMPLE_CHEMICAL", 1486, 1498], ["Listeria monocytogenes", "SPECIES", 1024, 1046], ["Cryptococcus neoformans", "SPECIES", 1104, 1127], ["Pneumocystis carinii", "SPECIES", 1129, 1149], ["Toxoplasma gondii", "SPECIES", 1151, 1168], ["Oorzaken van verworven neutropenieSpecifiek: T-lymfocyten en macrofagen Defecten van de specifieke cellulaire afweer kunnen het gevolg zijn van stoornissen van de T-lymfocyten en van de macrofagen", "SPECIES", 626, 822], ["Listeria monocytogenes", "SPECIES", 1024, 1046], ["Salmonella sp, mycobacteri\u00ebn", "SPECIES", 1048, 1076], ["Cryptococcus neoformans", "SPECIES", 1104, 1127], ["Pneumocystis carinii", "SPECIES", 1129, 1149], ["Toxoplasma gondii", "SPECIES", 1151, 1168], ["door cytostatische behandeling", "PROBLEM", 162, 192], ["tekort aan bouwstoffen (vitamine B", "TREATMENT", 351, 385], ["beenmergaandoeningen als leukemie", "PROBLEM", 419, 452], ["T-lymfocyten en macrofagen", "TREATMENT", 671, 697], ["lymfocyten en van de macrofagen", "TREATMENT", 791, 822], ["herpessimplexvirus", "PROBLEM", 965, 983], ["varicellazostervirus", "PROBLEM", 985, 1005], ["cytomegalovirus", "PROBLEM", 1007, 1022], ["Listeria monocytogenes", "PROBLEM", 1024, 1046], ["Salmonella", "PROBLEM", 1048, 1058], ["mycobacteri\u00ebn", "PROBLEM", 1063, 1076], ["Nocardia", "PROBLEM", 1078, 1086], ["Candida spp", "TEST", 1091, 1102], ["Cryptococcus neoformans", "PROBLEM", 1104, 1127], ["Pneumocystis carinii", "PROBLEM", 1129, 1149], ["Toxoplasma gondii", "PROBLEM", 1151, 1168], ["alcoholisme en levercirrose", "TREATMENT", 1354, 1381], ["virale infecties", "PROBLEM", 1397, 1413], ["EBV", "PROBLEM", 1423, 1426], ["CMV en gebruik van bepaalde immuunsuppressiva", "TREATMENT", 1428, 1473], ["prednison", "TREATMENT", 1475, 1484], ["ciclosporine", "TREATMENT", 1486, 1498], ["methotrexaat", "TREATMENT", 1500, 1512], ["Listeria monocytogenes", "OBSERVATION", 1024, 1046], ["Cryptococcus neoformans", "OBSERVATION", 1104, 1127], ["Pneumocystis carinii", "OBSERVATION", 1129, 1149], ["Toxoplasma gondii", "OBSERVATION", 1151, 1168]]], ["Het klassieke voorbeeld is echter de immuundefici\u00ebntie die optreedt in het eindstadium van een hiv-infectie.Oorzaken van verworven neutropenieNaast voorgaande stoornissen zijn er zeldzame aangeboren stoornissen van de cellulaire afweer.", [["Naast voorgaande stoornissen zijn", "TREATMENT", 142, 175]]], ["Deze stoornissen worden hier buiten beschouwing gelaten.TherapieDe therapie bij een chronische afwijking in de specifieke cellulaire afweer bestaat voornamelijk uit antibioticaprofylaxe tegen de genoemde verwekkers.8.4Infectie met humaan immunodefici\u00ebntievirus 1 (hiv-1) Infectie met het humane immuundefici\u00ebntievirus type 1 (hiv-1) is momenteel een van de grootste uitdagingen van de volksgezondheid.", [["Infectie", "TEST", 218, 226], ["humaan immunodefici\u00ebntievirus", "TEST", 231, 260], ["hiv", "TEST", 264, 267], ["Infectie", "PROBLEM", 271, 279]]], ["In tegenstelling tot het hiv-2-virus, dat vooral in West-Afrika voorkomt, is er bij hiv-1 sprake van een pandemie met wereldwijd 33 miljoen ge\u00efnfecteerden.8.4Hiv-1 behoort tot de retroviridae, genus lentivirus.", [["hiv-2-virus", "ORGANISM", 25, 36], ["lentivirus", "ORGANISM", 199, 209], ["Hiv", "TEST", 158, 161], ["behoort tot de retroviridae", "TREATMENT", 164, 191], ["genus lentivirus", "PROBLEM", 193, 209], ["genus lentivirus", "OBSERVATION", 193, 209]]], ["Transmissie vindt plaats via onbeschermd sek-sueel contact dan wel bloed-bloedcontact.", [["onbeschermd sek-sueel", "CHEMICAL", 29, 50]]], ["Hiv-1 infecteert CD4 positieve cellen van het immuunsysteem, waaronder de CD4 positieve T-lymfocyten ('CD4-cellen') en leidt zoals hiervoor beschreven tot een stoornis van de cellulaire afweer.", [["CD4", "PROTEIN", 103, 106], ["Hiv", "TEST", 0, 3], ["lymfocyten ('CD4-cellen'", "TREATMENT", 90, 114], ["en leidt zoals hiervoor", "TREATMENT", 116, 139]]], ["Via glycoprote\u00efnen gp121 en gp41 op het virale membraan vindt na binding met het CD4-molecuul en de chemokinecoreceptoren (CCR5 en CXCR4) op de targetcel uiteindelijk fusie plaats.", [["CCR5", "GENE_OR_GENE_PRODUCT", 123, 127], ["CXCR4", "GENE_OR_GENE_PRODUCT", 131, 136], ["gp41", "PROTEIN", 28, 32], ["CD4", "PROTEIN", 81, 84], ["CCR5", "PROTEIN", 123, 127], ["CXCR4", "PROTEIN", 131, 136], ["glycoprote\u00efnen", "TEST", 4, 18], ["na binding", "TEST", 62, 72], ["het CD4", "TEST", 77, 84], ["molecuul en de chemokinecoreceptoren (CCR5 en CXCR4)", "TREATMENT", 85, 137]]], ["Het genetisch materiaal van het hiv-1-virus bestaat uit RNA, dat door het enzym reverse transcriptase wordt omgezet in DNA dat vervolgens in het DNA van de gastheer wordt ge\u00efntegreerd door het enzym integrase.", [["DNA", "CELLULAR_COMPONENT", 119, 122], ["virus bestaat uit RNA", "RNA", 38, 59], ["dat door het enzym reverse transcriptase", "PROTEIN", 61, 101], ["ge\u00efntegreerd door het enzym integrase", "DNA", 171, 208], ["Het", "TEST", 0, 3]]], ["Vervolgens kan, via het eigen cellulaire apparaat, transcriptie van dit DNA plaatsvinden en kunnen nieuwe viruspartikels worden gegenereerd die weer andere (CD4 positieve) cellen kunnen infecteren.", [["Vervolgens kan", "TREATMENT", 0, 14], ["het eigen cellulaire apparaat", "TREATMENT", 20, 49]]], ["Het hiv-1 virus kan gedurende lange tijd latent aanwezig zijn in de gastheercel.8.4Na infectie treedt er een geleidelijke daling op van het aantal CD4-cellen, de snelheid van daling varieert tussen pati\u00ebnten.", [["Na", "CHEMICAL", 83, 85], ["Na", "CHEMICAL", 83, 85], ["Het hiv-1 virus", "ORGANISM", 0, 15], ["Het hiv", "TREATMENT", 0, 7], ["Na infectie", "TEST", 83, 94]]], ["Waarschijnlijk leidt chronische immuunactivatie door de hiv-1-infectie tot verlies van CD4 positieve cellen.Acute infectiePrimaire of acute hiv-infectie wordt gedefinieerd als de periode tussen de hiv-besmetting en het ontstaan van de chronische infectie en duurt ongeveer 3 tot 24 weken.", [["CD4", "PROTEIN", 87, 90], ["Waarschijnlijk leidt chronische immuunactivatie door de hiv-1-infectie tot verlies van CD4 positieve cellen", "SPECIES", 0, 107], ["acute hiv-infectie", "PROBLEM", 134, 152], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["hiv", "OBSERVATION", 140, 143]]], ["Vaak voorkomende symptomen zijn koorts, spier-/gewrichtspijn, moeheid, malaise, keelpijn, opgezette lymfeklieren en huidafwijkingen.", [["malaise", "PROBLEM", 71, 78], ["keelpijn", "TREATMENT", 80, 88]]], ["Maar ook zeldzamere complicaties, zoals een aseptische meningitis kunnen optreden.Acute infectieIn de acute fase daalt initieel het aantal CD4cellen, waarna vervolgens weer herstel optreedt.Chronische infectieTijdens de chronische fase van de hiv-infectie daalt het aantal CD4-cellen geleidelijk.", [["meningitis", "DISEASE", 55, 65], ["infectieIn", "CHEMICAL", 88, 98], ["CD4", "PROTEIN", 273, 276], ["Chronische infectieTijdens de chronische fase van de hiv-infectie daalt het aantal CD4-cellen geleidelijk", "SPECIES", 190, 295], ["zeldzamere complicaties", "TREATMENT", 9, 32], ["zoals", "TREATMENT", 34, 39], ["meningitis", "PROBLEM", 55, 65], ["Acute infectieIn de acute fase daalt", "PROBLEM", 82, 118], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["fase daalt", "OBSERVATION", 108, 118]]], ["Voorkomen en type van opportunistische infecties hangen af van het aantal CD4-cellen.", [["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD4", "PROTEIN", 74, 77]]], ["Bij het opstellen van een differentiaaldiagnose van een acuut infectieus probleem bij een hiv-1 positieve pati\u00ebnt is het daarom van elementair belang op de hoogte te zijn van het actuele aantal CD4-cellen.", [["CD4", "PROTEIN", 194, 197], ["Bij het opstellen van een differentiaaldiagnose van een acuut infectieus probleem bij een hiv-1 positieve pati\u00ebnt is het daarom van elementair belang op de hoogte te zijn van het actuele aantal CD4-cellen", "SPECIES", 0, 204]]], ["Primaire profylaxe Afhankelijk van het aantal CD4-cellen dient primaire profylaxe gegeven te worden ter preventie van Pneumocystis carinii infectie (< 200 CD4-cellen).", [["Pneumocystis carinii infectie", "DISEASE", 118, 147], ["CD4", "PROTEIN", 155, 158], ["Pneumocystis carinii", "SPECIES", 118, 138], ["Primaire profylaxe", "TREATMENT", 0, 18], ["primaire profylaxe", "TREATMENT", 63, 81], ["van Pneumocystis carinii infectie", "PROBLEM", 114, 147], ["Pneumocystis carinii", "OBSERVATION", 118, 138]]], ["De therapie van keuze is lage dosis (480 mg) cotrimoxazol.", [["cotrimoxazol", "CHEMICAL", 45, 57], ["cotrimoxazol", "CHEMICAL", 45, 57], ["cotrimoxazol", "SIMPLE_CHEMICAL", 45, 57], ["cotrimoxazol", "TREATMENT", 45, 57]]], ["Bij 50% van de pati\u00ebnten treedt echter na enkele weken een rash op waarschijnlijk door de hiv-ge\u00efnduceerde immuundisregulatie en wordt meestal overgegaan op maandelijkse verneveling met pentamidine.DiagnoseVoor het stellen van de diagnose wordt naast het klinische beeld gebruikgemaakt van een aantal laboratoriumtechnieken.", [["pentamidine", "CHEMICAL", 186, 197], ["pentamidine", "CHEMICAL", 186, 197], ["pentamidine", "SIMPLE_CHEMICAL", 186, 197], ["een rash", "PROBLEM", 55, 63], ["pentamidine", "TREATMENT", 186, 197]]], ["De 'viral load' (het aantal viruskopie\u00ebn) in het plasma kan worden bepaald, tegenwoordig wordt hier vaak een 'reverse transcriptase polymerase chain reaction (RT-PCR)' assay voor gebruikt.", [["plasma", "ANATOMY", 49, 55], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["reverse transcriptase", "PROTEIN", 110, 131], ["De 'viral load'", "PROBLEM", 0, 15], ["transcriptase polymerase chain reaction", "PROBLEM", 118, 157], ["RT-PCR", "TREATMENT", 159, 165]]], ["Voor het bepalen van het aantal CD4 positieve T-lymfocyten wordt vaak gebruikgemaakt van immuunfluorescentie.PreventieBelangrijkste preventieve maatregel is het voorkomen van onveilig seksueel contact (condoom) of bloedcontact met een potentieel hiv-1 ge\u00efnfecteerd persoon.PreventieIndien een dergelijk onveilig contact toch heeft plaatsgevonden kan (na consultatie met een viroloog of een internist-infectioloog) post-exposure profylaxe (PEP) voorgeschreven worden.", [["na", "CHEMICAL", 351, 353], ["profylaxe", "CHEMICAL", 428, 437]]], ["Momenteel wordt er (vooral in derdewereldlanden) veel onderzoek gedaan naar zogenoemde pre-exposure profylaxe (PrEP), bijvoorbeeld door middel van het toedienen van vaginale cr\u00e8mes, maar de resultaten hiervan zijn nog inconsistent.Specialistische therapie'Highly active antiretroviral therapy' (HAART) Zie ook hoofdstuk 25 Antimicrobi\u00eble therapie.Specialistische therapieHiv-1-pati\u00ebnten worden in Nederland behandeld in zogeheten hiv-behandelcentra, waar er momenteel 25 van zijn.", [["profylaxe", "CHEMICAL", 100, 109], ["Specialistische therapie'", "TREATMENT", 231, 256], ["active antiretroviral therapy' (HAART)", "TREATMENT", 263, 301], ["Antimicrobi\u00eble therapie", "TREATMENT", 323, 346]]], ["De behandeling bestaat uit het voorschrijven van 'highly active antiretroviral therapy' (HAART), ook wel combinatie antiretrovirale therapie (cART) genoemd.", [["active antiretroviral therapy", "TREATMENT", 57, 86], ["HAART", "TREATMENT", 89, 94]]], ["Dit houdt in dat er behandeld wordt met een combinatie van meerdere (minimaal 3) antiretrovirale geneesmiddelen.", [["antiretrovirale geneesmiddelen", "TREATMENT", 81, 111]]], ["De gedachte hierachter is, dat op deze manier de kans dat resistentie van het hiv-1-virus tegen antiretrovirale middelen optreedt minder groot is.Specialistische therapieMomenteel zijn er vier klassen antiretrovirale geneesmiddelen: remmers van het enzym reverse transcriptase (nucleos(t)ide revers transcriptase inhibitors (NRTI) en non-nucleoside reverse transcriptase inhibitors (NNRTI)), remmers van het integrase enzym (integraseremmers), remmers van het protease-enzym (proteaseremmers) en remmers van hiv-entree in de cel (CCR5 coreceptor antagonisten en fusieremmers).Specialistische therapieDoor de jaren heen zijn de bijwerkingen en de hoeveelheid tabletten die moeten worden ingenomen afgenomen.", [["CCR5 coreceptor", "PROTEIN", 530, 545], ["van het hiv", "TEST", 70, 81], ["Specialistische therapieMomenteel zijn", "TREATMENT", 146, 184], ["van het enzym reverse transcriptase (nucleos(t)ide revers transcriptase inhibitors", "TREATMENT", 241, 323], ["NRTI) en non-nucleoside reverse transcriptase inhibitors", "TREATMENT", 325, 381], ["van het protease", "TREATMENT", 452, 468], ["entree in de cel (CCR5 coreceptor antagonisten en fusieremmers", "TREATMENT", 512, 574]]], ["Belangrijkste bijwerkingen zijn metabole complicaties, zoals afwijkingen van de gemeten lipiden in het bloed, stoornissen in de vetverdeling over het lichaam (zich uitend in lipoatrofie dan wel -dystrofie) en gastro-intestinale klachten.Specialistische therapieDoel van de behandeling is het bereiken van langdurige suppressie van de viral load (ondetecteer-bare viral load beneden de 50 kopie\u00ebn/ml) en herstel van het immuunsysteem door stijging van het aantal CD4-cellen tot normale waarden.Specialistische therapieWaar tot voor kort pas gestart werd met HAART in een gevorderd stadium van de ziekte, zijn er nu steeds meer aanwijzingen dat het beter is om eerder te starten.", [["Belangrijkste", "TREATMENT", 0, 13], ["gastro-intestinale klachten", "TREATMENT", 209, 236], ["bare viral load beneden", "TREATMENT", 358, 381], ["HAART", "TREATMENT", 557, 562], ["gastro", "ANATOMY", 209, 215]]], ["In Nederland wordt momenteel geadviseerd in ieder geval te starten beneden de 350 CD4-cellen en op individuele basis kan overwogen worden te starten tussen de 350-500 CD4-cellen.", [["CD4", "PROTEIN", 82, 85], ["CD4", "PROTEIN", 167, 170]]], ["Er is een aantal indicaties voor het starten van HAART ongeacht het aantal CD4-cellen, zoals zwangerschap, hiv-geassocieerde neuropathie en hepatitis-B-virus co-infectie met een behandelindicatie.", [["hepatitis-B", "DISEASE", 140, 151], ["hiv", "TEST", 107, 110], ["geassocieerde neuropathie", "PROBLEM", 111, 136], ["en hepatitis", "PROBLEM", 137, 149]]], ["De duur van de behandeling is levenslang; het hiv-1virus kan latent aanwezig blijven in CD4-cellen, onbereikbaar voor antiretrovirale therapie.Specialistische therapieResistentie Hiv-1-virus is een snel replicerend virus waarbij veel mutaties voorkomen.", [["Specialistische therapieResistentie Hiv-1-virus", "ORGANISM", 143, 190], ["CD4", "PROTEIN", 88, 91], ["Hiv-1-virus", "TREATMENT", 179, 190]]], ["Hier schuilt het gevaar van resistentie tegen antiretrovirale middelen.", [["tegen antiretrovirale", "SPECIES", 40, 61], ["Hier schuilt het gevaar van resistentie tegen antiretrovirale middelen", "SPECIES", 0, 70]]], ["Om vervolgens deze pati\u00ebnt weer succesvol te behandelen moet er een nieuwe combinatie antiretrovirale middelen gezocht worden, werkzaam tegen dit resistente hiv-1-virus.Specialistische therapiePrognose Sinds de introductie van HAART in 1996 is de prognose van pati\u00ebnten ge\u00efnfecteerd met het hiv-1-virus sterk verbeterd, zodanig dat de mortaliteit steeds meer die van de algehele populatie benaderd.Infectieuze diarreeZie ook hoofdstuk 10 Kindergeneeskunde en 12 Maag-, darm-en leverziekten.Infectieuze diarreeAcute diarree komt zeer frequent voor en maar een klein deel van de pati\u00ebnten raadpleegt een arts.", [["Infectieuze", "TEST", 398, 409], ["Maag-", "TEST", 462, 467]]], ["Virale verwekkers komen het vaakst voor: bij volwassenen zijn de norovirussen de belangrijkste verwekkers, bij jonge kinderen de rotavirussen.", [["Virale", "TEST", 0, 6]]], ["De meest voorkomende bacteri\u00eble verwekkers zijn Salmonella, Campylobacter en Shigella.", [["Salmonella", "PROBLEM", 48, 58], ["Campylobacter en Shigella", "PROBLEM", 60, 85]]], ["Het eten van besmet voedsel kan leiden tot een darminfectie met E. coli.", [["E. coli", "ORGANISM", 64, 71], ["E. coli", "SPECIES", 64, 71], ["E. coli", "SPECIES", 64, 71], ["Het eten van besmet voedsel kan leiden", "TREATMENT", 0, 38], ["E. coli", "PROBLEM", 64, 71], ["E. coli", "OBSERVATION", 64, 71]]], ["Parasitaire infec-ties zijn slechts zelden de oorzaak van diarree.", [["Parasitaire infec", "TREATMENT", 0, 17]]], ["Bij kinderen kan Giardia lamblia diarree geven, in tropische landen dient uiteraard rekening te worden gehouden met amoebiasis.Infectieuze diarreeVeruit de meeste darminfecties gaan vanzelf over en behoeven geen specifieke diagnostiek of therapie.DiagnostiekDe belangrijkste complicatie bij darminfecties is uitdroging.", [["amoebiasis", "DISEASE", 116, 126], ["Giardia lamblia", "SPECIES", 17, 32], ["amoebiasis", "PROBLEM", 116, 126], ["lamblia diarree", "OBSERVATION", 25, 40], ["amoebiasis", "OBSERVATION", 116, 126], ["bij darminfecties", "OBSERVATION", 287, 304]]], ["Zoals bekend zijn een slechte huidturgor, verwardheid, duidelijk verminderde urineproductie en neiging tot collaps tekenen van uitdroging.", [["Zoals", "TREATMENT", 0, 5]]], ["Bij bloed en slijm bij de ontlasting, aanhoudende koorts en bij pati\u00ebnten met een verminderde weerstand dient rekening te worden gehouden met een gecompliceerd beloop.", [["een verminderde", "TREATMENT", 78, 93]]], ["Dit geldt ook voor pati\u00ebnten die in de levensmiddelenindustrie of de horeca werken.TherapieOp de allereerste plaats is goede voorlichting nodig over het voorkomen en behandelen van dehydratie door voldoende vochtinname en het gebruik van ORS: 10-20 mg/kg/uur, te bereiden volgens de gebruiksaanwijzing.", [["van dehydratie door voldoende vochtinname en het gebruik van ORS: 10-20 mg/kg/uur", "SPECIES", 177, 258]]], ["Medicamenteuze behandeling is zoals al gezegd slechts bij hoge uitzondering noodzakelijk: antimicrobi\u00eble behandeling geschiedt dan op geleide van de kweek en in overleg met een infectioloog.", [["een infectioloog", "OBSERVATION", 173, 189]]], ["Bij ernstige ziekteverschijnselen kan zonder diagnose een driedaagse behandeling met azitromycine worden overwogen.", [["Bij ernstige ziekteverschijnselen kan", "TREATMENT", 0, 37]]], ["Een Giardiainfectie kan eventueel met metronidazol worden behandeld.8.6Luchtweginfecties Zie ook hoofdstuk 11 Longziekten.8.6De volgende luchtweginfecties worden hierna zeer kort besproken: otitis media, acute rinosinusitis, acute faryngitis en tonsillitis, acute bronchitis en pneumonie.", [["metronidazol", "CHEMICAL", 38, 50], ["otitis", "DISEASE", 190, 196], ["acute rinosinusitis", "DISEASE", 204, 223], ["tonsillitis", "DISEASE", 245, 256], ["acute bronchitis en pneumonie", "DISEASE", 258, 287], ["metronidazol", "CHEMICAL", 38, 50], ["metronidazol", "TREATMENT", 38, 50], ["otitis media", "PROBLEM", 190, 202], ["acute rinosinusitis", "PROBLEM", 204, 223], ["acute faryngitis en tonsillitis", "PROBLEM", 225, 256], ["acute bronchitis en pneumonie", "PROBLEM", 258, 287], ["otitis", "OBSERVATION", 190, 196], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["rinosinusitis", "OBSERVATION", 210, 223], ["acute", "OBSERVATION_MODIFIER", 225, 230], ["tonsillitis", "OBSERVATION", 245, 256], ["acute", "OBSERVATION_MODIFIER", 258, 263], ["bronchitis", "OBSERVATION", 264, 274]]], ["Voor een uitgebreidere bespreking kan men de desbetreffende NHG-Standaarden raadplegen.8.6Otitis media is een infectie van het middenoor waarbij in ongeveer de helft van de gevallen een bacteri\u00eble verwekker kan worden aangetoond en die vooral bij kinderen voorkomt.", [["Otitis", "DISEASE", 90, 96], ["men", "SPECIES", 38, 41], ["Otitis media", "PROBLEM", 90, 102]]], ["Na twee tot drie dagen nemen de klachten meestal al af.8.6Acute rinosinusitis is een ontsteking van het neusslijmvlies en de bijholten.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na twee tot drie", "TREATMENT", 0, 16], ["Acute rinosinusitis", "PROBLEM", 58, 77], ["Acute", "OBSERVATION_MODIFIER", 58, 63], ["rinosinusitis", "OBSERVATION", 64, 77]]], ["Het natuurlijk beloop varieert van \u00e9\u00e9n tot drie weken.8.6Acute faryngitis en/of tonsillitis is in gemiddeld 30% van de gevallen een bacteri\u00eble infectie (hemolytische streptokokken) en duurt ongeacht de verwekker ongeveer zeven tot tien dagen.8.6Acute bronchitis is een ontsteking van de lagere luchtweg.", [["tonsillitis", "DISEASE", 80, 91], ["bronchitis", "DISEASE", 251, 261], ["Acute faryngitis", "PROBLEM", 57, 73], ["tonsillitis", "PROBLEM", 80, 91], ["een bacteri\u00eble infectie", "PROBLEM", 128, 151], ["Acute bronchitis", "PROBLEM", 245, 261], ["Acute", "OBSERVATION_MODIFIER", 57, 62], ["faryngitis", "OBSERVATION", 63, 73], ["tonsillitis", "OBSERVATION", 80, 91], ["Acute", "OBSERVATION_MODIFIER", 245, 250], ["bronchitis", "OBSERVATION", 251, 261]]], ["Een onderscheid tussen trache\u00eftis en bronchitis is op klinische gronden niet te maken.", [["bronchitis", "DISEASE", 37, 47], ["onderscheid tussen trache\u00eftis", "SPECIES", 4, 33], ["Een onderscheid tussen", "SPECIES", 0, 22], ["Een onderscheid", "TREATMENT", 0, 15], ["trache\u00eftis en bronchitis", "TREATMENT", 23, 47], ["op klinische gronden niet te", "TREATMENT", 51, 79], ["bronchitis", "OBSERVATION", 37, 47]]], ["In ongeveer 20% van de gevallen is een bacteri\u00eble verwekker aan te tonen. (met name Streptococcus pneumoniae en Haemophilus influenzae).", [["Haemophilus influenzae", "DISEASE", 112, 134], ["Streptococcus pneumoniae", "ORGANISM", 84, 108], ["Haemophilus influenzae", "ORGANISM", 112, 134], ["Streptococcus pneumoniae", "SPECIES", 84, 108], ["Haemophilus influenzae", "SPECIES", 112, 134], ["Streptococcus pneumoniae", "SPECIES", 84, 108], ["Haemophilus influenzae", "SPECIES", 112, 134], ["Streptococcus pneumoniae en Haemophilus influenzae", "PROBLEM", 84, 134]]], ["Het natuurlijk beloop is niet goed bekend, omdat er slechts zelden afgewacht wordt.DiagnostiekDe diagnostiek van otitis media berust op anamnese (oorpijn, koorts) en lichamelijk onderzoek (rood bomberend trommelvlies).DiagnostiekDe diagnostiek van rinosinusitis berust voornamelijk op de aanwezigheid van klachten van neus en bijholten.", [["otitis", "DISEASE", 113, 119], ["DiagnostiekDe diagnostiek van otitis media", "TREATMENT", 83, 125]]], ["Aanvullend onderzoek, bijvoorbeeld r\u00f6ntgenonderzoek, heeft geen toegevoegde waarde.DiagnostiekBij faryngitis en tonsillitis wijzen koorts, beslag op de tonsillen, gezwollen klieren in de hals, en de afwezigheid van hoest op een bacteri\u00eble infectie.", [["tonsillitis", "DISEASE", 112, 123], ["Aanvullend onderzoek", "TREATMENT", 0, 20], ["DiagnostiekBij faryngitis", "PROBLEM", 83, 108]]], ["Ten tweede is de winst van antimicrobi\u00eble behandeling bij bacteri\u00eble keelinfecties beperkt: een \u00e0 twee dagen korter klachten.DiagnostiekBij lagere luchtweginfecties is met name van belang een onderscheid te maken tussen acute bronchitis en pneumonie.", [["acute bronchitis en pneumonie", "DISEASE", 220, 249], ["acute bronchitis en pneumonie", "PROBLEM", 220, 249], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["bronchitis", "OBSERVATION", 226, 236]]], ["Het probleem is dat enke-le symptomen, zoals eenzijdige afwijkingen bij auscultatie en percussie wel enige positief voorspellende waarde hebben, dat wil zeggen dat als deze afwijkingen aanwezig zijn de kans op pneumonie is verhoogd, maar afwezigheid van deze afwijkingen sluiten een pneumonie niet uit.", [["le symptomen", "PROBLEM", 25, 37]]], ["Twee recente studies lieten zien dat het meten van CRP in capillair bloed wel toegevoegde waarde had.", [["CRP", "PROTEIN", 51, 54], ["Twee recente studies", "TEST", 0, 20], ["van CRP", "TEST", 47, 54]]], ["Daarbij werd gezien dat kinderen jonger dan twee jaar met dubbelzijdige otitis en kinderen met een loopoor bij het eerste contact baat hadden bij antimicrobi\u00eble behandeling.", [["otitis", "DISEASE", 72, 78], ["Daarbij", "TREATMENT", 0, 7], ["otitis", "PROBLEM", 72, 78]]], ["Daarnaast dienen kinderen met een verhoogde kans op complicaties te worden behandeld, met name kinderen jonger dan zes maanden, kinderen met aangeboren of verworven anatomische afwijkingen en kinderen met een gestoorde afweer.", [["Daarnaast dienen kinderen", "TREATMENT", 0, 25]]], ["Als algemene stelregel geldt dat een volwassene met middenoorontsteking behandeld moet worden met een antibioticum.TherapieNeusdruppels hebben bij kinderen met middenoorontsteking geen effect op de oorontsteking.", [["Als algemene stelregel", "TREATMENT", 0, 22], ["TherapieNeusdruppels", "TREATMENT", 115, 135]]], ["Vaak wordt te weinig pijnstilling gegeven aan kinderen met oorpijn; paracetamol, 10 mg per kg lichaamsgewicht 4-6 dd oraal of 3-4 dd rectaal zorgt voor een redelijk tot goede pijnstilling.", [["oorpijn", "CHEMICAL", 59, 66], ["paracetamol", "CHEMICAL", 68, 79], ["paracetamol", "CHEMICAL", 68, 79], ["paracetamol", "SIMPLE_CHEMICAL", 68, 79], ["paracetamol", "TREATMENT", 68, 79]]], ["Bij rinosinusitis bij verder gezonde volwassenen zijn er geen aanwijzingen dat antibiotica een relevant effect hebben, ook niet als de klachten langer dan een week bestaan.", [["Bij rinosinusitis bij verder gezonde volwassenen zijn er geen aanwijzingen dat antibiotica een relevant effect hebben, ook niet als de klachten langer dan een week bestaan", "SPECIES", 0, 171], ["Bij rinosinusitis bij verder gezonde", "TREATMENT", 0, 36]]], ["Alleen bij pati\u00ebnten met een gestoorde afweer, met ernstige ziekteverschijnselen en met recidiverende klachten hebben antibiotica wellicht effect.", [["klachten", "TREATMENT", 102, 110]]], ["Als er een antibioticum wordt voorgeschreven, dan is doxycycline of amoxicilline een goede keuze.TherapieBij acute keelontsteking hebben zoals gezegd antibiotica slechts een beperkt effect.", [["doxycycline", "CHEMICAL", 53, 64], ["amoxicilline", "CHEMICAL", 68, 80], ["doxycycline", "CHEMICAL", 53, 64], ["doxycycline", "SIMPLE_CHEMICAL", 53, 64], ["doxycycline", "TREATMENT", 53, 64], ["amoxicilline", "TREATMENT", 68, 80], ["TherapieBij acute keelontsteking hebben", "TREATMENT", 97, 136], ["gezegd antibiotica", "TREATMENT", 143, 161]]], ["Gezien de goede gevoeligheid van alle typen b\u00e8tahemolytische streptokokken is een smalspectrumpenicilline, bijvoorbeeld feniticilline, eerste keuze.TherapieBij gezonde volwassenen met acute bronchitis heeft antimicrobi\u00eble behandeling geen relevant effect.", [["volwassenen", "CHEMICAL", 168, 179], ["bronchitis", "DISEASE", 190, 200], ["TherapieBij gezonde volwassenen", "SPECIES", 148, 179], ["TherapieBij", "TREATMENT", 148, 159], ["acute bronchitis", "PROBLEM", 184, 200], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["bronchitis", "OBSERVATION", 190, 200]]], ["Over het algemeen wordt aangeraden om behandeling met een antibioticum te overwegen bij heel jonge kinderen en ouderen, met name als zij duidelijke symptomen hebben zoals benauwdheid en koorts en wanneer zij lijden aan chronische aandoeningen zoals COPD, hartfalen of diabetes mellitus.", [["COPD", "DISEASE", 249, 253], ["diabetes mellitus", "DISEASE", 268, 285], ["COPD", "PROBLEM", 249, 253], ["diabetes mellitus", "PROBLEM", 268, 285], ["heel", "ANATOMY", 88, 92], ["diabetes mellitus", "OBSERVATION", 268, 285]]], ["Doxycycline en amoxicilline zijn eerstekeuze preparaten.", [["Doxycycline", "CHEMICAL", 0, 11], ["amoxicilline zijn eerstekeuze", "CHEMICAL", 15, 44], ["Doxycycline", "CHEMICAL", 0, 11], ["Doxycycline", "SIMPLE_CHEMICAL", 0, 11], ["Doxycycline en amoxicilline zijn eerstekeuze preparaten", "TREATMENT", 0, 55]]], ["Doxycycline heeft als nadeel dat in Nederland ongeveer 10% van de pneumokokken hiertegen resistent is.", [["Doxycycline", "CHEMICAL", 0, 11], ["Doxycycline", "CHEMICAL", 0, 11], ["Doxycycline", "TREATMENT", 0, 11]]], ["Amoxicilline kent nauwelijks resistentie bij pneumokokken, maar van de in Nederland bekende Haemophilus influenzae stammen is wel ongeveer 15% resistent tegen dit middel.", [["Amoxicilline", "CHEMICAL", 0, 12], ["Haemophilus influenzae", "DISEASE", 92, 114], ["Haemophilus influenzae stammen", "ORGANISM", 92, 122], ["Haemophilus influenzae", "SPECIES", 92, 114], ["Haemophilus influenzae stammen", "SPECIES", 92, 122], ["Amoxicilline", "TREATMENT", 0, 12], ["Haemophilus influenzae stammen", "TEST", 92, 122]]], ["Rekening houden met Mycoplasma als verwekker is niet nodig, zo is uit verschillende studies gebleken.", [["Mycoplasma als verwekker", "PROBLEM", 20, 44]]], ["Deze verwekker komt in kleine epidemie\u00ebn voor en heeft gemiddeld genomen een mild verloop.Neonatale infectiesZie hoofdstuk 10 Kindergeneeskunde.8.8Urineweginfecties Zie ook hoofdstuk 13 Nefrologie en 21 Urologie.8.8Als definitie van een urineweginfectie wordt meestal gehanteerd: de aanwezigheid van klachten en ten minste 103 bacteri\u00ebn per ml vers geloosde urine.", [["urine", "ORGANISM_SUBSTANCE", 358, 363], ["een mild verloop", "PROBLEM", 73, 89], ["Neonatale infecties", "TEST", 90, 109], ["Kindergeneeskunde", "TEST", 126, 143], ["Urineweginfecties", "TEST", 147, 164], ["geloosde urine", "TEST", 349, 363], ["mild", "OBSERVATION_MODIFIER", 77, 81], ["verloop", "OBSERVATION", 82, 89]]], ["Bij bejaarden komt asymptomatische bacteriurie veel vaker voor (tot 50%).", [["Bij bejaarden komt asymptomatische bacteriurie veel vaker voor (tot 50", "SPECIES", 0, 70]]], ["Klachten bij een urineweginfectie zijn pijn en/of branderig gevoel bij plassen, frequente mictie, loze aandrang, bloed bij de urine, koorts, pijn in de onderbuik, pijn in de rug, pijn in de zij.8.8Het overgrote deel van de bacteri\u00eble infecties wordt veroorzaakt door E. coli.DiagnostiekPijnlijke frequente mictie duidt bij volwassen vrouwen in 50 tot 90% van de gevallen op een daadwerkelijke infectie.", [["urine", "ORGANISM_SUBSTANCE", 126, 131], ["E. coli", "SPECIES", 267, 274], ["Klachten bij een urineweginfectie zijn pijn en/of branderig gevoel bij plassen", "SPECIES", 0, 78], ["E. coli", "SPECIES", 267, 274], ["Klachten", "TREATMENT", 0, 8], ["branderig gevoel bij plassen", "TREATMENT", 50, 78], ["E. coli", "PROBLEM", 267, 274], ["DiagnostiekPijnlijke", "TREATMENT", 275, 295], ["E. coli", "OBSERVATION", 267, 274]]], ["Aanvullend onderzoek kan in die gevallen dus achterwege blijven.DiagnostiekVoor aanvullend onderzoek is verse urine nodig, dat wil zeggen urine die korter dan een half uur voor onderzoek is geloosd.", [["urine", "ANATOMY", 110, 115], ["urine", "ORGANISM_SUBSTANCE", 110, 115], ["urine", "ORGANISM_SUBSTANCE", 138, 143], ["urine nodig", "TEST", 110, 121], ["dat wil zeggen urine", "TEST", 123, 143]]], ["Eventueel kan eerder opgevangen urine in een schoon potje in de ijskast worden bewaard.", [["urine", "ORGANISM_SUBSTANCE", 32, 37]]], ["Extra maatregelen als opvangen van midstream urine of het wassen en of spreiden van de labia hebben geen toegevoegde waarde.", [["urine", "ORGANISM_SUBSTANCE", 45, 50]]], ["De pati\u00ebnt moet niet korter dan twee uur voor het produceren van de urine hebben geplast.DiagnostiekEen positieve nitriettest in combinatie met klachten betekent dat de kans dat er een echte infectie aanwezig is ongeveer 80-90% bedraagt.", [["urine", "ORGANISM_SUBSTANCE", 68, 73]]], ["Kweek met resistentiebepaling dient altijd te worden verricht bij kinderen, zwangeren, mannen en bij volwassen vrouwen met een mogelijke pyelonefritis of persisterende klachten na behandeling.DiagnostiekDe leukotest (een teststrip zoals de nitriettest) heeft weinig toegevoegde waarde naast de nitriettest.", [["na", "CHEMICAL", 177, 179], ["DiagnostiekDe", "TEST", 192, 205], ["leukotest", "TEST", 206, 215], ["een teststrip zoals", "TREATMENT", 217, 236]]], ["Het sediment is bewerkelijk en de betrouwbaarheid is erg afhankelijk van uitvoering en beoordelaar.DiagnostiekScreening op asymptomatische bacteriurie heeft geen zin, ook niet bij zwangeren.TherapieDe keuze voor een antibioticum hangt af van bacteri\u00eble resistentie, ernst van de infectie en, in laatste instantie, kosten.", [["sediment", "OBSERVATION", 4, 12]]], ["Vanwege resistentie zijn trimetroprim (ongeveer 20%) en amoxicilline (meer dan 30%) geen middelen meer van eerste keuze.", [["trimetroprim", "CHEMICAL", 25, 37], ["amoxicilline", "CHEMICAL", 56, 68], ["trimetroprim", "CHEMICAL", 25, 37], ["amoxicilline", "CHEMICAL", 56, 68], ["amoxicilline", "SIMPLE_CHEMICAL", 56, 68], ["Vanwege resistentie zijn trimetroprim", "TREATMENT", 0, 37], ["en amoxicilline (meer dan", "TREATMENT", 53, 78]]], ["Bij de behandeling van ongecompliceerde infecties bij volwassen vrouwen is nitrofuranto\u00efne (2 dd 100 mg, 5 dagen) eerste keuze.", [["nitrofuranto\u00efne", "CHEMICAL", 75, 90], ["nitrofuranto\u00efne", "TREATMENT", 75, 90]]], ["Ook bij meisjes ouder dan vier jaar, jongens ouder dan 12 en mannen die geen koorts hebben of andere klachten die wijzen op een prostatitis of pyelonefritis kan in eerste instantie nitrofuranto\u00efne worden voorgeschreven, de NHG-Standaard adviseert bij deze groepen wel 7 in plaats van 5 dagen te behandelen.", [["prostatitis", "DISEASE", 128, 139], ["prostatitis", "OBSERVATION", 128, 139]]], ["Ook bij pati\u00ebnten met diabetes mellitus wordt geadviseerd zeven dagen te behandelen bij een ongecompliceerde infectie.", [["diabetes mellitus", "DISEASE", 22, 39], ["diabetes mellitus", "PROBLEM", 22, 39]]], ["Nitrofuranto\u00efne mag niet meer worden gebruikt als de bevalling binnen een week wordt verwacht.", [["Nitrofuranto\u00efne", "CHEMICAL", 0, 15], ["Nitrofuranto\u00efne mag", "TREATMENT", 0, 19]]], ["Bij alle hier niet genoemde groepen, dus bij meisjes van vier jaar of jonger, jongens jonger dan 12, en pati\u00ebnten met tekenen van weefselinvasie (pyelonefritis, prostatitis) dient amoxicilline met clavulaanzuur te worden voorgeschreven gedurende tien dagen.TherapieFosfomycine lijkt een goed alternatief bij ongecompliceerde infecties bij vrouwen.", [["prostatitis", "DISEASE", 161, 172], ["prostatitis", "PROBLEM", 161, 172], ["amoxicilline", "TREATMENT", 180, 192], ["TherapieFosfomycine lijkt een", "TREATMENT", 257, 286], ["prostatitis", "OBSERVATION", 161, 172]]], ["Quinolonen dienen alleen te worden voorgeschreven bij een contra-indicatie voor een van de hiervoor genoemde middelen.TherapieControle en verwijzen Bij urineweginfecties bij mannen, kinderen en zwangeren dient na de behandeling ter controle een dipslide te worden verricht.", [["na", "CHEMICAL", 210, 212], ["Quinolonen", "SIMPLE_CHEMICAL", 0, 10], ["Quinolonen", "TREATMENT", 0, 10], ["TherapieControle", "TREATMENT", 118, 134]]], ["Volgens de NHG-Standaard kan bij mannen \u00e9\u00e9n ongecompliceerde infectie na succesvolle behandeling nog worden afgewacht.", [["na", "CHEMICAL", 70, 72]]], ["Kinderen jonger dan zes maanden dienen direct te worden doorgestuurd.8.9Zo\u00f6nosen Een zo\u00f6nose is een ziekte die van dier op mens kan overgaan of andersom.", [["Zo\u00f6nosen Een zo\u00f6nose", "TREATMENT", 72, 92]]], ["Zo heeft 55% van de Nederlandse gezinnen \u00e9\u00e9n of meer huisdieren, zijn er voedselproducerende landbouwhuisdieren en komen mensen in contact met dieren in het wild.8.9Veel van de nieuwe ziektebeelden waarmee we te maken krijgen, zijn zo\u00f6nosen.", [["zijn zo\u00f6nosen", "TREATMENT", 227, 240]]], ["Voorbeelden uit het recente verleden zijn de SARS-epidemie in 2003 door contact met civetkatten.", [["SARS-epidemie", "DISEASE", 45, 58], ["civetkatten", "CHEMICAL", 84, 95]]], ["Maar ook infecties met het hepatitis-E-virus berusten op contact met dieren of dierlijk materiaal.8.9Een in Nederland veelvoorkomende zo\u00f6nose is kattenkrabziekte, en in 2010 hebben de opkomende zo\u00f6nosen Q-koorts en de Mexicaanse griep voor veel onrust gezorgd.", [["hepatitis", "DISEASE", 27, 36], ["het hepatitis-E-virus", "ORGANISM", 23, 44], ["E-virus berusten", "SPECIES", 37, 53], ["Maar", "TEST", 0, 4], ["infecties", "PROBLEM", 9, 18], ["het hepatitis", "TEST", 23, 36], ["hepatitis", "OBSERVATION", 27, 36]]], ["Deze laatste drie worden hier kort besproken.KattenkrabziekteKattenkrabziekte wordt veroorzaakt door Bartonella henselae.", [["Bartonella henselae", "DISEASE", 101, 120], ["Bartonella henselae", "ORGANISM", 101, 120], ["Bartonella henselae", "SPECIES", 101, 120], ["Deze laatste drie worden hier kort besproken.", "SPECIES", 0, 45], ["Bartonella henselae", "SPECIES", 101, 120], ["KattenkrabziekteKattenkrabziekte", "TREATMENT", 45, 77], ["Bartonella henselae", "PROBLEM", 101, 120], ["Bartonella henselae", "OBSERVATION", 101, 120]]], ["De bacterie is moeilijk te kweken en groeit alleen op specifieke voedingsbodems.KattenkrabziekteWanneer de mens ge\u00efnfecteerd wordt, ontstaat op de plek van de krab of de beet na drie tot zes dagen een laesie, die na enkele dagen geneest.", [["na", "CHEMICAL", 213, 215], ["beet na drie tot zes dagen een laesie, die na enkele dagen", "SPECIES", 170, 228], ["tot zes", "TREATMENT", 183, 190]]], ["Een derde van de pati\u00ebnten heeft lichte koorts, hoofdpijn en algemene malaise.", [["algemene malaise", "DISEASE", 61, 77], ["malaise", "PROBLEM", 70, 77]]], ["E\u00e9n tot twee weken na de primaire laesie ontwikkelt zich een regionale lymfadenitis (hals, oksel, lies), waarbij meestal \u00e9\u00e9n maar soms ook meerdere lymfeklieren zijn aangetast.", [["een regionale lymfadenitis", "PROBLEM", 57, 83], ["regionale lymfadenitis", "OBSERVATION", 61, 83]]], ["De lymfeklieren zijn groot, zacht en gevoelig en draineren soms naar de oppervlakte.", [["De lymfeklieren zijn groot", "TREATMENT", 0, 26], ["zacht en gevoelig", "TREATMENT", 28, 45]]], ["Na enkele weken neemt de lymfadenitis over het algemeen af en geneest spontaan, ook zonder behandeling.", [["Na", "CHEMICAL", 0, 2], ["Na", "CHEMICAL", 0, 2], ["Na", "TEST", 0, 2]]], ["Ongeveer 2% van ge\u00efnfecteerde pati\u00ebnten heeft een ooginfectie met conjunctivitis, lymfeklierzwelling en koorts (parinaud oculoglandulair syndroom).", [["conjunctivitis", "DISEASE", 66, 80], ["conjunctivitis", "PROBLEM", 66, 80], ["lymfeklierzwelling en koorts (parinaud oculoglandulair syndroom", "TREATMENT", 82, 145], ["conjunctivitis", "OBSERVATION", 66, 80]]], ["Enkele pati\u00ebnten (1 tot 3%) kunnen een meer gecompliceerd verloop vertonen, met onder andere ontstekingshaarden in bot (osteomyelitis), hart (endocarditis), lever, milt of long en zelfs uitbreiding naar het centrale zenuwstelsel.", [["osteomyelitis", "DISEASE", 120, 133], ["endocarditis", "DISEASE", 142, 154], ["osteomyelitis", "PROBLEM", 120, 133], ["hart (endocarditis)", "PROBLEM", 136, 155], ["long en zelfs", "PROBLEM", 172, 185], ["osteomyelitis", "OBSERVATION", 120, 133], ["endocarditis", "OBSERVATION", 142, 154]]], ["Deze beelden worden voornamelijk gevonden bij pati\u00ebnten met een verzwakte afweer.KattenkrabziekteDiagnostiek IgM-en IgG-antistoffen in serum zijn aan te tonen met ELISA-of immunofluorescentietechnieken.KattenkrabziekteIgG-antistoffen zijn echter ook bij een deel van de gezonde mensen aantoonbaar en zijn daardoor minder goed bruikbaar voor het stellen van de diagnose.", [["serum", "ANATOMY", 135, 140], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["IgM", "PROTEIN", 109, 112], ["IgG", "PROTEIN", 116, 119], ["KattenkrabziekteIgG-antistoffen zijn echter ook bij een deel van de gezonde mensen aantoonbaar en zijn daardoor minder goed bruikbaar voor het stellen", "SPECIES", 202, 352], ["KattenkrabziekteDiagnostiek", "TEST", 81, 108], ["IgM", "TEST", 109, 112], ["IgG", "TEST", 116, 119], ["antistoffen", "TREATMENT", 120, 131], ["ELISA", "TEST", 163, 168], ["immunofluorescentietechnieken", "PROBLEM", 172, 201], ["KattenkrabziekteIgG", "TREATMENT", 202, 221], ["antistoffen zijn echter", "TREATMENT", 222, 245]]], ["De meest gevoelige methode voor antigeendetectie is de PCR op pus en biopsiemateriaal.TherapieBij ontstoken lymfeklieren heeft behandeling met antibiotica bij immuuncompetente pati\u00ebnten meestal weinig effect en is de ziekte uiteindelijk zelflimiterend.", [["TherapieBij", "TREATMENT", 86, 97]]], ["Het verwijderen van pus uit de opgezette klieren leidt tot verlichting en verkort de duur van de klachten.", [["Het verwijderen van pus uit de opgezette klieren leidt tot verlichting en verkort de duur van de klachten", "SPECIES", 0, 105]]], ["Bij immuungecompromitteerde pati\u00ebnten is de infectie niet zelflimiterend, maar reageert over het algemeen goed op antibiotica.", [["op antibiotica", "TREATMENT", 111, 125]]], ["De middelen van eerste keuze zijn op dit moment doxycycline of een van de macroliden.Q-koortsQ-koorts, een infectie veroorzaakt door de kleine obligaat intracellulaire bacterie Coxiella burnetii, komt in Nederland sinds lang sporadisch voor vanuit contact met dieren.", [["doxycycline", "CHEMICAL", 48, 59], ["doxycycline", "CHEMICAL", 48, 59], ["kleine obligaat intracellulaire bacterie Coxiella burnetii", "ORGANISM", 136, 194], ["obligaat intracellulaire", "SPECIES", 143, 167], ["Coxiella burnetii", "SPECIES", 177, 194], ["Coxiella burnetii", "SPECIES", 177, 194], ["De middelen van eerste keuze zijn op dit moment doxycycline", "TREATMENT", 0, 59], ["een van de macroliden", "TREATMENT", 63, 84], ["koorts", "TREATMENT", 95, 101], ["Coxiella burnetii", "PROBLEM", 177, 194]]], ["Sinds 2007 blijkt in Noord-Brabant en Gelderland echter sprake te zijn van massale besmetting en overdracht naar de bevolking vanuit voornamelijk geitenhouderijen.Q-koortsIn 2009 zijn er ruim 2.350 gevallen gemeld, zes pati\u00ebnten overleden aan de ziekte.", [["Brabant en Gelderland echter sprake", "TREATMENT", 27, 62], ["zes", "TREATMENT", 215, 218]]], ["Tot mei 2010 waren er ruim 300 gevallen.Q-koortsDe ziekte komt tegenwoordig niet alleen meer in Noord-Brabant en Gelderland voor.", [["Tot mei 2010 waren er ruim 300 gevallen", "SPECIES", 0, 39]]], ["De actuele verspreiding is te vinden op www.rivm.nl.ZiektebeeldenNa inhalatie van de bacterie ontstaat een ontsteking die meestal (in 60% van de gevallen) symptoomloos verloopt.", [["ZiektebeeldenNa inhalatie van de bacterie", "TREATMENT", 52, 93]]], ["We onderscheiden acute Q-koorts en een chronische vorm.ZiektebeeldenDe infectie kan leiden tot een pneumonie met soms ernstige algemene ziekte en ook hepatitis.", [["hepatitis", "DISEASE", 150, 159], ["ZiektebeeldenDe infectie kan leiden", "TREATMENT", 55, 90], ["een pneumonie", "TREATMENT", 95, 108], ["hepatitis", "PROBLEM", 150, 159], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["hepatitis", "OBSERVATION", 150, 159]]], ["Ook de polymerase chain reaction (PCR) wordt steeds meer gebruikt, maar is voornamelijk positief in de eerste week van de acute ziekte of bij endocarditis.DiagnostiekTherapie Q-koorts is meestal een zelflimiterende milde ziekte waarvoor geen therapie nodig is, tenzij er sprake is van een onderliggende ziekte.", [["endocarditis", "DISEASE", 142, 154], ["bij endocarditis", "PROBLEM", 138, 154], ["DiagnostiekTherapie", "TREATMENT", 155, 174], ["meestal een zelflimiterende", "TREATMENT", 187, 214], ["bij", "ANATOMY", 138, 141], ["endocarditis", "OBSERVATION", 142, 154]]], ["Voor de acute Q-koorts is doxycycline het middel van eerste keuze, Moxifloxacine kan ook worden gebruikt.", [["doxycycline", "CHEMICAL", 26, 37], ["Moxifloxacine", "CHEMICAL", 67, 80], ["doxycycline", "TREATMENT", 26, 37]]], ["Bij chronische infecties, zoals endocarditis, wordt behandeld met een combinatie van geneesmiddelen gedurende ten minste anderhalf jaar.DiagnostiekBij verdenking op deze infectie lijkt verwijzing naar een centrum met veel ervaring of een afdeling Infectieziekten aangewezen.Mexicaanse griepInfluenzavirussen behoren tot de familie van de Orthomyxoviridae en worden op basis van antigene, genetische en structurele verschillen onder-verdeeld in drie typen: influenza A, influenza B en influenza C. Influenza A en B zijn voor de mens de belangrijkste.Mexicaanse griepIn 2009 verscheen een nieuw pandemisch virus, het 'nieuwe H1N1-virus' (de 'Mexicaanse griep').", [["zoals endocarditis", "DISEASE", 26, 44], ["nieuw pandemisch virus", "ORGANISM", 587, 609], ["nieuwe H1N1-virus", "ORGANISM", 616, 633], ["Mexicaanse griepIn 2009 verscheen een nieuw pandemisch virus, het 'nieuwe H1N1-virus", "SPECIES", 549, 633], ["Bij chronische infecties", "PROBLEM", 0, 24], ["zoals endocarditis", "PROBLEM", 26, 44], ["DiagnostiekBij", "TEST", 136, 150], ["influenza", "PROBLEM", 456, 465], ["influenza", "PROBLEM", 469, 478], ["Influenza", "PROBLEM", 497, 506], ["Mexicaanse griepIn", "TREATMENT", 549, 567], ["endocarditis", "OBSERVATION", 32, 44]]], ["Dit virus is ontstaan door een recente uitwisseling van genen tussen twee verschillende varkensgriepvirussen die elk eerder \u00f3fwel rechtstreeks afkomstig waren van een aviair (vogel)virus, \u00f3fwel het resultaat waren van uitwisseling van genen tussen menselijke, aviaire en varkensgriepvirussen.Mexicaanse griepHet nieuwe H1N1-virus heeft zich in 2009 razendsnel over de gehele wereld verspreid en aanleiding gegeven tot een relatief milde pandemie.", [["Mexicaanse griep", "CHEMICAL", 292, 308], ["Dit virus", "ORGANISM", 0, 9], ["Het nieuwe H1N1-virus", "ORGANISM", 308, 329], ["H1N1-virus", "SPECIES", 319, 329], ["Dit virus", "PROBLEM", 0, 9], ["Mexicaanse", "TREATMENT", 292, 302], ["H1N1", "OBSERVATION", 319, 323]]], ["De toekomst zal uitwijzen of dit virus, net als na voorgaande pandemie\u00ebn, als enig circulerende seizoensgriepvariant overblijft.Preventie en therapieDe besmettingsweg voor nieuwe influenza-A (H1N1) is niet anders dan voor de seizoensinfluenza.", [["influenza-A", "DISEASE", 179, 190], ["nieuwe influenza-A", "ORGANISM", 172, 190], ["H1N1", "ORGANISM", 192, 196], ["dit virus", "PROBLEM", 29, 38], ["influenza", "PROBLEM", 179, 188]]], ["Kleine deeltjes met een diameter van 1 tot 5 microm lijken het meest effectief.", [["Kleine deeltjes", "TREATMENT", 0, 15], ["een diameter van", "TREATMENT", 20, 36], ["een diameter", "OBSERVATION_MODIFIER", 20, 32]]], ["De minimale aerogene besmettingsdosis is zeer laag, waarschijnlijk in de orde van \u00e9\u00e9n of enkele virusdeeltjes.", [["aerogene besmettingsdosis", "OBSERVATION", 12, 37]]], ["Het nieuwe influenz-A-(H1N1-)virus is gevoelig voor de neuraminidaseremmers oseltamivir (Tamiflu \u00ae ) en zanamivir (Relenza \u00ae ), maar resistent tegen de M2-ionkanaalblokkers amantadine en rimantadine.Virale hepatitisZie ook hoofdstuk 12 Maag-, darm-en leverziekten.Virale hepatitisEr zijn meerdere hepatitisvirussen.", [["oseltamivir", "CHEMICAL", 76, 87], ["Tamiflu \u00ae", "CHEMICAL", 89, 98], ["zanamivir", "CHEMICAL", 104, 113], ["amantadine", "CHEMICAL", 173, 183], ["rimantadine", "CHEMICAL", 187, 198], ["oseltamivir", "CHEMICAL", 76, 87], ["Tamiflu", "CHEMICAL", 89, 96], ["zanamivir", "CHEMICAL", 104, 113], ["amantadine", "CHEMICAL", 173, 183], ["rimantadine", "CHEMICAL", 187, 198], ["Het nieuwe influenz-A-(H1N1-)virus", "ORGANISM", 0, 34], ["neuraminidaseremmers oseltamivir", "SIMPLE_CHEMICAL", 55, 87], ["Tamiflu \u00ae", "SIMPLE_CHEMICAL", 89, 98], ["zanamivir", "SIMPLE_CHEMICAL", 104, 113], ["Relenza \u00ae", "SIMPLE_CHEMICAL", 115, 124], ["M2-ionkanaalblokkers amantadine", "SIMPLE_CHEMICAL", 152, 183], ["rimantadine", "SIMPLE_CHEMICAL", 187, 198], ["zijn meerdere hepatitisvirussen", "SPECIES", 283, 314], ["Het nieuwe influenz-A-(H1N1-)virus", "SPECIES", 0, 34], ["Virale hepatitisEr zijn meerdere hepatitisvirussen", "SPECIES", 264, 314], ["influenz", "TEST", 11, 19], ["H1N1", "PROBLEM", 23, 27], ["virus", "PROBLEM", 29, 34], ["oseltamivir (Tamiflu \u00ae", "TREATMENT", 76, 98], ["en zanamivir (Relenza \u00ae", "TREATMENT", 101, 124], ["maar resistent tegen", "TREATMENT", 128, 148], ["amantadine en rimantadine", "TREATMENT", 173, 198], ["Virale", "TEST", 199, 205], ["hepatitisZie", "TEST", 206, 218], ["hoofdstuk", "TEST", 223, 232], ["Maag", "TEST", 236, 240], ["Virale hepatitisEr zijn meerdere hepatitisvirussen", "TREATMENT", 264, 314]]], ["Op diagnostisch en therapeutisch gebied zijn enorme ontwikkelingen gaande betreffende hepatitis-B en hepa-titis-C.", [["hepatitis", "DISEASE", 86, 95], ["zijn enorme", "SPECIES", 40, 51], ["hepatitis", "PROBLEM", 86, 95]]], ["In Nederland zijn vooral infecties met het hepatitis-A-virus (HAV), het hepatitis-B-virus (HBV) en het hepatitis-C-virus (HCV) oorzaken van virushepatitis.", [["hepatitis-A-virus", "DISEASE", 43, 60], ["HAV", "DISEASE", 62, 65], ["hepatitis-B", "DISEASE", 72, 83], ["hepatitis-C-virus", "DISEASE", 103, 120], ["het hepatitis-A-virus", "ORGANISM", 39, 60], ["HAV", "ORGANISM", 62, 65], ["het hepatitis-B-virus", "ORGANISM", 68, 89], ["HBV", "ORGANISM", 91, 94], ["het hepatitis-C-virus", "ORGANISM", 99, 120], ["HCV", "ORGANISM", 122, 125], ["hepatitis-B-virus", "SPECIES", 72, 89], ["hepatitis-C-virus", "SPECIES", 103, 120], ["HAV", "SPECIES", 62, 65], ["hepatitis-B-virus", "SPECIES", 72, 89], ["HBV", "SPECIES", 91, 94], ["HCV", "SPECIES", 122, 125], ["Nederland zijn vooral infecties", "TEST", 3, 34], ["het hepatitis", "PROBLEM", 39, 52], ["A-virus (HAV", "PROBLEM", 53, 65], ["het hepatitis", "TEST", 68, 81], ["virus", "PROBLEM", 84, 89], ["HBV", "TEST", 91, 94], ["en het hepatitis", "TEST", 96, 112], ["C-virus (HCV)", "PROBLEM", 113, 126], ["van virushepatitis", "PROBLEM", 136, 154], ["hepatitis", "OBSERVATION", 43, 52], ["hepatitis", "OBSERVATION", 72, 81]]], ["Daarom bespreken we alleen HAV, HBV en HCV.Door immigratie, toename van het internationale reizigersverkeer en gerichte voorlichtingscampagnes van de overheid, zal de huisarts in toenemende mate te maken krijgen met vragen over preventie en diagnostiek van virushepatitis.", [["virushepatitis", "DISEASE", 257, 271], ["HAV", "ORGANISM", 27, 30], ["HBV", "ORGANISM", 32, 35], ["HBV", "SPECIES", 32, 35], ["HCV", "SPECIES", 39, 42], ["HBV en HCV", "PROBLEM", 32, 42]]], ["Goede samenwerking tussen huisartsen, maag-darm-leverartsen of internist-infectiologen en GGD's is van belang om tot optimale voorlichting te komen aan en behandeling van deze pati\u00ebnten.titis-C.", [["maag", "TEST", 38, 42]]], ["In Nederland zijn vooral infecties met het hepatitis-A-virus (HAV), het hepatitis-B-virus (HBV) en het hepatitis-C-virus (HCV) oorzaken van virushepatitis.", [["hepatitis-A-virus", "DISEASE", 43, 60], ["HAV", "DISEASE", 62, 65], ["hepatitis-B", "DISEASE", 72, 83], ["hepatitis-C-virus", "DISEASE", 103, 120], ["het hepatitis-A-virus", "ORGANISM", 39, 60], ["HAV", "ORGANISM", 62, 65], ["het hepatitis-B-virus", "ORGANISM", 68, 89], ["HBV", "ORGANISM", 91, 94], ["het hepatitis-C-virus", "ORGANISM", 99, 120], ["HCV", "ORGANISM", 122, 125], ["hepatitis-B-virus", "SPECIES", 72, 89], ["hepatitis-C-virus", "SPECIES", 103, 120], ["HAV", "SPECIES", 62, 65], ["hepatitis-B-virus", "SPECIES", 72, 89], ["HBV", "SPECIES", 91, 94], ["HCV", "SPECIES", 122, 125], ["Nederland zijn vooral infecties", "TEST", 3, 34], ["het hepatitis", "PROBLEM", 39, 52], ["A-virus (HAV", "PROBLEM", 53, 65], ["het hepatitis", "TEST", 68, 81], ["virus", "PROBLEM", 84, 89], ["HBV", "TEST", 91, 94], ["en het hepatitis", "TEST", 96, 112], ["C-virus (HCV)", "PROBLEM", 113, 126], ["van virushepatitis", "PROBLEM", 136, 154], ["hepatitis", "OBSERVATION", 43, 52], ["hepatitis", "OBSERVATION", 72, 81]]], ["Daarom bespreken we alleen HAV, HBV en HCV.Wereldwijd zijn meer dan twee miljard mensen in contact geweest met het hepatitis-B-virus (HBV) en ongeveer 400 miljoen mensen zijn chronisch ge\u00efnfecteerd.", [["hepatitis-B-virus", "DISEASE", 115, 132], ["HAV", "ORGANISM", 27, 30], ["HBV", "ORGANISM", 32, 35], ["hepatitis-B-virus", "ORGANISM", 115, 132], ["HBV", "ORGANISM", 134, 137], ["HBV", "SPECIES", 32, 35], ["HCV", "SPECIES", 39, 42], ["HBV en HCV", "PROBLEM", 32, 42], ["virus (HBV)", "TREATMENT", 127, 138]]], ["Jaarlijks sterven meer dan 500.000 mensen aan HBV-geassocieerde leverziekte, voornamelijk door cirrose of een hepatocellulair carcinoom (HCC).", [["HCC", "ANATOMY", 137, 140], ["HCC", "DISEASE", 137, 140], ["HCC", "CANCER", 137, 140], ["aan HBV", "TEST", 42, 49], ["een hepatocellulair carcinoom (HCC", "PROBLEM", 106, 140]]], ["In Nederland is een HBV-infectie relatief zeldzaam.", [["een HBV", "PROBLEM", 16, 23], ["een HBV", "OBSERVATION", 16, 23]]], ["Naar schatting is in Nederland ongeveer 0,2% van de bevolking chronische drager van het virus en heeft 2,1% een HBV-infectie doorgemaakt.", [["een HBV", "TEST", 108, 115]]], ["In Nederland hebben naar schatting 75.000 mensen een chronische hepatitis B, waarvan ruim 30% een actieve chronische hepatitis is die voor behandeling in aanmerking komt.titis-C.", [["hepatitis B", "DISEASE", 64, 75], ["hepatitis", "DISEASE", 117, 126], ["een chronische hepatitis B", "TREATMENT", 49, 75], ["waarvan ruim", "TREATMENT", 77, 89], ["chronische hepatitis", "PROBLEM", 106, 126], ["hepatitis", "OBSERVATION", 117, 126]]], ["In Nederland zijn vooral infecties met het hepatitis-A-virus (HAV), het hepatitis-B-virus (HBV) en het hepatitis-C-virus (HCV) oorzaken van virushepatitis.", [["hepatitis-A-virus", "DISEASE", 43, 60], ["HAV", "DISEASE", 62, 65], ["hepatitis-B", "DISEASE", 72, 83], ["hepatitis-C-virus", "DISEASE", 103, 120], ["het hepatitis-A-virus", "ORGANISM", 39, 60], ["HAV", "ORGANISM", 62, 65], ["het hepatitis-B-virus", "ORGANISM", 68, 89], ["HBV", "ORGANISM", 91, 94], ["het hepatitis-C-virus", "ORGANISM", 99, 120], ["HCV", "ORGANISM", 122, 125], ["hepatitis-B-virus", "SPECIES", 72, 89], ["hepatitis-C-virus", "SPECIES", 103, 120], ["HAV", "SPECIES", 62, 65], ["hepatitis-B-virus", "SPECIES", 72, 89], ["HBV", "SPECIES", 91, 94], ["HCV", "SPECIES", 122, 125], ["Nederland zijn vooral infecties", "TEST", 3, 34], ["het hepatitis", "PROBLEM", 39, 52], ["A-virus (HAV", "PROBLEM", 53, 65], ["het hepatitis", "TEST", 68, 81], ["virus", "PROBLEM", 84, 89], ["HBV", "TEST", 91, 94], ["en het hepatitis", "TEST", 96, 112], ["C-virus (HCV)", "PROBLEM", 113, 126], ["van virushepatitis", "PROBLEM", 136, 154], ["hepatitis", "OBSERVATION", 43, 52], ["hepatitis", "OBSERVATION", 72, 81]]], ["Daarom bespreken we alleen HAV, HBV en HCV.Er zijn bevolkingsgroepen waarin HBV/HCVinfectie frequenter voorkomt, bijvoorbeeld bij immigranten, mannen die seks hebben met mannen, ooit intraveneus druggebruik en bij mensen met wisselende seksuele partners.titis-C.", [["HAV", "ORGANISM", 27, 30], ["HBV", "ORGANISM", 32, 35], ["HBV", "SPECIES", 32, 35], ["HCV", "SPECIES", 39, 42], ["HBV en HCV", "PROBLEM", 32, 42], ["Er zijn bevolkingsgroepen", "TREATMENT", 43, 68]]], ["In Nederland zijn vooral infecties met het hepatitis-A-virus (HAV), het hepatitis-B-virus (HBV) en het hepatitis-C-virus (HCV) oorzaken van virushepatitis.", [["hepatitis-A-virus", "DISEASE", 43, 60], ["HAV", "DISEASE", 62, 65], ["hepatitis-B", "DISEASE", 72, 83], ["hepatitis-C-virus", "DISEASE", 103, 120], ["het hepatitis-A-virus", "ORGANISM", 39, 60], ["HAV", "ORGANISM", 62, 65], ["het hepatitis-B-virus", "ORGANISM", 68, 89], ["HBV", "ORGANISM", 91, 94], ["het hepatitis-C-virus", "ORGANISM", 99, 120], ["HCV", "ORGANISM", 122, 125], ["hepatitis-B-virus", "SPECIES", 72, 89], ["hepatitis-C-virus", "SPECIES", 103, 120], ["HAV", "SPECIES", 62, 65], ["hepatitis-B-virus", "SPECIES", 72, 89], ["HBV", "SPECIES", 91, 94], ["HCV", "SPECIES", 122, 125], ["Nederland zijn vooral infecties", "TEST", 3, 34], ["het hepatitis", "PROBLEM", 39, 52], ["A-virus (HAV", "PROBLEM", 53, 65], ["het hepatitis", "TEST", 68, 81], ["virus", "PROBLEM", 84, 89], ["HBV", "TEST", 91, 94], ["en het hepatitis", "TEST", 96, 112], ["C-virus (HCV)", "PROBLEM", 113, 126], ["van virushepatitis", "PROBLEM", 136, 154], ["hepatitis", "OBSERVATION", 43, 52], ["hepatitis", "OBSERVATION", 72, 81]]], ["Daarom bespreken we alleen HAV, HBV en HCV.De prevalentie van HCV in de algemene bevolking is onbekend, maar wordt geschat op 0,3-0,4%.", [["HAV", "ORGANISM", 27, 30], ["HBV", "ORGANISM", 32, 35], ["HBV", "SPECIES", 32, 35], ["HCV", "SPECIES", 39, 42], ["HBV en HCV", "PROBLEM", 32, 42]]], ["Van de 4.000 dialysepati\u00ebnten heeft ongeveer 3% antistoffen.DiagnostiekBij verdenking op een acute (virus)hepatitis zal dit eerst bevestigd moeten worden door het bepalen van afwijkende transaminasen (ALT, zie tabel 8.2 en figuur 8.1).", [["hepatitis", "DISEASE", 106, 115], ["hepatitis zal dit eerst bevestigd moeten worden door het bepalen van afwijkende transaminasen", "SPECIES", 106, 199], ["DiagnostiekBij", "TEST", 60, 74], ["een acute (virus)hepatitis zal dit", "PROBLEM", 89, 123], ["transaminasen", "TEST", 186, 199], ["ALT", "TEST", 201, 204], ["zie tabel", "TEST", 206, 215], ["acute", "OBSERVATION_MODIFIER", 93, 98]]], ["Meestal bestaat bij een acute hepatitis ook icterus.", [["hepatitis ook icterus", "DISEASE", 30, 51], ["een acute hepatitis", "PROBLEM", 20, 39], ["icterus", "PROBLEM", 44, 51], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["hepatitis", "OBSERVATION", 30, 39], ["icterus", "OBSERVATION", 44, 51]]], ["Zijn er (bij routinematig onderzoek gevonden) licht verhoogde transaminasewaarden (ALAT en ASAT anderhalf-tot vijfmaal de bovengrens van normaal; recent zijn de normaalwaarden naar beneden bijgesteld tot voor een man: < 30 IU/ ml en voor een vrouw < 19 IU/ml), dan worden deze na ongeveer vier weken opnieuw bepaald.", [["Zijn er", "CHEMICAL", 0, 7], ["man", "SPECIES", 213, 216], ["Zijn er (bij routinematig onderzoek gevonden) licht verhoogde transaminasewaarden (ALAT en ASAT anderhalf-tot vijfmaal de bovengrens van normaal; recent zijn de normaalwaarden naar beneden bijgesteld tot voor een man: < 30 IU/ ml en voor een vrouw < 19 IU/ml)", "SPECIES", 0, 259], ["Zijn er (bij routinematig onderzoek gevonden", "TREATMENT", 0, 44], ["ALAT en ASAT anderhalf", "TREATMENT", 83, 105], ["tot vijfmaal de bovengrens van normaal", "TREATMENT", 106, 144], ["recent zijn de normaalwaarden naar beneden", "TREATMENT", 146, 188]]], ["Zijn de waarden nog steeds verhoogd, dan neemt de huisarts een anamnese af met specifieke aandacht voor gebruik van geneesmiddelen, alcohol en drugs, verricht lichamelijk onderzoek gericht op de meest voorkomende oorzaken van leverschade en verricht aanvullend onderzoek gericht op hepatitis B en C bij personen behorende tot een risicogroep.", [["alcohol", "CHEMICAL", 132, 139], ["hepatitis B", "DISEASE", 282, 293], ["hepatitis B en C bij personen", "TREATMENT", 282, 311], ["tot een risicogroep", "TREATMENT", 322, 341]]], ["Risicogroepen voor een virushepatitis zijn: -pati\u00ebnten met icterus bij wie geen verdenking bestaat op pathologie van de galblaas of galwegen of een maligniteit; -pati\u00ebnten met algemene malaise bij wie tevens verdenking bestaat op virushepatitis omdat: c zij behoren tot een risicogroep (zie boven) voor deze aandoening; of c er een risicocontact is geweest voor virushepatitis; of c zij eerder hepatitis B of C doormaakten. c Is het HBeAg positief en/of het ALAT verhoogd, dan is er een chronische actieve ontsteking van de lever.", [["icterus", "DISEASE", 59, 66], ["hepatitis B", "DISEASE", 394, 405], ["HBeAg", "CHEMICAL", 433, 438], ["c", "GENE_OR_GENE_PRODUCT", 424, 425], ["C doormaakten", "SPECIES", 409, 422], ["icterus", "PROBLEM", 59, 66], ["malaise", "PROBLEM", 185, 192], ["zij behoren tot een risicogroep", "TREATMENT", 254, 285], ["voor virushepatitis", "PROBLEM", 357, 376], ["C doormaakten", "TREATMENT", 409, 422], ["HBeAg", "OBSERVATION", 433, 438]]], ["Deze pati\u00ebnten worden verwezen naar een maag-darm-leverarts, met specifieke belangstelling voor hepatitis of naar een internist-infectioloog. c Is bij een negatief HBeAg het ALAT gedurende drie jaar normaal dan is er zeer waarschijnlijk geen chronische leverontsteking en kan de pati\u00ebnt uit controle worden ontslagen. c Is bij een negatief HBeAg het ALAT wel een keer verhoogd, dan volgt alsnog verwijzing, omdat de ontstekingsactiviteit in de tijd kan fluctueren.", [["hepatitis", "DISEASE", 96, 105], ["HBeAg", "CHEMICAL", 164, 169], ["HBeAg", "CHEMICAL", 340, 345], ["c", "GENE_OR_GENE_PRODUCT", 142, 143], ["c", "GENE_OR_GENE_PRODUCT", 318, 319], ["infectioloog", "PROBLEM", 128, 140]]], ["De NHG-richtlijn maakt nog onderscheid tussen HbeAg-negatieve en -positieve pati\u00ebnten.", [["HbeAg", "TEST", 46, 51]]], ["Recente gegevens laten echter zien dat Hbe-Ag-negatieve chronische hepatitis B wat agressiever ver-loopt en bovendien het beloop (ontstaan van cirrose en/of hepatocellulair carcinoom = HCC) redelijk voorspeld kan worden door het bepalen van de virale lading bij deze pati\u00ebnten.", [["HCC", "ANATOMY", 185, 188], ["hepatitis B", "DISEASE", 67, 78], ["HCC", "DISEASE", 185, 188], ["B wat agressiever ver-loopt en bovendien het beloop (ontstaan van cirrose en/of hepatocellulair carcinoom = HCC)", "SPECIES", 77, 189], ["Hbe", "TEST", 39, 42], ["Ag", "TEST", 43, 45], ["hepatitis", "PROBLEM", 67, 76], ["ver-loopt en bovendien het beloop (ontstaan van cirrose en/of hepatocellulair carcinoom", "TREATMENT", 95, 182], ["HCC", "PROBLEM", 185, 188]]], ["Ook zwangeren moeten worden doorverwezen, omdat ook bij hen de virale lading voorspelt of de moeder antivirale behandeling behoeft, naast vaccinatie van de baby en het toedienen van antistoffen tegen HBsAg aan de pasgeborene.Ter voorkoming van besmetting van anderen geeft de huisarts de volgende adviezen.Pati\u00ebnten met hepatitis-B Bespreek de besmettelijkheid van bloed en lichaamsvloeistoffen bij hepatitis-B en hoe overdracht naar anderen te vermijden.", [["HBs", "DISEASE", 200, 203], ["Ag aan", "CHEMICAL", 203, 209], ["pasgeborene", "CHEMICAL", 213, 224], ["hepatitis", "DISEASE", 320, 329], ["hepatitis", "DISEASE", 399, 408], ["Ag", "CHEMICAL", 203, 205], ["pasgeborene", "CHEMICAL", 213, 224], ["pasgeborene", "SIMPLE_CHEMICAL", 213, 224], ["Ag", "PROTEIN", 203, 205], ["hen", "SPECIES", 56, 59], ["naast vaccinatie van de baby en het toedienen van antistoffen tegen HBs", "SPECIES", 132, 203], ["hepatitis", "PROBLEM", 320, 329], ["hepatitis", "PROBLEM", 399, 408], ["hepatitis", "OBSERVATION", 320, 329], ["hepatitis", "OBSERVATION", 399, 408]]], ["Ontraad pati\u00ebnten met hepatitis-B onveilige seksuele contacten en motiveer ze om met hun contacten te bespreken dat deze zich laten vaccineren (zie NHG-Standaard Het SOA-consult).", [["hepatitis", "DISEASE", 22, 31], ["hepatitis", "PROBLEM", 22, 31], ["hepatitis", "OBSERVATION", 22, 31]]], ["Geef adviezen ter voorkoming van contact met bloed van ge\u00efnfecteerden.Ter voorkoming van besmetting van anderen geeft de huisarts de volgende adviezen.Pati\u00ebnten met hepatitis-C Bespreek de besmettelijkheid van bloed bij hepatitis-C, en hoe overdracht naar anderen te vermijden.", [["hepatitis", "DISEASE", 165, 174], ["hepatitis", "DISEASE", 220, 229], ["hepatitis", "PROBLEM", 165, 174], ["hepatitis", "OBSERVATION", 165, 174]]], ["De kans op overdracht van hepatitis-C bij seksueel contact is klein, behalve bij homoseksuele mannen die met hiv zijn ge\u00efnfecteerd en seksuele risicocontacten hebben waarbij verwonding optreedt.", [["hepatitis", "DISEASE", 26, 35]]], ["Daarnaast moet de pati\u00ebnt opletten bij huidlaesies zoals wondjes, open eczeem en impetigo.", [["impetigo", "DISEASE", 81, 89]]], ["Dit geldt vooral indien de ge\u00efnfecteerde werkt in de gezondheidszorg en daar risicovolle handelingen verricht.Ter voorkoming van besmetting van anderen geeft de huisarts de volgende adviezen.Personen uit de directe omgeving van een pati\u00ebnt met hepatitis-C Geef adviezen gericht op het voorkomen van contact met bloed van de pati\u00ebnt.Ter voorkoming van besmetting van anderen geeft de huisarts de volgende adviezen.In aansluiting op de gegeven mondelinge voor-TherapieHepatitis-B De effectiviteit van antivirale therapie bij chronisch ge\u00efnfecteerden is uitsluitend aangetoond voor HbSAg-postieve en HBeAg-negatieve pati\u00ebnten met een hoog gehalte HBV-DNA (> 2,0 \u00d7 10 4 IU/ml bij Hbe-Ag-positieve-en > 2,0 \u00d7 10 3 IU/ml bij HbeAg-negatieve pati\u00ebnten) en verhoogde serumtransaminasewaarden.", [["hepatitis", "DISEASE", 244, 253], ["HBeAg", "CHEMICAL", 597, 602], ["Hbe-Ag", "CHEMICAL", 676, 682], ["Ag", "CHEMICAL", 680, 682], ["DNA", "CELLULAR_COMPONENT", 648, 651], ["Ag", "PROTEIN", 680, 682], ["hepatitis", "PROBLEM", 244, 253], ["HbSAg", "TEST", 579, 584], ["HBeAg", "TEST", 597, 602], ["HBV", "TEST", 644, 647], ["DNA", "TEST", 648, 651], ["bij", "TEST", 672, 675], ["Hbe", "TEST", 676, 679], ["Ag", "TEST", 680, 682], ["positieve", "TEST", 683, 692], ["bij", "TEST", 715, 718], ["HbeAg", "TEST", 719, 724], ["hepatitis", "OBSERVATION", 244, 253]]], ["Een samenvatting van de indicaties voor de verschillende middelen bij de verschillende pati\u00ebntengroepen staat beschreven in hoofdstuk 25 Antimicrobi\u00eble therapie.", [["Antimicrobi\u00eble therapie", "TREATMENT", 137, 160]]], ["Bij HBeAgpositieve pati\u00ebnten is HBeAg-seroconversie en het ondetecteerbaar worden van het virus het na te streven effect.", [["HBeAg", "CHEMICAL", 32, 37], ["na", "CHEMICAL", 100, 102], ["HBeAg", "GENE_OR_GENE_PRODUCT", 32, 37], ["HBeAg", "TEST", 32, 37]]], ["Het ultieme doel van de behandeling is HBsAgklaring of HBsAg-seroconversie, omdat dit leidt tot betere overlevingskansen en reductie van het optreden van HCC.", [["HCC", "ANATOMY", 154, 157], ["HBsAgklaring of HBsAg-seroconversie", "CHEMICAL", 39, 74], ["HCC", "DISEASE", 154, 157], ["optreden van HCC", "CANCER", 141, 157], ["HBsAg", "TEST", 55, 60]]], ["Omdat dit doel echter zelden wordt bereikt, zijn er ook andere maten om de effectiviteit van behandeling aan af te meten: normalisering van de transaminasen, daling van HBV-DNA tot < 400 IU/ml en negatief worden van het HBeAg (indien aanwezig); HBeAg-seroconversie met ontwikkeling van anti-HBe en histologische afname van de ontsteking zonder verdere toename van de leverfibrose.TherapieTot voor kort was de eerste keuze behandeling peginterferon (bij pati\u00ebnten met serotype A), omdat de kans op blijvende remissie na staken van de behandeling groter is dan bij gebruik van de (oude) virusremmers als lamivudine.", [["HBeAg", "CHEMICAL", 220, 225], ["HBeAg", "CHEMICAL", 245, 250], ["peginterferon", "CHEMICAL", 434, 447], ["na", "CHEMICAL", 516, 518], ["lamivudine", "CHEMICAL", 602, 612], ["lamivudine", "CHEMICAL", 602, 612], ["lamivudine", "SIMPLE_CHEMICAL", 602, 612], ["zijn er ook andere maten om de effectiviteit van behandeling aan af te meten: normalisering van de transaminasen, daling van HBV-DNA tot < 400 IU/ml en negatief worden van het HBeAg (indien aanwezig", "SPECIES", 44, 242], ["van het HBeAg", "TEST", 212, 225], ["HBeAg", "TEST", 245, 250], ["peginterferon", "TREATMENT", 434, 447], ["lamivudine", "TREATMENT", 602, 612]]], ["Circa 35% van de HBeAg-positieven en circa 25% van de HBeAg-negatieven heeft blijvende remissie na \u00e9\u00e9n jaar behandeling met peginterferon.", [["HBeAg", "CHEMICAL", 17, 22], ["HBeAg", "CHEMICAL", 54, 59], ["na", "CHEMICAL", 96, 98], ["peginterferon", "CHEMICAL", 124, 137], ["peginterferon", "CHEMICAL", 124, 137], ["Circa", "TEST", 0, 5], ["HBeAg", "TEST", 17, 22], ["HBeAg", "TEST", 54, 59], ["peginterferon", "TREATMENT", 124, 137]]], ["Bijwerkingen van peginterferon zijn griepverschijnselen en stemmingsveranderingen, zoals prikkelbaarheid en depressie.", [["Bijwerkingen van peginterferon zijn griepverschijnselen en stemmingsveranderingen", "TREATMENT", 0, 81]]], ["Daarnaast komen trombocytopenie en neutropenie veel voor.", [["Daarnaast", "TREATMENT", 0, 9]]], ["Deze nucleoside-en nucleotideanalogen als lamivudine, telbivudine, tenofovir en entecavir werden vroeger vooral gegeven aan pati\u00ebnten die niet responderen op een behandeling met peginterferon of de behandeling niet verdragen.", [["Deze nucleoside-en nucleotideanalogen", "CHEMICAL", 0, 37], ["lamivudine", "CHEMICAL", 42, 52], ["telbivudine", "CHEMICAL", 54, 65], ["tenofovir", "CHEMICAL", 67, 76], ["entecavir", "CHEMICAL", 80, 89], ["peginterferon", "CHEMICAL", 178, 191], ["nucleoside", "CHEMICAL", 5, 15], ["lamivudine", "CHEMICAL", 42, 52], ["telbivudine", "CHEMICAL", 54, 65], ["tenofovir", "CHEMICAL", 67, 76], ["Deze nucleoside", "SIMPLE_CHEMICAL", 0, 15], ["lamivudine", "SIMPLE_CHEMICAL", 42, 52], ["telbivudine", "SIMPLE_CHEMICAL", 54, 65], ["tenofovir", "SIMPLE_CHEMICAL", 67, 76], ["Deze nucleoside", "TREATMENT", 0, 15], ["en nucleotideanalogen als lamivudine", "TREATMENT", 16, 52], ["telbivudine", "TREATMENT", 54, 65], ["tenofovir", "TREATMENT", 67, 76], ["entecavir", "TREATMENT", 80, 89], ["peginterferon", "TREATMENT", 178, 191]]], ["Resistentie treedt op bij meer dan 70% van de pati\u00ebnten na vijf jaar behandeling met lamivudine, maar de nieuwere behandelingsopties geven een veel lagere kans op antivirale resistentie.", [["lamivudine", "CHEMICAL", 85, 95], ["lamivudine", "TREATMENT", 85, 95]]], ["Na 7 jaar behandeling met entecavir heeft meer dan 90% van de pati\u00ebnten een HBV-DNA-concentratie < 400 kopie\u00ebn/ml en slechts 0,8% ontwikkelt antivirale resistentie.TherapieBij zwangeren met chronische actieve hepatitis B, blijkend uit een zeer hoog HBV-DNA (> 1,0 \u00d7 10 9 kopie\u00ebn/ml), kan behandeling met lamivudine de kans op het falen van vaccinatie bij de pasgeborene verminderen.", [["Na", "CHEMICAL", 0, 2], ["entecavir", "CHEMICAL", 26, 35], ["hepatitis B", "DISEASE", 209, 220], ["lamivudine", "CHEMICAL", 304, 314], ["Na", "CHEMICAL", 0, 2], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["Na", "TEST", 0, 2], ["entecavir", "TREATMENT", 26, 35], ["een HBV", "TEST", 72, 79], ["DNA", "TEST", 80, 83], ["concentratie", "TEST", 84, 96], ["hepatitis B", "PROBLEM", 209, 220], ["lamivudine", "TREATMENT", 304, 314]]], ["Dit is van belang omdat de bescherming van de pasgeborene door respectievelijk passieve immunisatie en vaccinatie niet 100% is.", [["respectievelijk passieve immunisatie en vaccinatie niet", "TREATMENT", 63, 118]]], ["Behandeling wordt in dit geval gegeven vanaf week 32 tot aan de bevalling.TherapieHepatitis-C De belangrijkste indicatie voor behandeling is progressieve leverziekte, gekenmerkt door aanwezigheid van significante leverfibrose (ten minste porto-portale fibrose).", [["TherapieHepatitis", "TEST", 74, 91]]], ["De behandelingsmogelijkheden bestaan uit een combinatie van peginterferon-alfa en ribavirine (zie hoofdstuk 25 Antimicrobi\u00eble therapie).", [["peginterferon-alfa en ribavirine", "CHEMICAL", 60, 92], ["ribavirine", "SIMPLE_CHEMICAL", 82, 92], ["De behandelingsmogelijkheden bestaan uit een combinatie van peginterferon-alfa en ribavirine (zie hoofdstuk 25 Antimicrobi\u00eble therapie", "SPECIES", 0, 134], ["van peginterferon", "TREATMENT", 56, 73], ["alfa en ribavirine", "TREATMENT", 74, 92], ["zie hoofdstuk 25 Antimicrobi\u00eble therapie", "TREATMENT", 94, 134]]], ["Ook hier hangt het succes van de behandeling af van de leeftijd van de pati\u00ebnt, de mate van leverschade, het genotype van het virus, de snelheid van response op vier weken (RVR), de keuze/combinatie van de middelen, de bijwerkingen (therapietrouw) en eventuele co-infectie met hepatitis-B-virus of HIV.", [["hepatitis-B", "DISEASE", 277, 288], ["HIV", "DISEASE", 298, 301], ["hepatitis-B-virus", "ORGANISM", 277, 294], ["HIV", "ORGANISM", 298, 301], ["Ook hier hangt het succes van de behandeling af van de leeftijd van de pati\u00ebnt, de mate van leverschade, het genotype van het virus, de snelheid van response op vier weken (RVR), de keuze/combinatie van de middelen", "SPECIES", 0, 214], ["hepatitis", "PROBLEM", 277, 286], ["HIV", "PROBLEM", 298, 301], ["hepatitis", "OBSERVATION", 277, 286]]], ["Combinatietherapie van peginterferon en ribavirine is succesvoller dan peginterferon als monotherapie; combinatietherapie is daarom nu de standaardbehandeling.", [["Combinatietherapie van peginterferon en ribavirine", "CHEMICAL", 0, 50], ["succesvoller dan peginterferon als monotherapie", "CHEMICAL", 54, 101], ["combinatietherapie", "CHEMICAL", 103, 121], ["Combinatietherapie van peginterferon en ribavirine", "TREATMENT", 0, 50], ["peginterferon als monotherapie", "TREATMENT", 71, 101]]], ["Bij pati\u00ebnten met een chronische hepatitis-C-infectie veroorzaakt door virusgenotype 1 is na 48 weken combinatietherapie met peginterferon-alfa-2b en ribavirine het virus bij 42-46% blijvend verdwenen.", [["hepatitis", "DISEASE", 33, 42], ["na", "CHEMICAL", 90, 92], ["peginterferon-alfa-2b", "CHEMICAL", 125, 146], ["een chronische hepatitis-C-infectie", "ORGANISM", 18, 53], ["peginterferon-alfa-2b", "SIMPLE_CHEMICAL", 125, 146], ["ribavirine het virus", "ORGANISM", 150, 170], ["C-infectie", "SPECIES", 43, 53], ["een chronische hepatitis", "PROBLEM", 18, 42], ["infectie", "PROBLEM", 45, 53], ["na", "TEST", 90, 92], ["combinatietherapie", "TEST", 102, 120], ["peginterferon", "TREATMENT", 125, 138], ["alfa", "TREATMENT", 139, 143], ["2b en ribavirine het virus bij", "TREATMENT", 144, 174]]], ["Bij pati\u00ebnten met virusgenotype 2 of 3 wordt klaring van het virus in bijna 80% van de gevallen al bereikt na 24 weken combinatietherapie.", [["na", "CHEMICAL", 107, 109]]], ["Ook bij kinderen zijn de behandelingsmogelijkheden in gunstige zin aan het veranderen.TherapieBehandeling tijdens zwangerschap is wegens teratogeniteit niet mogelijk.TherapieBehandeling van een acute hepatitis-C-infectie is in 90-100% van de gevallen effectief en daarom moeten deze pati\u00ebnten onmiddellijk worden verwezen.Sepsis en septische shockSepsis is een systemische ziekte veroorzaakt door micro-organismen (meestal bacteri\u00ebn) of bacteri\u00eble toxines die in het bloed terechtgekomen zijn.", [["hepatitis-C-infectie", "DISEASE", 200, 220], ["Sepsis", "DISEASE", 322, 328], ["acute hepatitis", "PROBLEM", 194, 209], ["infectie", "PROBLEM", 212, 220], ["Sepsis en septische shockSepsis", "PROBLEM", 322, 353], ["bacteri\u00eble toxines die", "PROBLEM", 437, 459], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["hepatitis", "OBSERVATION", 200, 209]]], ["Severe sepsis wordt gedefinieerd als sepsis met tekenen van orgaandisfunctie.", [["sepsis", "DISEASE", 7, 13], ["sepsis", "DISEASE", 37, 43], ["Severe sepsis", "PROBLEM", 0, 13], ["als sepsis", "PROBLEM", 33, 43], ["sepsis", "OBSERVATION", 7, 13]]], ["Men spreekt van septische shock wanneer hypotensie persisteert ondanks adequate volumeresuscitatie.Sepsis en septische shockMet een incidentie van circa 3 per 1.000 personen per jaar en een mortaliteit van ongeveer 40 per 100.000 personen per jaar, is sepsis een ernstig ziektebeeld.", [["Sepsis", "DISEASE", 99, 105], ["shock", "DISEASE", 119, 124], ["sepsis", "DISEASE", 252, 258], ["Men", "SPECIES", 0, 3], ["hypotensie", "PROBLEM", 40, 50], ["Sepsis en septische shock", "PROBLEM", 99, 124], ["sepsis", "PROBLEM", 252, 258], ["septische shock", "OBSERVATION", 109, 124], ["sepsis", "OBSERVATION", 252, 258]]], ["Sepsis komt voor op alle leeftijden.Sepsis en septische shockSepsis ontstaat wanneer natuurlijke barri\u00e8res in het lichaam door micro-organismen worden doorbroken.", [["Sepsis", "DISEASE", 0, 6], ["Sepsis", "DISEASE", 36, 42], ["Sepsis", "PROBLEM", 0, 6], ["Sepsis", "PROBLEM", 36, 42]]], ["Voorbeelden zijn de huid, de mucosa van het gastro-intestinale systeem, de urinewegen of de luchtwegen.", [["mucosa", "ANATOMY", 29, 35]]], ["Indien deze barri\u00e8res door medisch handelen al zijn beschadigd (urinekatheter, intraveneus infuus), is de kans op het ontstaan van sepsis uiteraard groter.Sepsis en septische shockVervolgens vindt een cascade van inflammatoire processen plaats, waarbij ontstekingmedi\u00ebrende cellen en eiwitten in het bloed vrijkomen.", [["sepsis", "DISEASE", 131, 137], ["Sepsis", "DISEASE", 155, 161], ["intraveneus infuus", "SPECIES", 79, 97], ["Sepsis", "PROBLEM", 155, 161], ["en septische shock", "TREATMENT", 162, 180], ["een cascade", "TREATMENT", 197, 208]]], ["Dit leidt ten slotte tot de klinische symptomen van sepsis.Sepsis en septische shockEen aangeboren of verworven immuundefici\u00ebntie kan predisponeren tot het ontstaan van sepsis.", [["sepsis", "DISEASE", 52, 58], ["Sepsis", "DISEASE", 59, 65], ["sepsis", "DISEASE", 169, 175], ["van sepsis", "PROBLEM", 48, 58], ["Sepsis", "PROBLEM", 59, 65], ["sepsis", "PROBLEM", 169, 175]]], ["Een bekend voorbeeld is sepsis op basis van gekapselde bacteri\u00ebn, die snel en fulminant kan verlopen bij mensen zonder (functionele) milt.Sepsis en septische shockDe klinische presentatie loopt uiteen van zeer mild met nauwelijks symptomen (vooral bij jonge kinderen), tot ernstig ziek met zelfs comateuze toestanden.", [["sepsis", "DISEASE", 24, 30], ["fulminant", "DISEASE", 78, 87], ["Sepsis", "DISEASE", 138, 144], ["sepsis", "PROBLEM", 24, 30], ["Sepsis", "PROBLEM", 138, 144], ["mild met nauwelijks symptomen", "PROBLEM", 210, 239], ["sepsis", "OBSERVATION", 24, 30]]], ["De symptomen zijn zeer uiteenlopend en onder andere afhankelijk van de oorsprong van de sepsis.", [["sepsis", "DISEASE", 88, 94], ["sepsis", "PROBLEM", 88, 94], ["sepsis", "OBSERVATION", 88, 94]]], ["Lokaliserende klachten kunnen een aanwijzing geven voor het focus van de sepsis.", [["sepsis", "DISEASE", 73, 79], ["Lokaliserende klachten kunnen een", "TREATMENT", 0, 33], ["sepsis", "PROBLEM", 73, 79], ["sepsis", "OBSERVATION", 73, 79]]], ["Dit kan zich uiten in soms subtiele verschijnselen als verminderde diurese, verwardheid of een versnelde ademhaling.DiagnoseMen stelt de diagnose sepsis indien er een infectieus focus is met daarnaast 2 of meer SIRS-criteria.", [["sepsis", "DISEASE", 146, 152], ["SIRS", "DISEASE", 211, 215], ["sepsis", "PROBLEM", 146, 152], ["sepsis", "OBSERVATION", 146, 152]]], ["Dit zijn de zogenoemde 'Systemic Inflammatory Response Syndrome'-criteria, die uiting zijn van een gegeneraliseerde ontstekingsreactie.", [["Syndrome'-", "DISEASE", 55, 65], ["Dit zijn de zogenoemde", "TREATMENT", 0, 22]]], ["De SIRS-criteria zijn lichaamstemperatuur < 36 of > 38\u00b0Celsius, ademhalingsfrequentie > 20 per minuut, hartslag > 90 per minuut en leukocyten in het perifere bloed < 4.000/ml of > 12.000/ml.DiagnoseEr is geen unieke marker in het bloed om sepsis aan te tonen of uit te sluiten; wel vindt men frequent afwijkende laboratoriumwaarden die op een sepsis kunnen wijzen: leukocytose of leukopenie, stollingsstoornissen en trombopenie, hypoxemie en een verhoging van het CRP of lactaat.", [["SIRS", "DISEASE", 3, 7], ["sepsis", "DISEASE", 239, 245], ["sepsis", "DISEASE", 343, 349], ["CRP", "PROTEIN", 464, 467], ["men", "SPECIES", 288, 291], ["De SIRS", "TEST", 0, 7], ["zijn lichaamstemperatuur", "TEST", 17, 41], ["Celsius", "TEST", 55, 62], ["ademhalingsfrequentie", "TEST", 64, 85], ["hartslag", "TEST", 103, 111], ["sepsis", "PROBLEM", 239, 245], ["frequent afwijkende laboratoriumwaarden", "PROBLEM", 292, 331], ["leukopenie", "PROBLEM", 380, 390], ["hypoxemie", "PROBLEM", 429, 438], ["lactaat", "TEST", 471, 478], ["sepsis", "OBSERVATION", 239, 245]]], ["Afhankelijk van de anamnese en het lichamelijk onderzoek, zal men diagnostiek verrichten gericht op de mogelijke oorzaak van de sepsis (X-thorax, urinesediment, beeldvorming van de buik etc.).DiagnoseVan groot belang zijn goede kweken, af te nemen alvorens antibiotische behandeling gestart wordt (zie hoofdstuk 25 Antimicrobi\u00eble therapie).", [["sepsis", "DISEASE", 128, 134], ["men", "SPECIES", 62, 65], ["sepsis", "PROBLEM", 128, 134], ["DiagnoseVan", "TREATMENT", 192, 203], ["sepsis", "OBSERVATION", 128, 134], ["thorax", "ANATOMY", 138, 144]]], ["Bloedkweken bevestigen het klinische vermoeden, maar leveren meestal op zijn vroegst na 24 uur een verwekker op.", [["Bloedkweken bevestigen het klinische vermoeden, maar leveren meestal op zijn vroegst na 24 uur een verwekker op", "SPECIES", 0, 111], ["Bloedkweken", "TEST", 0, 11], ["maar", "TEST", 48, 52]]], ["Tot die tijd zal men empirisch een antibiotische behandeling moeten starten.TherapieGezien de ernst van het ziektebeeld, geldt voor alle behandelprincipes: hoe sneller, hoe beter.", [["men", "SPECIES", 17, 20]]], ["Bij hemodynamische instabiliteit of respiratoire insuffici\u00ebntie zal een pati\u00ebnt op een IC-afdeling moeten worden behandeld.", [["respiratoire insuffici\u00ebntie", "TREATMENT", 36, 63]]], ["Hier is men beter in staat de vitale parameters frequent te controleren en direct naar bevinden te handelen.TherapieAntibiotische therapie is de hoeksteen van de behandeling.", [["men", "ORGANISM", 8, 11], ["men", "SPECIES", 8, 11], ["frequent te controleren en direct naar bevinden te handelen", "TREATMENT", 48, 107]]], ["Hierbij wordt uiteraard rekening gehouden met het meest waarschijnlijke focus van de sepsis.", [["sepsis", "DISEASE", 85, 91], ["sepsis", "PROBLEM", 85, 91], ["sepsis", "OBSERVATION", 85, 91]]], ["Zie hiervoor hoofdstuk 25 Antimicrobi\u00eble therapie.TherapieIndien de huisarts fulminante meningokokkensepsis of postsplenectomiesepsis vermoedt, wordt aanbevolen reeds thuis met parenterale therapie (bijv. cefuroxim 750 mg i.v. of i.m.) te beginnen en de pati\u00ebnt zo snel mogelijk naar het ziekenhuis te laten transporteren.TherapieMen streeft vervolgens naar een agressief volumeherstel, zeker indien de pati\u00ebnt in shock verkeert.", [["shock verkeert", "DISEASE", 414, 428], ["Zie hiervoor hoofdstuk", "TREATMENT", 0, 22], ["Antimicrobi\u00eble therapie", "TREATMENT", 26, 49], ["cefuroxim", "TREATMENT", 205, 214], ["shock verkeert", "OBSERVATION", 414, 428]]], ["Hierbij streeft men naar een gemiddelde bloeddruk hoger dan 65 mmHg en een diurese boven de 30 ml/uur.", [["men", "SPECIES", 16, 19]]], ["De voorkeur gaat uit naar intraveneuze toediening van vocht, liefst kristallo\u00efden (NaCl 0,9%) of een collo\u00efde oplossing.", [["NaCl", "CHEMICAL", 83, 87], ["NaCl", "CHEMICAL", 83, 87], ["NaCl", "TREATMENT", 83, 87], ["een collo\u00efde oplossing", "TREATMENT", 97, 119]]], ["Indien met voldoende vocht toedienen de bloeddruk onvoldoende op peil kan worden gehouden, zal men inotropica toedienen.TherapieVerder is een goede saturatie van groot belang, waarbij in ieder geval wordt gestreefd naar een saturatie boven de 90%, gemeten aan de vinger.", [["men", "SPECIES", 95, 98]]], ["Dan besluit men tot intubatie en mechanische ventilatie.TherapieIn zeldzame gevallen (bij pati\u00ebnten met een moeilijk controleerbare septische shock of een bacteri\u00eble meningitis) zal men intraveneus corticostero\u00efden toedienen.", [["meningitis", "DISEASE", 166, 176], ["men", "SPECIES", 12, 15], ["men", "SPECIES", 182, 185], ["en mechanische ventilatie", "TREATMENT", 30, 55], ["TherapieIn zeldzame", "TREATMENT", 56, 75], ["een moeilijk controleerbare septische shock", "TREATMENT", 104, 147], ["een bacteri\u00eble meningitis", "TREATMENT", 151, 176]]], ["Het rationale is een relatieve bijnierschorsinsuffici\u00ebntie gedurende de acute fase van de sepsis en het voorkomen van neurologische complicaties bij bacteri\u00eble meningitis.TherapieVoor andere ondersteunende maatregelen wordt verwezen naar hoofdstuk 19 Spoedeisende geneeskunde.PreventieDeze richt zich op specifieke verwekkers (o.a. vaccinatie tegen pneumokokken, groep-Cmeningokokken en Haemophilus influenzae type b).Toxic shock syndroomToxic shock syndroom (TSS) is een ernstig, maar relatief zeldzaam ziektebeeld dat wordt veroorzaakt door toxines van Staphylococcus aureus (S-TSS) of groep-A-streptokokken (GAS-TSS).", [["sepsis", "DISEASE", 90, 96], ["meningitis", "DISEASE", 160, 170], ["shock syndroomToxic shock syndroom", "DISEASE", 424, 458], ["Haemophilus influenzae type b", "GENE_OR_GENE_PRODUCT", 387, 416], ["GAS", "DNA", 611, 614], ["TSS", "DNA", 615, 618], ["Haemophilus influenzae", "SPECIES", 387, 409], ["Staphylococcus aureus", "SPECIES", 555, 576], ["PreventieDeze richt zich op specifieke verwekkers", "SPECIES", 276, 325], ["Haemophilus influenzae", "SPECIES", 387, 409], ["Staphylococcus aureus", "SPECIES", 555, 576], ["sepsis", "PROBLEM", 90, 96], ["bij bacteri\u00eble meningitis", "PROBLEM", 145, 170], ["PreventieDeze", "TREATMENT", 276, 289], ["vaccinatie tegen pneumokokken", "TREATMENT", 332, 361], ["Toxic shock syndroomToxic shock syndroom", "PROBLEM", 418, 458], ["van Staphylococcus aureus", "TEST", 551, 576], ["groep", "TEST", 588, 593], ["bacteri\u00eble meningitis", "OBSERVATION", 149, 170], ["shock", "OBSERVATION_MODIFIER", 424, 429], ["syndroomToxic shock", "OBSERVATION", 430, 449]]], ["GAS-TSS komt echter op alle leeftijden en bij beide geslachten ongeveer evenveel voor.", [["GAS", "DNA", 0, 3], ["GAS", "TEST", 0, 3], ["TSS", "TEST", 4, 7]]], ["Beide ziektebeelden treffen meestal tevoren gezonde individuen.", [["Beide ziektebeelden", "TREATMENT", 0, 19]]], ["Toch zijn er los van het tampongebruik (speciale niet meer in Nederland verkrijgbare) enkele risicogroepen aan te wijzen.", [["Toch zijn er los van het tampongebruik (speciale niet meer in Nederland verkrijgbare) enkele risicogroepen aan te wijzen", "SPECIES", 0, 120]]], ["Vooral een voorafgaand huiddefect (trauma, operatie, brandwond) of een banale virusinfectie predisponeren tot het ontstaan van TSS.", [["trauma", "DISEASE", 35, 41], ["virusinfectie predisponeren", "SPECIES", 78, 105]]], ["De mortaliteit is circa 5% bij S-TSS versus meer dan 30% bij GAS-TSS.Toxic shock syndroomToxines spelen een belangrijke pathogenetische rol bij het ontstaan van TSS.", [["TSS", "DNA", 33, 36], ["meer dan 30% bij GAS", "DNA", 44, 64], ["TSS", "DNA", 65, 68], ["circa", "TEST", 18, 23], ["Toxic shock syndroomToxines", "PROBLEM", 69, 96], ["shock syndroomToxines", "OBSERVATION", 75, 96]]], ["Grote hoeveelheden cytokines zorgen vervolgens voor de klinische symptomen, via capillaire lekkage en directe weefselschade.Toxic shock syndroomBeide ziektebeelden presenteren zich acuut.", [["cytokines", "PROTEIN", 19, 28], ["Toxic shock syndroomBeide", "PROBLEM", 124, 149], ["shock syndroomBeide", "OBSERVATION", 130, 149]]], ["Hoge koorts en hypotensie staan op de voorgrond.Toxic shock syndroomBij GAS-TSS staat lokale, heftige pijn ter hoogte van huid of weke delen centraal.", [["shock", "DISEASE", 54, 59], ["Toxic shock syndroomBij GAS", "PROBLEM", 48, 75], ["TSS", "PROBLEM", 76, 79], ["shock", "OBSERVATION", 54, 59]]], ["Vaak zijn er ook andere lokale symptomen van ontsteking aanwezig, maar deze kunnen bij presentatie nog geheel afwezig zijn.Toxic shock syndroomBij S-TSS is er in het acute stadium vaak een diffuus exantheem.", [["shock", "DISEASE", 129, 134], ["TSS", "DNA", 149, 152], ["Toxic shock syndroomBij S", "PROBLEM", 123, 148], ["TSS", "PROBLEM", 149, 152], ["shock syndroomBij", "OBSERVATION", 129, 146], ["acute", "OBSERVATION_MODIFIER", 166, 171]]], ["Ook de handpalmen, voetzolen en mucosae van orofarynx en vagina kunnen aangedaan zijn.Toxic shock syndroomDaarnaast zijn er bij beide shocksyndromen vaak verschijnselen van aantasting van \u00e9\u00e9n of meerdere orgaansystemen: spierpijn, braken en diarree, conjunctivitis of faryngitis, hoofdpijn en verwardheid, of stoornissen in nier-en leverfuncties.", [["conjunctivitis", "DISEASE", 250, 264], ["voetzolen en mucosae van orofarynx", "TREATMENT", 19, 53], ["Toxic shock", "PROBLEM", 86, 97], ["spierpijn", "TREATMENT", 220, 229], ["conjunctivitis", "PROBLEM", 250, 264], ["faryngitis", "PROBLEM", 268, 278], ["vagina", "ANATOMY", 57, 63], ["shock", "OBSERVATION", 92, 97], ["conjunctivitis", "OBSERVATION", 250, 264]]], ["Onbehandeld leidt TSS meestal tot multipel orgaanfalen en overlijden op korte termijn.Diagnose en differentiaaldiagnose (zie tabel 8.3)Men moet altijd denken aan een TSS, wanneer een tevoren gezonde persoon zich met hoge koorts en hypotensie presenteert (tabel 8.3).", [["Men", "SPECIES", 135, 138], ["Diagnose en differentiaaldiagnose (zie tabel", "TREATMENT", 86, 130]]], ["Differentiaaldiagnostisch kan men hierbij uiteraard ook denken aan ernstige sepsis (bijvoorbeeld door meningokokken, waarbij eveneens huidafwijkingen kunnen ontstaan), necrotiserende fasciitis (vooral wanneer lokale pijn op de voorgrond staat zoals bij GAS-TSS), syndroom van Stevens-Johnson, M. Kawasaki (bij kinderen), een ernstige zonnesteek, leptospirose of een hemorragische koorts.Diagnose en differentiaaldiagnose (zie tabel 8.3)Bij GAS-TSS is de bloedkweek in circa 60% positief, bij S-TSS slechts bij 5%.", [["sepsis", "DISEASE", 76, 82], ["fasciitis", "DISEASE", 183, 192], ["Bij GAS", "DNA", 436, 443], ["TSS", "DNA", 444, 447], ["bij S", "DNA", 488, 493], ["TSS", "DNA", 494, 497], ["men", "SPECIES", 30, 33], ["necrotiserende fasciitis (vooral wanneer lokale pijn op de voorgrond staat zoals bij GAS-TSS)", "SPECIES", 168, 261], ["sepsis", "PROBLEM", 76, 82], ["necrotiserende fasciitis", "PROBLEM", 168, 192], ["een ernstige zonnesteek", "TREATMENT", 321, 344], ["Diagnose en differentiaaldiagnose (zie tabel", "TEST", 387, 431], ["Bij GAS", "TEST", 436, 443], ["bij S-TSS slechts bij", "TREATMENT", 488, 509], ["sepsis", "OBSERVATION", 76, 82], ["fasciitis", "OBSERVATION", 183, 192]]], ["Lokale wondkweken of kweken van vaginaal vocht kunnen de verwekker aantonen.TherapieDeze steunt op vier pijlers: chirurgische behandeling, antibiotica, agressieve ondersteunende therapie en intraveneuze immunoglobulines.TherapieBij verdenking op GAS-TSS zal direct een chirurgische exploratie van de wond moeten plaatsvinden, omdat anders necrotiserende fasciitis ontstaat en de pati\u00ebnt snel overlijdt.", [["antibiotica", "TREATMENT", 139, 150], ["TherapieBij", "TEST", 220, 231], ["verdenking op GAS", "TEST", 232, 249], ["fasciitis", "PROBLEM", 354, 363], ["fasciitis", "OBSERVATION", 354, 363]]], ["Bij S-TSS zo snel mogelijk tampon verwijderen.TherapieEmpirisch start men met clindamycine en een b\u00e8talactamantibioticum als ceftriaxon i.v.", [["men", "ORGANISM", 70, 73], ["men", "SPECIES", 70, 73], ["Bij S", "TREATMENT", 0, 5], ["TSS zo snel mogelijk tampon", "TREATMENT", 6, 33], ["TherapieEmpirisch", "TREATMENT", 46, 63], ["clindamycine en een b\u00e8talactamantibioticum als ceftriaxon", "TREATMENT", 78, 135]]], ["Clindamycine onderdrukt de bacteri\u00eble toxineproductie.", [["Clindamycine", "CHEMICAL", 0, 12], ["Clindamycine", "TREATMENT", 0, 12], ["bacteri\u00eble toxineproductie", "OBSERVATION", 27, 53]]], ["Bij groep-A-streptokok (GAS-)TSS vervangt men het breedspectrum b\u00e8talactamantibioticum door penicilline en bij door stafylokokken veroorzaakte TSS door flucloxacilline, zodra het antibiogram bekend is.", [["flucloxacilline", "CHEMICAL", 152, 167], ["men", "ORGANISM", 42, 45], ["men", "SPECIES", 42, 45], ["Bij", "TEST", 0, 3], ["GAS", "TEST", 24, 27], ["TSS", "PROBLEM", 29, 32], ["penicilline", "TREATMENT", 92, 103], ["flucloxacilline", "TREATMENT", 152, 167], ["zodra het antibiogram", "TREATMENT", 169, 190]]], ["Therapieduur in overleg, minimaal 14 dagen.TherapieMeestal worden pati\u00ebnten op de intensive care behandeld.", [["Therapieduur", "CHEMICAL", 0, 12]]], ["Vochttoediening is essentieel, vaak vele liters per dag.TherapieBij ernstige gevallen wordt intraveneus immunoglobulinetherapie aanbevolen.", [["TherapieBij", "TREATMENT", 56, 67]]], ["Hiermee worden de toxines onschadelijk gemaakt.TherapieBij invasieve GAS-infecties dienen de familieleden profylactisch antibiotica te ontvangen (zie www.rivm.nl).8.13Ziekenhuisinfecties Een ziekenhuisinfectie is een infectie die wordt opgelopen tijdens het verblijf in een ziekenhuis, als de pati\u00ebnt niet naar het ziekenhuis was gekomen, had hij de infectie niet gekregen.8.13Voor een deel van de infecties geldt dat deze te voorkomen zijn door het toepassen van hygi\u00ebnische maatregelen, echter niet alle infecties zijn te voorkomen.", [["TherapieBij", "TEST", 47, 58], ["GAS", "TEST", 69, 72], ["infecties", "PROBLEM", 73, 82], ["Ziekenhuisinfecties Een ziekenhuisinfectie", "TREATMENT", 167, 209]]], ["Indien, door onhygi\u00ebnisch handelen, een operatiepati\u00ebnt een postoperatieve wondinfectie ontwikkelt, dan is deze infectie te beschouwen als een ziekenhuisinfectie die voorkomen had kunnen worden.8.13Als een pati\u00ebnt, die al wekenlang op de intensive care verblijft, een urosepsis ontwikkeld met een verwekker die al eerder werd gevonden in zijn katheterurine, dan voldoet deze infectie ook aan de criteria van een ziekenhuisinfectie.", [["een urosepsis", "PROBLEM", 264, 277], ["urosepsis", "OBSERVATION", 268, 277]]], ["Het is echter bekend dat een urinekatheter binnen enkele dagen na inbrengen gekoloniseerd raakt met fecale en omgevingsflora; deze urosepsis was niet te voorkomen door het toepassen van goede hygi\u00ebnische maatregelen.8.13De verwekkers die een rol spelen bij ziekenhuisinfecties kunnen dezelfde zijn als die ook in de thuissituatie kunnen worden aangetroffen.", [["aangetroffen", "CHEMICAL", 344, 356], ["deze urosepsis", "PROBLEM", 126, 140], ["urosepsis", "OBSERVATION", 131, 140]]], ["Daarnaast kunnen ook verwekkers aangetroffen worden die resistent zijn voor verschillende antibiotica die in het ziekenhuis vaak worden voorgeschreven.", [["Daarnaast", "TREATMENT", 0, 9]]], ["Voorbeelden van resistente ziekenhuisbacteri\u00ebn zijn meticilline resistente Staphylococcus aureus (MRSA), vancomycine resistente Enterococcus faecium (VRE) en Extended Spectrum Beta-lactamase (ESBL) producerende gramnegatieve bacteri\u00ebn.", [["Staphylococcus aureus", "DISEASE", 75, 96], ["vancomycine resistente Enterococcus faecium", "CHEMICAL", 105, 148], ["resistente ziekenhuisbacteri\u00ebn zijn meticilline resistente Staphylococcus aureus", "ORGANISM", 16, 96], ["vancomycine resistente Enterococcus faecium", "ORGANISM", 105, 148], ["Extended Spectrum Beta-lactamase", "SIMPLE_CHEMICAL", 158, 190], ["producerende gramnegatieve bacteri\u00ebn", "ORGANISM", 198, 234], ["Staphylococcus aureus", "SPECIES", 75, 96], ["MRSA", "SPECIES", 98, 102], ["Enterococcus faecium", "SPECIES", 128, 148], ["producerende gramnegatieve", "SPECIES", 198, 224], ["Staphylococcus aureus", "SPECIES", 75, 96], ["Enterococcus faecium", "SPECIES", 128, 148], ["Staphylococcus aureus", "PROBLEM", 75, 96], ["MRSA", "PROBLEM", 98, 102], ["vancomycine", "TREATMENT", 105, 116], ["Enterococcus faecium", "PROBLEM", 128, 148], ["VRE", "PROBLEM", 150, 153], ["Spectrum Beta-lactamase", "TEST", 167, 190], ["(ESBL) producerende gramnegatieve bacteri\u00ebn", "PROBLEM", 191, 234], ["Staphylococcus aureus", "OBSERVATION", 75, 96]]], ["Bovendien kunnen ziekenhuisinfecties veroorzaakt worden door andere soorten verwekkers, die uitgeselecteerd worden in de ziekenhuisomgeving.", [["Bovendien", "TREATMENT", 0, 9]]], ["Voorbeelden van typisch uitgeselecteerde ziekenhuisbacteri\u00ebn zijn Pseudomonas aeruginosa, Acinetobacter baumannii en Stenotrophomonas maltophilia.8.13Sommige verwekkers beschikken over eigenschappen die ze bijzonder geschikt maakt om zich te kunnen verspreiden in een ziekenhuisomgeving.", [["Voorbeelden van typisch uitgeselecteerde ziekenhuisbacteri\u00ebn zijn Pseudomonas aeruginosa", "ORGANISM", 0, 88], ["Acinetobacter baumannii", "ORGANISM", 90, 113], ["Stenotrophomonas maltophilia", "ORGANISM", 117, 145], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["Acinetobacter baumannii", "SPECIES", 90, 113], ["Pseudomonas aeruginosa", "SPECIES", 66, 88], ["Acinetobacter baumannii", "SPECIES", 90, 113], ["Pseudomonas aeruginosa", "PROBLEM", 66, 88], ["Acinetobacter baumannii en Stenotrophomonas maltophilia", "PROBLEM", 90, 145]]], ["Een goed voorbeeld hiervan is Clostridium difficile.", [["Clostridium difficile", "DISEASE", 30, 51], ["Clostridium difficile", "ORGANISM", 30, 51], ["Clostridium difficile", "SPECIES", 30, 51], ["Clostridium difficile", "SPECIES", 30, 51], ["Clostridium difficile", "PROBLEM", 30, 51], ["Clostridium difficile", "OBSERVATION", 30, 51]]], ["Dragerschap of kolonisatie kan Het bevorderen van goede huishygi\u00ebne binnen het ziekenhuis is een van de kernactiviteiten van de afdeling Ziekenhuishygi\u00ebne en infectiepreventie.", [["kolonisatie kan", "TREATMENT", 15, 30]]], ["Ook worden isolatiemaatregelen geadviseerd wanneer duidelijk wordt dat een pati\u00ebnt gekoloniseerd is met een bijzonder resistente verwekker, waarvan het voork\u00f3men van verspreiding naar anderen in het ziekenhuis van belang is.Infecties met meticilline resistente S. aureus (MRSA)Meticilline resistente S. aureus is een Staphylococcus aureus die ongevoelig is voor de eerste keus antibiotica.", [["meticilline", "CHEMICAL", 238, 249], ["meticilline resistente S. aureus", "ORGANISM", 238, 270], ["Meticilline resistente S. aureus", "ORGANISM", 277, 309], ["een Staphylococcus aureus", "ORGANISM", 313, 338], ["S. aureus", "SPECIES", 261, 270], ["MRSA", "SPECIES", 272, 276], ["S. aureus", "SPECIES", 300, 309], ["Staphylococcus aureus", "SPECIES", 317, 338], ["eerste keus antibiotica", "SPECIES", 365, 388], ["S. aureus", "SPECIES", 261, 270], ["S. aureus", "SPECIES", 300, 309], ["Staphylococcus aureus die ongevoelig", "SPECIES", 317, 353], ["Infecties", "TEST", 224, 233], ["meticilline resistente S. aureus", "PROBLEM", 238, 270], ["MRSA", "PROBLEM", 272, 276], ["S. aureus", "PROBLEM", 300, 309], ["een Staphylococcus aureus die", "PROBLEM", 313, 342], ["aureus", "OBSERVATION_MODIFIER", 264, 270], ["MRSA", "OBSERVATION", 272, 276], ["aureus", "OBSERVATION", 303, 309], ["Staphylococcus aureus", "OBSERVATION", 317, 338]]], ["Meestal is er alleen sprake van dragerschap met MRSA, maar ook infectie kan voorkomen.", [["MRSA", "SPECIES", 48, 52], ["MRSA", "PROBLEM", 48, 52]]], ["Alle soorten infecties die geassocieerd zijn met S. aureus kunnen ook door MRSA veroorzaakt worden.Infecties met meticilline resistente S. aureus (MRSA)Panton-Valentine Leukocidine (PVL) is een S. aureus-specifiek exotoxine dat zowel door meticilline gevoelige als resistente S. aureus-stammen wordt geproduceerd als de betreffende twee genen (lukF-PV en lukS-PV) aanwezig zijn.", [["meticilline", "CHEMICAL", 113, 124], ["Panton-Valentine Leukocidine", "CHEMICAL", 152, 180], ["S. aureus", "ORGANISM", 49, 58], ["meticilline resistente S. aureus", "ORGANISM", 113, 145], ["S. aureus", "ORGANISM", 276, 285], ["S. aureus", "SPECIES", 49, 58], ["MRSA", "SPECIES", 75, 79], ["S. aureus", "SPECIES", 136, 145], ["MRSA", "SPECIES", 147, 151], ["S. aureus", "SPECIES", 194, 203], ["S. aureus", "SPECIES", 276, 285], ["S. aureus kunnen ook door MRSA veroorzaakt worden", "SPECIES", 49, 98], ["S. aureus", "SPECIES", 136, 145], ["S. aureus-stammen wordt geproduceerd als de betreffende twee genen (lukF-PV en lukS-PV", "SPECIES", 276, 362], ["Alle soorten infecties", "PROBLEM", 0, 22], ["MRSA veroorzaakt worden", "PROBLEM", 75, 98], ["Infecties", "TEST", 99, 108], ["meticilline resistente S. aureus", "PROBLEM", 113, 145], ["MRSA", "PROBLEM", 147, 151], ["Panton", "TEST", 152, 158], ["Valentine Leukocidine (PVL)", "TREATMENT", 159, 186], ["een S. aureus", "TEST", 190, 203], ["exotoxine", "TEST", 214, 223], ["meticilline gevoelige", "TREATMENT", 239, 260], ["S. aureus", "PROBLEM", 276, 285], ["aureus", "OBSERVATION_MODIFIER", 52, 58], ["aureus", "OBSERVATION", 139, 145], ["aureus", "OBSERVATION", 279, 285]]], ["De aanwezigheid van PVL-genen in S. aureus-stammen is geassocieerd met ernstige huidinfecties en necrotiserende pneumonie.DiagnoseDe aanwezigheid van MRSA kan worden aangetoond door het kweken van uitstrijkjes van de keel, neus en het perineum.", [["perineum", "ANATOMY", 235, 243], ["S. aureus-stammen", "ORGANISM", 33, 50], ["perineum", "ORGANISM_SUBDIVISION", 235, 243], ["S. aureus", "SPECIES", 33, 42], ["MRSA", "SPECIES", 150, 154], ["De aanwezigheid van PVL-genen", "SPECIES", 0, 29], ["S. aureus-stammen", "SPECIES", 33, 50], ["De aanwezigheid van PVL", "TEST", 0, 23], ["S. aureus", "PROBLEM", 33, 42], ["aureus", "OBSERVATION", 36, 42], ["perineum", "ANATOMY", 235, 243]]], ["De neus is de voorkeursplaats voor het dragerschap, maar daarnaast kan ook een wond, een insteekplaats van een infuus of ander lichaamsvreemd materiaal zoals een beademingstube MRSA bevatten.", [["MRSA", "SPECIES", 177, 181]]], ["Kweekstokken of bijvoorbeeld pus wordt op het medisch-microbiologisch laboratorium in een selectief vloeibaar medium ge\u00ebnt, dit om de hoogste opbrengst te behalen.", [["bijvoorbeeld pus", "PROBLEM", 16, 32], ["pus", "OBSERVATION", 29, 32]]], ["Deze test is uitstekend geschikt om in korte tijd (circa twee uur) en op betrouwbare wijze MRSA-dragerschap uit te sluiten; in dat geval kan de isolatie worden opgeheven.", [["MRSA", "SPECIES", 91, 95], ["Deze test", "TEST", 0, 9], ["MRSA", "PROBLEM", 91, 95], ["MRSA", "OBSERVATION", 91, 95]]], ["In sommige gevallen zal deze test MRSA-dragerschap niet kunnen uitsluiten; dan zullen de kweekresultaten afgewacht moeten worden.", [["MRSA", "SPECIES", 34, 38], ["MRSA", "PROBLEM", 34, 38]]], ["Het advies is om de test vooral aan te vragen bij klinische pati\u00ebnten, gezien de kostenbesparing voor de kliniek door het snel opheffen van de isolatie.PreventieIn Nederland is de prevalentie van MRSA dankzij het 'search and destroy' beleid nog steeds erg laag: < 1%.", [["MRSA", "SPECIES", 196, 200], ["erg laag", "TEST", 252, 260]]], ["Dit beleid wordt uitgevaardigd door de Werkgroep Infectie Preventie en houdt in dat pati\u00ebnten die een verhoogde kans hebben op MRSA-dragerschap bij opname in het ziekenhuis in isolatie worden verpleegd totdat dragerschap is uitgesloten.", [["MRSA", "SPECIES", 127, 131], ["MRSA", "PROBLEM", 127, 131]]], ["Ook bij polikliniekbezoek worden hygi\u00ebnische maatregelen geadviseerd.PreventieRisico op MRSA-dragerschap bestaat indien een pati\u00ebnt in de afgelopen 6 maanden opgenomen is geweest of behandeld is in een buitenlandse zorginstelling of indien het een uit het buitenland geadopteerd kind betreft met een medische voorgeschiedenis.PreventieSinds enige tijd is bekend dat personen die beroepsmatig contact hebben met levende varkens of vleeskalveren of personen die wonen op een varkens-of vleeskalverenhouderij ook een verhoogde kans hebben op MRSA-dragerschap; daarom is ook deze groep toegevoegd aan de categorie personen met verhoogde kans op dragerschap.Specialistische therapieIn Nederland wordt voor de behandeling van MRSA-dragerschap de SWAB-richtlijn (www.swab. nl) (Stichting werkgroep antibioticagebruik) gehanteerd.", [["MRSA", "SPECIES", 88, 92], ["MRSA", "SPECIES", 539, 543], ["MRSA", "SPECIES", 720, 724], ["MRSA", "PROBLEM", 88, 92], ["MRSA", "PROBLEM", 539, 543], ["MRSA", "OBSERVATION", 88, 92]]], ["Hierbij kan behandeling worden gestart zodra de risicofactoren voor langdurig dragerschap verdwenen zijn (wonden hersteld, infuus is eruit, huidafwijkingen, bijv. eczeem, zijn tot rust gekomen).", [["zijn tot rust gekomen", "SPECIES", 171, 192], ["eczeem", "TREATMENT", 163, 169]]], ["Ook onderkleding en beddengoed wordt dagelijks verschoond.Specialistische therapieAls deze behandeling niet effectief blijkt te zijn, wordt de kuur herhaald met toevoeging van twee orale antibiotica op geleide van het antibiogram, volgens het voorkeursschema van de SWAB.Infecties met vancomycine resistente enterokokken (VRE)Enterokokken zijn in principe weinig virulente bacteri\u00ebn, maar bij immuungecompromitteerde pati\u00ebnten kunnen enterokokken wel degelijk een klinische rol van betekenis spelen.", [["Infecties", "PROBLEM", 271, 280], ["vancomycine resistente enterokokken", "TREATMENT", 285, 320], ["VRE", "PROBLEM", 322, 325], ["Enterokokken zijn", "TREATMENT", 326, 343]]], ["Amoxicilline is het antibioticum van eerste keuze, maar aangezien resistentie voor dit middel in toenemende mate voorkomt, is vancomycine het 'laatste' redmiddel.", [["Amoxicilline", "CHEMICAL", 0, 12], ["Amoxicilline", "CHEMICAL", 0, 12], ["Amoxicilline", "SIMPLE_CHEMICAL", 0, 12], ["Amoxicilline", "TREATMENT", 0, 12], ["vancomycine", "TREATMENT", 126, 137]]], ["Om verspreiding binnen het ziekenhuis te voorkomen worden hygi\u00ebnische maatregelen geadviseerd.DiagnoseDragerschap met VRE kan worden aangetoond door een rectum-of feceskweek in te sturen, die specifiek gekweekt wordt in een bouillon.", [["rectum", "ANATOMY", 153, 159], ["rectum", "ORGAN", 153, 159], ["rectum", "ANATOMY", 153, 159]]], ["Indien er sprake is van een infectie met VRE, wordt deze in het klinische materiaal aangetoond.PreventieIn het ziekenhuis worden pati\u00ebnten die gekoloniseerd zijn met VRE met isolatiemaatregelen verpleegd om verspreiding te voorkomen.", [["VRE", "PROBLEM", 41, 44], ["VRE", "PROBLEM", 166, 169]]], ["Dragerschap van maanden tot jaren is in de literatuur beschreven.Specialistische therapieIndien er sprake is van een infectie die behandeling noodzakelijk maakt, is op geleide van het antibiogram, in overleg met de arts-microbioloog of internist-infectioloog behandeling vaak mogelijk.Infecties met multiresistente gramnegatieve staven (MR-GNS)In een ziekenhuisomgeving komt kolonisatie of infectie met gramnegatieve bacteri\u00ebn geregeld voor.", [["MR", "PROTEIN", 337, 339], ["Infecties", "TEST", 285, 294], ["MR", "TEST", 337, 339]]], ["Voor het opsporen van dragerschap met MR-GNS kan het afnemen van een rectumwat geadviseerd worden.PreventieAfhankelijk van de verwekker en het type resistentie kunnen hygi\u00ebnische maatregelen geadviseerd worden, zoals het dragen van schort en handschoenen bij direct contact met de pati\u00ebnt.Specialistische therapieOp geleide van het antibiogram kan passende antibiotische therapie geadviseerd worden bij een infectie.", [["MR", "PROTEIN", 38, 40], ["MR", "PROBLEM", 38, 40], ["Specialistische therapieOp geleide van het antibiogram kan passende antibiotische therapie", "TREATMENT", 289, 379], ["een infectie", "OBSERVATION", 403, 415]]], ["Een effectieve dragerschapbehandeling is nooit beschreven.Infecties met clostridium difficileClostridium difficile is een sporenvormende anaerobe grampositieve staafvormige bacterie die normaal voorkomt in de darm.", [["Clostridium difficile", "DISEASE", 93, 114], ["clostridium difficile", "ORGANISM", 72, 93], ["clostridium difficile", "SPECIES", 72, 93], ["Clostridium difficile", "SPECIES", 93, 114], ["clostridium difficile", "SPECIES", 72, 93], ["Clostridium difficile", "SPECIES", 93, 114], ["Infecties", "PROBLEM", 58, 67], ["clostridium difficile", "PROBLEM", 72, 93], ["Clostridium difficile", "PROBLEM", 93, 114], ["clostridium", "OBSERVATION_MODIFIER", 72, 83], ["difficile", "OBSERVATION", 84, 93], ["difficile", "OBSERVATION", 105, 114]]], ["Het gebruik van bepaalde antibiotica, zoals ciproxin of cefalosporine, is geassocieerd met het ontstaan van Clostridium-diarree, doordat de darmflora grotendeels onderdrukt wordt.DiagnoseHet aantonen van toxine is mogelijk in de feces, ook een bacteriologische kweek is mogelijk.PreventieGoede handenhygi\u00ebne is van essentieel belang.", [["zoals ciproxin of cefalosporine", "CHEMICAL", 38, 69], ["cefalosporine", "SIMPLE_CHEMICAL", 56, 69], ["feces", "ORGANISM_SUBSTANCE", 229, 234], ["cefalosporine", "TREATMENT", 56, 69]]], ["Het schoonmaken van de pati\u00ebntenkamer dient met chloor te gebeuren.Specialistische therapieTherapie met metronidazol is de eerste keuze, in hardnekkige gevallen kan vancomycine uitkomst bieden.Specialistische therapieOver het algemeen zijn deze pathogenen (behoudens C. difficile) onschuldig in de thuissituatie.", [["C. difficile", "SPECIES", 267, 279], ["Specialistische therapieTherapie", "TREATMENT", 67, 99], ["metronidazol", "TREATMENT", 104, 116], ["Specialistische therapieOver", "TREATMENT", 193, 221], ["C. difficile", "PROBLEM", 267, 279]]]], "6613e46fe371b6aa063ff2bc8adbdcc57ed63804": [["The variables A, \u03b1, B, \u03b2, C and \u03b3 are the intermediate variables calculated using patient parameters.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 17, 18], ["B", "GENE_OR_GENE_PRODUCT", 20, 21], ["\u03b2", "GENE_OR_GENE_PRODUCT", 23, 24], ["C", "GENE_OR_GENE_PRODUCT", 26, 27], ["\u03b3", "GENE_OR_GENE_PRODUCT", 32, 33], ["patient", "ORGANISM", 82, 89], ["\u03b1", "PROTEIN", 17, 18], ["B", "PROTEIN", 20, 21], ["\u03b2", "PROTEIN", 23, 24], ["C", "PROTEIN", 26, 27], ["\u03b3", "PROTEIN", 32, 33], ["patient", "SPECIES", 82, 89], ["The variables", "TEST", 0, 13], ["patient parameters", "TEST", 82, 100]]], ["The control parameters -propofol dose rate (D i ), time at which dose was given (t Di ), and total infusion time (T inf ) -can be changed by the clinician to adjust a patient's propofol concentration.", [["propofol", "CHEMICAL", 24, 32], ["propofol", "CHEMICAL", 177, 185], ["propofol", "CHEMICAL", 24, 32], ["propofol", "CHEMICAL", 177, 185], ["propofol", "SIMPLE_CHEMICAL", 24, 32], ["patient", "ORGANISM", 167, 174], ["propofol", "SIMPLE_CHEMICAL", 177, 185], ["patient", "SPECIES", 167, 174], ["propofol dose rate (D i )", "TREATMENT", 24, 49], ["total infusion time (T inf )", "TREATMENT", 93, 121], ["a patient's propofol concentration", "TREATMENT", 165, 199]]], ["This equation considers up to n changes in propofol dosage, indexed by i.", [["propofol", "CHEMICAL", 43, 51], ["propofol", "CHEMICAL", 43, 51], ["propofol", "SIMPLE_CHEMICAL", 43, 51], ["This equation", "TEST", 0, 13], ["propofol dosage", "TREATMENT", 43, 58]]], ["After infusion discontinuation, the residual concentration of propofol in a patient's blood can be estimated by a separate equation [2] :", [["blood", "ANATOMY", 86, 91], ["propofol", "CHEMICAL", 62, 70], ["propofol", "CHEMICAL", 62, 70], ["propofol", "SIMPLE_CHEMICAL", 62, 70], ["patient", "ORGANISM", 76, 83], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["patient", "SPECIES", 76, 83], ["infusion discontinuation", "TREATMENT", 6, 30], ["the residual concentration of propofol", "TREATMENT", 32, 70]]]], "bb811b1dbc06b152a694ab95099baf4ced91c8cb": [["Th1Th1 cells were fi rst described by Mossman et al. ( 1986 ) by their ability to express interferon-gamma (IFN-g ).", [["Th1Th1 cells", "ANATOMY", 0, 12], ["Th1Th1 cells", "CELL", 0, 12], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 90, 106], ["IFN-g", "GENE_OR_GENE_PRODUCT", 108, 113], ["Th1Th1 cells", "CELL_LINE", 0, 12], ["interferon-gamma", "PROTEIN", 90, 106], ["IFN", "PROTEIN", 108, 111], ["Th1 cells", "OBSERVATION", 3, 12], ["gamma", "ANATOMY", 101, 106]]], ["Th1 cell development requires the transcription factors T-bet (Szabo et al. 2000 ) and these cells can differentiate from na\u00efve T-cell precursors in the presence of Th1-polarizing cytokines such as IL-12p70 which is a heterodimeric cytokine consisting of IL-12p35 and IL-12p40 (Wolf et al. 1991 ) .", [["Th1 cell", "ANATOMY", 0, 8], ["cells", "ANATOMY", 93, 98], ["T-cell", "ANATOMY", 128, 134], ["Th1 cell", "CELL", 0, 8], ["T-bet", "GENE_OR_GENE_PRODUCT", 56, 61], ["cells", "CELL", 93, 98], ["T-cell precursors", "CELL", 128, 145], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 198, 206], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 255, 263], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 268, 276], ["transcription factors", "PROTEIN", 34, 55], ["T-bet", "PROTEIN", 56, 61], ["na\u00efve T-cell precursors", "CELL_TYPE", 122, 145], ["Th1-polarizing cytokines", "PROTEIN", 165, 189], ["IL-12p70", "PROTEIN", 198, 206], ["heterodimeric cytokine", "PROTEIN", 218, 240], ["IL", "PROTEIN", 255, 257], ["these cells", "TEST", 87, 98], ["Th1-polarizing cytokines", "TREATMENT", 165, 189], ["IL", "TEST", 198, 200], ["IL", "TEST", 255, 257], ["IL", "TREATMENT", 268, 270], ["cell precursors", "OBSERVATION", 130, 145]]], ["Th1 responses can also occur independent of IL-12 and type I interferons have been Signal 1 consists of activation through the T-cell receptor followed by signal 2 which is mediated through co-stimulatory molecules such as ICOSL, CD28, and cytotoxic T lymphocyte-associated protein .", [["T-cell", "ANATOMY", 127, 133], ["T lymphocyte", "ANATOMY", 250, 262], ["IL-12", "GENE_OR_GENE_PRODUCT", 44, 49], ["type I interferons", "GENE_OR_GENE_PRODUCT", 54, 72], ["Signal 1", "GENE_OR_GENE_PRODUCT", 83, 91], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 127, 142], ["signal 2", "GENE_OR_GENE_PRODUCT", 155, 163], ["ICOSL", "GENE_OR_GENE_PRODUCT", 223, 228], ["CD28", "GENE_OR_GENE_PRODUCT", 230, 234], ["cytotoxic T lymphocyte-associated protein", "GENE_OR_GENE_PRODUCT", 240, 281], ["IL-12", "PROTEIN", 44, 49], ["type I interferons", "PROTEIN", 54, 72], ["Signal 1", "PROTEIN", 83, 91], ["T-cell receptor", "PROTEIN", 127, 142], ["co-stimulatory molecules", "PROTEIN", 190, 214], ["ICOSL", "PROTEIN", 223, 228], ["CD28", "PROTEIN", 230, 234], ["cytotoxic T lymphocyte-associated protein", "PROTEIN", 240, 281], ["type I interferons", "TREATMENT", 54, 72], ["the T-cell receptor", "TREATMENT", 123, 142], ["CD28", "TEST", 230, 234], ["cytotoxic T lymphocyte", "TEST", 240, 262]]], ["T-cell differentiation occurs under speci fi c cytokine signals.", [["T-cell", "ANATOMY", 0, 6], ["T-cell", "CELL", 0, 6], ["speci fi c", "GENE_OR_GENE_PRODUCT", 36, 46], ["cytokine", "PROTEIN", 47, 55], ["cytokine signals", "TEST", 47, 63], ["cell differentiation", "OBSERVATION", 2, 22]]], ["IFNg can induce T-bet via STAT1 signaling which in turn can regulate IL-12bR2 expression making Th1 cells responsive to IL-12p70.", [["Th1 cells", "ANATOMY", 96, 105], ["IFNg", "CHEMICAL", 0, 4], ["IFNg", "SIMPLE_CHEMICAL", 0, 4], ["T-bet", "GENE_OR_GENE_PRODUCT", 16, 21], ["STAT1", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-12bR2", "GENE_OR_GENE_PRODUCT", 69, 77], ["Th1 cells", "CELL", 96, 105], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 120, 128], ["IFNg", "PROTEIN", 0, 4], ["STAT1", "PROTEIN", 26, 31], ["12bR2", "PROTEIN", 72, 77], ["Th1 cells", "CELL_TYPE", 96, 105], ["IL-12p70", "PROTEIN", 120, 128], ["STAT1 signaling", "PROBLEM", 26, 41], ["Th1 cells", "PROBLEM", 96, 105], ["IL", "TREATMENT", 120, 122], ["Th1 cells", "OBSERVATION", 96, 105]]], ["IL-4 induces Gata3 which augments IL-4 producing which supports the differentiation of Th2 cells.", [["Th2 cells", "ANATOMY", 87, 96], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["Gata3", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-4", "GENE_OR_GENE_PRODUCT", 34, 38], ["Th2 cells", "CELL", 87, 96], ["IL-4", "PROTEIN", 0, 4], ["Gata3", "PROTEIN", 13, 18], ["IL-4", "PROTEIN", 34, 38], ["Th2 cells", "CELL_TYPE", 87, 96], ["Gata3", "OBSERVATION", 13, 18], ["IL", "OBSERVATION_MODIFIER", 34, 36], ["Th2 cells", "OBSERVATION", 87, 96]]], ["Th2 cells produce IL-4, IL-5, and IL-13 as their effector cytokines.", [["Th2 cells", "ANATOMY", 0, 9], ["Th2 cells", "CELL", 0, 9], ["IL-4", "GENE_OR_GENE_PRODUCT", 18, 22], ["IL-5", "GENE_OR_GENE_PRODUCT", 24, 28], ["IL-13", "GENE_OR_GENE_PRODUCT", 34, 39], ["Th2 cells", "CELL_LINE", 0, 9], ["IL-13", "PROTEIN", 34, 39], ["effector cytokines", "PROTEIN", 49, 67], ["Th2 cells", "TEST", 0, 9], ["IL", "TEST", 18, 20], ["IL", "TEST", 24, 26], ["IL", "TEST", 34, 36], ["IL", "OBSERVATION_MODIFIER", 18, 20], ["effector cytokines", "OBSERVATION", 49, 67]]], ["TGF b and IL-6 can induce ROR g T expression as well as activation of STAT3 that induces IL-23 receptor expression and the combination of these cytokines supports the differentiation and proliferation of Th17 cells.", [["Th17 cells", "ANATOMY", 204, 214], ["TGF b", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-6", "GENE_OR_GENE_PRODUCT", 10, 14], ["ROR g T", "GENE_OR_GENE_PRODUCT", 26, 33], ["STAT3", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-23 receptor", "GENE_OR_GENE_PRODUCT", 89, 103], ["Th17 cells", "CELL", 204, 214], ["TGF b", "PROTEIN", 0, 5], ["IL-6", "PROTEIN", 10, 14], ["STAT3", "PROTEIN", 70, 75], ["IL-23 receptor", "PROTEIN", 89, 103], ["cytokines", "PROTEIN", 144, 153], ["Th17 cells", "CELL_TYPE", 204, 214], ["TGF", "TEST", 0, 3], ["IL-23 receptor expression", "TREATMENT", 89, 114], ["these cytokines", "TREATMENT", 138, 153], ["proliferation of Th17 cells", "PROBLEM", 187, 214], ["cytokines", "OBSERVATION", 144, 153], ["proliferation", "OBSERVATION_MODIFIER", 187, 200], ["Th17 cells", "OBSERVATION", 204, 214]]], ["These cells produce the cytokines IL-17/IL-17F, IL-22, and IL-21.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["IL-17", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-17F", "GENE_OR_GENE_PRODUCT", 40, 46], ["IL-22", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-21", "GENE_OR_GENE_PRODUCT", 59, 64], ["cytokines", "PROTEIN", 24, 33], ["IL-22", "PROTEIN", 48, 53], ["IL-21", "PROTEIN", 59, 64], ["These cells", "TEST", 0, 11], ["the cytokines IL", "TEST", 20, 36], ["IL", "TEST", 40, 42], ["IL", "TEST", 48, 50], ["IL", "TEST", 59, 61]]], ["IL-21 can signal in an autocrine fashion to reinforce the differentiation of the Th17 lineage shown to facilitate Th1 differentiation in certain situations (Longhi et al. 2009 ) .", [["Th17 lineage", "ANATOMY", 81, 93], ["IL-21", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th17 lineage", "CELL", 81, 93], ["IL-21", "PROTEIN", 0, 5], ["Th17 lineage", "CELL_TYPE", 81, 93], ["the Th17 lineage", "TREATMENT", 77, 93]]], ["IFN-g once produced by differentiating Th1 cells can signal in an autocrineparacrine fashion to further amplify Th1 differentiation and lineage commitment.", [["Th1 cells", "ANATOMY", 39, 48], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th1 cells", "CELL", 39, 48], ["Th1", "CELL", 112, 115], ["IFN", "PROTEIN", 0, 3], ["Th1 cells", "CELL_TYPE", 39, 48], ["an autocrineparacrine fashion", "TREATMENT", 63, 92]]], ["IFN-g signals via a receptor complex consisting of two IFN-g R1 and two IFN-g R2 chains which are widely expressed on myeloid-derived cells such as macrophages and dendritic cells as well as structural cells in the lung such as epithelial cells and fi broblasts (Gough et al. 2008 ) .", [["myeloid-derived cells", "ANATOMY", 118, 139], ["macrophages", "ANATOMY", 148, 159], ["dendritic cells", "ANATOMY", 164, 179], ["cells", "ANATOMY", 202, 207], ["lung", "ANATOMY", 215, 219], ["epithelial cells", "ANATOMY", 228, 244], ["broblasts", "ANATOMY", 252, 261], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-g R1", "GENE_OR_GENE_PRODUCT", 55, 63], ["myeloid-derived cells", "CELL", 118, 139], ["macrophages", "CELL", 148, 159], ["dendritic cells", "CELL", 164, 179], ["cells", "CELL", 202, 207], ["lung", "ORGAN", 215, 219], ["epithelial cells", "CELL", 228, 244], ["fi broblasts", "CELL", 249, 261], ["IFN", "PROTEIN", 0, 3], ["receptor complex", "PROTEIN", 20, 36], ["IFN", "PROTEIN", 55, 58], ["IFN-g R2 chains", "PROTEIN", 72, 87], ["myeloid-derived cells", "CELL_TYPE", 118, 139], ["macrophages", "CELL_TYPE", 148, 159], ["dendritic cells", "CELL_TYPE", 164, 179], ["structural cells", "CELL_TYPE", 191, 207], ["epithelial cells", "CELL_TYPE", 228, 244], ["IFN-g signals", "TEST", 0, 13], ["a receptor complex", "TEST", 18, 36], ["macrophages", "PROBLEM", 148, 159], ["dendritic cells", "PROBLEM", 164, 179], ["structural cells in the lung", "PROBLEM", 191, 219], ["epithelial cells", "PROBLEM", 228, 244], ["g R1", "ANATOMY_MODIFIER", 59, 63], ["g R2", "ANATOMY_MODIFIER", 76, 80], ["chains", "ANATOMY_MODIFIER", 81, 87], ["myeloid", "OBSERVATION", 118, 125], ["derived cells", "OBSERVATION", 126, 139], ["macrophages", "OBSERVATION", 148, 159], ["dendritic cells", "OBSERVATION", 164, 179], ["structural cells", "OBSERVATION", 191, 207], ["lung", "ANATOMY", 215, 219], ["epithelial cells", "OBSERVATION", 228, 244]]], ["These receptors can activate Janus-associated kinases 1 and 2 which phosphorylate STAT1 which allows STAT1 homodimerization and translocation to the nucleus, followed by binding to gamma-activated sequences (GAS) that regulate gene transcription (Gough et al. 2008 ) .", [["nucleus", "ANATOMY", 149, 156], ["Janus-associated kinases 1", "GENE_OR_GENE_PRODUCT", 29, 55], ["2", "GENE_OR_GENE_PRODUCT", 60, 61], ["STAT1", "GENE_OR_GENE_PRODUCT", 82, 87], ["STAT1", "GENE_OR_GENE_PRODUCT", 101, 106], ["nucleus", "CELLULAR_COMPONENT", 149, 156], ["GAS", "GENE_OR_GENE_PRODUCT", 208, 211], ["Janus-associated kinases 1 and 2", "PROTEIN", 29, 61], ["STAT1", "PROTEIN", 82, 87], ["STAT1", "PROTEIN", 101, 106], ["gamma-activated sequences", "DNA", 181, 206], ["GAS", "DNA", 208, 211], ["associated kinases 1", "PROBLEM", 35, 55], ["phosphorylate STAT1", "TEST", 68, 87], ["STAT1 homodimerization", "TREATMENT", 101, 123], ["nucleus", "ANATOMY", 149, 156]]], ["IFN-g regulates cellular immunity to many intracellular infections including Mycobacterium tuberculosis , Listeria monocytogenes , and Salmonella typhimurium .", [["cellular", "ANATOMY", 16, 24], ["intracellular", "ANATOMY", 42, 55], ["infections", "DISEASE", 56, 66], ["Mycobacterium tuberculosis", "DISEASE", 77, 103], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 16, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 55], ["Mycobacterium tuberculosis", "ORGANISM", 77, 103], ["Listeria monocytogenes", "ORGANISM", 106, 128], ["Salmonella typhimurium", "ORGANISM", 135, 157], ["IFN", "PROTEIN", 0, 3], ["Mycobacterium tuberculosis", "SPECIES", 77, 103], ["Listeria monocytogenes", "SPECIES", 106, 128], ["Salmonella typhimurium", "SPECIES", 135, 157], ["Mycobacterium tuberculosis", "SPECIES", 77, 103], ["Listeria monocytogenes", "SPECIES", 106, 128], ["Salmonella typhimurium", "SPECIES", 135, 157], ["IFN", "TREATMENT", 0, 3], ["many intracellular infections", "PROBLEM", 37, 66], ["Mycobacterium tuberculosis", "PROBLEM", 77, 103], ["Listeria monocytogenes", "PROBLEM", 106, 128], ["Salmonella typhimurium", "PROBLEM", 135, 157], ["intracellular", "OBSERVATION_MODIFIER", 42, 55], ["infections", "OBSERVATION", 56, 66], ["Mycobacterium tuberculosis", "OBSERVATION", 77, 103], ["Listeria monocytogenes", "OBSERVATION", 106, 128], ["Salmonella typhimurium", "OBSERVATION", 135, 157]]], ["Patients with IL-12p40 mutations can develop BCG or S. typhimurium infection but some patients can be managed with antibiotics and theoretically they can respond to interferon (Picard et al. 2002 ) .", [["S. typhimurium infection", "DISEASE", 52, 76], ["Patients", "ORGANISM", 0, 8], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 14, 22], ["S. typhimurium", "ORGANISM", 52, 66], ["patients", "ORGANISM", 86, 94], ["interferon", "GENE_OR_GENE_PRODUCT", 165, 175], ["IL", "PROTEIN", 14, 16], ["interferon", "PROTEIN", 165, 175], ["Patients", "SPECIES", 0, 8], ["S. typhimurium", "SPECIES", 52, 66], ["patients", "SPECIES", 86, 94], ["S. typhimurium", "SPECIES", 52, 66], ["IL-12p40 mutations", "TREATMENT", 14, 32], ["BCG", "PROBLEM", 45, 48], ["S. typhimurium infection", "PROBLEM", 52, 76], ["antibiotics", "TREATMENT", 115, 126], ["interferon", "TREATMENT", 165, 175], ["infection", "OBSERVATION", 67, 76]]], ["For example, patients with IFN-g receptor mutations can develop disseminated infection with bacillus Calmette-Guerin (BCG) that is resistant to antibiotics and IFN-g therapy (Dorman et al. 2004 ; Sologuren et al. 2011 ) .Th1Patients with IL-12p40 mutations can develop BCG or S. typhimurium infection but some patients can be managed with antibiotics and theoretically they can respond to interferon (Picard et al. 2002 ) .", [["infection", "DISEASE", 77, 86], ["bacillus Calmette-Guerin", "CHEMICAL", 92, 116], ["IFN", "CHEMICAL", 160, 163], ["S. typhimurium infection", "DISEASE", 276, 300], ["patients", "ORGANISM", 13, 21], ["IFN-g receptor", "GENE_OR_GENE_PRODUCT", 27, 41], ["bacillus Calmette-Guerin", "ORGANISM", 92, 116], ["BCG", "ORGANISM", 118, 121], ["IFN-g", "SIMPLE_CHEMICAL", 160, 165], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 238, 246], ["S. typhimurium", "ORGANISM", 276, 290], ["patients", "ORGANISM", 310, 318], ["interferon", "GENE_OR_GENE_PRODUCT", 389, 399], ["IFN", "PROTEIN", 27, 30], ["IFN", "PROTEIN", 160, 163], ["IL", "PROTEIN", 238, 240], ["interferon", "PROTEIN", 389, 399], ["patients", "SPECIES", 13, 21], ["S. typhimurium", "SPECIES", 276, 290], ["patients", "SPECIES", 310, 318], ["bacillus Calmette-Guerin", "SPECIES", 92, 116], ["S. typhimurium", "SPECIES", 276, 290], ["IFN-g receptor mutations", "TREATMENT", 27, 51], ["disseminated infection", "PROBLEM", 64, 86], ["bacillus Calmette", "TREATMENT", 92, 109], ["Guerin (BCG", "TREATMENT", 110, 121], ["antibiotics", "TREATMENT", 144, 155], ["IFN-g therapy", "TREATMENT", 160, 173], ["IL-12p40 mutations", "TREATMENT", 238, 256], ["BCG", "PROBLEM", 269, 272], ["S. typhimurium infection", "PROBLEM", 276, 300], ["antibiotics", "TREATMENT", 339, 350], ["interferon", "TREATMENT", 389, 399], ["disseminated", "OBSERVATION_MODIFIER", 64, 76], ["infection", "OBSERVATION", 77, 86]]], ["Thus, there is strong evidence that this pathway is essential for human control of these intracellular pathogens.Th2Th2 cells differentiation requires the transcription factor GATA3 and STAT5 (Paul 2010 ) , although initial differentiation and activation of these transcription factors can occur independently of IL-4.", [["intracellular", "ANATOMY", 89, 102], ["Th2Th2 cells", "ANATOMY", 113, 125], ["human", "ORGANISM", 66, 71], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["Th2Th2 cells", "CELL", 113, 125], ["GATA3", "GENE_OR_GENE_PRODUCT", 176, 181], ["STAT5", "GENE_OR_GENE_PRODUCT", 186, 191], ["IL-4", "GENE_OR_GENE_PRODUCT", 313, 317], ["Th2Th2 cells", "CELL_LINE", 113, 125], ["transcription factor", "PROTEIN", 155, 175], ["GATA3", "PROTEIN", 176, 181], ["STAT5", "PROTEIN", 186, 191], ["Paul 2010", "PROTEIN", 193, 202], ["transcription factors", "PROTEIN", 264, 285], ["IL-4", "PROTEIN", 313, 317], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["these intracellular pathogens", "PROBLEM", 83, 112], ["these transcription factors", "PROBLEM", 258, 285], ["intracellular", "OBSERVATION_MODIFIER", 89, 102], ["pathogens", "OBSERVATION", 103, 112]]], ["GATA3 binds to the Il4 locus and IL-4 and signaling via STAT6 is critical for further TH2 proliferation and lineage commitment (Paul 2010 ) .", [["GATA3", "GENE_OR_GENE_PRODUCT", 0, 5], ["Il4", "GENE_OR_GENE_PRODUCT", 19, 22], ["IL-4", "GENE_OR_GENE_PRODUCT", 33, 37], ["STAT6", "GENE_OR_GENE_PRODUCT", 56, 61], ["TH2", "GENE_OR_GENE_PRODUCT", 86, 89], ["GATA3", "PROTEIN", 0, 5], ["Il4 locus", "DNA", 19, 28], ["IL-4", "DNA", 33, 37], ["STAT6", "PROTEIN", 56, 61], ["GATA3 binds", "PROBLEM", 0, 11], ["the Il4 locus", "TEST", 15, 28], ["IL", "TEST", 33, 35], ["further TH2 proliferation", "PROBLEM", 78, 103], ["Il4", "ANATOMY", 19, 22]]], ["Th2 cells produce interleukin (IL)-4, IL-5, and IL-13 and mediate immunity against infections with helminths ( Fig. 3 .2 ).", [["Th2 cells", "ANATOMY", 0, 9], ["infections", "DISEASE", 83, 93], ["helminths", "DISEASE", 99, 108], ["Th2 cells", "CELL", 0, 9], ["interleukin (IL)-4", "GENE_OR_GENE_PRODUCT", 18, 36], ["IL-5", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-13", "GENE_OR_GENE_PRODUCT", 48, 53], ["Th2 cells", "CELL_LINE", 0, 9], ["interleukin (IL)-4", "PROTEIN", 18, 36], ["Th2 cells", "TEST", 0, 9], ["interleukin (IL)", "TEST", 18, 34], ["IL", "TEST", 38, 40], ["IL", "TEST", 48, 50], ["infections", "PROBLEM", 83, 93]]], ["These cells also facilitate B-cell differentiation and antibody responses to T-cell dependent protein antigens (Willart and Hammad 2011 ) .", [["cells", "ANATOMY", 6, 11], ["B-cell", "ANATOMY", 28, 34], ["T-cell", "ANATOMY", 77, 83], ["cells", "CELL", 6, 11], ["B-cell", "CELL", 28, 34], ["T-cell", "CELL", 77, 83], ["T-cell dependent protein antigens", "PROTEIN", 77, 110], ["These cells", "TEST", 0, 11], ["B-cell differentiation", "TEST", 28, 50], ["antibody responses", "TEST", 55, 73], ["cell differentiation", "OBSERVATION", 30, 50]]], ["Deletion of Gata3 in mice results in embryonic lethality but conditional deletion in T-cell con fi rms its essential role in Th2 differentiation and the expulsion of helminths from the gastrointestinal tract (Zhu et al. 2004 ) .", [["embryonic", "ANATOMY", 37, 46], ["T-cell", "ANATOMY", 85, 91], ["gastrointestinal tract", "ANATOMY", 185, 207], ["helminths from the gastrointestinal tract", "DISEASE", 166, 207], ["Gata3", "GENE_OR_GENE_PRODUCT", 12, 17], ["mice", "ORGANISM", 21, 25], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 46], ["T-cell con fi rms", "GENE_OR_GENE_PRODUCT", 85, 102], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 185, 207], ["Gata3", "PROTEIN", 12, 17], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["Deletion of Gata3", "PROBLEM", 0, 17], ["embryonic lethality", "PROBLEM", 37, 56], ["conditional deletion", "PROBLEM", 61, 81], ["the expulsion of helminths from the gastrointestinal tract", "PROBLEM", 149, 207], ["Gata3", "OBSERVATION", 12, 17], ["Th2 differentiation", "OBSERVATION", 125, 144], ["gastrointestinal tract", "ANATOMY", 185, 207]]], ["IL-5 is the principal growth factor that regulates eosinophilopoiesis and IL-5 deleted mice show marked reduction of peripheral and bone marrow eosinophils (Kopf et al. 1996 ; Fallon et al. 2002 ) .", [["peripheral", "ANATOMY", 117, 127], ["bone marrow eosinophils", "ANATOMY", 132, 155], ["IL-5", "GENE_OR_GENE_PRODUCT", 0, 4], ["eosinophilopoiesis", "GENE_OR_GENE_PRODUCT", 51, 69], ["IL-5", "GENE_OR_GENE_PRODUCT", 74, 78], ["mice", "ORGANISM", 87, 91], ["peripheral", "CELL", 117, 127], ["bone marrow eosinophils", "CELL", 132, 155], ["IL-5", "PROTEIN", 0, 4], ["IL-5", "PROTEIN", 74, 78], ["peripheral and bone marrow eosinophils", "CELL_TYPE", 117, 155], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["eosinophilopoiesis", "TEST", 51, 69], ["IL", "TEST", 74, 76], ["marked reduction of peripheral and bone marrow eosinophils", "PROBLEM", 97, 155], ["marked", "OBSERVATION_MODIFIER", 97, 103], ["reduction", "OBSERVATION_MODIFIER", 104, 113], ["peripheral", "ANATOMY_MODIFIER", 117, 127], ["bone", "ANATOMY", 132, 136], ["marrow eosinophils", "OBSERVATION", 137, 155]]], ["Transgenic over-expression of IL-5 results in eosinophilia (Dent et al. 1990 ) .", [["eosinophilia", "DISEASE", 46, 58], ["IL-5", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-5", "PROTEIN", 30, 34], ["eosinophilia", "PROBLEM", 46, 58], ["eosinophilia", "OBSERVATION", 46, 58]]], ["IL-13 signaling via STAT6 in airway smooth muscle and in airway epithelium leads to airways hyperresponsiveness to methacholine (Wills-Karp et al. 1998 ; Grunig et al. 1998 ) .", [["airway smooth muscle", "ANATOMY", 29, 49], ["airway epithelium", "ANATOMY", 57, 74], ["airways", "ANATOMY", 84, 91], ["methacholine", "CHEMICAL", 115, 127], ["methacholine", "CHEMICAL", 115, 127], ["IL-13", "GENE_OR_GENE_PRODUCT", 0, 5], ["STAT6", "GENE_OR_GENE_PRODUCT", 20, 25], ["airway smooth muscle", "TISSUE", 29, 49], ["airway epithelium", "TISSUE", 57, 74], ["airways", "MULTI-TISSUE_STRUCTURE", 84, 91], ["methacholine", "SIMPLE_CHEMICAL", 115, 127], ["IL-13", "PROTEIN", 0, 5], ["STAT6", "PROTEIN", 20, 25], ["IL", "TEST", 0, 2], ["airways hyperresponsiveness", "PROBLEM", 84, 111], ["methacholine", "TREATMENT", 115, 127], ["airway", "ANATOMY", 29, 35], ["smooth muscle", "ANATOMY", 36, 49], ["airway", "ANATOMY", 57, 63], ["epithelium", "ANATOMY_MODIFIER", 64, 74], ["airways", "ANATOMY", 84, 91], ["hyperresponsiveness", "OBSERVATION", 92, 111]]], ["Moreover IL-13 is a major factor in mucous production and goblet cell differentiation in the airway (Wills-Karp et al. 1998 ; Grunig et al. 1998 ) .", [["mucous", "ANATOMY", 36, 42], ["goblet cell", "ANATOMY", 58, 69], ["airway", "ANATOMY", 93, 99], ["IL-13", "GENE_OR_GENE_PRODUCT", 9, 14], ["mucous", "MULTI-TISSUE_STRUCTURE", 36, 42], ["goblet cell", "CELL", 58, 69], ["airway", "MULTI-TISSUE_STRUCTURE", 93, 99], ["IL-13", "PROTEIN", 9, 14], ["a major factor in mucous production", "PROBLEM", 18, 53], ["goblet cell differentiation in the airway", "PROBLEM", 58, 99], ["mucous production", "OBSERVATION", 36, 53], ["goblet cell differentiation", "OBSERVATION", 58, 85], ["airway", "ANATOMY", 93, 99]]], ["Th2 cell and their effector cytokines have been widely implicated in atopic diseases such as allergic rhinitis, atopic dermatitis, and asthma (Barnes 2008 ) .", [["Th2 cell", "ANATOMY", 0, 8], ["atopic diseases", "DISEASE", 69, 84], ["allergic rhinitis", "DISEASE", 93, 110], ["atopic dermatitis", "DISEASE", 112, 129], ["asthma", "DISEASE", 135, 141], ["Th2 cell", "CELL", 0, 8], ["Th2 cell", "CELL_TYPE", 0, 8], ["effector cytokines", "PROTEIN", 19, 37], ["atopic diseases", "PROBLEM", 69, 84], ["allergic rhinitis", "PROBLEM", 93, 110], ["atopic dermatitis", "PROBLEM", 112, 129], ["asthma", "PROBLEM", 135, 141], ["effector cytokines", "OBSERVATION", 19, 37], ["atopic diseases", "OBSERVATION", 69, 84], ["allergic rhinitis", "OBSERVATION", 93, 110], ["atopic dermatitis", "OBSERVATION", 112, 129], ["asthma", "OBSERVATION", 135, 141]]], ["Furthermore, IL-13 has been implicated in fi brotic processes in the lung in response to drugs such as Bleomycin (Belperio et al. 2002 ; Liu et al. 2004 ; Jakubzick et al. 2003 ) .", [["lung", "ANATOMY", 69, 73], ["Bleomycin", "CHEMICAL", 103, 112], ["Bleomycin", "CHEMICAL", 103, 112], ["IL-13", "GENE_OR_GENE_PRODUCT", 13, 18], ["lung", "ORGAN", 69, 73], ["Bleomycin", "SIMPLE_CHEMICAL", 103, 112], ["IL-13", "PROTEIN", 13, 18], ["drugs", "TREATMENT", 89, 94], ["Bleomycin", "TREATMENT", 103, 112], ["lung", "ANATOMY", 69, 73]]], ["It has been recently recognized that Th2 cell priming can be driven by a number of cytokines produced by lung epithelium including TSLP, IL-25, and IL-33 (Willart and Hammad 2011 ) .Th17The initial dichotomy of T-cell subsets however could not explain all of the infections complications of CD4+ T-cell de fi ciency.", [["Th2 cell", "ANATOMY", 37, 45], ["lung epithelium", "ANATOMY", 105, 120], ["T-cell", "ANATOMY", 211, 217], ["T-cell", "ANATOMY", 296, 302], ["infections", "DISEASE", 263, 273], ["Th2 cell", "CELL", 37, 45], ["lung epithelium", "TISSUE", 105, 120], ["TSLP", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL-25", "GENE_OR_GENE_PRODUCT", 137, 142], ["IL-33", "GENE_OR_GENE_PRODUCT", 148, 153], ["T-cell", "CELL", 211, 217], ["CD4", "GENE_OR_GENE_PRODUCT", 291, 294], ["T-cell", "CELL", 296, 302], ["cytokines", "PROTEIN", 83, 92], ["TSLP", "PROTEIN", 131, 135], ["IL", "PROTEIN", 137, 139], ["T-cell subsets", "CELL_TYPE", 211, 225], ["CD4", "PROTEIN", 291, 294], ["Th2 cell priming", "TREATMENT", 37, 53], ["T-cell subsets", "TREATMENT", 211, 225], ["the infections complications", "PROBLEM", 259, 287], ["Th2 cell", "OBSERVATION", 37, 45], ["lung", "ANATOMY", 105, 109], ["epithelium", "ANATOMY_MODIFIER", 110, 120], ["cell subsets", "OBSERVATION", 213, 225], ["could not explain", "UNCERTAINTY", 234, 251], ["infections", "OBSERVATION", 263, 273]]], ["For example, CD4+ T-cells are essential for host resistance to Pneumocystis pneumonia, however, mice de fi cient in IL-4 (Garvy et al. 1997a ) , IFN-g (Garvy et al. 1997b ) , STAT4, and/ or STAT6 (unpublished observations) all clear Pneumocystis suggesting additional CD4+ T effector populations.", [["CD4+ T-cells", "ANATOMY", 13, 25], ["CD4+ T effector populations", "ANATOMY", 268, 295], ["Pneumocystis pneumonia", "DISEASE", 63, 85], ["Pneumocystis", "DISEASE", 233, 245], ["CD4", "GENE_OR_GENE_PRODUCT", 13, 16], ["Pneumocystis", "ORGANISM", 63, 75], ["mice", "ORGANISM", 96, 100], ["IL-4", "GENE_OR_GENE_PRODUCT", 116, 120], ["STAT4", "GENE_OR_GENE_PRODUCT", 175, 180], ["STAT6", "GENE_OR_GENE_PRODUCT", 190, 195], ["Pneumocystis", "ORGANISM", 233, 245], ["CD4", "GENE_OR_GENE_PRODUCT", 268, 271], ["CD4", "PROTEIN", 13, 16], ["T-cells", "CELL_TYPE", 18, 25], ["IFN", "PROTEIN", 145, 148], ["STAT4", "PROTEIN", 175, 180], ["STAT6", "PROTEIN", 190, 195], ["CD4", "PROTEIN", 268, 271], ["T effector populations", "CELL_TYPE", 273, 295], ["mice", "SPECIES", 96, 100], ["Pneumocystis pneumonia", "SPECIES", 63, 85], ["mice", "SPECIES", 96, 100], ["CD4", "TEST", 13, 16], ["T-cells", "PROBLEM", 18, 25], ["host resistance", "PROBLEM", 44, 59], ["Pneumocystis pneumonia", "PROBLEM", 63, 85], ["IFN", "TEST", 145, 148], ["Pneumocystis", "PROBLEM", 233, 245], ["T effector populations", "PROBLEM", 273, 295], ["essential for", "UNCERTAINTY", 30, 43], ["host resistance", "OBSERVATION", 44, 59], ["Pneumocystis", "OBSERVATION_MODIFIER", 63, 75], ["pneumonia", "OBSERVATION", 76, 85], ["Pneumocystis", "OBSERVATION", 233, 245]]], ["IL-17 was cloned in 1993 (Rouvier et al. 1993 ) and the fi rst IL-17 receptor (IL-17RA) was cloned in 1996 (Yao et al. 1995 ) .", [["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-17 receptor", "GENE_OR_GENE_PRODUCT", 63, 77], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 79, 86], ["IL-17", "PROTEIN", 0, 5], ["fi rst IL-17 receptor", "PROTEIN", 56, 77], ["IL", "PROTEIN", 79, 81], ["17RA", "PROTEIN", 82, 86], ["the fi rst IL", "TREATMENT", 52, 65]]], ["IL-17 mRNA was largely restricted to CD4 memory cells and early studies using intracellular cytokine staining showed that T-cell that produced IL-17 were divergent than those that produced IFN-g but often co-expressed TNF and GM-CSF (Infante-Duarte et al. 2000 ) .", [["CD4 memory cells", "ANATOMY", 37, 53], ["intracellular", "ANATOMY", 78, 91], ["T-cell", "ANATOMY", 122, 128], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["cells", "CELL", 48, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["T-cell", "CELL", 122, 128], ["IL-17", "GENE_OR_GENE_PRODUCT", 143, 148], ["IFN-g", "GENE_OR_GENE_PRODUCT", 189, 194], ["TNF", "GENE_OR_GENE_PRODUCT", 218, 221], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 226, 232], ["IL-17 mRNA", "RNA", 0, 10], ["CD4 memory cells", "CELL_TYPE", 37, 53], ["IL-17", "PROTEIN", 143, 148], ["IFN", "PROTEIN", 189, 192], ["TNF", "PROTEIN", 218, 221], ["IL", "TEST", 0, 2], ["early studies", "TEST", 58, 71], ["intracellular cytokine staining", "TEST", 78, 109], ["T-cell", "PROBLEM", 122, 128], ["IL", "TEST", 143, 145], ["IFN", "TEST", 189, 192], ["TNF", "TEST", 218, 221], ["GM", "TEST", 226, 228], ["CSF", "TEST", 229, 232]]], ["Pivotal studies published in 2005 showed that these cells develop independently of STAT4 or STAT6 and the canonical Th transcription factors T-bet or GATA3 demonstrating that Th17 cells are a distinct CD4+ T-cell lineage (Harrington et al. 2005 ; Park et al. 2005 ) .", [["cells", "ANATOMY", 52, 57], ["Th17 cells", "ANATOMY", 175, 185], ["CD4+", "ANATOMY", 201, 205], ["T-cell lineage", "ANATOMY", 206, 220], ["cells", "CELL", 52, 57], ["STAT4", "GENE_OR_GENE_PRODUCT", 83, 88], ["STAT6", "GENE_OR_GENE_PRODUCT", 92, 97], ["T-bet", "GENE_OR_GENE_PRODUCT", 141, 146], ["GATA3", "GENE_OR_GENE_PRODUCT", 150, 155], ["Th17 cells", "CELL", 175, 185], ["CD4", "GENE_OR_GENE_PRODUCT", 201, 204], ["T-cell lineage", "CELL", 206, 220], ["STAT4", "PROTEIN", 83, 88], ["STAT6", "PROTEIN", 92, 97], ["canonical Th transcription factors", "PROTEIN", 106, 140], ["T-bet", "PROTEIN", 141, 146], ["GATA3", "PROTEIN", 150, 155], ["Th17 cells", "CELL_TYPE", 175, 185], ["CD4", "PROTEIN", 201, 204], ["T-cell lineage", "CELL_TYPE", 206, 220], ["Pivotal studies", "TEST", 0, 15], ["these cells", "PROBLEM", 46, 57], ["Th17 cells", "PROBLEM", 175, 185], ["Th17 cells", "OBSERVATION", 175, 185], ["distinct", "OBSERVATION_MODIFIER", 192, 200], ["CD4", "OBSERVATION", 201, 204], ["cell lineage", "OBSERVATION", 208, 220]]], ["Subsequently it was demonstrated that Th17 development requires STAT3, and two nuclear hormone receptors RORA and RORC for development from na\u00efve CD4+ T-cells (Yang et al. 2008 ; Ivanov et al. 2006 ) .", [["nuclear", "ANATOMY", 79, 86], ["na\u00efve CD4+ T-cells", "ANATOMY", 140, 158], ["Th17", "CELL", 38, 42], ["STAT3", "GENE_OR_GENE_PRODUCT", 64, 69], ["RORA", "GENE_OR_GENE_PRODUCT", 105, 109], ["RORC", "GENE_OR_GENE_PRODUCT", 114, 118], ["CD4", "GENE_OR_GENE_PRODUCT", 146, 149], ["STAT3", "PROTEIN", 64, 69], ["nuclear hormone receptors", "PROTEIN", 79, 104], ["RORA", "PROTEIN", 105, 109], ["RORC", "PROTEIN", 114, 118], ["na\u00efve CD4+ T-cells", "CELL_TYPE", 140, 158], ["two nuclear hormone receptors RORA", "TEST", 75, 109], ["RORC", "TEST", 114, 118], ["Th17", "OBSERVATION", 38, 42], ["RORC", "ANATOMY", 114, 118]]], ["It was initially believed that one of the critical instructional cytokines for Th17 differentiation was IL-23 (Aggarwal et al. 2003 ) ; however, IL-23 receptor is not expressed on na\u00efve CD4 T-cells.", [["Th17", "ANATOMY", 79, 83], ["CD4 T-cells", "ANATOMY", 186, 197], ["Th17", "CELL", 79, 83], ["IL-23", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-23 receptor", "GENE_OR_GENE_PRODUCT", 145, 159], ["CD4 T-cells", "CELL", 186, 197], ["cytokines", "PROTEIN", 65, 74], ["IL-23 receptor", "PROTEIN", 145, 159], ["na\u00efve CD4 T-cells", "CELL_TYPE", 180, 197], ["IL", "TEST", 104, 106], ["IL", "TEST", 145, 147]]], ["Several groups showed that a critical fi rst step in Th17 differentiation is stimulation with TGF-b and IL-6 which allows induction of IL-23R (Veldhoen et al. 2006 ; Bettelli et al. 2006 ; Mangan et al. 2006 ) .", [["Th17", "CELL", 53, 57], ["TGF-b", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["IL-23R", "GENE_OR_GENE_PRODUCT", 135, 141], ["TGF-b and IL-6", "PROTEIN", 94, 108], ["IL-23R", "PROTEIN", 135, 141], ["TGF", "TEST", 94, 97]]], ["Signaling via IL-23 allows terminal differentiation and expansion of Th17 cells (McGeachy et al. 2009 ) .", [["Th17 cells", "ANATOMY", 69, 79], ["IL-23", "GENE_OR_GENE_PRODUCT", 14, 19], ["Th17 cells", "CELL", 69, 79], ["IL-23", "PROTEIN", 14, 19], ["Th17 cells", "CELL_TYPE", 69, 79], ["expansion of Th17 cells", "PROBLEM", 56, 79], ["expansion", "OBSERVATION_MODIFIER", 56, 65], ["Th17 cells", "OBSERVATION", 69, 79]]], ["Another critical effector cytokine produced by Th17 cells is IL-22 which is controlled by IL-23 as well as the transcription factor aryl hydrocarbon receptor (Ahr) (Veldhoen et al. 2008 ) .", [["Th17 cells", "ANATOMY", 47, 57], ["aryl hydrocarbon", "CHEMICAL", 132, 148], ["Th17 cells", "CELL", 47, 57], ["IL-22", "GENE_OR_GENE_PRODUCT", 61, 66], ["IL-23", "GENE_OR_GENE_PRODUCT", 90, 95], ["aryl hydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 132, 157], ["Ahr", "GENE_OR_GENE_PRODUCT", 159, 162], ["effector cytokine", "PROTEIN", 17, 34], ["Th17 cells", "CELL_TYPE", 47, 57], ["IL-22", "PROTEIN", 61, 66], ["IL-23", "PROTEIN", 90, 95], ["transcription factor", "PROTEIN", 111, 131], ["aryl hydrocarbon receptor", "PROTEIN", 132, 157], ["Ahr", "PROTEIN", 159, 162], ["IL", "TEST", 61, 63], ["effector cytokine", "OBSERVATION", 17, 34]]], ["Th17 cells also produce IL-21 (Nurieva et al. 2007 ; Korn et al. 2007 ) which can function in an autocrine manner to further expand Th17 differentiation ( Fig. 3 .1 ).T-Follicular Helper CellsT FH cells are a subgroup of CD4+ T-cells that are found in the B-cell follicle region in secondary lymphoid tissues such as bronchial associated lymphoid tissues or lymph nodes in the lung.", [["Th17 cells", "ANATOMY", 0, 10], ["Th17", "ANATOMY", 132, 136], ["Follicular Helper CellsT FH cells", "ANATOMY", 169, 202], ["CD4+", "ANATOMY", 221, 225], ["T-cells", "ANATOMY", 226, 233], ["B-cell follicle", "ANATOMY", 256, 271], ["lymphoid tissues", "ANATOMY", 292, 308], ["bronchial", "ANATOMY", 317, 326], ["lymphoid tissues", "ANATOMY", 338, 354], ["lymph nodes", "ANATOMY", 358, 369], ["lung", "ANATOMY", 377, 381], ["Th17 cells", "CELL", 0, 10], ["IL-21", "GENE_OR_GENE_PRODUCT", 24, 29], ["Th17", "CELL", 132, 136], ["CD4", "GENE_OR_GENE_PRODUCT", 221, 224], ["T-cells", "CELL", 226, 233], ["B-cell follicle", "TISSUE", 256, 271], ["secondary lymphoid tissues", "TISSUE", 282, 308], ["bronchial associated lymphoid tissues", "TISSUE", 317, 354], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 358, 369], ["lung", "ORGAN", 377, 381], ["Th17 cells", "CELL_TYPE", 0, 10], ["IL", "PROTEIN", 24, 26], ["Follicular Helper CellsT FH cells", "CELL_TYPE", 169, 202], ["CD4", "PROTEIN", 221, 224], ["T-cells", "CELL_TYPE", 226, 233], ["Th17 cells", "TEST", 0, 10], ["IL", "TEST", 24, 26], ["Fig.", "TEST", 155, 159], ["T-cells", "TEST", 226, 233], ["secondary lymphoid tissues", "PROBLEM", 282, 308], ["bronchial associated lymphoid tissues", "PROBLEM", 317, 354], ["lymph nodes in the lung", "PROBLEM", 358, 381], ["IL", "OBSERVATION_MODIFIER", 24, 26], ["B-cell follicle", "OBSERVATION", 256, 271], ["secondary lymphoid tissues", "OBSERVATION", 282, 308], ["bronchial", "ANATOMY", 317, 326], ["lymphoid tissues", "OBSERVATION", 338, 354], ["lymph nodes", "OBSERVATION", 358, 369], ["lung", "ANATOMY", 377, 381]]], ["These cells are critical for T-cell-dependent B-cell activation through the expression of CD40L and IL-21 (Crotty 2011 ) .", [["cells", "ANATOMY", 6, 11], ["T-cell", "ANATOMY", 29, 35], ["B-cell", "ANATOMY", 46, 52], ["cells", "CELL", 6, 11], ["T-cell", "CELL", 29, 35], ["B-cell", "CELL", 46, 52], ["CD40L", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-21", "GENE_OR_GENE_PRODUCT", 100, 105], ["CD40L", "PROTEIN", 90, 95], ["IL", "PROTEIN", 100, 102], ["T", "TEST", 29, 30], ["CD40L and IL", "TREATMENT", 90, 102], ["cell activation", "OBSERVATION", 48, 63]]], ["Their transcriptional program is distinct from other CD4+ T-cell lineages and they develop after stimulation with ICOS.", [["T-cell", "ANATOMY", 58, 64], ["CD4", "GENE_OR_GENE_PRODUCT", 53, 56], ["T-cell", "CELL", 58, 64], ["ICOS", "GENE_OR_GENE_PRODUCT", 114, 118], ["CD4", "PROTEIN", 53, 56], ["T-cell lineages", "CELL_TYPE", 58, 73], ["ICOS", "PROTEIN", 114, 118], ["cell lineages", "OBSERVATION", 60, 73]]], ["These cells also require the transcription factor Bcl-6 for development as well (Crotty 2011 ) .T-Regulatory CellsTregs develop under the transcription factors Foxp3 and STAT5 and are critical for mediating tolerance to inhaled antigen in the lung and preventing or reducing allergic in fl ammation (Josefowicz et al. 2012 ) .", [["cells", "ANATOMY", 6, 11], ["lung", "ANATOMY", 243, 247], ["allergic", "DISEASE", 275, 283], ["cells", "CELL", 6, 11], ["Bcl-6", "GENE_OR_GENE_PRODUCT", 50, 55], ["Foxp3", "GENE_OR_GENE_PRODUCT", 160, 165], ["STAT5", "GENE_OR_GENE_PRODUCT", 170, 175], ["lung", "ORGAN", 243, 247], ["transcription factor", "PROTEIN", 29, 49], ["Bcl-6", "PROTEIN", 50, 55], ["transcription factors", "PROTEIN", 138, 159], ["Foxp3", "PROTEIN", 160, 165], ["STAT5", "PROTEIN", 170, 175], ["the transcription factor Bcl", "TEST", 25, 53], ["Regulatory CellsTregs", "TREATMENT", 98, 119], ["mediating tolerance", "PROBLEM", 197, 216], ["allergic", "PROBLEM", 275, 283], ["lung", "ANATOMY", 243, 247]]], ["They can suppress the effector activity of many T-helper subsets and can be thymically derived (natural Tregs) or induced in the periphery (iTregs).", [["Tregs", "ANATOMY", 104, 109], ["periphery", "ANATOMY", 129, 138], ["iTregs", "ANATOMY", 140, 146], ["T-helper subsets", "CELL", 48, 64], ["Tregs", "CELL", 104, 109], ["iTregs", "CELL", 140, 146], ["T-helper subsets", "CELL_TYPE", 48, 64], ["natural Tregs", "CELL_TYPE", 96, 109], ["periphery", "ANATOMY_MODIFIER", 129, 138]]], ["An exhaustive review of these cells is beyond the scope of this chapter but the reader is referred to an excellent thorough review of these cells if they seek a more in-depth description of these cells (Josefowicz et al. 2012 ; Ray et al. 2010 ) .g d T-Cellsg d T-cells are resident in lung tissue and produce a variety of effector cytokine including IFN-g , IL-4, Il-17, and IL-22 (Bonneville et al. 2010 ) .", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 140, 145], ["cells", "ANATOMY", 196, 201], ["T-Cellsg d T-cells", "ANATOMY", 251, 269], ["lung tissue", "ANATOMY", 286, 297], ["cells", "CELL", 30, 35], ["cells", "CELL", 140, 145], ["cells", "CELL", 196, 201], [".g d T-Cellsg d T-cells", "CELL", 246, 269], ["lung tissue", "TISSUE", 286, 297], ["IFN-g", "GENE_OR_GENE_PRODUCT", 351, 356], ["IL-4", "GENE_OR_GENE_PRODUCT", 359, 363], ["Il-17", "GENE_OR_GENE_PRODUCT", 365, 370], ["IL-22", "GENE_OR_GENE_PRODUCT", 376, 381], ["T-Cellsg d T-cells", "CELL_LINE", 251, 269], ["effector cytokine", "PROTEIN", 323, 340], ["IFN", "PROTEIN", 351, 354], ["IL", "PROTEIN", 359, 361], ["IL", "PROTEIN", 376, 378], ["effector cytokine", "TREATMENT", 323, 340], ["IFN", "TREATMENT", 351, 354], ["IL", "TEST", 359, 361], ["Il", "TEST", 365, 367], ["IL", "TEST", 376, 378], ["lung", "ANATOMY", 286, 290]]], ["In the context of pulmonary infection with bacteria these cells provide a substantial amount of early IL-17 and are regulated by IL-23 and IL-1 b (Lockhart et al. 2006 ; Shibata et al. 2007 a; Sutton et al. 2009 ; Martin et al. 2009 ; Chen et al. 2011 ) .", [["pulmonary", "ANATOMY", 18, 27], ["cells", "ANATOMY", 58, 63], ["pulmonary infection", "DISEASE", 18, 37], ["pulmonary", "ORGAN", 18, 27], ["cells", "CELL", 58, 63], ["IL-17", "GENE_OR_GENE_PRODUCT", 102, 107], ["IL-23", "GENE_OR_GENE_PRODUCT", 129, 134], ["IL-1 b", "GENE_OR_GENE_PRODUCT", 139, 145], ["IL-17", "PROTEIN", 102, 107], ["IL", "PROTEIN", 129, 131], ["pulmonary infection", "PROBLEM", 18, 37], ["bacteria these cells", "PROBLEM", 43, 63], ["early IL", "TREATMENT", 96, 104], ["IL", "TEST", 129, 131], ["pulmonary", "ANATOMY", 18, 27], ["infection", "OBSERVATION", 28, 37], ["bacteria", "OBSERVATION", 43, 51], ["substantial", "OBSERVATION_MODIFIER", 74, 85], ["amount", "OBSERVATION_MODIFIER", 86, 92], ["early", "OBSERVATION_MODIFIER", 96, 101], ["IL", "OBSERVATION_MODIFIER", 102, 104]]], ["As these cells express the g d T-cell receptor, it is unclear if these cells are responding directly to cytokine stimulation alone or whether they also require endogenous TCR-dependent signals as well in the lung. g d T-cells have recently been shown to limit pathology in RSV infection (Dodd et al. 2009 ) .", [["cells", "ANATOMY", 9, 14], ["g d T-cell", "ANATOMY", 27, 37], ["cells", "ANATOMY", 71, 76], ["lung", "ANATOMY", 208, 212], ["g d T-cells", "ANATOMY", 214, 225], ["TCR", "CHEMICAL", 171, 174], ["RSV infection", "DISEASE", 273, 286], ["cells", "CELL", 9, 14], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 31, 46], ["cells", "CELL", 71, 76], ["TCR", "GENE_OR_GENE_PRODUCT", 171, 174], ["lung", "ORGAN", 208, 212], ["T-cells", "CELL", 218, 225], ["RSV", "ORGANISM", 273, 276], ["g d T-cell receptor", "PROTEIN", 27, 46], ["cytokine", "PROTEIN", 104, 112], ["TCR", "PROTEIN", 171, 174], ["T-cells", "CELL_TYPE", 218, 225], ["RSV", "SPECIES", 273, 276], ["the g d T-cell receptor", "TREATMENT", 23, 46], ["these cells", "PROBLEM", 65, 76], ["cytokine stimulation", "TREATMENT", 104, 124], ["endogenous TCR-dependent signals", "PROBLEM", 160, 192], ["g d T-cells", "TEST", 214, 225], ["RSV infection", "PROBLEM", 273, 286], ["endogenous TCR", "OBSERVATION", 160, 174], ["dependent", "OBSERVATION_MODIFIER", 175, 184], ["lung", "ANATOMY", 208, 212], ["RSV", "ANATOMY", 273, 276], ["infection", "OBSERVATION", 277, 286]]], ["These cells have also been shown to produce IL-10 and can play a regulatory role in other pulmonary infections such as Pneumocystis infection (Steele et al. 2000 ) .NKT-CellsNKT-cells are another source of multiple effector cytokines in the lung including IL-4, IFN g , and IL-17 (Michel et al. 2007 ) .", [["cells", "ANATOMY", 6, 11], ["pulmonary", "ANATOMY", 90, 99], ["NKT-CellsNKT-cells", "ANATOMY", 165, 183], ["lung", "ANATOMY", 241, 245], ["pulmonary infections", "DISEASE", 90, 110], ["Pneumocystis infection", "DISEASE", 119, 141], ["cells", "CELL", 6, 11], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["pulmonary", "ORGAN", 90, 99], ["Pneumocystis", "ORGANISM", 119, 131], ["NKT-CellsNKT-cells", "CELL", 165, 183], ["lung", "ORGAN", 241, 245], ["IL-4", "GENE_OR_GENE_PRODUCT", 256, 260], ["IFN g", "GENE_OR_GENE_PRODUCT", 262, 267], ["IL-17", "GENE_OR_GENE_PRODUCT", 274, 279], ["IL", "PROTEIN", 44, 46], ["NKT-CellsNKT-cells", "CELL_LINE", 165, 183], ["multiple effector cytokines", "PROTEIN", 206, 233], ["other pulmonary infections", "PROBLEM", 84, 110], ["Pneumocystis infection", "PROBLEM", 119, 141], ["NKT", "TEST", 165, 168], ["multiple effector cytokines in the lung", "PROBLEM", 206, 245], ["IL", "TEST", 256, 258], ["pulmonary", "ANATOMY", 90, 99], ["infections", "OBSERVATION", 100, 110], ["Pneumocystis", "OBSERVATION", 119, 131], ["multiple", "OBSERVATION_MODIFIER", 206, 214], ["effector cytokines", "OBSERVATION", 215, 233], ["lung", "ANATOMY", 241, 245]]], ["One population that has extensively studied is a population that expresses an invariant T-cell receptor (iNKT cells) that recognizes a galactolipid Sphingomonas, alpha-galactosylceramide Burdin et al. 1998 ) .", [["T-cell", "ANATOMY", 88, 94], ["iNKT cells", "ANATOMY", 105, 115], ["alpha-galactosylceramide", "CHEMICAL", 162, 186], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 88, 103], ["iNKT cells", "CELL", 105, 115], ["invariant T-cell receptor", "PROTEIN", 78, 103], ["iNKT cells", "CELL_TYPE", 105, 115], ["a galactolipid Sphingomonas", "TEST", 133, 160], ["population", "OBSERVATION", 4, 14], ["iNKT cells", "OBSERVATION", 105, 115]]], ["These cells have been found to be elevated in the bronchial alveolar lavage fl uid of patients with asthma (Akbari et al. 2006 ; Pettersson et al. 1985 ) .", [["cells", "ANATOMY", 6, 11], ["bronchial alveolar lavage fl uid", "ANATOMY", 50, 82], ["asthma", "DISEASE", 100, 106], ["cells", "CELL", 6, 11], ["alveolar lavage", "ORGANISM_SUBSTANCE", 60, 75], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["elevated", "PROBLEM", 34, 42], ["the bronchial alveolar lavage", "TEST", 46, 75], ["asthma", "PROBLEM", 100, 106], ["elevated", "OBSERVATION_MODIFIER", 34, 42], ["bronchial", "ANATOMY", 50, 59], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["lavage fl", "OBSERVATION", 69, 78], ["asthma", "OBSERVATION", 100, 106]]], ["These cells can also produce IFN g in response to Streptococcus pneumoniae pulmonary infection (Nakamatsu et al. 2007 ) .", [["cells", "ANATOMY", 6, 11], ["pulmonary", "ANATOMY", 75, 84], ["Streptococcus pneumoniae pulmonary infection", "DISEASE", 50, 94], ["cells", "CELL", 6, 11], ["IFN g", "GENE_OR_GENE_PRODUCT", 29, 34], ["Streptococcus pneumoniae", "ORGANISM", 50, 74], ["pulmonary", "ORGAN", 75, 84], ["IFN g", "PROTEIN", 29, 34], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["These cells", "PROBLEM", 0, 11], ["IFN g", "TREATMENT", 29, 34], ["Streptococcus pneumoniae pulmonary infection", "PROBLEM", 50, 94], ["Streptococcus", "OBSERVATION_MODIFIER", 50, 63], ["pneumoniae", "OBSERVATION_MODIFIER", 64, 74], ["pulmonary", "ANATOMY", 75, 84], ["infection", "OBSERVATION", 85, 94]]], ["These cells also produce IL-17 in response to Escherichia coli LPS (Michel et al. 2007 ) as well as ozone (Pichavant et al. 2008 ) .", [["cells", "ANATOMY", 6, 11], ["ozone", "CHEMICAL", 100, 105], ["ozone", "CHEMICAL", 100, 105], ["cells", "CELL", 6, 11], ["IL-17", "GENE_OR_GENE_PRODUCT", 25, 30], ["Escherichia coli", "ORGANISM", 46, 62], ["LPS", "ORGANISM", 63, 66], ["ozone", "SIMPLE_CHEMICAL", 100, 105], ["IL-17", "PROTEIN", 25, 30], ["Escherichia coli", "SPECIES", 46, 62], ["Escherichia coli", "SPECIES", 46, 62], ["IL", "TEST", 25, 27], ["Escherichia coli LPS", "PROBLEM", 46, 66], ["IL", "OBSERVATION_MODIFIER", 25, 27], ["Escherichia coli", "OBSERVATION", 46, 62]]], ["NK cells can develop under the control of IL-15 and express antiviral molecules such as IFN-g as well as cytotoxic molecules (Steel et al. 2012 ) .Innate Lymphoid CellsAnother cell population that produces effector cytokines in the lung is innate lymphoid cell.", [["NK cells", "ANATOMY", 0, 8], ["Lymphoid CellsAnother cell", "ANATOMY", 154, 180], ["lung", "ANATOMY", 232, 236], ["lymphoid cell", "ANATOMY", 247, 260], ["NK cells", "CELL", 0, 8], ["IL-15", "GENE_OR_GENE_PRODUCT", 42, 47], ["IFN-g", "GENE_OR_GENE_PRODUCT", 88, 93], ["Lymphoid CellsAnother cell", "CELL", 154, 180], ["lung", "ORGAN", 232, 236], ["innate lymphoid cell", "CELL", 240, 260], ["NK cells", "CELL_TYPE", 0, 8], ["IL-15", "PROTEIN", 42, 47], ["antiviral molecules", "PROTEIN", 60, 79], ["IFN", "PROTEIN", 88, 91], ["cytotoxic molecules", "PROTEIN", 105, 124], ["Innate Lymphoid CellsAnother cell population", "CELL_LINE", 147, 191], ["effector cytokines", "PROTEIN", 206, 224], ["innate lymphoid cell", "CELL_TYPE", 240, 260], ["NK cells", "PROBLEM", 0, 8], ["IL", "TEST", 42, 44], ["antiviral molecules", "PROBLEM", 60, 79], ["IFN-g", "TREATMENT", 88, 93], ["Innate Lymphoid CellsAnother cell population", "TREATMENT", 147, 191], ["effector cytokines in the lung", "PROBLEM", 206, 236], ["Lymphoid CellsAnother cell population", "OBSERVATION", 154, 191], ["effector cytokines", "OBSERVATION", 206, 224], ["lung", "ANATOMY", 232, 236], ["innate lymphoid cell", "OBSERVATION", 240, 260]]], ["These cells are de fi ned by lacking lineage markers, a lack of T-cell receptors but require IL-7 signaling for their development.", [["cells", "ANATOMY", 6, 11], ["T-cell", "ANATOMY", 64, 70], ["cells", "CELL", 6, 11], ["T-cell receptors", "GENE_OR_GENE_PRODUCT", 64, 80], ["IL-7", "GENE_OR_GENE_PRODUCT", 93, 97], ["T-cell receptors", "PROTEIN", 64, 80], ["IL-7", "PROTEIN", 93, 97], ["IL", "TREATMENT", 93, 95], ["lineage markers", "OBSERVATION", 37, 52]]], ["Thus these cells are present in RAG1 or RAG2 \u2212/\u2212 mice but are lacking in RAG2, yC double-deleted mice (Halim et al. 2012 ; Spits and Cupedo 2012 ) .", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["RAG1", "GENE_OR_GENE_PRODUCT", 32, 36], ["RAG2", "GENE_OR_GENE_PRODUCT", 40, 44], ["RAG2", "GENE_OR_GENE_PRODUCT", 73, 77], ["yC", "GENE_OR_GENE_PRODUCT", 79, 81], ["RAG1", "PROTEIN", 32, 36], ["RAG2", "PROTEIN", 40, 44], ["RAG2", "PROTEIN", 73, 77], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 97, 101]]], ["ROR g T expressing cells are critical for the formation of secondary lymphoid tissues (via regulation of lymphotoxin expression) and play critical roles in mucosal immunology in the gastrointestinal tract through the production of IL-17 and IL-22 (Ouyang et al. 2008 ) .", [["cells", "ANATOMY", 19, 24], ["lymphoid tissues", "ANATOMY", 69, 85], ["mucosal", "ANATOMY", 156, 163], ["gastrointestinal tract", "ANATOMY", 182, 204], ["ROR g T", "GENE_OR_GENE_PRODUCT", 0, 7], ["lymphoid tissues", "TISSUE", 69, 85], ["lymphotoxin", "GENE_OR_GENE_PRODUCT", 105, 116], ["mucosal", "MULTI-TISSUE_STRUCTURE", 156, 163], ["gastrointestinal tract", "ORGAN", 182, 204], ["IL-17", "GENE_OR_GENE_PRODUCT", 231, 236], ["IL-22", "GENE_OR_GENE_PRODUCT", 241, 246], ["ROR g T expressing cells", "CELL_TYPE", 0, 24], ["lymphotoxin", "PROTEIN", 105, 116], ["IL", "PROTEIN", 231, 233], ["secondary lymphoid tissues", "PROBLEM", 59, 85], ["lymphotoxin expression", "TREATMENT", 105, 127], ["IL", "TEST", 231, 233], ["expressing cells", "OBSERVATION", 8, 24], ["secondary lymphoid tissues", "OBSERVATION", 59, 85], ["mucosal", "ANATOMY", 156, 163], ["gastrointestinal tract", "ANATOMY", 182, 204]]], ["Type 2 ILCs produce IL-5 and IL-13 and participate in the clearance of helminths from the GI tract (Neill and McKenzie 2011 ) .", [["ILCs", "ANATOMY", 7, 11], ["GI tract", "ANATOMY", 90, 98], ["helminths from the GI tract", "DISEASE", 71, 98], ["IL-5", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-13", "GENE_OR_GENE_PRODUCT", 29, 34], ["GI tract", "ORGANISM_SUBDIVISION", 90, 98], ["ILCs", "CELL_TYPE", 7, 11], ["IL-5 and IL-13", "PROTEIN", 20, 34], ["IL", "TEST", 20, 22], ["IL", "TEST", 29, 31], ["ILCs", "OBSERVATION", 7, 11], ["GI tract", "ANATOMY", 90, 98]]], ["These cells appear to be regulated by IL-25 (IL-17E) as well as IL-33, a member of the IL-1 family.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["IL-25", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-17E", "GENE_OR_GENE_PRODUCT", 45, 51], ["IL-33", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-25 (IL-17E", "PROTEIN", 38, 51], ["IL-33", "PROTEIN", 64, 69], ["IL-1 family", "PROTEIN", 87, 98]]], ["Recently it has been demonstrated that a population of ILCs prices IL-13 in response to IL-33 induced by viral infection and these cells mediate in part, viral-induced exacerbation of allergic disease in the lung (Kim et al. 2012 ) .", [["ILCs", "ANATOMY", 55, 59], ["cells", "ANATOMY", 131, 136], ["lung", "ANATOMY", 208, 212], ["viral infection", "DISEASE", 105, 120], ["allergic disease", "DISEASE", 184, 200], ["ILCs", "CELL", 55, 59], ["IL-13", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL-33", "GENE_OR_GENE_PRODUCT", 88, 93], ["cells", "CELL", 131, 136], ["lung", "ORGAN", 208, 212], ["ILCs", "CELL_TYPE", 55, 59], ["IL-13", "PROTEIN", 67, 72], ["IL-33", "PROTEIN", 88, 93], ["ILCs prices IL", "TREATMENT", 55, 69], ["IL", "TEST", 88, 90], ["viral infection", "PROBLEM", 105, 120], ["these cells", "PROBLEM", 125, 136], ["allergic disease in the lung", "PROBLEM", 184, 212], ["population", "OBSERVATION_MODIFIER", 41, 51], ["viral infection", "OBSERVATION", 105, 120], ["allergic disease", "OBSERVATION", 184, 200], ["lung", "ANATOMY", 208, 212]]], ["In addition to viruses, these cells can also be activated by protease allergens to drive eosinophilic airways in fl ammation as well as airways hyperresponsiveness (Halim et al. 2012 ) .", [["cells", "ANATOMY", 30, 35], ["eosinophilic airways", "ANATOMY", 89, 109], ["airways", "ANATOMY", 136, 143], ["airways hyperresponsiveness", "DISEASE", 136, 163], ["cells", "CELL", 30, 35], ["airways", "MULTI-TISSUE_STRUCTURE", 102, 109], ["airways", "MULTI-TISSUE_STRUCTURE", 136, 143], ["protease allergens", "PROTEIN", 61, 79], ["viruses", "PROBLEM", 15, 22], ["these cells", "PROBLEM", 24, 35], ["protease allergens", "TREATMENT", 61, 79], ["eosinophilic airways", "PROBLEM", 89, 109], ["airways hyperresponsiveness", "PROBLEM", 136, 163], ["viruses", "OBSERVATION", 15, 22], ["airways", "ANATOMY", 136, 143], ["hyperresponsiveness", "OBSERVATION", 144, 163]]], ["In this allergen setting the activation of these cells required IL-33 and TSLP (Halim et al. 2012 ) .", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["IL-33", "GENE_OR_GENE_PRODUCT", 64, 69], ["TSLP", "GENE_OR_GENE_PRODUCT", 74, 78], ["IL-33", "PROTEIN", 64, 69], ["TSLP", "PROTEIN", 74, 78], ["IL", "TEST", 64, 66]]], ["Thus these cells recapitulate many aspects of CD4+ T-cell immunity in that there are subsets that express similar effector molecules, yet these cells are activated early and their activation is independent of TCR stimulation.Type 1 EffectorsAs mentioned above, receptors for IFN g are expressed on a variety of lung cells including alveolar macrophages, dendritic cells, fi broblasts, and lung epithelial cells.", [["cells", "ANATOMY", 11, 16], ["CD4+", "ANATOMY", 46, 50], ["T-cell", "ANATOMY", 51, 57], ["cells", "ANATOMY", 144, 149], ["lung cells", "ANATOMY", 311, 321], ["alveolar macrophages", "ANATOMY", 332, 352], ["dendritic cells", "ANATOMY", 354, 369], ["broblasts", "ANATOMY", 374, 383], ["lung epithelial cells", "ANATOMY", 389, 410], ["TCR", "CHEMICAL", 209, 212], ["cells", "CELL", 11, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["T-cell", "CELL", 51, 57], ["cells", "CELL", 144, 149], ["TCR", "GENE_OR_GENE_PRODUCT", 209, 212], ["Type 1 EffectorsAs", "GENE_OR_GENE_PRODUCT", 225, 243], ["IFN g", "GENE_OR_GENE_PRODUCT", 275, 280], ["lung cells", "CELL", 311, 321], ["alveolar macrophages", "CELL", 332, 352], ["dendritic cells", "CELL", 354, 369], ["fi broblasts", "CELL", 371, 383], ["lung epithelial cells", "CELL", 389, 410], ["CD4", "PROTEIN", 46, 49], ["effector molecules", "PROTEIN", 114, 132], ["TCR", "PROTEIN", 209, 212], ["Type 1 EffectorsAs", "PROTEIN", 225, 243], ["IFN g", "PROTEIN", 275, 280], ["lung cells", "CELL_TYPE", 311, 321], ["alveolar macrophages", "CELL_TYPE", 332, 352], ["dendritic cells", "CELL_TYPE", 354, 369], ["fi broblasts", "CELL_TYPE", 371, 383], ["lung epithelial cells", "CELL_TYPE", 389, 410], ["TCR stimulation", "TREATMENT", 209, 224], ["Type 1 EffectorsAs", "PROBLEM", 225, 243], ["IFN g", "PROBLEM", 275, 280], ["lung cells", "PROBLEM", 311, 321], ["alveolar macrophages", "PROBLEM", 332, 352], ["dendritic cells", "PROBLEM", 354, 369], ["fi broblasts", "PROBLEM", 371, 383], ["lung epithelial cells", "PROBLEM", 389, 410], ["CD4", "OBSERVATION", 46, 49], ["cell immunity", "OBSERVATION", 53, 66], ["effector molecules", "OBSERVATION", 114, 132], ["lung", "ANATOMY", 311, 315], ["alveolar macrophages", "OBSERVATION", 332, 352], ["dendritic cells", "OBSERVATION", 354, 369], ["lung", "ANATOMY", 389, 393], ["epithelial cells", "OBSERVATION", 394, 410]]], ["There are several mechanisms of action by which IFN-g is thought to be critical for control of lung immunity against intracellular pathogens.", [["lung", "ANATOMY", 95, 99], ["intracellular", "ANATOMY", 117, 130], ["IFN", "CHEMICAL", 48, 51], ["IFN-g", "GENE_OR_GENE_PRODUCT", 48, 53], ["lung", "ORGAN", 95, 99], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["IFN", "PROTEIN", 48, 51], ["intracellular pathogens", "PROBLEM", 117, 140], ["lung", "ANATOMY", 95, 99], ["pathogens", "OBSERVATION", 131, 140]]], ["The fi rst is through macrophage priming and the induction of intracellular microbicidal activity of macrophages (Murray 1988 ) .", [["macrophage", "ANATOMY", 22, 32], ["intracellular", "ANATOMY", 62, 75], ["macrophages", "ANATOMY", 101, 112], ["fi rst", "GENE_OR_GENE_PRODUCT", 4, 10], ["macrophage", "CELL", 22, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["macrophages", "CELL", 101, 112], ["macrophages", "CELL_TYPE", 101, 112], ["macrophage priming", "TREATMENT", 22, 40], ["macrophage", "OBSERVATION", 22, 32], ["microbicidal activity", "OBSERVATION", 76, 97]]], ["IFN-g priming of macrophages results in signi fi cantly augmented TLR signaling (Schroder et al. 2006 ) .", [["macrophages", "ANATOMY", 17, 28], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 17, 28], ["TLR", "GENE_OR_GENE_PRODUCT", 66, 69], ["IFN", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 17, 28], ["TLR", "PROTEIN", 66, 69], ["IFN", "TEST", 0, 3], ["macrophages", "PROBLEM", 17, 28]]], ["IFN-g also increases microbicidal activity in part, through the induction of inducible nitric oxide synthase which can increase the production of reactive nitrogen intermediates (Xie et al. 1992 (Xie et al. , 1993 as well as by increasing the production of reactive oxygen species.", [["IFN", "CHEMICAL", 0, 3], ["nitric oxide", "CHEMICAL", 87, 99], ["oxygen", "CHEMICAL", 266, 272], ["nitric oxide", "CHEMICAL", 87, 99], ["nitrogen", "CHEMICAL", 155, 163], ["oxygen", "CHEMICAL", 266, 272], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 87, 108], ["reactive nitrogen intermediates", "SIMPLE_CHEMICAL", 146, 177], ["reactive oxygen species", "SIMPLE_CHEMICAL", 257, 280], ["IFN", "PROTEIN", 0, 3], ["nitric oxide synthase", "PROTEIN", 87, 108], ["microbicidal activity", "TREATMENT", 21, 42], ["inducible nitric oxide synthase", "TREATMENT", 77, 108], ["reactive nitrogen intermediates", "PROBLEM", 146, 177], ["reactive oxygen species", "TREATMENT", 257, 280], ["increases", "OBSERVATION_MODIFIER", 11, 20], ["microbicidal activity", "OBSERVATION", 21, 42], ["reactive nitrogen", "OBSERVATION", 146, 163], ["reactive", "OBSERVATION_MODIFIER", 257, 265], ["oxygen species", "OBSERVATION", 266, 280]]], ["These activities may explain the therapeutic bene fi t of IFN-g in patients with chronic granulomatous disease due to mutations in NADPH oxidase (Naderi et al. 2012 ; Segal et al. 2011 ; Fernandez-Boyanapalli et al. 2010 ) .", [["granulomatous", "ANATOMY", 89, 102], ["IFN", "CHEMICAL", 58, 61], ["chronic granulomatous disease", "DISEASE", 81, 110], ["NADPH", "CHEMICAL", 131, 136], ["IFN-g", "GENE_OR_GENE_PRODUCT", 58, 63], ["patients", "ORGANISM", 67, 75], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 131, 144], ["IFN", "PROTEIN", 58, 61], ["NADPH oxidase", "PROTEIN", 131, 144], ["patients", "SPECIES", 67, 75], ["IFN-g", "TREATMENT", 58, 63], ["chronic granulomatous disease", "PROBLEM", 81, 110], ["mutations in NADPH oxidase", "PROBLEM", 118, 144], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["granulomatous", "OBSERVATION", 89, 102]]], ["This increase in microbicidal activity has been termed classically activation of macrophages (Gordon 2003 ) .", [["macrophages", "ANATOMY", 81, 92], ["macrophages", "CELL", 81, 92], ["macrophages", "CELL_TYPE", 81, 92], ["This increase in microbicidal activity", "PROBLEM", 0, 38], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["microbicidal activity", "OBSERVATION", 17, 38], ["macrophages", "OBSERVATION_MODIFIER", 81, 92]]], ["IFN-g markedly upregulates class II MHC molecules as well as co-stimulatory molecules such as CD80 and CD86 which can augment antigen presentation to na\u00efve T-cells.", [["T-cells", "ANATOMY", 156, 163], ["IFN", "CHEMICAL", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["class II MHC", "GENE_OR_GENE_PRODUCT", 27, 39], ["CD80", "GENE_OR_GENE_PRODUCT", 94, 98], ["CD86", "GENE_OR_GENE_PRODUCT", 103, 107], ["T-cells", "CELL", 156, 163], ["IFN", "PROTEIN", 0, 3], ["class II MHC molecules", "PROTEIN", 27, 49], ["co-stimulatory molecules", "PROTEIN", 61, 85], ["CD80", "PROTEIN", 94, 98], ["CD86", "PROTEIN", 103, 107], ["na\u00efve T-cells", "CELL_TYPE", 150, 163], ["markedly upregulates class II MHC molecules", "PROBLEM", 6, 49], ["co-stimulatory molecules", "PROBLEM", 61, 85]]], ["Of course, one of the IFN-g 's fi rst observed activities was its ability to suppress viral replication in many target cells including macrophages, fi broblasts, and lung epithelial cells (Hovanessian et al. 1980 ) .", [["cells", "ANATOMY", 119, 124], ["macrophages", "ANATOMY", 135, 146], ["broblasts", "ANATOMY", 151, 160], ["lung epithelial cells", "ANATOMY", 166, 187], ["IFN-g", "GENE_OR_GENE_PRODUCT", 22, 27], ["fi rst", "GENE_OR_GENE_PRODUCT", 31, 37], ["cells", "CELL", 119, 124], ["macrophages", "CELL", 135, 146], ["fi broblasts", "CELL", 148, 160], ["lung epithelial cells", "CELL", 166, 187], ["IFN", "PROTEIN", 22, 25], ["target cells", "CELL_TYPE", 112, 124], ["macrophages", "CELL_TYPE", 135, 146], ["fi broblasts", "CELL_TYPE", 148, 160], ["lung epithelial cells", "CELL_TYPE", 166, 187], ["the IFN", "TEST", 18, 25], ["viral replication", "PROBLEM", 86, 103], ["macrophages", "PROBLEM", 135, 146], ["fi broblasts", "PROBLEM", 148, 160], ["lung epithelial cells", "PROBLEM", 166, 187], ["lung", "ANATOMY", 166, 170], ["epithelial cells", "OBSERVATION", 171, 187]]], ["This occurs in part though the induction of many anti-viral genes such as MxA (Ronni et al. 1995 ) ; however, other respiratory viruses such as SARS coronavirus are controlled by IFN g via MxA independent mechanisms (Spiegel et al. 2004 ) .Type 1 EffectorsIFN-g also induces chemokines such as CXCL9, CXCL10, and CXCL10 which are all ligands for CXCR3 which is expressed on Th1 cells and thus, IFN-g can increase the recruitment of Th1 cells and this is critical for granuloma formation which is essential for control of many intracellular pathogens such as M. tuberculosis (Aly et al. 2007 ; Chakravarty et al. 2007 ) .", [["Th1 cells", "ANATOMY", 374, 383], ["Th1 cells", "ANATOMY", 432, 441], ["granuloma", "ANATOMY", 467, 476], ["intracellular", "ANATOMY", 526, 539], ["respiratory viruses", "DISEASE", 116, 135], ["SARS coronavirus", "DISEASE", 144, 160], ["granuloma", "DISEASE", 467, 476], ["M. tuberculosis", "DISEASE", 558, 573], ["MxA", "GENE_OR_GENE_PRODUCT", 74, 77], ["SARS coronavirus", "ORGANISM", 144, 160], ["IFN g", "GENE_OR_GENE_PRODUCT", 179, 184], ["MxA", "GENE_OR_GENE_PRODUCT", 189, 192], ["EffectorsIFN-g", "GENE_OR_GENE_PRODUCT", 247, 261], ["CXCL9", "GENE_OR_GENE_PRODUCT", 294, 299], ["CXCL10", "GENE_OR_GENE_PRODUCT", 301, 307], ["CXCL10", "GENE_OR_GENE_PRODUCT", 313, 319], ["CXCR3", "GENE_OR_GENE_PRODUCT", 346, 351], ["Th1 cells", "CELL", 374, 383], ["IFN-g", "GENE_OR_GENE_PRODUCT", 394, 399], ["Th1 cells", "CELL", 432, 441], ["granuloma", "PATHOLOGICAL_FORMATION", 467, 476], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 526, 539], ["M. tuberculosis", "ORGANISM", 558, 573], ["anti-viral genes", "DNA", 49, 65], ["MxA", "PROTEIN", 74, 77], ["IFN g", "PROTEIN", 179, 184], ["MxA", "PROTEIN", 189, 192], ["chemokines", "PROTEIN", 275, 285], ["CXCL9", "PROTEIN", 294, 299], ["CXCL10", "PROTEIN", 301, 307], ["CXCL10", "PROTEIN", 313, 319], ["CXCR3", "PROTEIN", 346, 351], ["Th1 cells", "CELL_TYPE", 374, 383], ["IFN", "PROTEIN", 394, 397], ["Th1 cells", "CELL_TYPE", 432, 441], ["M. tuberculosis", "SPECIES", 558, 573], ["SARS coronavirus", "SPECIES", 144, 160], ["M. tuberculosis", "SPECIES", 558, 573], ["many anti-viral genes", "TREATMENT", 44, 65], ["other respiratory viruses", "PROBLEM", 110, 135], ["SARS coronavirus", "PROBLEM", 144, 160], ["Type 1 EffectorsIFN", "PROBLEM", 240, 259], ["CXCL9", "TEST", 294, 299], ["CXCL10", "TEST", 301, 307], ["CXCL10", "TEST", 313, 319], ["CXCR3", "TEST", 346, 351], ["Th1 cells", "PROBLEM", 374, 383], ["IFN", "TREATMENT", 394, 397], ["the recruitment of Th1 cells", "TREATMENT", 413, 441], ["granuloma formation", "PROBLEM", 467, 486], ["many intracellular pathogens", "PROBLEM", 521, 549], ["M. tuberculosis", "PROBLEM", 558, 573], ["respiratory viruses", "OBSERVATION", 116, 135], ["recruitment", "OBSERVATION_MODIFIER", 417, 428], ["Th1 cells", "OBSERVATION", 432, 441], ["granuloma", "OBSERVATION", 467, 476], ["intracellular pathogens", "OBSERVATION", 526, 549]]], ["In fact both systemic and aerosolized IFN-g have been investigated for the potential adjunctive treatment of TB.", [["IFN", "CHEMICAL", 38, 41], ["TB", "DISEASE", 109, 111], ["IFN-g", "GENE_OR_GENE_PRODUCT", 38, 43], ["IFN", "PROTEIN", 38, 41], ["aerosolized IFN-g", "TREATMENT", 26, 43], ["the potential adjunctive treatment", "TREATMENT", 71, 105], ["TB", "PROBLEM", 109, 111], ["both", "OBSERVATION_MODIFIER", 8, 12], ["systemic", "OBSERVATION_MODIFIER", 13, 21], ["aerosolized", "OBSERVATION", 26, 37], ["TB", "OBSERVATION", 109, 111]]], ["A recent meta-analysis showed that IFN-g was well tolerated and associated with higher sputum sterilization rates (Gao et al. 2011 ) ; however, de fi nitive randomized control trials are lacking to make fi rm conclusions on the ef fi cacy of this cytokine.Type 2 EffectorsBoth IL-4 and IL-13 can activate STAT6 signaling in a variety of lung cells including alveolar macrophages, fi broblasts, airway smooth muscle, and airway epithelium.", [["sputum", "ANATOMY", 87, 93], ["lung cells", "ANATOMY", 337, 347], ["alveolar macrophages", "ANATOMY", 358, 378], ["broblasts", "ANATOMY", 383, 392], ["airway smooth muscle", "ANATOMY", 394, 414], ["airway epithelium", "ANATOMY", 420, 437], ["IFN", "CHEMICAL", 35, 38], ["IFN-g", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-4", "GENE_OR_GENE_PRODUCT", 277, 281], ["IL-13", "GENE_OR_GENE_PRODUCT", 286, 291], ["STAT6", "GENE_OR_GENE_PRODUCT", 305, 310], ["lung cells", "CELL", 337, 347], ["alveolar macrophages", "CELL", 358, 378], ["fi broblasts", "CELL", 380, 392], ["airway smooth muscle", "TISSUE", 394, 414], ["airway epithelium", "TISSUE", 420, 437], ["IFN", "PROTEIN", 35, 38], ["cytokine", "PROTEIN", 247, 255], ["Type 2 EffectorsBoth IL-4", "PROTEIN", 256, 281], ["IL-13", "PROTEIN", 286, 291], ["STAT6", "PROTEIN", 305, 310], ["lung cells", "CELL_TYPE", 337, 347], ["alveolar macrophages", "CELL_TYPE", 358, 378], ["fi broblasts", "CELL_TYPE", 380, 392], ["A recent meta-analysis", "TEST", 0, 22], ["IFN", "TEST", 35, 38], ["higher sputum sterilization rates", "PROBLEM", 80, 113], ["fi nitive randomized control trials", "TREATMENT", 147, 182], ["Type 2 EffectorsBoth IL", "TREATMENT", 256, 279], ["IL", "TREATMENT", 286, 288], ["STAT6 signaling", "PROBLEM", 305, 320], ["alveolar macrophages", "PROBLEM", 358, 378], ["airway epithelium", "PROBLEM", 420, 437], ["lung", "ANATOMY", 337, 341], ["alveolar macrophages", "OBSERVATION", 358, 378], ["airway", "ANATOMY", 394, 400], ["smooth muscle", "OBSERVATION", 401, 414], ["airway", "ANATOMY", 420, 426], ["epithelium", "ANATOMY_MODIFIER", 427, 437]]], ["Activation of the STAT6 pathway leads to alternative macrophage activation characterized by the expression of arginase 1, YM1, YM2, and the macrophage mannose receptor (Gordon and Martinez 2010 ) .", [["macrophage", "ANATOMY", 53, 63], ["mannose", "CHEMICAL", 151, 158], ["STAT6", "GENE_OR_GENE_PRODUCT", 18, 23], ["macrophage", "CELL", 53, 63], ["arginase 1", "GENE_OR_GENE_PRODUCT", 110, 120], ["YM1", "GENE_OR_GENE_PRODUCT", 122, 125], ["YM2", "GENE_OR_GENE_PRODUCT", 127, 130], ["macrophage mannose receptor", "GENE_OR_GENE_PRODUCT", 140, 167], ["STAT6", "PROTEIN", 18, 23], ["arginase 1", "PROTEIN", 110, 120], ["YM1", "PROTEIN", 122, 125], ["YM2", "PROTEIN", 127, 130], ["macrophage mannose receptor", "PROTEIN", 140, 167], ["the STAT6 pathway", "TREATMENT", 14, 31], ["alternative macrophage activation", "TREATMENT", 41, 74]]], ["IL-4 treatment of macrophages reduces their phagocytic ability although it increases the clearance of apoptotic neutrophils (Gordon and Martinez 2010 ) .", [["macrophages", "ANATOMY", 18, 29], ["neutrophils", "ANATOMY", 112, 123], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophages", "CELL", 18, 29], ["neutrophils", "CELL", 112, 123], ["IL-4", "PROTEIN", 0, 4], ["macrophages", "CELL_TYPE", 18, 29], ["apoptotic neutrophils", "CELL_TYPE", 102, 123], ["IL", "TREATMENT", 0, 2], ["macrophages", "PROBLEM", 18, 29], ["macrophages", "OBSERVATION", 18, 29], ["phagocytic ability", "OBSERVATION", 44, 62]]], ["It has been suggested that AAMs have regulatory roles in helminth infection and can reduce immunopathology (Gordon and Martinez 2010 ) .", [["helminth infection", "DISEASE", 57, 75], ["immunopathology", "DISEASE", 91, 106], ["AAMs", "GENE_OR_GENE_PRODUCT", 27, 31], ["helminth infection", "PROBLEM", 57, 75], ["helminth", "OBSERVATION_MODIFIER", 57, 65], ["infection", "OBSERVATION", 66, 75]]], ["AAMs also have increased expression of Dectin-1 in addition to macrophage mannose receptor and thus they may have greater fungicidal activity.", [["macrophage", "ANATOMY", 63, 73], ["mannose", "CHEMICAL", 74, 81], ["AAMs", "SIMPLE_CHEMICAL", 0, 4], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 39, 47], ["macrophage mannose receptor", "GENE_OR_GENE_PRODUCT", 63, 90], ["Dectin-1", "PROTEIN", 39, 47], ["macrophage mannose receptor", "PROTEIN", 63, 90], ["Dectin", "TREATMENT", 39, 45], ["macrophage mannose receptor", "TREATMENT", 63, 90], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["expression", "OBSERVATION_MODIFIER", 25, 35], ["greater", "OBSERVATION_MODIFIER", 114, 121], ["fungicidal activity", "OBSERVATION", 122, 141]]], ["Recently it has been shown that Francisella tularensis , a virulent pathogen in the lung can subvert classical activation of macrophages and thus prolong its intracellular survival (Shirey et al. 2008 ) .Type 2 EffectorsIL-13 has profound effects on airway epithelium by increasing the expression of several mucin genes including Muc5ac and Muc5b as well as inducing goblet cell hyperplasia, by activation of STAT6 (Rose et al. 2000 ) .", [["lung", "ANATOMY", 84, 88], ["macrophages", "ANATOMY", 125, 136], ["intracellular", "ANATOMY", 158, 171], ["airway epithelium", "ANATOMY", 250, 267], ["goblet cell", "ANATOMY", 367, 378], ["EffectorsIL-13", "CHEMICAL", 211, 225], ["Francisella tularensis", "ORGANISM", 32, 54], ["lung", "ORGAN", 84, 88], ["macrophages", "CELL", 125, 136], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["EffectorsIL-13", "GENE_OR_GENE_PRODUCT", 211, 225], ["airway epithelium", "TISSUE", 250, 267], ["mucin", "GENE_OR_GENE_PRODUCT", 308, 313], ["Muc5ac", "GENE_OR_GENE_PRODUCT", 330, 336], ["Muc5b", "GENE_OR_GENE_PRODUCT", 341, 346], ["goblet cell", "CELL", 367, 378], ["STAT6", "GENE_OR_GENE_PRODUCT", 409, 414], ["macrophages", "CELL_TYPE", 125, 136], ["mucin genes", "DNA", 308, 319], ["Muc5ac", "DNA", 330, 336], ["Muc5b", "DNA", 341, 346], ["STAT6", "PROTEIN", 409, 414], ["Francisella tularensis", "SPECIES", 32, 54], ["Francisella tularensis", "SPECIES", 32, 54], ["Francisella tularensis", "PROBLEM", 32, 54], ["a virulent pathogen in the lung", "PROBLEM", 57, 88], ["Type 2 EffectorsIL", "PROBLEM", 204, 222], ["profound effects on airway epithelium", "PROBLEM", 230, 267], ["Muc5ac and Muc5b", "TREATMENT", 330, 346], ["goblet cell hyperplasia", "PROBLEM", 367, 390], ["Francisella", "OBSERVATION_MODIFIER", 32, 43], ["tularensis", "OBSERVATION", 44, 54], ["virulent", "OBSERVATION_MODIFIER", 59, 67], ["pathogen", "OBSERVATION", 68, 76], ["lung", "ANATOMY", 84, 88], ["macrophages", "OBSERVATION", 125, 136], ["airway", "ANATOMY", 250, 256], ["epithelium", "ANATOMY_MODIFIER", 257, 267], ["goblet cell hyperplasia", "OBSERVATION", 367, 390]]], ["These effects are critical for host defenses against helminths such as Nippostrongylus brasiliensis (Price et al. 2010 ) but contribute to pathology in allergy/asthma.", [["helminths", "DISEASE", 53, 62], ["Nippostrongylus brasiliensis", "DISEASE", 71, 99], ["allergy", "DISEASE", 152, 159], ["asthma", "DISEASE", 160, 166], ["Nippostrongylus brasiliensis", "ORGANISM", 71, 99], ["Nippostrongylus brasiliensis", "SPECIES", 71, 99], ["Nippostrongylus brasiliensis", "SPECIES", 71, 99], ["Nippostrongylus brasiliensis", "PROBLEM", 71, 99], ["pathology in allergy", "PROBLEM", 139, 159], ["asthma", "PROBLEM", 160, 166], ["Nippostrongylus brasiliensis", "OBSERVATION", 71, 99], ["asthma", "OBSERVATION", 160, 166]]], ["During viral infection of the airways mucins can not only prevent viral spread but also may contribute to airway obstruction.", [["airways", "ANATOMY", 30, 37], ["airway", "ANATOMY", 106, 112], ["viral infection", "DISEASE", 7, 22], ["airway obstruction", "DISEASE", 106, 124], ["airways mucins", "GENE_OR_GENE_PRODUCT", 30, 44], ["airway obstruction", "PATHOLOGICAL_FORMATION", 106, 124], ["viral infection of the airways mucins", "PROBLEM", 7, 44], ["viral spread", "PROBLEM", 66, 78], ["airway obstruction", "PROBLEM", 106, 124], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["airways", "ANATOMY", 30, 37], ["may contribute to", "UNCERTAINTY", 88, 105], ["airway", "ANATOMY", 106, 112], ["obstruction", "OBSERVATION", 113, 124]]], ["Moreover IL-13 has recently been shown to increase the susceptibility of epithelial cells to infection with rhinovirus (Lachowicz-Scroggins et al. 2010 ) .Type 17 EffectorsHuman bronchial epithelium express IL-17RA and IL-17RC which allow these cells to respond to IL-17A and IL-17F as well as IL-22R and IL-10R2, the receptors for IL-22 (Fig. 3.3 ) .", [["epithelial cells", "ANATOMY", 73, 89], ["bronchial epithelium", "ANATOMY", 178, 198], ["cells", "ANATOMY", 245, 250], ["infection", "DISEASE", 93, 102], ["IL-13", "GENE_OR_GENE_PRODUCT", 9, 14], ["epithelial cells", "CELL", 73, 89], ["rhinovirus", "ORGANISM", 108, 118], ["bronchial epithelium", "TISSUE", 178, 198], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 207, 214], ["IL-17RC", "GENE_OR_GENE_PRODUCT", 219, 226], ["cells", "CELL", 245, 250], ["IL-17A", "GENE_OR_GENE_PRODUCT", 265, 271], ["IL-17F", "GENE_OR_GENE_PRODUCT", 276, 282], ["IL-22R", "GENE_OR_GENE_PRODUCT", 294, 300], ["IL-10R2", "GENE_OR_GENE_PRODUCT", 305, 312], ["IL-22", "GENE_OR_GENE_PRODUCT", 332, 337], ["IL-13", "PROTEIN", 9, 14], ["epithelial cells", "CELL_TYPE", 73, 89], ["IL", "PROTEIN", 207, 209], ["17RA", "PROTEIN", 210, 214], ["IL", "PROTEIN", 219, 221], ["17RC", "PROTEIN", 222, 226], ["IL", "PROTEIN", 265, 267], ["IL", "PROTEIN", 305, 307], ["10R2", "PROTEIN", 308, 312], ["IL", "PROTEIN", 332, 334], ["epithelial cells", "PROBLEM", 73, 89], ["infection", "PROBLEM", 93, 102], ["rhinovirus", "PROBLEM", 108, 118], ["Type 17 EffectorsHuman bronchial epithelium express IL", "TREATMENT", 155, 209], ["IL", "TREATMENT", 219, 221], ["IL", "TREATMENT", 265, 267], ["IL", "TREATMENT", 276, 278], ["IL", "TREATMENT", 294, 296], ["IL", "TREATMENT", 305, 307], ["IL", "TEST", 332, 334], ["epithelial cells", "OBSERVATION", 73, 89], ["infection", "OBSERVATION", 93, 102], ["rhinovirus", "OBSERVATION", 108, 118], ["bronchial", "ANATOMY", 178, 187], ["epithelium", "ANATOMY_MODIFIER", 188, 198]]], ["Since IL-17A and IL-17F can be co-expressed in the same cell, it has been reported that these two IL-17 family members can form three cytokines including IL-17A homodimers, IL-17A/F heterodimers which has intermediate activity compared to IL-17A homodimers, and IL-17F homodimers which has the least potent activity (Wright et al. 2007 ) .", [["cell", "ANATOMY", 56, 60], ["IL-17A", "GENE_OR_GENE_PRODUCT", 6, 12], ["IL-17F", "GENE_OR_GENE_PRODUCT", 17, 23], ["cell", "CELL", 56, 60], ["IL-17", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-17A", "GENE_OR_GENE_PRODUCT", 154, 160], ["IL-17A", "GENE_OR_GENE_PRODUCT", 173, 179], ["F", "GENE_OR_GENE_PRODUCT", 180, 181], ["IL-17A", "GENE_OR_GENE_PRODUCT", 239, 245], ["IL-17F", "GENE_OR_GENE_PRODUCT", 262, 268], ["IL-17A and IL-17F", "PROTEIN", 6, 23], ["IL-17 family members", "PROTEIN", 98, 118], ["cytokines", "PROTEIN", 134, 143], ["IL-17A homodimers", "PROTEIN", 154, 171], ["IL-17A/F heterodimers", "PROTEIN", 173, 194], ["IL-17A homodimers", "PROTEIN", 239, 256], ["IL-17F homodimers", "PROTEIN", 262, 279], ["IL", "TREATMENT", 17, 19], ["IL", "TREATMENT", 154, 156], ["IL", "TREATMENT", 173, 175], ["17A/F heterodimers", "TREATMENT", 176, 194], ["IL-17A homodimers", "TREATMENT", 239, 256], ["IL-17F homodimers", "TREATMENT", 262, 279]]], ["IL-17 receptors are also expressed on lung fi broblasts, pulmonary vascular endothelium, and bronchial smooth muscle.", [["lung fi broblasts", "ANATOMY", 38, 55], ["pulmonary vascular endothelium", "ANATOMY", 57, 87], ["bronchial smooth muscle", "ANATOMY", 93, 116], ["IL-17 receptors", "GENE_OR_GENE_PRODUCT", 0, 15], ["lung fi broblasts", "CELL", 38, 55], ["pulmonary vascular endothelium", "TISSUE", 57, 87], ["bronchial smooth muscle", "TISSUE", 93, 116], ["IL-17 receptors", "PROTEIN", 0, 15], ["IL-17 receptors", "TREATMENT", 0, 15], ["lung", "ANATOMY", 38, 42], ["fi", "ANATOMY_MODIFIER", 43, 45], ["broblasts", "OBSERVATION", 46, 55], ["pulmonary", "ANATOMY_MODIFIER", 57, 66], ["vascular endothelium", "ANATOMY", 67, 87], ["bronchial smooth muscle", "ANATOMY", 93, 116]]], ["Using CXCL1 as a model CXCR2 ligand, it has been shown that a major effect of IL-17 signaling is increasing mRNA stability of this transcript (Hartupee et al. 2007 ; Sun et al. 2011 ) resulting in augmented protein production.", [["CXCL1", "GENE_OR_GENE_PRODUCT", 6, 11], ["CXCR2", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-17", "GENE_OR_GENE_PRODUCT", 78, 83], ["CXCL1", "PROTEIN", 6, 11], ["CXCR2 ligand", "PROTEIN", 23, 35], ["IL-17", "PROTEIN", 78, 83], ["a model CXCR2 ligand", "TEST", 15, 35], ["IL", "TREATMENT", 78, 80], ["augmented protein production", "PROBLEM", 197, 225], ["increasing", "OBSERVATION_MODIFIER", 97, 107], ["mRNA stability", "OBSERVATION_MODIFIER", 108, 122], ["protein production", "OBSERVATION", 207, 225]]], ["A similar activity has also been reported for IL-17-mediated increases in G-CSF production (Cai et al. 1998 ) .", [["IL-17", "GENE_OR_GENE_PRODUCT", 46, 51], ["G-CSF", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-17", "PROTEIN", 46, 51], ["IL", "TEST", 46, 48], ["activity", "OBSERVATION_MODIFIER", 10, 18], ["increases", "OBSERVATION_MODIFIER", 61, 70]]], ["IL-17RA is also abundantly expressed on myeloid can also induce ligands for CXCR3 that increase the recruitment of IFN g \u2212producing Th1 cells that can also help control intracellular pathogen growth cells; however, these cells express very little IL-17RC and thus IL-17A and IL-17F have limited activity on myeloid cells.", [["myeloid", "ANATOMY", 40, 47], ["Th1 cells", "ANATOMY", 132, 141], ["intracellular", "ANATOMY", 169, 182], ["cells", "ANATOMY", 199, 204], ["cells", "ANATOMY", 221, 226], ["myeloid cells", "ANATOMY", 307, 320], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 0, 7], ["myeloid", "CELL", 40, 47], ["CXCR3", "GENE_OR_GENE_PRODUCT", 76, 81], ["Th1 cells", "CELL", 132, 141], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 169, 182], ["cells", "CELL", 199, 204], ["cells", "CELL", 221, 226], ["IL-17RC", "GENE_OR_GENE_PRODUCT", 247, 254], ["IL-17A", "GENE_OR_GENE_PRODUCT", 264, 270], ["IL-17F", "GENE_OR_GENE_PRODUCT", 275, 281], ["myeloid cells", "CELL", 307, 320], ["IL", "PROTEIN", 0, 2], ["17RA", "PROTEIN", 3, 7], ["CXCR3", "PROTEIN", 76, 81], ["Th1 cells", "CELL_TYPE", 132, 141], ["intracellular pathogen growth cells", "CELL_TYPE", 169, 204], ["IL", "PROTEIN", 247, 249], ["17RC", "PROTEIN", 250, 254], ["IL-17A and IL-17F", "PROTEIN", 264, 281], ["myeloid cells", "CELL_TYPE", 307, 320], ["CXCR3", "TEST", 76, 81], ["IFN g \u2212producing Th1 cells", "TREATMENT", 115, 141], ["intracellular pathogen growth cells", "PROBLEM", 169, 204], ["IL", "TEST", 264, 266], ["limited activity on myeloid cells", "PROBLEM", 287, 320], ["myeloid cells", "OBSERVATION", 307, 320]]], ["It has been reported that IL-17 can enhance IL-12p70 in alveolar macrophages (Lin et al. 2009 ) as well CCL2, CCL3, GM-CSF, IL-1 b , and IL-9 in CD4+ T-cells (Ishigame et al. 2009 ) .", [["alveolar macrophages", "ANATOMY", 56, 76], ["CD4+ T-cells", "ANATOMY", 145, 157], ["IL-17", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 44, 52], ["alveolar macrophages", "CELL", 56, 76], ["CCL2", "GENE_OR_GENE_PRODUCT", 104, 108], ["CCL3", "GENE_OR_GENE_PRODUCT", 110, 114], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 116, 122], ["IL-1 b", "GENE_OR_GENE_PRODUCT", 124, 130], ["IL-9", "GENE_OR_GENE_PRODUCT", 137, 141], ["CD4", "GENE_OR_GENE_PRODUCT", 145, 148], ["IL-17", "PROTEIN", 26, 31], ["IL-12p70", "PROTEIN", 44, 52], ["alveolar macrophages", "CELL_TYPE", 56, 76], ["CCL2", "PROTEIN", 104, 108], ["CCL3", "PROTEIN", 110, 114], ["CSF", "PROTEIN", 119, 122], ["IL", "PROTEIN", 124, 126], ["IL-9", "PROTEIN", 137, 141], ["CD4", "PROTEIN", 145, 148], ["T-cells", "CELL_TYPE", 150, 157], ["IL", "TEST", 26, 28], ["IL", "TEST", 44, 46], ["CCL2", "TEST", 104, 108], ["CCL3", "TEST", 110, 114], ["GM", "TEST", 116, 118], ["CSF", "TEST", 119, 122], ["IL", "TEST", 124, 126], ["IL", "TEST", 137, 139], ["CD4", "TEST", 145, 148], ["alveolar macrophages", "ANATOMY", 56, 76], ["CSF", "ANATOMY", 119, 122]]], ["It has recently been shown that Th17 cells express IL-17RA and IL-17RE, the receptor for IL-17C and IL-17C, and increase the production of IL-17 by these cells (Song et al. 2011 ; Ramirez-Carrozzi et al. 2011 ; Chang et al. 2011 ) .", [["Th17 cells", "ANATOMY", 32, 42], ["cells", "ANATOMY", 154, 159], ["Th17 cells", "CELL", 32, 42], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 51, 58], ["IL-17RE", "GENE_OR_GENE_PRODUCT", 63, 70], ["IL-17C", "GENE_OR_GENE_PRODUCT", 89, 95], ["IL-17C", "GENE_OR_GENE_PRODUCT", 100, 106], ["IL-17", "GENE_OR_GENE_PRODUCT", 139, 144], ["cells", "CELL", 154, 159], ["Th17 cells", "CELL_TYPE", 32, 42], ["IL", "PROTEIN", 51, 53], ["17RA", "PROTEIN", 54, 58], ["IL", "PROTEIN", 63, 65], ["17RE", "PROTEIN", 66, 70], ["IL", "PROTEIN", 100, 102], ["IL-17", "PROTEIN", 139, 144], ["Th17 cells", "PROBLEM", 32, 42], ["IL", "TREATMENT", 63, 65], ["IL", "TEST", 89, 91], ["IL", "TREATMENT", 100, 102], ["the production of IL", "TREATMENT", 121, 141], ["Ramirez", "TEST", 180, 187], ["Th17 cells", "OBSERVATION", 32, 42]]], ["IL-17C can be expressed in lung epithelium (unpublished observations) and thus can serve as a feed forward mechanism by which the epithelium could in fl uence interstitial T-cell responses.", [["lung epithelium", "ANATOMY", 27, 42], ["epithelium", "ANATOMY", 130, 140], ["interstitial T-cell", "ANATOMY", 159, 178], ["IL-17C", "GENE_OR_GENE_PRODUCT", 0, 6], ["lung epithelium", "TISSUE", 27, 42], ["epithelium", "TISSUE", 130, 140], ["interstitial T-cell", "CELL", 159, 178], ["IL-17C", "PROTEIN", 0, 6], ["IL", "TREATMENT", 0, 2], ["lung", "ANATOMY", 27, 31], ["epithelium", "ANATOMY_MODIFIER", 32, 42]]], ["IL-17A can also augment apical bicarbonate anion transport in polarized NHBE cells and this activity may be important in mediated IL-17A's antimicrobial effect in the lung as bicarbonate anion has been shown to greatly augment the bioactivity of human defensins (Kreindler et al. 2009 ) .", [["apical", "ANATOMY", 24, 30], ["NHBE cells", "ANATOMY", 72, 82], ["lung", "ANATOMY", 167, 171], ["bicarbonate", "CHEMICAL", 31, 42], ["bicarbonate", "CHEMICAL", 175, 186], ["bicarbonate", "CHEMICAL", 31, 42], ["bicarbonate", "CHEMICAL", 175, 186], ["IL-17A", "GENE_OR_GENE_PRODUCT", 0, 6], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 30], ["bicarbonate", "SIMPLE_CHEMICAL", 31, 42], ["anion", "SIMPLE_CHEMICAL", 43, 48], ["NHBE cells", "CELL", 72, 82], ["IL-17A", "GENE_OR_GENE_PRODUCT", 130, 136], ["lung", "ORGAN", 167, 171], ["bicarbonate anion", "SIMPLE_CHEMICAL", 175, 192], ["human", "ORGANISM", 246, 251], ["IL-17A", "PROTEIN", 0, 6], ["polarized NHBE cells", "CELL_LINE", 62, 82], ["human", "SPECIES", 246, 251], ["human", "SPECIES", 246, 251], ["apical bicarbonate anion transport", "TREATMENT", 24, 58], ["polarized NHBE cells", "TREATMENT", 62, 82], ["bicarbonate anion", "TREATMENT", 175, 192], ["apical", "ANATOMY_MODIFIER", 24, 30], ["NHBE cells", "OBSERVATION", 72, 82], ["lung", "ANATOMY", 167, 171]]], ["IL-17RA is required not only for host resistance to the extracellular pathogens Klebsiella pneumoniae (Ye et al. 2001 ) but also for the intracellular pathogen F. tularensis (Lin et al. 2009 ) .", [["extracellular", "ANATOMY", 56, 69], ["intracellular", "ANATOMY", 137, 150], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 0, 7], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["pathogens", "ORGANISM", 70, 79], ["Klebsiella pneumoniae", "ORGANISM", 80, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 137, 150], ["F. tularensis", "ORGANISM", 160, 173], ["IL", "PROTEIN", 0, 2], ["17RA", "PROTEIN", 3, 7], ["Klebsiella pneumoniae", "SPECIES", 80, 101], ["F. tularensis", "SPECIES", 160, 173], ["Klebsiella pneumoniae", "SPECIES", 80, 101], ["F. tularensis", "SPECIES", 160, 173], ["IL", "TREATMENT", 0, 2], ["the extracellular pathogens Klebsiella pneumoniae", "PROBLEM", 52, 101], ["the intracellular pathogen", "PROBLEM", 133, 159]]], ["In the former scenario, IL-17 regulates G-CSF and neutrophil recruitment (Ye et al. 2001 ) and dominant sources in primary infection are lung g d T-cells ) .", [["neutrophil", "ANATOMY", 50, 60], ["lung g d T-cells", "ANATOMY", 137, 153], ["primary infection", "DISEASE", 115, 132], ["IL-17", "GENE_OR_GENE_PRODUCT", 24, 29], ["G-CSF", "GENE_OR_GENE_PRODUCT", 40, 45], ["neutrophil", "CELL", 50, 60], ["lung g d T-cells", "CELL", 137, 153], ["IL-17", "PROTEIN", 24, 29], ["T-cells", "CELL_TYPE", 146, 153], ["IL", "TEST", 24, 26], ["neutrophil recruitment", "TEST", 50, 72], ["dominant sources in primary infection", "PROBLEM", 95, 132], ["lung g d T-cells", "PROBLEM", 137, 153], ["neutrophil recruitment", "OBSERVATION", 50, 72], ["primary", "OBSERVATION_MODIFIER", 115, 122], ["infection", "OBSERVATION", 123, 132], ["lung", "ANATOMY", 137, 141]]], ["In the case of F. tularensis , IL-17 regulates IL-12p70 production by macrophages which are required for Th1 immunity which is ultimately the effector cell required for control of the pathogen (Lin et al. 2009 ) .", [["macrophages", "ANATOMY", 70, 81], ["cell", "ANATOMY", 151, 155], ["F. tularensis", "ORGANISM", 15, 28], ["IL-17", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 47, 55], ["macrophages", "CELL", 70, 81], ["Th1", "GENE_OR_GENE_PRODUCT", 105, 108], ["cell", "CELL", 151, 155], ["IL-17", "PROTEIN", 31, 36], ["macrophages", "CELL_TYPE", 70, 81], ["F. tularensis", "SPECIES", 15, 28], ["F. tularensis", "SPECIES", 15, 28], ["IL", "TEST", 31, 33], ["Th1 immunity", "TREATMENT", 105, 117], ["the effector cell", "PROBLEM", 138, 155], ["the pathogen", "PROBLEM", 180, 192]]], ["IL-22 activates STAT3 in NHBE cells as well as increases their clonogenic potential in colony assays (Aujla et al. 2008 ) .", [["NHBE cells", "ANATOMY", 25, 35], ["colony", "ANATOMY", 87, 93], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["STAT3", "GENE_OR_GENE_PRODUCT", 16, 21], ["NHBE cells", "CELL", 25, 35], ["IL-22", "PROTEIN", 0, 5], ["STAT3", "PROTEIN", 16, 21], ["NHBE cells", "CELL_LINE", 25, 35], ["IL", "TREATMENT", 0, 2], ["STAT3 in NHBE cells", "TREATMENT", 16, 35], ["colony assays", "TEST", 87, 100], ["NHBE cells", "OBSERVATION", 25, 35]]], ["Moreover in mature epithelium IL-22 augments epithelial repair in response to mechanical injury (Fig. 3.", [["epithelium", "ANATOMY", 19, 29], ["epithelial", "ANATOMY", 45, 55], ["epithelium", "TISSUE", 19, 29], ["IL-22", "GENE_OR_GENE_PRODUCT", 30, 35], ["epithelial", "TISSUE", 45, 55], ["IL-22", "PROTEIN", 30, 35], ["mature epithelium IL", "TREATMENT", 12, 32], ["augments epithelial repair", "TREATMENT", 36, 62], ["mechanical injury", "PROBLEM", 78, 95], ["mature", "OBSERVATION_MODIFIER", 12, 18], ["epithelium", "OBSERVATION_MODIFIER", 19, 29], ["IL", "OBSERVATION_MODIFIER", 30, 32], ["epithelial repair", "OBSERVATION", 45, 62], ["mechanical injury", "OBSERVATION", 78, 95]]], ["IL-22 also induces antimicrobial genes in lung epithelium including lipocalin 2 (Aujla et al. 2008 ) and regenerating islet-derived protein three-g ) .", [["lung epithelium", "ANATOMY", 42, 57], ["islet", "ANATOMY", 118, 123], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung epithelium", "TISSUE", 42, 57], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 68, 79], ["islet-derived protein", "GENE_OR_GENE_PRODUCT", 118, 139], ["IL-22", "PROTEIN", 0, 5], ["antimicrobial genes", "DNA", 19, 38], ["regenerating islet-derived protein", "PROTEIN", 105, 139], ["IL", "TREATMENT", 0, 2], ["antimicrobial genes in lung epithelium", "PROBLEM", 19, 57], ["lipocalin", "TEST", 68, 77], ["regenerating islet", "TREATMENT", 105, 123], ["antimicrobial genes", "OBSERVATION", 19, 38], ["lung", "ANATOMY", 42, 46], ["epithelium", "ANATOMY_MODIFIER", 47, 57]]], ["Blockade of IL-22 during experimental K. pneumoniae lung infection results in rapid dissemination of bacteria from the lung and increased mortality due to bacteremia.", [["lung", "ANATOMY", 52, 56], ["lung", "ANATOMY", 119, 123], ["lung infection", "DISEASE", 52, 66], ["bacteremia", "DISEASE", 155, 165], ["IL-22", "GENE_OR_GENE_PRODUCT", 12, 17], ["K. pneumoniae", "ORGANISM", 38, 51], ["lung", "ORGAN", 52, 56], ["lung", "ORGAN", 119, 123], ["IL-22", "PROTEIN", 12, 17], ["K. pneumoniae", "SPECIES", 38, 51], ["K. pneumoniae", "SPECIES", 38, 51], ["Blockade of IL", "TREATMENT", 0, 14], ["experimental K. pneumoniae lung infection", "PROBLEM", 25, 66], ["bacteria from the lung", "PROBLEM", 101, 123], ["increased mortality", "PROBLEM", 128, 147], ["bacteremia", "PROBLEM", 155, 165], ["IL", "ANATOMY", 12, 14], ["pneumoniae", "OBSERVATION_MODIFIER", 41, 51], ["lung", "ANATOMY", 52, 56], ["infection", "OBSERVATION", 57, 66], ["rapid", "OBSERVATION_MODIFIER", 78, 83], ["dissemination", "OBSERVATION", 84, 97], ["bacteria", "OBSERVATION", 101, 109], ["lung", "ANATOMY", 119, 123], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["mortality", "OBSERVATION", 138, 147], ["bacteremia", "OBSERVATION", 155, 165]]], ["In this model IL-22 is regulated by IL-23 and recombinant IL-22 can rescue IL-23-de fi cient mice (Aujla et al. 2008 ) .", [["IL-22", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-23", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-22", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-23", "SIMPLE_CHEMICAL", 75, 80], ["mice", "ORGANISM", 93, 97], ["IL-22", "PROTEIN", 14, 19], ["IL-23", "PROTEIN", 36, 41], ["recombinant IL-22", "PROTEIN", 46, 63], ["mice", "SPECIES", 93, 97], ["IL", "TEST", 36, 38], ["recombinant IL", "TREATMENT", 46, 60]]], ["IL-22 has also been shown to decrease lung leak in response to ventilator-induced lung injury (Hoegl et al. 2011 ) .", [["lung", "ANATOMY", 38, 42], ["lung", "ANATOMY", 82, 86], ["lung injury", "DISEASE", 82, 93], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 38, 42], ["lung", "ORGAN", 82, 86], ["IL-22", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["lung leak", "PROBLEM", 38, 47], ["ventilator", "TREATMENT", 63, 73], ["lung injury", "PROBLEM", 82, 93], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["lung", "ANATOMY", 38, 42], ["leak", "OBSERVATION", 43, 47], ["lung", "ANATOMY", 82, 86], ["injury", "OBSERVATION", 87, 93]]], ["These data support a potential therapeutic role of IL-22 in diseases such as severe pneumonia or acute respiratory distress syndrome.Type 17 EffectorsAs stated above in primary infection, early sources of IL-17 and IL-22 can be from innate lymphoid cells (Crellin et al. 2010 ) , NK or NKT cells (Crellin et al. 2010 ; Cella et al. 2009 ) , or g d T-cells (Lockhart et al. 2006 ; Shibata et al. 2007 b; Simonian et al. 2009 ) .", [["respiratory", "ANATOMY", 103, 114], ["lymphoid cells", "ANATOMY", 240, 254], ["NK", "ANATOMY", 280, 282], ["NKT cells", "ANATOMY", 286, 295], ["g d T-cells", "ANATOMY", 344, 355], ["pneumonia", "DISEASE", 84, 93], ["acute respiratory distress syndrome", "DISEASE", 97, 132], ["primary infection", "DISEASE", 169, 186], ["IL-22", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-17", "GENE_OR_GENE_PRODUCT", 205, 210], ["IL-22", "GENE_OR_GENE_PRODUCT", 215, 220], ["innate lymphoid cells", "CELL", 233, 254], ["Crellin et al. 2010", "CELL", 256, 275], ["NK", "CELL", 280, 282], ["NKT cells", "CELL", 286, 295], ["T-cells", "CELL", 348, 355], ["IL-22", "PROTEIN", 51, 56], ["IL", "PROTEIN", 205, 207], ["IL-22", "PROTEIN", 215, 220], ["innate lymphoid cells", "CELL_TYPE", 233, 254], ["NK or NKT cells", "CELL_TYPE", 280, 295], ["T-cells", "CELL_TYPE", 348, 355], ["IL", "TREATMENT", 51, 53], ["diseases", "PROBLEM", 60, 68], ["severe pneumonia", "PROBLEM", 77, 93], ["acute respiratory distress syndrome", "PROBLEM", 97, 132], ["Type 17 EffectorsAs", "PROBLEM", 133, 152], ["primary infection", "PROBLEM", 169, 186], ["IL", "TEST", 205, 207], ["IL", "TEST", 215, 217], ["Cella et al.", "TEST", 319, 331], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["pneumonia", "OBSERVATION", 84, 93], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory distress syndrome", "OBSERVATION", 103, 132], ["infection", "OBSERVATION", 177, 186], ["lymphoid cells", "OBSERVATION", 240, 254], ["NK", "ANATOMY", 280, 282], ["NKT", "ANATOMY", 286, 289]]], ["Classic Th17 cells can also be elicited in the lung in the setting of vaccination and in this setting they play roles in protection against a diverse set of organisms including both intracellular and extracellular bacteria as well as fungi.", [["Th17 cells", "ANATOMY", 8, 18], ["lung", "ANATOMY", 47, 51], ["intracellular", "ANATOMY", 182, 195], ["extracellular bacteria", "ANATOMY", 200, 222], ["Th17 cells", "CELL", 8, 18], ["lung", "ORGAN", 47, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 200, 213], ["Th17 cells", "CELL_TYPE", 8, 18], ["Classic Th17 cells", "PROBLEM", 0, 18], ["vaccination", "TREATMENT", 70, 81], ["organisms", "PROBLEM", 157, 166], ["both intracellular and extracellular bacteria", "PROBLEM", 177, 222], ["fungi", "PROBLEM", 234, 239], ["Th17 cells", "OBSERVATION", 8, 18], ["lung", "ANATOMY", 47, 51], ["extracellular bacteria", "OBSERVATION", 200, 222]]], ["Using an ESAT-6 peptide Khader et al. showed that Th17 cells are primed in the lung prior to robust Th1 responses and that Th17 cells regulated local expression of ligands for CXCR3 (expressed on Th1 cells) and through this mechanism, Th17 cells could augment the recruitment of Th1 cells into the lung (Khader et al. 2007 ) .", [["Th17 cells", "ANATOMY", 50, 60], ["lung", "ANATOMY", 79, 83], ["Th17 cells", "ANATOMY", 123, 133], ["Th1 cells", "ANATOMY", 196, 205], ["Th17 cells", "ANATOMY", 235, 245], ["Th1 cells", "ANATOMY", 279, 288], ["lung", "ANATOMY", 298, 302], ["Th17 cells", "CELL", 50, 60], ["lung", "ORGAN", 79, 83], ["Th17 cells", "CELL", 123, 133], ["CXCR3", "GENE_OR_GENE_PRODUCT", 176, 181], ["Th1 cells", "CELL", 196, 205], ["Th17 cells", "CELL", 235, 245], ["Th1 cells", "CELL", 279, 288], ["lung", "ORGAN", 298, 302], ["Th17 cells", "CELL_TYPE", 50, 60], ["Th17 cells", "CELL_TYPE", 123, 133], ["CXCR3", "PROTEIN", 176, 181], ["Th1 cells", "CELL_TYPE", 196, 205], ["Th17 cells", "CELL_TYPE", 235, 245], ["Th1 cells", "CELL_TYPE", 279, 288], ["an ESAT", "TREATMENT", 6, 13], ["Th17 cells", "PROBLEM", 50, 60], ["Th17 cells", "PROBLEM", 123, 133], ["CXCR3", "TEST", 176, 181], ["Th1 cells", "TREATMENT", 196, 205], ["Th17 cells", "TREATMENT", 235, 245], ["Th17 cells", "OBSERVATION", 50, 60], ["lung", "ANATOMY", 79, 83], ["Th17 cells", "OBSERVATION", 123, 133], ["Th17 cells", "OBSERVATION", 235, 245], ["recruitment", "OBSERVATION_MODIFIER", 264, 275], ["Th1 cells", "OBSERVATION", 279, 288], ["lung", "ANATOMY", 298, 302]]], ["Fungal-speci fi c Th17 cells have also been shown to be critical for vaccineinduced protection against Coccidioides posadasii , Histoplasma capsulatum , and Blasto myces dermatitidis infection (Wuthrich et al. 2011 ) .", [["Th17 cells", "ANATOMY", 18, 28], ["Coccidioides posadasii", "DISEASE", 103, 125], ["Histoplasma capsulatum", "DISEASE", 128, 150], ["Blasto myces dermatitidis infection", "DISEASE", 157, 192], ["Fungal-speci fi c Th17 cells", "CELL", 0, 28], ["Coccidioides posadasii", "ORGANISM", 103, 125], ["Histoplasma capsulatum", "ORGANISM", 128, 150], ["Blasto myces dermatitidis", "ORGANISM", 157, 182], ["Fungal-speci fi c Th17 cells", "CELL_LINE", 0, 28], ["Coccidioides posadasii", "SPECIES", 103, 125], ["Histoplasma capsulatum", "SPECIES", 128, 150], ["Blasto myces dermatitidis", "SPECIES", 157, 182], ["Coccidioides posadasii", "SPECIES", 103, 125], ["Histoplasma capsulatum", "SPECIES", 128, 150], ["Blasto myces dermatitidis", "SPECIES", 157, 182], ["Fungal-speci fi c Th17 cells", "TEST", 0, 28], ["vaccineinduced protection", "TREATMENT", 69, 94], ["Coccidioides posadasii", "PROBLEM", 103, 125], ["Histoplasma capsulatum", "PROBLEM", 128, 150], ["Blasto myces dermatitidis infection", "PROBLEM", 157, 192], ["Th17 cells", "OBSERVATION", 18, 28], ["Histoplasma capsulatum", "OBSERVATION", 128, 150]]], ["This protection was also dependent on neutrophils.", [["neutrophils", "ANATOMY", 38, 49], ["neutrophils", "CELL", 38, 49], ["neutrophils", "CELL_TYPE", 38, 49], ["neutrophils", "TEST", 38, 49]]], ["IL-17 has also been shown to mediate serotype-independent immunity using a whole cell polysaccharide vaccine from S. pneumoniae (Malley et al. 2006 ) .", [["cell", "ANATOMY", 81, 85], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 81, 85], ["S. pneumoniae", "ORGANISM", 114, 127], ["IL-17", "PROTEIN", 0, 5], ["S. pneumoniae", "SPECIES", 114, 127], ["S. pneumoniae", "SPECIES", 114, 127], ["a whole cell polysaccharide vaccine", "TREATMENT", 73, 108], ["S. pneumoniae", "PROBLEM", 114, 127], ["pneumoniae", "OBSERVATION", 117, 127]]], ["Recently, Chen et al. showed that Th17 cells elicited by K. pneumoniae vaccination recognize conserved outer membrane proteins in the cell wall of the bacteria and these antigens could also provide serotype-independent immunity through Th17 cells that conferred heterologous protection against multiple serotypes of the organism .", [["Th17 cells", "ANATOMY", 34, 44], ["outer membrane", "ANATOMY", 103, 117], ["cell wall", "ANATOMY", 134, 143], ["Th17 cells", "ANATOMY", 236, 246], ["Th17 cells", "CELL", 34, 44], ["K. pneumoniae", "ORGANISM", 57, 70], ["outer membrane", "CELLULAR_COMPONENT", 103, 117], ["cell wall", "CELLULAR_COMPONENT", 134, 143], ["Th17 cells", "CELL", 236, 246], ["Th17 cells", "CELL_TYPE", 34, 44], ["outer membrane proteins", "PROTEIN", 103, 126], ["Th17 cells", "CELL_TYPE", 236, 246], ["K. pneumoniae", "SPECIES", 57, 70], ["K. pneumoniae", "SPECIES", 57, 70], ["Th17 cells", "PROBLEM", 34, 44], ["K. pneumoniae vaccination", "TREATMENT", 57, 82], ["outer membrane proteins", "PROBLEM", 103, 126], ["the bacteria", "PROBLEM", 147, 159], ["serotype-independent immunity through Th17 cells", "TREATMENT", 198, 246], ["heterologous protection", "TREATMENT", 262, 285], ["multiple serotypes of the organism", "PROBLEM", 294, 328], ["Th17 cells", "OBSERVATION", 34, 44], ["cell", "OBSERVATION", 134, 138], ["wall", "ANATOMY_MODIFIER", 139, 143], ["bacteria", "OBSERVATION", 151, 159]]], ["Again this protection was meditated by neutrophils.", [["neutrophils", "ANATOMY", 39, 50], ["neutrophils", "CELL", 39, 50], ["neutrophils", "CELL_TYPE", 39, 50]]], ["What is unclear from these studies to date are the speci fi c aspects of Th17 function that are required for protection.", [["speci fi c", "GENE_OR_GENE_PRODUCT", 51, 61], ["Th17", "GENE_OR_GENE_PRODUCT", 73, 77], ["these studies", "TEST", 21, 34], ["Th17 function", "TREATMENT", 73, 86]]], ["For examples, what homing receptors are required to elicit these cells ef fi ciently in the lung?", [["cells", "ANATOMY", 65, 70], ["lung", "ANATOMY", 92, 96], ["cells", "CELL", 65, 70], ["lung", "ORGAN", 92, 96], ["homing receptors", "PROTEIN", 19, 35], ["these cells", "TEST", 59, 70], ["lung", "ANATOMY", 92, 96]]], ["Is only IL-17A required or is there a role for IL-17F or IL-17A/F heterodimers?", [["IL-17A", "GENE_OR_GENE_PRODUCT", 8, 14], ["IL-17F", "GENE_OR_GENE_PRODUCT", 47, 53], ["IL-17A", "GENE_OR_GENE_PRODUCT", 57, 63], ["F", "GENE_OR_GENE_PRODUCT", 64, 65], ["IL-17A", "PROTEIN", 8, 14], ["IL-17F or IL-17A/F heterodimers", "PROTEIN", 47, 78], ["IL", "TEST", 47, 49], ["IL", "TREATMENT", 57, 59], ["heterodimers", "TREATMENT", 66, 78]]], ["Is IL-22 also important?", [["IL-22", "GENE_OR_GENE_PRODUCT", 3, 8], ["IL", "PROTEIN", 3, 5]]], ["What are the critical target cells that IL-17 is signaling in the lung to afford vaccine-induced immunity?", [["cells", "ANATOMY", 29, 34], ["lung", "ANATOMY", 66, 70], ["cells", "CELL", 29, 34], ["IL-17", "GENE_OR_GENE_PRODUCT", 40, 45], ["lung", "ORGAN", 66, 70], ["IL-17", "PROTEIN", 40, 45], ["IL", "TEST", 40, 42], ["vaccine", "TREATMENT", 81, 88], ["lung", "ANATOMY", 66, 70]]], ["Are there truly memory Th17 cells that can persist in the host or will these cells require periodic boosting to recall these responses?", [["Th17 cells", "ANATOMY", 23, 33], ["cells", "ANATOMY", 77, 82], ["memory Th17 cells", "CELL", 16, 33], ["cells", "CELL", 77, 82], ["memory Th17 cells", "CELL_TYPE", 16, 33], ["periodic boosting", "TREATMENT", 91, 108], ["memory Th17 cells", "OBSERVATION", 16, 33]]], ["What is the role of plasticity in the function and fate of these cells?ConclusionsCD4 T-cells play critical roles in lung immunity and when these cells are impacted by HIV or other modes of immunosuppression, the host is susceptible to many opportunistic infections by bacteria, fungi, and viruses.", [["cells", "ANATOMY", 65, 70], ["ConclusionsCD4 T-cells", "ANATOMY", 71, 93], ["lung", "ANATOMY", 117, 121], ["cells", "ANATOMY", 146, 151], ["opportunistic infections", "DISEASE", 241, 265], ["cells", "CELL", 65, 70], ["ConclusionsCD4 T-cells", "CELL", 71, 93], ["lung", "ORGAN", 117, 121], ["cells", "CELL", 146, 151], ["HIV", "ORGANISM", 168, 171], ["ConclusionsCD4 T-cells", "CELL_TYPE", 71, 93], ["HIV", "SPECIES", 168, 171], ["these cells", "PROBLEM", 140, 151], ["immunosuppression", "TREATMENT", 190, 207], ["many opportunistic infections", "PROBLEM", 236, 265], ["bacteria", "PROBLEM", 269, 277], ["fungi", "PROBLEM", 279, 284], ["viruses", "PROBLEM", 290, 297], ["lung", "ANATOMY", 117, 121], ["opportunistic", "OBSERVATION_MODIFIER", 241, 254], ["infections", "OBSERVATION", 255, 265]]], ["These cells will be critical targets to achieve therapeutic vaccines against intracellular pathogens such as M. tuberculosis .", [["cells", "ANATOMY", 6, 11], ["intracellular", "ANATOMY", 77, 90], ["M. tuberculosis", "DISEASE", 109, 124], ["cells", "CELL", 6, 11], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["M. tuberculosis", "ORGANISM", 109, 124], ["M. tuberculosis", "SPECIES", 109, 124], ["M. tuberculosis", "SPECIES", 109, 124], ["therapeutic vaccines", "TREATMENT", 48, 68], ["intracellular pathogens", "PROBLEM", 77, 100], ["M. tuberculosis", "PROBLEM", 109, 124], ["tuberculosis", "OBSERVATION", 112, 124]]], ["Furthermore these cells are now becoming attractive targets for other pathogens such as fungi and encapsulated bacteria.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["other pathogens", "PROBLEM", 64, 79], ["fungi", "PROBLEM", 88, 93], ["encapsulated bacteria", "PROBLEM", 98, 119], ["encapsulated bacteria", "OBSERVATION", 98, 119]]], ["To this end, much work lies ahead to understand the generation of these cellular responses and how they can be manipulated therapeutically.", [["cellular", "ANATOMY", 72, 80], ["cellular", "CELL", 72, 80]]]], "PMC7413098": [["INTRODUCTIONPlatypnea-orthodeoxia syndrome (POS) is a rare clinical syndrome characterized by orthostatic dyspnea and a measurable drop in arterial oxygen saturation of >5% or a PaO2 >4 mmHg (Agrawal et al., 2017).", [["arterial", "ANATOMY", 139, 147], ["INTRODUCTIONPlatypnea-orthodeoxia syndrome", "DISEASE", 0, 42], ["orthostatic dyspnea", "DISEASE", 94, 113], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 148, 154], ["arterial", "MULTI-TISSUE_STRUCTURE", 139, 147], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["orthodeoxia syndrome", "PROBLEM", 22, 42], ["a rare clinical syndrome", "PROBLEM", 52, 76], ["orthostatic dyspnea", "PROBLEM", 94, 113], ["a measurable drop", "PROBLEM", 118, 135], ["arterial oxygen saturation", "TEST", 139, 165], ["a PaO2", "TEST", 176, 182], ["orthostatic dyspnea", "OBSERVATION", 94, 113], ["measurable", "OBSERVATION_MODIFIER", 120, 130], ["drop", "OBSERVATION_MODIFIER", 131, 135], ["arterial", "ANATOMY", 139, 147], ["oxygen saturation", "OBSERVATION", 148, 165]]], ["At our centre, we observed the novel finding of POS in patients with severe 2019 novel coronavirus disease (COVID-19), and, therefore aim to describe the clinical characteristics and outcome of these affected individuals.METHODSWe retrospectively reviewed medical records of all severe COVID-19 cases admitted to the intensive care unit (ICU) at the National Centre for Infectious Diseases (NCID), Singapore over a 4-month period (29/01/2020 to 29/05/2020).", [["coronavirus disease", "DISEASE", 87, 106], ["COVID", "DISEASE", 286, 291], ["Infectious Diseases", "DISEASE", 370, 389], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["severe 2019 novel coronavirus disease", "PROBLEM", 69, 106], ["COVID", "TEST", 108, 113], ["these affected individuals", "PROBLEM", 194, 220], ["coronavirus disease", "OBSERVATION", 87, 106], ["Infectious", "OBSERVATION", 370, 380]]], ["Only individuals with POS who survived the ICU stay were included for analysis.", [["analysis", "TEST", 70, 78]]], ["Patients who did not require invasive mechanical ventilation (IMV) or admitted to the ICU for non-respiratory complications were excluded.", [["non-respiratory", "ANATOMY", 94, 109], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["invasive mechanical ventilation", "TREATMENT", 29, 60], ["IMV", "TREATMENT", 62, 65], ["non-respiratory complications", "PROBLEM", 94, 123]]], ["The baseline characteristics, physiology, ventilator settings and the outcomes of ICU stay are described and compared to cases without POS.", [["ventilator settings", "TREATMENT", 42, 61]]], ["Informed consent and institutional ethics board review were waived under the provision of the Infectious Disease Act, Singapore.RESULTSThirty-five patients received IMV for respiratory failure during the study period: 20 survived, 8 remained in the ICU and 7 died.", [["respiratory", "ANATOMY", 173, 184], ["Infectious Disease", "DISEASE", 94, 112], ["respiratory failure", "DISEASE", 173, 192], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["IMV", "TREATMENT", 165, 168], ["respiratory failure", "PROBLEM", 173, 192], ["Infectious", "OBSERVATION", 94, 104], ["respiratory failure", "OBSERVATION", 173, 192]]], ["POS was observed in 5 of 20 survivors; median age (and range) was 64 (54-71) years, body mass index was 24.7 (21.1-26.5) kg/m (Radermacher et al., 2017) and ICU presentation occurred on Day 7 (Agrawal et al., 2017; Radermacher et al., 2017; Lumb, 2010; Hert and Albert, 1994; McGregor et al., 1961; Fox et al., 2020; Dessap et al., 2010; Ministry of Health, Singapore, 2020) of COVID-19 illness.", [["body", "ANATOMY", 84, 88], ["illness", "DISEASE", 387, 394], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["body mass index", "TEST", 84, 99]]], ["All cases received lung protective ventilation for acute respiratory distress syndrome (ARDS) and were responsive to incremental positive end-expiratory pressure (PEEP).", [["lung", "ANATOMY", 19, 23], ["respiratory", "ANATOMY", 57, 68], ["acute respiratory distress syndrome", "DISEASE", 51, 86], ["ARDS", "DISEASE", 88, 92], ["lung", "ORGAN", 19, 23], ["lung protective ventilation", "TREATMENT", 19, 46], ["acute respiratory distress syndrome", "PROBLEM", 51, 86], ["ARDS", "PROBLEM", 88, 92], ["incremental positive end-expiratory pressure", "TREATMENT", 117, 161], ["PEEP", "TREATMENT", 163, 167], ["lung", "ANATOMY", 19, 23], ["protective ventilation", "OBSERVATION", 24, 46], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory distress", "OBSERVATION", 57, 77]]], ["Baseline characteristics, investigations, ventilator settings, and respiratory physiology are described in Table 1.", [["respiratory", "ANATOMY", 67, 78], ["investigations", "TEST", 26, 40], ["ventilator settings", "TREATMENT", 42, 61], ["respiratory physiology", "OBSERVATION", 67, 89]]], ["CT thorax showed changes of multi-lobar mixed ground glass opacities and consolidation particularly in the posterior lung segments and lower lobes (Fig. 1).", [["thorax", "ANATOMY", 3, 9], ["posterior lung segments", "ANATOMY", 107, 130], ["lower lobes", "ANATOMY", 135, 146], ["thorax", "ORGAN", 3, 9], ["posterior lung segments", "MULTI-TISSUE_STRUCTURE", 107, 130], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 135, 146], ["CT thorax", "TEST", 0, 9], ["multi-lobar mixed ground glass opacities", "PROBLEM", 28, 68], ["consolidation", "PROBLEM", 73, 86], ["thorax", "ANATOMY", 3, 9], ["multi-lobar", "OBSERVATION_MODIFIER", 28, 39], ["mixed", "OBSERVATION_MODIFIER", 40, 45], ["ground glass opacities", "OBSERVATION", 46, 68], ["consolidation", "OBSERVATION", 73, 86], ["posterior", "ANATOMY_MODIFIER", 107, 116], ["lung", "ANATOMY", 117, 121], ["segments", "ANATOMY_MODIFIER", 122, 130], ["lower lobes", "ANATOMY", 135, 146]]], ["Other findings were interstitial thickening and early fibrotic change (Patient 1 and 5), cavitary pneumonia (Patient 2; no positive microbiology) and a small segmental pulmonary embolism (Patient 5).", [["interstitial", "ANATOMY", 20, 32], ["pulmonary", "ANATOMY", 168, 177], ["pneumonia", "DISEASE", 98, 107], ["pulmonary embolism", "DISEASE", 168, 186], ["pulmonary", "ORGAN", 168, 177], ["Patient", "SPECIES", 71, 78], ["Patient", "SPECIES", 109, 116], ["Patient", "SPECIES", 188, 195], ["interstitial thickening", "PROBLEM", 20, 43], ["early fibrotic change", "PROBLEM", 48, 69], ["cavitary pneumonia", "PROBLEM", 89, 107], ["a small segmental pulmonary embolism", "PROBLEM", 150, 186], ["interstitial", "OBSERVATION_MODIFIER", 20, 32], ["thickening", "OBSERVATION", 33, 43], ["early", "OBSERVATION_MODIFIER", 48, 53], ["fibrotic", "OBSERVATION", 54, 62], ["cavitary", "OBSERVATION_MODIFIER", 89, 97], ["pneumonia", "OBSERVATION", 98, 107], ["small", "OBSERVATION_MODIFIER", 152, 157], ["segmental", "ANATOMY_MODIFIER", 158, 167], ["pulmonary", "ANATOMY", 168, 177], ["embolism", "OBSERVATION", 178, 186]]], ["Patients 1-3 received lopinavir/ritonavir and interferon-1B therapy while Patients 4 and 5 received remdesivir.", [["lopinavir/ritonavir", "CHEMICAL", 22, 41], ["interferon-1B", "CHEMICAL", 46, 59], ["remdesivir", "CHEMICAL", 100, 110], ["lopinavir", "CHEMICAL", 22, 31], ["ritonavir", "CHEMICAL", 32, 41], ["remdesivir", "CHEMICAL", 100, 110], ["Patients", "ORGANISM", 0, 8], ["lopinavir", "SIMPLE_CHEMICAL", 22, 31], ["ritonavir", "SIMPLE_CHEMICAL", 32, 41], ["interferon-1B", "GENE_OR_GENE_PRODUCT", 46, 59], ["Patients", "ORGANISM", 74, 82], ["remdesivir", "SIMPLE_CHEMICAL", 100, 110], ["interferon", "PROTEIN", 46, 56], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 74, 82], ["lopinavir", "TREATMENT", 22, 31], ["ritonavir", "TREATMENT", 32, 41], ["interferon", "TREATMENT", 46, 56], ["1B therapy", "TREATMENT", 57, 67], ["remdesivir", "TREATMENT", 100, 110]]], ["Two patients had microbiologically confirmed ventilator-associated pneumonia (Patient 3: Klebsiella pneumoniae and, Patient 4: Enterobacter aerogenes).RESULTSPOS was discovered during physiotherapy when affected individuals were sat up from a recumbent position.", [["ventilator-associated pneumonia", "DISEASE", 45, 76], ["Klebsiella pneumoniae", "DISEASE", 89, 110], ["patients", "ORGANISM", 4, 12], ["Klebsiella pneumoniae", "ORGANISM", 89, 110], ["Enterobacter aerogenes", "ORGANISM", 127, 149], ["individuals", "ORGANISM", 212, 223], ["patients", "SPECIES", 4, 12], ["Patient", "SPECIES", 78, 85], ["Klebsiella pneumoniae", "SPECIES", 89, 110], ["Patient", "SPECIES", 116, 123], ["Enterobacter aerogenes", "SPECIES", 127, 149], ["Klebsiella pneumoniae", "SPECIES", 89, 110], ["Enterobacter aerogenes", "SPECIES", 127, 149], ["ventilator-associated pneumonia", "PROBLEM", 45, 76], ["Klebsiella pneumoniae", "PROBLEM", 89, 110], ["Enterobacter aerogenes", "PROBLEM", 127, 149], ["affected individuals", "PROBLEM", 203, 223], ["sat", "TEST", 229, 232], ["ventilator", "OBSERVATION", 45, 55], ["pneumonia", "OBSERVATION", 67, 76]]], ["Oxygen desaturation of 8-12% was associated with varying degrees of dyspnea and tachypnea (Fig. 1).", [["desaturation", "DISEASE", 7, 19], ["dyspnea", "DISEASE", 68, 75], ["tachypnea", "DISEASE", 80, 89], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen desaturation", "PROBLEM", 0, 19], ["dyspnea", "PROBLEM", 68, 75], ["tachypnea", "PROBLEM", 80, 89], ["desaturation", "OBSERVATION_MODIFIER", 7, 19], ["varying degrees", "OBSERVATION_MODIFIER", 49, 64], ["dyspnea", "OBSERVATION", 68, 75], ["tachypnea", "OBSERVATION", 80, 89]]], ["Repeated orthostatic desaturation was present in all patients.", [["orthostatic desaturation", "DISEASE", 9, 33], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Repeated orthostatic desaturation", "PROBLEM", 0, 33], ["orthostatic desaturation", "OBSERVATION", 9, 33]]], ["In patient 1, re-intubation was considered during an episode of persistent orthostatic desaturation requiring 100% high flow oxygen following extubation but later resolved upon lying supine.", [["orthostatic desaturation", "DISEASE", 75, 99], ["oxygen", "CHEMICAL", 125, 131], ["oxygen", "CHEMICAL", 125, 131], ["patient", "ORGANISM", 3, 10], ["oxygen", "SIMPLE_CHEMICAL", 125, 131], ["patient", "SPECIES", 3, 10], ["re-intubation", "TREATMENT", 14, 27], ["persistent orthostatic desaturation", "PROBLEM", 64, 99], ["100% high flow oxygen", "TREATMENT", 110, 131], ["extubation", "TREATMENT", 142, 152], ["persistent", "OBSERVATION_MODIFIER", 64, 74], ["orthostatic desaturation", "OBSERVATION", 75, 99]]], ["A modified physiotherapy approach was instituted: bed exercises, pre-emptive increases in supplemental oxygen in anticipation of movement and/or exercise, and interval training with multiple breaks.", [["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["A modified physiotherapy approach", "TREATMENT", 0, 33], ["bed exercises", "TREATMENT", 50, 63], ["pre-emptive increases", "TREATMENT", 65, 86], ["supplemental oxygen", "TREATMENT", 90, 109], ["movement and/or exercise", "TREATMENT", 129, 153], ["interval training", "TREATMENT", 159, 176]]], ["POS resolved over a median (range) of 17 (6-39) days.", [["resolved", "OBSERVATION_MODIFIER", 4, 12]]], ["Compared to ICU survivors without POS, patients with POS were older and had lower body mass index, elevated arterial-alveolar carbon dioxide partial pressure gradient on the last day of IMV and elevated alveolar-arterial oxygen gradient following extubation (Table 1).DISCUSSIONTo the best of our knowledge, we report the first observations of POS following severe COVID-19 ARDS.", [["body", "ANATOMY", 82, 86], ["arterial", "ANATOMY", 108, 116], ["alveolar", "ANATOMY", 117, 125], ["alveolar", "ANATOMY", 203, 211], ["arterial", "ANATOMY", 212, 220], ["carbon dioxide", "CHEMICAL", 126, 140], ["oxygen", "CHEMICAL", 221, 227], ["ARDS", "DISEASE", 374, 378], ["carbon dioxide", "CHEMICAL", 126, 140], ["oxygen", "CHEMICAL", 221, 227], ["patients", "ORGANISM", 39, 47], ["body", "ORGANISM_SUBDIVISION", 82, 86], ["arterial", "MULTI-TISSUE_STRUCTURE", 108, 116], ["alveolar", "MULTI-TISSUE_STRUCTURE", 117, 125], ["alveolar", "MULTI-TISSUE_STRUCTURE", 203, 211], ["arterial", "MULTI-TISSUE_STRUCTURE", 212, 220], ["oxygen", "SIMPLE_CHEMICAL", 221, 227], ["patients", "SPECIES", 39, 47], ["lower body mass index", "PROBLEM", 76, 97], ["elevated arterial-alveolar carbon dioxide partial pressure gradient", "PROBLEM", 99, 166], ["IMV", "TREATMENT", 186, 189], ["elevated alveolar-arterial oxygen gradient", "PROBLEM", 194, 236], ["severe COVID", "PROBLEM", 358, 370], ["ARDS", "PROBLEM", 374, 378], ["mass", "OBSERVATION", 87, 91], ["elevated", "OBSERVATION", 99, 107], ["arterial", "ANATOMY_MODIFIER", 108, 116], ["alveolar", "ANATOMY_MODIFIER", 117, 125], ["carbon dioxide", "OBSERVATION", 126, 140], ["pressure", "OBSERVATION_MODIFIER", 149, 157], ["gradient", "OBSERVATION_MODIFIER", 158, 166], ["elevated", "OBSERVATION", 194, 202], ["alveolar", "ANATOMY_MODIFIER", 203, 211], ["arterial", "ANATOMY", 212, 220], ["oxygen gradient", "OBSERVATION", 221, 236], ["ARDS", "OBSERVATION", 374, 378]]], ["Although often attributed to right-to-left intracardiac shunting, POS occurs in settings of increased venous admixture secondary to intrapulmonary anatomical (e.g. pulmonary arteriovenous malformation) or rarer physiological pulmonary shunts, due to basal-predominant parenchymal diseases (Agrawal et al., 2017).", [["intracardiac", "ANATOMY", 43, 55], ["venous", "ANATOMY", 102, 108], ["intrapulmonary", "ANATOMY", 132, 146], ["pulmonary arteriovenous malformation", "ANATOMY", 164, 200], ["pulmonary", "ANATOMY", 225, 234], ["parenchymal", "ANATOMY", 268, 279], ["pulmonary arteriovenous malformation", "DISEASE", 164, 200], ["parenchymal diseases", "DISEASE", 268, 288], ["intracardiac", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 55], ["venous", "MULTI-TISSUE_STRUCTURE", 102, 108], ["pulmonary arteriovenous", "PATHOLOGICAL_FORMATION", 164, 187], ["pulmonary", "ORGAN", 225, 234], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 268, 279], ["right-to-left intracardiac shunting", "PROBLEM", 29, 64], ["increased venous admixture", "PROBLEM", 92, 118], ["intrapulmonary anatomical (e.g. pulmonary arteriovenous malformation", "PROBLEM", 132, 200], ["rarer physiological pulmonary shunts", "PROBLEM", 205, 241], ["basal-predominant parenchymal diseases", "PROBLEM", 250, 288], ["right", "ANATOMY_MODIFIER", 29, 34], ["left", "ANATOMY_MODIFIER", 38, 42], ["intracardiac", "ANATOMY", 43, 55], ["shunting", "OBSERVATION", 56, 64], ["POS", "OBSERVATION", 66, 69], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["venous admixture", "OBSERVATION", 102, 118], ["intrapulmonary", "ANATOMY", 132, 146], ["anatomical", "ANATOMY_MODIFIER", 147, 157], ["pulmonary arteriovenous", "ANATOMY", 164, 187], ["malformation", "OBSERVATION", 188, 200], ["pulmonary", "ANATOMY", 225, 234], ["shunts", "OBSERVATION", 235, 241], ["basal", "ANATOMY_MODIFIER", 250, 255], ["predominant", "OBSERVATION_MODIFIER", 256, 267], ["parenchymal", "ANATOMY_MODIFIER", 268, 279], ["diseases", "OBSERVATION", 280, 288]]], ["Our patients fulfilled criteria for moderate-severe ARDS.", [["ARDS", "DISEASE", 52, 56], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["moderate-severe ARDS", "PROBLEM", 36, 56], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["ARDS", "OBSERVATION", 52, 56]]], ["Venous admixture or intrapulmonary shunting is a recognized pathophysiological mechanism of hypoxemia in ARDS (Radermacher et al., 2017).", [["Venous", "ANATOMY", 0, 6], ["intrapulmonary", "ANATOMY", 20, 34], ["hypoxemia", "DISEASE", 92, 101], ["ARDS", "DISEASE", 105, 109], ["Venous", "MULTI-TISSUE_STRUCTURE", 0, 6], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 20, 34], ["Venous admixture", "PROBLEM", 0, 16], ["intrapulmonary shunting", "PROBLEM", 20, 43], ["hypoxemia", "PROBLEM", 92, 101], ["ARDS", "PROBLEM", 105, 109], ["intrapulmonary", "ANATOMY", 20, 34], ["shunting", "OBSERVATION", 35, 43], ["hypoxemia", "OBSERVATION", 92, 101], ["ARDS", "OBSERVATION", 105, 109]]], ["However, the underlying mechanisms of POS, particularly in the context of severe COVID-19 illness are likely more complex.", [["COVID", "DISEASE", 81, 86], ["POS", "MULTI-TISSUE_STRUCTURE", 38, 41], ["severe COVID-19 illness", "PROBLEM", 74, 97], ["POS", "OBSERVATION", 38, 41], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["more complex", "OBSERVATION_MODIFIER", 109, 121]]], ["Alveolar hypoventilation has a role, for instance by increasing the proportion of \u2018wasted\u2019 ventilation (zone 1 phenomenon) which is compounded by reduced cardiac output, and an imbalanced load-capacity conferred by reduced lung compliance and critical illness myopathy (Fig. 2) (Radermacher et al., 2017; Lumb, 2010; Hert and Albert, 1994; McGregor et al., 1961).", [["Alveolar", "ANATOMY", 0, 8], ["cardiac", "ANATOMY", 154, 161], ["lung", "ANATOMY", 223, 227], ["hypoventilation", "DISEASE", 9, 24], ["reduced cardiac output", "DISEASE", 146, 168], ["myopathy", "DISEASE", 260, 268], ["Alveolar", "MULTI-TISSUE_STRUCTURE", 0, 8], ["cardiac", "ORGAN", 154, 161], ["lung", "ORGAN", 223, 227], ["Alveolar hypoventilation", "PROBLEM", 0, 24], ["\u2018wasted\u2019 ventilation", "TREATMENT", 82, 102], ["reduced cardiac output", "PROBLEM", 146, 168], ["an imbalanced load-capacity", "PROBLEM", 174, 201], ["reduced lung compliance", "PROBLEM", 215, 238], ["critical illness myopathy", "PROBLEM", 243, 268], ["hypoventilation", "OBSERVATION", 9, 24], ["reduced", "OBSERVATION_MODIFIER", 146, 153], ["cardiac output", "OBSERVATION", 154, 168], ["lung", "ANATOMY", 223, 227], ["compliance", "OBSERVATION", 228, 238], ["illness myopathy", "OBSERVATION", 252, 268]]], ["Zone 1 phenomenon is also exaggerated in the presence of microthrombi, and microangiopathy observed in severe COVID-19 disease (Fox et al., 2020).", [["microthrombi", "DISEASE", 57, 69], ["microangiopathy", "DISEASE", 75, 90], ["COVID-19 disease", "DISEASE", 110, 126], ["Zone 1 phenomenon", "PROBLEM", 0, 17], ["microthrombi", "PROBLEM", 57, 69], ["microangiopathy", "PROBLEM", 75, 90], ["severe COVID-19 disease", "PROBLEM", 103, 126], ["exaggerated", "OBSERVATION_MODIFIER", 26, 37], ["microthrombi", "OBSERVATION", 57, 69], ["microangiopathy", "OBSERVATION", 75, 90], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["19 disease", "OBSERVATION", 116, 126]]], ["This could explain the disparity in severity of symptoms where individuals with the worst dyspnea had highest D-dimer levels (Fig. 1).", [["dyspnea", "DISEASE", 90, 97], ["D-dimer", "GENE_OR_GENE_PRODUCT", 110, 117], ["symptoms", "PROBLEM", 48, 56], ["the worst dyspnea", "PROBLEM", 80, 97], ["disparity", "OBSERVATION_MODIFIER", 23, 32]]], ["Therefore, we hypothesize that POS is a gravitational exacerbation of intrapulmonary shunt in ARDS due to COVID-19 related vasculopathy and increased wasted ventilation.DISCUSSIONThe main limitations of our clinical findings are the lack of definitive exclusion of intra-cardiac anatomical shunting, e.g. by contrast-enhanced echocardiography or scintigraphy with macroaggregated albumin.", [["intrapulmonary", "ANATOMY", 70, 84], ["ARDS", "DISEASE", 94, 98], ["COVID-19", "CHEMICAL", 106, 114], ["vasculopathy", "DISEASE", 123, 135], ["intrapulmonary", "ORGAN", 70, 84], ["albumin", "GENE_OR_GENE_PRODUCT", 380, 387], ["macroaggregated albumin", "PROTEIN", 364, 387], ["a gravitational exacerbation", "PROBLEM", 38, 66], ["intrapulmonary shunt", "TREATMENT", 70, 90], ["ARDS", "PROBLEM", 94, 98], ["COVID", "TEST", 106, 111], ["vasculopathy", "PROBLEM", 123, 135], ["increased wasted ventilation", "TREATMENT", 140, 168], ["intra-cardiac anatomical shunting", "PROBLEM", 265, 298], ["contrast-enhanced echocardiography", "TEST", 308, 342], ["scintigraphy", "TEST", 346, 358], ["macroaggregated albumin", "TREATMENT", 364, 387], ["gravitational", "OBSERVATION_MODIFIER", 40, 53], ["exacerbation", "OBSERVATION_MODIFIER", 54, 66], ["intrapulmonary shunt", "OBSERVATION", 70, 90], ["ARDS", "OBSERVATION", 94, 98], ["vasculopathy", "OBSERVATION", 123, 135], ["increased", "OBSERVATION_MODIFIER", 140, 149], ["wasted ventilation", "OBSERVATION", 150, 168], ["main", "OBSERVATION_MODIFIER", 183, 187], ["anatomical shunting", "OBSERVATION", 279, 298]]], ["In our institution, these tests present logistical challenges in a negative pressure isolation setting.", [["these tests", "TEST", 20, 31], ["a negative pressure isolation setting", "TREATMENT", 65, 102]]], ["While present in one-fifth of ARDS patients, we believe that the likelihood of patent foramen ovale is low due to: 1) the absence of paradoxical hypoxemia despite incremental PEEP, 2) no obvious chamber enlargement on bedside echocardiography, and 3) eventual resolution of POS over time (Dessap et al., 2010).", [["ARDS", "DISEASE", 30, 34], ["patent foramen ovale", "DISEASE", 79, 99], ["hypoxemia", "DISEASE", 145, 154], ["patients", "ORGANISM", 35, 43], ["foramen", "MULTI-TISSUE_STRUCTURE", 86, 93], ["patients", "SPECIES", 35, 43], ["ARDS", "PROBLEM", 30, 34], ["patent foramen ovale", "PROBLEM", 79, 99], ["paradoxical hypoxemia", "PROBLEM", 133, 154], ["incremental PEEP", "TREATMENT", 163, 179], ["obvious chamber enlargement", "PROBLEM", 187, 214], ["bedside echocardiography", "TEST", 218, 242], ["ARDS", "OBSERVATION", 30, 34], ["patent", "OBSERVATION", 79, 85], ["foramen", "ANATOMY_MODIFIER", 86, 93], ["ovale", "OBSERVATION", 94, 99], ["paradoxical", "OBSERVATION_MODIFIER", 133, 144], ["hypoxemia", "OBSERVATION", 145, 154], ["no obvious", "UNCERTAINTY", 184, 194], ["chamber", "ANATOMY_MODIFIER", 195, 202], ["enlargement", "OBSERVATION", 203, 214]]], ["Hepatopulmonary shunting was also unlikely with normal liver function.DISCUSSIONAs of 29th May 2020, Singapore has seen 33,860 COVID-19 cases (Ministry of Health, Singapore, 2020).", [["Hepatopulmonary", "ANATOMY", 0, 15], ["liver", "ANATOMY", 55, 60], ["liver", "ORGAN", 55, 60], ["Hepatopulmonary shunting", "PROBLEM", 0, 24], ["shunting", "OBSERVATION", 16, 24], ["also unlikely", "UNCERTAINTY", 29, 42], ["normal", "OBSERVATION", 48, 54], ["liver", "ANATOMY", 55, 60]]], ["Our centre managed 42 of 113 (37%) patients who required ICU care.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["ICU care", "TREATMENT", 57, 65]]], ["POS is notably a shared feature in a quarter of our COVID-19 ICU survivors, and may be a feature of older patients with more severe COVID-19 disease and/or inflammation.", [["inflammation", "DISEASE", 156, 168], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["more severe COVID-19 disease", "PROBLEM", 120, 148], ["inflammation", "PROBLEM", 156, 168], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["19 disease", "OBSERVATION", 138, 148], ["inflammation", "OBSERVATION", 156, 168]]], ["The reported finding of peripheral and dependent consolidation in more severely ill patients on sequential CT scans is also observed in our patients (Shi et al., 2020).", [["ill", "DISEASE", 80, 83], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 140, 148], ["peripheral and dependent consolidation", "PROBLEM", 24, 62], ["sequential CT scans", "TEST", 96, 115], ["peripheral", "ANATOMY_MODIFIER", 24, 34], ["dependent", "OBSERVATION_MODIFIER", 39, 48], ["consolidation", "OBSERVATION", 49, 62], ["more", "OBSERVATION_MODIFIER", 66, 70], ["severely", "OBSERVATION_MODIFIER", 71, 79], ["ill", "OBSERVATION_MODIFIER", 80, 83]]], ["POS is rarely reported post-ARDS, illustrating a potential key observation in severe COVID-19 (Hert and Albert, 1994).", [["ARDS", "DISEASE", 28, 32], ["ARDS", "PROBLEM", 28, 32], ["severe COVID", "PROBLEM", 78, 90], ["ARDS", "OBSERVATION", 28, 32], ["severe", "OBSERVATION_MODIFIER", 78, 84]]], ["Of note, however, exercise-related oxygen desaturation, which shares some key pathophysiological mechanisms to orthodeoxia is described post-ARDS, and, POS may represent a more severe form of exertional desaturation (Hert and Albert, 1994; Herridge et al., 2003).", [["oxygen", "CHEMICAL", 35, 41], ["desaturation", "DISEASE", 42, 54], ["orthodeoxia", "DISEASE", 111, 122], ["ARDS", "DISEASE", 141, 145], ["exertional desaturation", "DISEASE", 192, 215], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["oxygen desaturation", "PROBLEM", 35, 54], ["ARDS", "PROBLEM", 141, 145], ["exertional desaturation", "PROBLEM", 192, 215], ["oxygen desaturation", "OBSERVATION", 35, 54], ["ARDS", "OBSERVATION", 141, 145], ["more severe", "OBSERVATION_MODIFIER", 172, 183], ["exertional", "OBSERVATION_MODIFIER", 192, 202], ["desaturation", "OBSERVATION", 203, 215]]], ["In our experience, detecting POS in the late or post-ICU setting following severe COVID-19 illness likely reflects the increased physiotherapy-related intervention from prolonged hospitalisation, thereby \u2018unmasking\u2019 intrapulmonary shunting during postural change.", [["intrapulmonary", "ANATOMY", 216, 230], ["COVID", "DISEASE", 82, 87], ["illness", "DISEASE", 91, 98], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 216, 230], ["severe COVID-19 illness", "PROBLEM", 75, 98], ["the increased physiotherapy", "PROBLEM", 115, 142], ["unmasking\u2019 intrapulmonary shunting", "PROBLEM", 205, 239], ["postural change", "PROBLEM", 247, 262], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["physiotherapy", "OBSERVATION", 129, 142], ["intrapulmonary", "ANATOMY", 216, 230], ["shunting", "OBSERVATION", 231, 239], ["postural change", "OBSERVATION", 247, 262]]], ["Another reason is alveolar de-recruitment as evident by the increased in alveolar-arterial oxygen gradient following extubation.", [["alveolar", "ANATOMY", 18, 26], ["alveolar", "ANATOMY", 73, 81], ["arterial", "ANATOMY", 82, 90], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 91, 97], ["alveolar", "MULTI-TISSUE_STRUCTURE", 18, 26], ["alveolar", "TISSUE", 73, 81], ["arterial", "MULTI-TISSUE_STRUCTURE", 82, 90], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["alveolar de-recruitment", "PROBLEM", 18, 41], ["the increased in alveolar-arterial oxygen gradient", "PROBLEM", 56, 106], ["alveolar de-recruitment", "OBSERVATION", 18, 41], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["alveolar", "ANATOMY_MODIFIER", 73, 81], ["arterial", "ANATOMY", 82, 90], ["oxygen gradient", "OBSERVATION", 91, 106]]], ["Furthermore, increased detection of POS is likely due to the close remote surveillance monitoring using continuous wearable devices, routine practice at our centre in post-ICU care.CONCLUSIONPOS is an under-recognized clinical feature in severe COVID-19 ARDS.", [["COVID", "DISEASE", 245, 250], ["ARDS", "DISEASE", 254, 258], ["close remote surveillance monitoring", "TEST", 61, 97], ["continuous wearable devices", "TREATMENT", 104, 131], ["routine practice", "TREATMENT", 133, 149], ["post-ICU care", "TREATMENT", 167, 180], ["severe COVID", "PROBLEM", 238, 250], ["ARDS", "PROBLEM", 254, 258], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["POS", "OBSERVATION", 36, 39], ["likely due to", "UNCERTAINTY", 43, 56], ["severe", "OBSERVATION_MODIFIER", 238, 244], ["ARDS", "OBSERVATION", 254, 258]]], ["Healthcare personnel should be made aware of the possibility for POS in severe COVID-19 ICU care.", [["ICU care", "TREATMENT", 88, 96]]], ["In relatively resource-constrained or overwhelmed healthcare settings, we propose direct clinical observation with bedside SpO2 monitoring during positional change focusing on patients who are older and with more severe disease.", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["bedside SpO2 monitoring", "TEST", 115, 138], ["more severe disease", "PROBLEM", 208, 227], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["disease", "OBSERVATION", 220, 227]]], ["Recognising POS can reduce morbidity, unnecessary alarm, improve patient safety and allow for adjustments in the rehabilitation process.", [["POS", "MULTI-TISSUE_STRUCTURE", 12, 15], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["the rehabilitation process", "TREATMENT", 109, 135]]], ["Our report calls for further studies on the intermediate and long-term clinical outcomes of post-ICU COVID-19 survivors, including those with, and without POS.FundingThis work was funded in part by the Singapore National Medical Research Council through the COVID-19 Research Fund (Ref: COVID19RF-001).", [["further studies", "TEST", 21, 36], ["post-ICU COVID", "TEST", 92, 106]]]]}